<SEC-DOCUMENT>0001274737-21-000015.txt : 20210316
<SEC-HEADER>0001274737-21-000015.hdr.sgml : 20210316
<ACCEPTANCE-DATETIME>20210316172207
ACCESSION NUMBER:		0001274737-21-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210316
DATE AS OF CHANGE:		20210316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		21747098

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exdx-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a,d:46297aecc50342189ce6ad0511b1efd6--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:exdx="http://www.exagen.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV81LTEtMS0xLTA_1514ecab-4413-4396-a445-82805306ee12">2020</ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV82LTEtMS0xLTA_d79d13fe-3a32-4555-9ccf-ad352e713a47">FY</ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV83LTEtMS0xLTA_6bbeae4d-7c6f-4bd5-9b75-c8745bd3010a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGV4dHJlZ2lvbjo2MjM2N2JhMGE2ODc0ODYwOGY0ZTg0ODJkM2NlY2ViZV84MA_4b9dd082-c1b1-4fa4-9a88-9a72bd8da972">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="i69d2e2c6f0774bcdb394050b9d53ee76_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia8548f93c1bc48f8ae505f3a7aa3a457_D20190906-20190906" decimals="7" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83ODQvZnJhZzpkNDJkNTc2ZDc1OTI0ZjUyYWEyMmE5Njk2NjAzMWI2Ni90ZXh0cmVnaW9uOmQ0MmQ1NzZkNzU5MjRmNTJhYTIyYTk2OTY2MDMxYjY2XzI3NDg3NzkwNjk1NjA_fe834be9-baa0-4754-80a9-5e38fdb6143e">.0054456</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iac638a334d2d4a41982db55571d79004_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i140e1c0c979f493ab5bbee92875a255d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ied1333e512914d588c7ba153b4b54d39_I20210312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161aa9f12f5040b598e25e1d7896f041_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616b08c4738d433b924c1dc44c268b4f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3617efc1423e40249453b903e951175d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6884440164f1463aa6e4fed299d3fe16_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5cbdb8b75149f1a2107742fed852bf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e3a91a5115e431d98f3d1ae4a1da9ec_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000894d3cadd4d209d2620841a05dcf0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69da35ef92234938bcda9473aefd88f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724b6d08dcb54c94ae1352b8b23c595f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85d4c855b6840b89f8a4974a7609bdd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e794abff7a43f59c1e323fa7e55d45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6dbfbafdf8a408ca1bbfc730926cc14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79849924192d4855a9bbf663964883f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9563b9ab6fbe4adcbdfbac8e2cf19b22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c6b3ac4c664091b47227b153e9eb44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac265b2ebdbc43e59ef20ea50e78de9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb52827a0d5e4d20bbb2e688d4965f2b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90ff0582bfa4beb88fa29365bcf05c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075b7f5ce30f4250b3fa7b1319fa76d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbc755e54584988a46ac09b03ba0a03_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia683090804ac4bbea90d92b75159efe3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031b116f01f44ea5890d77e14040a529_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5031346fd2374b0e97451ce84bad8260_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76b41f869c640688904f2ecf988e33e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09521d642ec49dd9f6fb93b6226a986_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc34f2aa5b494ba4b697db93d5108663_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e601deab964329936be94a4d256bc9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b8ceb139cf4e0d97db9be7ea8aacf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd041b98c6ab476eb80888f8676c3df5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5690cf2946e8412bb86195a6c74a9316_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcaa2249e3c640468e6ad463c58824a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5f71713fcf420b86e6051da049e7ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18229da67eb54a6b8110b348c32b2f80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06930bdf59ec4a7490fb90caaee4d192_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d5f0f3606b4c66949b12896e3d82ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2d0f3c92004d4d8ea0b1587e20bd73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26b529fa0544e3fa5ffa639ffaaa3da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43dd45431384ad48a4a7cd39396b772_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f51ada9f8b45298c0c793b85f782e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3c2fa4dc5f49e8b1099bc7e449e3a2_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d2e2c6f0774bcdb394050b9d53ee76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4573db3dc09e4fa8a58677b574d5c416_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc003e40daf641ccbe499297076b288b_D20190923-20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-23</xbrli:startDate><xbrli:endDate>2019-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i854adb164db541fa9bd24fb1ccb21010_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c2c61809374714a756188ab1adadbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce5a530334e4915b0436079dca953ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20146f37e33a40dab402238b6ea56800_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9156fd411b7741a8a39d1c43983a5800_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>exdx:unit</xbrli:measure></xbrli:unit><xbrli:context id="ic0b7b9ea1d814dbbbeed9b14692e78ca_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d6c90706d94887a50acb583e7d32ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcc6ed5d40246baabade8cb1d9fba6b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695ae53d59f94e27b87eefce82393e8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a03a4097faf4d70895448f0b1cdccc9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f45eef28e7d4c2e8752293801f70ab3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62cb5f8c97194f02924e255c54bed267_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf6e035476945cfb9d2423367a0fd96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358dc56770ab42ceace2ba4c29570329_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf8dba0b2d464952ad492cfb4b91e9c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33102e8052874bcf8f4819af73b17cd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1320fd0f2999411e8bd7d1a4b841aa24_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e558ece6214f16b6c3df7e771db6be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc02f1f51b5c4b199fc8848ae372e425_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib235ec96e6b1472d9f54d1de7b43b02f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1e7be53ff34ffab13c26e9df1ddc43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="if8fa1a8305f5404892b12cd15d2ac129_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280bdc8f8aa947aaa8f3ba67d5a4d42e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa0e2237a4349c6975a3792c1a40fc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856d0b8d5d514828b59f52af21200f9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674956e7e0a8446f921f15096e981198_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9f4988242043ae86e49c5b25240e58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6f34cf3e1b429c8056d14a2e90b57a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i611274158822483e99565868e2143ccd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c15b3b387924344b6a488918b7724a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3795b5fddf0a474ca1f456c3011836fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d22bc21e2b4d42828df3456f0b74ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddb14c3a29441f2a69234c84b0a601e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife50f4946ea24f0c9f4e38cbd7f1110e_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e6b9922db74a3a9cb86c52f2a90cc9_D20181207-20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-07</xbrli:startDate><xbrli:endDate>2018-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id42bbd7899154e72a4ec0bed957b96f6_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>exdx:payment</xbrli:measure></xbrli:unit><xbrli:context id="i0e96141de3c64fe29a0de8fc804cff2f_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5149cc8ef1ff4fac911ed00c49b7db71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5ddd398de1458e8e1e64f2e9afd8d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b28ea3fe8a47bb9b1c724647721207_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd6af4be1f145b0979bab0cafe7ad2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626d033bbe12451bb544fb9ccd602d11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5eb4831058d4b62a7506f80397c58e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90378dc8f33d4c0db9c9f5e510cefc73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13eef4c0f9f34ead9206411d3e70f27f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b416cd8bb1f4d6f86d98f542ac3cc5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0eeb17dc7c4414a87f1ab0a5c0341f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d0579e1e494431ae288f59027174a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a61521b77e46aa90eed63b0c7ba9b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a24aaf692c5444cbf9b46ed5a052bee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb32079e8ef4b6ab57b666c86ab1379_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9202b030fd1b4086bdec9b70b92d1d84_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80f1b4b2b84440db98c9a7375a7570f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf86d568866c4251832b028da29ff071_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b650b6b9d754c97a85b32a60d451667_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ccae1c8177a4c3b9f45dfceb5efa42f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e709efd0a0841ec93329ef2a03791d0_I20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73d28ff344b45b7be16393a226e65c1_D20190923-20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-23</xbrli:startDate><xbrli:endDate>2019-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466315a145504f92bab9954a4653b6ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a60c0a83494af48451bdffb74f8657_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c677925f1f405988f482d6e0c41691_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8548f93c1bc48f8ae505f3a7aa3a457_D20190906-20190906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-06</xbrli:startDate><xbrli:endDate>2019-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2f80c2b6c5444ba34456f703d38c67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dcffc3099e440189a3fa6ca69d78390_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9df7a83f79940ddb50644d9534b8e4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3119fce349b4f6587c19f908367b2dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c062635dbd2451889987f0af257f830_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039ef34e84814a89a51794da58440c49_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeaded307e5245739ed101c326ac2e81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b5f6bca8d2400bb78d64d3ee723516_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702cbb6d8580485a8ed9b7d9da8a2093_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a70ce52ba824bfda7ecfd9065c1b7c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703d6361d7e7459d8f59cb73b645d79e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d73be98d664ccfa3f52b1b3925d8b1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id612b120136c4606a30275dd302975ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeed2007d8ce423190963dac6498acc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d9a5ee720049a2943b6461407a26c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4954aca44d475bbcf2bdfd5f3e8918_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonStockOptionGrantsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib009a5d12eec454f807f70204c3f2c94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderTheStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95195c5be0cf48859f028de27b41c233_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7dd8fe1c69457ebd695bca19af30c8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801df2af82e6463ebc78fe5a1417689d_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic992af68648c493b97deed5f40c92944_D20200416-20200416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-16</xbrli:startDate><xbrli:endDate>2020-04-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i46297aecc50342189ce6ad0511b1efd6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV84NA_bc5de619-f932-4f3d-9868-bcaf5615d07b">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8xLTAtMS0xLTA_32d5726a-db96-4f7f-b11d-8b082220a7ce">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzI3MmYxZmFlODQ0MzBmOTY4MjUyZWFhNTY2Yzg1N18zMA_b78ed932-761c-48e4-9abb-25185bec0f76"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzI3MmYxZmFlODQ0MzBmOTY4MjUyZWFhNTY2Yzg1N18zMA_63660815-1a2e-4f0b-8d33-4eea793f2470">December 31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8zLTAtMS0xLTA_44d1329a-2ad0-4fdb-9f62-223ef3b308a8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from     to     .</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xNzQ_6e1e8aa6-529e-404f-9989-66638415a9f3">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><img src="exdx-20201231_g1.jpg" alt="exdx-20201231_g1.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xNzg_49fd3bd6-66e1-40e0-bf2e-d5d561a683c9">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8wLTAtMS0xLTA_f51ea8de-ea3f-4664-b7ad-2a0676cf401b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8wLTYtMS0xLTA_cf5d64b8-f71d-4987-ab27-52d9f28bb0bd">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8zLTEtMS0xLTA_52d608fd-30d1-4d79-95f6-9be4e3c73330">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTEtMS0xLTA_1e3dc09b-b0d8-4c93-8d2f-343243b544cd">Vista</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTItMS0xLTA_982cc3d8-5934-458a-a2f4-c42294c873f6">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTYtMS0xLTA_ba6d3d2c-044c-4aa4-b8fa-a3019c40cadb">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.766%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6YTFkMDRkZWI0NmRmNGM5MzgwMmQ4YzdkOGU2NGRhOTYvdGFibGVyYW5nZTphMWQwNGRlYjQ2ZGY0YzkzODAyZDhjN2Q4ZTY0ZGE5Nl8wLTAtMS0xLTA_1ac1dd49-fa3c-4323-845d-ea6928db0893">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6YTFkMDRkZWI0NmRmNGM5MzgwMmQ4YzdkOGU2NGRhOTYvdGFibGVyYW5nZTphMWQwNGRlYjQ2ZGY0YzkzODAyZDhjN2Q4ZTY0ZGE5Nl8wLTEtMS0xLTA_cb6a946c-5502-42c2-b17b-81ead4028d16">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:35.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTAtMS0xLTA_30fa1133-b121-49c7-b12d-fb597dfada62">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTItMS0xLTA_f1749afe-babe-4df3-b058-e60efc705188">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTQtMS0xLTA_1e608a9b-de5f-42f5-94f0-7c3efd240d17">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTcz_085025c4-613e-4384-85ec-82b7dbd62ba8">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTc0_a779178d-cee9-4b3d-b086-ad0de7151288">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV85Nzg_07a5142d-1331-4d9e-9e81-5a57a11da851">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xMjgw_3f8c3bb3-072a-46f5-b8a1-f7ce6eab168c">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M18yLTAtMS0xLTA_7e8c37fa-4fd0-4948-b160-369f6eee6a5b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M18yLTQtMS0xLTA_e6d75e67-a3a3-4e9a-8dd5-57b3bd5493a0">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M180LTQtMS0xLTA_1bd81a4e-4543-46ea-a7a9-50e455fad29f">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xOTE1_47afb3b4-130b-4b65-9e9c-0804ad5e229e">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on the attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8zMjk4NTM0ODg3Mzg5_81af924c-e234-4665-bf7c-6c51fff4eb0a">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yMDM1_bffc0dbb-11f7-4687-8b4c-24d0df8fcdbd">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2020 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i140e1c0c979f493ab5bbee92875a255d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yMTg4_b9f8e9a7-8a8c-44a1-9023-73bfee4f021c">83.4</ix:nonFraction>&#160;million, based on the closing price of the registrant's common stock on the Nasdaq Global Market of $12.41 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on March&#160;12, 2021 was <ix:nonFraction unitRef="shares" contextRef="ied1333e512914d588c7ba153b4b54d39_I20210312" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yNjIw_54f53d00-cbde-42ad-8f53-86449bf436f9">12,669,816</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTc1_010eab0e-6370-404a-b2a1-6936291a92b5" escape="true">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2021 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_16">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_19">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_22">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_25">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_28">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_34">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_34">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_37">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_40">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_40">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_55">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_55">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_58">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_58">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_61">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_61">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_64">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_64">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_67">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_67">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_73">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_73">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_76">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_76">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_79">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_79">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_82">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_82">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_85">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_85">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_91">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_91">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_94">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_94">94</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_166">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_166">124</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements and Market Data</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, the impact of the COVID-19 pandemic, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing with therapeutics strategy, the expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This Annual Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by terms such as "believe," "may," "will," "should," "predict," "goal," "strategy," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "seek," and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use our trademarks in this Annual Report as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases, or CTDs, and other related diseases with overlapping symptoms. The comprehensive nature of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD allows for the testing of a number of relevant biomarkers in one convenient blood draw, as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic process. We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD may provide clinical utility for over 23 million patients in the United States suffering from these diseases, which include SLE, RA, Sj&#246;gren&#8217;s syndrome, antiphospholipid syndrome, or APS, other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and patient advocacy organizations. In December 2018, we entered into a co-promotion agreement, or the Janssen Agreement, with Janssen Biotech, Inc., or Janssen, to exclusively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (golimumab) in order to advance our integrated testing and therapeutics strategy, and we began direct promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in January 2019. We also have agreements with other leading pharmaceutical companies and clinical research organizations, including GlaxoSmithKline LLC, or GSK, Covance Inc. and Parexel that leverage our testing products and/or the data generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of an early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease activity. We partner with academic research centers and patient advocacy organizations, such as Brigham and Women's Hospital, Hospital for Special Surgery, and Duke University as well as the Lupus Foundation of America, to help improve the quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional partnerships that are synergistic with our evolving portfolio of testing products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have demonstrated a strong track record of developing innovative testing products that meet the needs of diagnosing, prognosing and monitoring CTDs, as illustrated below: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20201231_g2.jpg" alt="exdx-20201231_g2.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:725px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD leverages our proprietary CB-CAPs technology to enable the differential diagnosis SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD provides rheumatologists and their patients with sensitive and specific results that allow for potentially faster and more accurate differential diagnosis of SLE as compared to other currently-marketed testing methods. Beyond SLE, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD allows rheumatologists to accurately diagnose other overlapping autoimmune and autoimmune-related diseases, including RA, with the same blood sample. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor testing product also leverages our proprietary CB-CAPs technology by measuring two CB-CAPs biomarkers that offer insight into a patient&#8217;s disease activity. This test is designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor may be utilized by patients multiple times a year throughout their lives. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing products using our specialized salesforce. Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2020, we have delivered over 487,000 of these tests. For the year ended December&#160;31, 2020, 100,450 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered, representing an approximate 5% decline over the same period in 2019. The number of ordering healthcare providers reached a record of 2,500 for the year ended December&#160;31, 2020, representing approximately 5% growth over the same period in 2019. In the fourth quarter of 2020, the number of ordering healthcare providers reached 1,690 compared to 1,707 in the same period in 2019, and we reached a record 635 adopting healthcare providers (defined as those who previously prescribed at least 11 diagnostic tests in the corresponding period) compared to 572 in the same period in 2019. A high percentage of adopting healthcare providers continue to order tests in subsequent quarters, including a retention rate of approximately 99% among adopting healthcare providers from the third quarter of 2020 that order at least one diagnostic test in the fourth quarter of 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we continue to populate a growing proprietary database of de-identified patient test results from our clinical studies and our clinical laboratory. We believe the insight emerging from these results has the potential to unlock value for pharmaceutical and biotechnology companies in the development and commercialization of therapeutics. We believe we also have the ability to further leverage our database to optimize patient selection in clinical trials for companies developing therapeutics for autoimmune and autoimmune-related diseases. We plan to collaborate with our existing and future pharmaceutical and biotechnology partners to help maximize the full value of our in-house database. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our integrated testing and therapeutics strategy differentiates us from other diagnostic and pharmaceutical companies, and results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and who have a history using our portfolio of testing products. We intend to leverage our integrated testing and therapeutics strategy to establish additional partnerships.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are led by an experienced management team with unique capabilities to execute on our strategy of integrating the promotion of testing products and therapeutics. Our senior management has an average of over 20 years of experience in the healthcare industry with a focus on integrating diagnostics and therapeutics. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We develop and commercialize next-generation testing products and promote synergistic therapeutics to ultimately improve the continuum of care for patients suffering from debilitating and chronic autoimmune diseases. The key tenets of our business strategy include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Continue our track record of developing innovative testing products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have demonstrated a strong track record of developing testing products that address the challenges in the differential diagnosis, prognosis and monitoring of patients with autoimmune and autoimmune-related diseases. We are leveraging our proprietary CB-CAPs and methotrexate polyglutamate, or MTXPG, technologies to develop additional testing products designed to have superior clinical utility for CTDs. We believe our commitment to innovating our portfolio of testing products will further strengthen our relationships with rheumatologists and our value proposition to our existing and future pharmaceutical and biotechnology partners.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Drive additional market penetration for our testing products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of testing products enables the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. We have demonstrated a strong track record of commercial growth from our testing products, leveraging our specialized salesforce and expansive network of relationships with rheumatologists across the United States. We believe we are uniquely positioned to continue expanding our commercial presence within the autoimmune disease market and plan to continue to invest in our salesforce in order to achieve the optimal reach and frequency with rheumatologists. This will support our strategy of integrating the promotion of testing products and therapeutics. In addition, we will continue to expand our efforts in the targeted promotion and education of rheumatologists and payors as to the clinical and cost benefits of our testing products. We believe these efforts will position us to capture additional market share for our portfolio of testing products.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Integrate the promotion of testing products and therapeutics for autoimmune and autoimmune-related diseases and establish additional partnerships. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our integrated testing and therapeutics strategy leverages our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products to promote therapeutics. In January 2019, we began our exclusive promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. In addition, we believe our agreements with leading pharmaceutical companies and clinical research organizations validate our unique value proposition to partners seeking a competitive edge for developing and commercializing therapeutics for autoimmune and autoimmune-related diseases. We intend to leverage our integrated testing and therapeutics strategy to establish additional partnerships with a focus on the development and commercialization of therapeutics that are synergistic with our testing products.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Maintain meaningful margin. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We realized an increase to our gross margins beginning in the first quarter of 2020 following the expiration of a 10% annual royalty on our CB-CAPs technology. We believe we are well positioned to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payor coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. However, our efforts to maintain a meaningful margin may be partially offset by our ability to generate meaningful co-promotion revenue in 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Autoimmune and Connective Tissue Diseases </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Autoimmune diseases encompass a broad range of serious, chronic and debilitating conditions in which a person&#8217;s immune system creates antibodies that mistakenly react against normal healthy tissues causing inflammation and irreversible tissue damage. These antibodies are called autoantibodies and their detection through blood tests can help diagnose, prognose and monitor the course of autoimmune diseases. However, knowing when and which autoantibody to test for is challenging due to the vagueness of symptoms, the unexplained flaring and remission of symptoms, and the many conditions which can mimic autoimmune disease. Early and accurate diagnosis of the conditions causing these overlapping symptoms is critical as an incorrect diagnosis can lead to toxicity from inappropriate medications, irreversible tissue damage and other comorbidities associated with uncontrolled disease. There is no known cause or cure for these chronic conditions and current treatment interventions are targeted at managing symptoms and limiting disease progression. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTDs are a sub-category of autoimmune diseases involving inflammation of the joints, tissues and internal organs. Persons with CTDs often present to their rheumatologist with complaints of joint pain, fatigue, unexplained fever, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">inflammation, rash, stiffness and muscle aches. These symptoms overlap among numerous CTDs, including SLE, one of the most severe CTDs and historically difficult to rule out, as well as other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. Based on a study we commissioned in 2014, we estimate that there are approximately 23 million undiagnosed patients in the United States who are symptomatic of these conditions and who may benefit from the differential diagnosis of CTDs. Of these patients, we estimate approximately seven million are potentially referable to rheumatologists and would be candidates for an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, representing a total addressable market of approximately $3.7 billion, based on the current Medicare allowable reimbursement rate. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $5 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Systemic Lupus Erythematosus </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE, the most common and severe form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and internal organs. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage and are one indicator of immune system abnormalities. SLE is characterized by a rise in symptoms and/or abnormal laboratory test results. SLE varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. Detection of these autoantibodies can assist rheumatologists in the diagnosis of SLE. Diagnosis of SLE allows rheumatologists to initiate the most appropriate therapy to minimize irreversible organ damage and reduce morbidity and mortality. Current treatment for SLE involves the use of antimalarials, corticosteroids, immunosuppressants and biologic agents to prevent or suppress active disease or flares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standard laboratory tests for diagnosing SLE include measuring immunological biomarkers, such as antinuclear antibodies, or ANA, anti-double stranded DNA, or anti-dsDNA, and other autoantibody tests. ANA are a group of autoantibodies produced by a person&#8217;s immune system when it fails to adequately distinguish between self and non-self. The ANA test detects these autoantibodies in the blood and is a useful screening tool for SLE and other autoimmune and autoimmune-related diseases. The vast majority of SLE patients test positive for ANA. However, the high sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. Sensitivity measures the proportion of patients who are correctly identified as having a particular condition, while specificity measures the proportion of patients who are correctly identified as not having a particular condition. Therefore, the majority of individuals who test positive for ANA do not have SLE. Only approximately 11-13% of individuals with a positive ANA test have SLE. This lack of specificity leads to many inappropriate non-autoimmune referrals to the rheumatologist from primary care physicians. For example, it has been reported that 30% of fibromyalgia patients may test positive for ANA, potentially generating as many as four million inappropriate rheumatology referrals. In addition, a study published in 2012 reported the estimated prevalence of a positive ANA test in the normal, healthy, U.S. population to be 13.8%, or 32 million people, indicating a significant need for a highly-specific test for this disease. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-dsDNA are autoantibodies that target a person&#8217;s double stranded DNA. The anti-dsDNA antibody test is a very specific test for SLE as anti-dsDNA antibodies are rarely found in autoimmune diseases other than SLE. A strongly positive anti-dsDNA antibody test makes it very likely that a person has SLE, although if the test is negative it does not necessarily rule out SLE. Approximately 30-70% of people with SLE have a negative anti-dsDNA antibody test, reaffirming the need for an effective testing product which adds clarity to the rheumatologist&#8217;s clinical assessment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activation of the complement system is an integral part of the disease process of SLE. Thus, rheumatologists measure components of the complement system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease activity. In 2012, the Systemic Lupus Collaborating Clinics added low C3 and low C4 as immunologic criteria for classifying SLE. In active SLE, C3 and C4 complement proteins are consumed and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest a diagnosis of SLE and that the disease is active. However, variability in the levels of C3 and C4 can occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, C3 and C4 are acute phase reactants and produced during inflammation. As a result, many SLE patients have normal complement levels even when the disease is active. Although relatively specific for SLE, low complement levels can also be seen in certain chronic infections, including non-lupus related kidney inflammation, severe liver disease and other autoimmune diseases. CB-CAPs are formed when the fragments of complement activation products from C4 bind permanently to circulating cells such as red blood cells, b-cells and platelets. This binding lasts for the life of the cell and represents a more stable and reliable indicator of complement activation than measuring C3 and C4 alone. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2011, the first new biologic targeting treatment of SLE in over 50 years, GSK&#8217;s Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was approved by the U.S. Food and Drug Administration, or the FDA, and in December 2020, the FDA approved this biologic drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the treatment of lupus nephritis. It is the only approved biologic for the treatment of active, antibody-positive SLE who are receiving standard therapy, and in December 2020, the FDA approved this biologic for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Since Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'s approval, there have been a number of drug development programs that have failed in SLE, which may suggest that guidelines for classifying SLE patients and the endpoints used to determine clinical effectiveness have not adequately addressed the complexity of the disease process and its heterogeneous population. We believe biopharmaceutical companies would benefit from the differential diagnosis enabled by our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in order to better identify sub-populations of SLE patients for targeted therapies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rheumatoid Arthritis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is a chronic, systemic autoimmune disease in which the immune system attacks the joints and can also affect other organ systems. The annual incidence and prevalence of RA in the United States is estimated to be 75,000 and 1.75 million, respectively. Patients suffering from RA develop joint damage that is associated with painful inflammation which often progresses to irreversible damage of cartilage and bone leading to significant disability and a reduction in quality of life and the ability to work. Early diagnosis and effective treatment of RA is critically important to prevent erosive bone or joint damage and disability. Rheumatologists are compelled to reach a definitive diagnosis quickly and administer effective treatment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diagnosis of RA involves performing a complete medical history with physical and/or radiographic examination of the number and distribution of swollen, tender and painful joints that have persisted for more than six weeks. Laboratory testing for rheumatoid factor, or RF, anti-cyclic citrullinated peptide, or CCP, antibodies, and testing for general, nonspecific inflammation with erythrocyte sedimentation rate, or the ESR, and C-reactive protein tests are used to assist in the diagnosis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of care for the treatment for RA involves the use of Disease Modifying Anti-Rheumatic Drugs, or DMARDs, which have shown, in clinical studies, the ability to slow or stop disease progression. Methotrexate remains the most commonly used DMARD, due to its low cost, effectiveness, and the extensive clinical experience with its use. It is estimated that approximately 74% of RA patients in the United States, or 1.3 million patients, are treated with methotrexate, either as a monotherapy or in combination with another DMARD. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biologics DMARDs are proteins that have been genetically modified to target cellular components of the immune system that attack healthy tissues causing the symptoms of RA. They are a targeted form of therapy, which makes them different from traditional RA treatments, such as methotrexate. The first FDA approved biologics for RA were the anti-TNFs. ENBREL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was approved for RA in 1998 and the latest, SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was approved in 2009. The anti-TNFs dominate the therapy for RA and generally are the first biologics chosen to augment methotrexate when patients are not achieving a satisfactory response. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Solution </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. Our product portfolio integrates our proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing SLE. We are focused on leveraging our portfolio of testing products to co-promote therapeutics with existing partners and future partners through our sales channel targeting the approximately 5,000 rheumatologists across the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Proprietary Technologies </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have two core proprietary technologies, CB-CAPs and MTXPGs, which form the backbone of several of our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CB-CAPs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary CB-CAPs technology determines the blood levels of complement activation proteins permanently deposited on hematopoietic cells. The determination of complement proteins in a patient&#8217;s blood is a mainstay in clinical laboratory science, and state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. While the limitations and drawbacks of measuring standard </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">components of the complement system, such as C3 and C4, are well recognized by the medical community, these laboratory biomarkers are part of international guidelines for the classification of SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the availability of novel complement biomarkers supporting or replacing standard C3 and C4 measures will be of great value for rheumatologists and ultimately their patients. Our CB-CAPs technology directly measures protein products of complement activation, such as C4d, the product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. As such, the determination of CB-CAPs in the blood provides benefits when compared to the traditional complement measurement. These include the stable, accurate and unequivocal information of complement activation that enable consistent measurement and an improved ability to assess and monitor changes in biological activity related to activation of the complement system. In a head-to-head study published in 2014, CB-CAPs (EC4d or BC4d) showed 22% higher sensitivity (66%) than C3 and C4 (44%) in diagnosing SLE, with specificity fixed at 91%. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTXPGs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Methotrexate is the standard of care and first-line treatment of many autoimmune diseases including RA and psoriatic arthritis. Our proprietary technology measures blood levels of MTXPGs, which are the active metabolite of methotrexate. The technology uses a dried capillary blood-based collection method coupled with liquid chromatographic tandem mass spectrometry and quantifies nanomolar concentrations of MTXPG using at least two orders of magnitude lower blood volume than venipuncture. MTXPG blood levels are actionable clinical utility checkpoints and can help clinicians identify causes for a lack of response to methotrexate, such as poor activation to active metabolites, underexposure secondary to poor absorption or poor compliance, all of which are limiting factors to the achievement of a robust clinical response with this first-line treatment. We believe we can leverage this technology to optimize anti-TNF treatment by reducing the formation of anti-drug antibodies that are known to impact the clinical efficacy of these drugs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Testing Products </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have been committed to developing and commercializing innovative testing products that address the challenges rheumatologists face in differentially diagnosing, prognosing and monitoring complex autoimmune and autoimmune-related diseases. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $5 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Diagnosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> CTD </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, is a comprehensive test that aids in the differential diagnosis of SLE versus other common CTDs. The SLE portion of the test employs our proprietary CB-CAPs technology and specifically measures activation of the complement system by quantifying the level of two CB-CAPs biomarkers in the patient&#8217;s blood, B-cell C4d, or BC4d, and erythrocyte bound C4d, or EC4d, which are higher in patients with SLE compared to patients with other CTDs. In addition, the comprehensive nature of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables testing for a series of biomarkers (23 as of December 31, 2020) in one convenient blood draw to further aid in the differential diagnosis of a wide variety of CTDs and other diseases which can be challenging to diagnose as a result of overlapping symptoms. These diseases include SLE, RA, Sj&#246;gren&#8217;s syndrome, APS, other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. Our test&#8217;s ability to allow rheumatologists to effectively rule out SLE and differentially diagnose other CTDs such as RA adds clarity to the rheumatologist&#8217;s assessment, thereby making the evaluation process more efficient and accurate. The clinical performance of our proprietary biomarkers and the convenience of a single blood draw make AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD an attractive choice among rheumatologists.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Lupus </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test employs our proprietary CB-CAPs technology and is the cornerstone of the SLE assessment within our more comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus measures activation of the complement system by quantifying the level of BC4d and EC4d in the patient&#8217;s blood. Rheumatologists choose to order the comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test or the more focused AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test based on medical necessity, which is determined by each patient&#8217;s symptoms and medical history. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> APS </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">APS consists of a specialized panel of eight autoantibody tests. This test aids in both the diagnosis and management of APS, a hyper-coagulation state leading to thrombosis, pregnancy complications, and even death. Rheumatologists would typically request the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> APS test in patients who initially tested positive for one or more APS biomarkers contained in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, or in the management of patients experiencing a high-risk pregnancy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Vasculitis AAV </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, we launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Vasculitis AAV which utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody, or ANCA, associated vasculitis, or AAV. AAV is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prognosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Prognostic </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic is a ten-biomarker panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, strokes and heart attacks related to lupus. Rheumatologists rely on insights from the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic test to help tailor their treatment approach. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Anti-CarP </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP, which measures anti-carbamylated protein antibody, or anti-CarP, was developed by the Leiden University Medical Center, and we introduced it as a biomarker-driven RA prognostic test through a distribution agreement with Inova Diagnostics, Inc. with the goal of identifying patients prone to more severe disease. We were the first commercial laboratory to make testing for anti-CarP available in the United States with the introduction of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP in 2018. This test uniquely addresses two major challenges facing rheumatologists today &#8211; (1) patients presenting with RA symptoms but lacking the common confirmatory blood tests for anti-RF or anti-CCP, known as sero-negative patients, and (2) the lack of a serologic indicator, which indicates a poor prognosis and helps guide treatment decisions. Anti-CarP can be positive in up to 26% of RA patients who are negative for anti-CCP. Furthermore, RA patients positive for Anti-CarP have an increased risk for more severe RA disease, including permanent joint damage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> PC4d </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> PC4d, introduced in 2018, reflects over 10 years of research efforts and employs our proprietary CB-CAPs technology. This proprietary CB-CAP biomarker measures platelet- bound C4d, or PC4d, and has been shown in clinical studies to have significant association with thrombosis and ischemic stroke in SLE. These thrombotic events can be among the most damaging and deadly forms of lupus flares and often strike without warning. Because of its strong association with thrombosis, we believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> PC4d promises to be a valuable tool for SLE disease monitoring. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Monitoring </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Monitor</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor is a six-biomarker blood test that employs our proprietary CB-CAPs technology and is intended to assess the condition of a patient that has been diagnosed with SLE. It offers a unique combination of biomarkers that measure for EC4d, which has shown greater accuracy in tracking disease activity than C3 and C4, and PC4d, which is associated with thrombosis risk in SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor offers additional insight into a patient&#8217;s disease activity as well as possible adverse events. Rheumatologists have limited methods for evaluating the extent of disease activity taking place inside the body of an SLE patient. They rely on imperfect biomarkers, overt symptoms or flares, and patient reported history, all of which leave the rheumatologists looking for greater insights. In surveys conducted with SLE patients, it has been reported that patients tend to under report their symptoms and over 70% of healthcare providers are unaware of this bias. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor demonstrates correlation to SLE disease activity and is therefore designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Additionally, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor measures EC4d, anti-C1q, C3, C4 and anti-dsDNA which can assist physicians with managing their lupus nephritis patients. Depending on disease severity, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor testing product may be utilized by patients multiple times a year and throughout their lives. We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor will play an increasingly important role in the management of SLE patients and further solidify the role and relationship of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for these patients. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2021, physicians will have the option to obtain complete blood counts with differential (CBC+diff) and serum creatinine and C-reactive protein measurements for their patients along with their AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor test order.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> MTX </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MTX is a patented and validated blood test that precisely measures blood levels of MTXPG, the active metabolite of methotrexate linked to disease control in RA patients. There is large variability in the way patients absorb and metabolize methotrexate, leaving rheumatologists unsure of what steps to take when a patient has an inadequate response. Methotrexate is the most widely prescribed drug by rheumatologists in the treatment of RA. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. When faced with a patient who is not responding to methotrexate therapy, the options include increasing the dose, switching to a parenteral delivery method and/or advancing to a more costly biologic therapy. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an appropriate response to methotrexate, also known as the therapeutic level, or if the MTXPG blood levels are too low to produce adequate effects. The rheumatologists can then make informed therapeutic decisions to optimize methotrexate therapy and give patients their best chance at achieving an optimal response. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX is compatible with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Touch, our low-volume test sample collection method that allows for a micro-volume blood sample to be collected anywhere from a simple fingerstick. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Touch has a number of advantages, including empowering rheumatologists to collect and submit samples without full phlebotomy services, convenience for patients who have trouble with venipuncture and potential patient self-collection. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> HCQ </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ is a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine, or HCQ, in whole blood as they treat patients with SLE and other CTDs, including RA. HCQ is typically prescribed to patients to control SLE disease activity and prevent flares. However, there is large variability in the response to HCQ therapy, the drug can sometimes take weeks or months to have a therapeutic effect and compliance has been documented to be an issue in CTD patients. We believe measuring HCQ makes the patient accountable, and also helps to determine whether HCQ blood levels are adequate and consistent with clinical efficacy. The addition of new and costly biologic therapies approved for the treatment of SLE may drive interest by all healthcare stakeholders, especially payors, to adopt an approach that optimizes a generic drug before advancing to a costlier alternative. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ is also compatible with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Touch. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Test Reports </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide the results of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in a comprehensive and easy-to-understand test report typically sent to rheumatologists within five business days following receipt of the blood specimen. As shown below, the result of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus portion of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report displays a gradient illustrating the likelihood of the presence of lupus, which facilitates interpretation and discussion of the result with the patient versus only reporting a numerical value. In addition, all biomarker results for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD are reported and organized by disease state, providing clarity and convenience for the rheumatologists. A sample of the full AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report is shown below: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CTD Report </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20201231_g3.jpg" alt="exdx-20201231_g3.jpg" style="height:844px;margin-bottom:5pt;vertical-align:text-bottom;width:657px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20201231_g4.jpg" alt="exdx-20201231_g4.jpg" style="height:842px;margin-bottom:5pt;vertical-align:text-bottom;width:661px"/></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Therapeutics </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, we entered into the Janssen Agreement to exclusively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic diseases, and we began direct promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to rheumatologists with our specialized salesforce in January 2019. We believe our salesforce allows us to reach the approximately 5,000 rheumatologists in the United States. Additionally, we believe that educating providers regarding SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has and will continue to facilitate greater acceptance of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX test can identify methotrexate patients with inadequate methotrexate exposure who are potential candidates for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapy. Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP test can identify RA patients with more severe disease requiring more aggressive therapy, such as anti-TNF biologics like SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We believe our strategy of integrating the promotion of testing products and therapeutics, combined with our specialized salesforce, uniquely position us to expand SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;s U.S. market share. We recognized co-promotional revenue of approximately $5.1 million and $1.5 million during the years ended December&#160;31, 2020 and 2019, respectively. For more information regarding the Janssen Agreement, including predetermined baselines and minimum promotion fee levels for 2021, see &#8220;&#8212;Agreements with Pharmaceutical Companies.&#8221; </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In recent years, advancements in the understanding of the autoimmune and autoimmune-related disease process have led to a significant number of novel biologic drugs and drug development initiatives, especially in RA and SLE, and we intend to leverage our integrated testing and therapeutics strategy to establish additional partnerships with a focus on the development and commercialization of therapeutics that are synergistic with our testing products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline and Growth Opportunities </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, we formed a Scientific Advisory Board consisting of national experts in the clinical management of rheumatic autoimmune diseases including RA and lupus to help guide the organization&#8217;s leadership team on the design and execution of research projects as well as weigh-in on known and anticipated advances in technologies affecting clinical management of autoimmune diseases. We believe there is significant potential to capitalize on our proprietary CB-CAPs and MTXPG technologies by integrating those technologies with commercially validated biomarkers to develop testing products with superior clinical utility. The complement pathway is widely implicated in the pathogenesis of a variety of conditions, including autoimmune diseases and organ transplant rejection, and emerging data suggests its implication in cancer development. We believe that our proprietary CB-CAPs technology, owing to its stability and reliability, will allow us to produce meaningful and differentiated proprietary solutions for rheumatologists. For example, we are focused on leveraging our proprietary CB-CAPs technology by developing a thrombosis risk score with PC4d in prognosing cardiovascular events in SLE. In addition, we are developing a panel of assays that we believe may have high diagnostic and/or prognostic value in patients with fibromyalgia, RA, Sj&#246;gren&#8217;s and myositis, and we continue to evaluate the use of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Touch and microfluidics for our broader portfolio of testing products to increase convenience and cost-effectiveness. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales and Marketing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our specialized salesforce is focused on targeting the approximately 5,000 rheumatologists across the United States. Our sales representatives generally have extensive experience in healthcare sales with backgrounds in rheumatology, biologics, specialty therapeutics and/or testing. In addition, our sales representatives complete a comprehensive disease-level sales training program and are required to participate in regular, ongoing training activities and certifications. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our sales model involves integrating the promotion of testing products and therapeutics in a unique approach that will enable our sales representatives to gain greater access and time with rheumatologists. The test information available to our sales representatives creates a different dynamic as compared to a traditional drug sales representative&#8217;s product detail. It enables a timely, extended, patient-focused discussion that naturally transitions to a therapeutic discussion during the same sales call. Our goal is for our sales representative to be viewed as a collaborative consultant versus a traditional drug sales representative. We intend to capitalize on our established reputation, market presence and expertise to sell additional products and services into the autoimmune and autoimmune-related disease market. We believe that a collaborative relationship with rheumatologists helps build a lasting sales channel through which additional products and services can be introduced. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, our overall sales team consisted of approximately 66 members. We have a salesforce of 53 representatives, who are managed by a team of seven regional sales directors. Our salesforce is organized into seven regions which include, Pacific, Southwest, Midwest, Great Lakes, Southeast, Atlantic and Northeast. As of December&#160;31, 2020, our salesforce was covering a total of 56 territories within the seven regions. We expanded the reach and frequency of our salesforce by adding seven new territories in 2021 for a total of 63 territories, as well as the creation of an inside salesforce to further our reach with rheumatologists in white space, complementing our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decentralized salesforce and covering vacant territories. In addition, we expect to increase our salesforce in 2021, which is expected to significantly increase the number of sales calls made per year, helping us to cultivate a strong collaborative relationship with rheumatologists through increased interactions. To further support our promotional efforts, we have a centralized, dedicated client services department with a high level of technical training that augments our specialized salesforce and marketing activities and enhances sales efficiency and customer satisfaction by providing personalized customer support. We believe our salesforce allows us to reach the approximately 5,000 rheumatologists in the United States.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Right Doctor, Right Message, Right Frequency </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our sales model of integrating the promotion of testing products and therapeutics will be complemented by our focused &#8220;high-touch&#8221; selling approach that emphasizes execution in three core areas: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">targeting, messaging and call frequency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We strategically </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">target</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the highest-potential practices by utilizing various data sources (e.g., market analytics, demographic data, historical biologic and diagnostic product usage trends). Furthermore, we believe the increased access afforded by our testing products will allow for patient-focused </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">messaging </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the increased accuracy of our testing products over current standard of care diagnostic methodologies. Finally, we execute a high-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">frequency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> promotional strategy for our top targeted rheumatologists and their office personnel to build knowledge, understanding and retention of the benefits of our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to leverage core channels for building awareness and adoption including our participation with multiple patient advocacy organizations, such as the Lupus Foundation of America, or LFA, and medical societies, such as the American College of Rheumatology, or ACR. We have also established strong relationships with multiple rheumatology care management organizations, or super groups, which can be key in influencing favorable reimbursement. Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX testing product has been included in the clinical guidelines for two of these groups. We believe our experience with advancing a testing product from initial development through clinical adoption differentiates us and uniquely positions us to replicate success with our other testing products. Beyond working with these groups, we intend to continue to augment field selling activity with a balanced marketing mix including print and digital advertising, direct marketing, continuing medical education programs and working with key opinion leaders to support peer-to-peer educational events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reimbursement, Clinical Validation and Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek reimbursement for our testing products from several sources, including commercial third-party payors, government payors and patients. Payment from commercial third-party payors differs depending on whether we have entered into a contract with the payor as a participating provider or do not have a contract and are considered to be an out-of-network provider. When we contract to serve as a participating provider, reimbursements are made pursuant to a percentage of our charges or a negotiated fee schedule amount. Where we are not reimbursed in full, we may elect to appeal the insurer&#8217;s underpayment or denial of payment or seek payment from the patient. We continue to focus on expanding coverage among existing contracted providers and achieving coverage with commercial payors, laboratory benefit managers and evidence review organizations. We employ a multi-pronged strategy designed to achieve broad coverage and reimbursement for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Meet the evidence standards necessary to be consistent with leading clinical guidelines. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe inclusion in leading clinical guidelines plays a critical role in payors&#8217; coverage decisions. In order to change clinical guidelines, tests must carry a high level of published evidence demonstrating analytical validity, clinical validity, clinical utility and cost effectiveness. When studies with such evidence are published in peer-reviewed journals, the authors of clinical guidelines may assess the level of evidence and determine whether modifying existing guidelines to include new technology is warranted. For example, we previously conducted peer-reviewed, published clinical studies for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus which helped us secure favorable coverage from various commercial plans. We have conducted, and continue to conduct, clinical validation and clinical utility studies for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, which we believe will provide a basis for the ACR White Paper and/or UpToDate to consider inclusion of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus in their respective guidelines. In the future, we also intend to conduct similar studies in order to develop similar supporting literature with respect to our other testing products.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Execute an internal managed care policy and claims adjudication function as part of our core business operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We employ a team of in-house claims processing and reimbursement specialists who work with patients and payors to obtain maximum reimbursement. In parallel, a managed care team collaborates with our reimbursement specialists to ensure our payor outreach strategy reacts and anticipates the changing needs of our customer base. Our customer service team is an integral part of our reimbursement strategy, working with patients and rheumatologists to navigate the claims process.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Cultivate a network of key opinion leaders. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Validation </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus in a study of 794 patients conducted from 2010 to 2014 across multiple leading academic centers. The primary endpoint of the study was the specificity and sensitivity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus compared to common autoantibodies used to diagnose SLE and other CTDs, such as ANA and anti-dsDNA. The final results of this study showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other CTDs and fibromyalgia, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We further demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus for detection of probable SLE, or pSLE, in a 246 subject multi-center, prospective, cross-sectional study, first published in the Arthritis &amp; Rheumatology Journal in September 2019. The objective of this study was to evaluate the frequency of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and CB-CAPs as a marker of complement activation in patients with pSLE and the usefulness of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test as a predictor of the evolution of pSLE into classified SLE by the ACR criteria. Of the 92 pSLE patients, more pSLE were positive for CB-CAPs (28%) or AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (40%) than for low complement (9%) at the enrollment visit (p=0.0001, for each) and an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus index score &gt;0.08 prospectively associated with the development from pSLE to SLE by ACR classification criteria within 18 months (hazard ratio = 3.11, p&lt;0.01).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have collaborated with both academic and community clinicians to demonstrate the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic tests in physician diagnosis, impact on patient management decisions, patient reported outcomes and health economics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sponsored a longitudinal, case-control, retrospective review of medical charts in 2016 to assess the value and clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus to rheumatologists. The results of this study were published in the Open Rheumatology Journal in 2016 and suggested that a positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test aids in the diagnosis of SLE versus standard diagnostic tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2018, we initiated CARE for Lupus, a prospective, randomized, multi-site study to assess the performance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic laboratory tests, or SDLT. A total of 145 patients were enrolled across 32 sites between July 2017 and December 2018, with 73 patients enrolled in the SDLT group and 72 patients in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group. The CARE study was published in September 2019 in Lupus Science &amp; Medicine. Results showed among patients who tested positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=9), 44% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a higher likelihood of SLE, compared with 9% in the SDLT group (p=0.127), whereas among patients who tested negative for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=63), 60% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a lower likelihood of SLE, compared with 37% in the SDLT group (p=0.012). In the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, positive test results associated significantly with initiation of prednisone (p=0.03) and a similar trend was observed with HCQ therapy (p=0.11). Finally, in the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, a positive test result associated with an increase in patient-reported outcomes measuring health-related quality of life using five-level EQ-5D, or EQ5D-5L index score, from enrollment to visit 2 (p=0.028), and greater improvements were detectable when compared to the group of patients positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and randomized to the SDLT arm (p=0.049).  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Economics</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, a study in collaboration with leading health economic experts was published in the journal ACR Open Rheumatology, titled "Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel (MAP)." This was the first ever evaluation of the economics of diagnosing SLE with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (MAP) compared to standard diagnostic laboratory tests in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated an estimated total direct cost savings of approximately $2.0 million, or $1,991 per patient. In addition, the year one savings was $655,403, or $655 per eligible patient, with the use of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, which aligns with early benefit to health plans looking for savings in the first year. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The above referenced studies are included in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus Dossier. In March 2020, we announced coverage and in-network contract with three California Medical Groups followed by coverage and an in-network agreement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with TRICARE East Humana Military and Highmark BCBS coverage policy. We anticipate continued coverage determinations and in-network contracting announcements in 2021 and beyond. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our reimbursement strategy, including establishing the clinical validation, clinical utility and health economics of our testing products will continue to allow us to drive an expansion in reimbursement coverage for our testing products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Laboratory Operations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in our approximately 8,000 square foot clinical laboratory, which is certified by the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists, or CAP, and located in Vista, California. Our laboratory is certified for the performance of high-complexity testing by the Centers for Medicare and Medicaid Services, or CMS, in accordance with CLIA. We are approved to offer our products in all 50 states. Our clinical laboratory reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product results within five business days. In the fourth quarter of 2020, we completed the build-out of approximately 2,000 additional square feet to our clinical laboratory. We believe that our existing laboratory facilities are adequate to meet our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quality Assurance </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quality assurance function oversees the quality of our laboratory as well as research and development, client services, billing, sales and marketing operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions, and employee training processes that we believe achieves excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products is traditional methods used by healthcare providers to test patients with CTD like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Progentec Diagnostics Inc., Scipher Medicine Corporation, Genalyte Inc., Oncimmune plc, DxTerity Diagnostics Inc. and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Direct competition for the promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes all other companies with anti-TNF biologics and the marketing companies supporting their distribution and promotion. These products include HUMIRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Abbvie Inc., ENBREL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Amgen Inc., CIMZIA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from UCB, INFLECTRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Pfizer Inc., or Pfizer, (biosimilar REMICADE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and RENFLEXIS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Merck &amp; Co. (biosimilar REMICADE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). Additionally, we are restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the Janssen Agreement without Janssen's consent. Additional competitors include companies with other biologic drugs indicated for RA that have significant sales or sales potential. Specifically, these include ORENCIA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Bristol-Myers Squibb Company, ACTEMRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Roche Holding AG, or Roche, RITUXAN</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Roche, XELJANZ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Pfizer, KEVZARA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Sanofi S.A., RINVOQ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Abbvie Inc. and OLUMIANT</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Eli Lilly and Company. There are also several late-stage RA drug and biosimilar development programs and several additional RA products that have minimal sales to date or that are indicated for other rheumatic indications competitive to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> such as psoriatic arthritis and ankylosing spondylitis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; safety and efficacy with respect to promoted therapeutics; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Agreements with Pharmaceutical Companies </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janssen Agreement </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, we and Janssen entered into the Janssen agreement to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. We are responsible for the costs associated with our salesforce over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> under the Janssen agreement. In exchange for our sales and co-promotional services, we are entitled to a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over a predetermined baseline for the quarters ended March 31, 2019 to December 31, 2020. The predetermined average baseline for quarters ended March 31, 2019 to March 31, 2020 was approximately 29,000 prescribed units per quarter, subject to adjustment under certain circumstances. In June 2020, due in part to COVID-19, we amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for each remaining quarter in 2020, starting with the quarter ending June 30, 2020, was adjusted from approximately 29,000 to approximately 26,000 prescribed units per quarter, and subject to adjustment under certain circumstances. For each of the third and fourth quarters of 2020, we received a minimum promotion fee of $0.3 million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, we further amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021 was adjusted to approximately 28,750 prescribed units per quarter, subject to further adjustment under certain circumstances. For the first and second quarter of 2021, we will be entitled to an amended quarterly tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over the predetermined baseline. We refer to the Janssen Agreement, as amended in June 2020 and December 2020, as the Amended Janssen Agreement. Pursuant to the Amended Janssen Agreement, for each of the first and second quarters of 2021, we will receive a minimum promotion fee of $0.3 million and the fee will be capped at 10% above the adjusted predetermined baseline. We continued to receive a minimum promotion fee of $0.3 million and the fee was capped at 5% above the adjusted predetermined baseline for the quarter ended December 31, 2020. The quarterly tiered promotion fee for the remaining term of the Amended Janssen Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to the amendment, with no minimum promotion fee and no cap on predetermined baseline units.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Janssen Agreement expires on December 31, 2021, unless extended by us for an additional 12 months upon 180 days written notice prior to the end of the current term. If we elect to extend the term, the predetermined baseline for 2022 will be subject to future agreement by us and Janssen. Janssen can terminate the agreement at any time for any reason upon 30 days&#8217; notice to us, and we can terminate the agreement for any reason at the end of any calendar quarter upon 30 days&#8217; notice to Janssen. Either party may terminate the agreement in the event of the other party&#8217;s default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Agreement with GSK </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2018, we entered into a collaboration agreement with GSK, pursuant to which we provide GSK with our test result data to provide market insight into and help increase awareness on the benefits of an early and accurate diagnosis of SLE. The agreement was amended in November 2018 to, among other things, include data from our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ testing products and extend the term of the agreement through December 31, 2019. The agreement was further amended in November 2019 and November 2020 to, among other things, extend the term of the agreement through December 31, 2020 and December 31, 2021, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are required to deliver weekly de-identified data files to GSK covering all data obtained from the performance of certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, subject to applicable requirements under the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, internal policy requirements and other applicable laws. During the term of the agreement, the data we provide to GSK may not be provided, directly or through a third party, to any other pharmaceutical company that is marketing or developing a product for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment of SLE. GSK made a single upfront payment in exchange for the right to receive the applicable data files. In addition, GSK has agreed to create a joint steering committee to cooperate with us in order to raise awareness and physician support for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, including through the development and delivery of approved promotional materials and the implementation of a related training plan for each party&#8217;s sales personnel. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The joint committee will meet at least 120 days prior to the end of the term of the agreement in order to discuss renewal options. Either party may terminate the agreement for breach and, in certain cases, such breach must remain uncured for a certain period of time following receipt of written notice of such breach. In addition, GSK may terminate the agreement immediately if we become insolvent or for convenience upon 60 days&#8217; prior written notice. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our testing products and services and any other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, to defend and enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to preserve the confidentiality of our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our testing products and services. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial know-how and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for the diagnosis, prognosis and monitoring of autoimmune and autoimmune-related diseases, and are generally directed to CB-CAPs, red blood cell MTXPG exposure assessments, and anti-MCV antibodies. We intend to leverage the intellectual property surrounding our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products as an important component of our business strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Protection for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Testing Products </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of patents and patent applications related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products generally relates to three aspects: CB-CAPs, red blood cell MTXPG exposure assessments, and anti-MCV antibodies. The patent families which we believe are important for the protection of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are summarized below in the section entitled &#8220;&#8212;License Agreements.&#8221; As of February 8, 2021, our portfolio primarily consisted of the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CB-CAPs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the exclusive licensee of five patent families related to CB-CAPs technology from the University of Pittsburgh, or UPitt. We expect that these patent families (U.S. Patent Nos. 7,361,517; 7,390,631; 7,585,640; 7,588,905; 8,080,382; and 8,126,654) will expire in 2024 or 2025. A foreign patent corresponding to U.S. Patent No. 7,361,517 has issued in Europe (EP 1,756,571). Foreign patents corresponding to U.S. Patent No. 7,390,631 have issued in Japan (JP 4570872 and JP 4906898). Foreign patents corresponding to U.S. Patent No. 7,585,640 have issued in Australia (AU 2005242719) and Canada (CA 2,564,492). A foreign patent corresponding to U.S. Patent Nos. 7,588,905 and 8,126,654 has issued in Japan (JP 4550051). We also own one issued patent (US 10,132,813), two pending U.S. nonprovisional patent applications, a pending PCT application, and a pending U.S. provisional application that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus products. Foreign patents corresponding to US 10,132,813 have issued in Europe (EP 2,673,644) and Japan (JP 5,990,542) and Hong Kong (HK112316). In order to manage our foreign filing costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of several of our foreign patents and patent applications related to our CB-CAPs technology, including EP 1,432,731; EP 1,618,379; EP 1,635,692; EP 1,745,287; EP 2,214,014; EP 2,216,650, and certain of their corresponding family members</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTX Exposure Assessment Products and Services </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the exclusive licensee of four patents that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX product and methods for monitoring methotrexate therapy using red blood cell MTXPG exposure assessments. These patents and patent applications are owned by Prometheus and are exclusively licensed to us for all uses except for use in gastrointestinal diseases. These patents include U.S. Patent Nos. 6,921,667; 7,563,590; 7,582,282 and 7,695,908, which are expected to expire between 2023 and 2027. We also are the exclusive licensee of two issued US patents (US 9,261,509 and US 9,822,391) that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Proprietary Rights and Processes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may rely, in some circumstances, on proprietary technology and processes (including trade secrets) to protect our technology. However, these can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors, or any future collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221; </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">License Agreements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amended and Restated Exclusive License Agreement with the University of Pittsburgh </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2011, we entered into an amended and restated exclusive license agreement with UPitt, to amend and restate the exclusive license agreement we obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, or the Cypress Purchase, and to obtain an exclusive license to UPitt&#8217;s patent rights in certain inventions, or the UPitt Patent Rights, related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. The agreement was amended three times, once in May 2012 to, among other things, limit the territory of the license to the United States and exclude certain foreign patents and applications from the agreement, once in September 2013 to add (1) an additional U.S. patent to the UPitt Patent Rights licensed under the agreement and (2) the field of monitoring of organ transplantation and organ rejection to the scope of the license, and once in June 2016 to, among other things, clarify the definition of combination products for determining royalties due under the license. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection, and to sublicense such rights. UPitt retained the right to practice under the UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In addition, this agreement is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent Rights throughout the world. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the first and second anniversaries of the agreement that increased on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We also made a $0.2 million milestone payment to UPitt with the achievement of certain levels of net sales which we met in 2014. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the UPitt Patent Rights, and we have agreed to meet certain development and commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. In addition, if we fail to meet a milestone relating to development of the UPitt Patent Rights in the monitoring of organ transplantation and organ rejection field, UPitt may remove that field from our licensed rights. We are currently in compliance with these milestone requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon six months&#8217; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement with the University of Pittsburgh </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We made an economic decision to cease the maintenance and licensing of UPitt Patent Rights outside the United States, which led to such rights returning to UPitt. We subsequently made the determination to re-license these foreign patent rights from UPitt, but at the time of re-licensing these patent rights, a number of the foreign patent rights had permanently lapsed. Accordingly, in September 2013, we entered into an exclusive license agreement with UPitt to obtain an exclusive license to UPitt&#8217;s remaining ex-U.S. patent rights in certain inventions, or the ex-U.S. UPitt Patent Rights, related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the ex-U.S. UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection outside of the United States, and to sublicense such rights. UPitt retained the right to practice under the ex-U.S. UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to UPitt. We are also required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the ex-U.S. UPitt Patent Rights sold by us or our affiliates, subject to adjustment in certain circumstances. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the ex-U.S. UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed ex-U.S. UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the ex-U.S. UPitt Patent Rights, and we have agreed to meet certain commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. We are currently in compliance with these milestone requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon six months&#8217; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License Agreement with Prometheus Laboratories, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Cypress Purchase, we acquired a license agreement, dated September 2007, between Prometheus Laboratories, Inc., or Prometheus, and Proprius Pharmaceuticals, Inc., or Proprius, a company which had been previously acquired by Cypress. Pursuant to this agreement, we obtained an exclusive, worldwide license to Prometheus&#8217;s patent rights in certain inventions, or the Prometheus Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and services. This agreement was subsequently amended in October 2013. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to research, develop, manufacture and commercialize products utilizing the Prometheus Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with Prometheus&#8217;s consent. We are not permitted to develop or commercialize products utilizing the Prometheus Patent Rights for use in diagnosing or treating any gastrointestinal diseases or to promote any such products to gastroenterologists. Pursuant to the agreement, we are obligated to use reasonable commercial efforts to undertake certain development activities with respect to products utilizing the Prometheus Patent Rights, including the completion of certain clinical studies. In addition, in the event that we do not timely complete these studies or approved substitute studies, we will become obligated to pay to Prometheus a one-time payment of $50,000. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to make a milestone payment of $2.0 million upon the achievement of certain net sales. In addition, we are required to pay Prometheus tiered royalties in the mid-single-digit range on sales of any products utilizing the Prometheus Patent Rights by us, our affiliates or our sublicensees. Our royalty obligations continue on a licensed-product-by-licensed-product and country-by-country basis until the expiration, lapse or invalidation of the last valid claim in a licensed patent covering the applicable licensed product in such country. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the Prometheus Patent Rights, we are obligated to pay to Prometheus a fee based on a percentage of sublicense fees received by us, which percentage is in the mid-twenties. In addition, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are also required to pay to Prometheus a percentage of the royalty payments we receive from our sublicensees, which may not be less than a certain low single-digit percentage of net sales of products or services sold by our sublicensees that utilize the sublicensed Prometheus Patent Rights, nor more than a certain mid-single digit percentage of such net sales. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may unilaterally terminate the agreement for any reason upon 60-days&#8217; written notice to Prometheus. Either party may terminate the agreement in the event of the other party&#8217;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach or in the event of the other party&#8217;s insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Prometheus Patent Rights. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Asset Purchase Agreement with Cypress (Royalty Pharma) and Proprius </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2010, we completed the Cypress Purchase pursuant to an asset purchase agreement with Cypress and its wholly-owned subsidiary, Proprius, under which we obtained certain assets related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and services. The agreement was amended six times, once in March 2011 to change certain obligations relating to certain accounts receivable we acquired from Cypress, once in August 2012 to convert a one-time payment obligation to a payment plan over four years with interest, once in February 2013 to convert a one-time contingent milestone payment obligation concerning a CB-CAPs monitoring assay to a payment plan over two years with interest, once in October 2013 to, among other things, provide consent for Exagen to use its IP as collateral on a financing round, once in January 2016 to restate an annual sales milestone, and once in February 2017 to restate specifics of the monitoring assay royalty.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2011, Royalty Pharma Collection Trust, or Royalty Pharma, acquired Cypress and became its successor-in-interest under the agreement. In consideration for the acquisition, we made certain initial cash payments to Cypress and we are currently making payments to Royalty Pharma, as a successor-in-interest to Cypress, pursuant to the August 2012 amendment, which payments are subject to acceleration in certain circumstances. Under our agreements with Royalty Pharma, we are required to pay Royalty Pharma a low double-digit royalty on the world wide net sales of CB-CAPs products and a low double-digit royalty on the net sales of certain new products in each case, for a period of eight years, which eight year period expired in January 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are required to make certain one-time contingent milestone payments for two third-party commercial programs, for the launch of a CB-CAPs monitoring assay, and for the achievement of an annual, worldwide net sales level for CB-CAPs products. Our agreement with Royalty Pharma requires that we use commercially reasonable efforts to cause each of the milestones to be achieved. In December 2015, we achieved the specified annual world-wide nets sales of CB-CAPs products which required us to make a $2.0 million milestone payment to Royalty Pharma. We paid the applicable $2.0 million milestone payment in 2016. In February 2017, we amended our agreements with Royalty Pharma relating to the launch of a monitoring product using CB-CAPs technology. As a result of this amendment, a prior obligation to make a one-time payment of $1.0 million upon the launch of a monitoring product incorporating CB-CAPs technology was replaced with an agreement to pay Royalty Pharma a one-time payment of $100,000 upon the launch of such a product, plus a 2.5% royalty based on future cash collections from sales of that product which incorporate the licensed technology. Future royalties under this arrangement are limited to the lesser of $1,200,000 (including the upfront payment of $100,000) or the total royalty earned through January 1, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dr. Thierry Dervieux and De Novo Diagnostics, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2011, we entered into a license agreement with Dr. Thierry Dervieux, our former Chief Scientific Officer, and his company De Novo Diagnostics, Inc., under which we obtained an exclusive, worldwide (except for Australia and New Zealand) license to Dr. Dervieux&#8217;s patent rights and know-how in certain inventions, or the Dervieux Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and services. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to develop, manufacture and commercialize products utilizing the Dervieux Patent Rights in the human healthcare market, and to sublicense such rights. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In considerations for the rights granted to us under the agreement, we are required to make milestone payments, up to an aggregate of $600,000, upon achievement of certain sales milestones. In addition, we are required to pay Dr. Dervieux a mid-single-digit royalty on net sales by us or our affiliates of any products utilizing the Dervieux Patent Rights, subject to adjustment in certain circumstances. We are also obligated to pay Dr. Dervieux a percentage in the mid-twenties of sublicense fees and royalties received by us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the Dervieux Patent Rights, and we have agreed to use commercially reasonable efforts to bring technology covered by the Dervieux Patent Rights to market as soon as practicable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may unilaterally terminate the agreement upon 12 months&#8217; written notice to Dr. Dervieux. Either party may terminate this agreement in the event of the other party&#8217;s nonperformance of any of its obligations under the agreement if such nonperformance remains uncured for a specified period of time following receipt of written notice of such nonperformance or in the event of the other party&#8217;s insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Dervieux Patent Rights. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Laboratory Improvement Amendments of 1988 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a clinical reference laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA compliance and certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have current certification under CLIA to perform testing at our Vista facility. To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for non-compliance with CLIA requirements include suspension, limitation or revocation of the laboratory&#8217;s CLIA certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">State Laboratory Licensing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to federal certification requirements of laboratories under CLIA, licensure is required and maintained for our Vista clinical reference laboratory under California law. Such laws establish standards for the day-to-day operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we receive specimens from New York, our clinical reference laboratory is required to be licensed by New York, under New York laws and regulations, which establish standards for:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">physical requirements of a facility;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">equipment; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">validation and quality control.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in New York. If a laboratory is out of compliance with New York statutory or regulatory standards, the New York Department of Health, or NYDOH, may suspend, limit, revoke or annul the laboratory&#8217;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#8217;s operator being found guilty of a misdemeanor under New York law. NYDOH also must approve the LDT before the test is offered in New York. We have received written approval from NYDOH to offer our products in New York.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to New York and California, other states, including Maryland, Pennsylvania and Rhode Island, require licensing of out-of-state laboratories under certain circumstances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal Oversight of Laboratory Developed Tests </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests like AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX are regulated under CLIA, as administered by CMS, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro testing products are considered by the FDA to be subject to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are designed, manufactured, and used within a single laboratory for use only in that laboratory, which are referred to as laboratory developed tests, or LDTs. We believe that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX are LDTs, as are our near-term pipeline candidate tests. As a result, we believe many of our diagnostic services are currently subject to the FDA&#8217;s enforcement discretion and are not subject to the FDA&#8217;s oversight. However, reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Legislative and administrative proposals proposing to amend the FDA&#8217;s oversight of LDTs have been introduced in recent years and we expect that new legislative and administrative proposals will continue to be introduced from time to time. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory requirements for us to continue to offer our LDTs or to develop and introduce new tests as LDTs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, in recent years, FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. For example, on July 31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October 3, 2014, the FDA issued two draft guidance documents entitled &#8220;Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),&#8221; or the Framework Guidance, and &#8220;FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs),&#8221; or the Reporting Guidance. The Framework Guidance stated that FDA intends to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the classification of medical devices generally in Classes I through III. The Reporting Guidance would have further enabled FDA to collect information regarding the LDTs currently being offered for clinical use through a notification process, as well as to enforce its regulations for reporting safety issues and collecting information on any known or suspected adverse events related to the use of an LDT. On November 18, 2016, the FDA announced that it would not finalize either guidance document to allow for further public discussion on an appropriate oversight approach to LDTs and to give Congressional authorizing committees the opportunity to develop a legislative solution, and the FDA issued a discussion paper on possible approaches to LDT regulation in January 2017. Moreover, in August 2020, the U.S. Department of Health and Human Services announced that FDA will not require premarket review of LDTs absent notice-and-comment rulemaking, as opposed to through guidance documents and other informal issuances.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA could ultimately modify its current approach to LDTs in a way that would subject LDTs to additional regulatory requirements. Moreover, legislative measures have could likewise result in a change to the approach to FDA's regulation over LDTs, including a requirement for premarket review of LDTs, among other things.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medical Device Regulatory Framework </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we currently market our proprietary testing products as LDTs, which are currently subject to enforcement discretion, we could be subject to more onerous FDA compliance obligations in the future. Specifically, if the FDA begins to actively regulate LDTs, then, unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the U.S. will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a premarket approval, or PMA, application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Device Classification </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the FDCA, medical devices are classified into one of three classes-Class I, Class II or Class III depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#8217;s quality system regulation, or QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Class II devices are those that are subject to the General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time-consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The 510(k) Clearance Process </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. The de novo classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which are low to moderate risk. A manufacturer can submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. De novo classification may also be available after receipt of a &#8220;not substantially equivalent&#8221; letter following submission of a 510(k) to FDA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite application(s).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.  For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. These proposals have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More recently, in September 2019, the FDA published revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the recommended testing methods for such device types.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The PMA Approval Process </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes to ensure compliance with the QSR. PMA devices are also subject to the payment of user fees, and an annual establishment registration fee.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use. New PMA applications or PMA supplements may also be required for modifications to any approved diagnostic tests, including modifications to our manufacturing processes, device labeling and device design, based on the findings of post-approval studies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Trials</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, the sponsor, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Post-market Regulation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establishment registration and device listing with the FDA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#8216;&#8216;off-label&#8217;&#8217; uses of cleared or approved products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">requirements related to promotional activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Device manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, will be subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, manufacturing operations and the recall or seizure of products. The discovery of previously unknown problems with any marketed medical device products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on a medical device, including the removal of the product from the market or voluntary or mandatory device recalls.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">recalls, withdrawals, or administrative detention or seizure of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refusal to grant export approvals; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Physician Self-Referral Prohibitions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions, such as California&#8217;s Physician Ownership and Referral Act, or PORA, and other comparable state laws. Together these restrictions generally prohibit us from billing a patient or any governmental or private payor for certain designated health services, including clinical laboratory services, when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a financial interest, such as an ownership or investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanctions for a Stark Law violation include the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">denial of payment for the services provided in violation of the prohibition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">refunds of amounts collected by an entity in violation of the Stark Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">significant civil penalties for each bill or claim for a service arising out of the prohibited referral, and additional penalties for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law's prohibition;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the imposition of up to three times the amounts for each item or service wrongfully claimed; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">possible exclusion from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These prohibitions apply regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act, which can result in additional civil and criminal penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, a violation of PORA is a misdemeanor and could result in civil penalties and criminal fines. Other states also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or California law. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Anti-Kickback Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal Anti-kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce business that is reimbursable under any federal health care program. A violation of the Anti-kickback Statute may result in imprisonment for up to ten years and significant fines for each violation and additional administrative civil money penalties, plus up to three times the amount of the remuneration paid. Convictions under the Anti-kickback Statute result in mandatory exclusion from federal health care programs for a minimum of five years. In addition, The U.S. Department of Health and Human Services, or HHS, has the authority to impose civil assessments and fines and to exclude health care providers and others engaged in prohibited activities from Medicare, Medicaid and other federal health care programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the Anti-kickback Statute constitutes a false or fraudulent claim under the Federal False Claims Act, which is discussed in greater detail below. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Anti-kickback Statute applies only to items and services reimbursable under any federal health care program, a number of states, including California, have passed statutes substantially similar to the Anti-kickback Statute that apply to all third-party payors, including commercial insurers, and in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as HHS and the courts have interpreted the Anti-kickback Statute. Penalties of such state laws include imprisonment and significant monetary fines. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal and state law enforcement authorities scrutinize arrangements between health care providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. Generally, courts have taken a broad interpretation of the scope of the Anti-kickback Statute, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to statutory exceptions to the Anti-kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor, it is deemed not to violate the Anti-kickback Statute. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to meet the requirements of the safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances. There are no regulatory safe harbors under California laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Federal and State Health Care Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the requirements discussed above, several other health care fraud and abuse laws could have an effect on our business. For example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal health care programs substantially in excess of its usual charges for its services. The terms &#8220;usual charge&#8221; and &#8220;substantially in excess&#8221; are subject to varying interpretations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval and from, making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim in order to secure payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government intervenes and is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government&#8217;s involvement, then the plaintiff </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions that prohibit the filing of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in fines, imprisonment or both, and possible exclusion from Medicare or Medicaid programs. Several states, including California, have enacted comparable false claims laws which may be broader in scope and may apply regardless of payor. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. A person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for significant civil monetary penalties for each wrongful act and up to three times the amount improperly claimed. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and False Claims Act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of Inspector General of HHS, or OIG, emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by commercial payors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, among other things, also imposed annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians (as defined under the statute) and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the fraud and abuse laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">International Regulations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the U.S. Foreign Corrupt Practices Act, or FCPA, and/or other applicable anti-corruption laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, including its books and records provisions and its anti-bribery provisions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of intent and knowledge under the FCPA&#8217;s anti-bribery provisions is minimal intent and knowledge are usually inferred from the fact that bribery took place. The FCPA&#8217;s accounting provisions do not require intent. Violations of the FCPA&#8217;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the UK Bribery Act. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When marketing our testing products outside of the U.S., we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the U.S. or the import of tissue into the U.S., and marketing approval. These requirements vary by jurisdiction, differ from those in the U.S. and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the U.S., coverage, pricing and reimbursement approvals are also required. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Privacy and Security Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Data Privacy and Security Laws</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by certain entities including health care providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in certain health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA and HITECH laws and regulations include civil and criminal penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities as well as business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a business associate. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The HIPAA security regulations establish requirements for safeguarding the confidentiality, integrity, and availability of PHI that is electronically transmitted or electronically stored. The HIPAA breach notification regulations impose certain reporting requirements on covered entities and their business associates in the event of a breach of PHI. The HIPAA privacy and security regulations establish a uniform federal &#8220;floor&#8221; and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, such as us, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">litigation. The State of California, for example, recently adopted the California Consumer Privacy Act of 2018, or the CCPA, which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. It also creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GDPR and Foreign Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to foreign privacy laws in the foreign jurisdictions in which we sell our testing products. The interpretation, application and interplay of consumer and health-related data protection laws in the U.S., Europe and elsewhere are often uncertain, contradictory and in flux. In Europe, the General Data Protection Regulation, or GDPR, went into full effect in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is collected and used, limitations on retention of information, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data, mandatory data breach notification requirements, more robust rights for individuals in regard to their personal data and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. It provides that European Union, or EU, and European Economic Area, or EEA, member states may make their own further laws and regulations, which may impose further limitations, including in relation to the processing of biometric or health data, which may result in differences between member state laws, limit our ability to use and share personal data, cause our costs to increase, and/or harm our business and/or financial condition. Among other requirements, the GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the European Union, or EU, and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Billing and Government Reimbursement for Clinical Laboratory Services </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. With respect to Medicare coverage, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare&#8217;s molecular diagnostic services program, or MolDX Program, issued a local coverage determination, or LCD, that provides coverage for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX test. The MAC responsible for administering Medicare claims submitted by our laboratory, Noridian Healthcare Solutions, has adopted Palmetto&#8217;s positive coverage policy, along with a related local coverage article that identifies a unique billing identifier for this test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Medicare, payment for our laboratory tests are generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act, or PAMA, which included substantial changes to the way in which clinical laboratory services will be paid under Medicare. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule are required to report to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS, beginning in 2017 and every three years thereafter (or annually for &#8220;advanced diagnostic laboratory tests&#8221;), private payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As required under PAMA, CMS uses the rates and volumes reported by laboratories to develop Medicare payment rates for laboratory tests equal to the volume-weighted median of the private payor payment rates for the tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests are based upon these reported private payor rates. For clinical diagnostic laboratory tests that are assigned a new or substantially revised CPT code, initial payment rates will be assigned by the gap-fill methodology, as under prior law. Initial payment rates for new advanced diagnostic laboratory tests will be based on the actual list charge for the laboratory test. Any reductions to payment rates resulting from the new methodology are limited to 10% per test per year in each of the years 2018 through 2020 and to 15% per test per year in each of the years 2021 through 2023. At the beginning of 2020, PAMA&#8217;s impact on Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD was a reduction of 7.3% compared to levels experienced in 2019. Effective March 2020, as a result of our change in the composition of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, PAMA's impact on Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD was a reduction of 5.3% compared to levels experienced in 2019. We do not expect PAMA to impact Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2021 compared to levels experienced in 2020. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, signed into law on March 27, 2020 provides clinical laboratories a one-year reprieve from reporting requirements under the Protecting Access to Medicare Act, as well as a one-year delay of rate cuts scheduled to take place next year. Reporting was not required between January 1, 2020 to December 31, 2020. Instead, it is required between January 1, 2022 and March 31, 2022. Additionally, the next round of rate cuts was pushed from 2021 to 2022, with tests receiving cuts of up to 15% a year from 2022 through 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PAMA also authorizes the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests, as well as advanced diagnostic laboratory tests. The AMA&#8217;s CPT Editorial Panel has approved a proposal to create a new section of billing codes to facilitate implementation of this section of PAMA. These proprietary laboratory analyses codes, or PLA codes, may be requested by a clinical laboratory or manufacturer to specifically identify their test. If approved, the codes are issued by the AMA on a quarterly basis. While our testing products are not presently identified by any PLA codes, we may seek a specific PLA code or codes to describe some of our testing products in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for diagnostic testing can be complicated. Depending on the billing arrangement and applicable law, we must bill various payors, such as insurance companies, Medicare, Medicaid, physicians, hospitals, employer groups and patients, all of which have different billing requirements. Additionally, compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. Changes in laws and regulations could negatively impact our ability to bill our clients or increase our costs. CMS also establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing government programs. Missing or incorrect information on test requisitions adds complexity to and slows the billing process, creates backlogs of unbilled tests, and generally increases the aging of accounts receivable and bad debt expense. Failure to timely or correctly bill may lead to our not being reimbursed for our services or an increase in the aging of our accounts receivable, which could adversely affect our results of operations and cash flows. Failure to comply with applicable laws relating to billing federal healthcare programs could also lead to various penalties, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">overpayments and recoupments of reimbursement received;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">exclusion from participation in Medicare/Medicaid programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">asset forfeitures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">civil and criminal fines and penalties; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the loss of various licenses, certificates and authorizations necessary to operate our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these penalties or sanctions could have a material adverse effect on our results of operations or cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Healthcare Reform </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2010, the ACA was enacted in the U.S. The ACA made a number of substantial changes to the way healthcare is financed by governmental and private insurers. The ACA, among other things, included provisions governing enrollment in federal and state healthcare programs, reimbursement matters and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict. Additionally, on December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the tax-based shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which went into effect on April 1, 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additional state and federal health care reform measures may also be adopted in the future, any of which could have a material adverse effect on the clinical laboratory industry.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, we had 181 full-time employees, and 2 part-time employees in the United States. These included 35 in laboratory operations, 12 in research and development, 71 in sales and marketing and 63 in general and administrative functions. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability to support our business and operations, our pipeline, and also protect the long-term interests of our securityholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages and ensuring we listen to our employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We value innovation, passion, data-driven decision making, persistence and honesty, and are building a diverse environment where our employees can thrive and be inspired to make exceptional contributions to bring novel testing products to patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, motivating and integrating our existing and future employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through grants of stock-based compensation awards and payments of cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives. We are committed to providing a competitive and comprehensive benefits package to our employees. Our benefits package provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our employees. We plan to continue to refine our efforts related to optimizing our use of human capital as we grow, including improvements in the way we hire, develop, motivate and retain employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Suppliers </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for the critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also purchase components used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Information </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We manage our operations and allocate resources as a single reporting segment. Financial information regarding our operations, assets and liabilities, including our net loss for the years ended December 31, 2020 and 2019 and our total assets as of December 31, 2020 and 2019, is included in our Financial Statements in Item 8 of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we change our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261 Liberty Way, Vista, California 92081. Our telephone number is (760) 560-1501. Our website address is www.exagen.com. The information contained in, or accessible through, our website is not part of, and is not incorporated by reference into, this Annual Report. Investors should not rely on any such information in deciding whether to purchase our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other information with the Securities and Exchange Commission, or SEC. Our filings with the SEC are available free of charge on the SEC&#8217;s website at www.sec.gov and on the &#8220;Investors&#8221; section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. You may also read and copy, at SEC prescribed rates, any document we file with the SEC at the SEC&#8217;s Public Reference Room located at 100 F Street, N.E., Washington D.C. 20549. You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, including our financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in this Item 1A:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our business is subject to risks arising from epidemic diseases, such as the global pandemic of the COVID-19 coronavirus;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing and future proprietary testing products with the promotion of therapeutics, and we may be unsuccessful in our promotion efforts for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which could adversely affect our ability to implement this strategy;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may be unable to manage our ongoing growth effectively, which could make it difficult to execute our business strategy;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we lose or are unable to secure partners for our integrated testing and therapeutics strategy, or if our partners do not apply adequate resources to their relationships with us or are unable to provide, on a timely basis, an adequate and reliable supply of the therapeutics that we promote, our potential for profitability may be adversely affected;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends on attaining and maintaining significant market acceptance of our testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to fund replacements or transition to alternative suppliers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products or promoted therapeutics, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be compromised;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our sole laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain intellectual property protection our competitive position could be harmed; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to risks arising from epidemic diseases, such as the global pandemic of the COVID-19 coronavirus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun re-opening only to return to restrictions due to increases in new COVID-19 cases. Even in areas where "stay-at-home" restrictions have been lifted and the number of COVID-19 cases have declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, third-party shipping carries, government and third-party payors and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020. We experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume decrease of approximately 5% in the year ended December&#160;31, 2020 as compared to 2019. By the end of the third quarter of 2020, the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered substantially recovered to pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests reported in the first quarter of 2020, and in the fourth quarter of 2020, the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered exceeded our pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests reported in the first quarter of 2020. For the three months ended December&#160;31, 2020 as compared to the same period in 2019, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume increase of approximately 5%. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The economic downturn may also result in closures of the practices of our primary customers. As it relates to our promotion efforts of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we may experience decreased demand for or discontinued treatment with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from patients who are infected by COVID-19 or who may be at higher risk of infection if it is determined that such patients should minimize exposure to immunosuppressant therapies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve or re-negotiate volume-based discounts with our key suppliers and to absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. Our salesforce has been, and for an extended period of time may continue to be limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We have also experienced delays in procurement of our testing supplies due to the resurgence of varying forms of "stay-at-home" orders in the fourth quarter of 2020, which may continue into the future, and our partners, including Janssen, may also experience a disruption in their ability to readily obtain supply. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory operations, including laboratory employees and medical directors, may be subject to closure or shut down, either due to the spread of the disease within these individuals, or as part of a larger scale government recommendation or mandate. Any disruption in our laboratory operations would have a material adverse effect on our business and would impede our ability to process tests in a timely manner, or at all.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital on a timely basis or at all. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 may also have the effect of heightening many of the other risks described in this section.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2020 and 2019, we incurred net losses of $16.7 and $12.0 million, respectively, and we expect to incur additional losses in 2021 and in future years. As of December&#160;31, 2020, we had an accumulated deficit of $181.3 million. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products, to develop future testing products and to continue to execute our integrated testing and therapeutics strategy. We have experienced and may continue to experience decreases in test volumes due to the impact of the COVID-19 pandemic. We may not be able to generate sufficient revenue to achieve and maintain profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We only recently began transitioning toward an integrated testing and therapeutics strategy, and have experienced material fluctuations in our ability to drive meaningful revenue from the promotion of therapeutics. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer history of utilizing an integrated testing and therapeutics strategy in addition to the sale of our testing products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant majority of our historical revenue has been derived from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD. We are in various stages of research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to commercialize these testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we may not be able to sustain this growth or maintain existing revenue levels. Further, we cannot ensure the continued </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or successfully develop and commercialize additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing and future proprietary testing products with the promotion of therapeutics, and we may be unsuccessful in our promotion efforts for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">, which could adversely affect our ability to implement this strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the process of integrating our historical testing products business with the promotion of therapeutics in an integrated testing and therapeutics strategy. Our integrated testing and therapeutics strategy leverages our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products to promote therapeutics. As a result, our future growth is dependent, in part, on our ability to leverage our unique commercial model of offering testing products combined with therapeutics, including with respect to the Janssen Agreement, which we entered into in December 2018 to exclusively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. Pursuant to the Janssen Agreement, we are entitled to receive a tiered promotion fee based on the total number of incremental prescriptions written above an established baseline. Our ability to continue to effectively co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> will require us to be successful in a range of activities, including creating demand for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> through our commercial and sales activities as well as those of Janssen. Moreover, we may encounter difficulties in maintaining an effective salesforce in furtherance of our promotion efforts for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which could have a material impact on our ability to continue to successfully generate co-promotion revenue. If we encounter difficulties promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, our ability to generate significant revenue under the Amended Janssen Agreement will be harmed. In addition, in June 2020 we amended the Janssen Agreement, pursuant to which the predetermined average baseline for each remaining quarter in 2020, starting with the quarter ended June 30, 2020, was adjusted to approximately 26,000 prescribed units per quarter, due in part to COVID-19 and subject to adjustment under certain circumstances. In December 2020, we further amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to further adjustment under certain circumstances. Pursuant to the Amended Janssen Agreement, for each of the first and second quarters of 2021, we will receive a minimum promotion fee of $0.3 million and the fee will be capped at 10% above the adjusted predetermined baseline. The quarterly tiered promotion fee for the remaining term of the Amended Janssen Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to the amendment, with no minimum promotion fee and no cap on predetermined baseline units. However, based on the revised predetermined baseline we don't anticipate generating meaningful revenue beyond the minimum promotion fee for the first half of 2021, and may not generate any meaningful revenue thereafter. The Janssen Agreement expires on December 31, 2021, unless extended by us for an additional 12 months upon 180 days written notice prior to the end of the current term. Janssen also has the right to terminate the Janssen Agreement with or without cause after 30-days&#8217; notice, including if we are unable to agree to a new baseline for 2022. If Janssen were to exercise this right, we may be unable to recoup substantial investments we have made and intend to make in order to support the promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We have a limited history partnering with pharmaceutical companies for the promotion of therapeutics. Consequently, any predictions made about our future success or viability with respect to our promotion activities may not be as accurate as they could be if we had a history of successfully co-promoting therapeutics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to successfully promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, our ability to implement our integrated testing and therapeutics strategy and generate sufficient revenue to grow and sustain our business, and our business, financial condition and results of operations, will be materially adversely affected. This may also adversely affect our ability to secure additional therapeutic promotion opportunities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to manage our ongoing and future growth effectively, which could make it difficult to execute our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the need to scale our testing capacity, our future growth plans will also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In particular, we have 53 representatives as of December&#160;31, 2020 compared to 50 representatives as of December 31, 2019, and expect to continue to expand our salesforce in 2021, which we believe will help increase reach and frequency and support our integrated promotion of testing products and therapeutics. In addition, rapid and significant growth may strain our administrative and operational infrastructure and require us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our ability to manage our business and growth, as well as function as a public company, will require us to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we lose or are unable to secure partners for our integrated testing and therapeutics strategy, or if our partners do not apply adequate resources to their relationships with us or are unable to provide, on a timely basis, an adequate and reliable supply of the therapeutics that we promote, our potential for profitability may be adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the Janssen Agreement, we plan to opportunistically evaluate, and may continue to enter into, additional agreements with pharmaceutical companies to integrate the promotion of our testing products with their therapeutics. We have also entered into, and may continue to enter into, other agreements that leverage our testing products and/or data generated from such tests. For example, we provide GSK our test result data to provide market insight into and help increase awareness of the benefits of an early and accurate diagnosis of SLE and monitoring disease activity. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount and timing of resources applied by our current or potential future partners are largely outside of our control. For example, we have limited control over, and rely on Janssen for, numerous activities that are critical to our ability to successfully promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, such as pricing decisions, manufacture and supply of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, reimbursement support, marketing materials, the prosecution and enforcement of patents and other intellectual property rights related to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and public communications and presentations regarding SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We likewise have limited control of how our other partners use the information provided by our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of our current or future partners breaches or terminates our agreements, or fails to conduct the activities contemplated by our agreements in a timely manner, our success promoting the applicable therapeutics, testing products or information provided thereby could be diminished or blocked completely. It is possible that partners will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. For example, under the Janssen Agreement, Janssen is not prohibited from developing or commercializing products that are competitive with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If Janssen commercializes any competing products, it may provide lower levels of support to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> or may terminate our agreement entirely. The effectiveness of our partners, if any, in marketing the applicable therapeutics will also affect our revenue and earnings. In addition, if our other partners encounter problems with our testing products or information provided by our testing products that they rely on as part of their efforts, our reputation and that of our testing products could be damaged, and it could impair our ability to enter into future agreements to promote therapeutics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on Janssen to provide, on a timely basis, an adequate and reliable supply of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Any delay or interruption of supply or Janssen&#8217;s failure to comply with regulatory or other requirements could limit its ability to make, or cause it to cease sales, of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Any manufacturing defect or error discovered after SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has been produced and distributed could result in even more significant consequences, including costly recall procedures. In addition, the importation of pharmaceutical products into the United States is subject to regulation by the FDA, and the FDA can refuse to allow an imported product into the United States if it appears that the product fails to comply with applicable laws or regulations. Moreover, Janssen and its third-party manufacturers and suppliers may experience difficulties related to their overall business and financial stability. For example, in December 2019, a novel strain of coronavirus, COVID-19, has resulted in business closures and a limit on travel, as well as creating uncertainty in the broader economy and financial markets. Any disruption, including the extent to which COVID-19 has an effect on Janssen, may impact our ability to readily obtain supply and other requirements under our agreement with Janssen. To the extent Janssen faces manufacturing difficulties or is unable to provide an adequate and reliable supply of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on a timely basis, our reputation could be harmed and our business could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have the capability and do not intend to discover or develop therapeutics on our own. Therefore, the success of our integrated testing and therapeutics strategy depends in part on our ability to acquire additional rights to promote therapeutics from new or existing partners. Other companies, many of which have substantially greater financial, marketing and sales resources than we do, also compete with us for the acquisition of rights to therapeutics. In addition, under the Janssen Agreement, we are prohibited from selling or promoting certain types of products that are used to treat the same indications that SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is used to treat. We may not be able to successfully negotiate any additional agreements to promote therapeutics and, if established, these relationships may not be successful. For example, potential partners, particularly those that are actively marketing their own therapeutics, may be unwilling to license commercialization rights to us or otherwise enter into terms that allow us to meaningfully participate in sales growth for their products, which could limit the potential availability and value to us of additional agreements to promote therapeutics. The inability to enter into agreements for additional therapeutics </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">could limit the overall growth of our business and adversely affect our business, financial condition and results of operations. Disputes could also arise between us and our existing or future partners, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes would be both expensive and time-consuming and may result in delays in the success of therapeutics or could damage our relationship with a partner. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience limits on our revenue if rheumatologists decide not to order our testing products or our promoted therapeutics or if we are otherwise unable to create or maintain demand for our testing products and promoted therapeutics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to create or maintain demand for either our testing products or promoted therapeutics in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate rheumatologists about the benefits of our testing products through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. For example, in the fourth quarter of 2020, we were featured in six scientific presentations at the 2020 American College of Rheumatology's (ACR) Virtual Annual Conference, ACR Convergence 2020. We will also need to generate demand for both our testing products and promoted therapeutics through one-on-one education by our salesforce. We also plan to focus on educating patients about the benefits of these testing products and therapeutics, which we believe will be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement from third-party payors may limit adoption by rheumatologists, as well as third-party payors exerting pressure on rheumatologists and healthcare providers to order in-network testing products which could adversely affect our revenue. With respect to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in particular, if we are unable to generate sales above certain thresholds agreed to with Janssen, we will not generate meaningful revenue under the Amended Janssen Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatologists may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends on our ability to continue to develop and market testing products and promote therapeutics that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product or promoted therapeutic that we offer may not gain or maintain market acceptance among rheumatologists, third-party payors, patients and the medical community. Market acceptance of our testing products and promoted therapeutics depends on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the perceived accuracy of our test results by rheumatologists and patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential and perceived advantages of our testing products and promoted therapeutics over alternative products and therapeutics;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demonstration in clinical studies of the performance and clinical validity of our testing products, the results of which studies may not replicate the positive results from earlier studies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demonstration of clinical efficacy and safety of our promoted therapeutics compared to other more-established products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the introduction of new tests or therapeutics products that compete with our testing products or our promoted therapeutics or the introduction of generic versions of our promoted therapeutics;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the product cost in relation to alternative products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prevalence and severity of any adverse effects from our promoted therapeutics;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of rheumatologists to prescribe these therapies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any restrictions on the use of our promoted therapeutics, if approved, together with other medications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">publicity concerning our testing products and promoted therapeutics or competing products and treatments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or our partners had to withdraw a product from the market, it could harm our business and could impact market acceptance of our other testing products or promoted therapeutics. Further, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD consists of various biomarkers, any of which could independently encounter issues with manufacturing, supply or overall quality. If any of the biomarkers in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test were to encounter any issues, we may experience an impact in the overall success of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD as a whole, including a reduction in average selling price or overall revenue, until such time as it can be remedied. Moreover, if our testing products and promoted therapeutics do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payors or patients, we may not generate sufficient revenue from that testing product or therapeutic and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our testing products and promoted therapeutics may require significant resources and may never be successful. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sizes of the markets for our testing products and promoted therapeutics have not been established with precision, and may be smaller than we estimate. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates of the annual total addressable markets for our current and potential future testing products and promoted therapeutics are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future testing products and promoted therapeutics may prove to be incorrect. If the actual number of patients who would benefit from our testing products and promoted therapeutics, the price at which we and our partners can sell future testing products, or the annual total addressable market for our testing products and promoted therapeutics is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may expend our limited resources to pursue a particular testing product or promoted therapeutic and fail to capitalize on other testing products or promoted therapeutics that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on specific testing products and promoted therapeutics. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing products. If we do not accurately evaluate the commercial potential or target market for a potential testing product or promoted therapeutic, we may forego other similar arrangements which would have been more advantageous for us to pursue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully market and sell our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and continue to promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement from third-party payors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">public health crises such as the COVID-19 pandemic; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our testing products, which may change from time to time, and our ability to successfully commercialize new testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of demand for our testing products and promoted therapeutics, which may vary significantly; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the receipt, timing and mix of revenue for our testing products and promoted therapeutics; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the rate and extent to which payors make an overpayment determination and require us to return all or some portion of payments which we received in a prior period; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could have a material adverse effect on our business, financial condition and results or operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to find replacements or transition to alternative suppliers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing products. We also purchase components used in our testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products, including as a result of the COVID-19 pandemic, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. For example, in November 2019, we identified a potential quality issue with reagents for Anti-CarP, a biomarker that can be ordered with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, that was resolved in September 2020. However, if we are unable to remedy future potential quality issues with unique reagent suppliers, or otherwise find a supplier for future biomarkers with issues, we may experience difficulties obtaining market acceptance for our products. Moreover, any issues with quality may result in a change from time to time of the composition of our tests, including our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD test, which could impact the average selling price and revenues received from sales of such test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If demand for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. We are also currently collaborating with third parties in an effort to implement multiplex technology in our laboratory. We may experience difficulties securing a partner for this technology and integrating such technology into our existing laboratory operations, which could affect our ability to meet demand for our testing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">products. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products or promoted therapeutics, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be compromised. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Successful commercialization of our testing products depends, in large part, on the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as Medicare and Medicaid and private insurers. For the testing products that we develop and commercialize as well as the therapeutics we promote, each third-party payor decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement by third-party payors may depend on a number of factors, including the payor&#8217;s determination that tests using our technologies are: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not experimental or investigational; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medically necessary; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">demonstrated lead to improved patient outcomes; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">appropriate for the specific patient; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">cost-saving or cost-effective; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">supported by peer-reviewed medical journals; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">included in clinical guidelines. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenue and our ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payors pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected. Moreover, the COVID-19 pandemic may cause a delay in coverage decisions from Medicare and third-party payors, and have delayed ongoing and planned clinical trials involving our testing products, the occurrence of which may have a material adverse effect on our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be used by third-party payors and health care providers as grounds to deny coverage for or refuse to use a test or procedure. In addition, third-party payors, have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective April 25, 2012, Palmetto GBA, the Medicare molecular diagnostic services program, or MolDx Program, contractor, assigned the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients diagnosed with RA on methotrexate. Our current Medicare Administrative Contractor, Noridian Healthcare Solutions, LLC, or Noridian, has adopted this coverage policy. Other third-party payors make their own decisions as to whether to establish a policy to reimburse our testing products, however, and because approvals must be sought on a payor by payor basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payors who have not yet established a coverage policy applicable to our testing products. In addition, several Blue Cross Blue Shield plans and Aetna issued non-coverage policies with respect to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, determining that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our testing products are reimbursed by a number of third-party payors, we do not currently have contracts with significant private payors. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payors due to changes in their internal processes, documentation requirements and other issues, which could cause our revenue to fluctuate from period to period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payors currently reimburse for our testing products, such payors may withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our testing products altogether, any of which would reduce our revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various third-party payors, including Medicare and private insurance companies, as well as patients, all of which have different billing requirements. We generally bill third-party payors for our testing products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several factors contribute to the complexity of the billing process, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences between the list price for our testing products and the reimbursement rates of third-party payors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing Medicare; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disputes among third-party payors as to which party is responsible for payment; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in coverage among third-party payors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of patient deductibles, co-payments or co-insurance; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in information and billing requirements among third-party payors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes to billing codes used for our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risk of government audits related to billing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incorrect or missing billing information; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, in order to obtain reimbursement for services that we provide, we may challenge coverage and payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, established a requirement for providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, from time to time, third-party payors change processes that may affect timely payment. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payors. With respect to payments received from governmental programs, factors such as a prolonged government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal government healthcare programs. In addition, third-party payors may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, Noridian posted the calendar year 2021 Medicare Physician Fee Schedule, or MPFS, and Clinical Laboratory Fee Schedule, or CLFS, which establishes the reimbursement rates to be paid by Medicare for our jurisdiction for services performed on or after January 1, 2021. We have estimated that the implementation of these reimbursement rates will not result in a reduction in anticipated reimbursements from Medicare for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product compared to levels experienced in 2020. On March 27, 2020, the CARES Act included the temporary suspension of Medicare sequestration of 2% during the period beginning on May 1, 2020 and ending on December 31, 2020. The Consolidated Appropriations Act of 2021, signed into law on December 27, 2020, extends the suspension period to March 31, 2021. Revenue from Medicare comprised 20% and 25% of our revenue for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">years ended December&#160;31, 2020 and 2019, respectively. Revenue from the sale of our AVISE&#174; CTD testing products comprised 70% and 82% of our revenue for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on a third-party provider to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as well as not submitting claims to payors within the timeframe required. If claims for our testing products are not submitted to payors on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At times, we share our proprietary technology and confidential information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant safety or efficacy issues could arise for our promoted therapeutics, which could have an adverse effect on our revenue and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety or efficacy issues are reported or if new scientific information becomes available (including results of post-marketing Phase 4 trials), or if governments change standards regarding safety, efficacy or labeling, our partners may be required to amend the conditions of use for a therapeutic. For example, a partner may voluntarily provide or be required to provide updated information on a therapeutics' label or narrow its approved indication, either of which could reduce the therapeutics' market acceptance. If safety or efficacy issues with a partner&#8217;s therapeutic arise, sales of the therapeutic could be halted by the partner or by regulatory authorities. Safety or efficacy issues affecting suppliers&#8217; or competitors&#8217; products also may reduce the market acceptance of one of our partner&#8217;s therapeutics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New data about a partner&#8217;s therapeutics, or products similar to a partner&#8217;s therapeutics, could negatively impact demand for such therapeutics due to real or perceived safety issues or uncertainty regarding efficacy and, in some cases, could result in product withdrawal. Furthermore, new data and information, including information about therapeutic misuse, may lead government agencies, professional societies, practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of such therapeutics or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of the applicable therapeutics and reduce our revenue or otherwise adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain or expand our sales and marketing force to adequately address our customers&#8217; and current or future partners&#8217; needs, our business may be adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sell our testing products through our own specialized salesforce and have increased our salesforce in order to achieve the optimal reach and frequency and support our strategy of integrating the promotion of testing products and therapeutics. Our testing products compete in a concentrated specialty market, that of autoimmune and autoimmune-related diseases, and utilizing a specialized salesforce is integral to our integrated testing and therapeutics strategy. As such, we believe it is necessary to maintain a salesforce that includes sales representatives with specific technical backgrounds and industry expertise. For example, we have a salesforce of 53 representatives as of December&#160;31, 2020, and expect to continue to expand our salesforce in 2021. Additional agreements for the promotion of therapeutics may require us to further expand our specialized salesforce. Training of additional sales representatives can be costly and time consuming, particularly given the level of experience and sophistication we seek in our salesforce. In addition, until recently, not all of our sales representatives have promoted therapeutics, including SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as part of our organization, and they will need to complete additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">training in order to effectively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and any other therapeutics that we promote through additional agreements. If we are unable to effectively retain, train and integrate additional sales representatives, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future sales will depend in large part on our ability to maintain an effective salesforce. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as anti-nuclear antibodies, or ANA, and anti-double-stranded DNA, or anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Progentec Diagnostics Inc., Scipher Medicine Corporation, Genalyte Inc., Oncimmune plc, DxTerity Diagnostics Inc., and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Direct competition for the promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes all other companies with anti-TNF biologics and the marketing companies supporting their distribution and promotion. These products include HUMIRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Abbvie Inc., ENBREL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Amgen Inc., CIMZIA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from UCB, INFLECTRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Pfizer, (biosimilar REMICADE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and RENFLEXIS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Merck &amp; Co. (biosimilar REMICADE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). Additionally, we are restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the Janssen Agreement without Janssen's consent. Additional competitors include companies with other biologic drugs indicated for RA that have significant sales or sales potential. Specifically, these include ORENCIA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Bristol-Myers Squibb Company, ACTEMRA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Roche, RITUXAN</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Roche, XELJANZ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Pfizer, KEVZARA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Sanofi S.A., RINVOQ&#8482; from Abbvie Inc. and OLUMIANT</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from Eli Lilly and Company. There are also several late-stage RA drug and biosimilar development programs and several additional RA products that have minimal sales to date or that are indicated for other rheumatic indications competitive to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> such as psoriatic arthritis and ankylosing spondylitis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; safety and efficacy with respect to promoted therapeutics; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective and that we are effective in promoting therapeutics. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to devote considerable resources to the research and development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful validation studies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as our testing products, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from any solution. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, we have not acquired other companies or therapeutics and, except with respect to certain collaboration agreements executed in connection with our integrated testing and therapeutics strategy, we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The diagnostics and therapeutics industries are subject to rapidly changing technology, which could make our testing products, promoted therapeutics and other testing products we develop obsolete. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could decline and our competitive position could be harmed. In addition, if our promoted therapeutics become obsolete and we are unable to expand such agreements or find new partners, our sales could decline and our competitive position could be harmed. For example, with respect to SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and the treatment of RA, active psoriatic arthritis, or active ankylosing spondylitis, there are many novel therapeutic approaches in development and we expect that the competition in this market will increase dramatically. If new therapeutics make SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> obsolete or diminish the degree to which rheumatologists prescribe it, our ability to generate revenue under the Janssen Agreement will be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing and future customers and therefore materially adversely impact our business and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of claims related to testing products we may develop in the future. Any errors or omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation or cause the applicable partner to suspend sales of its therapeutics. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as designed, which could lead increase costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends largely on the skills, experience and performance of key members of our executive management team, including Fortunato Ron Rocca, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our testing products and the sale of promoted therapeutics. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time. Other than with respect to Mr. Rocca, we do not carry key man insurance for any of our employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our sole laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including earthquake, fire, flood, power loss, communications failure or terrorism, or public health crises such as the COVID-19 pandemic. In particular, we store all of our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, including as a result of the COVID-19 pandemic, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our proprietary technology to a third party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to rely on a third party to perform the tests contained in our testing products, we would need to engage another facility with established state licensure and Clinical Laboratory Improvement Amendments of 1988, or CLIA, accreditation under the scope of which tests could be performed following validation and other required procedures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to establish an additional clinical reference laboratory facility, we would have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. Beyond this time frame, we may need to further expand our laboratory space. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our process of determining CB-CAPs, which is part of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus product, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the College of American Pathologists, or CAP, at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems because: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient specimens must be received, tracked and processed on a timely basis; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">test results must be reported on a timely basis; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">billings and collections for all customers must be managed efficiently and accurately; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">third-party ancillary billing services require proper tracking and reporting; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pricing and other information related to our services is needed by our salesforce and other personnel in a timely manner to conduct business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient-identifiable health information must be securely held and kept confidential; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory compliance requires proper tracking and reporting; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business, results of operations and financial condition may be adversely affected if, among other things: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">services relating to our information technology, telephone or other systems are not kept current; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is lost or unable to be restored or processed; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is corrupted due to a breach of security. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as legally protected health information, including de-identified test reports, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events. In addition, we have limited control over the storage of sensitive data by our third-party therapeutics partners as well as risks related to the transfer and sale of de-identified data files to such partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Additionally, as a result of the COVID-19 pandemic, most of our employees are working remotely, which may increase the risk of security breaches, loss of data, and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe that we have experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, as amended by the HITECH Act, and their implementing regulations and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business. Additionally, in connection with the ongoing COVID-19 pandemic, most of our employees are working remotely, which may increase the risk of security breaches, loss of data, and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expedited, reliable shipping is essential to our operations. We have been utilizing both United Parcel Service and Federal Express Corporation for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, United Parcel Service, or any other carrier we may use in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time or disruption to delivery service, whether due to bad weather, natural disaster, public health epidemics or pandemics (including, for example, the COVID-19 pandemic), terrorist attacks or threats, or for other reasons, could adversely affect our ability to receive and process patient specimens on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we, Federal Express, or United Parcel Service were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express and United Parcel Service. If any new provider does not provide, or if Federal Express or United Parcel Service does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by &#8220;5-percent shareholders,&#8221; as defined in the Code, over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. We previously completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from our formation through December 31, 2019. Based upon this study, we determined that ownership changes had occurred in 2003, 2008, 2012, 2017 and 2019, and that our ability to use a significant portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. If we undergo an ownership change as a result of subsequent shifts in our stock ownership, our ability to utilize our NOL carryforwards and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code. Similar provisions of state tax law may also apply. In addition, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income. As a result of the foregoing, if we earn net taxable income, our ability to use NOL carryforwards and other tax attributes to offset taxable income and taxes, as applicable, may be limited. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recently enacted U.S. tax legislation, known as the Tax Cuts and Jobs Act of 2017, has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and U.S. Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. Based on our current evaluation of this legislation, the reduction of the U.S. corporate income tax rate required a provisional write-down of our deferred income tax assets (including the value of our NOL carryforwards and our tax credit carryforwards). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There may be other material adverse effects resulting from the legislation that we have not yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into the loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, or Innovatus, which we subsequently amended in November 2019, or the Amended Loan Agreement. The Amended Loan Agreement is collateralized by substantially all of our personal property, including our intellectual property. The Amended Loan Agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million and achieve certain minimum amounts of annual revenue, as measured on a rolling twelve-month basis, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Innovatus, which we may not be able to obtain. As of December&#160;31, 2020, there was $25.0 million in principal outstanding under the term loan and an additional $1.8 million outstanding representing interest at 2.0% per annum payable in-kind by adding the amount to the outstanding principal balance of the term loans. Under the Amended Loan Agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a two-year period commencing on December 1, 2022. Our revenues for the twelve-month period ended September 30, 2020 were lower than the specified targets in the Amended Loan Agreement, and as a result, we and Innovatus agreed on a new management plan and target to bring us back into compliance with the Amended Loan Agreement. At December&#160;31, 2020, we were in compliance with all covenants of the Amended Loan Agreement. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the Amended Loan Agreement, the occurrence of a material adverse change in our business as defined in the Amended Loan Agreement, our breach of any representation or warranty in the Amended Loan Agreement, our breach of any covenant in the Amended Loan Agreement (subject to a cure period in some cases), a change in control as defined in the Amended Loan Agreement, our default on any debt payments to a third party in an amount exceeding $500,000 or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the Amended Loan Agreement, Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Innovatus or any other debt we may incur in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect capital expenditures and operating expenses to increase over the next several years as we expand our infrastructure, commercial operations and research and development activities. We believe, based on our current plan, that our current cash and cash equivalents and anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, including as a result of the COVID-19 pandemic, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If our available cash balances and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or promoted therapeutics or lower-than-expected rates of reimbursement from commercial third-party payors and government payors, or other risks described in this &#8220;Risk Factors&#8221; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. In the case of the incurrence of further indebtedness, the Amended Loan Agreement, subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus. Under the Amended Loan Agreement, we are required to make monthly interest payments at a rate equal to 8.5% (provided that 2.0% of the 8.5% is payable in-kind by adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; our ability to successfully promote therapeutics; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our Amended Loan Agreement restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products, promoted therapeutics or market development programs, which could lower the economic value of those programs to our company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market our in vitro diagnostic testing products in the United States as LDTs. LDTs are in vitro diagnostic tests that are intended for clinical use and are designed, manufactured, and used within a single laboratory. Although LDTs are classified as medical devices and the FDA has statutory authority to ensure that medical devices are safe and effective for their intended uses, the FDA has historically exercised enforcement discretion and has not enforced certain applicable FDA requirements, including premarket review, with respect to LDTs. Moreover, in August 2020, the U.S. Department of Health and Human Services, or HHS, announced that FDA will not require premarket review of LDTs absent notice-and-comment rulemaking. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Legislative and administrative proposals proposing to amend the FDA&#8217;s oversight of LDTs have been introduced in recent years and we expect that new legislative and administrative proposals will continue to be introduced from time to time. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory requirements for us to continue to offer our LDTs or to develop and introduce new tests as LDTs.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, the FDA could modify its current approach to LDTs in a way that would subject our tests that we market as LDTs to the enforcement of additional regulatory requirements. In recent years, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. Specifically, on July 31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October 3, 2014, the FDA issued two draft guidance documents entitled &#8220;Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),&#8221; or the Framework Guidance, and &#8220;FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs),&#8221; or the Reporting Guidance. The FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, and FDA issued a discussion paper on possible approaches to LDT regulation in January 2017.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the FDA and Congress have, for over the past decade, considered a number of proposals to end the FDA&#8217;s enforcement discretion policy for LDTs and subject LDTs to additional regulatory requirements. For example, Congress has recently been working on legislation to create an LDT and in vitro diagnostic regulatory framework for all in vitro clinical tests, or IVCTs, that would be separate and distinct from the existing medical device regulatory framework. In March 2020, members of the U.S. House of Representatives formally introduced the VALID Act (Verifying Accurate Leading-edge IVCT Development Act of 2020) in the House and an identical version of the bill was introduced in the U.S. Senate. If passed in its current form, the VALID Act would create a new category of medical products separate from medical devices called &#8220;in vitro clinical tests,&#8221; or IVCTs, and bring all such products within the scope of FDA&#8217;s oversight. As proposed, the bill grandfathers many existing tests from the proposed premarket approval, quality systems, and labeling requirements, but would require such tests to comply with other regulatory requirements (for example, registration and notification, adverse event reporting). The bill also provides for IVCTs introduced before the effective date (drafted to be approximately four years after the enactment date) to be transitional and remain on the market subject to certain conditions. It is unclear whether the VALID Act or any other legislative proposals would be passed by Congress or signed into law by the President. Depending on the approach adopted under any legislation, certain LDTs (likely those of higher risk) could become subject to some form of premarket review, potentially with a transition period for compliance and a grandfathering provision.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if the FDA does not modify its policy of enforcement discretion, whether due to changes in FDA policy or legislative action, the FDA may disagree that we are marketing our LDTs within the scope of its policy of enforcement discretion and may impose significant regulatory requirements, including the requirement for premarket review and clearance or approval. We may also be required to conduct clinical studies to support our currently marketed products or planned product launches. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are required to conduct such clinical trials, delays in the commencement or completion of clinical testing could significantly increase our test development costs and delay commercialization of any currently-marketed tests that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third-parties would not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When conducting clinical trials, we and our third-party contractors are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA, and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA, Competent Authorities of the Member States of the EEA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third-parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our testing products. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our testing products, or to achieve sustained profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices, known as the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contribute to a death or serious injury if it were to recur; labeling regulations, including the FDA&#8217;s general prohibition against promoting products for unapproved or &#8220;off-label&#8221; uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we were able to obtain FDA clearance or approval for one or more of our testing products, if required, a testing product may be subject to limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the product. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has broad post-market enforcement powers, and if unanticipated problems with our testing products arise, or if we or our suppliers fail to comply with regulatory requirements following FDA clearance or approval, we may become subject to enforcement actions such as: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">operating restrictions, partial suspension or total shutdown of production; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">customer notifications or repair, replacement or refunds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refusing our requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new testing products, new intended uses or modifications to existing testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">FDA refusal to issue certificates to foreign governments needed to export testing products for sale in other countries; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">criminal prosecution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approvals. For example, the results of the 2020 U.S. Presidential Election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these orders will be implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of the new administration are unknown and could materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Regulatory and Compliance Matters </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare policy and payment changes may have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement to healthcare providers, such as specialized diagnostic service providers like us, is subject to continuing change in policies by third-party payors including governmental payors, such as Medicare and Medicaid, private insurers and other private payors, such as hospitals and private medical groups. Statutory and regulatory changes, retroactive rate adjustments and administrative rulings, and other policy changes may be implemented with little or no prior notice, all of which could materially decrease the range of services for which we are reimbursed or the reimbursement rates paid for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, implemented a new payment system for clinical laboratory tests reimbursed under the CLFS. Under the law, clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes. The reported data must include the payment rate and the volume of each test that was paid by each private third-party payor. Laboratories that fail to report the required payment information may be subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">substantial civil monetary penalties. We bill Medicare for our testing products, and therefore we are subject to reporting requirements under PAMA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The PAMA ruling issued on June 17, 2016 included data for reporting for the new PAMA process began in 2017, and in 2018, the Medicare payment rate for each clinical diagnostic lab test, with some exceptions, equaled the weighted median of the reported private third-party payor payment for the test, as calculated using data collected by applicable laboratories during the data collection period and reported to the Centers for Medicare and Medicaid Services, or CMS, during a specified data reporting period. At the beginning of 2020, these revisions to the CLFS have altered payment rates for clinical diagnostic lab tests under the CLFS, the estimated reduction in Medicare reimbursement rate for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD of 7.3% compared to levels experienced in 2019. Effective March 2020, as a result of our change in the composition of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, the estimated reduction to the Medicare reimbursement rate for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD was 5.3% compared to levels experienced in 2019. We do not expect the revisions to the CLFS to impact Medicare reimbursement rate for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2021 compared to levels experienced in 2020. On March 27, 2020, the CARES Act delayed the next reporting period until 2022 resulting in a 0% reduction for 2021, and the 15% reduction limits would apply in 2022-2024. We cannot be sure how revisions to the CLFS will affect reimbursement rates in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other laws make changes impacting clinical laboratories, many of which have already gone into effect. The ACA, enacted in March 2010, among other things, include provisions regarding the coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the tax-based shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it remains unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA or our business. Further, it is possible that additional governmental action be taken in response to the COVID-19 pandemic. We are monitoring the impact of the ACA in order to enable us to determine the trends and changes that may be necessitated by the legislation and that, in turn, may potentially impact our business over time. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Budget Control Act of 2011, among other things, resulted in aggregate reductions to Medicare payments to providers of 2% per fiscal year, beginning April 1, 2013, and due to additional legislative amendments to the statute, these reductions will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our flow cytometry tests are reimbursed by the Medicare program under the MPFS. On April 16, 2015, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which, among other actions, repealed the previous statutory formula by which CMS established annual updates to MPFS rates. MACRA created the Merit-Based Incentive Payment System which, beginning in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare payments are significant to our business, not only because approximately 23% and 25% of the total payments we received from payors for the years ended December&#160;31, 2020 and 2019, respectively, were derived from the Medicare program, but also because other payors often use the MPFS and CLFS amounts as a benchmark to develop their payment rates. We cannot predict whether Medicare and other third-party payor reimbursement rates that mirror Medicare&#8217;s will be sufficient to make our testing products commercially attractive. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, some third-party payors have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it could have a negative impact on our revenue in the short term. It is possible that third-party payors will resist reimbursement for testing products that we offer in favor of less expensive tests, may require pre-approval for our testing products or may impose additional pricing pressure on and substantial administrative burden for reimbursement for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product pricing by companies is currently, and is expected to continue to be, under close scrutiny. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business in the future, or the effect any future legislation or regulation will have on us, including any initiatives implemented by the new Biden administration. Although we cannot predict the full effect of the recent legislative changes discussed above, cost reduction measures, the expansion in government&#8217;s role in the U.S. healthcare industry and PAMA&#8217;s changes to the reimbursement methodology under the CLFS, such changes individually or in the aggregate may result in decreased profits to us and/or lower reimbursement by third-party payors for our testing products, which may adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform testing through our accreditation by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratory. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as an out of state laboratory and our testing products, as LDTs, must be approved by the New York Department of Health, or NYDOH, on a product-by-product basis before they are offered in New York. We are also be subject to periodic inspection by the NYDOH and required to demonstrate ongoing compliance with NYDOH regulations and standards. To the extent NYDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our testing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">products. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYDOH approval for our laboratory developed tests in New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states which would limit our revenue. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and our partners, including those with whom we may enter into co-promotion or co-marketing arrangements, are also subject to healthcare fraud and abuse regulation by both the federal government and the states in which we or our partners conduct our business. These laws include, without limitation, state and federal anti-kickback, self-referral, fraud and abuse, false claims, and physician sunshine laws and regulations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service, including laboratory services, reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Federal Anti-Kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not make the conduct per se illegal under the Federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Federal Anti-Kickback Statute has been violated. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. in order to have committed a violation In addition, the government may assert that a claim including items or services resulting from a violation of the Federal Anti-kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 25, 2014, the Office of Inspector General of the Department of Health and Human Services, or the OIG, released a Special Fraud Alert, expressing concern regarding laboratory payments made to referring physicians and physician group practices for blood specimen collection, processing, and packaging. Specifically, the OIG expressed concern that such arrangements may implicate the Federal Anti-Kickback Statute when laboratories make payments to physicians for services that are already covered and reimbursed by Medicare, or are not commercially reasonable or exceed fair market value, all in order to induce physicians to order tests from such laboratory. Because the choice of laboratory and the decision to order laboratory tests is made or strongly influenced by the physician, with little or no input from patients, such payment may induce physicians to order more laboratory tests than are medically necessary, particularly when the payments are tied to, or take into account, the volume or value of business generated by the physician. We had entered into certain arrangements with physicians for services related to specimen collection, transporting and handling. Effective August 2015, we terminated all such agreements. To date, no regulatory authorities have contacted us regarding these arrangements. To the extent our prior arrangements are found to be inconsistent with applicable laws, we may be subject to significant penalties, including criminal penalties, and exclusion from participation in U.S. federal or state health care programs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal civil and criminal false claims law, including the False Claims Act, prohibit, among other things, any person from knowingly presenting or causing to be presented a false claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false or fraudulent claim paid by the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, private individuals have the ability to bring actions under these false claims laws in the name of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">government alleging false and fraudulent claims presented to or paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring Medicare patients for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a prohibited referral. In addition, the government may assert that a claim including items or services resulting from a violation of the Stark Law constitutes a false or fraudulent claim for purposes of the false claims laws. Many states have their own self-referral laws as well, which in some cases apply to all third-party payors, not just Medicare and Medicaid. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, under the federal civil monetary penalties statute, a person is prohibited from offering or transferring to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Federal Anti-Kickback Statute and civil False Claims Act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payors may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA, among other things, also imposed new reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians (as defined by the statute) and their immediate family members. Manufacturers must submit reports by the 90th day of each calendar year. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that some of our business activities could be subject to challenge under one or more of such laws, including our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is subject to restriction of off-label use discussions. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state health care programs, such as Medicare and Medicaid in the U.S. and similar programs outside the U.S., a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with HIPAA, the HITECH Act, their implementing regulations, and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous federal, state and foreign laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, disclosure, security, use and confidentiality of individually identifiable health informationhealth-related and other personal information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of individually identifiable health information, or PHI, within our company and with third-parties. The privacy, security and breach notification rules promulgated under HIPAA, as amended by the HITECH Act, Standards for Privacy of Individually Identifiable Health Information, or Privacy Standards, and the Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities, such as us, to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA also requires us to provide individuals with certain rights with respect to their PHI. If we engage a business associate to help us carry out health care activities and functions, we must have a written business associate contract or other arrangement with the business associate that establishes specifically what the business associate has been engaged to do and requires the business associate to comply with the requirements of HIPAA. Further, in the event of a breach of unsecured PHI we must notify each individual whose PHI is breached as well as federal regulators and in some cases, must publicize the breach in local or national media.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, made certain of the Security Standards directly applicable to business associates. Further, the HITECH Act and the Final HIPAA Omnibus Rule that was promulgated in 2013, made additional parts of HIPAA directly applicable to business associates. As a result, both covered entities and business associates are now subject to significant civil and criminal penalties for failure to comply with the Privacy Standards and/or the Security Standards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as certain health care providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the conduct of our business, we process, maintain, and transmit sensitive data, including PHI. There can be no assurance that a breach of privacy or security will not occur. If there is a breach, we could be subject to various lawsuits, penalties, and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for failure to comply with a requirement of HIPAA vary significantly depending on the nature of violation and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA requires covered entities to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of individually identifiable health information, restricts certain disclosures and sales of individually identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The Final HIPAA Omnibus Rule modifies the breach reporting standard in a manner that will likely make more data </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">security incidents qualify as reportable breaches. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney fees and costs associated with pursuing federal civil actions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. For example, the California Consumer Privacy Act, or the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the CPRA recently passed in California, which will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future growth may depend, in part, on our ability to develop and commercialize our testing products and promote therapeutics in foreign markets. We are not permitted to market or promote any of our testing products or promote therapeutics before we or our partners receive regulatory approval from applicable regulatory authorities in foreign markets, and we or they may never receive such regulatory approvals for any of our testing products or promoted therapeutics. To obtain separate regulatory approval in many other countries, parties must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we or our partners obtain regulatory approval of our testing products and promoted therapeutics, and ultimately commercialize our testing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">products or promoted therapeutics in foreign markets, we would be subject to additional risks and uncertainties, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">different regulatory requirements for approval of drugs in foreign countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced protection for intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the existence of additional third-party patent rights of potential relevance to our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign reimbursement, pricing and insurance regimes; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is common; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Intellectual Property </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain intellectual property protection our competitive position could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to protect our technologies such as CB-CAPs and methotrexate polyglutamates, or MTXPGs, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will be considered patentable or enforceable by the United States Patent and Trademark Office, or the USPTO, courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We apply for patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we own or have an exclusive license to 13 issued U.S. patents, and certain corresponding foreign counterpart patents, relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also own one issued U.S. patent, two pending U.S. patent applications, a pending PCT patent application, a pending U.S. provisional patent application, and certain corresponding foreign counterpart patents and patent applications relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or prevent others from designing around our claims. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">employees, consultants, contractors and other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, such as AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our CB-CAPs technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our testing products pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting and defending patents on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in all countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection and patent prosecution for some of our testing products may be dependent on third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our testing products, which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our testing products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, certain patent rights related to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus are licensed from the University of Pittsburgh, certain patent rights related to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX are licensed from Prometheus. Our existing license agreements as related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Additionally, we may not always have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be compromised by our licensors&#8217; acts or omissions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from the University of Pittsburgh related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, and our partner may be unable to acquire any necessary rights for our promoted therapeutics. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or our partners consider necessary or attractive in order to promote their therapeutic. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we or our partner are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and promote therapeutics, and our business, financial condition and prospects for growth could suffer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures bring the possibility of third-party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products may give rise to claims of infringement of the patent rights of others. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that any of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us from marketing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, there may be third-party patents of which we are currently unaware with claims to materials or methods of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">manufacture related to the use or manufacture of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. If a third party that owns such a patent asserts it successfully against one of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and technology. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, the defendant could counterclaim that the patent covering such AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such a loss of patent protection could have a material adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. We are not aware of any third-party </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#8217;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The public trading price for our common stock is affected by a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated variations in our and our competitors&#8217; financial condition and results of operations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in reimbursement by current or potential third-party payors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issuance of new securities analysts&#8217; reports or changed recommendations for our stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated changes in regulatory oversight of our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any major change in our management; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcement or expectation of additional financing efforts; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future sales of our common stock by our executive officers, directors and other stockholders; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets, including as a result of the COVID-19 pandemic. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the trading price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our directors and executive officers may establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by directors and executive officers, or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the holders of 5,167,230 shares of common stock and holders of warrants to purchase 426,827 shares of common stock are entitled to rights with respect to registration of such shares under the Securities Act pursuant to an investors&#8217; rights agreement between such holders and us.  If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling additional shares to raise capital and are required to include shares held by these holders pursuant to the exercise of their registration rights, our ability to raise capital may be impaired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 74% of our outstanding capital stock. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our Amended Loan Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">An active, liquid trading market for our common stock may not be maintained </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to our IPO, there had been no public market for our common stock. Our common stock only recently began trading on the Nasdaq Global Market, or Nasdaq, but we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to meet the continued listing requirements of the Nasdaq Global Market, or Nasdaq, could result in a delisting of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. Currently, we have limited analyst coverage and we do not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering, or IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim condensed financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the Securities and Exchange Commission, or the SEC, and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our testing products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to Section 404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2020. When we lose our status as an &#8220;emerging growth company&#8221; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we are in process of upgrading our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our testing products. Our ability to obtain clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to securities class action litigation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_19"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Vista, California, where we lease approximately 27,000 square feet of office and laboratory space under a lease that expires in 2026, with an option to extend a portion of the lease for an additional five-year period. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease an additional approximately 19,500 square feet office space in Vista, California, under a lease that is co-terminus with our other lease expiring in 2026, with an option to extend the lease for an additional five-year period. We believe that our current facilities are adequate for our current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_25"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_28"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items 4. Mine Safety Disclosures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II.</span></div><div style="text-align:center"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_34"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on The Nasdaq Global Market on September 19, 2019 under the symbol "XGN." Prior to September 19, 2019, there was no public market for our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;12, 2021, there were approximately 47 stockholders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in "street" name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is currently prohibited by the terms of our Amended Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part III, Item 12 of this Annual Report under the section titled "Security Ownership of Certain Beneficial Owners and Management" for information about our equity compensation plans which is incorporated by reference herein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. At the closing of the offering on September 23, 2019, we issued and sold 4,140,00 shares of our common stock at the initial public offering price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, which resulted in net proceeds of approximately $50.4 million and offering-related transaction costs of approximately $7.5 million. Cowen and Company, LLC, Cantor Fitzgerald &amp; Co. and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have used approximately $16.8 million of the proceeds from our IPO primarily related to selling and marketing activities. There has been no material change in the planned use of such proceeds from that described in the final prospectus filed by us with the SEC on September 20, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_37"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Selected Financial Data</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables set forth our selected historical financial data as of, and for the periods ended on, the dates indicated. We have derived the selected statements of operations data for the years ended December 31, 2020 and 2019 and the balance sheet data as of December 31, 2020 and 2019 from our audited financial statements included elsewhere in this Annual Report on Form 10-K. We have derived the selected statements of operations data for the years ended December 31, 2018 and 2017 and the balance sheet data as of December 31, 2018 and 2017 from our audited financial statements not included in this Annual Report on Form 10-K. You should read this data together with our audited financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and the section of this prospectus entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Our historical results for any prior period are not necessarily indicative of our future results.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statements of Operations Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue (excluding amortization of purchased technology)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of acquisition-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,643&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,836)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of share purchase rights and 2013 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,766)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,013)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,954)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,687)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,038)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,012)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recorded in connection with financing transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,687)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,482)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,774)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.32)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.46)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293.34)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(520.18)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,632,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings, non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital lease obligations, including current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96,684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">We define working capital as current assets less current liabilities. See our audited financial statements and the related notes included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities.</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should read the "Special note regarding forward-looking statements" and "Risk Factors" section of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_43"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, several of which are based on our proprietary CB-CAPs technology. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and revenue from this product comprised 70% and 82% of our revenue for the years ended December&#160;31, 2020 and 2019, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and patient advocacy organizations. In December 2018 we entered into the Janssen Agreement to exclusively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to advance our integrated testing and therapeutics strategy and we began direct promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2019. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> promotion efforts contributed approximately $5.1 million and $1.5 million in revenue for the years ended December&#160;31, 2020 and 2019, respectively, with our quarterly tiered promotion fee based on the incremental increase in total prescribed units above a predetermined average baseline. See "-Janssen Promotion Agreement" below for additional terms of the agreement. We also have agreements with GSK, Covance Inc. and Parexel, among others, that leverage our testing products and/or the information generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease activity. We partner with academic research centers and patient advocacy organizations, such as Brigham and Women's Hospital, Hospital for Special Surgery, and Duke University as well as the Lupus Foundation of America, to help improve the quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional strategic partnerships that are synergistic with our evolving portfolio of testing products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tests in our approximately 8,000 square foot clinical laboratory, which is certified by CLIA and accredited by CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA. We are approved to offer our products in all 50 states. Our clinical laboratory reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing product results within five business days. In the fourth quarter of 2020, we completed the build-out of approximately 2,000 additional square feet to our clinical laboratory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products using our specialized salesforce. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using our portfolio of testing products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for our testing services comes from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare, and patients. Reimbursement rates vary by product and payor. We continue to focus on expanding coverage among existing contracted rheumatologists and to achieve coverage with commercial payors, laboratory benefit managers and evidence review organizations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception we have devoted substantially all our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of December&#160;31, 2020 we had an accumulated deficit of $181.3&#160;million. We incurred net losses of $16.7&#160;million and $12.0 million for the years ended December&#160;31, 2020 and 2019, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. Through the date of our initial public offering (IPO) in September 2019, our operations were financed primarily from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO of 4,140,000 shares of our common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of our common stock. Including the option exercise, the aggregate net proceeds to us from the offering was approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. As of December&#160;31, 2020, we had $57.4&#160;million of cash and cash equivalents. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun re-opening only to return to restrictions due to increases in new COVID-19 cases. Even in areas where "stay-at-home" restrictions have been lifted and the number of COVID-19 cases have declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020. We experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD volume decrease of approximately 5% in the year ended December&#160;31, 2020 as compared to 2019. By the end of the third quarter of 2020, the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered substantially recovered to pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests reported in the first quarter of 2020, and in the fourth quarter of 2020, the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD delivered exceeded our pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests reported in the first quarter of 2020. For the three months ended December&#160;31, 2020 as compared to the same period in 2019, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD volume increase of approximately 5%. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve volume-based pricing discounts with our key suppliers and absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. We have also experienced delays in procurement of our testing supplies due to the resurgence of varying forms of "stay-at-home" orders in the fourth quarter of 2020, which may continue into the future, and our partners, including Janssen, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may also experience a disruption in their ability to readily obtain supply. Our salesforce has been, and for an extended period of time may continue to be limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have curtailed non-essential travel and equipped most of our employees with the ability to work remotely with the exception of our clinical laboratory employees, and implemented measures to protect the health of our employees and to support the functionality of our clinical laboratory, such as providing personal protective equipment (including face masks or shields) and maintaining social distancing. In addition, in the second quarter of 2020, our salesforce recommenced certain field-based interactions and scaled marketing spend, although access to healthcare providers remains limited and the use of virtual sales tools has increased. From March 2020 through December&#160;31, 2020, as a result of the COVID-19 pandemic, we terminated our temporary employees and 18 full-time employees, which included three employees at the vice president level. The full extent of which the COVID-19 pandemic will directly or indirectly continue to impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of COVID-19, we believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Continued Adoption of Our Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and through December&#160;31, 2020, we have delivered over 487,000 of these tests. For the year ended December&#160;31, 2020, 100,450 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests were delivered, representing an approximate 5% decline over the same period in 2019. The number of ordering healthcare providers reached a record 2,500 for the year ended December&#160;31, 2020, representing approximately 5% growth over the same period in 2019. In the fourth quarter of 2020, the number of ordering healthcare providers reached 1,690 compared to 1,707 in the same period in 2019, and we had a record 635 adopting healthcare providers (defined as those who previously prescribed at least 11 diagnostic tests in the corresponding period) compared to 572 in the same period in 2019. A high percentage of adopting healthcare providers continue to order tests in subsequent quarters, as approximately 99% of adopting healthcare providers from the third quarter of 2020 that order at least one diagnostic test in the fourth quarter of 2020. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial and government payors such as Medicare. Payment from third-party payors differs depending on whether we have entered into a contract with the payors as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payors will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We began promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States under the Janssen Agreement in January 2019. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> promotion efforts contributed approximately $5.1 million and $1.5 million in revenue for the years ended December&#160;31, 2020 and 2019, respectively. We may continue to encounter difficulties in successfully promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and generating significant revenue under the Janssen Agreement. Our ability to effectively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will require us to be successful in a range of activities, including creating demand for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through our own sales activities as well as those of Janssen. In interest of supporting these efforts we plan to continue to evaluate the reach and frequency of our salesforce and the dedication of time and resources to supporting the co-promotion efforts of SIMPONI as compared to other aspects of our business. We expect to encounter difficulties being able to maintain meaningful co-promotion revenue based on sales over the predetermined baseline in 2021 and we may not be successful in materially increasing market share, potentially resulting in the recognition of the minimum promotion fee of $0.3 million in the first and second quarter of 2021, which would cause us to continue to rely on our existing testing products to drive revenue growth. Additionally, there is no minimum promotion fee for the second half of 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Development of Additional Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We realized an increase to our gross margins beginning in the first quarter of 2020 following the expiration of a 10% annual royalty on our CB-CAPs technology. We believe we are well positioned to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payor coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. However, our efforts to maintain a meaningful margin may be partially offset by our ability to generate meaningful co-promotion revenue in 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, we entered into the Janssen Agreement, under which we are responsible for the costs associated with our salesforce in promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. Janssen is responsible for all other costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> under the Janssen Agreement. In exchange for our sales and co-promotional services, we are entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over a predetermined baseline. For the years ended December 31, 2020 and 2019, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020 we amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> approximately 26,000 prescribed units per quarter, and subject to adjustment under certain circumstances. For each of the third and fourth quarters of 2020, we received a minimum promotion fee of $0.3 million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, we further amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the quarters ending December 31, 2020, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to further adjustment under certain circumstances. For the first and second quarter of 2021, we will be entitled to an amended quarterly tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over the predetermined baseline. Pursuant to the Amended Janssen Agreement, for each of the first and second quarters of 2021, we will receive a minimum promotion fee of $0.3 million and the fee will be capped at 10% above the adjusted predetermined baseline. We continued to receive a minimum promotion fee of $0.3 million and the fee was capped at 5% above the adjusted predetermined baseline for the quarter ended December 31, 2020. The quarterly tiered promotion fee for the remaining term of the Amended Janssen Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to the amendment, with no minimum promotion fee and no cap on predetermined baseline units. The Janssen Agreement expires on December 31, 2021, unless extended by us for an additional 12 months upon 180 days written notice prior to the end of the current term. If we elect to extend the term, the predetermined baseline for 2022 will be subject to future agreement by us and Janssen. Janssen may terminate the agreement at any time for any reason upon 30 days' notice to us, and we may terminate the agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $5.1 million and $1.5 million in revenue for the year ended December&#160;31, 2020 and 2019, respectively, for our promotional efforts under the Janssen Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seasonality</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, including medical conferences, climate and weather conditions in our markets, seasonal conditions that may affect medical practices and provider activity, including for example influenza outbreaks that may reduce the percentage of patients that can be seen, and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services, or payors, consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. These assessments require significant judgment by management.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered, as well as our ability to continue to generate meaningful co-promotion revenue. We expect to encounter difficulties promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above the predetermined baseline potentially resulting in us receiving the minimum promotion fee of $0.3 million in the first and second quarter of 2021. Additionally, there is no minimum promotion fee for the second half of 2021. Our average reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD decreased in 2020 as compared to 2019 due to the impacts of the PAMA rate reduction as well as changes to payor mix. However, PAMA is not expected to have an impact on our 2021 average reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD as compared to 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered in the third quarter of 2020 substantially recovered to the pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests reported in the first quarter of 2020, and the number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered in the fourth quarter of 2020 exceeded pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests reported in the first quarter of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each payor, commercial third-party, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each month's billings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming future testing volumes are not negatively impacted by the spread of COVID-19, we expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. As discussed above, the continued spread of COVID-19 may adversely affect testing volumes which may result in an increase in cost per test due to our inability to realize volume efficiencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to evaluate the reach and frequency of our sales and sales support functions, expected additions to headcount and increases for personnel costs, including stock-based compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to invest in research and development activities related to our existing testing products and product candidates, expected additions to headcount and increases for personnel costs, including stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our Amended Loan Agreement with Innovatus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to remain consistent in 2021 as compared to 2020, and remain consistent thereafter until 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Financial Instruments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of our IPO, we classified our outstanding warrants to purchase shares of our redeemable convertible preferred stock as liabilities on our balance sheets at their estimated fair value since the underlying redeemable convertible preferred stock was classified as temporary equity. At the end of each reporting period, changes in the estimated fair value during the period were recorded as a component of other income (expense).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of our IPO in September 2019, all outstanding warrants to purchase shares of our redeemable convertible preferred stock either terminated or were converted into warrants to purchase shares of our common stock and accordingly, will no longer be subject to measurement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, consists primarily of interest income earned on our cash and cash equivalents and an amount received under the CARES Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit (Expense)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include federal and state income taxes in the United States.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_52"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,766)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,687)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,038)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,649)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $1.6&#160;million, or 3.9%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, primarily due to an increase in revenue to approximately $5.1 million from the co-promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020 compared to approximately $1.5 million for the year ended December&#160;31, 2019. The increase in revenue was partially offset by a decrease in the number of diagnostic tests delivered due in part to impacts of the COVID-19 pandemic, coupled with a decrease in average reimbursement per AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests, which accounted for 70% of revenue for the year ended December&#160;31, 2020, decreased to 100,450 tests delivered in the year ended December&#160;31, 2020 compared to 105,370 tests delivered in the same 2019 period. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests increased to 28,601 for the three months ended December&#160;31, 2020 compared to 27,133 tests delivered in the same 2019 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by rheumatologists for the year ended December&#160;31, 2020 increased to 2,500 ordering healthcare providers as compared to 2,389 ordering healthcare providers in the same 2019 period. The number of ordering healthcare providers decreased to 1,690 for the three months ended December&#160;31, 2020 compared to 1,707 in the same 2019 period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue decreased $2.2&#160;million, or 12.0%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. This decrease was primarily due to decreased direct costs such as materials and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supplies associated with the decrease in test volume and decreased royalty costs associated with the expiration of a royalty on our CB-CAPs technology for the year ended December&#160;31, 2020 compared to the same 2019 period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $8.3&#160;million, or 29.0%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. This increase was primarily due to an increase of $5.6 million of employee related expenses, including stock-based compensation and recruitment expenses, increases related to insurance expenses of $1.0 million, legal fees of $0.7 million and audit and professional services of $0.7 million. The year ended December&#160;31, 2020 included one-time restructuring charges of approximately $0.2 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $1.4 million, or 64.0%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. The increase was primarily due to an increase of $1.2 million of employee related expenses, including stock-based compensation and recruitment expenses, and an increase related to clinical study expenses of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $0.9&#160;million, or 26.5%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. This decrease was primarily due to the lower interest rate under our long-term borrowing arrangements for the year ended December&#160;31, 2020 compared to the prior year period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of financial instruments decreased $0.3&#160;million for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. This decrease is due to the conversion of warrants to purchase preferred stock into warrants to purchase our common stock in connection with the completion of our IPO in September 2019. As a result, such warrants no longer require liability accounting which resulted in the recognition of income or expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, increased $0.5 million for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. This increase is primarily due to the $0.7 million received under the CARES Act due to lost revenues attributable to COVID-19 during the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit (Expense)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit increased $0.1 million for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 due to a change in tax law under the CARES Act. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the years ended December&#160;31, 2020 and 2019, we incurred a net loss of $16.7 million and $12.0&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of December&#160;31, 2020, we had an accumulated deficit of $181.3&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of our IPO in September 2019, our operations were financed primarily from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of our common stock. Including the option exercise, the aggregate net proceeds to us from the offering was approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. As of December&#160;31, 2020, we had $57.4&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we entered into the loan and security agreement with Innovatus under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. In November 2019, we amended the loan and security agreement with Innovatus, which we collectively refer to as the Amended Loan Agreement. Pursuant to the Amended Loan Agreement, the loan term is for five years with a final maturity date of November 2024. The Amended Loan Agreement accrues interest at an annual rate of 8.5%, of which 2.0%, during the first 36 months, will be treated as paid in-kind interest. Paid in-kind interest is added to the principal balance each period. After the initial 36 months of the loan, the entire 8.5% will be paid in cash at the end of each period. On or after the first anniversary of the Loan Amendment, but before the second anniversary of the Loan Amendment, we may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium. Prepayment before the second anniversary of the Loan Amendment may only occur for specified reasons in the Amended Loan Agreement. The prepayment premium decreases by 1% during each subsequent twelve-month period after the first anniversary of the Loan Amendment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels of minimum liquidity of $2.0&#160;million and achieve certain minimum amounts of revenue, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, within sixty days of failing to achieve the performance covenant, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. Our revenues for the twelve-month period ended September 30, 2020 were lower than the specified targets, and as a result, we and Innovatus agreed to a new management plan and target to bring us back into compliance with the Loan Amendment. At December&#160;31, 2020, we were in compliance with all covenants of the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the loan and security agreement with Innovatus in November 2017, we issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&#160;F redeemable convertible preferred stock at an exercise price of $0.078&#160;per share, and in December 2018, in connection with the additional $5.0 million borrowed under the loan and security agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. In connection with the completion of our IPO in September 2019, the warrants were automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock at an exercise price of $14.32.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to our agreement to comply with the Department of Health &amp; Human Services', or HHS, standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support healthcare-related expenses or lost revenue attributable to COVID-19. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal salesforce to drive increased adoption of and reimbursement for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products, promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We believe we have sufficient laboratory capacity to support increased test volume. We expect to make material additions for laboratory equipment and capital expenditures in the near term related to our laboratory facilities and expansion of research capabilities. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and payments for capital leases related to our laboratory equipment (see footnote 4 and footnote 5 in the audited financial statements included in this Annual Report on Form 10-K). Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business, including challenges resulting from social distancing and stay-at-home orders through a reduction in testing volumes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fluctuations in working capital;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the additional costs we may incur as a result of operating as a public company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the expansion of our sales capabilities, and the extent and timing of generating revenue from such promotion; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as Janssen. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,711)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,636)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2020 was $14.1 million and primarily resulted from our net loss of $16.7 million adjusted for non-cash charges of $3.9 million related to stock-based compensation, non-cash interest, depreciation, amortization and deferred income taxes and changes in our net operating assets of $1.3&#160;million related to net increases in account receivables and prepaid expenses and other current assets, partially offset by net increases in accounts payables and accrued liabilities and other current liabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2019 was $9.7&#160;million and primarily resulted from our net loss of $12.0&#160;million adjusted for non-cash charges of $2.2 million related to depreciation, amortization, stock-based compensation, non-cash interest and the revaluation of our preferred stock liabilities. The net cash used in operating activities was partially offset by changes in our net operating assets of $0.2 million related to net increases in accounts payable and accrued liabilities and other current liabilities, partially offset by decreases in prepaid expenses and other current assets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2020 and 2019 was $0.5&#160;million and $0.1 million, respectively, and was due to net purchases of property and equipment.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December&#160;31, 2020 was $0.1 million and primarily resulted from principal payments on capital lease obligations, as well as proceeds from the Paycheck Protection Program loan, which was subsequently repaid in May 2020, partially offset by proceeds from Employee Stock Purchase Plan purchases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2019 was $68.7&#160;million and primarily resulted from the net proceeds received from our IPO of $50.4 million, as well as net proceeds received from the issuance of our redeemable convertible preferred stock of $18.4 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Management Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these audited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the audited financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management's judgement and estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, substantially all of our revenue has been derived from sales of our testing products. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our services and to whom test results are reported are generally not responsible for payment for these services. The parties that pay for these services consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e. hospitals, other laboratories, etc.) and patient self-pays.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at our list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors. We follow a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of our net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation by management.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into the Janssen Agreement to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Our obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a series of single performance obligations since Janssen simultaneously receives and consumes the benefits provided by our sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-lived assets are comprised principally of our property and equipment, finite lived intangible assets, and goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize all finite lived intangible assets over their respective estimated useful lives. In considering whether intangible assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If we identify events or circumstances indicate that the associated carrying amount of assets within a group may not be recoverable, we will consider the assets in the group impaired if the carrying value of the group&#8217;s assets and directly associated liabilities exceed the estimated cash flows expected to be generated over the estimated useful life of the assets in the group. Management&#8217;s estimates of future cash flows are impacted by projected levels of tests and levels of reimbursement, as well as expectations related to the future cost structure of the entity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually or more frequently whenever a triggering event or change in circumstances occurs, at the reporting unit level. For our goodwill impairment analysis, we operate in a single reporting unit, and allocate all goodwill to this reporting unit. We are required to recognize an impairment charge if the carrying amount of the reporting unit exceeds its fair value. Management first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If a quantitative assessment is deemed necessary, management uses all available information to make this fair value determination, including the present values of expected future cash flows using discount rates commensurate with the risks involved in the assets and observed market multiples of operating cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments and estimates involved in identifying and quantifying the impairment of long-lived assets or goodwill involve inherent uncertainties, and the measurement of the fair value is dependent on the accuracy of the assumptions used in making the estimates and how those estimates compare to our future operating performance. No goodwill impairments were recorded during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of our IPO in September 2019, our stock price and associated market capitalization will also be considered in the determination of reporting unit fair value. A prolonged or significant decline in our share price could provide evidence of a need to record a material impairment to goodwill.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense related to stock-based awards to employees and directors based on the estimated fair value of the awards on the date of grant over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The grant date fair value, and the resulting stock-based compensation expense, is estimated using the Black-Scholes option pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded stock-based compensation expense of approximately $2.7 million and $0.6 million for the years ended December&#160;31, 2020 and 2019, respectively. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share attributable to common stockholders could have been significantly different. See Notes 2 and 9 to our audited financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted in the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Determination of the Fair Value of Our Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of our IPO in September 2019, our board of directors, with the assistance of management, determined the fair value of our common stock on each grant date. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of our initial public offering, our board of directors determines the fair value of our common stock based on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Redeemable Convertible Preferred Stock Warrants and Other Financial Instruments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, we entered into agreements with existing stockholders of our redeemable convertible preferred stock that contained future purchase obligations of redeemable convertible preferred stock at a fixed price. We evaluated these share purchase right agreements and assessed whether they meet the definition of a freestanding instrument and, if so, determined the fair value of the share purchase right liability and recorded it on the balance sheet. The share purchase right liability was revalued at each reporting period with changes in the fair value of the liability recorded as a component of other income (expense) in the statement of operations. The share purchase right liability was revalued at settlement and the resultant fair value was then reclassified to redeemable convertible preferred stock at that time. The estimated fair value of the share purchase right liability was determined using valuation models that consider the probability of achieving the requisite milestones, our cost of capital, the estimated time period the preferred stock right would be outstanding, consideration received for the convertible preferred stock, the number of shares to be issued to satisfy the preferred stock purchase right and at what price, and probability of the consummation of an initial public offering, as applicable.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for our redeemable convertible preferred stock warrant liabilities as freestanding instruments for shares that were puttable or redeemable. These warrants were classified as liabilities on our balance sheet and were recorded at their estimated fair values. At the end of each reporting period, changes in estimated fair value during the period were recorded as a component of other income (expense), net in the accompanying statement of operations. We continued to re-measure the fair value of the warrant liabilities until: (i) exercise; (ii) expiration of the related warrant; or (iii) conversion of the preferred stock underlying the security into common stock, which occurred in connection with the completion of our IPO in September 2019. We estimated the fair values of our warrant liabilities using an option pricing model based on inputs as of the valuation measurement dates, including the fair value of our redeemable convertible preferred stock, the estimated volatility of the price of our redeemable convertible preferred stock, the expected term of the warrants and the risk-free interest rates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were significant judgments and estimates inherent in the determination of the fair values of our preferred stock purchase right liabilities and redeemable convertible preferred stock warrant liabilities. If we had made different assumptions, the carrying value of these liabilities, net loss and net loss per share attributable to common stockholders could have been significantly different.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in, and are subject to tax authorities in, various tax jurisdictions in the United States. To date, we have not been audited by the Internal Revenue Service or any state income tax authority. All tax years remain open for examination by federal and state tax authorities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. We previously completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from our formation through December 31, 2019. Based upon this study, we determined that ownership </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes had occurred in 2003, 2008, 2012, 2017 and 2019, and that our ability to use a significant portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. In addition, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to reduce our deferred tax assets by a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We must use judgment in assessing the potential need for a valuation allowance, which requires an evaluation of both negative and positive evidence. The weight given to the potential effect of negative and positive evidence should be commensurate with the extent to which it can be objectively verified. In determining the need for and amount of our valuation allowance, if any, we assess the likelihood that we will be able to recover our deferred tax assets using historical levels of income, estimates of future income and tax planning strategies. As a result of historical cumulative losses and uncertainties surrounding our ability to generate future taxable income and, based on all available evidence, we believe it is more likely than not that our recorded net deferred tax assets will not be realized. Accordingly, we have recorded a valuation allowance against all of our net deferred tax assets at December&#160;31, 2020. We will continue to maintain a full valuation allowance on our deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of this allowance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP. There are also areas in which our management&#8217;s judgment in selecting any available alternative would not produce a materially different result. Please see our audited financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K, which contain accounting policies and other disclosures required by GAAP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Notes to the Financial Statements-Note 2-Recent Accounting Pronouncements" of our annual financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented we did not have, nor do we currently have any off-balance sheet arrangements, as defined under the rules and regulations of the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_55"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_58"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplemental data required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_61"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_64"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for "emerging growth companies."</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment of Chief Operating Officer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, our board of directors appointed of Mark Hazeltine, age 47, as our Chief Operating Officer, effective as of March 15, 2021. Mark Hazeltine has served in various positions of increasing responsibility since joining Exagen in March 2015, including general manager. Mr. Hazeltine received his Bachelor of Business Administration degree from the University of San Diego and Master of Business Administration degree from the Marshall School of Business at the University of Southern California. Additional information regarding Mr. Hazeltine's background, business and experience will appear in our Definitive Proxy Statement on Schedule 14A, to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, under the heading's "Executive Officers."</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of Mr. Hazeltine's offer letter, as amended effective as of March 15, 2021 in connection with his promotion, Mr. Hazeltine will receive an annual base salary of $375,950 and will be eligible to receive an annual incentive bonus at an initial target for calendar year 2021 of 45% of his annual base salary. The offer letter with Mr. Hazeltine provides for an indefinite term and for at-will employment. Mr. Hazeltine is also entitled to participate in all employee benefit plans, programs and arrangements maintained by the company and made available to employees generally.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships between Mr. Hazeltine and any of our directors or executive officers that are required to be disclosed pursuant to Item 401(d) of Regulation S-K. In addition, there are no transactions between us and Mr. Hazeltine, or any member of Mr. Hazeltine's immediate family, that are required to be disclosed pursuant to Item 404(a) of Regulation S-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Change in Control Severance Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2021, the Compensation Committee of our board of directors adopted the Exagen Inc. Executive Change in Control Severance Plan, or the Severance Plan. The Severance Plan provides for the payment of cash severance and other benefits to our executives, including Fortunato Ron Rocca (President and Chief Executive Officer), Kamal Adawi (Chief Financial Officer and Corporate Secretary) and Mark Hazeltine (Chief Operating Officer), in the event of a qualifying termination of employment with us in connection with a change in control.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Severance Plan, in the event of a termination of an executive&#8217;s employment by us without &#8220;cause&#8221; or by the executive for &#8220;good reason&#8221;, in either case, on or within twelve months following a &#8220;change in control&#8221;, the executive will be eligible to receive the following payments and benefits:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cash payment equal to 100% (or, for Mr. Rocca, 125%) of the sum of (i) the executive&#8217;s then-current annual base salary, plus (ii) the executive&#8217;s target cash performance bonus for the year in which the termination occurs, to be paid in a lump sum on the 30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day following the executive&#8217;s termination; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cash payment equal to the executive&#8217;s pro-rated cash performance bonus (based on actual performance) for the year in which the termination occurs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Company-subsidized COBRA premium payments for the executive and his or her covered dependents for up to 12 (or, for Mr. Rocca, 15) months; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">full accelerated vesting of all outstanding equity awards of our company that vest solely based on the passage of time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The executive&#8217;s right to receive the severance payments and benefits described above is subject to the executive&#8217;s delivery and, as applicable, non-revocation of a general release of claims in our favor and the executive&#8217;s continued compliance with any applicable restrictive covenants.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the event that any payment under the Severance Plan, together with any other amounts paid to the executive by us, would subject the executive to an excise tax under Section 4999 of the Internal Revenue Code, such payments will be reduced to the extent that such reduction would produce a better net after-tax result for the executive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Severance Plan is qualified in its entirety by reference to the full text of the Severance Plan, a copy of which is filed as Exhibit 10.46 to this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III.</span></div><div style="text-align:center"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_73"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.exagen.com. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_79"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_82"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_85"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_91"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Financial Statement Schedules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) All financial statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Exagen Inc., together with the report thereon of BDO USA, LLP, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page 96.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Financial statement schedules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of exhibits is set form on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_100">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_100">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_103">Balance Sheets as of December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_103">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_106">Statements of Operations for the Years Ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_106">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_109">Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity for the Years Ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_109">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_112">Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_112">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_115">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_115">101</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stockholders and Board of Directors </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vista, California </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying balance sheets of Exagen Inc. (&#8220;the Company&#8221;) as of December 31, 2020 and 2019, the related statements of operations, redeemable convertible preferred stock and stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ BDO USA, LLP </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2017. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;16, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMtNC0xLTEtMA_31ae29bf-59d4-4c45-b747-58e7dee32781">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMtNi0xLTEtMA_d51bb770-f1e6-41e7-9ddd-f211e061eaa6">72,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzQtNC0xLTEtMA_9818f7da-b40d-47a0-a695-6f8ac1919543">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzQtNi0xLTEtMA_7dddff8d-04d5-465e-acf4-e82ebda9828a">5,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzUtNC0xLTEtMA_0a3f2208-1277-4efb-95a8-6931f8ddd676">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzUtNi0xLTEtMA_da9b0535-dc40-413b-8a20-abe2ed31b1c8">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzYtNC0xLTEtMA_3dfa1f97-ee8b-4e5e-bcff-ae4c924213e5">70,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzYtNi0xLTEtMA_051bb0e3-def0-4e56-8924-63b0a5dd7c54">81,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzctNC0xLTEtMA_c54b5f37-32c5-4023-9175-feb7a1e5b2b7">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzctNi0xLTEtMA_02ee460f-7ae7-423f-b98e-278983c9f6e5">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzgtNC0xLTEtMA_ad98b527-1e49-4523-bd46-da513e4f3078">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzgtNi0xLTEtMA_1252ce76-9508-4c06-917a-576550c51119">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzktNC0xLTEtMA_00030cc6-0887-43d0-809e-38d8f960d30a">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzktNi0xLTEtMA_6bd890a9-f5dc-4067-b22e-bc3d12be7958">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEwLTQtMS0xLTA_c2b745fa-5960-4dd2-a365-f0d9d0789ba6">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEwLTYtMS0xLTA_4a0136da-fe74-4333-87b6-3e57a9683257">88,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEzLTQtMS0xLTA_58ce0402-cbba-4163-8947-b38b63c21645">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEzLTYtMS0xLTA_5c1a3bf3-3f7e-4f8f-8824-e7e531b8c1e8">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE0LTQtMS0xLTA_9e5d88d1-9ac5-4c04-a877-65765b1f5cdf">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE0LTYtMS0xLTA_c28d522a-08bc-4b72-b582-3fe369d6dc89">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE2LTQtMS0xLTA_45282170-a20f-4c37-85aa-5234561b169a">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE2LTYtMS0xLTA_eb8959a9-822b-470d-88cf-2f296a5b6ffc">5,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE3LTQtMS0xLTA_5221d41a-126f-4031-995b-1b97e0b016f7">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE3LTYtMS0xLTA_9ce14864-4600-4db3-a773-a62216099e95">25,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE5LTQtMS0xLTA_ba3930f0-83f0-4c13-b8e4-a48595ade7a8">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE5LTYtMS0xLTA_79e227e0-be2e-4336-8230-4fa9f94c05d2">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIwLTQtMS0xLTA_fc080b07-7d5f-43bd-9c97-20ce667212c0">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIwLTYtMS0xLTA_619310af-9d54-46d4-8512-b032c678a2ae">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIxLTQtMS0xLTA_d10735e7-c6f2-465f-8bfd-8e963b5552fa">36,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIxLTYtMS0xLTA_20b37527-4f50-4f25-8ef3-d93fff63caa7">32,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIyLTQtMS0xLTA_3333b57a-3d85-4185-907b-4530cc19fafd"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIyLTYtMS0xLTA_860c2a37-f9be-40c9-8944-d0d7db736229"></ix:nonFraction></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8yMQ_643c2f96-1e5d-4842-aea7-5cb379bc4a7d"><ix:nonFraction unitRef="usdPerShare" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8yMQ_8d15e96e-441b-436e-8cce-8a91f6d658cb">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8zNQ_7cd2a1f1-c9ff-4e48-9eec-718e7dec2b96"><ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8zNQ_a6ca3629-6c72-45d9-a0e8-85bc92f5a290">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_27dd6383-9461-4db5-963d-376d18075343"><ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_5e846a68-1142-4fd3-bdad-073d59e7fb00"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_989460a6-c762-453a-88a2-1ea4b6a845a7"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_fba9d52f-f838-44d0-86b7-51638eda7268">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2020 and December 31, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTQtMS0xLTA_236e174b-4d72-467d-b7f3-3d11190b93e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTYtMS0xLTA_9a706612-c859-4875-b768-1a798936d5ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xOA_578a4852-7f86-415f-977e-434dda58a912"><ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xOA_795f99a9-5e4a-48f1-a2b2-cc9bd8174754">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18zMg_397770a0-e3fe-4611-b89f-dc0f3bebcbd1"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18zMg_c9b2a9a1-1f53-41cf-85a0-ca5e3dcbb2f0">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2020 and December 31, 2019; <ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMTg_466c6449-e9f1-4c2b-a8b3-dc86d9d4ad60"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMTg_9660ed2d-c441-487f-98c9-c3d2a28a5334">12,652,308</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMjU_084ebfef-3b44-45ab-b280-4a0d300cad0d"><ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMjU_778fe8fd-6b35-4f73-9745-15da24e9432c">12,560,990</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTQtMS0xLTA_9ed1327f-8984-418c-84cf-e988d1a3fdab">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTYtMS0xLTA_062b9263-c1e2-48a1-9ffe-38b6f53ef77a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI3LTQtMS0xLTA_dc52b1dd-81b2-436c-92c3-8f964e34de2a">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI3LTYtMS0xLTA_86a2a8b3-de20-4572-8c65-a86eb83e2f22">220,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI4LTQtMS0xLTA_73145ba2-8e17-44b9-b32c-ca116ed141c1">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI4LTYtMS0xLTA_9eb3174f-a1c5-4fcc-9a75-a02ae83ce3e8">164,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI5LTQtMS0xLTA_3eccc39b-17b2-47e3-b893-d6667207b9a4">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI5LTYtMS0xLTA_daa5c10e-965d-4305-8670-19a86ea17540">55,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMwLTQtMS0xLTA_a58f0e3f-e0af-47f6-8fd0-65d9ca8aeb15">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMwLTYtMS0xLTA_01b2291a-2b91-41ac-9b25-122d203fb888">88,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzMtNi0xLTEtMA_b6b1f265-b538-43b9-a293-69624e6092e6">41,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzMtOC0xLTEtMA_a07d6680-4963-42d5-8615-1fb03525cf12">40,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzUtNi0xLTEtMA_92cec360-2f8b-404b-93e9-1fb0de2308f6">16,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzUtOC0xLTEtMA_d8bdf4f1-4d26-4dcf-97fd-14ce1f8b8747">18,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzYtNi0xLTEtMA_703a186d-dfaf-449f-bc3f-dead8e6e4e81">37,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzYtOC0xLTEtMA_6e2e969b-2855-4e96-8c0f-a5d5103e3d4c">28,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzctNi0xLTEtMA_ec352c04-9aa6-463b-bac1-3a370c8195c1">3,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzctOC0xLTEtMA_c353d09d-8b5c-4914-8cb3-883afbce8d5f">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEwLTYtMS0xLTA_001ed7d2-295c-436c-9dde-736406708d49">57,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEwLTgtMS0xLTA_cb90f252-d9f3-4705-a7c8-1c8fdeb69f5a">49,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzExLTYtMS0xLTA_c484398c-bd3c-41a3-9846-c30b73d8341e">15,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzExLTgtMS0xLTA_7fa6d723-05c3-4dfd-a0b5-01f4db519db5">9,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEyLTYtMS0xLTA_ac19ee01-2c00-43ef-a81f-29e6873d6f71">2,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEyLTgtMS0xLTA_79a1ff69-2450-4fbf-b0d9-d0ec0bbab5b4">3,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEzLTYtMS0xLTA_1c2eb117-7ad1-4bc0-9ea4-4ab3e4e0d8f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEzLTgtMS0xLTA_3edc9866-24fb-40f1-ae26-29f011deaf72">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE0LTYtMS0xLTA_3555c0ec-b81a-4620-a897-3ace6538de33">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE0LTgtMS0xLTA_58388825-79a0-43bb-840a-b7fadc4c5663">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE1LTYtMS0xLTA_09e7a421-fd85-4629-9beb-20a10fd091db">16,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE1LTgtMS0xLTA_7ecc3d7f-dfa8-43c8-b37a-603b5491df71">12,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE2LTYtMS0xLTA_626bef7a-32e4-49ae-9a87-d5609750fcd8">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE2LTgtMS0xLTA_a408641a-7920-48a3-8ffa-8929d0f50cc7">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE3LTYtMS0xLTA_58ff90b5-d72e-4115-bf48-89331be0595e">16,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE3LTgtMS0xLTA_2263a104-b12a-4c7c-bddf-010dd70f9973">12,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE4LTYtMS0xLTA_0ad703c7-6537-426e-a8ed-ef3154dec86c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE4LTgtMS0xLTA_b90f6b98-a5a9-4342-a588-c1af483726f2">4,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recorded in connection with financing transactions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE5LTYtMS0xLTA_800ce1e2-4101-46ab-9c15-b3a55021d2b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE5LTgtMS0xLTA_454940ba-7a79-4016-bc85-7b09b3c00c17">13,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIwLTYtMS0xLTA_bbb3fd8c-48dc-4e4b-a015-02d74f88c509">16,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIwLTgtMS0xLTA_5aa7e53a-8773-4878-8037-1c5ab00ee131">30,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIxLTYtMS0xLTA_636e3f0d-d82b-4bfd-b580-2a98cfd845f8">1.32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIxLTgtMS0xLTA_02e5aa83-bb50-4e20-b7fe-a443a1df4f7d">8.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIyLTYtMS0xLTA_63331411-3b44-4548-9426-8cc931464be6">12,632,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIyLTgtMS0xLTA_df3085f6-37b2-4105-9df1-ac766d416d96">3,578,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.583%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMi0xLTEtMA_11372114-e4ff-41b8-80e6-7b0f8ac098c8">532,606,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtNC0xLTEtMA_dedbf4a9-ca59-481e-b1ed-e22ac0629497">105,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6884440164f1463aa6e4fed299d3fe16_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtNi0xLTEtMA_84379aad-9ca0-43ab-aef0-51df3a847c75">63,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6884440164f1463aa6e4fed299d3fe16_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtOC0xLTEtMA_2ea54a7e-5830-4fd0-9df8-ae85e915ef3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5cbdb8b75149f1a2107742fed852bf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTAtMS0xLTA_aac02bd1-2f90-4d9e-928b-729b3410f694">40,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e3a91a5115e431d98f3d1ae4a1da9ec_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTItMS0xLTA_bbbce9c5-e542-42d3-b09c-7b4e9eace0e0">152,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTQtMS0xLTA_df2db667-dfcd-4cc9-9b84-509df52798d1">111,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktNC0xLTEtMA_cccc8424-405e-4187-81e7-bbbbed87e642">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktMTAtMS0xLTA_7b2022d7-75f5-4e21-b234-79a9cf9c739a">4,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktMTQtMS0xLTA_5722380f-d786-4290-80bf-e9e9e6493203">4,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTYtMS0xLTA_0641b0a6-a66e-4d95-b081-48c638ffe2ed">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTEwLTEtMS0w_69009976-ec7e-4b48-9ffe-a68199d1b272">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTE0LTEtMS0w_dd7d13e2-f456-45e1-8dd0-a25c6b534c0d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzExLTEwLTEtMS0w_adaec370-8482-4b30-90e8-8c4832512672">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzExLTE0LTEtMS0w_e466d560-4df6-4655-851e-d18a13ac8f72">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTA0ZGNkYTkyNWQ0MTI2YjliMzNhOGVhMDlhNjE0M185MA_63a43e61-7508-45c5-b4a4-c629fff5d530">0.078</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTA0ZGNkYTkyNWQ0MTI2YjliMzNhOGVhMDlhNjE0M18xMjk_d640c9c1-9508-436e-8e44-9dca3a311435">124</ix:nonFraction> (Note 7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTItMS0xLTA_3f564dd3-b161-4f44-8278-4a75f6b865f9">148,928,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTQtMS0xLTA_7c35bcde-5c40-4c33-9edd-96f3b57bcf17">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZTAyOTliODZkMGI0ZjI0ODZjNzFiMjgwZTUxYTc2N185MA_f18c8003-d7f1-4e82-835c-7a82759cfc54">0.047</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZTAyOTliODZkMGI0ZjI0ODZjNzFiMjgwZTUxYTc2N18xMjk_2c072dee-3e7f-4a35-ab69-424258cce0b8">318</ix:nonFraction> (Note 7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTItMS0xLTA_6bd5fc8c-8feb-4fa0-8d3d-d01a0b4c03d7">233,446,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTQtMS0xLTA_45cb176b-684c-401a-8172-23762601eddb">3,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTEwLTEtMS0w_82f5fc95-2305-48e3-b7bc-eefbcc10115d">6,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTE0LTEtMS0w_a6302082-e0dd-40c9-966e-8d0765d22962">6,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTQtMS0xLTA_d25d3094-df8d-4796-b06e-8644899e2bdf">6,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTEwLTEtMS0w_593dc169-3771-446b-8ce9-290f66b39c2e">6,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTE0LTEtMS0w_b4982da8-fcbe-4eb3-b764-26237bc6f0b9">6,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTItMS0xLTA_d06c6d4f-6dbd-4be0-be2b-22f682082de1">97,592,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTQtMS0xLTA_65b4c8d4-e618-44aa-811b-41535eec6412">6,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTEwLTEtMS0w_aadd7a60-b421-4b28-81a9-7e7f2ed0c101">6,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTE0LTEtMS0w_d52e4b4f-2bda-465b-8305-7741312b1ba2">6,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock in connection with initial public offering (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesRedeemedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTItMS0xLTA_775e49fe-cc64-44c8-8e3f-dc8f2e959e51">1,012,573,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesRedeemedUponConversionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTQtMS0xLTA_93a2e433-5a07-4b74-bbb9-710a40ba53b8">138,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTYtMS0xLTA_96420639-73b1-4ecc-9e0e-5d6443466338">7,816,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTgtMS0xLTA_97ce7924-441b-4e38-a6cb-e03c8ba64a50">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTEwLTEtMS0w_f05dda18-6ea1-40a6-8d67-bffe751e1658">138,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTE0LTEtMS0w_887ff9da-021a-4e11-b578-88d7ba55396a">138,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTYtMS0xLTA_0bcea484-4660-4863-8189-a9ddacaa66b5">4,140,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTgtMS0xLTA_4fd5418f-d55d-4a13-a21f-aefdb162d47e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTEwLTEtMS0w_773cb117-d9ef-42e9-8239-eff30cea5dad">50,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTE0LTEtMS0w_1bedad57-1c68-4ea9-b609-8f2d8c0cd6ff">50,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net exercise of common and preferred stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTYtMS0xLTA_dc3c8003-28f7-46f2-8f24-75274f5acda4">539,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTgtMS0xLTA_9b5a15ac-b50c-4bfc-83d2-3a844e3eed7b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTEwLTEtMS0w_572211d0-10c4-4f17-b3de-670b05355713">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTE0LTEtMS0w_cf6648f0-2301-4832-986c-fecc3cd4cf9d">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE5LTEwLTEtMS0w_ce7d3c92-f868-44fb-b832-81f8d559845f">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE5LTE0LTEtMS0w_d504f147-7acd-41b5-baa8-01c5349ef09e">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000894d3cadd4d209d2620841a05dcf0_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIwLTEyLTEtMS0w_b97eefb9-b941-43ad-b7c8-80dc2a581d82">12,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIwLTE0LTEtMS0w_b452239a-5410-41b7-96b4-492eb585a534">12,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTItMS0xLTA_a4f284f1-7e31-4793-97b8-d04a5e11b5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTQtMS0xLTA_4c53b5e3-f7ea-45e9-8a51-fba69df1b640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTYtMS0xLTA_ba779cf6-0ce9-4725-8961-7f170e3f7875">12,560,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTgtMS0xLTA_c703d93a-23e1-41e0-a984-cecf3f67adcc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69da35ef92234938bcda9473aefd88f5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTEwLTEtMS0w_112169c8-0b08-4310-9524-6ae660c368cf">220,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724b6d08dcb54c94ae1352b8b23c595f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTEyLTEtMS0w_adbd3310-eda9-4352-900b-7057f7deda56">164,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTE0LTEtMS0w_d310e147-bd0a-47b2-97f8-fe965c4d8fd0">55,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTYtMS0xLTEwMQ_2ac8db5b-8a82-4dab-a992-49a569857210">47,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTEwLTEtMS0xMjg_62a9a885-58b5-44ba-b106-5360f05a458e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTE0LTEtMS0xMzY_75d88d91-b0e3-480a-a85f-c33d2fd8882f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTYtMS0xLTEwMQ_420a8f71-3ec0-4cfe-9be9-40c73f18f258">11,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTEwLTEtMS0xMjg_c7601199-efd6-4da0-accd-7a032511b003">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTE0LTEtMS0xMzY_d5d7d842-0769-4a6c-a14c-e82fba8c79a3">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI0LTEwLTEtMS0xMjg_017b1b2b-9640-43a6-9a43-99693162f3ec">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI0LTE0LTEtMS0xMzY_17f4afd5-a44d-4565-a4b0-02f5849d282c">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTYtMS0xLTEwMQ_3815202f-ca3a-4620-b50a-19394bc139ee">32,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTEwLTEtMS0xMjg_09c21b16-9589-4e80-aad0-47c6fe445f2d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTE0LTEtMS0xMzY_88215e08-84b1-4348-b92f-e6c4251f323b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85d4c855b6840b89f8a4974a7609bdd_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI2LTEyLTEtMS0xMzI_0d87408b-8f22-4713-a295-3ebad6397366">16,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI2LTE0LTEtMS0xMzY_212dbc3d-666f-4146-a10f-2fa4cb4d7fa9">16,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTItMS0xLTExNg_135806b6-4b88-4290-b9a6-3606a2771312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTQtMS0xLTEyMA_435f6593-6603-4972-9be2-47222ae51ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTYtMS0xLTEwMQ_1be86c69-a8ef-4584-b547-15d29ad2236d">12,652,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTgtMS0xLTEyNA_5e1a1975-21f7-452d-92e1-93fdfa1c07bf">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e794abff7a43f59c1e323fa7e55d45_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTEwLTEtMS0xMjg_b726ffbc-2a4b-48c2-b549-7b9cee742182">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6dbfbafdf8a408ca1bbfc730926cc14_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTEyLTEtMS0xMzI_ed5fd58f-f5b2-4444-9995-c2f73de39058">181,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTE0LTEtMS0xMzY_37694814-8a9c-4dbb-8d88-823d1701fd4e">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_112"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQtNi0xLTEtMA_6e6568cb-a1d5-46bb-b0d9-37dd8306d335">16,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQtOC0xLTEtMA_2950fafb-9df1-4c05-84de-76b8f9d92bd6">12,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzYtNi0xLTEtMA_544089f1-91ac-4ddd-90ad-0a66f4b8d2d5">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzYtOC0xLTEtMA_de231a07-54bb-4d04-b450-dfe7d37e1357">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzctNi0xLTEtMA_c7731aad-a730-4a53-8c09-8434ffae897d">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzctOC0xLTEtMA_a5500d03-f03d-4f05-9a61-1e710b35f4e1">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzgtNi0xLTEtMA_f0a5b4f6-62d2-4601-a5f9-ec5f9ab17b2f">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzgtOC0xLTEtMA_f8a6eacc-c849-459f-a2b4-127d9d5a5205">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revaluation of warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzktNi0xLTEtMA_7d43e419-a1a0-4126-acb4-776643240df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzktOC0xLTEtMA_92de762e-6017-4c3e-8522-f264a384302b">267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEwLTYtMS0xLTA_88951393-4b7b-4751-a917-07b0ff2a1851">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEwLTgtMS0xLTA_40835c0c-cbe8-4112-a0f4-444567431776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzExLTYtMS0xLTA_f49b5148-d87f-46d9-951a-914e8d7853b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzExLTgtMS0xLTA_1e049ecf-b56e-48ce-b8d8-50f113a4b111">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEyLTYtMS0xLTA_2b5bb34c-0fdc-40fd-a2e9-6866bd28f9fe">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEyLTgtMS0xLTA_a86aa1fa-c3d7-4c46-bd86-20eb881cdcd2">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE0LTYtMS0xLTA_823e7f9b-6be2-45da-b7f8-5816c3f8f98d">3,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE0LTgtMS0xLTA_c082547c-876e-47d1-aaa8-9728cfd3d57f">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE1LTYtMS0xLTA_d058f9f1-9642-465f-bd8e-834b5859f6b7">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE1LTgtMS0xLTA_756330f0-ffef-47fc-bb72-2d3aae38d7dc">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE2LTYtMS0xLTA_9eaa92f1-2f25-4ebc-947d-24bb97d7c2c1">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE2LTgtMS0xLTA_f53b7687-d037-45ea-ac64-6878f8b97e61">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE3LTYtMS0xLTA_ba5c5ce8-8f3c-42d8-8b70-c4a5af9443b7">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE3LTgtMS0xLTA_4ab790fd-495a-4fde-bdf1-bd030079cec4">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE4LTYtMS0xLTA_c2e371f7-e7fd-4ed4-b0a4-691404f26d00">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE4LTgtMS0xLTA_ec0e59cb-2446-410e-abe8-c6fceef5ccf1">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIwLTYtMS0xLTA_8241f105-2e87-49ce-a562-6870a87775fb">14,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIwLTgtMS0xLTA_9efd2d4d-d576-430a-b36e-4f072e841568">9,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIyLTYtMS0xLTA_2d7cf7ea-596c-4f14-8c9c-3408c670d2a5">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIyLTgtMS0xLTA_4fd19c63-677f-4117-81ec-814ff8fbd6bd">403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIzLTYtMS0xLTA_156ced16-2eda-4895-a403-25cfac089c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIzLTgtMS0xLTA_d837d82c-261e-4fd8-8b42-957c230bd986">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI2LTYtMS0xLTA_f80b3dc9-a1e8-4311-b837-c5bda66420b9">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI2LTgtMS0xLTA_ef98572f-8068-4872-8c93-655466cadab8">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from sale of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI4LTYtMS0xLTA_68d91bfd-a7d3-4121-aa44-d4c0248702f2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI4LTgtMS0xLTA_748d45cf-de48-40ed-9f85-2112da12b83b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTYtMS0xLTE2Mw_7a8dae1e-c7a4-4b7f-b246-d271c3eb00ae">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTgtMS0xLTE1OQ_3c525bd4-0f94-444d-9135-87e7c3051526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMwLTYtMS0xLTE2Mw_79366000-65f4-4298-abb4-2af38f77281a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMwLTgtMS0xLTE1OQ_7138ad5e-b575-4c98-8cf0-a4554e1ca3ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal payment on capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTYtMS0xLTA_d3aa1031-5205-4c59-8257-61b1f5d4ddb9">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTgtMS0xLTA_733b0fba-d5a6-47d7-923e-fdaeecb61a4e">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTYtMS0xLTE3MQ_b87bcd42-503b-4203-a6ad-a6184cb57f15">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTgtMS0xLTE2Nw_72f6b3a2-6d52-45ab-afdc-1953633eda7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTYtMS0xLTE3MQ_3e25f041-8ffc-43e9-9963-7c826ad6c8d5">2,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTgtMS0xLTE2Nw_3655a537-9776-4be9-bd6c-396668ec9c2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from initial public offering, net of issuance costs and offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMxLTYtMS0xLTA_d6a8f464-c015-4bd9-8224-9b7d5bc35682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMxLTgtMS0xLTA_fdf03ebb-8d32-4a94-a3cf-e063deaf0660">50,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of Series G redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTYtMS0xLTA_47237215-49ca-4059-874d-61f91b3e5add">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTgtMS0xLTA_1b8b5334-3c50-4fd4-bb7f-68977eb1f33b">7,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of Series H redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTYtMS0xLTA_807defa2-56da-4c67-b6c6-621aaf783a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTgtMS0xLTA_af94cf32-f49a-4e41-98ef-4d784b29431f">10,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments of deferred offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM1LTYtMS0xLTA_047adf37-f4f4-40a0-b6cd-e1eece6f4868">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM1LTgtMS0xLTA_801fc878-064a-49b2-8668-feceaff429b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM2LTYtMS0xLTA_5dbd50e2-87d0-49da-8bda-8f055d01008b">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM2LTgtMS0xLTA_c0985424-f20c-4b1b-a8d6-5c47ad0d6e05">68,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM3LTYtMS0xLTA_b5a6f063-5c48-4504-92b0-0ba6e64d8844">14,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM3LTgtMS0xLTA_72fa05a7-afbc-4432-984f-6d8c06a1cc15">58,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM4LTYtMS0xLTA_0554a641-94c0-48da-b3e9-f5878bac6d1b">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM4LTgtMS0xLTA_9ec18dde-fa8b-4124-890c-c2d4a42b2bed">13,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM5LTYtMS0xLTA_d587f621-a239-43bb-80ae-ae58755e5581">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM5LTgtMS0xLTA_cea1ab2d-d93d-4765-9893-ff7ef0bf4bad">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQxLTYtMS0xLTA_7858ab3c-8ad8-417c-8d14-274d1718268d">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQxLTgtMS0xLTA_ec7871c2-c7ee-4d0e-b8d5-46f272fa71c6">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accretion to redemption value of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQzLTYtMS0xLTA_ae05c099-bd68-4d7b-a3de-f1b6c6fba137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQzLTgtMS0xLTA_fb8ebeab-6518-412e-9812-da6e23467c67">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equipment purchased under capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ0LTYtMS0xLTA_2a75bd17-72ed-4d23-93dd-98acf1c444ee">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ0LTgtMS0xLTA_b8342b7e-5df2-48a5-b629-30e9f6ea0e07">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ2LTYtMS0xLTA_00606cc5-4a13-4a53-95aa-c0cb3384b767">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ2LTgtMS0xLTA_eb0a4927-fa96-45ec-b181-b2246212cdbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ3LTYtMS0xLTA_320eda23-4d80-4354-a263-8df93880a140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ3LTgtMS0xLTA_3d866601-3a30-4314-a9a7-2ae6a60ce323">138,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net exercise of common and preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:NoncashExerciseOfStockPurchaseWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ4LTYtMS0xLTA_32087ccc-c63a-41c2-91b1-1b84b0e908e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:NoncashExerciseOfStockPurchaseWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ4LTgtMS0xLTA_26343829-cde3-40d4-af53-6b62dcd54ebb">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ5LTYtMS0xLTA_e203bf8d-4fa3-4844-b6e8-e983c9779fe2">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ5LTgtMS0xLTA_cea6ebde-9ea2-44fe-aa3c-2a594c47d8c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUwLTYtMS0xLTA_49480aac-3f35-4e51-81ad-5f1fde831dec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUwLTgtMS0xLTA_5da337a1-ea36-4775-a18b-99aca4cab77c">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUxLTYtMS0xLTA_c9f58ab3-9269-4f99-9085-9739d7618c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUxLTgtMS0xLTA_5f620cbc-4ba9-4e34-81ee-4f12f85bf8d9">6,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUyLTYtMS0xLTA_0d924560-2b7e-407f-b206-81e54d94d7d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUyLTgtMS0xLTA_88957708-a2e5-4665-8be4-c659472fb27f">6,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series G to Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:ConversionOfTemporaryEquityAmountConverted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUzLTYtMS0xLTA_b195f0c1-1e4b-444c-8962-a027493b6274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:ConversionOfTemporaryEquityAmountConverted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUzLTgtMS0xLTA_ab81e2bb-0184-4c76-a908-caa64a5e1cc7">11,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_118"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzQwMTU_f93de78d-3cc0-47a8-93db-d4f9e1f20771" continuedAt="i8c1797c825114e08aa838b5a6bda56c1" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i8c1797c825114e08aa838b5a6bda56c1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2020, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzI0ODM_58b599c0-d0f5-4970-8418-72b616c966f9">57.4</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzI1MjA_6879f0c1-cf85-4ac7-a2a7-61e934f5b7b3">181.3</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its initial public offering (IPO) and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAw_447dfdd8-bae9-4ec9-94ac-f86e7eaf8dab" continuedAt="i78d6c73b5dbe46179b5abe90633a0af1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i78d6c73b5dbe46179b5abe90633a0af1" continuedAt="ie798620eb74e4aacb994a9b588a8032b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAx_01b44d5e-32ac-499f-909b-1cf9214e4481" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie798620eb74e4aacb994a9b588a8032b" continuedAt="i4756fb9946c642b5814205efa18e7a4c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEw_d952876c-b8b7-4bb4-ad10-087a353ee92a" continuedAt="i8441b7be0a274dd0817ea4c5faca5bbc" escape="true">For each significant payor and customers, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i8441b7be0a274dd0817ea4c5faca5bbc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzMtNi0xLTEtMA_6b85d91b-db94-4899-be63-9d4ed443d945">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9563b9ab6fbe4adcbdfbac8e2cf19b22_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzMtOC0xLTEtMA_2f2ae038-ac49-4228-9be1-ffa12bac0154">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c6b3ac4c664091b47227b153e9eb44_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtNi0xLTEtNDU5Nw_3ced5803-dcac-42b6-9e58-52d8aa9143e9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac265b2ebdbc43e59ef20ea50e78de9f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtNi0xLTEtMA_5e60cef5-bb34-4bd6-b66a-e05359e468be">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb52827a0d5e4d20bbb2e688d4965f2b_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtOC0xLTEtMA_5f51a9a7-943c-4c7c-bfe8-7d0e6aa0e652">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id90ff0582bfa4beb88fa29365bcf05c9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzYtNi0xLTEtNDYwMg_7626cd86-40d8-4ba2-8148-fa4e42d37166">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i075b7f5ce30f4250b3fa7b1319fa76d0_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzYtOC0xLTEtNDYwMg_70b39b76-51ec-4772-9976-42bb3b525345">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7cbc755e54584988a46ac09b03ba0a03_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzUtOC0xLTEtMA_f2054647-bc87-41b5-b8be-ab37a54de351">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia683090804ac4bbea90d92b75159efe3_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzMtNC0xLTEtMA_c8c04030-ae16-45f4-a127-011adc74a969">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i031b116f01f44ea5890d77e14040a529_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzMtNi0xLTEtMA_ec1fc714-b57c-43ab-aff7-a14973888d98">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5031346fd2374b0e97451ce84bad8260_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzQtNC0xLTEtMA_01582b63-6a84-48c7-b0e8-716b3a3ee0df">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if76b41f869c640688904f2ecf988e33e_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzQtNi0xLTEtMA_853b8bd5-b190-4f63-a75a-c54acbd53bcb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie09521d642ec49dd9f6fb93b6226a986_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzUtNi0xLTEtMA_c2e7ad11-beae-4dac-99c0-195df49026b2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, approximately <ix:nonFraction unitRef="number" contextRef="icc34f2aa5b494ba4b697db93d5108663_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIxNTU_2887f0e9-d7a5-49b9-baf6-d8671f0ea997">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie6e601deab964329936be94a4d256bc9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzYxODI_e4bba5cc-5373-4ddb-8ff5-93cde687156a">82</ix:nonFraction>% of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2020 and 2019, approximately <ix:nonFraction unitRef="number" contextRef="i15b8ceb139cf4e0d97db9be7ea8aacf7_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIzNDI_010665e5-564c-4d57-9c26-767827e742d1"><ix:nonFraction unitRef="number" contextRef="ifd041b98c6ab476eb80888f8676c3df5_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIzNDI_61879554-e021-4d6e-b52c-5a8298ae2e16">97</ix:nonFraction></ix:nonFraction>% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEx_ba84613a-6c22-42f4-a28e-ab411b8316cb" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5690cf2946e8412bb86195a6c74a9316_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzMtNi0xLTEtMA_ce1f3fd0-049e-4b0a-a499-48b1cad70d00">22,456</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcaa2249e3c640468e6ad463c58824a6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzMtOC0xLTEtMA_b8fcf027-401f-4524-b266-c9e89bead76e">23,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5f71713fcf420b86e6051da049e7ac_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzQtNi0xLTEtMA_0bdda7ec-5b20-4d81-a08a-7ca9715b7ddf">8,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18229da67eb54a6b8110b348c32b2f80_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzQtOC0xLTEtMA_e2179643-da60-4dbd-977d-4117f0e8b59f">9,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06930bdf59ec4a7490fb90caaee4d192_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzUtNi0xLTEtMA_274bcbae-ae65-47c0-a89a-9cd460f610ea">5,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d5f0f3606b4c66949b12896e3d82ad_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzUtOC0xLTEtMA_1d54e436-6182-4e2f-bad7-0b04fd44822a">4,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2d0f3c92004d4d8ea0b1587e20bd73_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzYtNi0xLTEtMA_b4b4a2b9-1bb0-4052-ac07-7942bf421f35">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26b529fa0544e3fa5ffa639ffaaa3da_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzYtOC0xLTEtMA_eff468e1-dcf4-418a-b6cf-3dab1d08a002">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43dd45431384ad48a4a7cd39396b772_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzctNi0xLTEtMA_98271406-a712-46af-8cae-b446f3fcecc1">5,128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f51ada9f8b45298c0c793b85f782e6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzctOC0xLTEtMA_71ce1de2-7649-44ae-b5aa-7a913871dae2">1,476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzgtNi0xLTEtMA_8dc8aab5-d051-4bfc-b916-81ba1d29e02f">41,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzgtOC0xLTEtMA_ee0573e1-1d58-4399-aab0-33efadf7f6eb">40,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk1_b8872d3e-6981-4fae-9c5c-6e4d835a1fe7" continuedAt="i708da4af0f4341229b9802d5c3ecd9c8" escape="true">Fair Value Measurements</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4756fb9946c642b5814205efa18e7a4c" continuedAt="ifb098b02db2941e59f44fee091a1a73c"><ix:continuation id="i708da4af0f4341229b9802d5c3ecd9c8"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, the Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div></ix:continuation><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA2_13b4d5fc-04ea-4bc5-8675-2915b1898c3f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $<ix:nonFraction unitRef="usd" contextRef="i4e3c2fa4dc5f49e8b1099bc7e449e3a2_I20161231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzUyMDk_85601167-8b3e-42cf-a7be-5a1a49563cae">0.1</ix:nonFraction> million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA0_0a9459aa-0aaf-4c4f-a0be-8b9342e1f971" escape="true"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA0_4f5a02b8-d59e-4593-9edd-22d232d5e263" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzItNC0xLTEtMA_ae56ecac-9fbc-4f62-ac6a-a050b71e3de9">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzItNi0xLTEtMA_0e39f14f-751e-4a58-a28d-3d93e89df7a0">72,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzMtNC0xLTEtMA_c44a2ee0-62ee-4c11-a7af-972b1c941e3a">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzMtNi0xLTEtMA_fe3b52a2-c1c6-40e7-a4ed-2ab6a5022df6">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzQtNC0xLTEtMA_b400e13f-8388-4cd8-a0e6-118560c53280">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzQtNi0xLTEtMA_a040391f-745f-40ec-ae46-a2b019125655">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTky_f2dde299-75aa-4a58-a7a3-678754aeebd9" continuedAt="ia210160d563848cf9590ccf8fbdc247a" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f">three</span> and <ix:nonNumeric contextRef="i4573db3dc09e4fa8a58677b574d5c416_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNTk_8d8d09f8-f9b9-4980-906e-811e236f99a7">five years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifb098b02db2941e59f44fee091a1a73c" continuedAt="i03a3994d3168422a825c504e1ba9a8b7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia210160d563848cf9590ccf8fbdc247a">accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized.</ix:continuation> </span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA1_453e97bb-42c8-4cb4-9da6-7828e2ce1c53" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="exdx:ClinicalStudyPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAy_d7a52ea7-4134-4655-a2f7-1fa8bead2377" continuedAt="id22e25de670948a48b64f7d56bad7ff8" escape="true">Clinical Studies</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id22e25de670948a48b64f7d56bad7ff8">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzEwOTk1MTE2NjQ4NzA_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448"><ix:nonFraction unitRef="shares" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MjA4NDY_383cdc71-882b-4912-84e3-4dfe925a28f6">7,816,643</ix:nonFraction></ix:nonFraction> shares of common stock, excluding warrant conversions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#8217; equity.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i03a3994d3168422a825c504e1ba9a8b7" continuedAt="i314cd306ef494aa0b9eeaa5f7c1d18a9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 8 for further discussion on the remaining warrants.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk3_c96ea6ed-c49e-44ab-984d-d45342ff420c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNzY_8738f572-fb83-4103-903d-08d112ac0515">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing</ix:nonNumeric>. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The Company is responsible for the costs associated with its salesforce over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the years ended December 31, 2020 and 2019, the tiered promotion fee ranged from $<ix:nonFraction unitRef="usd" contextRef="i854adb164db541fa9bd24fb1ccb21010_I20181231" decimals="-3" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5NTQ_6305ff44-5e3f-497c-be7f-5c5700dc75a3">750</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="ia5c2c61809374714a756188ab1adadbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5NjA_9548cad7-4ac2-4e94-bd0f-d9abf4ea8c5e">1,250</ix:nonFraction> per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement). In accordance with the June Amended Janssen Agreement, the predetermined average baseline for prescribed units for each remaining quarter in 2020 was adjusted and is subject to further adjustment, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $<ix:nonFraction unitRef="usd" contextRef="i9ce5a530334e4915b0436079dca953ff_I20200930" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5Njg_3974ee25-4ace-4bf6-8595-0aca80b9c37b"><ix:nonFraction unitRef="usd" contextRef="i20146f37e33a40dab402238b6ea56800_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5Njg_83d5e84b-8edb-456d-b6a6-dff4e9f3b745">0.3</ix:nonFraction></ix:nonFraction>&#160;million and the fee was capped at <ix:nonFraction unitRef="number" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTA_753bb84d-08b7-4ba0-8729-94b7372a131c"><ix:nonFraction unitRef="number" contextRef="i9156fd411b7741a8a39d1c43983a5800_I20200930" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTA_f8b46d92-f3f1-498c-bf0c-1bdfeaf966cf">5</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately <ix:nonFraction unitRef="unit" contextRef="ic0b7b9ea1d814dbbbeed9b14692e78ca_D20201001-20201231" decimals="INF" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPrescribedUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyODc_1e2245f9-8bfe-43af-af96-83ff0d70bde1">28,750</ix:nonFraction> prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarters of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $<ix:nonFraction unitRef="usd" contextRef="ic3d6c90706d94887a50acb583e7d32ad_I20210630" decimals="-3" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODI_9578bf39-d791-407c-aaf7-a7bfdddd82ec"><ix:nonFraction unitRef="usd" contextRef="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331" decimals="-3" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODI_a5b4b7e0-b168-41d4-a0d3-c0d81313cc58">500</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i9dcc6ed5d40246baabade8cb1d9fba6b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODg_1d2400e4-6892-48cc-a975-27779e53a7d5"><ix:nonFraction unitRef="usd" contextRef="i695ae53d59f94e27b87eefce82393e8a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODg_1e6a9e87-df3d-4162-9888-e4bb25e3fc10">1,000</ix:nonFraction></ix:nonFraction> per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $<ix:nonFraction unitRef="usd" contextRef="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5OTY_3a79296f-801d-42c9-add4-37d356f7f341"><ix:nonFraction unitRef="usd" contextRef="ic3d6c90706d94887a50acb583e7d32ad_I20210630" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5OTY_e9ac6035-b8bd-40d4-af75-8948ad958fe2">0.3</ix:nonFraction></ix:nonFraction>&#160;million and the fee will be capped at <ix:nonFraction unitRef="number" contextRef="i3a03a4097faf4d70895448f0b1cdccc9_I20210630" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTQ_27811fca-383e-4923-a418-ceee0451399b"><ix:nonFraction unitRef="number" contextRef="i0f45eef28e7d4c2e8752293801f70ab3_I20210331" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTQ_62604043-de50-4a57-aeef-372b98d335d8">10</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. The Company continued to receive a minimum promotion fee of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwNDA_c275ff58-685e-4762-bfe8-62b76742c9df">0.3</ix:nonFraction>&#160;million and the fee was capped at <ix:nonFraction unitRef="number" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwNTQ_0472941c-c024-44bf-af04-d141ac19670f">5</ix:nonFraction>% above the adjusted predetermined baseline for the quarter ended December 31, 2020. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i314cd306ef494aa0b9eeaa5f7c1d18a9" continuedAt="idcf1273b71a9424aabf17ad5cc7702b2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional 12 months upon 180 days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon 30 days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i62cb5f8c97194f02924e255c54bed267_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzIyMTc_03eb8742-5936-4df9-8608-e165f5454168">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddf6e035476945cfb9d2423367a0fd96_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzIyMzM_80b9deed-174d-4096-ba2f-44c9d164f15b">1.5</ix:nonFraction> million during the years ended December&#160;31, 2020 and 2019, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk0_78a4044e-745e-421e-a27f-0f9f0d33504e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTkx_5d23dd8a-d69a-447c-9cd5-aab3f5d2ca01" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NjEw_124738af-bdc9-4e57-93fa-d8cf622b5a21">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NjI1_34f3431a-1620-4806-b4a9-58ca56f9df13">1.6</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i358dc56770ab42ceace2ba4c29570329_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2OTY3_c3560e08-afa2-433f-aa88-2dbb73bbae25"><ix:nonFraction unitRef="usd" contextRef="iaf8dba0b2d464952ad492cfb4b91e9c4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2OTY3_f662338a-efcc-41ad-a95d-fbd6de922587">1.4</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk4_f6d524c6-06d4-4d10-84ca-4d59ab296cbc" continuedAt="i0557f333fd7a453abe0920a7c474e622" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was <ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNzc_a586d33b-6e1b-4730-9dc6-7eab56fb6e5e">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0557f333fd7a453abe0920a7c474e622">Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idcf1273b71a9424aabf17ad5cc7702b2" continuedAt="i6ea9bd99be78463eaa12860bc1acd060"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk5_6f466a75-c962-4a87-bf95-669d14e47959" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTkw_2ad1aea9-b55e-44c7-aaa9-d962cce0bf0b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAz_29be53ff-9528-4f57-803c-18d7fd148b19" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock, options outstanding under the Company's stock option plans and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the years ended December&#160;31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEy_d81b7d16-1a39-4b52-98ae-9959ea4875fe" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33102e8052874bcf8f4819af73b17cd3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzQtNi0xLTEtMA_18e96241-b0b8-42e7-8481-2168b3a5f01b">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1320fd0f2999411e8bd7d1a4b841aa24_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzQtOC0xLTEtMA_6fe9d694-efa6-4e1c-8be0-5997522ffc39">461,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01e558ece6214f16b6c3df7e771db6be_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzUtNi0xLTEtMA_16c82196-11c3-4141-a764-ae4fdeb60a19">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc02f1f51b5c4b199fc8848ae372e425_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzUtOC0xLTEtMA_85e1ce03-12c5-4914-8512-71c8abadcf70">1,375,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib235ec96e6b1472d9f54d1de7b43b02f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtNi0xLTEtNzM4NQ_249dce89-9ae7-4662-a888-2e81dd906d45">11,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1e7be53ff34ffab13c26e9df1ddc43_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtOC0xLTEtNzM5MQ_a8079a40-652d-4718-b4c1-03fa52c562a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtNi0xLTEtMA_3a9d9b9d-b51a-463c-8b7d-c806cb4c4e5d">2,414,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtOC0xLTEtMA_054831ec-967a-4fe3-b1e6-644d02f19c0b">1,836,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and are included in other income, net in the accompanying statements of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ea9bd99be78463eaa12860bc1acd060"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA4_3e488d74-03fb-4bef-9ee4-a850619c73e7" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTg_cef3e900-9a7b-45bb-9a4f-8789460144c5">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA5_42aa40fc-e189-40e2-ab31-916443130951" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company does not anticipate the adoption will have a material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company adopted this guidance on January 1, 2020, and the adoption did not have a material impact on its financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_127"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyOA_d0d79432-2fe2-4a15-90e3-34503b98149a" continuedAt="i88805715205a41828d4ea75a4af0a158" escape="true">Other Financial Information</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i88805715205a41828d4ea75a4af0a158" continuedAt="ida7fe629d02644828a0c53fd2d4c61a0">Prepaid Expenses and Other Current Assets</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ida7fe629d02644828a0c53fd2d4c61a0"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNQ_005cccfd-07fc-492f-be0c-0af5adb9e9d2" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzItMi0xLTEtMA_86d19727-0f9f-4cb9-8054-26e8074c8ea4">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzItNC0xLTEtMA_fd3b6389-662d-404e-926b-5b5879329c0b">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzMtMi0xLTEtMA_536005cc-3cc7-4c39-9995-3a9f1ac4b5c9">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzMtNC0xLTEtMA_3d58af98-9844-4f9d-a16f-520792bb1c7d">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzQtMi0xLTEtMA_c422ec39-8906-41ac-9242-934f2416262d">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzQtNC0xLTEtMA_424f5335-1469-4146-b0dc-7112f98ce14b">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzUtMi0xLTEtMA_84ef1dc1-5537-44bf-9f30-c193fa79d143">659</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzUtNC0xLTEtMA_fa5fc4bb-c3ba-427f-86f1-694a24f3e7e2">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzYtMi0xLTEtMA_45e0eeba-a16e-43e6-8048-e2f1a6b2a7da">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzYtNC0xLTEtMA_048e85f6-f542-46fe-8044-956bc606ff1b">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNg_685d05cd-fd39-4af2-b393-de401ff1130d" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fa1a8305f5404892b12cd15d2ac129_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzItMi0xLTEtMA_b3041513-a89b-4383-8cd4-1d273713e8d8">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280bdc8f8aa947aaa8f3ba67d5a4d42e_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzItNC0xLTEtMA_feaeaddd-938c-4d2e-a988-903e8dba6c38">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa0e2237a4349c6975a3792c1a40fc6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzMtMi0xLTEtMA_790644e7-ca4e-40a8-92bc-84caaac6a1c9">2,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d0b8d5d514828b59f52af21200f9c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzMtNC0xLTEtMA_2ff6e9b7-fa85-4de8-842d-16933f7f5ea5">2,228</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674956e7e0a8446f921f15096e981198_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzQtMi0xLTEtMA_47c27849-71c3-46e6-89fa-f07aa7677ece">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9f4988242043ae86e49c5b25240e58_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzQtNC0xLTEtMA_a3180a84-ae49-4f47-9031-5fbe9e379fa5">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6f34cf3e1b429c8056d14a2e90b57a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzUtMi0xLTEtMA_bade0bfc-85e0-4963-b5c9-73ff487e6676">1,072</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611274158822483e99565868e2143ccd_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzUtNC0xLTEtMA_a5142d3f-7080-406e-a68f-52b1c5d324ba">424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c15b3b387924344b6a488918b7724a2_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzYtMi0xLTEtMA_720a7478-87a6-419d-908a-f3b859780dd6">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3795b5fddf0a474ca1f456c3011836fa_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzYtNC0xLTEtMA_c9a3ef7a-7b03-4494-b225-4b08796ffd13">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzctMi0xLTEtMA_34a023d9-c87e-4286-a963-865360ef548f">5,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzctNC0xLTEtMA_60379ed0-fc24-4d11-99d5-3b867ad48fbe">3,775</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzgtMi0xLTEtMA_6f3f2354-33c8-4751-b24b-a4df204015f2">2,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzgtNC0xLTEtMA_2875bb1f-5a2c-42b2-8dc4-0168a1abec65">2,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzktMi0xLTEtMA_ed66b1a5-021b-48af-ac40-276051475988">2,102</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzktNC0xLTEtMA_60f01cad-6c64-41c2-a952-b5e3df1f4fc1">1,380</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019, was approximately $<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzM1Mg_e78952e1-0f0f-45ce-99db-2a30a78af63e">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzE2NDkyNjc0NDIzMDE_28085f8b-1d6d-4571-8b73-47519dc5d242">0.6</ix:nonFraction> million, respectively. At December&#160;31, 2020 and December 31, 2019, the gross book value of assets under capital lease was $<ix:nonFraction unitRef="usd" contextRef="i12d22bc21e2b4d42828df3456f0b74ad_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzQzMw_7bcbbd88-b76f-4f8b-93e5-7be2e64f923d">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ddb14c3a29441f2a69234c84b0a601e_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzQ0OA_06517220-556d-45cb-b758-bb6c6a6a0f3d">0.8</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNw_9fd1334f-45a5-4760-9331-b29cb3e9eaa5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzItMi0xLTEtMA_c5a1e0b5-52d2-4b26-9f98-4ae064a0a1dd">3,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzItNC0xLTEtMA_aa6715aa-8b92-47ee-98ba-e6ea203328b4">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzQtMi0xLTEtMA_5e9d3873-e59a-4137-b912-1a9cbbdc281e">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzQtNC0xLTEtMA_2f1be1a7-7948-4782-be90-c7e02422a931">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzUtMi0xLTEtMA_205edd23-7bea-4b3f-a729-cd932086467b">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzUtNC0xLTEtMA_d1401c83-5141-4e49-98d0-812d8b5ce458">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzYtMi0xLTEtMA_9780a7c9-97ff-4c6f-9d7d-d75a1bfaa973">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzYtNC0xLTEtMA_fc703410-8710-458a-804b-f37331530b6f">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzctMi0xLTEtMA_5bf15af6-61f0-4d05-9e5d-0c915d82ac26">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzctNC0xLTEtMA_3986ae98-cce0-4ae1-a882-ffa9e6ce417a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzgtMi0xLTEtMA_01a494dc-26bd-4b06-98dd-0e4ea5ca9eed">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzgtNC0xLTEtMA_ab1fe99c-e8ef-4563-a6ef-d8e2b32f6ea6">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzktMi0xLTEtMA_974b1658-c772-48b8-84b2-a1d26bbd474d">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzktNC0xLTEtMA_db581f9a-3cfa-45c6-83b4-80e0aae96728">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzEwLTItMS0xLTA_4bc84171-5484-450a-94c2-47a06e46704e">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzEwLTQtMS0xLTA_949041de-aeb3-4216-bab5-5941dbe51143">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_130"></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzYyNjA_78faf463-c778-4781-9e6f-e575d89fd71d" continuedAt="i885cbff4ca4146d48ee008c01ec43771" escape="true">Borrowings</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i885cbff4ca4146d48ee008c01ec43771" continuedAt="i840dda991e8c456b822b8c6eaa52cfcb">2017 Term Loan</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i840dda991e8c456b822b8c6eaa52cfcb" continuedAt="i9eaa7fd7c47f4cc2b3abf8ebb0def912"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $<ix:nonFraction unitRef="usd" contextRef="ife50f4946ea24f0c9f4e38cbd7f1110e_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE5Ng_1039ca99-c422-4f97-b84d-e4e63aac4c8d">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzIwMA_b74293dd-ea04-48f9-b756-0826ef3492c2">17.8</ix:nonFraction> million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i54e6b9922db74a3a9cb86c52f2a90cc9_D20181207-20181207" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzM4NA_a0accddf-db26-4ac0-9168-68e9d63aee77">5.0</ix:nonFraction> million under the 2017 Term Loan. At December&#160;31, 2020, no additional amounts remain available to borrow under the 2017 Term Loan. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is <ix:nonFraction unitRef="number" contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzY3Mg_a54cbcd6-b559-4111-bef3-a64dfc8c9b06">8.5</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzY4NQ_5fff7f58-bd56-4cd0-b378-0379012838ac">2.0</ix:nonFraction>% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzgzMA_a54cbcd6-b559-4111-bef3-a64dfc8c9b06">8.5</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzkyMQ_0ad3e638-a09c-4cab-b793-77f468f3ee39">10</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in <ix:nonFraction unitRef="payment" contextRef="i0e96141de3c64fe29a0de8fc804cff2f_D20191101-20191130" decimals="INF" format="ixt-sec:numwordsen" name="exdx:DebtInstrumentPeriodicPrincipalNumberOfPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3NjE_511c55ab-a0d3-4615-815f-b49d1b0f6626">twenty-four</ix:nonFraction> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzEyOTA_c1f41086-2500-47d7-a192-46f71ee1fb94">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the years ended December&#160;31, 2020 and 2019, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="i5149cc8ef1ff4fac911ed00c49b7db71_D20200101-20201231" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE0OTA_4ad86c41-4d8f-4700-be6b-1694fdb79229"><ix:nonFraction unitRef="usd" contextRef="i6e5ddd398de1458e8e1e64f2e9afd8d4_D20190101-20191231" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE0OTA_5e71b29b-ea62-4533-a449-ddb26e9b8781">0.5</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE2NDI_632075b6-eb35-44e7-8953-ec847587144d">3</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="2" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3MDA_51af8d64-d137-4818-b824-7de4c1da91f8">1</ix:nonFraction>% during each subsequent twelve-month period after November&#160;19, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling <ix:nonNumeric contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231" format="ixt-sec:durwordsen" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc4MjE_c5159251-87a9-4712-8919-9e12e01f2193">twelve-month</ix:nonNumeric> basis, and commencing with the quarter ending December 31, 2019. The consequences of failing to achieve the performance covenant may be cured if, within <ix:nonNumeric contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231" format="ixt-sec:durwordsen" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3Nzc_aebbe43e-b250-4489-990a-2fd92ce372c4">sixty days</ix:nonNumeric> of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Company's revenues for the <ix:nonNumeric contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231" format="ixt-sec:durwordsen" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc4MjI_35001460-bb4a-46a5-8426-9eca16d3ba9d">twelve-month</ix:nonNumeric> ended September 30, 2020 were lower than the specified targets, as a result, the Company and Innovatus agreed on a new management plan and target to bring the Company back into compliance with the Loan Amendment. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity. The Company is required to maintain an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzMwNjI_365c5ed7-65d1-4446-92ac-78ba419a4a78">2.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company was in compliance with all covenants of the Loan Amendment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231" decimals="INF" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzQ0MzE_14233ada-041c-400c-95d2-33d64cf996fd">4.0</ix:nonFraction>% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzYyNjE_ff725a3a-b648-4b4c-9b69-0cae915a9e2a" continuedAt="ie9267be98b3747b2b1d06545f6f7437a" escape="true">As of December&#160;31, 2020, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9eaa7fd7c47f4cc2b3abf8ebb0def912"><ix:continuation id="ie9267be98b3747b2b1d06545f6f7437a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzMtMi0xLTEtMA_4affd64f-34b2-442e-a606-d34cbed3b895">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzQtMi0xLTEtMA_7086c7f1-9e4c-4c66-969a-021aced9566a">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzUtMi0xLTEtMA_0f7146f8-c624-4353-89e6-96efbafdd795">15,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzYtMi0xLTEtMA_d33af9a9-b236-4558-9d8d-fa14660ea1c1">14,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtIncludingUndiscountedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzctMi0xLTEtMA_9bda6c13-479f-4c72-8fd4-2231e2c649c9">34,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzktMi0xLTEtMA_edde505b-6e24-4137-88a7-aec2d0342abd">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtUndiscountedInterestAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzEwLTItMS0xLTA_476dcbb3-69ed-4c47-a847-f1efd16e8959">7,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzExLTItMS0xLTA_0558d1fe-eb07-454f-8ba2-9063e82f9fad">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_136"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODc_f46f0ced-b805-4cbb-891a-2d1340f3c202" continuedAt="i0a7298c542e049909514e84088c29fbb" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i0a7298c542e049909514e84088c29fbb" continuedAt="idd19f991afd546b7a8f812c83757cd48"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional <ix:nonNumeric contextRef="ic0b28ea3fe8a47bb9b1c724647721207_D20200101-20201231" format="ixt-sec:durwordsen" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4MTc_5a476150-bbed-4186-9a5e-4f30bab2bb92">5-year</ix:nonNumeric> period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional <ix:nonNumeric contextRef="i1cd6af4be1f145b0979bab0cafe7ad2b_D20200101-20201231" format="ixt-sec:durwordsen" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4NDA_2b4c0d0c-335a-4c1e-affa-5204851a17c1">5-year</ix:nonNumeric> period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODg_90ae3ed9-82f6-4df7-833f-9610cbfe09d8" escape="true"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODk_1f340024-0914-40cd-943e-18d404d79680" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEtMi0xLTEtMA_30d7d8e3-9e72-4e0a-aa86-b9b99ad436c8">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEtNC0xLTEtMA_77580fa0-fd91-440b-8e93-c98e0122870d">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzItMi0xLTEtMA_a968358c-e9c2-4575-8ad7-d325d2d21c14">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzItNC0xLTEtMA_82339cf4-76e3-4477-a940-92165950752b">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzMtMi0xLTEtMA_4412dc76-dd1d-43fc-957e-006b66d212cb">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzMtNC0xLTEtMA_e5cbbfd5-11cd-4d62-8a57-e20bedae57bc">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzQtMi0xLTEtMA_722bf575-0a36-480e-9920-5db761103bac">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzQtNC0xLTEtMA_67802f9a-f9cb-4142-bafd-da2f33340c80">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzUtMi0xLTEtMA_7da67c09-197e-4367-a785-d22618e7b934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzUtNC0xLTEtMA_268aefd7-1973-4046-8cad-ab3c9919e0c7">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtMi0xLTEtMTUzNA_ac943596-3036-4946-94d4-f95649fc961c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtNC0xLTEtMTUyNw_7e425711-aef0-46f6-8328-13b1dda273ff">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtMi0xLTEtMA_8425e70d-69de-4ebd-b783-4462461cea1f">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtNC0xLTEtMA_54a13c61-a3ea-4f39-a180-f6ee232b3eac">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzctMi0xLTEtMA_0be59907-de05-47d1-94b0-edb62dd81891">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzgtMi0xLTEtMA_3802f8a1-9a05-40cc-9ffa-909f817e11f5">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzktMi0xLTEtMA_ef24b2af-7027-40a4-a3ce-d8cbdcf3161d">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEwLTItMS0xLTA_1709ed05-c73f-45c2-85e0-37ea26ceccf9">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, rent expense was $<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzY5OQ_906b456e-4b9d-4b48-9c65-c85e390f588d">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzcxNA_537bdb0b-9a16-4bae-a432-76d404f101ad">0.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $<ix:nonFraction unitRef="usd" contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEyOTM_c228474f-18bb-4371-840f-b31798162cdb">2.0</ix:nonFraction> million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be <ix:nonFraction unitRef="usd" contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE0MDA_2f98fd2e-d285-4273-880a-6d76a60dc397"><ix:nonFraction unitRef="usd" contextRef="i626d033bbe12451bb544fb9ccd602d11_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE0MDA_3b767749-0cbc-4310-a3c5-28f2cf224421">zero</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of <ix:nonFraction unitRef="number" contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE1Njg_a1b680cb-d4fd-4cb7-937d-e6c14ac662d4">2.5</ix:nonFraction>%. Future royalties payable under these arrangements are limited to the lesser </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idd19f991afd546b7a8f812c83757cd48"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIzMTA_377badf6-c79d-4077-9299-e8c2f02e569c">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdvancePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE3MTc_d53bd181-9f03-4f00-9393-409cc0bcab03">100,000</ix:nonFraction>) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from <ix:nonFraction unitRef="number" contextRef="if5eb4831058d4b62a7506f80397c58e7_I20201231" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzIxMTk_3ca7cfce-2d9f-4e90-9f33-7fe5152c1279">2.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i90378dc8f33d4c0db9c9f5e510cefc73_I20201231" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzIxMjU_4defd53f-c965-47c2-a411-2a46cde8b9f9">3.0</ix:nonFraction>%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIwMzM_d82edece-5451-4e12-a4d4-4f6f343690f2">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIwNDA_32dd2429-cce4-43e0-be65-47b33620b6ac">6.0</ix:nonFraction> million for years ended December 31, 2021 and 2022, respectively, with a <ix:nonFraction unitRef="number" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4MDY_314cb15c-affe-445c-b27d-5afc331bcff9">15</ix:nonFraction>% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_139"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90ZXh0cmVnaW9uOmFlYTQyNjAzYTJlZjQxYjVhYjFkYjJiNTVjMWUwODY5XzY3NQ_8e33f583-87e3-40a0-8cbd-4165aa13151c" continuedAt="i58311c9819fe454d9e7d1c3210598ec6" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i58311c9819fe454d9e7d1c3210598ec6"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90ZXh0cmVnaW9uOmFlYTQyNjAzYTJlZjQxYjVhYjFkYjJiNTVjMWUwODY5XzY3Ng_fccc6a66-33d7-4f8b-9be4-83954fe1d760" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtMi0xLTEtMA_863309f0-7c2b-4283-a818-8070837c4a9a">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13eef4c0f9f34ead9206411d3e70f27f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtNC0xLTEtMA_f6db0336-8fdb-41d7-b802-a5e4e12cefb9">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b416cd8bb1f4d6f86d98f542ac3cc5d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtNi0xLTEtMA_f8c2c774-ead6-4986-b05b-662a16c3e9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0eeb17dc7c4414a87f1ab0a5c0341f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtOC0xLTEtMA_376cf697-839c-448a-b3f4-7c044498a4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d0579e1e494431ae288f59027174a1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtMi0xLTEtMA_b2838666-de05-47dd-94e0-bbc7226fe032">70,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a61521b77e46aa90eed63b0c7ba9b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtNC0xLTEtMA_c6e69e56-a6f0-453c-aff9-22cbe7643587">70,760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a24aaf692c5444cbf9b46ed5a052bee_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtNi0xLTEtMA_7e06d124-1c0e-4cc0-9818-432b72851b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb32079e8ef4b6ab57b666c86ab1379_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtOC0xLTEtMA_48ba90c3-4b93-42ab-a8c1-001fb5374ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's money market funds is based on quoted market prices.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_142"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="exdx:TemporaryEquityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzI3NDg3NzkwODQ4OTQ_89ece0e2-f99b-4a84-ba7b-b0eae7818e79" continuedAt="i9f78adcf365e49f18672b1ecfcfcae6f" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="i9f78adcf365e49f18672b1ecfcfcae6f" continuedAt="i4b1798a0615c4be0b74ed69f411d9f2c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series G Financing</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9202b030fd1b4086bdec9b70b92d1d84_D20190101-20190131" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzM0MTc_daee7d80-8cba-4284-b37c-b7485ccafbbc">0.078</ix:nonFraction> in each closing. In conjunction with the issuance of the Series H redeemable convertible preferred stock, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4b1798a0615c4be0b74ed69f411d9f2c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each share of issued and outstanding Series G redeemable convertible preferred stock was converted into shares of Series H redeemable convertible preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series H Financing</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731" decimals="5" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzU4NTY_760b5aa6-80cb-4a09-bbb4-de58e19b66d1">0.04712</ix:nonFraction>. The Company accounted for the difference between the effective conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731" decimals="5" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzY3NDY_4cccd382-ae85-47e9-a002-c2b9e4a6195d">0.04712</ix:nonFraction> and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic80f1b4b2b84440db98c9a7375a7570f_D20190701-20190930" decimals="-5" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzY5OTY_64c6a421-3c42-45b3-b2b4-53f545316b41">6.7</ix:nonFraction> million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders&#8217; equity. Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $<ix:nonFraction unitRef="usd" contextRef="iaf86d568866c4251832b028da29ff071_D20190701-20190930" decimals="-5" name="exdx:TemporaryEquityDeemedDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzc2MTA_3f125328-80b9-4959-ae40-48c96fb20e50">6.9</ix:nonFraction> million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders' equity.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Company's IPO in September 2019, an aggregate of <ix:nonFraction unitRef="shares" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzE2NDkyNjc0NTU4ODI_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversion, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, <ix:nonFraction unitRef="shares" contextRef="i5b650b6b9d754c97a85b32a60d451667_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzMyOTg1MzQ4OTc5OTc_493523ce-a319-4e8d-bd8d-e3ead4fadde9"><ix:nonFraction unitRef="shares" contextRef="i0ccae1c8177a4c3b9f45dfceb5efa42f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzMyOTg1MzQ4OTc5OTc_6bb60c65-e849-47ce-ab77-1ce2cbea3cc6">no</ix:nonFraction></ix:nonFraction> shares of redeemable convertible preferred stock remained outstanding at December 31, 2020 and 2019.</span></div></ix:continuation><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_145"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEwOTk1MTE2MjgzMDIw_a6c87178-a088-444f-9d7e-c78ddadd48b9" continuedAt="if651d52b3c5f4493af0921564ef65f4d" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="if651d52b3c5f4493af0921564ef65f4d" continuedAt="ie645cfffb38442e98801ffbf2fdb4673"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying financial statements and notes to the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2019, the Company closed its IPO of <ix:nonFraction unitRef="shares" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzk5MA_6be84362-5132-4224-8add-cd33027d6e6b">4,140,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e709efd0a0841ec93329ef2a03791d0_I20190923" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEwNDg_0462092a-e1f9-48a7-8509-16cfc31da57b">14.00</ix:nonFraction> per share, including the exercise in full by the underwriters of their option to purchase <ix:nonFraction unitRef="shares" contextRef="ia73d28ff344b45b7be16393a226e65c1_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzExNDE_cb3ecbd6-e93f-4fb8-b16b-02dbdefe656e">540,000</ix:nonFraction> additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $<ix:nonFraction unitRef="usd" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEzMzk_33597de9-5ed5-42e2-b9df-58a2cdacd4d8">50.4</ix:nonFraction> million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i7e709efd0a0841ec93329ef2a03791d0_I20190923" decimals="-3" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE0NjM_3b6fbad8-dde2-4844-9273-7d0c61ee7d78">7.5</ix:nonFraction> million. In addition, an aggregate of <ix:nonFraction unitRef="shares" contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE1MDQ_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzMyOTg1MzQ4ODY4OTg_15295c4b-cf04-4246-bd36-f6ba5eecb03c" continuedAt="i458aef39788d4bea85589c6a1dc377ad" escape="true">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2020:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie645cfffb38442e98801ffbf2fdb4673"><div style="margin-bottom:6pt;margin-top:12pt"><ix:continuation id="i458aef39788d4bea85589c6a1dc377ad"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzEtMS0xLTEtMTg0Mw_fab855ab-936d-423a-87ff-713b0c0114f7">252,798</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzEtMy0xLTEtNTI4OQ_b74bd5d9-a96f-48bf-bdf0-0d05caaf8490">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i466315a145504f92bab9954a4653b6ef_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzItMS0xLTEtMTg0Mw_c713a43e-75fb-4f1e-8ac7-fea95c592ba7">69,176</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i466315a145504f92bab9954a4653b6ef_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzItMy0xLTEtNTI4OQ_c12b56c9-16f9-48b6-bed2-be71b7d9b922">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzMtMS0xLTEtMTg0Mw_71955b5f-bdc4-4a83-b544-de3d3491041d">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzMtMy0xLTEtNTI4OQ_1ae3c647-9d07-4a3c-a129-1d5482034d46">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8a60c0a83494af48451bdffb74f8657_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzQtMS0xLTEtMTg0Mw_11702e10-02a6-41eb-8898-2e89d03e6184">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8a60c0a83494af48451bdffb74f8657_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzQtMy0xLTEtNTI4OQ_cb5e5a07-6e57-44c5-8849-4d65ba90e741">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01c677925f1f405988f482d6e0c41691_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzUtMS0xLTEtMTg0Mw_e47239ee-06b8-428a-924a-b4220cd41c08">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01c677925f1f405988f482d6e0c41691_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzUtMy0xLTEtNTI4OQ_2dffc826-9d4b-4b91-aa88-e54d7529c232">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzYtMS0xLTEtMTg0Mw_da7cd686-f65c-4377-bf66-c28c547ec201">426,827</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, warrants to purchase common stock were exercised resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE2NDkyNjc0NDUwNjY_6c1d2869-4f4a-4f9f-9faf-4aec562c5481">32,120</ix:nonFraction> shares of the Company's common stock and cash proceeds of an immaterial amount.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_148"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODI_93ae94bc-e517-4d8a-8374-eb9a45ae839b" continuedAt="icc854874cd684b7ea943d5b8641c949e" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="icc854874cd684b7ea943d5b8641c949e" continuedAt="i11ca6bfa12c346e9b3c3a72e06ec6369"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). A total of (i) <ix:nonFraction unitRef="shares" contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDYxNjE_2579dd28-debd-429f-9961-f1e9fa2d905a">2,011,832</ix:nonFraction> shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and was initially be reserved for issuance under the 2019 Plan. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzNzQzODk1MzU2MDc2_35b68021-200c-4453-865d-13ec0512ced1">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzNzQzODk1MzU2MDc1_1bf27ebd-3ee9-4c55-b763-c9709db0b73b">four years</ix:nonNumeric> from the date of grant. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzMzg_a05d5fae-4f3d-49b2-b8f0-30e66cf739a2">4</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE0NzI_a3ffbf36-2cf2-49f4-a468-c2064e34264a">1,139,323</ix:nonFraction> shares remained available for future awards. Under the evergreen provision, on January 1, 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i2dcffc3099e440189a3fa6ca69d78390_I20210101" decimals="INF" format="ixt:numdotdecimal" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE1ODU_ff71be1b-1d33-4904-8614-472d38509970">506,092</ix:nonFraction> shares became available for issuance under the 2019 Plan.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODM_e4cc3e15-b738-4081-beff-bd196ec0a3bb" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtMi0xLTEtMA_79721e9d-28b1-465b-9d09-25dda1dc8e89">1,375,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtNC0xLTEtMA_740b8529-58d2-40a6-9340-95d23336371e">8.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtNi0xLTEtMA_0e4e5dc9-6777-466a-a47e-137e6aebe100">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtOC0xLTEtMA_09c4b2b3-b5e6-4c51-a9a0-f536b8976a3b">23,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzItMi0xLTEtMA_9bc21f86-133b-46ca-bc82-7f3b3d817797">951,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzItNC0xLTEtMA_de5e9994-2949-4e67-a19b-ced430286b22">16.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzMtMi0xLTEtMA_f6edc8e5-cd69-47dc-aefe-e954fbdc8085">47,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzMtNC0xLTEtMA_23990498-8b15-4d82-86f7-dd1988b3ee43">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzQtMi0xLTEtMA_3f0aad63-896c-4d04-a90a-d247274a2bdd">293,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzQtNC0xLTEtMA_005ee4ac-e3f4-4184-95f0-b1ec40807570">10.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzUtMi0xLTEtMA_70e8f1cb-48dc-4ee5-b871-ff20b3986393">9,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzUtNC0xLTEtMA_52978c14-8681-43c1-8656-9b23f7ce11b3">29.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtMi0xLTEtMA_6b871a89-beb5-48eb-a357-4d6d31989918">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtNC0xLTEtMA_c849805e-0b30-412d-88e2-6803cc5747b5">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtNi0xLTEtMA_e9c09f5f-31f2-4790-877c-f9b7eac4ee34">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtOC0xLTEtMA_a88b97b8-c605-4c7d-b70a-082246b38b0e">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctMi0xLTEtMA_258193e4-7661-433d-95c9-77c58b648b25">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctNC0xLTEtMA_32ecd42d-e14f-4fc1-8163-b7cba3da0ec2">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctNi0xLTEtMA_10adb853-cc71-426a-b314-1b65114f50c0">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctOC0xLTEtMA_5cb29cd9-501d-4e61-8e28-d399595151dd">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtMi0xLTEtMA_a899c502-41b6-4bb3-94db-71cfa1635c7c">464,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtNC0xLTEtMA_fdc79410-5740-4852-8926-db94d07aa043">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtNi0xLTEtMA_8855d3a4-cd75-4793-a615-6e55b379f386">8.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtOC0xLTEtMA_1d67d251-dfc7-49cd-83ae-42731f3c2088">3,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIwNTQ_17b3950b-f4a2-474b-8cca-3d5ae006a0c4">7.55</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIwNjE_b5dca806-a06f-44ea-b043-a3d727873d88">7.79</ix:nonFraction>, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock is $<ix:nonFraction unitRef="usdPerShare" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIyNzc_1c2ad7f8-2e3a-4fc9-b57c-c168ef1d7952">13.20</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIyODQ_968a80f2-6562-420f-baa0-70f8781c44eb">25.40</ix:nonFraction> per share at December&#160;31, 2020 and 2019, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDY5OTY_47d4155b-3f19-4a9e-bdc7-c4adaefca20b"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDY5OTY_de88747c-a7d1-4912-b5b6-84ca185ca7ad">1.0</ix:nonFraction></ix:nonFraction> million and an immaterial amount, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwNzc_aacb9fed-9080-4971-8f32-79372d52f410" continuedAt="if2c2d6186a7b4087ac4d48ce49ae9bca" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i11ca6bfa12c346e9b3c3a72e06ec6369"><div style="margin-bottom:6pt"><ix:continuation id="if2c2d6186a7b4087ac4d48ce49ae9bca" continuedAt="if3d28ccac0184835b3b2c968e6b4b090"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItNi0xLTEtMC90ZXh0cmVnaW9uOjNhYjVjYThkOWQ1ZDQyNDNiMjliODY2MmExMDVlNWVmXzQ_9aaa0051-29ef-4558-a578-287d3a470f42">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItNi0xLTEtMC90ZXh0cmVnaW9uOjNhYjVjYThkOWQ1ZDQyNDNiMjliODY2MmExMDVlNWVmXzc_67beea30-c0af-4d46-b186-8038354b7bfd">53</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItOC0xLTEtMC90ZXh0cmVnaW9uOjYyY2MyNjVlMWE4OTRkYzZhZGVmMWM2ZmJmZDdiNTA1XzE2NDkyNjc0NDE2NzU_4544e0af-5e2b-4e2a-bb11-ffa2a10ad8ea">46</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItOC0xLTEtMC90ZXh0cmVnaW9uOjYyY2MyNjVlMWE4OTRkYzZhZGVmMWM2ZmJmZDdiNTA1XzE2NDkyNjc0NDE2Nzk_325663c5-d1ce-46a1-b6fb-75f91d7d9200">59</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtNi0xLTEtMC90ZXh0cmVnaW9uOmI0YmEwMDdjMTA3NjRjYWM4MTViMmMxOWVjYTE4N2U1XzQ_08b594f7-7329-4fa3-a047-d6a9dd26186b">0.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtNi0xLTEtMC90ZXh0cmVnaW9uOmI0YmEwMDdjMTA3NjRjYWM4MTViMmMxOWVjYTE4N2U1Xzc_54b34635-c31a-43a3-a1f1-357f6704c183">1.7</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtOC0xLTEtMC90ZXh0cmVnaW9uOjk1NzJlMWQ5N2JlNDRkYTZiNWRjZjI4NzFlZjVlMjYyXzQ_f485cb0c-0f7d-45ee-a49e-cd1ae84c612d">1.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtOC0xLTEtMC90ZXh0cmVnaW9uOjk1NzJlMWQ5N2JlNDRkYTZiNWRjZjI4NzFlZjVlMjYyXzk_e8a87b5e-ace6-4496-a8c5-67859884b6aa">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzQtNi0xLTEtMA_d4c7d88b-0fc8-44b7-b237-9dd79d883e68">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzQtOC0xLTEtMA_3363579c-8ccd-40d1-b50f-d872c83ecec4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9df7a83f79940ddb50644d9534b8e4a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtNi0xLTEtMC90ZXh0cmVnaW9uOjY2YzlkNjZmZmM1YTQ4NzhhN2Y3MGIwOTlmMDFjMjQwXzE2NDkyNjc0NDE2NzQ_c5b1eb90-35d2-4f1a-bf04-98b2f08f98e8">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="ib3119fce349b4f6587c19f908367b2dc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtNi0xLTEtMC90ZXh0cmVnaW9uOjY2YzlkNjZmZmM1YTQ4NzhhN2Y3MGIwOTlmMDFjMjQwXzE2NDkyNjc0NDE2Nzk_fa6d3f71-d368-4bd4-840f-744f403df976">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c062635dbd2451889987f0af257f830_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtOC0xLTEtMC90ZXh0cmVnaW9uOjExY2I4M2VmNjEzYjRmMzhiM2YyOGMxMTQzZTVjMzgwXzE2NDkyNjc0NDE2Njk_aa28a0d7-0590-4028-909b-3e4dfa6d4e9e">5.75</ix:nonNumeric>-<ix:nonNumeric contextRef="i039ef34e84814a89a51794da58440c49_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtOC0xLTEtMC90ZXh0cmVnaW9uOjExY2I4M2VmNjEzYjRmMzhiM2YyOGMxMTQzZTVjMzgwXzE2NDkyNjc0NDE2NzI_69b1acf3-d48e-406a-9504-7ada22ea01a2">6.08</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzMyOTg1MzQ4OTE1NDI_6b5d3405-cc25-4d0d-884e-36a964e2f1c2">20</ix:nonFraction>% of their eligible compensation. A total of <ix:nonFraction unitRef="shares" contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEwOTk1MTE2MzQxMDM_975ef891-3ae1-476c-b85d-f0ef3a74fe8a">120,000</ix:nonFraction> shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 calendar year through January 1, 2029 in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzMyOTg1MzQ4OTE1NDc_615d6a5c-54da-4550-ba88-37e9f34d1d05">1</ix:nonFraction>% of the outstanding capital stock on December 31st, or (ii) such lesser amount determined by the Board of Directors. Under the evergreen provision, on January 1, 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i41b5f6bca8d2400bb78d64d3ee723516_I20210101" decimals="INF" format="ixt:numdotdecimal" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEwOTk1MTE2MzQ2NDk_0cf4c60b-c802-4b1c-bf07-69e0b53f1e7a">126,523</ix:nonFraction> shares became available for issuances under the ESPP. Stock-based compensation expense for the ESPP was an immaterial amount for the year ended December&#160;31, 2020.</span></div><ix:continuation id="if3d28ccac0184835b3b2c968e6b4b090"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzItNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmYxYTQyMTNiN2M3MTQ5YTdiOThlYjVjZjY3ODYyOTkzXzEwOTk1MTE2Mjc3OTA_bbb72f63-86a6-45cf-9e06-07edc8e971b3">58</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzItNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmYxYTQyMTNiN2M3MTQ5YTdiOThlYjVjZjY3ODYyOTkzXzEwOTk1MTE2Mjc3OTc_b4c99e66-3707-402a-8770-7a3e6ef83fab">83</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzMtNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmY5ZjUzOGI3MWE0ZDQ3MjliM2Q2MmI0NWY2NDFlYmFlXzEwOTk1MTE2Mjc3OTM_1e38dcc1-a779-4ccb-a555-306e5bec7273">0.1</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzMtNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmY5ZjUzOGI3MWE0ZDQ3MjliM2Q2MmI0NWY2NDFlYmFlXzEwOTk1MTE2Mjc4MDA_cc502fa1-2e4a-4733-8ff3-243daeb180c1">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzQtNi0xLTEtNTg4OQ_7c66489e-456b-49c8-bcbd-24c29bf38999">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzUtNi0xLTEtNTg4OQ_bd897ee5-6d1f-4174-a94f-4be1ef7d592b">0.5</ix:nonNumeric></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwNzg_a4ab0cd9-1e1e-4771-b856-654dcd512b6d" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702cbb6d8580485a8ed9b7d9da8a2093_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzItNi0xLTEtMA_e20a1eb2-580a-414f-bbb7-24a202cf8645">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a70ce52ba824bfda7ecfd9065c1b7c3_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzItOC0xLTEtMA_5c75006a-f45d-4193-bbcb-6326c971b3d6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703d6361d7e7459d8f59cb73b645d79e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzMtNi0xLTEtMA_a30affb2-3f37-49bc-afb3-1e64b8c72133">2,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d73be98d664ccfa3f52b1b3925d8b1_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzMtOC0xLTEtMA_5fc0876f-1200-42f7-80aa-6494c2f8c4f9">445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id612b120136c4606a30275dd302975ba_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzQtNi0xLTEtMA_54d37793-783c-4a85-9df0-f2d369f9fd41">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeed2007d8ce423190963dac6498acc6_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzQtOC0xLTEtMA_5ed61bc1-19fb-481d-89dc-b87e9cdd2de1">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzUtNi0xLTEtMA_ca2309ac-f90a-4c85-a18d-b355778a52d4">2,694</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzUtOC0xLTEtMA_409ed6ab-9dcc-4011-9b74-db582033ba27">572</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzI4Mjk_9d143de1-47fa-462e-855a-2d5d9251b04a">8.5</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzI5Mjg_980aee86-9ef7-4350-ad8b-ff1b280b9890">2.8</ix:nonNumeric>&#160;years.</span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODE_e5a20180-02cb-4049-bd4e-19ebd120e17a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance consists of the following at December&#160;31, 2020:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3d9a5ee720049a2943b6461407a26c4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzAtMi0xLTEtMA_8ad0721b-518e-4370-b07b-828f002a3cb5">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb4954aca44d475bbcf2bdfd5f3e8918_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzEtMi0xLTEtMA_483bccf2-54fc-4ce7-9c87-6432e2c84d85">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the stock option plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib009a5d12eec454f807f70204c3f2c94_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzItMi0xLTEtMA_640dcb91-2535-4270-84b3-e1536468cabd">1,139,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzMtMi0xLTEtMA_4e289750-76c6-4bfc-bb96-51fe58119e00">233,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzQtMi0xLTEtMA_8ec6d6c2-c808-44e0-9f1a-a6ee5861dc06">3,775,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjQ_414e4f30-6ac9-4184-a428-e23b0eb4a1dd" continuedAt="ieece929ffeef46d78f1f7747fb693406" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ieece929ffeef46d78f1f7747fb693406" continuedAt="ia5fd9cc5d300452a9f634b54ad45a403"><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjU_8f6bda9d-441f-44d2-a485-dfd7ff53edce" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzMtMi0xLTEtMA_57ce76a9-b3ea-4af4-9fdf-f5cb71f6f17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzMtNC0xLTEtMA_e3d88338-cd41-4ecf-9345-54bae71623c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzQtMi0xLTEtMA_c52d5a2f-d394-44c0-9527-a1e5e04c6407">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzQtNC0xLTEtMA_1f4ec0e5-55bb-4f1d-a832-c96c4a4d3d97">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzUtMi0xLTEtMA_18ec53c3-5c9f-45af-8749-80533c25d639">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzUtNC0xLTEtMA_863afb2a-09cf-4169-93d2-ef8f435fe5a0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzctMi0xLTEtMA_4d369936-153a-40fe-9690-7d3d489d2bb5">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzctNC0xLTEtMA_0dcb9e77-704f-496e-9f93-9becf6c44722">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzgtMi0xLTEtMA_40b57fc0-4cca-4b70-a9a9-3b61b6a63830">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzgtNC0xLTEtMA_276eaedf-2d8c-4803-839c-7bc87064eb1d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzktMi0xLTEtMA_d13021bd-343a-476e-baee-13aa269d9eb9">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzktNC0xLTEtMA_0261c533-277f-425c-81d2-6dbad9e5cbc5">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefit) provision for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzEwLTItMS0xLTA_5d782a67-edee-4d30-9df3-d6a4ca41d7a7">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzEwLTQtMS0xLTA_9b9ecac0-5b0b-4098-9a37-9499e09df1c7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjY_386048bf-748d-465c-9a3d-3f25f63a9cfb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzItMi0xLTEtMA_ed697b75-158b-468c-8cf4-f530b8c28fbc">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzItNC0xLTEtMA_433f9060-a663-4cc3-a2d6-1f8fc92921ea">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzMtMi0xLTEtMA_08d0321e-007a-433a-9ed4-6bc5c2ad24ed">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzMtNC0xLTEtMA_dba27235-8c43-488c-9d52-429338ff9460">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of preferred stock liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" format="ixt:zerodash" name="exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzQtMi0xLTEtMA_61a57bda-2cb1-4e51-931f-7f664e551b27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" name="exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzQtNC0xLTEtMA_ddfa92fd-65f7-458a-b6d4-c3e23db16e2f">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzUtMi0xLTEtMA_dd103b97-b179-4420-b9a5-e889f4128dce">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzUtNC0xLTEtMA_5742b95d-3b4a-4167-83f2-aa46aa2905c5">36.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Limitation of net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzYtMi0xLTEtMA_d5bc1ac4-d657-4d06-a9b2-7549a5b7eb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzYtNC0xLTEtMA_4d662c67-0e23-47bf-9bc4-b3dde79530aa">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzctMi0xLTEtMA_208a67bb-7132-4dac-9b40-a3ce5d9cb4ff">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzctNC0xLTEtMA_18a0b36b-fb48-400f-8bca-d5754f610345">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzgtMi0xLTEtMA_035831dc-d4d1-4753-a2cb-f99d16afa461">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzgtNC0xLTEtMA_1f330244-cde0-4b0c-8a2b-a832128c8c5a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019 are shown below. A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0Mjc_6f34b525-65ab-4ee7-9947-14a29ac51d59" continuedAt="ice04328204ba4ca9981ccc79177cece4" escape="true">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia5fd9cc5d300452a9f634b54ad45a403" continuedAt="ibc210ff24cfb493999b86d096bd29005"><div style="margin-bottom:6pt;margin-top:9pt"><ix:continuation id="ice04328204ba4ca9981ccc79177cece4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzMtMi0xLTEtMA_22645481-b322-4c94-84cc-7f4be2011cbc">17,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzMtNC0xLTEtMA_9ab4e2ea-64aa-48be-981f-98ceaaab38cf">15,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzQtMi0xLTEtMA_f0d46a9a-4338-4e85-8058-a7c775a066ac">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzQtNC0xLTEtMA_afb96717-c642-40a2-ac01-35defd072b17">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzUtMi0xLTEtMA_8c5aa826-4b03-4171-8487-1aa2ae278f36">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzUtNC0xLTEtMA_1d4478e4-e9e9-4f04-b78d-ecd9f2ddc1b0">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzYtMi0xLTEtMA_0bbb5bb2-074c-44f4-975c-ddefea9d514f">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzYtNC0xLTEtMA_e046d9ff-39d4-41d1-a3c1-9cdb94130dcc">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzctMi0xLTEtMA_7c7b6040-0082-4121-a94d-1afb382eb3cf">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzctNC0xLTEtMA_0924ee96-90b2-4d67-8546-674f30b44bfc">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzgtMi0xLTEtMA_1fc6da29-65c7-4ece-b124-7c658e817c13">21,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzgtNC0xLTEtMA_1997290f-5641-44db-bd56-53c4ae8557ba">17,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzktMi0xLTEtMA_c9e92e99-99ed-4c82-9089-9b3091c97da4">20,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzktNC0xLTEtMA_3ebce777-65ee-486e-9425-21dd025ec57a">16,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEwLTItMS0xLTA_d8390f52-8d6e-40ca-801c-7f2712bb271d">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEwLTQtMS0xLTA_9fa017d9-0458-4acd-abeb-f428b72b51cf">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEyLTItMS0xLTA_b730d8a3-6d68-4e5f-9747-ab561349adef">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEyLTQtMS0xLTA_777d976b-1b79-40b0-8ee4-cbc78d6e4e6e">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEzLTItMS0xLTA_4da26d93-4efe-4aba-b750-bce385a49767">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEzLTQtMS0xLTA_04290bee-5775-4e21-b7a4-068c08a1ad05">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE0LTItMS0xLTA_3c0e1cad-c678-48cf-93d3-cf37fedf2df9">795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE0LTQtMS0xLTA_381edc78-858f-4bf7-99c4-c5f8ba54e5d5">732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE1LTItMS0xLTA_66ad2656-f177-4c43-8b45-27e11db67d44">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE1LTQtMS0xLTA_cdc175bb-08e7-4a4a-84c4-79ad285a02f5">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0Mjg_7dd13d93-1467-416a-98a3-330833f1f6c3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2020 and 2019, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzItMi0xLTEtMA_d97f47bc-2e67-4d7f-b888-44dc6230ab07">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzItNC0xLTEtMA_09dd5e25-849b-457f-94a5-d76d633082a5">21,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases recorded as benefits to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzMtMi0xLTEtMA_93b20a29-2e6d-4604-9f07-01e6de131a1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzMtNC0xLTEtMA_9f59de48-6ac1-4776-9b11-34562be897c0">4,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzQtMi0xLTEtMA_6d8e3da8-5720-4ce8-b76a-0366c0da342f">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzQtNC0xLTEtMA_4d0a6fff-821c-4749-94b6-4e072987c9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzUtMi0xLTEtMA_4ddab1b9-80c4-4040-939b-e394c9c0074d">20,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzUtNC0xLTEtMA_55c78c67-d1bf-438a-9e90-4e634b67d728">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEwOTI_4339675c-8aba-463c-910b-3ad6cd6069ba">70.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzExMDc_20ce9b6f-6570-49ab-8d15-6bc699c6f3b2">60.7</ix:nonFraction> million, respectively. At December&#160;31, 2020 and 2019, the Company had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyMDc_3e482589-7e63-46bf-b831-8822eec1671a">48.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyMjI_e382eb9d-03cc-4955-8009-66f34e9788ff">43.5</ix:nonFraction> million, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyNjI_74f59515-e601-4bc8-af0e-79e80ddfdc66">43.5</ix:nonFraction> million of the federal tax loss carryforwards will begin to expire in 2022, unless previously utilized. The federal net operating loss carryforwards generated in after December 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzE0NTQ_78fe2e81-2937-407e-857b-4cf6b3a4f32b">27.1</ix:nonFraction> million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will expire in 2032, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019, the Company's deferred tax assets are primarily comprised of federal and state tax net operating loss carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $<ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="-5" name="exdx:OperatingLossCarryforwardsNotUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzIwNDY_c1fd82db-5581-42d3-98ad-72e4da4cf219">61.8</ix:nonFraction> million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize net operating loss carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#8217;s tax years for 2002 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibc210ff24cfb493999b86d096bd29005"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any accruals for, and did not recognize any, interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzMyNjU_0e5f1fcc-a055-4ad3-9e31-83618f320a14"><ix:nonFraction unitRef="usd" contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzMyNjU_b6b28be1-ac93-41a5-ab69-1539106ca7d8">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_154"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTQvZnJhZzo1NmJmNmRmNWNiYzE0N2QyYmU5YzczZTQzMjg4MGM5OS90ZXh0cmVnaW9uOjU2YmY2ZGY1Y2JjMTQ3ZDJiZTljNzNlNDMyODgwYzk5XzI1NDk_fdaa94e2-d0e0-41e6-831c-69fdb74d79f7" continuedAt="ic639a8227ecd4b31ae0a5f73d5b32441" escape="true">Related Parties</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic639a8227ecd4b31ae0a5f73d5b32441">The closings of the Series&#160;G financing and the Series H financing described in Note 7 were issued to existing holders of the Company's redeemable convertible preferred stock, including certain members of our Board of Directors.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i46297aecc50342189ce6ad0511b1efd6_157"></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzUxMQ_e3b44d3d-d92d-4a29-bdff-4d055fdef5b0" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. 401(k) Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2020 and 2019, the Company made contributions to the Plan at <ix:nonFraction unitRef="number" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzQzMw_2b823f2f-91aa-4396-a167-2fe13309f919"><ix:nonFraction unitRef="number" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzQzMw_dbe0ec20-7749-480c-b087-d11fa9ebf921">3</ix:nonFraction></ix:nonFraction>% of qualified employee compensation, which totaled approximately $<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzUwMA_f9b56f5d-82c9-4fe9-8908-4785116480f4">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzE2NDkyNjc0NDIxODY_378440df-cf78-4b31-b452-66252be099a7">0.4</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div id="i46297aecc50342189ce6ad0511b1efd6_760"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzMyOTg1MzQ4OTI4MzU_c2515fc1-4101-4ad4-b650-f77dfc923ffa" continuedAt="i6aab5497be684aa2b8492ba403a3a1f3" escape="true">COVID-19</ix:nonNumeric></span></div><ix:continuation id="i6aab5497be684aa2b8492ba403a3a1f3" continuedAt="ida6869bb277646e68647f89153058c20"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The reduction in headcount resulted in a restructuring charge for termination benefits of $<ix:nonFraction unitRef="usd" contextRef="i95195c5be0cf48859f028de27b41c233_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzEwOTk1MTE2NTAxMjk_08c07e19-1095-413b-a9ed-f914ff1cc9b2">0.3</ix:nonFraction> million which has been paid as of December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.   </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i9a7dd8fe1c69457ebd695bca19af30c8_I20200331" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk4ODE_c3298fe4-1f3a-4b48-8067-8d1d481f08f7">0.1</ix:nonFraction> million for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i801df2af82e6463ebc78fe5a1417689d_D20200401-20200430" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk5NTg_918e784f-759d-48b0-ab05-989d1fca6102">0.7</ix:nonFraction> million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' (HHS) standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida6869bb277646e68647f89153058c20" continuedAt="ic848a8fd3f1849e78a5f7eebb349875d">been met. For the year ended December&#160;31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzI3NDg3NzkwOTAwNzY_6ee78c31-d15b-4247-9caf-2e60597f9326">0.7</ix:nonFraction> million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its statements of operations.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic848a8fd3f1849e78a5f7eebb349875d">On April 16, 2020, the Company entered into a promissory note with BOKF, NA dba Bank of Oklahoma, the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $<ix:nonFraction unitRef="usd" contextRef="ic992af68648c493b97deed5f40c92944_D20200416-20200416" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk5OTM_a236acba-6ec0-4947-a0f6-e97970de1701">2.9</ix:nonFraction> million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the promissory note.</ix:continuation> </span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Form of Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex32.htm">Form of Amended Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated July  12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex47.htm">Amendment to Convertible Promissory Notes and Warrants, dated January 19, 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex49.htm">Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Registrant's 2018 loan agreement.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex101.htm">Exagen Corporation 2002 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex102.htm">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex105-formofrsuagreement20.htm">Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex105.htm">License Agreement, dated September  13, 2007, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Proprius, Inc.).</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex106.htm">First Amendment to License Agreement, dated October  23, 2013, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Cypress Bioscience, Inc.).</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1010.htm">Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1011.htm">Amendment No. One to Asset Purchase Agreement, dated March  10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1012.htm">Amendment No. Two to Asset Purchase Agreement, dated August  21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1013.htm">Amendment No. Three to Asset Purchase Agreement, dated February  6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">Amendment No. Four to Asset Purchase Agreement, dated October  8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1015.htm">Amendment No. Five to Asset Purchase Agreement, dated January  26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1016.htm">Amendment No. Six to Asset Purchase Agreement, dated February  16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1017.htm">Amended and Restated Exclusive License Agreement, dated August  2, 2011, by and between the University of Pittsburgh&#8212;Of the Commonwealth System of Higher Education and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1018.htm">First Amendment to Amended and Restated Exclusive License Agreement, dated May  17, 2012, by and between the University of Pittsburgh&#8212;Of the Commonwealth System of Higher Education and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1019.htm">Second Amendment to Amended and Restated Exclusive License Agreement, dated September  30, 2013, by and between the University of Pittsburgh&#8212;Of the Commonwealth System of Higher Education and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1020.htm">Third Amendment to Amended and Restated Exclusive License Agreement, dated June  24, 2016, by and between the University of Pittsburgh&#8212;Of the Commonwealth System of Higher Education and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1021.htm">Exclusive License Agreement, dated September  30, 2013, by and between the University of Pittsburgh&#8212;Of the Commonwealth System of Higher Education and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1022.htm">Exclusive License Agreement, dated September 5, 2011, by and between Thierry Dervieux, Ph.D. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1023.htm">Co-Promotion Agreement, dated December 10, 2018, by and between Janssen Biotech, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000077/ex101-amend1tocoxpromo.htm">Amendment #1 to Co-Promotion Agreement, dated January 1, 2019, by and between Janssen Biotech, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000077/ex102-amend2tocoxpromo.htm">Amendment #2 to Co-Promotion Agreement, dated June 18, 2020, by and between Janssen Biotech, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1025-amend3tocoxpromotio.htm">Amendment #3 to Co-Promotion Agreement, dated December 23, 2020, by and between Janssen Biotech, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1024.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated January 13, 2012, by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1025.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December  1, 2013, by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm">Second Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated April 29, 2016, by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm">Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated June 16, 2017, by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm">Fourth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated March 16, 2020, by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1030.htm">Standard Industrial/Commercial Single-Tenant Lease, dated September 4, 2014, by and between Geiger Court, LLC and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated August 2, 2017, by and between Geiger Court, LLC and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/a1221libertyway-leasea.htm">Extension of Lease to Standard Industrial/Commercial Single-Tenant Lease, dated March 12, 2020, by and between Liberty Vista and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1034-amend1to1221liberty.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated January 6, 2021, by and between Liberty Vista and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex10331261suitealeasev2.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated March 17, 2020 by and between RGS Properties and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1031.htm">Master Lease Agreement, dated February  1, 2018, by and between Celtic Commercial Finance, a division of MB Equipment Finance, LLC and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1032.htm">Loan and Security Agreement, dated September 7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1036-innovatusxexage.htm">First Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP dated November 19, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000097/ex101-innovatusacknowl.htm">Acknowledgement Letter to Loan and Security Agreement, by and between Innovatus Life Sciences Lending Fund I, LP and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.40#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1034.htm">Offer Letter, dated October 12, 2010, by and between Thierry Dervieux, Ph.D. and the Registrant, as amended on September 9, 2011 and September 6, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.42#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1036.htm">Offer Letter, dated October 7, 2011, by and between Fortunato Ron Rocca and the Registrant, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.43#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1037.htm">Offer Letter, dated May 16, 2017, by and between Kamal Adawi and the Registrant, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.44#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1041-zackofferletter.htm">Offer Letter dated February 21, 2020, by and between Debra Zack, MD Ph.D. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.45#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm">Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1046-executivecicseveran.htm">Executive Change in Control Severance Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231-2020bdoconsent.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i46297aecc50342189ce6ad0511b1efd6_166">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-123120.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-123120.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-123120.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i46297aecc50342189ce6ad0511b1efd6_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:56.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;16, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Power of Attorney</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Fortunato Ron Rocca and Kamal Adawi as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:5.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Fortunato Ron Rocca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Brian Birk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian Birk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jeff Elliott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeff Elliott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ James L.L. Tullis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;16, 2021</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">James L.L. Tullis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>2
<FILENAME>ex105-formofrsuagreement20.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i48c78ca16fc2498499118ce5071b35ee_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXAGEN INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2019 INCENTIVE AWARD PLAN</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK Unit Grant Notice</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exagen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), has granted to the participant listed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) the Restricted Stock Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) described in this Restricted Stock Unit Grant Notice (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions of the Exagen Inc. 2019 Incentive Award Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the Restricted Stock Unit Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), both of which are incorporated into this Grant Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Participant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;To be specified&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;To be specified&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of RSUs&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;To be specified&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;To be specified&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;To be specified&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By accepting (whether in writing, electronically or otherwise) the RSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">EXAGEN INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;Participant Name&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i48c78ca16fc2498499118ce5071b35ee_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms not specifically defined in this Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GENERAL</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Award of RSUs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company has granted the RSUs to Participant effective as of the Grant Date set forth in the Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Each RSU represents the right to receive one Share as set forth in this Agreement.  Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation of Terms of Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unsecured Promise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</font></div><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VESTING&#59; FORFEITURE AND SETTLEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting&#59; Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated.  In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;The RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event later than March 15 of the year following the year in which the RSU&#8217;s vesting date occurs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii))&#59; provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section&#160;409A.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TAXATION AND TAX WITHHOLDING</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of this award of RSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a) &#160;&#160;&#160;&#160;Subject to Section 3.2(b), payment of the withholding tax obligations with respect to the Award may be by any of the following, or a combination thereof, as determined by &#91;the Company in its sole discretion &#47; Participant or the Administrator&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i)&#160;&#160;&#160;&#160;Cash or check&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii)&#160;&#160;&#160;&#160;In whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii)&#160;&#160;&#160;&#160;In whole or in part by the Company withholding of Shares otherwise vesting or issuable under this Award in satisfaction of any applicable withholding tax obligations.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Unless &#91;the Company &#47; Participant or the Administrator&#93; otherwise determines, and subject to Section 9.10 of the Plan, payment of the withholding tax obligations with respect to the Award shall be by &#91;delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the applicable tax withholding obligations&#93; &#47; &#91;delivery (including electronically or telephonically to the extent permitted by the Company) by Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company that Participant has placed a market sell order with such broker with respect to Shares then-issuable upon settlement of the Award, and that the broker has been directed to deliver promptly to the Company funds sufficient to satisfy the applicable tax withholding obligations&#59; provided, that payment of such proceeds is then made to the Company at such time as may be required by the Administrator&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Subject to Section 9.5 of the Plan, the applicable tax withholding obligation will be determined based on Participant&#8217;s Applicable Withholding Rate.  Participant&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Applicable Withholding Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) if Participant is subject to Section 16 of the Exchange Act, the greater of (A) the minimum applicable statutory tax withholding rate or (B) with Participant&#8217;s consent, the maximum individual tax withholding rate permitted under the rules of the applicable taxing authority for tax withholding attributable to the underlying transaction, or (ii) if Participant is not subject to Section 16 of the Exchange Act, the minimum applicable statutory tax withholding rate or such other higher rate approved by the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (i) in no event shall Participant&#8217;s Applicable Withholding Rate exceed the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the liability classification of the applicable award under generally accepted accounting principles in the United States of America)&#59; and (ii) the number of Shares tendered or withheld, if applicable, shall be rounded up to the nearest whole Share sufficient to cover the applicable tax withholding obligation, to the extent rounding up to the nearest whole Share does not result in the liability classification of the RSUs under generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the RSUs.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares.  The Company and its </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> NTD&#58;  &#8220;Participant or the Administrator&#8221; for Section 16 individuals.  &#8220;The Company&#8221; for non-Section 16 individuals.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> NTD&#58;  Use second bracketed language for Section 16 individuals.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax liability.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Participant acknowledges that the RSUs and the Shares subject to the RSUs  are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Clawback.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Award and the Shares issuable hereunder shall be subject to any clawback or recoupment policy in effect on the Grant Date or as may be adopted or maintained by the Company following the Grant Date, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s General Counsel at the Company&#8217;s principal office or the General Counsel&#8217;s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company may assign any of its rights under this Agreement to a single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">suspended or terminated at any time or from time to time by the Administrator or the Board&#59; provided, however, that except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall materially and adversely affect the RSUs without the prior written consent of Participant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Not a Contract of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*&#160;*&#160;*&#160;*&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>ex1025-amend3tocoxpromotio.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i71762ac42b5440c392d82d0a5a066243_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.25</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT #3 TO CO-PROMOTION AGREEMENT </font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for October through December (4th Quarter) of 2020, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS&#47;Anthem data for the zip codes covered by Exagen sale representatives.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table will replace Section 2.2.2 Adjusted Baseline TRxU figures for Quarter ending December 31st, 2020 on page 2 and Section 2.12 Adjusted Baseline TRxU 4Q20, Maximum Payment and Actual Payout for 4Q20 on page 4 in the Amendment # 2 of Co-Promotion Agreement Contract No. C2020012644 and further amended via notice dated October 29th, 2020 Contract No. C2020023283.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.099%"><tr><td style="width:1.0%"></td><td style="width:12.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Q4 2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Baseline</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Max Payout</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties have agreed that the following sections of the Agreement are hereby amended as follows effective as the date of this notice&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Promotion Fee shall be adjusted for the quarters ending March 31, 2021 and June 30, 2021 as follows&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Promotion Fee shall be based on a unit value for each quarter over Baseline TRxU, allocated as follows&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quantities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotion Fee per unit</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit quantities below Baseline TRxU in a quarter will be counted as zero for purposes of calculating Quantities for Promotion Fee per unit.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen will pay Exagen a Minimum Promotion Fee of $300,000 for each of the quarters ending March 31, 2021 and June 30, 2021</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Promotion Fee will be capped at an amount reflecting the payment due in the event that Exagen's TRxU exceeds 10% above the Baseline TRxU for the quarters ending March 31, 2021 and June 30, 2021.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining quarters of the Contract Term Extension (July 1, 2021 &#8211; December 31, 2021) and any additional Third Term, the Promotion Fee payment terms shall revert to the terms set forth in the Co-Promotion Agreement, with no Minimum Promotion Fee and no Cap (Section 2.3.3).</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:3.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">***</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Confidential Information Omitted</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Amendment #2 dated June 18th, 2020 to the Agreement, please find the Second Term Baseline TRxU for the First Half of 2021&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:7.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarter ending</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Baseline TRxU</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please indicate your acceptance by signing the space provided below and returning to Janssen.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:35.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANSSEN BIOTECH, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Howard Reid</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Howard Reid</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Director of Marketing</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; Dec 23, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted and agreed</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date set forth above&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Mark Hazeltine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Mark Hazeltine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; General Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; Dec 23, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:3.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">***</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Confidential Information Omitted</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>4
<FILENAME>ex1034-amend1to1221liberty.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i406cf4d49492449c9034e4b0f95ceec5_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.34</font></div><div style="margin-top:3.35pt;padding-left:160.55pt;padding-right:160.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT OF LEASE</font></div><div style="margin-top:0.9pt"><font><br></font></div><div style="padding-left:50.8pt;padding-right:34pt"><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This First Amendment of Lease is made on December 30, 2020, between Liberty Vista, a California limited partnership, (&#34;Lessor&#34;), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., (&#34;Lessee&#34;), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Recitals.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Th</font><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">i</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s First Amendment of Lease is made with reference to the following facts and objectives&#58;</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a.</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Lessor and Lessee entered into a written Lease dated August 15, 2014, as extended February 1, 2018, and as extended February 25, 2020 (&#34;the Lease&#34;) in which Lessor leased to Lessee, and Lessee leased from Lessor, premises located in the City of Vista, County of San Diego, California, commonly known as 1221 Liberty Way, Vista, CA 92083, consisting of approximately 19,504 square feet (&#34;Premises&#34;)</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b.</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The term of the Lease expir</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s </font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n January </font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c.</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.78pt">Th</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e part</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">i</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s </font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">desire t</font><font style="color:#5b5b5b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o amend the Base Rent Schedule to include amortization of the additional tenant improvement allowance</font><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Tenant Improvement Allowance</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">.</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lessee used its &#34;Additional Allowance&#34; of Fifty Thousand Dollars ($50,000.00) and was reimbursed for the same by Lessor. Pursuant the terms of the Lease the $50,000 additional allowance shall be amortized at 7% annual interest over the remaining term and paid monthly by Lessee as additional Base Rent (as shown in the Base Monthly Rent Schedule below)</font><font style="color:#878787;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#878787;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Ba</font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">s</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">e Monthly Rent Schedule.</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.398%"><tr><td style="width:1.0%"></td><td style="width:38.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rent</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Base Rent </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Amortized TIA)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Base Rent</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2021 through January 31, 2022</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,000.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,990.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2022 through January 31, 2023</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,600.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,590.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2023 through January 31, 2024</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,200.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,190.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2024 through January 31, 2025</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,800.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,790.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2025 through January 31, 2026</font></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,390.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Effectiveness of Lease.</font><font style="color:#2f2f2f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </font><font style="color:#4b4b4b;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Except as set forth in this First Amendment of Lease, all the provisions of the Lease shall remain unchanged and in full force and effect</font><font style="color:#757575;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:51.5pt"><font><br></font></div><div style="padding-left:51.5pt"><font><br></font></div><div style="padding-left:51.5pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:51.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.017%"><tr><td style="width:1.0%"></td><td style="width:44.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LESSOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LESSEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Vista</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exagen Diagnostics, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A California Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; Hamann Property Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized Agent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Brendan Thiessen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brendan Thiessen - Asset Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fortunato Ron Rocca, President &#38; CEO</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date&#58; 1&#47;6&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date&#58; 1&#47;6&#47;2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:51.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>5
<FILENAME>ex1046-executivecicseveran.htm
<DESCRIPTION>EX-10.46
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie70f417fda1b411684283c6476ed1159_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.46</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Exagen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), has adopted this Exagen Inc. Executive Change in Control Severance Plan, including the attached Exhibits (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated.  The Plan, as set forth herein, is intended to provide severance protections to a select group of management or highly compensated employees (within the meaning of ERISA (as defined below)) in connection with qualifying terminations of employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Capitalized terms used but not otherwise defined herein shall have the meanings indicated below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Actual Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s cash performance bonus, if any, for the year in which the Date of Termination occurs, based on actual performance during the year in which the Date of Termination occurs.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s annual base salary rate in effect immediately prior to a CIC Termination, disregarding any reduction which gives rise to Good Reason.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the portion of a Participant&#8217;s Cash Severance that is based on the Participant&#8217;s Base Compensation determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Cash Salary Severance and, if applicable, the Incentive Compensation Severance, determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any one or more of the following events that the Board has determined, in good faith, has occurred&#58;  (i) the Participant&#8217;s failure to substantially perform the Participant&#8217;s duties (other than a failure resulting from the Participant&#8217;s disability), including the Participant&#8217;s failure to follow any lawful directive from the Board or the Participant&#8217;s immediate supervisor&#59; (ii) the Participant&#8217;s violation of any code or standard of behavior generally applicable to Employees or executives of the Company&#59; (iii) engaging in conduct that may reasonably result in reputational, economic or financial injury to the Company or its affiliates&#59; (iv) the Participant&#8217;s commission of, indictment for or plea of nolo contendere to a felony, any crime involving fraud or embezzlement under federal, state or local laws or a crime involving moral turpitude&#59; (v) the Participant&#8217;s failure to devote substantially all of the Participant&#8217;s working time to the business of the Company and its affiliates&#59; (vi) the Participant&#8217;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its affiliates or while performing the Participant&#8217;s duties and responsibilities for the Company or any of its affiliates&#59; (vii) the Participant&#8217;s commission of an act of fraud, willful misconduct or gross negligence with respect to the Company or its affiliates, or the Participant&#8217;s material breach of fiduciary duty against the Company or any of its affiliates&#59; (viii) the Participant&#8217;s engaging in misconduct in connection with the performance of any of the Participant&#8217;s duties, including by embezzlement or theft from the Company or its affiliates, misappropriating funds </font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from the Company or its affiliates or securing or attempting to secure personally any profit in connection with any transaction entered into on behalf of the Company or its affiliates&#59; or (ix) the Participant&#8217;s active disloyalty to the Company or its affiliates, including willfully aiding a competitor or improperly disclosing confidential information.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Company&#8217;s 2019 Incentive Award Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CIC Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the 12 month period beginning on a Change in Control and ending on and including the one-year anniversary of the date of a Change in Control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CIC Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Qualifying Termination which occurs during the CIC Protection Period.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 11.1 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the number of months during which the Participant is entitled to COBRA Premium Payments, determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto, as applicable.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA Premium Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.2(b) hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, or any successor thereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee of the Board, or such other committee as may be appointed by the Board to administer the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the effective date of the termination of the Participant&#8217;s employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an individual who is an employee (within the meaning of Code Section 3401(c)) of the Company or any of its subsidiaries.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Company equity award that vests solely based on the passage of time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.1 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any one or more of the following events without the Participant&#8217;s prior written consent, unless the Company fully corrects the circumstances constituting Good Reason (provided such circumstances are capable of correction) as provided below&#58;</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a change in the Participant&#8217;s position with the Company which materially diminishes such Participant&#8217;s duties, responsibilities, or authority&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a material diminution of the Participant&#8217;s Base Compensation and&#47;or Target Incentive Compensation&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a relocation of the Participant&#8217;s principal place of employment by more than twenty (20) miles.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Participant will not be deemed to have resigned for Good Reason unless (1) the Participant provides the Company with written notice setting forth in reasonable detail the facts and circumstances claimed by the Participant to constitute Good Reason within 90 days after the date of the occurrence of any event that the Participant knows or should reasonably have known to constitute Good Reason, (2) the Company fails to cure such acts or omissions within 30 days following its receipt of such notice, and (3) the effective date of the Participant&#8217;s termination for Good Reason occurs no later than 60 days after the expiration of the Company&#8217;s cure period.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Compensation Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the portion of a Participant&#8217;s Cash Severance that is based on the Participant&#8217;s Actual Incentive Compensation or Target Incentive Compensation, as applicable, as determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Advisors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.2 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each Employee who is selected by the Administrator to participate in the Plan and is provided with (and, if applicable, countersigns) a Participation Notice in accordance with Section 13.2 hereof, other than any Employee who, at the time of his or her termination of employment, is covered by a plan or agreement with the Company or a subsidiary that provides for cash severance or termination benefits that explicitly supersedes and&#47;or replaces the payments and benefits provided under this Plan.  For the avoidance of doubt, retention bonus payments, change in control bonus payments and other similar payments shall not constitute &#8220;cash severance&#8221; for purposes of this definition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13.2 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a termination of the Participant&#8217;s employment with the Company or a subsidiary, as applicable, by the Company or a subsidiary, as applicable, without Cause, or by the Participant for Good Reason.  A Qualifying Termination shall not include a termination due to the Participant&#8217;s death or disability.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.3 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the severance payments and benefits to which a Participant may become entitled pursuant to Section 4 of the Plan and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Target Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s target cash performance bonus, if any, for the year in which the Date of Termination occurs.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Total Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 7.1 hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Effectiveness of the Plan&#59; Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan shall become effective on March 15, 2021.  The Administrator shall, pursuant to a Participation Notice, notify each Participant that such Participant has been selected to participate in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 13.4 hereof, the Plan shall be interpreted, administered and operated by the Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which shall have complete authority, subject to the express provisions of the Plan, to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan, and to make all other determinations necessary or advisable for the administration of the Plan.  The Administrator may delegate any of its duties hereunder to a subcommittee, or to such person or persons from time to time as it may designate other than to any Participant in the Plan, and the Administrator may delegate (other than to any Participant in the Plan) its duty to provide a Participation Notice to a Participant in the Plan.  All decisions, interpretations and other actions of the Administrator (including with respect to whether a CIC Termination has occurred) shall be final, conclusive and binding on all parties who have an interest in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Employee who qualifies as a Participant and who experiences a CIC Termination is eligible to receive Severance Benefits under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CIC Termination Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that a Participant experiences a CIC Termination, then, subject to the Participant&#8217;s execution and, to the extent applicable, non-revocation of a Release in accordance with Section 4.3 hereof, and subject to any additional requirements specified in the Plan, the Company shall pay or provide to the Participant the following Severance Benefits&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall pay to the Participant an amount equal to the Cash Severance determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.  Subject to Section 6.2 hereof, the Cash Severance (as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) shall be paid in a lump sum on the 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> day following the Date of Termination.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the requirements of the Code, if the Participant properly elects healthcare continuation coverage under the Company&#8217;s group health plans pursuant to COBRA, to the extent that the Participant is eligible to do so, then the Company shall directly pay or, at its election, reimburse the Participant for the COBRA premiums for the Participant and the Participant&#8217;s covered dependents (in an amount determined based on the same benefit levels as would have applied if the Participant&#8217;s employment had not been terminated based on the Participant&#8217;s elections in effect on the Date of Termination) until the earlier of the end of the month during which the Participant&#8217;s COBRA Period, determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto, ends or the date the Participant becomes eligible for healthcare coverage under a subsequent employer&#8217;s health plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA Premium Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Code Section 409A under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover the Participant under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service </font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Act), then, in either case, an amount equal to each remaining Company reimbursement shall thereafter be paid to the Participant in substantially equal monthly installments over the COBRA Period (or the remaining portion thereof).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Award Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each outstanding Equity Award held by the Participant as of his or her Date of Termination shall become fully vested and, to the extent applicable, exercisable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, no Participant shall be eligible or entitled to receive or retain any Severance Benefits under the Plan unless he or she executes a general release of claims substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) within 21 days (or 45 days if necessary to comply with applicable law) after the Date of Termination and, if he or she is entitled to a seven day post-signing revocation period under applicable law, does not revoke such Release during such seven day period.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision of the Plan to the contrary, if a Participant&#8217;s status as an Employee is terminated for any reason other than due to a CIC Termination, the Participant shall not be entitled to receive any Severance Benefits under the Plan, and the Company shall not have any obligation to such Participant under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  To the extent applicable, the Plan shall be interpreted and applied consistent and in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder.  Notwithstanding any provision of the Plan to the contrary, to the extent that the Administrator determines that any payments or benefits under the Plan may not be either compliant with or exempt from Code Section 409A and related Department of Treasury guidance, the Administrator may in its sole discretion adopt such amendments to the Plan or take such other actions that the Administrator determines are necessary or appropriate to (a) exempt the compensation and benefits payable under the Plan from Code Section 409A and&#47;or preserve the intended tax treatment of such compensation and benefits, or (b) comply with the requirements of Code Section 409A and related Department of Treasury guidance&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that this Section 6.1 shall not create any obligation on the part of the Administrator to adopt any such amendment or take any other action, nor shall the Company have any liability for failing to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Potential Six-Month Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in the Plan, no amounts shall be paid to any Participant under the Plan during the six-month period following such Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Code Section 409A(a)(2)(A)(i) and Treasury Regulation Section 1.409A-1(h)) to the extent that the Administrator determines that paying such amounts at the time or times indicated in the Plan would result in a prohibited distribution under Code Section 409A(a)(2)(B)(i).  If the payment of any such amounts is delayed as a result of the previous sentence, then on the first business day following the end of such six-month period (or such earlier date upon which such amount can be paid under Code Section 409A without resulting in a prohibited distribution, including as a result of the Participant&#8217;s death), the Participant shall receive payment of a lump-sum amount equal to the cumulative amount that would have otherwise been payable to the Participant during such six-month period without interest thereon.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A termination of employment shall not be deemed to have occurred for purposes of any provision of the Plan providing for the payment of any amounts or benefits that constitute &#8220;nonqualified deferred compensation&#8221; under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of the Plan, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service&#8221;</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  To the extent that any payments or reimbursements provided to a Participant under the Plan are deemed to constitute compensation to the Participant to which Treasury Regulation Section 1.409A-3(i)(1)(iv) would apply, such amounts shall be paid or reimbursed reasonably promptly, but not later than December 31st of the year following the year in which the expense was incurred.  The amount of any such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and the Participant&#8217;s right to such payments or reimbursement of any such expenses shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Installments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of applying the provisions of Code Section 409A to the Plan, each separately identified amount to which a Participant is entitled under the Plan shall be treated as a separate payment.  In addition, to the extent permissible under Code Section 409A, the right to receive any installment payments under the Plan shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted under Treasury Regulation Section 1.409A-2(b)(2)(iii).  Whenever a payment under the Plan specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Best Pay Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan, in the event that any payment or benefit received or to be received by a Participant (including any payment or benefit received in connection with a termination of the Participant&#8217;s employment, whether pursuant to the terms of the Plan or any other plan, arrangement or agreement) (all such payments and benefits, including the Severance Benefits, being hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Total Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) would be subject (in whole or part), to the excise tax imposed under Code Section 4999 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then, after taking into account any reduction in the Total Payments provided by reason of Code Section 280G in such other plan, arrangement or agreement, the Cash Severance benefits under the Plan shall first be reduced, and any noncash severance payments hereunder shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (a) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (b) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Participant would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Exclusions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (a)&#160;no portion of the Total Payments, the receipt or retention of which the Participant has waived at such time and in such manner so as not to constitute a &#8220;payment&#8221; within the meaning of Code Section&#160;280G(b), will be taken into account&#59; (b)&#160;no portion of the Total Payments will be taken into account which, in the written opinion of an independent, nationally recognized accounting firm (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Advisors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) selected by the Company, does not constitute a &#8220;parachute payment&#8221; within the meaning of Code Section&#160;280G(b)(2) (including by reason of Code Section&#160;280G(b)(4)(A)) and, in calculating the Excise Tax, no portion of such Total Payments will be taken into account which, in the opinion of Independent Advisors, constitutes reasonable compensation for services actually rendered, within the meaning of Code Section&#160;280G(b)(4)(B), in excess of the &#8220;base amount&#8221; (as defined in Code Section&#160;280G(b)(3)) allocable to such reasonable compensation&#59; and (c)&#160;the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Independent Advisors in accordance with the principles of Code Sections 280G(d)(3) and (4).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  No Participant shall be required to seek other employment or attempt in any way to reduce or mitigate any Severance Benefits payable under the Plan and the amount of any such Severance Benefits shall not be reduced by any other compensation paid or provided to any Participant following such Participant&#8217;s termination of service.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan shall inure to the benefit of and shall be binding upon the Company and its successors and assigns.  Any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets shall assume and agree to perform the obligations of the Company under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan shall inure to the benefit of and be enforceable by each Participant&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees or other beneficiaries.  If a Participant dies while any amount remains payable to such Participant hereunder, all such amounts shall be paid in accordance with the terms of the Plan to the executors, personal representatives or administrators of such Participant&#8217;s estate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All communications relating to matters arising under the Plan shall be in writing and shall be deemed to have been duly given when hand delivered, faxed, emailed or mailed by reputable overnight carrier or United States certified mail, return receipt requested, addressed, if to a Participant, to the address or email address on file with the Company or to such other address or email address as the Participant may have furnished to the other in writing in accordance herewith and, if to the Company, to such address as may be specified from time to time by the Administrator, except that notice of change of address shall be effective only upon actual receipt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Claims Procedure&#59; Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Generally, Participants are not required to present a formal claim in order to receive benefits under the Plan.  If, however, any person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) believes that benefits are being denied improperly, that the Plan is not being operated properly, that fiduciaries of the Plan have breached </font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">their duties, or that the Claimant&#8217;s legal rights are being violated with respect to the Plan, the Claimant must file a formal claim, in writing, with the Administrator.  This requirement applies to all claims that any Claimant has with respect to the Plan, including claims against fiduciaries and former fiduciaries, except to the extent the Administrator determines, in its sole discretion that it does not have the power to grant all relief reasonably being sought by the Claimant.  A formal claim must be filed within 90 days after the date the Claimant first knew or should have known of the facts on which the claim is based, unless the Administrator consents otherwise in writing.  The Administrator shall provide a Claimant, on request, with a copy of the claims procedures established under Section 11.2 hereof.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator has adopted procedures for considering claims (which are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto), which it may amend or modify from time to time, as it sees fit.  These procedures shall comply with all applicable legal requirements.  These procedures may provide that final and binding arbitration shall be the ultimate means of contesting a denied claim (even if the Administrator or its delegates have failed to follow the prescribed procedures with respect to the claim).  The right to receive benefits under the Plan is contingent on a Claimant using the prescribed claims and arbitration procedures to resolve any claim.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Covenants.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A Participant&#8217;s right to receive and&#47;or retain the Severance Benefits payable under this Plan is conditioned upon and subject to the Participant&#8217;s continued compliance with any restrictive covenants (e.g., confidentiality, non-solicitation, non-competition, non-disparagement) contained in any other written agreement between the Participant and the Company, as in effect on the date of the Participant&#8217;s CIC Termination, as well as the restrictive covenants set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A Participant&#8217;s right to receive and&#47;or retain the Severance Benefits payable under the Plan is conditioned upon the Participant&#8217;s return to the Company of all Company documents (and all copies thereof) and other Company property (in each case, whether physical, electronic or otherwise) in the Participant&#8217;s possession or control.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Plan&#59; Relation to Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan, together with any Participation Notice issued in connection with the Plan, contains the entire understanding of the parties relating to the subject matter hereof and supersedes any prior agreement, arrangement and understanding between any Participant, on the one hand, and the Company and&#47;or any subsidiary, on the other hand, with respect to the subject matter hereof.  Severance payable under the Plan is not intended to duplicate any other severance benefits payable to a Participant by the Company. By participating in the Plan and accepting the Severance Benefits hereunder, the Participant acknowledges and agrees that any prior agreement, arrangement and understanding between any Participant, on the one hand, and the Company and&#47;or any subsidiary, on the other hand, with respect to the subject matter hereof is hereby revoked and ineffective with respect to the Participant (including with respect to any severance arrangement contained in an effective employment agreement or employment letter agreement by and between the Participant and the Company (and&#47;or any subsidiary)), but only to the extent such prior agreement, arrangement or understanding provides for severance during the CIC Protection Period.  For clarity, to the extent such agreement, arrangement or understanding provides severance protection to the Participant outside of the </font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CIC Protection Period, such agreement is not superseded by this Plan and any Participation Notice issued in connection with the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participation Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator shall have the authority, in its sole discretion, to select Employees to participate in the Plan and to provide written notice to any such Employee that he or she is a Participant in, and eligible to receive Severance Benefits under, the Plan (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at or any time prior to his or her termination of employment.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing contained in the Plan shall (a) confer upon any Participant any right to continue as an employee of the Company or any subsidiary, (b) constitute any contract of employment or agreement to continue employment for any particular period, or (c) interfere in any way with the right of the Company to terminate a service relationship with any Participant, with or without Cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination and Amendment of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Prior to the consummation of a Change in Control, the Plan may be amended or terminated by the Administrator at any time and from time to time, in its sole discretion. From and after the consummation of a Change in Control, the Plan may not be amended, modified, suspended or terminated except with the express written consent of each Participant who would be adversely affected by any such amendment, modification, suspension or termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Section 7 (Limitation on Payments), Section 11 (Claims Procedure&#59; Arbitration) and Section 12 (Covenants) hereof shall survive the termination or expiration of the Plan and shall continue in effect.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefit Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything contained herein, Severance Benefits paid or provided under the Plan may be paid or provided by the Company or any subsidiary employer, as applicable.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall have the authority and the right to deduct and withhold an amount sufficient to satisfy federal, state, local and foreign taxes required by law to be withheld with respect to any Severance Benefits payable under the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benefits Not Assignable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as otherwise provided herein or by law, no right or interest of any Participant under the Plan shall be assignable or transferable, in whole or in part, either directly or by operation of law or otherwise, including without limitation by execution, levy, garnishment, attachment, pledge or in any manner&#59; no attempted assignment or transfer thereof shall be effective&#59; and no right or interest of any Participant under the Plan shall be liable for, or subject to, any obligation or liability of such Participant. When a payment is due under the Plan to a Participant who is unable to care for his or her affairs, payment may be made directly to his or her legal guardian or personal representative.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan is intended to be an unfunded &#8220;top hat&#8221; pension plan within the meaning of U.S. Department of Labor Regulation Section 2520.104-23 and shall be interpreted, administered, and enforced as such in accordance with ERISA.  To the extent that state law is applicable, the statutes and common law of the State of Delaware, excluding any that mandate the use of another jurisdiction&#8217;s laws, will apply.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Validity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability of any other provision of the Plan, which shall remain in full force and effect. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The captions contained in the Plan are for convenience only and shall have no bearing on the meaning, construction or interpretation of the Plan&#8217;s provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The expenses of administering the Plan shall be borne by the Company or its successor, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unfunded Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Plan shall be maintained in a manner to be considered &#8220;unfunded&#8221; for purposes of ERISA.  The Company shall be required to make payments only as benefits become due and payable.  No person shall have any right, other than the right of an unsecured general creditor against the Company, with respect to the benefits payable hereunder, or which may be payable hereunder, to any Participant, surviving spouse or beneficiary hereunder.  If the Company, acting in its sole discretion, establishes a reserve or other fund associated with the Plan, no person shall have any right to or interest in any specific amount or asset of such reserve or fund by reason of amounts which may be payable to such person under the Plan, nor shall such person have any right to receive any payment under the Plan except as and to the extent expressly provided in the Plan.  The assets in any such reserve or fund shall be part of the general assets of the Company, subject to the control of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">*  *  *  *  *</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="ie70f417fda1b411684283c6476ed1159_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Annex A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESTRICTIVE COVENANTS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Participant shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data relating to the Company and its subsidiaries and affiliates, which shall have been obtained by the Participant in connection with the Participant&#8217;s employment by the Company and which shall not be or become public knowledge (other than by acts by the Participant or representatives of the Participant in violation of this Annex or Plan).  After termination of the Participant&#8217;s employment with the Company, the Participant shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data, to anyone other than the Company and those designated by it&#59; provided, however, that if the Participant receives actual notice that the Participant is or may be required by law or legal process to communicate or divulge any such information, knowledge or data, the Participant shall promptly so notify the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;While employed by the Company, the Participant shall not be engaged in any other business activity that would be competitive with the business of the Company and its subsidiaries or affiliates.  In addition, while employed by the Company and, for a period of 12 months after the Date of Termination, the Participant shall not directly or indirectly solicit, induce, or encourage any employee or consultant of the Company and&#47;or its subsidiaries and affiliates to terminate their employment or other relationship with the Company and its subsidiaries and affiliates or to cease to render services to the Company and&#47;or its subsidiaries and affiliates and the Participant shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking of any such actions by any other individual or entity except, in each case, to the extent the foregoing occurs as a result of general advertisements or other solicitations not specifically targeted to such employees and consultants.  During the Participant's employment with the Company and thereafter, the Participant shall not use any trade secret of the Company or its subsidiaries or affiliates to solicit, induce, or encourage any customer, client, vendor, or other party doing business with any member of the Company and its subsidiaries and affiliates to terminate its relationship therewith or transfer its business from any member of the Company and its subsidiaries and affiliates and the Participant shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking of any such actions by any other individual or entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Subject to Section (d) of this Annex, during the Participant&#8217;s service with the Company and thereafter, excepting any litigation between the parties, the Participant agrees not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on any of the Company or any of its subsidiaries or affiliates, or that are otherwise disparaging of any policies, procedures, practices, decision-making, conduct, professionalism or compliance with standards of the Company, its affiliates or any of their past or present officers, directors, employees, advisors or agents</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything in this Annex or the Plan to the contrary, nothing contained in this Annex or the Plan shall prohibit either party (or either party&#8217;s attorney(s)) from (i) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with the U.S. Securities and Exchange Commission, the </font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Annex A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Industry Regulatory Authority, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency, self-regulatory authority or federal, state or local regulatory authority (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation, (ii) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such information to such party&#8217;s attorney(s) or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding, and&#47;or (iii) receiving an award for information provided to any Government Agency.  Pursuant to 18 USC Section 1833(b), the Participant will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made&#58; (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  Further, nothing in this Annex or the Plan is intended to or shall preclude either party from providing truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law.  If the Participant is required to provide testimony, then unless otherwise directed or requested by a Government Agency or law enforcement, the Participant shall notify the Company as soon as reasonably practicable after receiving any such request of the anticipated testimony.</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Annex A-2</font></div></div></div><div id="ie70f417fda1b411684283c6476ed1159_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Calculation of Change in control Severance Amounts</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:7.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tier</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Salary Severance</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive Compensation Severance</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COBRA Period</font></td></tr><tr style="height:52pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.65pt;padding-right:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125% Base Compensation plus Target Incentive Compensation</font></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pro-rata Actual Incentive Compensation (pro-rated based on the number of days worked during the year in which the Date of Termination occurs, divided by the total number of days in such year)*</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15 months</font></td></tr><tr style="height:27pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.65pt;padding-right:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100% Base Compensation plus Target Incentive Compensation</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12 months</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* Payable on the date on which annual bonuses are generally paid (but no later than March 15 of the year following year in which the Date of Termination occurs).</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. A-1</font></div></div></div><div id="ie70f417fda1b411684283c6476ed1159_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF RELEASE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For valuable consideration, including the payments or benefits under Section 4 of the Exagen Inc. Executive Change in Control Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever discharge the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; hereunder, consisting of Exagen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and the Company&#8217;s partners, subsidiaries, associates, affiliates, successors, heirs, assigns, agents, directors, officers, employees, representatives, lawyers, insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs, attorneys&#8217; fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which the undersigned now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof.&#160; The Claims released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based upon, or related to the employment or termination of employment of the undersigned by the Releasees, or any of them&#59; any alleged breach of any express or implied contract of employment&#59; any alleged torts or other alleged legal restrictions on Releasees&#8217; right to terminate the employment of the undersigned&#59; and any alleged violation of any federal, state or local statute or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, the Americans With Disabilities Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claims Not Released</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding the foregoing, this general release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall not operate to release any rights or claims of the undersigned (i) to payments or benefits under Section 4 of the Severance Plan, with respect to the payments and benefits provided in exchange for this Release, (ii) to payments or benefits under any equity award agreement between the undersigned and the Company, (iii) to accrued or vested benefits the undersigned may have, if any, as of the date hereof under any applicable plan, policy, practice, program, contract or agreement with the Company, (iv) to any Claims, including claims for indemnification and&#47;or advancement of expenses arising under any indemnification agreement between the undersigned and the Company or under the bylaws, certificate of incorporation or other similar governing document of the Company, (v) to any Claims which cannot be waived by an employee under applicable law or (vi) with respect to the undersigned&#8217;s right to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unknown Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE UNDERSIGNED ACKNOWLEDGES THAT THE UNDERSIGNED HAS BEEN ADVISED BY LEGAL COUNSEL AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#8221;</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. B-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE UNDERSIGNED, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS THE UNDERSIGNED MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything in this Release to the contrary, nothing contained in this Release shall prohibit the undersigned from (i) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with any governmental agency or entity or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation and&#47;or (ii) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to, any federal, state or local government regulator (including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice) for the purpose of reporting or investigating a suspected violation of law, or from providing such information to the undersigned&#8217;s attorney or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding.  Pursuant to 18 USC Section 1833(b), the undersigned will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made&#58; (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The undersigned represents and warrants that there has been no assignment or other transfer of any interest in any Claim which the undersigned may have against Releasees, or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability, Claims, demands, damages, costs, expenses and attorneys&#8217; fees incurred by Releasees, or any of them, as the result of any such assignment or transfer or any rights or Claims under any such assignment or transfer.&#160; It is the intention of the parties that this indemnity does not require payment as a condition precedent to recovery by the Releasees against the undersigned under this indemnity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The undersigned agrees that if the undersigned hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to pay to Releasees, and each of them, in addition to any other damages caused to Releasees thereby, all attorneys&#8217; fees incurred by Releasees in defending or otherwise responding to said suit or Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Admission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The undersigned further understands and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed as an admission of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they have no liability whatsoever to the undersigned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OWBPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The undersigned agrees and acknowledges that this Release constitutes a knowing and voluntary waiver and release of all Claims the undersigned has or may have against the Company and&#47;or any of the Releasees as set forth herein, including, but not limited to, all Claims arising under the Older Worker&#8217;s Benefit Protection Act and the Age Discrimination in Employment Act. In accordance with the Older Worker&#8217;s Benefit Protection Act, the undersigned is hereby advised as follows&#58;</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. B-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the undersigned has read the terms of this Release, and understands its terms and effects, including the fact that the undersigned agreed to release and forever discharge the Company and each of the Releasees, from any Claims released in this Release&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the undersigned understands that, by entering into this Release, the undersigned does not waive any Claims that may arise after the date of the undersigned&#8217;s execution of this Release, including without limitation any rights or claims that the undersigned may have to secure enforcement of the terms and conditions of this Release&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the undersigned has signed this Release voluntarily and knowingly in exchange for the consideration described in this Release, which the undersigned acknowledges is adequate and satisfactory to the undersigned and which the undersigned acknowledges is in addition to any other benefits to which the undersigned is otherwise entitled&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the Company advises the undersigned to consult with an attorney prior to executing this Release&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the undersigned has been given at least &#91;21&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> days in which to review and consider this Release.  To the extent that the undersigned chooses to sign this Release prior to the expiration of such period, the undersigned acknowledges that the undersigned has done so voluntarily, had sufficient time to consider the Release, to consult with counsel and that the undersigned does not desire additional time and hereby waives the remainder of the &#91;21&#93;-day period&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the undersigned may revoke this Release within seven days from the date the undersigned signs this Release and this Release will become effective upon the expiration of that revocation period if the undersigned has not revoked this Release during such seven-day period.  If the undersigned revokes this Release during such seven-day period, this Release will be null and void and of no force or effect on either the Company or the undersigned and the undersigned will not be entitled to any of the payments or benefits which are expressly conditioned upon the execution and non-revocation of this Release.  Any revocation must be in writing and sent to &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;, via electronic mail at &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">email address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;, on or before &#91;5&#58;00 p.m. Pacific time&#93; on the seventh day after this Release is executed by the undersigned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Release is deemed made and entered into in the State of California, and in all respects shall be interpreted, enforced and governed under the internal laws of the State of California, to the extent not preempted by federal law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned has executed this Release this ____ day of ___________, ____.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                             &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;______&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NTD&#58;  Use 45 days in a group termination, and include information regarding terminated positions.</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. B-3</font></div></div></div><div id="ie70f417fda1b411684283c6476ed1159_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Claims Procedures</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claim Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Claims for benefits under the Plan shall be administered in accordance with Section 503 of ERISA and the Department of Labor Regulations thereunder.  The Administrator shall have the right to delegate its duties under this Exhibit and all references to the Administrator shall be a reference to any such delegate, as well.  The Administrator shall make all determinations as to the rights of any Participant, beneficiary, alternate payee or other person who makes a claim for benefits under the Plan (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). A Claimant may authorize a representative to act on his or her behalf with respect to any claim under the Plan. A Claimant who asserts a right to any benefit under the Plan he or she has not received, in whole or in part, must file a written claim with the Administrator.  All written claims shall be submitted to &#91;____&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regular Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The claims procedure in this subsection (a) shall apply to all claims for Plan benefits.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Timing of Denial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Administrator denies a claim in whole or in part (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">adverse benefit determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Administrator will provide notice of the decision to the Claimant within a reasonable period of time, not to exceed 90 days after the Administrator receives the claim, unless the Administrator determines that an extension of time for processing is required.  In the event that the Administrator determines that such an extension is required, written notice of the extension will be furnished to the Claimant before the end of the initial 90 day review period.  The extension will not exceed a period of 90 days from the end of the initial 90 day period, and the extension notice will indicate the special circumstances requiring such extension of time and the date by which the Administrator expects to render the benefit decision.    </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Denial Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator shall provide every Claimant who is denied a claim for benefits with a written or electronic notice of its decision.  The notice will set forth, in a manner to be understood by the Claimant&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the specific reason or reasons for the adverse benefit determination&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;reference to the specific Plan provisions on which the determination is based&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a description of any additional material or information necessary for the Claimant to perfect the claim and an explanation as to why such information is necessary&#59; and</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;an explanation of the Plan&#8217;s appeal procedure and the time limits applicable to such procedures, including a statement of the Claimant&#8217;s right to bring an action under Section 502(a) of ERISA after receiving a final adverse benefit determination upon appeal.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appeal of Denial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Claimant may appeal an initial adverse benefit determination by submitting a written appeal to the Administrator within 60 days of receiving notice of the denial of the claim.  The Claimant&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. C-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;may submit written comments, documents, records and other information relating to the claim for benefits&#59; </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;will be provided, upon request and without charge, reasonable access to and copies of all documents, records and other information relevant to the Claimant&#8217;s claim for benefits&#59; and</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;will receive a review that takes into account all comments, documents, records and other information submitted by the Claimant relating to the appeal, without regard to whether such information was submitted or considered in the initial benefit determination.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Decision on Appeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator will conduct a full and fair review of the claim and the initial adverse benefit determination.  The Administrator holds regularly scheduled meetings at least quarterly.  The Administrator shall make a benefit determination no later than the date of the regularly scheduled meeting that immediately follows the Plan&#8217;s receipt of an appeal request, unless the appeal request is filed within 30 days preceding the date of such meeting.  In such case, a benefit determination may be made by no later than the date of the second regularly scheduled meeting following the Plan&#8217;s receipt of the appeal request.  If special circumstances require a further extension of time for processing, a benefit determination shall be rendered no later than the third regularly scheduled meeting of the Administrator following the Plan&#8217;s receipt of the appeal request.  If such an extension of time for review is required, the Administrator shall provide the Claimant with written notice of the extension, describing the special circumstances and the date as of which the benefit determination will be made, prior to the commencement of the extension.  The Administrator generally cannot extend the review period any further unless the Claimant voluntarily agrees to a longer extension.  The Administrator shall notify the Claimant of the benefit determination as soon as possible but not later than five days after it has been made.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Determination on Appeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Administrator shall provide the Claimant with written or electronic notification of its benefit determination on review.  In the case of an adverse benefit determination, the notice shall set forth, in a manner intended to be understood by the Claimant&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the specific reason or reasons for the adverse benefit determination&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;reference to the specific Plan provisions on which the adverse benefit determination is based&#59; </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a statement that the Claimant is entitled to receive, upon request and without charge, reasonable access to, and copies of, all documents, records and other information relevant to the claim for benefits&#59;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a statement describing any voluntary appeal procedures offered by the Plan and the Claimant&#8217;s right to obtain the information about such procedures&#59; and</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. C-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;a statement of the Claimant&#8217;s right to bring an action under Section 502(a) of ERISA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhaustion&#59; Judicial Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  No action at law or in equity shall be brought to recover benefits under the Plan until the claim and appeal rights described in the Plan have been exercised and the Plan benefits requested in such appeal have been denied in whole or in part.  If any judicial proceeding is undertaken to appeal the denial of a claim or bring any other action under ERISA other than a breach of fiduciary claim, the evidence presented may be strictly limited to the evidence timely presented to the Administrator.  Any such judicial proceeding must be filed by the earlier of&#58; (a) one year after the Administrator&#8217;s final decision regarding the claim appeal or (b) one year after the Participant or other Claimant commenced payment of the Plan benefits at issue in the judicial proceeding.  The jurisdiction and venue for any judicial proceedings arising under or relating to the Plan will be exclusively in the courts in California, including the federal courts located there should federal jurisdiction exist.  This paragraph (c) shall not be construed to prohibit the enforcement of any arbitration agreements.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrator&#8217;s Decision is Binding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Benefits under the Plan shall be paid only if the Administrator decides in its sole discretion that a Claimant is entitled to them.  In determining claims for benefits, the Administrator has the authority to interpret the Plan, to resolve ambiguities, to make factual determinations, and to resolve questions relating to eligibility for and amount of benefits.  Subject to applicable law, any decision made in accordance with the above claims procedures is final and binding on all parties and shall be given the maximum possible deference allowed by law.  A misstatement or other mistake of fact shall be corrected when it becomes known and the Administrator shall make such adjustment on account thereof as it considers equitable and practicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exh. C-3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex231-2020bdoconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i03b7a18120c3413587b511be3436e2f2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vista, California</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statement Form S-3 (No. 333-250015) and Form S-8 (No.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-233878) of Exagen Inc. of our report dated March 16, 2021, relating to the financial statements, which appears in this Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 16, 2021</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>xgn311-123120.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibe55cc35c1f4477b9be6f4af84886e0f_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Fortunato Ron Rocca, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> &#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;16, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>xgn312-123120.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i480f9401e65c4168bb748844bf986a9f_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> &#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;16, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>xgn321-123120.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i70bb0beab2584f82971357becd407fbd_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2020 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;16, 2021</font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2020 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;16, 2021</font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>exdx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.exagen.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets - (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.exagen.com/role/StatementsofOperations">
        <link:definition>1003004 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity">
        <link:definition>1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.exagen.com/role/StatementsofCashFlows">
        <link:definition>1006007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>2111103 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>2312302 - Disclosure - Other Financial Information - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidexpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails">
        <link:definition>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandequipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails">
        <link:definition>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedliabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails">
        <link:definition>2416410 - Disclosure - Other Financial Information - Accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>2117104 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>2318303 - Disclosure - Borrowings - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>2419411 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureminimumpaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails">
        <link:definition>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>2121105 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables">
        <link:definition>2322304 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2423413 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails">
        <link:definition>2424414 - Disclosure - Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1" roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1">
        <link:definition>2424414 - Disclosure - Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>2125106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresandDisclosuresTables" roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables">
        <link:definition>2326305 - Disclosure - Fair Value Measures and Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>2427415 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2128107 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockDetails" roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails">
        <link:definition>2429416 - Disclosure - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>2130108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>2331306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2432417 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.exagen.com/role/StockholdersEquityDetails">
        <link:definition>2433418 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>2134109 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>2335307 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>2436419 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>2437420 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>2438421 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>2439422 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
        <link:definition>2440423 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exagen.com/role/IncomeTaxes">
        <link:definition>2141110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exagen.com/role/IncomeTaxesTables">
        <link:definition>2342308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2443424 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>2444425 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2445426 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeInValuationAllowanceDetails" roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails">
        <link:definition>2446427 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2447428 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.exagen.com/role/RelatedParties">
        <link:definition>2148111 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.exagen.com/role/A401kPlan">
        <link:definition>2149112 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.exagen.com/role/A401kPlanDetails">
        <link:definition>2450429 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19" roleURI="http://www.exagen.com/role/Covid19">
        <link:definition>2151113 - Disclosure - Covid-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19Details" roleURI="http://www.exagen.com/role/Covid19Details">
        <link:definition>2452430 - Disclosure - Covid-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_ClinicalStudyPolicyPolicyTextBlock" abstract="false" name="ClinicalStudyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" abstract="false" name="IncreaseDecreaseInFairValueOfFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderCapitalLease" abstract="false" name="EquipmentPurchasedUnderCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_MilestoneObligation" abstract="false" name="MilestoneObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividend" abstract="false" name="TemporaryEquityDeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" abstract="false" name="ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" abstract="false" name="JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" abstract="false" name="DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeasesRenewalTerm" abstract="false" name="OperatingLeasesRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_NoncashExerciseOfStockPurchaseWarrants" abstract="false" name="NoncashExerciseOfStockPurchaseWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFee" abstract="false" name="JointVentureQuarterlyPromotionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" abstract="false" name="ProceedsFromIssuanceOrSaleOfTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividendSharesIssued" abstract="false" name="TemporaryEquityDeemedDividendSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeePerPrescription" abstract="false" name="JointVentureQuarterlyPromotionFeePerPrescription" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CapitalRoyaltyPartnersIILPMember" abstract="true" name="CapitalRoyaltyPartnersIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" abstract="true" name="CommonStockOptionGrantsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" abstract="false" name="TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityTextBlock" abstract="false" name="TemporaryEquityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPrescribedUnits" abstract="false" name="JointVentureQuarterlyPrescribedUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AssetsUnderCapitalLeaseMember" abstract="true" name="AssetsUnderCapitalLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ConversionOfTemporaryEquityAmountConverted" abstract="false" name="ConversionOfTemporaryEquityAmountConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_SaleOfTemporaryEquityPricePerShare" abstract="false" name="SaleOfTemporaryEquityPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="exdx_TemporaryEquitySharesRedeemedUponConversion" abstract="false" name="TemporaryEquitySharesRedeemedUponConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" abstract="false" name="DeferredOfferingCostsIncludedWithinCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" abstract="true" name="ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MilestoneContingencyFairValueDisclosure" abstract="false" name="MilestoneContingencyFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" abstract="false" name="TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" abstract="true" name="CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_OperatingLossCarryforwardsNotUtilized" abstract="false" name="OperatingLossCarryforwardsNotUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquitySharesRedeemedUponConversionAmount" abstract="false" name="TemporaryEquitySharesRedeemedUponConversionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" abstract="false" name="TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuanceCosts" abstract="false" name="TemporaryEquityIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantRevenuePerformancePeriod" abstract="false" name="DebtInstrumentCovenantRevenuePerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" abstract="false" name="DebtInstrumentPeriodicPrincipalNumberOfPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>exdx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9749ef8d-ff78-4d6b-99ac-8f4df85b4cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6766d74f-f12f-4102-9796-1e2254562f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9749ef8d-ff78-4d6b-99ac-8f4df85b4cd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6766d74f-f12f-4102-9796-1e2254562f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_94a36e08-2601-4560-9760-1a6042d1b6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9749ef8d-ff78-4d6b-99ac-8f4df85b4cd7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_94a36e08-2601-4560-9760-1a6042d1b6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_8d713d66-453a-4865-bd1b-406794d7e1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9749ef8d-ff78-4d6b-99ac-8f4df85b4cd7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_8d713d66-453a-4865-bd1b-406794d7e1e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b147efa2-9659-4990-95e5-964c6ca86f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bab798a8-8b15-41b4-b8ca-cf225d96b0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b147efa2-9659-4990-95e5-964c6ca86f61" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bab798a8-8b15-41b4-b8ca-cf225d96b0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_733e7b21-a5a6-40b6-a915-a09d60fea103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b147efa2-9659-4990-95e5-964c6ca86f61" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_733e7b21-a5a6-40b6-a915-a09d60fea103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0b73076b-6720-47d2-9e87-8b63d6089450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b147efa2-9659-4990-95e5-964c6ca86f61" xlink:to="loc_us-gaap_AssetsCurrent_0b73076b-6720-47d2-9e87-8b63d6089450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db361d79-c490-47c1-9960-2defbab58355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b147efa2-9659-4990-95e5-964c6ca86f61" xlink:to="loc_us-gaap_Goodwill_db361d79-c490-47c1-9960-2defbab58355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13c5e098-0582-4745-8cdb-1d111a33e6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_33e30aed-6301-4384-b7ac-b7942e0e0bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_13c5e098-0582-4745-8cdb-1d111a33e6c6" xlink:to="loc_us-gaap_PreferredStockValue_33e30aed-6301-4384-b7ac-b7942e0e0bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c6f77b2b-110a-40ab-bd3b-723cd0d34f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_13c5e098-0582-4745-8cdb-1d111a33e6c6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c6f77b2b-110a-40ab-bd3b-723cd0d34f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea02d9de-1058-4e72-b2c8-90f1c1032929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_13c5e098-0582-4745-8cdb-1d111a33e6c6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea02d9de-1058-4e72-b2c8-90f1c1032929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1e9b85aa-10af-4fd6-be66-2de915f9b669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_13c5e098-0582-4745-8cdb-1d111a33e6c6" xlink:to="loc_us-gaap_CommonStockValue_1e9b85aa-10af-4fd6-be66-2de915f9b669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea63527-f953-424c-b1e8-19f86d8b9a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9122cf7f-e9f2-451a-a901-bc3211e098da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea63527-f953-424c-b1e8-19f86d8b9a7e" xlink:to="loc_us-gaap_StockholdersEquity_9122cf7f-e9f2-451a-a901-bc3211e098da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cc631bce-8b0b-4b0b-befc-739ed26b7dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea63527-f953-424c-b1e8-19f86d8b9a7e" xlink:to="loc_us-gaap_Liabilities_cc631bce-8b0b-4b0b-befc-739ed26b7dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_11e67d07-bb60-44e0-a0f0-145b6fdf785b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea63527-f953-424c-b1e8-19f86d8b9a7e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_11e67d07-bb60-44e0-a0f0-145b6fdf785b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18631ae2-ef7d-476c-a921-157a940ef867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7396007f-399b-4903-93c6-0f3700d063fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18631ae2-ef7d-476c-a921-157a940ef867" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7396007f-399b-4903-93c6-0f3700d063fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fd665518-fc41-4c5c-bbd6-59d1a5528e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18631ae2-ef7d-476c-a921-157a940ef867" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fd665518-fc41-4c5c-bbd6-59d1a5528e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e63edee5-4f98-4679-9ba2-7a6a9c45512b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18631ae2-ef7d-476c-a921-157a940ef867" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e63edee5-4f98-4679-9ba2-7a6a9c45512b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1d2c54e1-b874-4493-b638-f0c4d08830d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18631ae2-ef7d-476c-a921-157a940ef867" xlink:to="loc_us-gaap_LiabilitiesCurrent_1d2c54e1-b874-4493-b638-f0c4d08830d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ae71e201-0545-432e-914f-b757d5200cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_779fcec3-c2a2-4001-9f25-e2d8c23e2b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ae71e201-0545-432e-914f-b757d5200cce" xlink:to="loc_us-gaap_AccountsPayableCurrent_779fcec3-c2a2-4001-9f25-e2d8c23e2b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_845890a9-3e91-4b99-b421-c5507d1f9ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ae71e201-0545-432e-914f-b757d5200cce" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_845890a9-3e91-4b99-b421-c5507d1f9ed4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_977bb9a6-1845-44da-8d96-63ce4d2d7c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4742cf3-0f59-4b4a-bfeb-725f6c8cfcbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_977bb9a6-1845-44da-8d96-63ce4d2d7c6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4742cf3-0f59-4b4a-bfeb-725f6c8cfcbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_713809fe-d523-41c9-bb5e-b4a9c2b087b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_977bb9a6-1845-44da-8d96-63ce4d2d7c6c" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_713809fe-d523-41c9-bb5e-b4a9c2b087b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0505952b-39d0-4c4a-8ada-973548be2d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb38d1aa-0e60-48a9-bc31-4c737b9150b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0505952b-39d0-4c4a-8ada-973548be2d38" xlink:to="loc_us-gaap_CostsAndExpenses_cb38d1aa-0e60-48a9-bc31-4c737b9150b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f02d1fce-3dc1-40fb-81b0-b87eae442fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0505952b-39d0-4c4a-8ada-973548be2d38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f02d1fce-3dc1-40fb-81b0-b87eae442fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_31ceca9f-dbb7-4624-a9ec-42e1f9b5d7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fdcc568a-2371-49de-bf1f-dd36fbaacebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_31ceca9f-dbb7-4624-a9ec-42e1f9b5d7e7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fdcc568a-2371-49de-bf1f-dd36fbaacebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_85d99a2c-0fcf-43e7-a37f-afb7b52de8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_31ceca9f-dbb7-4624-a9ec-42e1f9b5d7e7" xlink:to="loc_us-gaap_InterestExpense_85d99a2c-0fcf-43e7-a37f-afb7b52de8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7de8877-79c1-477a-b234-8cfbe7fa4824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_31ceca9f-dbb7-4624-a9ec-42e1f9b5d7e7" xlink:to="loc_us-gaap_OperatingIncomeLoss_f7de8877-79c1-477a-b234-8cfbe7fa4824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_9ce306c3-c38c-496d-9959-f8784cc0788a" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_31ceca9f-dbb7-4624-a9ec-42e1f9b5d7e7" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_9ce306c3-c38c-496d-9959-f8784cc0788a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_080e44fc-d43c-4e30-9324-e1f6d2dd4841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_21f8f28d-935e-4b86-9bba-60db7107ec4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_080e44fc-d43c-4e30-9324-e1f6d2dd4841" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_21f8f28d-935e-4b86-9bba-60db7107ec4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_2c3114c7-0a41-42fa-92ac-2bd3c044bbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_080e44fc-d43c-4e30-9324-e1f6d2dd4841" xlink:to="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_2c3114c7-0a41-42fa-92ac-2bd3c044bbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cad30d9-8b72-4495-aa67-f18f81e49281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_080e44fc-d43c-4e30-9324-e1f6d2dd4841" xlink:to="loc_us-gaap_NetIncomeLoss_7cad30d9-8b72-4495-aa67-f18f81e49281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_be4a57a8-5f8b-49b3-8043-64107eae1475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e70af3e6-9dbe-42b5-bc92-9d78040a636a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be4a57a8-5f8b-49b3-8043-64107eae1475" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e70af3e6-9dbe-42b5-bc92-9d78040a636a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_339c3de0-323a-4f7f-8088-a497a8c3c75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be4a57a8-5f8b-49b3-8043-64107eae1475" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_339c3de0-323a-4f7f-8088-a497a8c3c75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14c256dc-98af-4d81-ba11-69528032605e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_be4a57a8-5f8b-49b3-8043-64107eae1475" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14c256dc-98af-4d81-ba11-69528032605e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_874ba733-9c1e-4cd4-bbb8-95acefdf16de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09d7bc0a-4b1e-4791-8286-50ce1042157a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_874ba733-9c1e-4cd4-bbb8-95acefdf16de" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09d7bc0a-4b1e-4791-8286-50ce1042157a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_acc2db6c-90fa-402f-8231-9df1bc035e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_874ba733-9c1e-4cd4-bbb8-95acefdf16de" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_acc2db6c-90fa-402f-8231-9df1bc035e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f409f32a-0ecc-4d1f-93c1-13fdb8ace9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_974e5355-c057-49a3-a572-ac03a73a31a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f409f32a-0ecc-4d1f-93c1-13fdb8ace9b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_974e5355-c057-49a3-a572-ac03a73a31a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6627caa4-f172-46b6-90dc-2e8dac521a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f409f32a-0ecc-4d1f-93c1-13fdb8ace9b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6627caa4-f172-46b6-90dc-2e8dac521a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b0ca750-55ba-4196-b60d-14528df4e317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f409f32a-0ecc-4d1f-93c1-13fdb8ace9b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b0ca750-55ba-4196-b60d-14528df4e317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3925ae70-d3ad-41ea-934b-8af0c8d79923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3925ae70-d3ad-41ea-934b-8af0c8d79923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_d7f9e2ec-4385-418c-b133-68c44ad5f482" xlink:href="exdx-20201231.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_d7f9e2ec-4385-418c-b133-68c44ad5f482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7bcb9868-7289-4b4b-ab10-06ab63782503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7bcb9868-7289-4b4b-ab10-06ab63782503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_a30876bb-30b1-4cbe-ac63-557e83644f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_a30876bb-30b1-4cbe-ac63-557e83644f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_245b144a-1b3c-4d5c-8a6a-0bf8ab743e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_245b144a-1b3c-4d5c-8a6a-0bf8ab743e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5a914a99-ffde-40bf-a514-69a8d2c7acf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5a914a99-ffde-40bf-a514-69a8d2c7acf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_ff6dd229-1986-4f80-b8b6-6d6b5baa1333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_ff6dd229-1986-4f80-b8b6-6d6b5baa1333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_e76bbcf5-2a60-4030-9190-88bee4ad9af2" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_e76bbcf5-2a60-4030-9190-88bee4ad9af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_cc269aaf-de49-458a-8c59-3880482aa7a1" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee397e92-84db-491e-8e8f-30571e6a9630" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_cc269aaf-de49-458a-8c59-3880482aa7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7471f751-4697-4eac-b2b2-32f3eda4939c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_NetIncomeLoss_7471f751-4697-4eac-b2b2-32f3eda4939c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7124e421-acde-42c8-9f8c-2aae30530d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_ShareBasedCompensation_7124e421-acde-42c8-9f8c-2aae30530d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c16a61ea-c63a-4e79-8e6a-1cfd7c8f6924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c16a61ea-c63a-4e79-8e6a-1cfd7c8f6924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cd2685f4-f668-4060-bdf1-e516559bd7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cd2685f4-f668-4060-bdf1-e516559bd7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_118baedc-37bf-458f-ac4a-0bf67fe97f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_118baedc-37bf-458f-ac4a-0bf67fe97f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0eafee16-42af-4580-af4c-57cd95b59084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0eafee16-42af-4580-af4c-57cd95b59084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1a9d7bf7-b06a-409e-958a-d8c5844be2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1a9d7bf7-b06a-409e-958a-d8c5844be2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b6ff6530-d356-4a08-9f98-5d2e1f5820b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b6ff6530-d356-4a08-9f98-5d2e1f5820b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_608f2338-f174-4c33-9085-aa37c2f1c591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_PaidInKindInterest_608f2338-f174-4c33-9085-aa37c2f1c591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_bdeee324-9e41-4021-acfc-e2d00f1c1225" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_bdeee324-9e41-4021-acfc-e2d00f1c1225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c4b87681-7e8b-4a02-a259-f38d9f75a0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c4b87681-7e8b-4a02-a259-f38d9f75a0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_19871773-3202-423d-99bd-7357bdac3e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_19871773-3202-423d-99bd-7357bdac3e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b363f628-0a22-4ab6-9d13-72da9e3bce5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff08340c-b5cb-4288-885a-18531f9985b6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b363f628-0a22-4ab6-9d13-72da9e3bce5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20201231.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14f97649-808d-47fe-a86a-ee0046e336a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3be93e80-5ec2-4e5d-afc4-7031ea6efd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14f97649-808d-47fe-a86a-ee0046e336a2" xlink:to="loc_us-gaap_RestrictedCash_3be93e80-5ec2-4e5d-afc4-7031ea6efd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16b498ce-8ee5-4a2c-84fd-60b00e3b8263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14f97649-808d-47fe-a86a-ee0046e336a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16b498ce-8ee5-4a2c-84fd-60b00e3b8263" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc284518-31f6-461a-98f4-aa68381c5518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ad655ff1-2d7e-4208-9f29-a41e7adcf1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc284518-31f6-461a-98f4-aa68381c5518" xlink:to="loc_us-gaap_OtherAssetsCurrent_ad655ff1-2d7e-4208-9f29-a41e7adcf1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_086c7bd7-1200-460f-9b6d-c79c286c305c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc284518-31f6-461a-98f4-aa68381c5518" xlink:to="loc_us-gaap_PrepaidRoyalties_086c7bd7-1200-460f-9b6d-c79c286c305c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_3d75fce9-8943-4356-b5db-52daa76ed78d" xlink:href="exdx-20201231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc284518-31f6-461a-98f4-aa68381c5518" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_3d75fce9-8943-4356-b5db-52daa76ed78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_c35bbc0f-70a1-4316-b6fa-8ae01b7d8f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc284518-31f6-461a-98f4-aa68381c5518" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_c35bbc0f-70a1-4316-b6fa-8ae01b7d8f80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5501f6b6-588b-4fb1-b92f-41fbbdeaa907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9687e7af-49fe-4c68-8656-67483f2b0f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5501f6b6-588b-4fb1-b92f-41fbbdeaa907" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9687e7af-49fe-4c68-8656-67483f2b0f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4ee7757-9f31-4124-bccb-5f3546a16857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5501f6b6-588b-4fb1-b92f-41fbbdeaa907" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4ee7757-9f31-4124-bccb-5f3546a16857" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_d9817da3-7096-4553-8827-23223e22deb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_us-gaap_AccruedSalariesCurrent_d9817da3-7096-4553-8827-23223e22deb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_db4186d9-93cf-4b80-bead-60f07af77d8b" xlink:href="exdx-20201231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_db4186d9-93cf-4b80-bead-60f07af77d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_b1de1722-9266-4216-89ab-bc22830ea926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_b1de1722-9266-4216-89ab-bc22830ea926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_20b5bbe9-0e9f-436e-b93a-cb556f035783" xlink:href="exdx-20201231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_20b5bbe9-0e9f-436e-b93a-cb556f035783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_e939d28a-f0cb-451e-aa66-7d0625b525f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_us-gaap_InterestPayableCurrent_e939d28a-f0cb-451e-aa66-7d0625b525f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_6921d0b4-ed29-433d-8749-a0c44324285f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_6921d0b4-ed29-433d-8749-a0c44324285f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51238cf2-86a1-41f0-bc82-40e24ecfb87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_87aff92a-39b1-41eb-949c-009bb4542892" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51238cf2-86a1-41f0-bc82-40e24ecfb87c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20201231.xsd#Borrowings"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9e4c9b73-1490-4136-bee0-4e7605452672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4f61bf1-3989-478a-90a2-a28ef0fc551a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9e4c9b73-1490-4136-bee0-4e7605452672" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4f61bf1-3989-478a-90a2-a28ef0fc551a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_f039ac17-b4cd-4f98-b35b-f33d474d5cf2" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9e4c9b73-1490-4136-bee0-4e7605452672" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_f039ac17-b4cd-4f98-b35b-f33d474d5cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6b67ac3e-159a-4226-9765-fea4d68903e3" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9e4c9b73-1490-4136-bee0-4e7605452672" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6b67ac3e-159a-4226-9765-fea4d68903e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b80ef2db-31a1-4a3e-8c6f-23d862b8affc" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce4adce3-0cff-4bb6-a7a0-dd86bd980ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b80ef2db-31a1-4a3e-8c6f-23d862b8affc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce4adce3-0cff-4bb6-a7a0-dd86bd980ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3ce5442e-abeb-4b16-bd0d-59df01156ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b80ef2db-31a1-4a3e-8c6f-23d862b8affc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3ce5442e-abeb-4b16-bd0d-59df01156ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3879ce0a-2635-4523-8838-f7cc7a653db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b80ef2db-31a1-4a3e-8c6f-23d862b8affc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3879ce0a-2635-4523-8838-f7cc7a653db5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_61d2247c-03cf-4a20-8acf-c30b55f8d94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b80ef2db-31a1-4a3e-8c6f-23d862b8affc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_61d2247c-03cf-4a20-8acf-c30b55f8d94f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingencies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2056438e-7ecf-4e5a-bc31-23f67e96dec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2056438e-7ecf-4e5a-bc31-23f67e96dec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_0bb47812-b61a-45d7-843d-46aec22b11bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_0bb47812-b61a-45d7-843d-46aec22b11bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_37e03804-212c-4b9f-97c7-fee8fa273475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_37e03804-212c-4b9f-97c7-fee8fa273475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_14481ff4-69b6-47b6-8544-f30e8a0fa6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_14481ff4-69b6-47b6-8544-f30e8a0fa6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d00d5d1e-e584-472c-a1b4-4234aa9e57c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d00d5d1e-e584-472c-a1b4-4234aa9e57c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f0e12588-8c24-4174-922c-1a20fb82086b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5fc20460-4d03-4eb8-bbb2-a34f0a4086b3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f0e12588-8c24-4174-922c-1a20fb82086b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_788ce5c6-4a3f-4790-8527-42c5e49f5212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_788ce5c6-4a3f-4790-8527-42c5e49f5212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_3c17035a-358b-48e5-adbd-4f118349f170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_3c17035a-358b-48e5-adbd-4f118349f170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_fbc6c5a1-f8ff-4525-92c1-f6602e948608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_fbc6c5a1-f8ff-4525-92c1-f6602e948608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9e87b44f-8337-4044-b815-8b7abe1efda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_9e87b44f-8337-4044-b815-8b7abe1efda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_fb05b8ae-ad2c-4154-a81b-8e9675e14eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_fb05b8ae-ad2c-4154-a81b-8e9675e14eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_a95ecc13-ffb3-42ca-a63b-f0111a5e3a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_5bbf61af-4a7b-4239-ab87-40a07a53c6bc" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_a95ecc13-ffb3-42ca-a63b-f0111a5e3a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_f7478329-7d92-481f-b524-86ded7196524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2b0de139-8f82-4e90-a24f-7f8e82d0740b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_f7478329-7d92-481f-b524-86ded7196524" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2b0de139-8f82-4e90-a24f-7f8e82d0740b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_a6dc66e8-3d78-4ed3-888d-256cdd687371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_f7478329-7d92-481f-b524-86ded7196524" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_a6dc66e8-3d78-4ed3-888d-256cdd687371" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_c15f4ed4-943d-4f58-b102-954f1c723ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_8ce310b7-0efe-4b41-ab80-8abcc82d37fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_c15f4ed4-943d-4f58-b102-954f1c723ef6" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_8ce310b7-0efe-4b41-ab80-8abcc82d37fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5ca271de-a6d3-4115-8347-e21459948690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_c15f4ed4-943d-4f58-b102-954f1c723ef6" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5ca271de-a6d3-4115-8347-e21459948690" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlan"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_49ecb269-a864-4c56-a13a-4158d30818a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e1c00d2c-d323-46d4-bad5-47e89fb5322e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_49ecb269-a864-4c56-a13a-4158d30818a7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e1c00d2c-d323-46d4-bad5-47e89fb5322e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ffb19ce4-aacb-483c-92aa-27a1c11f5c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_49ecb269-a864-4c56-a13a-4158d30818a7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ffb19ce4-aacb-483c-92aa-27a1c11f5c0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_810f4e49-7d4b-4a7c-9871-c23d6165d236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_84031122-2e57-4481-a316-7118645b2557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_810f4e49-7d4b-4a7c-9871-c23d6165d236" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_84031122-2e57-4481-a316-7118645b2557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2aed370-3071-493c-8b45-a5e1b7a93118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_810f4e49-7d4b-4a7c-9871-c23d6165d236" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2aed370-3071-493c-8b45-a5e1b7a93118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7de7dc26-729f-4a3b-a40b-bc009fdb4dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_40bc83d2-f14c-457e-bd69-0d467f3e65af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7de7dc26-729f-4a3b-a40b-bc009fdb4dd6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_40bc83d2-f14c-457e-bd69-0d467f3e65af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d2969eb1-500a-4efe-bd2c-21a0a5fffee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7de7dc26-729f-4a3b-a40b-bc009fdb4dd6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d2969eb1-500a-4efe-bd2c-21a0a5fffee1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2e7927d7-b6d7-4434-993e-83b95200d75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2e7927d7-b6d7-4434-993e-83b95200d75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fd8c311a-3d21-43f8-b918-1fdb757f0446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fd8c311a-3d21-43f8-b918-1fdb757f0446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_e3944393-97de-4679-9189-53ca840648a4" xlink:href="exdx-20201231.xsd#exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_e3944393-97de-4679-9189-53ca840648a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c6bf26a0-05a1-41c7-8034-d634b852e1be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c6bf26a0-05a1-41c7-8034-d634b852e1be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_57821dae-c01a-477c-9755-929218e0e400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_57821dae-c01a-477c-9755-929218e0e400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_fc099287-22ef-4a1b-bb80-cd253afef0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_995b2457-6782-4735-b85c-015f43c93190" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_fc099287-22ef-4a1b-bb80-cd253afef0c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_113d8aee-af22-4faf-8639-613474e56841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_228be686-7b7b-4ec8-8b82-9a8aa67900cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_113d8aee-af22-4faf-8639-613474e56841" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_228be686-7b7b-4ec8-8b82-9a8aa67900cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f4117abb-8bc3-4515-9892-d63f361eb745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_113d8aee-af22-4faf-8639-613474e56841" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f4117abb-8bc3-4515-9892-d63f361eb745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7eac15b9-bd78-44cb-b7ad-cdecf56495f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_e8960ee6-6e42-46a0-b19b-dc0171b0c6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7eac15b9-bd78-44cb-b7ad-cdecf56495f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_e8960ee6-6e42-46a0-b19b-dc0171b0c6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ee62bda4-bbc9-4610-95bb-69715eaa61d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7eac15b9-bd78-44cb-b7ad-cdecf56495f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ee62bda4-bbc9-4610-95bb-69715eaa61d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7ac03e37-2ec1-4ea8-b913-3766c4074e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7a199549-000d-468c-9990-da525eede2b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7ac03e37-2ec1-4ea8-b913-3766c4074e8f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7a199549-000d-468c-9990-da525eede2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b00f4bdd-a76d-4eaa-97a3-2b7724505073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7ac03e37-2ec1-4ea8-b913-3766c4074e8f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b00f4bdd-a76d-4eaa-97a3-2b7724505073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8017493-f72f-49bc-9205-4a180850432d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8017493-f72f-49bc-9205-4a180850432d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_281a907f-208a-4173-9d66-551650cc24ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_281a907f-208a-4173-9d66-551650cc24ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fd5cbd1d-564b-4bbc-8c9b-f3101240841f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fd5cbd1d-564b-4bbc-8c9b-f3101240841f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_42c71105-cca3-457e-8c10-8abdb64f565b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_42c71105-cca3-457e-8c10-8abdb64f565b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_79ca2dc5-0aee-4091-8f14-e4716e60a661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d4d0b63d-1fe6-4ff7-afec-ccd442111a7b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_79ca2dc5-0aee-4091-8f14-e4716e60a661" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20201231.xsd#RelatedParties"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlan"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlanDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19Details"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>exdx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended" id="i1b134c08264d48e688c534e12cc093f4_Cover"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended" id="id5a07191fedd42768d73226da829cbdc_BalanceSheets"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended" id="icbb1eef639d44966b199c323771f4c1b_BalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended" id="i96e63cbff5b249698cf400b7e9367a14_StatementsofOperations"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended" id="i754875abf8d545a384920a59b65356f1_StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_03565dea-ad23-402d-9348-9c389df0a02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_03565dea-ad23-402d-9348-9c389df0a02f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e7cb4854-671e-4152-a156-e327b6691f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e7cb4854-671e-4152-a156-e327b6691f34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_9f8693f2-2488-4185-a16a-15a99217eab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_9f8693f2-2488-4185-a16a-15a99217eab1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_4f50f34a-0058-4f40-b142-f2cb959caf18" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_4f50f34a-0058-4f40-b142-f2cb959caf18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_15a3081a-9908-42c1-9504-a9eb517fbe35" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_15a3081a-9908-42c1-9504-a9eb517fbe35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_6c70969c-32d5-4bb1-8c02-ddaeceb7297b" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_6c70969c-32d5-4bb1-8c02-ddaeceb7297b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_7a76d133-cd1d-4d52-8eb8-361f9a8cef19" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_7a76d133-cd1d-4d52-8eb8-361f9a8cef19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_2ad53b07-3883-4e17-8b77-f39876779857" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_2ad53b07-3883-4e17-8b77-f39876779857" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_ff82efeb-9ba5-4b41-a89b-8749c2a83bf3" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_ff82efeb-9ba5-4b41-a89b-8749c2a83bf3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_ed1d86e8-eea9-44b2-abf0-7841b3d60a16" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_ed1d86e8-eea9-44b2-abf0-7841b3d60a16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d4c8710a-ad0f-4b0c-9405-8f0df2c2053a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f113fcbf-c383-4cc8-83fd-ff624b973292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fd8908aa-be5e-4d63-be0c-1d42df56f2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fd8908aa-be5e-4d63-be0c-1d42df56f2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_692d5972-3ce4-44f6-8285-b239e078625c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockholdersEquity_692d5972-3ce4-44f6-8285-b239e078625c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_7562a119-71b2-475c-ae5e-e845a3066eed" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_7562a119-71b2-475c-ae5e-e845a3066eed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_768a9a5d-7e1c-45cf-a9e0-95663ef13330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_768a9a5d-7e1c-45cf-a9e0-95663ef13330" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad5a421c-ba5a-4a46-9dea-ac7c87f87711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad5a421c-ba5a-4a46-9dea-ac7c87f87711" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95d1cfd-2d33-48c0-9040-b29eb01706fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95d1cfd-2d33-48c0-9040-b29eb01706fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_5c25008b-8310-4c37-a469-79e31174e329" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_5c25008b-8310-4c37-a469-79e31174e329" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_7cb61e35-4654-44eb-ac58-ae4b4a218c22" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_7cb61e35-4654-44eb-ac58-ae4b4a218c22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_e1525320-eb6b-4173-8e40-1f6f020e1b49" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_e1525320-eb6b-4173-8e40-1f6f020e1b49" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e2e8e4e9-7daf-46f0-a2f5-b8a9bfb0e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e2e8e4e9-7daf-46f0-a2f5-b8a9bfb0e36f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0b488ab9-ef60-4935-bff9-fcf776e54050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0b488ab9-ef60-4935-bff9-fcf776e54050" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948530a6-41a7-4fff-ba95-5392f7e7e956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948530a6-41a7-4fff-ba95-5392f7e7e956" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c1061983-e3ce-4106-a94b-09e5ad5ecc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c1061983-e3ce-4106-a94b-09e5ad5ecc7e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_75a7fb20-127e-45a4-a535-20c72b5be8b7" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_75a7fb20-127e-45a4-a535-20c72b5be8b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_8f19aca8-5669-47b8-af40-41bb55d48e61" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_8f19aca8-5669-47b8-af40-41bb55d48e61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_5e318091-83cf-4138-9ada-48349df8dddc" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_5e318091-83cf-4138-9ada-48349df8dddc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6d47568-6354-4722-94d6-f8304ece0943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6d47568-6354-4722-94d6-f8304ece0943" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d9d121-5ef8-4cf3-bffa-7c887da4d188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d9d121-5ef8-4cf3-bffa-7c887da4d188" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d08f838-853e-402b-a7a0-b02c54bb54d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_NetIncomeLoss_3d08f838-853e-402b-a7a0-b02c54bb54d9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ba6b5bd-e91e-48ae-b877-148183942497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b70c407e-137b-4143-998d-00eae62a6b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:to="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26851b32-ddd1-46e0-af49-510cae2e041c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:to="loc_us-gaap_EquityComponentDomain_26851b32-ddd1-46e0-af49-510cae2e041c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:to="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_24d80a6d-6483-4bd2-8777-4a7a3d06f0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_CommonStockMember_24d80a6d-6483-4bd2-8777-4a7a3d06f0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6da0c0f2-4219-48c3-b89e-bcee0010585a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6da0c0f2-4219-48c3-b89e-bcee0010585a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fbfa834a-37d6-4a27-913e-4062b80b7bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_RetainedEarningsMember_fbfa834a-37d6-4a27-913e-4062b80b7bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:to="loc_us-gaap_ClassOfStockDomain_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:to="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_e66edf8f-cc28-42e7-a371-5a778d1ade26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_e66edf8f-cc28-42e7-a371-5a778d1ade26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_aad02872-1e03-4cee-872c-20e56cc24dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_aad02872-1e03-4cee-872c-20e56cc24dc1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="extended" id="i812082cfca14436d94c1441c1dc960d9_StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_df928c26-d85e-4944-9a8f-f843f6566659" xlink:href="exdx-20201231.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_df928c26-d85e-4944-9a8f-f843f6566659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts_0513fdb7-93b5-4ef2-bbb8-f0c80ae7cc71" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:to="loc_exdx_TemporaryEquityIssuanceCosts_0513fdb7-93b5-4ef2-bbb8-f0c80ae7cc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:to="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cacc84a7-3426-482e-bac8-478ce77c5b2d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:to="loc_us-gaap_ClassOfStockDomain_cacc84a7-3426-482e-bac8-478ce77c5b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:to="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_e3ed9c2e-aedd-49ff-aeeb-fcb0406770e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_e3ed9c2e-aedd-49ff-aeeb-fcb0406770e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_ac67b6cb-f447-45ff-aeae-9073354be45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_ac67b6cb-f447-45ff-aeae-9073354be45a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended" id="i1c2e9fc62b634a468c4616a57b2f3832_StatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ee9df80-f002-41ff-b00f-5b33ba016475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_NetIncomeLoss_0ee9df80-f002-41ff-b00f-5b33ba016475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b5b9f3da-f35e-43c3-ab65-23e911a10ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b5b9f3da-f35e-43c3-ab65-23e911a10ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f54ae90b-27f6-4df3-9627-b4b950f6b777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f54ae90b-27f6-4df3-9627-b4b950f6b777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_b1dc529d-2fd4-4190-9925-e3774b18ed85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_PaidInKindInterest_b1dc529d-2fd4-4190-9925-e3774b18ed85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_16ceb23f-ae8c-40c7-b95b-db93dffa698a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_16ceb23f-ae8c-40c7-b95b-db93dffa698a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ece42442-513c-4303-9479-b0849244d132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ece42442-513c-4303-9479-b0849244d132" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_74e6bb10-5782-4f3e-b9d9-c3ea192996c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_74e6bb10-5782-4f3e-b9d9-c3ea192996c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2fff782e-662f-4b6e-bb74-47d92ba61c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_ShareBasedCompensation_2fff782e-662f-4b6e-bb74-47d92ba61c8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_255adf65-d360-4ac1-ad31-54442c2c78be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_255adf65-d360-4ac1-ad31-54442c2c78be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_94b413e1-2827-4f2f-880a-7e23c956f4cf" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_94b413e1-2827-4f2f-880a-7e23c956f4cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_594ab21b-7ac3-4ba5-8687-f5fbd69ed358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_594ab21b-7ac3-4ba5-8687-f5fbd69ed358" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eae2d2f0-b168-49d5-9760-32afeed49ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eae2d2f0-b168-49d5-9760-32afeed49ff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2d139fa-6bff-4fbe-b1ad-365f275b9c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2d139fa-6bff-4fbe-b1ad-365f275b9c80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_302eb772-3fda-4b51-b2fe-a77f221c82b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_302eb772-3fda-4b51-b2fe-a77f221c82b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e33ea927-07a7-40c3-b648-4c91aa64fdb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e33ea927-07a7-40c3-b648-4c91aa64fdb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2ea94d1-f83d-4b1b-87fc-f980e6a3a98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2ea94d1-f83d-4b1b-87fc-f980e6a3a98d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb0f6c75-d677-4b06-af55-f15a448c8579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb0f6c75-d677-4b06-af55-f15a448c8579" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6eac89c6-d78d-424f-937e-4795acff1395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6eac89c6-d78d-424f-937e-4795acff1395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_1c84b103-1b03-451c-95e2-307f94c434d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromStockPlans_1c84b103-1b03-451c-95e2-307f94c434d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c3eb6cad-dcea-41a3-b610-785b81ce757b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c3eb6cad-dcea-41a3-b610-785b81ce757b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2a3b0d96-4c29-4713-a6c8-8fadfffe68ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2a3b0d96-4c29-4713-a6c8-8fadfffe68ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_07369354-a0b3-41f3-83b3-bab5d769fa51" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_07369354-a0b3-41f3-83b3-bab5d769fa51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_dc524f04-0398-4c56-9d59-c8916e0694c5" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_dc524f04-0398-4c56-9d59-c8916e0694c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5fdb31f1-b6ad-45a5-ae00-c797300cd625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5fdb31f1-b6ad-45a5-ae00-c797300cd625" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_1298371a-17b3-48b6-a1d6-10220b5b1688" xlink:href="exdx-20201231.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_1298371a-17b3-48b6-a1d6-10220b5b1688" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_00dfa7b6-fed7-4637-b1e3-ef857e1789ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_00dfa7b6-fed7-4637-b1e3-ef857e1789ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a252fab4-2f43-4544-81fb-ae450c05b11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a252fab4-2f43-4544-81fb-ae450c05b11c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2ff9a3f-d339-45a9-9bac-a2080033511c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2ff9a3f-d339-45a9-9bac-a2080033511c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3428f5cb-be3f-4f59-9d37-61372c1cbc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3428f5cb-be3f-4f59-9d37-61372c1cbc77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9be2713-27b8-420f-bc29-d4ebf3c88fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3922929c-6fbe-4bea-b452-f96e4c1e1487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:to="loc_us-gaap_InterestPaidNet_3922929c-6fbe-4bea-b452-f96e4c1e1487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_847343c2-3826-4ad8-8782-2746c22a894b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_847343c2-3826-4ad8-8782-2746c22a894b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_682c38c3-7927-427c-8faa-ff2c9f4e9619" xlink:href="exdx-20201231.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_682c38c3-7927-427c-8faa-ff2c9f4e9619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_69b805c6-9377-49d5-8afc-1a6d4e63c545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_69b805c6-9377-49d5-8afc-1a6d4e63c545" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_ef7d2ab5-4c57-47a3-b026-9f4c54a01455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_ef7d2ab5-4c57-47a3-b026-9f4c54a01455" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_b6d3c06d-e438-4ab5-991a-f72d3626f381" xlink:href="exdx-20201231.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_b6d3c06d-e438-4ab5-991a-f72d3626f381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_c537026a-8774-4e9b-8dea-9a078bab1c60" xlink:href="exdx-20201231.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_c537026a-8774-4e9b-8dea-9a078bab1c60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_06c56434-f3b9-42b9-a4da-ddfe2d346b0c" xlink:href="exdx-20201231.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_06c56434-f3b9-42b9-a4da-ddfe2d346b0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_d1f830b1-8b25-433d-bb76-39d0fa25c037" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_d1f830b1-8b25-433d-bb76-39d0fa25c037" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_d1a4a183-4ef7-4138-acd3-d6bd1b8baac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_d1a4a183-4ef7-4138-acd3-d6bd1b8baac9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted_c4ff3cdf-6a33-4e86-85b0-00362be4c732" xlink:href="exdx-20201231.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_ConversionOfTemporaryEquityAmountConverted_c4ff3cdf-6a33-4e86-85b0-00362be4c732" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_10a09cbe-2413-46d3-86b4-a2060803c8c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:to="loc_us-gaap_ClassOfStockDomain_10a09cbe-2413-46d3-86b4-a2060803c8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:to="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_bfe4438b-494e-4270-843c-5b24461da96d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_bfe4438b-494e-4270-843c-5b24461da96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_d6749c52-e81c-491e-8131-2c41ef89000a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_d6749c52-e81c-491e-8131-2c41ef89000a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20201231.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended" id="ib939de470b4c406b8b6300f14c7804c8_Organization"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended" id="ibb191ef2c7974a0eaf7c0340357bc5f1_OrganizationDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i0766ae4aefa6486aa2664c9a59709db5_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i0de68a952d1e465fbb4f34bb6944c0a6_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i87577bfc02754ef887cbdcd124a4e155_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="ibe1760c252fa45aba6cd0fa4f05fc687_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b994e5df-9231-458e-baab-d28a8babcda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b994e5df-9231-458e-baab-d28a8babcda0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_82e199ad-ebff-4135-9701-025c3b2170ae_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_82e199ad-ebff-4135-9701-025c3b2170ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_16f0f5d2-2f16-496f-a499-0c35458f64dd" xlink:href="exdx-20201231.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_MedicareMember_16f0f5d2-2f16-496f-a499-0c35458f64dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_9f1e8c7a-13ed-48f5-a99d-da1efa35f9a8" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_JanssenSIMPONIMember_9f1e8c7a-13ed-48f5-a99d-da1efa35f9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_e244241d-9dc7-4d34-b674-bd4c4028a590" xlink:href="exdx-20201231.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_BlueShieldMember_e244241d-9dc7-4d34-b674-bd4c4028a590" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_aba5c58a-cb92-4963-8858-14680644e91d" xlink:href="exdx-20201231.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_MedicareAdvantageMember_aba5c58a-cb92-4963-8858-14680644e91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_6b177f57-3ce9-4d15-9dca-a018b0ceafd4" xlink:href="exdx-20201231.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_UnitedHealthcareMember_6b177f57-3ce9-4d15-9dca-a018b0ceafd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c0d60f9d-fea7-4422-815b-d4c2ce91167c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:to="loc_us-gaap_SalesRevenueNetMember_c0d60f9d-fea7-4422-815b-d4c2ce91167c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_94696447-9b70-4af6-993b-ccc6b0ffaeb6" xlink:href="exdx-20201231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:to="loc_exdx_ReceivableBenchmarkMember_94696447-9b70-4af6-993b-ccc6b0ffaeb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26b8a925-0cf0-4021-ac21-b3ee8ec9a845_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26b8a925-0cf0-4021-ac21-b3ee8ec9a845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5d780d13-5d57-45d6-8305-a4bf15ac6412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5d780d13-5d57-45d6-8305-a4bf15ac6412" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="iaa7462f2b5714fd4ac2e49a77723a01d_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e1ae5fe9-5da1-4c36-bd5b-4ce8b77898bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e1ae5fe9-5da1-4c36-bd5b-4ce8b77898bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b1a9247e-0ef2-4e4d-86fa-392b5001f5b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_RestrictedCash_b1a9247e-0ef2-4e4d-86fa-392b5001f5b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3805cdef-1c64-45b2-b071-713e7f345035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3805cdef-1c64-45b2-b071-713e7f345035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_27c453b8-4000-416c-9489-1d3a99f7076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_27c453b8-4000-416c-9489-1d3a99f7076c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_0c64b3ac-0deb-46e7-9870-479f03a595f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_0c64b3ac-0deb-46e7-9870-479f03a595f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_c0e126fb-04f2-4115-a0e5-5085350dd283" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_c0e126fb-04f2-4115-a0e5-5085350dd283" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_7912c640-80ad-4449-b742-1822fb401c13" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_7912c640-80ad-4449-b742-1822fb401c13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cdc3a8a0-25e3-440a-8b14-adbc810dd52e" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cdc3a8a0-25e3-440a-8b14-adbc810dd52e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits_7b3de061-d155-4722-aef4-774e2d059158" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPrescribedUnits_7b3de061-d155-4722-aef4-774e2d059158" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41c075c0-1c53-4a50-b7b3-df93d503a3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41c075c0-1c53-4a50-b7b3-df93d503a3db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_d8347ca5-34fd-48ba-9f7b-777855e0c411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_AdvertisingExpense_d8347ca5-34fd-48ba-9f7b-777855e0c411" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_dac26ebe-b487-48b1-a966-e0e8b1e1693a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_CostOfRevenue_dac26ebe-b487-48b1-a966-e0e8b1e1693a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a74a06e3-c9a9-4552-b4c9-754f8dd4999d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a74a06e3-c9a9-4552-b4c9-754f8dd4999d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d69307a0-759a-4f08-97d7-77dda6619a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d69307a0-759a-4f08-97d7-77dda6619a67" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8437de92-64ad-48f2-9a6b-4d13bca17a21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8437de92-64ad-48f2-9a6b-4d13bca17a21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_a47d9d90-063a-4ae3-ba47-cb96672cca0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:to="loc_us-gaap_OtherAssetsMember_a47d9d90-063a-4ae3-ba47-cb96672cca0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_21dd0e28-5009-4775-b658-333b84be4697" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:to="loc_exdx_JanssenSIMPONIMember_21dd0e28-5009-4775-b658-333b84be4697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e191ce4b-bbf9-4821-a42d-7c28277bf8f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e191ce4b-bbf9-4821-a42d-7c28277bf8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7451066e-2a64-47d7-ab1b-7f1fcfd0c86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:to="loc_us-gaap_SalesRevenueNetMember_7451066e-2a64-47d7-ab1b-7f1fcfd0c86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d141ed8-6e73-4637-9dd0-1c37ff621e48_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:to="loc_srt_ProductsAndServicesDomain_9d141ed8-6e73-4637-9dd0-1c37ff621e48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:to="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_7f2b121c-7d08-4d51-b218-22db79942520" xlink:href="exdx-20201231.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:to="loc_exdx_AVISECTDTestMember_7f2b121c-7d08-4d51-b218-22db79942520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_b099fbe0-2947-439d-bc1f-7a1f965f04ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:to="loc_us-gaap_ShippingAndHandlingMember_b099fbe0-2947-439d-bc1f-7a1f965f04ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f4853743-8630-4217-805b-ce6c5b62b859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f4853743-8630-4217-805b-ce6c5b62b859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4c9a8d6f-a67b-440e-9e55-47802da6662b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4c9a8d6f-a67b-440e-9e55-47802da6662b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_aeeda7ba-2525-4b8a-9703-dd812f465e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_aeeda7ba-2525-4b8a-9703-dd812f465e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c28112bd-8b11-4e97-b76d-d0a19c9734b1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:to="loc_srt_RangeMember_c28112bd-8b11-4e97-b76d-d0a19c9734b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:to="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d4d6f1a-fc93-4fde-8875-95862c7e3819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:to="loc_srt_MinimumMember_4d4d6f1a-fc93-4fde-8875-95862c7e3819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e87ffcaa-3f0c-4ffe-9a2e-2c89ce9ce40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:to="loc_srt_MaximumMember_e87ffcaa-3f0c-4ffe-9a2e-2c89ce9ce40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9c8c8675-93d9-40a8-8212-8838c5f96645_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9c8c8675-93d9-40a8-8212-8838c5f96645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:to="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f5f22667-1991-48f2-9c98-1cd86b1da10a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:to="loc_srt_ScenarioForecastMember_f5f22667-1991-48f2-9c98-1cd86b1da10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:to="loc_us-gaap_EquityComponentDomain_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:to="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86e95ca5-b6de-4188-9cb6-213ad55e6d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:to="loc_us-gaap_CommonStockMember_86e95ca5-b6de-4188-9cb6-213ad55e6d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9dfb5085-2d45-4f23-bbdd-dde8dc7dcae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:to="loc_us-gaap_IPOMember_9dfb5085-2d45-4f23-bbdd-dde8dc7dcae8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="ica0bda04b59b4a6e8a533718fed7d140_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27c3533e-f046-47b7-84b0-63346cd5816a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27c3533e-f046-47b7-84b0-63346cd5816a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_34bb7125-635a-40db-8110-e2b042b19d9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:to="loc_us-gaap_SegmentDomain_34bb7125-635a-40db-8110-e2b042b19d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_808a6fc4-a6c8-4318-99fa-3eaaab1296a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:to="loc_us-gaap_SegmentDomain_808a6fc4-a6c8-4318-99fa-3eaaab1296a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:to="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_993da155-cded-4621-a4c3-1354e940c8a0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_993da155-cded-4621-a4c3-1354e940c8a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_ef6fd7bd-ebeb-4704-a3a1-0d42a01617b8" xlink:href="exdx-20201231.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_HealthcareInsurersMember_ef6fd7bd-ebeb-4704-a3a1-0d42a01617b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_fbc25a89-a298-4f96-b8b5-bf987dbaf050" xlink:href="exdx-20201231.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_Government1Member_fbc25a89-a298-4f96-b8b5-bf987dbaf050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_8b368aa5-5325-4b98-8cc0-5e19ba9f9fe0" xlink:href="exdx-20201231.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_ClientMember_8b368aa5-5325-4b98-8cc0-5e19ba9f9fe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_198cc09a-1029-495e-a6e1-784dfff4d480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_us-gaap_OtherCustomerMember_198cc09a-1029-495e-a6e1-784dfff4d480" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_b29bed6c-cf44-4f80-ac0d-c7cc78eda4f3" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_JanssenSIMPONIMember_b29bed6c-cf44-4f80-ac0d-c7cc78eda4f3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended" id="ib5d1b7fcc62b4c7eba6064bda2dbe4e6_SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="i0c51b15b36be4343b2d22e731b6e942b_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c31010b-d6f8-4151-87a6-f9391d9f03f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c31010b-d6f8-4151-87a6-f9391d9f03f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c19b10d2-18c6-4ad2-a776-7d56f456b16c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c19b10d2-18c6-4ad2-a776-7d56f456b16c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8546daa7-a587-41b5-9511-94f6f14600e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_WarrantMember_8546daa7-a587-41b5-9511-94f6f14600e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_4b702c4a-4dc1-4072-85e3-4c120c1775f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_StockOptionMember_4b702c4a-4dc1-4072-85e3-4c120c1775f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_78c5e382-653b-41b4-96d8-505bbc405910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_EmployeeStockMember_78c5e382-653b-41b4-96d8-505bbc405910" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended" id="i8e20e9a9ee9646ae849cb18c16654158_OtherFinancialInformation"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended" id="i42cdfffca3fc4aa4a0b158d3a52738f0_OtherFinancialInformationTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended" id="ice9a4b49d5384dda9836ed5e615856fe_OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended" id="i73f66dece36842ad908808f984b3ad8a_OtherFinancialInformationPropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bf24137-c0de-4309-873e-d6a92563261a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bf24137-c0de-4309-873e-d6a92563261a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a93f5e0-a30a-4817-8728-aff9cd038463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a93f5e0-a30a-4817-8728-aff9cd038463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffa061b2-c830-45df-98f1-efd03a5512ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ffa061b2-c830-45df-98f1-efd03a5512ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77b1bab8-45d8-448f-a347-8153f75b5d50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77b1bab8-45d8-448f-a347-8153f75b5d50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3202b152-fda3-4dd4-a285-f25ed81facdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3202b152-fda3-4dd4-a285-f25ed81facdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_3d4bb0b3-33d5-4e79-b8f4-046536d2046e" xlink:href="exdx-20201231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_exdx_LaboratoryEquipmentMember_3d4bb0b3-33d5-4e79-b8f4-046536d2046e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_32a33286-871b-4fc5-b6b8-f547e4cb1451" xlink:href="exdx-20201231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_32a33286-871b-4fc5-b6b8-f547e4cb1451" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a9fd2519-88e8-4db4-8548-44934de00f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a9fd2519-88e8-4db4-8548-44934de00f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_77539844-8191-47e2-9b41-ca5aea81a813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_ConstructionInProgressMember_77539844-8191-47e2-9b41-ca5aea81a813" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="ief0aa9f2562a44c497eef6dc6a677a0b_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1540d262-9d39-4d52-81dc-8b6aa7195300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1540d262-9d39-4d52-81dc-8b6aa7195300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_770c1a7b-0b26-464a-bf77-1fb949fea57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_770c1a7b-0b26-464a-bf77-1fb949fea57c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56b4ebf5-198d-4402-a186-95c748d32fa8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56b4ebf5-198d-4402-a186-95c748d32fa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_88c401fa-0bac-4fc3-84b8-4f086b11d32d" xlink:href="exdx-20201231.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_88c401fa-0bac-4fc3-84b8-4f086b11d32d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended" id="i5194c2e1a9004899b6736db2e96f1bef_OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20201231.xsd#Borrowings"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended" id="i8ff15a4a942e48f1b8204229c91090ac_Borrowings"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended" id="iec42ac4ae4fe4cb8ad2dae269660be97_BorrowingsTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i30d9a0afcd644f2db533f5152ba7e490_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2cb90fc0-b014-4e39-a027-2b7a7ccf775a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2cb90fc0-b014-4e39-a027-2b7a7ccf775a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5a947055-0efa-41fc-aa09-5ae972b66f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5a947055-0efa-41fc-aa09-5ae972b66f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3e2b978b-573e-4309-97be-ad1a324f99f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3e2b978b-573e-4309-97be-ad1a324f99f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_2efecab8-64e0-4e92-84da-de5d3b831541" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_2efecab8-64e0-4e92-84da-de5d3b831541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_09b68968-2683-4626-84af-a96e5beb49f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_09b68968-2683-4626-84af-a96e5beb49f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_711756bb-748d-4012-a547-efcddb33639d" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_711756bb-748d-4012-a547-efcddb33639d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c89459a2-4562-4f52-8b06-bc9bd7f28aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c89459a2-4562-4f52-8b06-bc9bd7f28aae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_d0e7b38c-3e71-4df9-a6dc-3b826253d5ce" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_d0e7b38c-3e71-4df9-a6dc-3b826253d5ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c4f801d1-d93e-4319-a549-5c814274ab8e" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c4f801d1-d93e-4319-a549-5c814274ab8e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c7e12dda-e195-4e45-9d01-93e71d27f6b0" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c7e12dda-e195-4e45-9d01-93e71d27f6b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_9ebe4359-c2a3-4f64-bda4-4d7714f3a494" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_9ebe4359-c2a3-4f64-bda4-4d7714f3a494" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_2c33f069-e24f-4b9d-8b3f-55fcf80ff69f" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_2c33f069-e24f-4b9d-8b3f-55fcf80ff69f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_84e11815-0676-4c8b-a04b-0f06e39e9429" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_84e11815-0676-4c8b-a04b-0f06e39e9429" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_7f31a04b-ee30-4426-8c98-26b19ba902b8" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_7f31a04b-ee30-4426-8c98-26b19ba902b8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea90ece5-ae17-4174-98db-306f51357d1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea90ece5-ae17-4174-98db-306f51357d1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_c6d1feb0-1668-45c5-a7c9-caacde32fbf3" xlink:href="exdx-20201231.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:to="loc_exdx_Term2017Member_c6d1feb0-1668-45c5-a7c9-caacde32fbf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0b784f5b-9ed1-4240-9a93-919cd1c1e911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:to="loc_us-gaap_LoansPayableMember_0b784f5b-9ed1-4240-9a93-919cd1c1e911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_aa150c68-c73c-43d5-954c-6a0629ae689d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_aa150c68-c73c-43d5-954c-6a0629ae689d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_e6e5834f-1f44-45c0-a3dc-46fd49382650_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_e6e5834f-1f44-45c0-a3dc-46fd49382650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_318edea6-25de-4a3b-80a8-f47677a93d45" xlink:href="exdx-20201231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_318edea6-25de-4a3b-80a8-f47677a93d45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_c2b3c699-3740-4cf5-9727-493a7d7e99f2" xlink:href="exdx-20201231.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_c2b3c699-3740-4cf5-9727-493a7d7e99f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended" id="iab993dc287ff44d59776a3e89a7e3db6_BorrowingsFutureminimumpaymentsDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingencies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended" id="i12384d933d0142b8a30424f9573eb9c1_CommitmentandContingencies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="extended" id="i89bee2b0574846d69ab98d98ba5645d6_CommitmentandContingenciesTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="iecd9b22eff8d491da5f1b8e4f7ee5d68_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_2d4bd42a-7abf-4b81-ba73-159c17abca48" xlink:href="exdx-20201231.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_2d4bd42a-7abf-4b81-ba73-159c17abca48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_fb2a54da-a579-4863-b269-9c2f3d1fb739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_LeaseAndRentalExpense_fb2a54da-a579-4863-b269-9c2f3d1fb739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_46e9e740-9780-4ecf-9d2b-a948caaee08c" xlink:href="exdx-20201231.xsd#exdx_MilestoneObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_MilestoneObligation_46e9e740-9780-4ecf-9d2b-a948caaee08c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_15a2faec-318d-46a3-a0dd-ede56b01ea8d" xlink:href="exdx-20201231.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_15a2faec-318d-46a3-a0dd-ede56b01ea8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_5f4947d0-415c-4f9c-a804-36c55db3eed2" xlink:href="exdx-20201231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_5f4947d0-415c-4f9c-a804-36c55db3eed2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_99164b63-c286-486c-8d17-8bc38cc10e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_99164b63-c286-486c-8d17-8bc38cc10e67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_b48c9617-f5c6-4691-b785-2c9f997a705b" xlink:href="exdx-20201231.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_AdvancePayment_b48c9617-f5c6-4691-b785-2c9f997a705b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0e3adfe0-1b28-4221-bcd5-a597066793e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0e3adfe0-1b28-4221-bcd5-a597066793e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_6fcadec5-b9ca-4eb3-ac04-b09f89315f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_6fcadec5-b9ca-4eb3-ac04-b09f89315f49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_a1395952-e7d1-4bbe-b9f2-8a7369160d5c" xlink:href="exdx-20201231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_a1395952-e7d1-4bbe-b9f2-8a7369160d5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_2c45f60a-3229-464b-8b26-fffce15b8936_default" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:to="loc_exdx_RentalPropertyByTypeDomain_2c45f60a-3229-464b-8b26-fffce15b8936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:to="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_38fabc7c-6cd2-403c-800c-1d91e98e0f2f" xlink:href="exdx-20201231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:to="loc_exdx_OfficeAndLaboratoryMember_38fabc7c-6cd2-403c-800c-1d91e98e0f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_669601e5-aad1-44c6-a62d-bd5dc7c90cb0" xlink:href="exdx-20201231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:to="loc_exdx_OfficeMember_669601e5-aad1-44c6-a62d-bd5dc7c90cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_39b26928-a15e-450c-8bff-123b6e1c83fd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_39b26928-a15e-450c-8bff-123b6e1c83fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_a60afdab-c014-4971-a93a-22deb3f80af3" xlink:href="exdx-20201231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_a60afdab-c014-4971-a93a-22deb3f80af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:to="loc_srt_RangeMember_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:to="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8cb1e52-6d1e-408d-b038-68b51f734f77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:to="loc_srt_MinimumMember_c8cb1e52-6d1e-408d-b038-68b51f734f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f63f130-6fb3-470a-96fa-dca10224e792" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:to="loc_srt_MaximumMember_1f63f130-6fb3-470a-96fa-dca10224e792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3e3dd523-8841-4091-972c-a416f8fdd4fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3e3dd523-8841-4091-972c-a416f8fdd4fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_95f687d0-c8be-40ac-947a-2a62141ed6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_95f687d0-c8be-40ac-947a-2a62141ed6e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="extended" id="ie8af3cd05ccf4ad7ae71d41b99c3423a_CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended" id="i83b754ed108d436986f9a672931fc442_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended" id="i0d5860e8c48546ccb31559bceb76c084_FairValueMeasuresandDisclosuresTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i71bb779184e6414aa3e7e35c284f6d5e_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4db933f9-14df-42af-b8a7-850e21df65f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4db933f9-14df-42af-b8a7-850e21df65f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e883ad4-1a71-473b-a984-47806ccfd3ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e883ad4-1a71-473b-a984-47806ccfd3ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_088857f0-1607-498c-b88f-9e8cc9d22574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_088857f0-1607-498c-b88f-9e8cc9d22574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fdb7f6a-28e7-4bf3-a731-ade36af6a920_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fdb7f6a-28e7-4bf3-a731-ade36af6a920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_74241265-c912-4575-9a11-e0b940318893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_74241265-c912-4575-9a11-e0b940318893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8e97d3d6-e858-4e9a-86d2-88162e9fec66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8e97d3d6-e858-4e9a-86d2-88162e9fec66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16c27716-e735-4588-bcc3-fb171e4ad19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16c27716-e735-4588-bcc3-fb171e4ad19d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc90d804-4706-4094-8158-ba39e928fafc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc90d804-4706-4094-8158-ba39e928fafc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_36673e76-ace2-4d95-8a29-272a65e1dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:to="loc_us-gaap_MoneyMarketFundsMember_36673e76-ace2-4d95-8a29-272a65e1dd90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" id="ia10801c63e46410f8c10514866c19248_RedeemableConvertiblePreferredStock"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended" id="i956de345d96843339feb87e71b14ae85_RedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_ad1c05de-e01a-4f60-972c-bae0e4df511a" xlink:href="exdx-20201231.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_ad1c05de-e01a-4f60-972c-bae0e4df511a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_2738693a-8238-468b-a901-8d02f0fd24e7" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_2738693a-8238-468b-a901-8d02f0fd24e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_37da8057-672b-4379-a684-e8f4f54ca5e4" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_37da8057-672b-4379-a684-e8f4f54ca5e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce976855-421e-425c-a70c-18e6e2ff96a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce976855-421e-425c-a70c-18e6e2ff96a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_40f4b2f7-64ea-452c-81a7-247c5cffb5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_40f4b2f7-64ea-452c-81a7-247c5cffb5d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:to="loc_us-gaap_ClassOfStockDomain_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:to="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_bd22e94f-6357-4047-8450-d6be5eaf83ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_bd22e94f-6357-4047-8450-d6be5eaf83ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_83d7b86d-560b-4041-99aa-8b0824cee65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_83d7b86d-560b-4041-99aa-8b0824cee65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e5b6081f-aba3-4fcd-9ffb-f1645c231e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e5b6081f-aba3-4fcd-9ffb-f1645c231e08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96b04c4a-db0b-4199-884a-30a618a729b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:to="loc_us-gaap_EquityComponentDomain_96b04c4a-db0b-4199-884a-30a618a729b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:to="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b538a261-af63-4fef-9737-6bd2e995e22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:to="loc_us-gaap_CommonStockMember_b538a261-af63-4fef-9737-6bd2e995e22a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31a8d1a1-8d78-456e-9b0a-d8553321f465_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31a8d1a1-8d78-456e-9b0a-d8553321f465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5f271ba0-0e28-4682-abad-91686f6a5dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:to="loc_us-gaap_IPOMember_5f271ba0-0e28-4682-abad-91686f6a5dd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended" id="ib821d51a844f4544860f78fa364a3466_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended" id="i7303267f9b9b4a7d97e50e61312a4c7b_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i5c88834b09af42f0a21cc59799d423d8_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_01ab2039-087d-4d33-98d8-08fbe8c6bd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_01ab2039-087d-4d33-98d8-08fbe8c6bd68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_baefa5ad-7122-4b6d-811f-61dbd47fd48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_baefa5ad-7122-4b6d-811f-61dbd47fd48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_94b3d699-f934-4416-a944-b4f2137a38f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_94b3d699-f934-4416-a944-b4f2137a38f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac3d2c01-d882-4a46-8cd8-b3a4fbe136e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac3d2c01-d882-4a46-8cd8-b3a4fbe136e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_e871208f-2d05-4414-a363-acafa4fe357c" xlink:href="exdx-20201231.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_exdx_StockIssuanceCosts_e871208f-2d05-4414-a363-acafa4fe357c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e0588f73-43aa-4a0f-a0e8-0bc2a167b83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e0588f73-43aa-4a0f-a0e8-0bc2a167b83d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5d2ae28-9aea-43ec-85c0-ef0559758a53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5d2ae28-9aea-43ec-85c0-ef0559758a53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5d74ed0f-c29a-4919-8d32-adbd58a4c22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:to="loc_us-gaap_IPOMember_5d74ed0f-c29a-4919-8d32-adbd58a4c22f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_03679b6e-51ba-4514-8e09-c7f1365c3922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_03679b6e-51ba-4514-8e09-c7f1365c3922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c934d30d-0ed1-479e-bc96-5dbb1042967f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:to="loc_us-gaap_EquityComponentDomain_c934d30d-0ed1-479e-bc96-5dbb1042967f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:to="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_56493418-d0c4-4bde-b778-43d6d46068fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:to="loc_us-gaap_CommonStockMember_56493418-d0c4-4bde-b778-43d6d46068fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended" id="i56b61380f83743fd9ca1316b10ac8e76_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6cbf318c-abf8-4495-9085-b05426589464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6cbf318c-abf8-4495-9085-b05426589464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_898a9b8a-5ed3-4ae9-b1a9-26213d57579c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_898a9b8a-5ed3-4ae9-b1a9-26213d57579c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_49e5db80-283e-4c98-a7a0-8e466f39a5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_49e5db80-283e-4c98-a7a0-8e466f39a5fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d561155c-5157-472c-ab72-36e9e249482e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d561155c-5157-472c-ab72-36e9e249482e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_aae6da14-bb02-4893-902a-1f30a08322f4" xlink:href="exdx-20201231.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationJan192026Member_aae6da14-bb02-4893-902a-1f30a08322f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_ebeaf357-bf95-45ab-96d6-7914733fc6e5" xlink:href="exdx-20201231.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationMar312026Member_ebeaf357-bf95-45ab-96d6-7914733fc6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_9d028396-d868-439b-a698-e7f15e35bb0b" xlink:href="exdx-20201231.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationApr12026Member_9d028396-d868-439b-a698-e7f15e35bb0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_d49efff7-170c-4c11-8b0f-6545f76fd872" xlink:href="exdx-20201231.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationSep72024Member_d49efff7-170c-4c11-8b0f-6545f76fd872" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_ea5f26d3-8cb4-4a40-9b79-2b66670021d7" xlink:href="exdx-20201231.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationDec72025Member_ea5f26d3-8cb4-4a40-9b79-2b66670021d7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlan"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended" id="i675f0fc35402404798922e4c77eb5281_StockOptionPlan"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended" id="i59bf3e0256f54466bbbba95a69a3b1ff_StockOptionPlanTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="i0bb60143beda46c1b1230f8e8d074054_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf2e9d86-06ef-49aa-8bab-70cd02bf9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf2e9d86-06ef-49aa-8bab-70cd02bf9aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_97b4942a-49e7-4a37-a6e1-39ac6a3baddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_97b4942a-49e7-4a37-a6e1-39ac6a3baddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30712351-75f2-424b-bb64-76c2bd9281da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30712351-75f2-424b-bb64-76c2bd9281da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_61e514a1-c49b-43d4-bcd6-a8bfcacd4852" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_61e514a1-c49b-43d4-bcd6-a8bfcacd4852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4d741b69-9bab-4f6b-a23f-716fccc08501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4d741b69-9bab-4f6b-a23f-716fccc08501" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_32088904-044f-42e3-a811-64b7fb5430e1" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_32088904-044f-42e3-a811-64b7fb5430e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d20bf71-3719-4a8b-a911-db0629644510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d20bf71-3719-4a8b-a911-db0629644510" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aed4c8c7-420f-4d59-805b-9c5a4d377c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aed4c8c7-420f-4d59-805b-9c5a4d377c6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6c27ea4-de70-4a32-941b-338196ea7bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6c27ea4-de70-4a32-941b-338196ea7bcd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_9c51160c-364f-4e32-999d-17aef22869b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_9c51160c-364f-4e32-999d-17aef22869b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dcacaecf-344a-4cdb-bb04-020ef33c344e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dcacaecf-344a-4cdb-bb04-020ef33c344e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_406d5524-c385-41df-8ad1-7a1289766154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_406d5524-c385-41df-8ad1-7a1289766154" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_90497a34-c955-4c30-80e8-639f79adef56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:to="loc_us-gaap_PlanNameDomain_90497a34-c955-4c30-80e8-639f79adef56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:to="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_da5079a7-4038-4d6d-9fab-c79238b453b4" xlink:href="exdx-20201231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_da5079a7-4038-4d6d-9fab-c79238b453b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24bd2fe6-c0d9-4025-b17d-11d3455a3f52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24bd2fe6-c0d9-4025-b17d-11d3455a3f52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb5e3c5b-9f7f-45a6-982a-94a5c8157b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb5e3c5b-9f7f-45a6-982a-94a5c8157b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_43334c0b-39bb-4f46-87a8-90f2ee31a110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:to="loc_us-gaap_EmployeeStockMember_43334c0b-39bb-4f46-87a8-90f2ee31a110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a6358813-c88d-470c-a223-8d842a451ff6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a6358813-c88d-470c-a223-8d842a451ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0ee7f117-3d22-4026-a5a2-91741b21d592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:to="loc_us-gaap_SubsequentEventMember_0ee7f117-3d22-4026-a5a2-91741b21d592" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="i034a4b604fc64e7494de388c94beefb2_StockOptionPlanStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="iaa15ff3a30864633b5cfc4a95769efed_StockOptionPlanFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c75c5f68-59ce-48a3-9f71-90a5c83fda1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c75c5f68-59ce-48a3-9f71-90a5c83fda1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9daa8222-e0d8-4286-a4ff-a86f4c95cfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9daa8222-e0d8-4286-a4ff-a86f4c95cfb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0402291c-a9e7-4ddc-b38b-585d727a716e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0402291c-a9e7-4ddc-b38b-585d727a716e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e544dee7-cab4-4588-a2cd-a37bca83842d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e544dee7-cab4-4588-a2cd-a37bca83842d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eb003031-14aa-4522-b5de-417746a473e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eb003031-14aa-4522-b5de-417746a473e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5a4053d-28cb-4fc6-bdef-c5e18b09c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5a4053d-28cb-4fc6-bdef-c5e18b09c2fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:to="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499fb442-4d8f-4ecb-a76a-b16396e28db8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499fb442-4d8f-4ecb-a76a-b16396e28db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2cfc8080-87e7-402b-9b6c-f3d5d8cce8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2cfc8080-87e7-402b-9b6c-f3d5d8cce8d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_37e47f9d-b5de-4c0c-9d93-22083c4b498d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:to="loc_us-gaap_EmployeeStockMember_37e47f9d-b5de-4c0c-9d93-22083c4b498d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:to="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08e87a71-f8b4-4468-b6d5-3e29232fb681_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:to="loc_srt_RangeMember_08e87a71-f8b4-4468-b6d5-3e29232fb681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:to="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2ad8728-a872-4823-95f8-897ecacaeda4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:to="loc_srt_MinimumMember_b2ad8728-a872-4823-95f8-897ecacaeda4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e48a4cef-0217-4228-9a08-3fed5f3aed4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:to="loc_srt_MaximumMember_e48a4cef-0217-4228-9a08-3fed5f3aed4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="i6654d5af1c3148f798d705f2a17e238a_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b33bfe9f-44d0-45c8-a227-8900234e9d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b33bfe9f-44d0-45c8-a227-8900234e9d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c3a38a3c-cb6e-4475-96a7-104e8bffb80e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_CostOfSalesMember_c3a38a3c-cb6e-4475-96a7-104e8bffb80e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17940aa7-c423-4470-96c1-9e79ebf30192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17940aa7-c423-4470-96c1-9e79ebf30192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_34a7efe5-edc2-4952-803f-9f5ff1c6b6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_34a7efe5-edc2-4952-803f-9f5ff1c6b6b1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" id="icdf9e592ca134616b6f3e84387cc14ce_StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_420e2efe-f6b4-4279-9745-9934f40028e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_420e2efe-f6b4-4279-9745-9934f40028e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:to="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f020c3-3766-4d9e-b90e-3af5e281caa5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f020c3-3766-4d9e-b90e-3af5e281caa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f08cc3b4-5da7-4f3e-a5ea-8d008fb55ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_us-gaap_WarrantMember_f08cc3b4-5da7-4f3e-a5ea-8d008fb55ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_7951dc3b-7f82-4698-ab4b-88ae9549241a" xlink:href="exdx-20201231.xsd#exdx_CommonStockOptionGrantsIssuedAndOutstandingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_7951dc3b-7f82-4698-ab4b-88ae9549241a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_c83202e0-5196-4db0-b581-3f3d10c0db81" xlink:href="exdx-20201231.xsd#exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_c83202e0-5196-4db0-b581-3f3d10c0db81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_edefea1c-d087-417f-b13c-485a720378c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_us-gaap_EmployeeStockMember_edefea1c-d087-417f-b13c-485a720378c8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended" id="i3d965a880eb2432eae79a02aabbd06db_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended" id="i387617fb99f347a8ab0de347a7ec151a_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="ife644e3df4ee41b5b093de3be038fe5c_IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended" id="id0b319b105d94b0fb4c1dd56700e1247_IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i29912f05c82e4384a669f3f422417187_IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended" id="i5aa8345cb3b84cc2a32ed9e8ff134201_IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="icc6c7d030914423eaa60f1868f62f42e_IncomeTaxesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20201231.xsd#RelatedParties"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended" id="i053b53333e9e46ed8605d4a50545d30d_RelatedParties"/>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlan"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended" id="i731f9f06888e49dfa346357e97099c67_A401kPlan"/>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlanDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended" id="i6d33456b78c145fab7437a628b0c7598_A401kPlanDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended" id="i11894a64b19b43e69ecebdfba1fb68b9_Covid19"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19Details"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended" id="id4c2f5b9769c484dbb42a4a642796925_Covid19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5da51042-f91a-4e54-bb91-cd792afd0c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_us-gaap_RestructuringCharges_5da51042-f91a-4e54-bb91-cd792afd0c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c8d72f9f-2e9b-4cbd-b85f-c71658aace46" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c8d72f9f-2e9b-4cbd-b85f-c71658aace46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_3b745e6c-688b-4d57-8adb-e3064d7685c4" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_3b745e6c-688b-4d57-8adb-e3064d7685c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_548a5def-2dde-4b17-8bcf-cabfda9db43a" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_548a5def-2dde-4b17-8bcf-cabfda9db43a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_62fa288f-dd5f-4740-bea3-4d441523e613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_62fa288f-dd5f-4740-bea3-4d441523e613" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>exdx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_d1907573-1483-4aaf-8a4e-1ef76fda3903_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_90936c03-9dc6-4f17-97c5-c04d3fd2effa_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ae6b6ca7-a64a-4009-9a58-67cd87d4b0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c6a74ad3-8ac4-4cb0-9216-7892efe4503b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9399194e-622c-4d3d-9723-01a8cfab2997_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2077a366-2915-4282-a380-734e538ed987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_580919e9-0b67-4b6d-a8ec-3ead296977d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d2689d0f-e63e-4d8d-9ed9-5a47ca6162b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d60591c5-6d3f-444a-9127-73b384365058_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_2bb0409d-859b-4c10-b184-795f0b9e5d4d_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20201231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b9345c8f-b51d-4f0c-aa81-3610d07e256f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6126e5e2-8569-4115-a93d-614e217645e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_913708fe-f5d0-4bf3-8a14-2b02e4e1e21a_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_18cf9416-a59d-4be3-9ee0-34f004875bd8_negatedTerseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_df097fe6-1c39-4691-b732-d5af55671d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_a2cc10d8-3931-469f-ad00-b6c91a08ce24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a9ff7644-5d35-46e6-b162-bd9d0e282cd6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_242a1def-0e14-4645-9b6b-7e1c8c11510f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5908201f-6869-41bc-b1b0-662890ee1072_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_da048651-b9b1-422c-9358-b6bbffa5a7c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b58d7aa2-4008-4351-b686-283bb4a7b73d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2915b5c2-41d2-429f-b098-377f3ba2fcd4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_08fecc16-d590-44db-8b5c-6a503edbb7c9_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covid-19</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_e3b8d915-a0a5-4e6c-a758-5e3405572e89_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividend" xlink:to="lab_exdx_TemporaryEquityDeemedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b158d398-51ff-4027-be05-b914e98be91a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0b84ebb4-14b7-4c12-b105-c8b04848df0b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_b0d9a8ea-ec6b-4d4c-a874-ddef2134a78d_terseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20201231.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_eddc887b-9c9f-4c0f-8049-6838de9e18ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_e4b5fc4a-aa6a-4d40-a133-29a4d078c815_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f3c3e56d-0e00-428a-96e1-b155c92daa50_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab307f81-d39c-4856-9fed-1034c4980c74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_364a1c65-0e93-4bad-845c-ff7e9b744c8b_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20201231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_83ff729c-7a91-485c-b455-9a545df40eec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d4decbe1-f774-4c1d-ae68-311ae1f89fe7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8b118e71-003b-4364-aec6-1e4995ba7f68_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cf119335-280e-4c59-9013-635c0fa6fd92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb5057f8-9e56-48eb-b79a-890157368ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f3903b32-1f5b-49f5-9b2f-dd59ccba16f6_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c68eb82c-fd27-4077-83e4-671764c46a60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_b825cc70-f529-47c4-a4ff-9e7298f637c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1999f5d5-1b3c-4966-b3fb-f5421ade91cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_22f943db-43de-4a3b-913f-52ae73be93f0_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred&#160;Stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f2d70164-bf05-4e10-b5a3-afa0f3ace9a6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_3d865e04-686c-4f8f-9b0b-8e5d6f68e4c8_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cbe05ee9-458a-4019-9e78-1c80d8ce227a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6c795110-470a-4035-be5a-939396f6be95_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_ae8a6225-b969-4e44-978d-10aff1e9609e_verboseLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of financial instruments</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Financial Instruments</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:to="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3bfdb487-a108-4572-a31a-4fa3da70023f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_f72c5bd3-d9ee-4591-a3de-8e2cc565d90d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_d1fc9919-6632-47fb-8d13-cb6344f2e3c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_afede019-50d8-4f29-a00c-874aeb95ba2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2019 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b2a5fafc-b86a-4a89-8713-b482ab8a46f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_64d59a5e-9557-444f-b008-aaacc3c76e31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7f949899-cfed-4d85-94de-b2af74cbdf2d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_9e00d139-43fe-4439-934b-734d13abcf5b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recorded in connection with financing transactions</link:label>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c5de7782-148f-493c-9542-295d3b7bd1ca_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_21936077-ec75-423e-a65d-3a9aef0236a0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_b327cc99-6e33-48cc-845d-3d394b703ebb_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, renewal term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_label_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_documentation_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm" xlink:href="exdx-20201231.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeasesRenewalTerm" xlink:to="lab_exdx_OperatingLeasesRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bd3b1f7d-40fc-4d6d-9deb-1485265703d3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fd5db108-d1a8-4e50-97d9-a95afa26f2ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_0037bd0b-7cc7-4eca-a24b-f3ffe629d346_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20201231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5c47302a-e724-451d-bd84-0c22f9356457_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3b35af9a-4943-4e53-9ae2-2651c126c8a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_f2c496b8-32c7-4298-a9b9-b20f7ad024af_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_36747768-fa94-44c5-9801-664f5a1bcffd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_c39bf04c-9fec-4bd7-abe5-4f6121c889bf_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab0c0a42-c530-41b4-aaf4-30d44e77e343_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0f6c768e-8879-475b-83f7-6f333321be54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_57512394-dfa2-45fc-a10d-026d51d82c98_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_5a9541bc-14c7-4987-b3ff-7090e107879a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_15c60249-0557-426c-9efd-46c61e6b84f1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_4eb491d7-e7d9-47a6-b643-243a133a5420_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20201231.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0de21755-9804-444c-a9bb-6a86e95507c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76cc1f72-05b3-4dd4-be07-fd25e3ea8673_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_4961b5d0-794e-4435-a7c2-8015d477da15_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5c4f31c9-b3d9-4d91-9187-bbf6743db6e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bc75c5a3-dea1-437a-b4c6-6d085fba359d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_f2e351f7-d14e-4c21-af3c-3438005f1d24_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a7737f0a-1c9a-4bcb-aaa2-5565378cb819_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_579e599e-5f05-48a0-84ce-82d345189e3d_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20201231.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_ea80ea4f-cb39-4d66-bc8f-a6b6749035bf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_2a73a20e-b2a0-4493-932a-ab329db25f19_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_7b59a57f-e4d1-4606-8b20-abd321ea2514_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20201231.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2935ffe6-ec15-4efc-94b7-22a6e3d045fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_e366a986-805e-4197-ac21-0f80c517a33f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5ee2f6be-8fa8-4967-a343-f7f681e52c07_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_c62105f0-b9e9-44cf-bb75-882ade21b15b_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_fc780c25-5fff-471c-bff0-a831c2016185_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402c19e9-ba92-43b0-b27b-07727e89424d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8db2a196-3f2c-4cd0-9c25-c1e0a5714d8d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_06dbac83-f846-4632-8296-e00d6aa2ac94_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_de5fd295-670c-46c5-97e1-1a66ff23e083_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_470865b0-a2ea-427a-9c35-7f568530ab0b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_198a6c25-c886-4384-a119-d2ddf73f39b7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b01d08c3-8608-4f60-8984-e9ee4c92217e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_af068261-4d35-456f-90a9-dff23b17da4c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_2eb27098-5348-472c-aa9e-5b4e9bdf6742_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20201231.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23d0df18-7c62-4a70-b6e5-5d92fd4f0a31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8410d17-7660-4f57-9242-588eb1140428_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ba325a89-1c48-4964-a1a1-c24dfb071c14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3c87c923-463b-415b-b112-3414f69cfa11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_9499e534-baeb-4691-8c3b-d41a8a6f89d7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_14aab14b-6be3-4d20-8bb0-bbba2b1b8b15_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1079b70c-2dac-47fd-b35c-768772665be4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_017d3a1a-ef8f-4422-974b-01ee996f99a3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_de315e6b-c7aa-43b2-9250-b797de0fd28b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_d67385ce-7bcb-40a3-a652-deea2aae7960_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture quarterly promotion fee cap</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_85c9e707-4b81-48c3-af70-4fd7b3504c2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_e0c2e445-0959-48cf-acf5-908550bb0002_terseLabel_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Studies</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Study, Policy [Policy Text Block]</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Study, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:href="exdx-20201231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:to="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_84b0026b-e266-42fe-bee5-78f297618d94_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7) (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend, Shares Issued</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:to="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_b6622c43-9a90-4a68-99e8-6e944a449387_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20201231.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e3f5417b-3d29-434e-8482-adbc23392502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance under Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ba6ba607-ef54-41b4-94a7-8b0e1c7f8e74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_9a3c29c4-e125-4e73-882e-fe3970bc5162_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_label_en-US" xlink:label="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Principal, Number Of Payments</link:label>
    <link:label id="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Principal, Number Of Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:to="lab_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_eb89c7d5-bfe5-413c-8569-571094a11a84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_92268296-a29f-4534-8a95-3e702a1d25de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a0aae6b7-cc48-4e09-8fc4-a2747b8dc75d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_15ab1d0b-3840-4c9c-8576-49c10fda2fc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_41d5662f-dff3-45a6-a71f-d0b8371bbf1b_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_d7e9ef96-da5a-4701-8ebc-997cb8d6104f_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20201231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_92d20011-9c2a-4a7e-8dec-17918ded8add_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b5de0014-2466-4d61-8454-0be27f572e70_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_02115772-d0cd-47dd-a0bd-bde102ae847a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b71431d1-3f87-495f-8794-5bfa11a16890_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_133c6d75-9a99-47e9-b4fc-ce70e8fa9ed4_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20201231.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_48343c89-7722-43db-aa06-c9a6239e1103_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_daca3bf7-0f43-48d1-8312-8064d0f66b71_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under capital lease obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:href="exdx-20201231.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:to="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_cb3b6a23-4811-4c5d-b704-9e3a9dd0d53e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_ab17d05d-9b5c-43f2-91a0-65e6c1abb8d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_aa058f42-68ce-4432-9f52-121cba92dbe6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_61516072-87f1-40cd-8bd4-42f0d591ed67_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_0a5351aa-2ca3-4d52-9a69-bb53c91535b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_93ff5592-50c1-44e6-bb89-72725ac92d7b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_1dc0bf38-11e0-4d2c-ab15-666a424e3bca_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_523f10b4-3f10-475b-bc91-7288496c0414_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_cdd8c53d-0d44-44a9-955e-91e1c9235a0c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_a69d4420-0bfc-4329-83e0-670179285ce5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for future issuance under ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ae3b06e8-0125-403f-8566-c01d4d3964e7_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ba6e8d94-c96c-4271-9840-0f5ab880ef41_netLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_95cd368f-dbaf-4609-9b9b-e4d268548c86_verboseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature, temporary equity</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:to="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a65900e0-00c3-46b8-aa49-0bd4bb00ec28_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_86506078-5fc7-4f8d-bd23-83011a96199e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_be61ea3e-2183-4667-9c1b-bb4196cc2796_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a77f0236-a1cf-45bd-a4aa-5bc1d7913406_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a06d57eb-3bd5-405e-9079-22d700c85d96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses table</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_afbe941d-95eb-4b84-a68f-8f70dc498953_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eb3eb337-a84d-46cc-a1d2-706d41184591_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8a1b490a-2b72-4cd4-8b34-fb72f5225ea1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_58bfd543-50ac-4ce9-815a-6df4710a0cbe_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20201231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4752dd3a-88ff-4a25-8e3a-100335bc4281_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cdb25d4-0a1b-4acc-913d-b71250f272b0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_544b6406-81de-4624-afed-724cea5de27a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6d166e61-375b-4150-bc1e-3962f8eb6fc7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_ef0d0443-e4d4-49f5-8cad-586a2e7e1cbf_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_d82133ed-f798-4bd7-bdfc-bb04e76dc008_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_fc7f7528-6c16-406c-9a7d-f57491f6e1f4_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20201231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_b7f57db7-b71d-4a79-adde-d8d909af6557_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_df5a632e-eddd-47f9-bb71-cf1a97c45891_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_674c3834-e93e-4e6a-a867-f568b594f4fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da9b49ac-cc39-464a-9952-c1f9b2aa2f13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee options, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_e6b63254-ae30-423f-a5f5-afa097b23c44_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_cc390243-a19e-4b57-a24e-11a0c44b48c3_negatedLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b2f7d26b-6b27-4def-a122-7fd5930ba860_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_50d8e9db-0f9b-4393-b81d-c15f6a49b5b5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_b7fe9ad0-98f9-4b8c-8df5-bae471b340b5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_3efe6d63-30e4-4b2a-9a7f-c3d6b0ca2964_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_edd106d9-2f9b-4727-ae53-8253b21042a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_c9bacf37-1d6c-4c6a-b79c-a8f1ea27b911_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_f2c0059e-8238-4f63-bdfb-b11c1a1fb2da_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_207bc172-149e-4be6-926f-7680c703f876_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term capital lease obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c5bb4f12-cd0c-4e22-9a15-5dbce21a4074_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_80596841-f33c-4911-abe1-57edbf7572e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_9b938004-0e2c-4cd3-86fc-5b3ceb94acfe_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7dcbcda4-9e98-4086-9aad-e9a403acad12_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_af4714eb-f72f-45d0-8edc-ebf8555c777d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_182da4d5-b707-4353-85a8-61672964f99b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dec704b7-8b38-46ed-8ee9-e88b302c0e47_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_bd5cfd09-a4b1-479c-97db-2d0a1714ff6e_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18fa0526-6752-4699-a9bd-dcbfef5ee4a3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_d0f993fd-81cb-45f5-adca-360444f33107_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_157efd9e-967b-4751-a1cc-997748fa3c72_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4d7af44b-c2f4-442c-8ab6-a3073e7536e7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_a7100ee9-7a94-4081-806b-6502496741aa_terseLabel_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for grant under the stock option plan</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_label_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Available For Grant Under The Stock Option Plan [Member]</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_documentation_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Available For Grant Under The Stock Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:href="exdx-20201231.xsd#exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:to="lab_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c8f3c2e4-4553-4d1c-a508-6adf76c6da35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_188f4d83-1858-4943-8b0a-224c1625a1f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_ae1038f0-ea8e-4c7c-a9b0-34c58871400c_negatedLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_label_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_documentation_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:to="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ee2849e7-00cf-4710-9dfa-05e1a8e52e47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_f8c4d199-672e-4109-ba32-2e467eb4e603_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_e7f80e25-13cb-4235-a821-07c013ef6aee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cd2b833a-34db-4027-af58-61bf5c3e0cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_110f0fc6-b141-4b45-b544-32f1e2ec0658_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_a29affbc-6b11-4a25-a15f-6b6b6ee1a1bc_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember" xlink:to="lab_us-gaap_SeriesGPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a52de7fb-834f-4f6c-93d9-d839c2524ae5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_6a73067e-31ff-4f68-8b32-9bde55007a3d_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20201231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_abd9d92a-beba-43d2-b3c8-17332082a35c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_057414d5-2793-43b7-af88-c750b0d0a5f5_negatedLabel_en-US" xlink:label="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock liabilities</link:label>
    <link:label id="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_label_en-US" xlink:label="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Liabilities, Percent</link:label>
    <link:label id="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_documentation_en-US" xlink:label="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Liabilities, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:href="exdx-20201231.xsd#exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:to="lab_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_717a4a4c-181e-408b-b99d-07a7ed4ab212_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a38d43c6-476a-4267-9048-c8a5fe9a23c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis differences in fixed and intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_5278e762-b27f-40f0-b76e-6a916be5b1fa_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in second year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2f47ccba-c7c2-491f-af8a-ee74e3349a46_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9577d65b-fb46-4955-82fb-80f32298f6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_eab5c4de-db0d-4658-8fa3-b8a38ed27bac_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio, common stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebeb9ff-fe62-491d-b07a-63501fa49be3_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_499926b8-1900-4391-80ed-0734c85b19b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_388d0311-e559-4ebd-a710-b80a145655c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5a81665f-6ce4-45eb-ad48-326f196845db_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_e721a057-46e5-49d0-b973-7f880e7d1ef3_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_afe6dcf1-389b-4ce8-a0bf-a73100d8ca76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, December&#160;31, 2020, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4af752b3-9f31-427d-a697-b2b2db6e7062_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_470f5343-7135-4320-a76a-eea4773aed2e_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_79583263-e138-4c45-ad2f-9a978aebd48c_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limitation of net operating losses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3cd0cfec-4ee5-49d3-96b6-5e0bfe1dc904_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_73a4b371-f15b-42c6-a629-9b3778639f38_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, number of units prescribed quarterly</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Prescribed Units</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Prescribed Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPrescribedUnits" xlink:to="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_577976e6-d344-4509-883a-82e6248ea06b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2019, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_228efe45-ec24-460b-a804-a37286dca522_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_229e1dd4-77d4-4bfc-84a0-1b176a2228c9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c23ed75f-a375-470d-8e27-bff8929d247c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_8c2e9657-76fb-4d4a-869c-d7f80f4e3ec3_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20201231.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f498acc0-5789-4431-b873-2a4bb881d5ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_56eabffb-4244-4b02-a028-1d655e6a2714_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in number of shares authorized (in shares)</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_16fa5447-1ad8-4475-9073-2d0861278927_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8831c7d6-83a0-4e61-97f8-7d66e70f22e6_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_042ab83b-b7b1-4834-88dc-7ceb78363b06_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1e6897f6-dee0-4b8e-8341-ac492a5dda61_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_8ab6aaaf-d4eb-444a-8048-3cd7908a3cc7_terseLabel_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax attribute carryforwards cannot be utilized under IRC Section 382</link:label>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_label_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Utilized</link:label>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_documentation_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLossCarryforwardsNotUtilized" xlink:href="exdx-20201231.xsd#exdx_OperatingLossCarryforwardsNotUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLossCarryforwardsNotUtilized" xlink:to="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_da17c76b-f257-4450-aff9-c1b95399b73d_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20201231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_f5f35988-c990-464f-8a20-e6af98ead51c_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuanceCosts" xlink:to="lab_exdx_TemporaryEquityIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3be111ee-41b4-4a42-9aa0-a6165a65a05d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_883f163d-eca2-4bfc-971a-b8778da4ab48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_eb0aa1a3-cdba-4683-94a2-4deb3c940faf_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net attributable to COVID-10</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Other Non-Operating Income (Expense)</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Other Non-Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_887c3694-3deb-4cb9-ab9c-bd0ff0394c3b_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_3e52103d-a20c-4ab3-bcab-7e066867931b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_f85ca2f7-6653-468f-b2ca-fd2bfbe69082_terseLabel_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_label_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Temporary Equity</link:label>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_documentation_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:href="exdx-20201231.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:to="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_2d31558d-5d18-438a-8c76-574c4b62dc90_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e1ee38b3-0e2f-4ed2-ae37-cf31beebd51a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_4eb5e078-b855-4d85-bdc4-66a085806550_negatedLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Note 7)</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_label_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion, Amount</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_documentation_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:to="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0a3cfe44-c7b6-4083-9f15-071666667696_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e33d5550-b191-4c67-94bb-476bae0876aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5d56c1ae-61d5-4c0a-b7a5-abb7e385c167_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_6e2d8756-8f50-4345-a6fd-5220a9edc069_verboseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common and preferred stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46f5ca84-3578-4147-9214-809951ed1f14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c8ccad01-c47c-4de9-84b9-4cb49b8b553f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_031590ad-df44-4ddb-bdb5-587c7f9d7db9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_54086261-e101-406e-8bf0-7adbb05eb53a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a36a9559-ccf9-4a79-a0e7-0bd69931b5a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7d06a8bc-d91a-42ae-b17c-5b77b4a09313_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_92bc06d5-7814-4b72-8d53-63984a57bd0c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bfbb48dd-82bb-4259-af4d-a395bef235e8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_69ca7978-3347-438f-bee4-696751551e77_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_cf5d46c3-f67e-4bb3-9d03-311d141a5f46_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20201231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_ac20ef84-b62d-4bfd-b1ae-820e9bd75112_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee per prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0a6fb0a2-ab31-42ec-b274-2649ecf8078c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60499ef5-fa9b-4960-8d20-3c08d2e21188_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_debffbd2-4449-4cf2-aea6-1c03bac89490_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_cf62a626-98f7-4b79-99c6-9ddd70ebab6a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9db77065-47cd-466e-a49b-7af03a6e03f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_3f446390-00c2-4904-9adb-f38a8f56640d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_015b33b6-1d59-43bc-b4b4-5a31dca9536e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_09108c74-9701-4698-b753-76e5b58edda8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_9d93b377-5742-4d0c-bc7e-13c3de2aeaa7_terseLabel_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series G to Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_label_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Temporary Equity, Amount Converted</link:label>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_documentation_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Temporary Equity, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:href="exdx-20201231.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:to="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_49e55899-8480-43e5-909c-b3e10895a61b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_0d94b59c-845f-43b1-bc10-4326744422d1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_68c06a6d-3787-4b45-97a8-e564b3e40902_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_748996f6-33f5-4a6d-9e9a-79c371cd3bf8_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c6cee5c3-772f-4eb1-b999-ec3db2fd27e0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_30040a00-1695-4408-af1f-269b111dcdf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_d567da9e-7e76-487b-b645-981588aa1812_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_5b1d6a68-686b-44f6-b28b-4ea947d67e25_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20201231.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReorganizationsAbstract_label_en-US" xlink:label="lab_us-gaap_ReorganizationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reorganizations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReorganizationsAbstract" xlink:to="lab_us-gaap_ReorganizationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_bf726c03-b110-4561-97d4-e44129e64727_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4398a9d8-dc34-4549-b1b8-0d633914781a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_ec2ffa47-143d-48a6-9a54-86995355ba3d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_28af4fcf-2555-4b36-864d-151a479c8ed7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9ac283dc-6ee1-4c87-a853-c4cc64a22369_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_09419353-57a9-4636-a875-45b95fe688d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_11127817-a249-45b2-ab80-40d39b9bb4f6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fc72f8c0-3c65-4971-ada9-676015292754_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_755064a6-ab35-4aaf-9d47-498f53031b93_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_b3986bc7-a122-4814-b61f-647f41464a54_terseLabel_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under capital lease</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_label_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease [Member]</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_documentation_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:href="exdx-20201231.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:to="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_e9191807-0765-4393-a167-f2d3d9ffa0ee_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_e3c33147-268c-4894-b6f8-9dbbd9df9222_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, number of days to cure covenant if performance measure is not met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:to="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c09bece6-877c-43b0-ad6f-ade187daed69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_66fb5353-3b0d-482b-91ea-8f84014ee331_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_label_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Text Block]</link:label>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityTextBlock" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityTextBlock" xlink:to="lab_exdx_TemporaryEquityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_e5c78c77-90e1-45c5-bcb9-26e810ea09e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_682ed505-97e4-4f40-ade2-0aae7abaee7c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5c7ead6d-e774-4852-a1d0-86e7e079d7f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e1fe2142-c02f-4bf7-b7a9-32b21f51a0f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_313102c4-1920-4523-b5ea-2b97d067667a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e162867a-9629-4782-a4da-fd8253e0327b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16f4fa9f-18af-4965-bd7c-694f47554eb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_34537696-f79f-452a-877e-b848d4efa264_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0fb682e8-2c1e-40dd-a34c-f600a6c1a5c5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_961f6f90-adb7-4b45-8dd0-e763780bc6b9_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued and other current liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:href="exdx-20201231.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:to="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_71cf6fcb-233f-4a4c-a66f-ac30dcf23132_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4104082e-c11d-4c7e-9be2-fb9ef922e8a1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_15155b9f-3d56-4f8c-9804-2c8581b04555_terseLabel_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of temporary equity, price per share (in dollars per share)</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_label_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Price Per Share</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_documentation_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare" xlink:href="exdx-20201231.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfTemporaryEquityPricePerShare" xlink:to="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e4fd52d6-8d9a-4f46-9625-132566e7e02b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_90d23cfc-a446-48ff-8724-ed7e5f9a3e96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_da6623f8-e186-498b-a211-f246401b3076_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount_aa563e79-5836-4410-9012-74546ae8029b_negatedTerseLabel_en-US" xlink:label="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases recorded as benefits to income tax provision</link:label>
    <link:label id="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount_label_en-US" xlink:label="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease Recorded As A Benefit To Income Tax Provision, Amount</link:label>
    <link:label id="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount_documentation_en-US" xlink:label="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease Recorded As A Benefit To Income Tax Provision, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:href="exdx-20201231.xsd#exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:to="lab_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_2f6bdaee-1b95-42b5-b166-f27a2e6e1b32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_48c76b1c-5d67-4107-86d7-8e92d8893331_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_804965cb-9cc9-429a-b469-7087a5d877b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, December 31, 2020 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_308921a1-7f87-4bb9-8877-4fad2008ab3a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ec928b08-253f-4d88-b487-47f55fbc2682_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_72f5ebee-efa8-40aa-986d-9c47ea28dad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_062cefaf-a0f1-4dde-93a5-6ab2d09c766b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_88f69f8d-b203-46ee-b206-090dc3582dca_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_14361611-8080-4986-bb86-ccb073c4676b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_8da4c777-c461-4259-8410-7558293fb3c7_negatedTerseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_47ab3906-382b-411f-a40c-48c2c86d5393_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_55405203-1a3f-43c0-8f9a-58e2b600bd04_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7126b1aa-6e8c-4f16-98a3-fc4586eb380e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Note 7)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cf3a7943-5a1b-405e-9d77-47b5926556af_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_758da224-62cc-48a2-b1a0-5085d5a33f3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_368deed9-6509-418d-bb9e-592fcc34f370_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_1bb6122c-4785-4d8a-baab-ab8b7491c4af_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6c8163fa-6a9c-4e61-b8e8-1ab15240f186_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0b673680-735d-4a83-bc2c-52a00170f693_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_46d8d626-8415-4a17-aad4-cd8283bb5567_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5f83b5d7-f9b2-48db-a6f1-902377c1bee4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_07939139-6598-4f82-8f3b-d383c02d1c0e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_71210141-bd20-4294-afb3-ec3729684d44_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_68899266-50f0-4bd7-9789-6e570fb65ca7_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ccd8046f-ead1-463f-8c84-71d01e96e7f6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_57ba0d45-517e-4ccf-a30b-96e684e8f5e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3253d6aa-0c47-479b-8a45-ecfa6803048e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ea5bf612-6957-444b-90a0-9d46c44b2a20_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_74c8ec4f-c283-4dde-bb86-168a040d0504_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesHPreferredStockMember" xlink:to="lab_us-gaap_SeriesHPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_91a179b4-1af2-447e-bfdb-8f5ff42a2a67_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6dc2cc8d-5b59-458e-a7e8-f714868efb1e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_76665f72-9f1f-48a1-bcee-552dffd686a9_terseLabel_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_label_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP [Member]</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_documentation_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:href="exdx-20201231.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:to="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_1c070204-b89d-49b2-bc5b-f1a1194898d5_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_c7e4efad-38e6-4594-b3fe-f02cfd30a341_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7e94f706-8d53-4d27-9bbf-aa453fd3ca2f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d73c3687-ba60-4473-87b0-ea289fa8d48c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_47d1a763-ca67-46ff-8442-d716f199a737_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b16621e5-b2db-4c7c-9610-30a9a7490941_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_1c62d86e-a200-49a4-8596-92280038f921_terseLabel_en-US" xlink:label="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock option grants issued and outstanding</link:label>
    <link:label id="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_label_en-US" xlink:label="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option Grants Issued And Outstanding [Member]</link:label>
    <link:label id="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_documentation_en-US" xlink:label="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option Grants Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:href="exdx-20201231.xsd#exdx_CommonStockOptionGrantsIssuedAndOutstandingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:to="lab_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5b3ec74e-6d45-4bb2-9c36-ab073ca93d32_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_23d03cfc-035c-42e4-89ca-2f742d6f4c1a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals, reserves and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_7fec3a76-e053-497d-89a6-e0a90789c8e6_negatedTerseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Paycheck Protection Program loan</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Repayments Of Loan</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Repayments Of Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e4ddebde-0988-4958-adcb-b3f42664517a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_30f56f6d-911e-419d-b44a-542e914b8d5a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c259464b-4bf7-4394-aa90-aa8b9a09fc13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_80faf5a6-1b08-47cf-b740-e3e5b01d364d_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20201231.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_dd66c7d9-5e4b-4780-97c5-9be983c72164_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:to="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8fb77b7d-ab88-45c5-ab5a-e0d489d24338_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_289f54c1-2918-4add-bd71-25e21328ea77_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4a941816-70eb-4d74-8d1c-2665f9e4b534_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_054f5039-d590-4c0b-8162-87aae854c90c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cf871046-2cd2-433e-9fd3-93ffdb153d2f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1c783e7d-927d-4a3b-9782-42a73530be26_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_79cb33eb-f4bc-41cd-9537-462715d41f9a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf6e3578-8645-458d-bd62-e88ba2ad1871_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_590ac454-9524-43ed-8f23-054a5a519f74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fdc61a56-be4c-4e4e-874c-45d587d1379f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_53b96d9c-aba9-46a3-95a7-54e1771d3092_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_30a1d100-e9f2-44b8-b080-65960c5b4262_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2b757805-c15c-46e2-a7b5-3c2084c48509_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_331ca980-b18e-4fd1-a739-e9aaf54af217_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9f7844e5-3912-4e8c-85eb-439f1e545b8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and December 31, 2019; 12,652,308 and 12,560,990 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_1f6be2f7-9268-4338-9b58-53567ffbb4e9_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20201231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_20dc583c-eec2-4860-be2d-b0c3723515e9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6b392f50-5b47-4485-a541-e38e83df25d3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_868ae8f7-1631-4ffb-ae0e-d63c1ef4ddbb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f63c0c91-5f01-4a6b-abe4-595b5cbee3bc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_19413262-d935-49ac-9e80-3a70cee27f18_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_dbba5895-49e6-40be-b389-169a5172ef3d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_114eb86b-9a73-4207-82ef-ce24a53c0608_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_425776b1-51fb-4e65-bc53-c52c841a4a07_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_78f414ff-0bf7-428d-b33b-aea05ad3d0bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_bab2f254-1c77-470e-be72-41367b5a8fc9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_4ce5bfd1-1a92-4455-a74c-717d3bbf97e5_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20201231.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_8cb34401-78ca-427f-9416-09c1bf7f1807_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:to="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4b99cc50-4a57-4b26-880b-14a2a36350de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_45801e0a-1829-42fe-8855-ef6daac97d5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_fc0cf654-5c0a-4a54-a1f1-7dabfb214317_negatedLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_86cf61e3-0163-418f-9279-d5b5fe5a51dd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, revenue performance period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:to="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_9445d158-bf5d-4a80-bf86-f34a21b95ea0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_babde39b-1599-4105-9630-97e1ca149861_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_24927366-b7dc-4377-a655-28fc7792b364_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_21fc8a18-041e-455f-a85a-945279d85a8d_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_307463cf-a6b5-4efc-aa8a-e4e554474451_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fbf883c1-ca29-4df7-b0e6-962bef38efe9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_af5b60d9-d8f3-43a6-9bb2-3dfb2faea247_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_289658f9-6745-4ead-b0be-3318fc704963_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f334c24c-8eff-4e0a-bf6f-fb1ec3d1eff5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_17ff82a7-80e6-4e2a-95bc-529ed4948a5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_29b6e470-9cc6-401a-a9d1-8bf8cf6f13f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_bd20e89c-a5d4-4cf2-8eda-383a1d194925_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_747705db-c45d-472d-8f69-21fe34f488a2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_f9e7d2e4-a0a9-42d8-abcc-0c61cd9217c6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b7aa157f-1506-448a-9320-36045948456d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c9b99584-87d2-4401-9a28-f2698d11f9a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4f4989fb-787b-45af-987e-2766f9af5203_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_60d83142-f18f-4f1b-99d7-c6520f4168ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_bfd1a0f5-cc7d-4220-8dd6-ec5438801197_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Paycheck Protection Program loan</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_9342efa8-4e8d-4d82-93d8-7f184abc7ced_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneObligation_8f240599-23b9-45d8-a531-ed2fe433ec74_terseLabel_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_label_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_documentation_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation" xlink:href="exdx-20201231.xsd#exdx_MilestoneObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneObligation" xlink:to="lab_exdx_MilestoneObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_cfb9b86d-8914-48e8-9ea6-a11dd1764633_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_08da3fda-5199-4503-bf58-5bc65fd337b4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ffad1005-c283-4a8b-bc29-df1bff60591d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_aa46f951-3ca6-44b8-af1f-c6d8b40619ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_81fcf801-c3a7-4e99-a84f-c250916d8c29_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20201231.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_43af9d36-712b-43f8-9bd8-94a56f97efbc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_ad4de153-5080-4e2b-bbde-7e7487d394fb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_9428f2b5-b9f4-4279-adc1-50d5507b2263_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4c343302-ecca-4a17-b63e-7a40f8a57484_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_642abf50-6778-4587-b418-ca82505ca5ff_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a276bd0a-3dac-4a4e-a3cf-67043762a96d_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e1ba8d52-c767-4154-8b90-be6ed7e3a208_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c9e141b1-afd1-4405-8b39-038158349ba9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_12d0361b-753e-4bb6-a6b2-2b687ae1e2fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e97e0209-913f-457e-8a25-7d29f4e27ebe_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5b96df21-2604-4e84-9363-03dcb7f113ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f39dd001-8af4-4993-a6f3-d3bf4509f5fc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_c9d35316-ebd4-4e4b-8aea-6f8670ff0c37_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7c42bc06-031d-479f-a145-11cae692c9bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cae1cc6c-6f48-49de-a0f7-44a86e016ec7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8c8b50f-323c-4b8d-8e80-a75d9f09d31f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e8c4490a-3637-4724-a521-f6d6c5c86744_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22faaacf-5d6a-42c1-9f07-e6d111728a8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_9f741d63-acae-4824-a193-348bf1b49a7b_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20201231.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_6366883c-abbb-46aa-92c3-87ae360062b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_5a3274c7-1798-4d03-a055-185b1544932b_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20201231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6fba4922-17d5-4b7d-92b8-74dfc51a96a0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_25de1e74-2e37-4f8f-8c41-fb8fb6492037_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3317cfac-816e-4578-ba21-824959707388_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_bbe576b2-186c-47c6-93d1-2e3614af13f5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_3e13315b-168f-46df-92c4-e0acf6c16203_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20201231.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_77e65137-af4e-4432-a982-85e58fbe157b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_7efcab2c-3f65-4ef7-974c-f475191024c4_terseLabel_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</link:label>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_label_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Temporary Equity and Liabilities to Permanent Equity</link:label>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_documentation_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Temporary Equity and Liabilities to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:href="exdx-20201231.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:to="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6e168f1-ddb6-48aa-968e-8a233da45ee2_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2a04383a-353f-4af5-80ec-1a8cc30b675b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c1b152-2f73-4004-a5e7-ef4e3455928e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e09f0295-4850-4242-b606-b099c7a3a6ce_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_99a6bee2-c7df-486b-968a-02ca8c22696c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_ee049a33-ffc5-4487-bd27-1e5e610eaf1c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_7fc2f0e5-1600-43aa-972c-c2a59220c523_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20201231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8491930b-a9dc-47bb-bda2-f1bec39a8cf8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_ce14c6ca-f85a-4dbc-8396-eb2a609c6cea_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fab163ae-603a-4910-8741-9e37ecdba44e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_191076ae-8d63-4662-8a47-5db6b75df4d5_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dac44a6e-5738-43d1-a81b-7137d5f03ebe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6eac8253-0b86-496b-9599-6d45e7844552_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d5bfab2-178f-41a4-a769-a43a3d2c12d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ff73cd96-b791-4276-aedf-8909be6a3c4d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d840667d-0e6d-4336-ae70-ed8a659ee4c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_39813431-71c3-4212-9a1d-270f58df1eb1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fc782af-fee3-4012-8589-3b41b4cfcb1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_854a4a26-ef8b-40bb-9daa-1b3191cfca02_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b5356a04-dbf9-48b6-a93c-0b2a14c7d2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c3caca7d-f6e8-4e5a-a844-c535d121a58a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_47713859-3e9c-4690-9f35-7ebc5ab470c4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified employee compensation contribution, amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_caa6db0c-007b-4a61-826f-200fa76ab255_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20201231.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_47e1f9ee-00d6-4bf6-83db-7ad4621f5527_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_389fa176-feba-4172-9468-cab86655987c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a4bd0886-2de4-43ac-8172-a7a907d320c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_97ea31de-a55b-417c-8a92-934c66d0cef4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_da6755a2-e679-4fa3-a1fc-6d11a803ff86_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5d1d8ba1-c741-4906-8bc6-d5bf9b88ce49_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_faa7def6-3f3f-48c4-afcf-d6f07aed3b0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_be2feebd-efb5-4b4f-a2cc-ae912e85fb53_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Noted 7) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4a52764c-9e59-4bcc-b78c-308b728ab197_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9e72e0b0-cec2-419b-bb06-2f8c33b1377c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_d7ad2105-f0f7-4d24-ad03-a4e99abdd026_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20201231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2ed2f7af-0a32-420a-984e-d4a126fb4c88_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_803e7a55-70a1-47cb-a809-b3625d39f4b4_terseLabel_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_label_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_documentation_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:href="exdx-20201231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:to="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9f827090-f2f4-49f6-9c48-ac74c455504d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1ac893ff-da4b-4c38-9a2e-5c850e3dc5ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f9e48bd5-f669-4b66-8df0-563ac05da71d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_034d65cd-c3e5-4063-90a5-61ed91ee0e60_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in Shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0b41c6c-0487-4af2-99a4-f95e6e038f49_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_fe6cebba-8196-4f1f-a0a3-b85e20d84cd3_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ddc879c7-45c7-48aa-8fcd-e0d801580729_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_291b06cd-15cd-452b-8090-fa8b2ba0a6db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2c1e6dd5-296e-4ce3-9864-0c04037f2d60_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_bf437e00-55ab-49df-a542-24ed7378d8d4_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a36a8622-3572-4fb2-8213-e0704e9cc507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_c948bb39-4b40-43a9-a101-17d7b5265b91_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing and acquisition-related liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a6004c76-31a6-4017-bf3a-b2bf9efa45d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_652022ca-56f3-4fb9-a9f5-cf44ebe6fbf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_be099c42-5815-4d9c-95a6-2402da9c9249_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e1d73f21-bf9e-4f80-b9fc-8482d1727be4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_25cac4fe-1593-4112-9988-e55e303922a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_96615f71-254c-416c-95ed-0129bc9874a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4d6b90ba-2f3d-4367-824d-534b49b98525_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b9010bc5-f0d9-4967-ae64-97975feacfab_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3e3ad8b2-6b11-421b-b4f6-5ea2327303b0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ae33b0ee-80f2-4398-b747-07012cc972a0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_0a0f13d2-6952-4bce-b239-ac71a49985b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carryforwards, carryforward indefinitely</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_af534ed3-f815-4895-ac14-90b730c4c7f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d8818d59-b6cc-4d31-b1ae-5011a83dad45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a687fd55-5036-44a6-a468-6849d7b7b808_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, net of issuance costs and offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ff99afbe-9692-46cc-9d30-d0d77f47fe17_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d0c8796b-413f-4ed9-b610-14539e395a63_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_119d0a24-949b-4a71-83de-ea74f597fe02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_495fdb02-cf91-4627-ad40-c7dd86365e66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6df994d0-1ee8-4d73-abf9-2a1a67d7be4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dd0fe2ab-a13b-431d-81af-5de29e411525_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit) provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_02929de7-f36e-45b1-936b-021b03e1f11d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_726448d2-f230-45f0-81d0-d2a6fb8c38f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4361e6f7-c117-4552-8d68-07c35cf7a667_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eeb59254-d5fc-4460-8762-4b96b0f83a7a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b919d76b-2619-42d0-975e-f4d558401faf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_02d56bb7-071e-49d1-a005-e16df9489af9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_556b3623-2608-46a1-8001-07e07e957d03_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4c341e5c-9853-41e0-a863-93a055d544bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b383e1a5-b222-4f62-8b75-5914c1ed1a17_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_a77d6707-2829-44d9-b314-5c95d1cdf9c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ac0a5302-c70a-4072-a01b-bc9057d7b1e6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_de3ea122-a9cd-4a9c-bcdc-b74501c84cd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_9320ae84-37f7-4352-9f94-a6d33b4882f0_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_0aa93b8d-504f-4f0e-a9a7-092489b67783_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2f7ca85c-29c6-4122-abac-b180737b82dc_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5fe43894-7f64-4a76-bd5b-89602ff9781a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_c3bad8b4-a377-47f5-962e-d6d77b02c51e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_4948ed64-dc03-49b0-a298-1bb0a4d3483b_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in shares available for issuance under the Plan</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4b0017bb-126a-42da-8a14-cf148679173c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cdd8f006-28b0-44dc-bbbc-f12212b511c2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_06dc8526-1b9e-41f5-acda-644417a5809e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2ea8d449-cdbb-4302-827f-60cbd6c08d77_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_8eea889a-c2f4-4f22-a379-eeb0ed802c6f_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20201231.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5ecbca7f-ec5b-47ad-9351-b38d9bb7b1c3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_ba328fe0-c848-4765-82af-04f404396b3c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_75a0fbe1-890e-4f78-b950-979de1c1a3f6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c7d3da16-9246-4afc-a137-a9f8bb0f1100_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_5c291c32-7c63-4deb-8e49-05deb600e216_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in next twelve months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_98af4a1a-3315-44e2-bdec-97a0a767c190_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dc9a9b44-9174-4bc1-a2a4-562f9d9dda2d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d86fc958-5b9f-4eb7-b880-33f3cf8bbca4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_7ff07d8e-9ff6-4ce1-bdc5-f906f0c69bf9_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses for aggregate expenses</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20201231.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_55efbfb5-c31f-49f9-989a-55a0040fd4aa_terseLabel_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common and preferred stock warrants</link:label>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_label_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Exercise of Stock Purchase Warrants</link:label>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_documentation_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Exercise of Stock Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:href="exdx-20201231.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:to="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ad328a27-0e71-48d4-a750-4c6c0e849032_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_460ca1b6-946e-453c-b036-91726c82d05d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8399a4a9-dbf0-40ef-a258-84a4734fca3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f2dbecae-fed1-47ea-8d9c-e16a04c8482d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_98b5f07c-f8f9-4853-9170-6b0265ce4029_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3aabc7a5-efd0-49c4-872f-51d5e685cf64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76a003e9-6e08-400f-a215-6b1d44b39086_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2cdeb298-7733-49e1-ab04-f7b45ddd76fa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_86fbba66-9aa5-4978-ba76-35086b759d15_terseLabel_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation, fair value</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_label_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_documentation_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:href="exdx-20201231.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:to="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_9a59bfdf-d16b-4957-bb6c-1ccbbf72999c_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common and preferred stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_7b8df1c4-35c2-4d1d-8484-321bf171c9f8_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 7)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_bf5f2c69-1695-4a6b-b26e-cecca13ae957_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_8b113a18-7008-4ed6-b2d3-13999f51ecfd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_b6b98b8b-d12d-49fa-a924-f626e95a5495_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_86f9f1cf-807c-447b-bd98-896cb2e2cf8f_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_786f4c3a-cedc-4cb7-9d3a-ff76e79a280e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7f134c41-c1d5-4443-bf36-e115fff9dae0_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_fcad821f-d35c-4917-b302-4135280ac6f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_51a06bd4-c728-47d7-951b-91d95b290119_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_a1e5dac9-f61d-47cf-83e6-557cb474aa7e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, timing of performance obligation and payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" xlink:to="lab_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3057bcf7-9aaf-4d5b-97a7-929fc9455ea2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3b10b8af-7be8-43d3-ac32-393610b9cde6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_359e4fb7-3c77-4e0f-903a-77d7e479e8f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_87f722bc-3a68-436d-8573-186204a94c9c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f522038c-83d1-401b-a089-02ff3b5267cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_65351399-5212-4455-9915-f8393f21be28_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b11b69c1-2554-4fdc-8539-389d6f0b6212_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3b66559a-8ff8-4f6c-bc1f-ad81c801d856_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>exdx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:df7b9813-5e72-463d-8cb1-6171c8849aab,g:00ced030-a7a6-4c0c-80c4-1e344ff98e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_beb0b071-2169-496f-b2a2-09a329dc1938" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentType_beb0b071-2169-496f-b2a2-09a329dc1938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e363dd14-8ace-449e-aa5e-73b43d8180fc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentAnnualReport_e363dd14-8ace-449e-aa5e-73b43d8180fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_788759b7-0ede-4c46-a874-2d0da17345a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentPeriodEndDate_788759b7-0ede-4c46-a874-2d0da17345a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a357bd02-2fd6-4b84-a5b8-063c6b89331b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentTransitionReport_a357bd02-2fd6-4b84-a5b8-063c6b89331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_49fa6139-9558-4db2-8825-ed18c227e6ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityFileNumber_49fa6139-9558-4db2-8825-ed18c227e6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ddefddba-ecd7-4121-8304-f694a4d682d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityRegistrantName_ddefddba-ecd7-4121-8304-f694a4d682d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f0e5068a-9b55-4a24-86e7-47a05bfd819b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f0e5068a-9b55-4a24-86e7-47a05bfd819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2adf03bc-9607-46aa-9e80-6f832648cc1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityTaxIdentificationNumber_2adf03bc-9607-46aa-9e80-6f832648cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_068991d7-071b-452e-88a8-89ef4bf4802f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityAddressAddressLine1_068991d7-071b-452e-88a8-89ef4bf4802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d1729e26-1be9-4361-bfa4-666df3d07dcf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityAddressCityOrTown_d1729e26-1be9-4361-bfa4-666df3d07dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ca2db7e2-7c55-4d87-9c58-24d4e2314649" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityAddressStateOrProvince_ca2db7e2-7c55-4d87-9c58-24d4e2314649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_781f9413-af24-4edc-b801-6501b2cba8e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityAddressPostalZipCode_781f9413-af24-4edc-b801-6501b2cba8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_00176d3a-e526-4389-929f-1cd10266d584" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_CityAreaCode_00176d3a-e526-4389-929f-1cd10266d584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4afddbb5-5efb-436b-986a-9252f0109143" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_LocalPhoneNumber_4afddbb5-5efb-436b-986a-9252f0109143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ebfd11b4-0a41-4a3b-adb2-b065cad70832" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_Security12bTitle_ebfd11b4-0a41-4a3b-adb2-b065cad70832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dbde1ac0-9562-4c87-9d93-c43cb5a26262" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_TradingSymbol_dbde1ac0-9562-4c87-9d93-c43cb5a26262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b6393fd4-fcbb-4639-9ce2-08183e6061c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_SecurityExchangeName_b6393fd4-fcbb-4639-9ce2-08183e6061c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8526f07c-37b4-4902-9397-65e5e1ed96be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8526f07c-37b4-4902-9397-65e5e1ed96be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_8c2e08f0-1e37-436c-9d8b-109569d326fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityVoluntaryFilers_8c2e08f0-1e37-436c-9d8b-109569d326fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_10cb603a-c304-4003-8a85-0d932495e619" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityCurrentReportingStatus_10cb603a-c304-4003-8a85-0d932495e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_86eddd3b-9306-43ed-9033-ba2afa44b9cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityInteractiveDataCurrent_86eddd3b-9306-43ed-9033-ba2afa44b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0f5f6e57-bb28-41b2-9bc4-fbc76e258b7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityFilerCategory_0f5f6e57-bb28-41b2-9bc4-fbc76e258b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4a888065-0cb0-4469-b892-6a613121f467" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntitySmallBusiness_4a888065-0cb0-4469-b892-6a613121f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d1f9e2ad-24ac-402c-b610-f97a5bdef637" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityEmergingGrowthCompany_d1f9e2ad-24ac-402c-b610-f97a5bdef637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_42ad793a-63f9-44bd-99e2-7ca48be44280" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityExTransitionPeriod_42ad793a-63f9-44bd-99e2-7ca48be44280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_585e5342-b516-4d20-804d-af6447abcc1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_IcfrAuditorAttestationFlag_585e5342-b516-4d20-804d-af6447abcc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_32fdab26-abf1-4d67-a2a1-ec9f8c5338f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityShellCompany_32fdab26-abf1-4d67-a2a1-ec9f8c5338f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_381ae858-b720-4143-b62a-a8c009cc7d92" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityPublicFloat_381ae858-b720-4143-b62a-a8c009cc7d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_57abecca-24a0-4ee6-b8d6-ab2b24d1e706" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_57abecca-24a0-4ee6-b8d6-ab2b24d1e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2c94a67b-6421-4074-b678-4f7ab6419cd6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2c94a67b-6421-4074-b678-4f7ab6419cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0fafcfb8-de63-41f4-a890-a71b90f3fd43" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_EntityCentralIndexKey_0fafcfb8-de63-41f4-a890-a71b90f3fd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d9771595-e632-47b0-920b-848ad791eb7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_CurrentFiscalYearEndDate_d9771595-e632-47b0-920b-848ad791eb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f3a42af0-6d66-439d-8a76-56a839a99f2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentFiscalYearFocus_f3a42af0-6d66-439d-8a76-56a839a99f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bddd853b-11ae-4c93-83e8-5344ac59b673" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bddd853b-11ae-4c93-83e8-5344ac59b673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_21bdbaed-df29-47b2-bc69-5e345437e691" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_85c3052b-4ca7-4772-ae51-9356b4160342" xlink:to="loc_dei_AmendmentFlag_21bdbaed-df29-47b2-bc69-5e345437e691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7e1f7d36-607a-4786-b1ff-262145e7aae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e1f7d36-607a-4786-b1ff-262145e7aae5" xlink:to="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4fd1299-f44b-441a-8474-db0af2f3c887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4fd1299-f44b-441a-8474-db0af2f3c887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6a5474a0-a1f8-48e0-a7fa-f36f35080bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6a5474a0-a1f8-48e0-a7fa-f36f35080bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_438519f4-73de-4f9e-baf9-a4c0373a28d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_438519f4-73de-4f9e-baf9-a4c0373a28d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c9752584-ee0d-4a3c-b629-070c72811934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ab142cae-4eb5-4caf-91e6-abcc0b08c489" xlink:to="loc_us-gaap_AssetsCurrent_c9752584-ee0d-4a3c-b629-070c72811934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_abcfa7ab-7856-48a5-8408-6351791b8d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_abcfa7ab-7856-48a5-8408-6351791b8d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b3627fb-15c6-483a-bb21-4e1f96f5e67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:to="loc_us-gaap_Goodwill_7b3627fb-15c6-483a-bb21-4e1f96f5e67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bf812493-39b8-4dcb-b6e1-383ecb005fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bf812493-39b8-4dcb-b6e1-383ecb005fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c929fdb6-cc0a-447f-b140-5fc37b0e6aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_922dfb71-26c0-4bf7-b34e-6f6f128b5b78" xlink:to="loc_us-gaap_Assets_c929fdb6-cc0a-447f-b140-5fc37b0e6aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e1f7d36-607a-4786-b1ff-262145e7aae5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2b36b63e-6697-4980-be07-2337d60aef66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2b36b63e-6697-4980-be07-2337d60aef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_773238a8-e629-49ba-95cc-3caceb1cbedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2b36b63e-6697-4980-be07-2337d60aef66" xlink:to="loc_us-gaap_AccountsPayableCurrent_773238a8-e629-49ba-95cc-3caceb1cbedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_aab3f160-62e6-4397-a000-86c487da12ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2b36b63e-6697-4980-be07-2337d60aef66" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_aab3f160-62e6-4397-a000-86c487da12ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d5d60f6b-5c1a-4374-b232-4bd875f6562f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2b36b63e-6697-4980-be07-2337d60aef66" xlink:to="loc_us-gaap_LiabilitiesCurrent_d5d60f6b-5c1a-4374-b232-4bd875f6562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e0e451ea-de00-463b-8645-ce2c781d2563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e0e451ea-de00-463b-8645-ce2c781d2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a2fd9cb3-128e-4a75-8543-b78bdc9514e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a2fd9cb3-128e-4a75-8543-b78bdc9514e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82331b-d267-4f50-be72-2ceca2bd4968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6b82331b-d267-4f50-be72-2ceca2bd4968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_abf4daa7-9638-4fee-b0e4-3f2e00a6cf7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_Liabilities_abf4daa7-9638-4fee-b0e4-3f2e00a6cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0843a61e-947a-4213-9528-a1249a7128d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0843a61e-947a-4213-9528-a1249a7128d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a52cf31a-ed15-4281-9dd1-3d1ac388ce1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:to="loc_us-gaap_PreferredStockValue_a52cf31a-ed15-4281-9dd1-3d1ac388ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fbe2d8cc-bcb5-439e-82d8-146ca18a9abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:to="loc_us-gaap_CommonStockValue_fbe2d8cc-bcb5-439e-82d8-146ca18a9abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7640348b-502f-4b0e-9c9f-05128d2e3307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7640348b-502f-4b0e-9c9f-05128d2e3307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f1307cd-e693-46b2-8822-add52a48de3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f1307cd-e693-46b2-8822-add52a48de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65005b63-fec8-4c63-a268-750d26c1221b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c485b3bd-d46a-4c18-924a-399cc4668fc2" xlink:to="loc_us-gaap_StockholdersEquity_65005b63-fec8-4c63-a268-750d26c1221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9ee7ad7-128e-4995-b42e-574654710656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7f7896a-cd0e-45a2-8f50-ca8aba51a108" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9ee7ad7-128e-4995-b42e-574654710656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e5238173-b25f-4a32-965a-9f50f240a3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5238173-b25f-4a32-965a-9f50f240a3fa" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90b76b98-e69b-400a-8db2-7c40ef3797af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90b76b98-e69b-400a-8db2-7c40ef3797af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12cb1202-6143-48f3-849c-3c025800736c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12cb1202-6143-48f3-849c-3c025800736c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dbe558ae-0264-4274-851c-26587ab33987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dbe558ae-0264-4274-851c-26587ab33987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8fb3b0a5-4ba2-4819-b2ac-a328ee40a3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4a8fde4a-5ae1-488c-b17a-bd1cef78a589" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8fb3b0a5-4ba2-4819-b2ac-a328ee40a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5238173-b25f-4a32-965a-9f50f240a3fa" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5f209270-0681-41d1-bfbd-43639783b1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5f209270-0681-41d1-bfbd-43639783b1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_db9d2897-cb0a-4bc0-b337-ae09b76adcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_db9d2897-cb0a-4bc0-b337-ae09b76adcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b77b0bb9-344b-48ae-afd3-cdf029f8dae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:to="loc_us-gaap_CommonStockSharesIssued_b77b0bb9-344b-48ae-afd3-cdf029f8dae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8ed7e45-f2e9-4904-81a3-769eb1041d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d024ae7a-6818-41f7-87ad-b3d981d78f8e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e8ed7e45-f2e9-4904-81a3-769eb1041d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2e95ba-cecd-40e4-bdbe-0471ca741958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2e95ba-cecd-40e4-bdbe-0471ca741958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8b5c9d7e-a15a-4a67-99fe-b69f3d716434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8b5c9d7e-a15a-4a67-99fe-b69f3d716434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1ecdfda4-2279-4d82-844a-971ab17b9549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1ecdfda4-2279-4d82-844a-971ab17b9549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9dcb8b88-967b-4eab-bfd2-2a69b58e9fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9dcb8b88-967b-4eab-bfd2-2a69b58e9fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5f750929-0959-4e71-81c0-0e23d2beabf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fd33a0c-02e4-4783-9776-77631bd98059" xlink:to="loc_us-gaap_CostsAndExpenses_5f750929-0959-4e71-81c0-0e23d2beabf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90a5b341-94aa-4cbb-8b5e-208b29703337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_OperatingIncomeLoss_90a5b341-94aa-4cbb-8b5e-208b29703337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eebc64f4-3cc4-4101-afbf-d20ba72f5b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_InterestExpense_eebc64f4-3cc4-4101-afbf-d20ba72f5b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_0eacaca9-976e-4fc3-a5be-647ce30791f9" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_0eacaca9-976e-4fc3-a5be-647ce30791f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9172c709-0360-45c8-92ad-234a064a1251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9172c709-0360-45c8-92ad-234a064a1251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_a9464a79-e436-4756-a4c4-19fecd76a9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_a9464a79-e436-4756-a4c4-19fecd76a9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_740694a4-e8cf-41e3-a32a-f3688694fa56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_740694a4-e8cf-41e3-a32a-f3688694fa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b7eacdbe-eba0-4ab9-8a1d-fcd9812098ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_NetIncomeLoss_b7eacdbe-eba0-4ab9-8a1d-fcd9812098ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_89cea492-5359-4fd9-857b-728c44ec2e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_89cea492-5359-4fd9-857b-728c44ec2e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_497ca5cb-a22f-449b-84ce-9ef5361eecb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_497ca5cb-a22f-449b-84ce-9ef5361eecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ed297b73-562d-479d-bd72-85c55da15863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ed297b73-562d-479d-bd72-85c55da15863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2bd79d10-64ef-4946-8e1b-0b0d7e180e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2bd79d10-64ef-4946-8e1b-0b0d7e180e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4314240e-c578-470f-abc5-0e2ef6e23980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2ea7ec8c-6ca3-45a9-a066-2e576363d877" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4314240e-c578-470f-abc5-0e2ef6e23980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d466739e-d106-4ea5-a3b4-331a6a83acb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d466739e-d106-4ea5-a3b4-331a6a83acb6" xlink:to="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_26851b32-ddd1-46e0-af49-510cae2e041c" xlink:to="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_24d80a6d-6483-4bd2-8777-4a7a3d06f0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_CommonStockMember_24d80a6d-6483-4bd2-8777-4a7a3d06f0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6da0c0f2-4219-48c3-b89e-bcee0010585a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6da0c0f2-4219-48c3-b89e-bcee0010585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fbfa834a-37d6-4a27-913e-4062b80b7bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1f0edbe4-66b6-447c-8b64-edb1e5665a8f" xlink:to="loc_us-gaap_RetainedEarningsMember_fbfa834a-37d6-4a27-913e-4062b80b7bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3eec7f5c-18f8-4c3c-9f4e-70d730d23cf3" xlink:to="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_e66edf8f-cc28-42e7-a371-5a778d1ade26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_e66edf8f-cc28-42e7-a371-5a778d1ade26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_aad02872-1e03-4cee-872c-20e56cc24dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7dfb93ab-5c7d-4313-a80c-6f3b4f1466db" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_aad02872-1e03-4cee-872c-20e56cc24dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_710d976f-1dcd-4d37-a003-585292af0914" xlink:to="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_03565dea-ad23-402d-9348-9c389df0a02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_03565dea-ad23-402d-9348-9c389df0a02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e7cb4854-671e-4152-a156-e327b6691f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e7cb4854-671e-4152-a156-e327b6691f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_9f8693f2-2488-4185-a16a-15a99217eab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_9f8693f2-2488-4185-a16a-15a99217eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_4f50f34a-0058-4f40-b142-f2cb959caf18" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_4f50f34a-0058-4f40-b142-f2cb959caf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_15a3081a-9908-42c1-9504-a9eb517fbe35" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_15a3081a-9908-42c1-9504-a9eb517fbe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_6c70969c-32d5-4bb1-8c02-ddaeceb7297b" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_6c70969c-32d5-4bb1-8c02-ddaeceb7297b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_7a76d133-cd1d-4d52-8eb8-361f9a8cef19" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_7a76d133-cd1d-4d52-8eb8-361f9a8cef19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_2ad53b07-3883-4e17-8b77-f39876779857" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_2ad53b07-3883-4e17-8b77-f39876779857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_ff82efeb-9ba5-4b41-a89b-8749c2a83bf3" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_ff82efeb-9ba5-4b41-a89b-8749c2a83bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_ed1d86e8-eea9-44b2-abf0-7841b3d60a16" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_ed1d86e8-eea9-44b2-abf0-7841b3d60a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d4c8710a-ad0f-4b0c-9405-8f0df2c2053a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d4c8710a-ad0f-4b0c-9405-8f0df2c2053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f113fcbf-c383-4cc8-83fd-ff624b973292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_748bf558-8a59-4f07-9282-b6e39a958e42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f113fcbf-c383-4cc8-83fd-ff624b973292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d0cacfed-20c5-4f4f-b850-e86bee904606" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fd8908aa-be5e-4d63-be0c-1d42df56f2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fd8908aa-be5e-4d63-be0c-1d42df56f2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_692d5972-3ce4-44f6-8285-b239e078625c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockholdersEquity_692d5972-3ce4-44f6-8285-b239e078625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_7562a119-71b2-475c-ae5e-e845a3066eed" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_7562a119-71b2-475c-ae5e-e845a3066eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_768a9a5d-7e1c-45cf-a9e0-95663ef13330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_768a9a5d-7e1c-45cf-a9e0-95663ef13330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad5a421c-ba5a-4a46-9dea-ac7c87f87711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad5a421c-ba5a-4a46-9dea-ac7c87f87711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95d1cfd-2d33-48c0-9040-b29eb01706fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95d1cfd-2d33-48c0-9040-b29eb01706fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_5c25008b-8310-4c37-a469-79e31174e329" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_5c25008b-8310-4c37-a469-79e31174e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_7cb61e35-4654-44eb-ac58-ae4b4a218c22" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_7cb61e35-4654-44eb-ac58-ae4b4a218c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_e1525320-eb6b-4173-8e40-1f6f020e1b49" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_e1525320-eb6b-4173-8e40-1f6f020e1b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e2e8e4e9-7daf-46f0-a2f5-b8a9bfb0e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e2e8e4e9-7daf-46f0-a2f5-b8a9bfb0e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0b488ab9-ef60-4935-bff9-fcf776e54050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0b488ab9-ef60-4935-bff9-fcf776e54050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948530a6-41a7-4fff-ba95-5392f7e7e956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948530a6-41a7-4fff-ba95-5392f7e7e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c1061983-e3ce-4106-a94b-09e5ad5ecc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c1061983-e3ce-4106-a94b-09e5ad5ecc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_75a7fb20-127e-45a4-a535-20c72b5be8b7" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_75a7fb20-127e-45a4-a535-20c72b5be8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_8f19aca8-5669-47b8-af40-41bb55d48e61" xlink:href="exdx-20201231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_8f19aca8-5669-47b8-af40-41bb55d48e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_5e318091-83cf-4138-9ada-48349df8dddc" xlink:href="exdx-20201231.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_5e318091-83cf-4138-9ada-48349df8dddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6d47568-6354-4722-94d6-f8304ece0943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6d47568-6354-4722-94d6-f8304ece0943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d9d121-5ef8-4cf3-bffa-7c887da4d188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d9d121-5ef8-4cf3-bffa-7c887da4d188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d08f838-853e-402b-a7a0-b02c54bb54d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_NetIncomeLoss_3d08f838-853e-402b-a7a0-b02c54bb54d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ba6b5bd-e91e-48ae-b877-148183942497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ba6b5bd-e91e-48ae-b877-148183942497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b70c407e-137b-4143-998d-00eae62a6b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7df05b90-96c5-4b72-be53-5f7ef69aea2c" xlink:to="loc_us-gaap_StockholdersEquity_b70c407e-137b-4143-998d-00eae62a6b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6fc05eba-5dd7-4bb6-8c2b-41f37d7642d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6fc05eba-5dd7-4bb6-8c2b-41f37d7642d5" xlink:to="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cacc84a7-3426-482e-bac8-478ce77c5b2d" xlink:to="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_e3ed9c2e-aedd-49ff-aeeb-fcb0406770e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_e3ed9c2e-aedd-49ff-aeeb-fcb0406770e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_ac67b6cb-f447-45ff-aeae-9073354be45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd8f17a9-3438-4530-8f6e-9f39be153bac" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_ac67b6cb-f447-45ff-aeae-9073354be45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9648d36a-ab5f-4896-8367-b1b805aa952b" xlink:to="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_df928c26-d85e-4944-9a8f-f843f6566659" xlink:href="exdx-20201231.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_df928c26-d85e-4944-9a8f-f843f6566659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts_0513fdb7-93b5-4ef2-bbb8-f0c80ae7cc71" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70a73ce0-4cfa-4f2c-aacd-b6256e9bc77c" xlink:to="loc_exdx_TemporaryEquityIssuanceCosts_0513fdb7-93b5-4ef2-bbb8-f0c80ae7cc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20201231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ae11b3bd-aec5-420e-9e8b-6c70948c4b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae11b3bd-aec5-420e-9e8b-6c70948c4b0b" xlink:to="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10a09cbe-2413-46d3-86b4-a2060803c8c1" xlink:to="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_bfe4438b-494e-4270-843c-5b24461da96d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_bfe4438b-494e-4270-843c-5b24461da96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_d6749c52-e81c-491e-8131-2c41ef89000a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4de591d8-4183-4634-8b8c-c39e809b1320" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_d6749c52-e81c-491e-8131-2c41ef89000a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bb30d374-d54c-4c3a-890d-e39626a5a519" xlink:to="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ee9df80-f002-41ff-b00f-5b33ba016475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_NetIncomeLoss_0ee9df80-f002-41ff-b00f-5b33ba016475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b5b9f3da-f35e-43c3-ab65-23e911a10ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b5b9f3da-f35e-43c3-ab65-23e911a10ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f54ae90b-27f6-4df3-9627-b4b950f6b777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f54ae90b-27f6-4df3-9627-b4b950f6b777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_b1dc529d-2fd4-4190-9925-e3774b18ed85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_PaidInKindInterest_b1dc529d-2fd4-4190-9925-e3774b18ed85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_16ceb23f-ae8c-40c7-b95b-db93dffa698a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_16ceb23f-ae8c-40c7-b95b-db93dffa698a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ece42442-513c-4303-9479-b0849244d132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ece42442-513c-4303-9479-b0849244d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_74e6bb10-5782-4f3e-b9d9-c3ea192996c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_74e6bb10-5782-4f3e-b9d9-c3ea192996c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2fff782e-662f-4b6e-bb74-47d92ba61c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_ShareBasedCompensation_2fff782e-662f-4b6e-bb74-47d92ba61c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3df00f5b-1dbb-4505-9338-21506674d11c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_255adf65-d360-4ac1-ad31-54442c2c78be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_255adf65-d360-4ac1-ad31-54442c2c78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_94b413e1-2827-4f2f-880a-7e23c956f4cf" xlink:href="exdx-20201231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_94b413e1-2827-4f2f-880a-7e23c956f4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_594ab21b-7ac3-4ba5-8687-f5fbd69ed358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_594ab21b-7ac3-4ba5-8687-f5fbd69ed358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eae2d2f0-b168-49d5-9760-32afeed49ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eae2d2f0-b168-49d5-9760-32afeed49ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2d139fa-6bff-4fbe-b1ad-365f275b9c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64410bfb-f887-4fe5-8989-0a5cc1d77c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2d139fa-6bff-4fbe-b1ad-365f275b9c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_302eb772-3fda-4b51-b2fe-a77f221c82b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_beb7eb3e-8160-43f8-b49c-b15a8d570fa4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_302eb772-3fda-4b51-b2fe-a77f221c82b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e33ea927-07a7-40c3-b648-4c91aa64fdb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e33ea927-07a7-40c3-b648-4c91aa64fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2ea94d1-f83d-4b1b-87fc-f980e6a3a98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2ea94d1-f83d-4b1b-87fc-f980e6a3a98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb0f6c75-d677-4b06-af55-f15a448c8579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2569ad82-e274-4521-aaaf-88d3802a87ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb0f6c75-d677-4b06-af55-f15a448c8579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6eac89c6-d78d-424f-937e-4795acff1395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6eac89c6-d78d-424f-937e-4795acff1395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_1c84b103-1b03-451c-95e2-307f94c434d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromStockPlans_1c84b103-1b03-451c-95e2-307f94c434d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c3eb6cad-dcea-41a3-b610-785b81ce757b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c3eb6cad-dcea-41a3-b610-785b81ce757b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2a3b0d96-4c29-4713-a6c8-8fadfffe68ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2a3b0d96-4c29-4713-a6c8-8fadfffe68ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_07369354-a0b3-41f3-83b3-bab5d769fa51" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_07369354-a0b3-41f3-83b3-bab5d769fa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_dc524f04-0398-4c56-9d59-c8916e0694c5" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan_dc524f04-0398-4c56-9d59-c8916e0694c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5fdb31f1-b6ad-45a5-ae00-c797300cd625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5fdb31f1-b6ad-45a5-ae00-c797300cd625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_1298371a-17b3-48b6-a1d6-10220b5b1688" xlink:href="exdx-20201231.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_1298371a-17b3-48b6-a1d6-10220b5b1688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_00dfa7b6-fed7-4637-b1e3-ef857e1789ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_00dfa7b6-fed7-4637-b1e3-ef857e1789ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a252fab4-2f43-4544-81fb-ae450c05b11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_538f14c0-9ab2-46db-aa7b-04f6d6ff7652" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a252fab4-2f43-4544-81fb-ae450c05b11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2ff9a3f-d339-45a9-9bac-a2080033511c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2ff9a3f-d339-45a9-9bac-a2080033511c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3428f5cb-be3f-4f59-9d37-61372c1cbc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3428f5cb-be3f-4f59-9d37-61372c1cbc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9be2713-27b8-420f-bc29-d4ebf3c88fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9be2713-27b8-420f-bc29-d4ebf3c88fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3922929c-6fbe-4bea-b452-f96e4c1e1487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f0345ef-b51d-46f3-803f-bd476f269967" xlink:to="loc_us-gaap_InterestPaidNet_3922929c-6fbe-4bea-b452-f96e4c1e1487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a03b6a4-c67d-49f5-90ec-ec99d9981f9c" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_847343c2-3826-4ad8-8782-2746c22a894b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_847343c2-3826-4ad8-8782-2746c22a894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_682c38c3-7927-427c-8faa-ff2c9f4e9619" xlink:href="exdx-20201231.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_682c38c3-7927-427c-8faa-ff2c9f4e9619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_69b805c6-9377-49d5-8afc-1a6d4e63c545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_69b805c6-9377-49d5-8afc-1a6d4e63c545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_ef7d2ab5-4c57-47a3-b026-9f4c54a01455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_ef7d2ab5-4c57-47a3-b026-9f4c54a01455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_b6d3c06d-e438-4ab5-991a-f72d3626f381" xlink:href="exdx-20201231.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_b6d3c06d-e438-4ab5-991a-f72d3626f381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_c537026a-8774-4e9b-8dea-9a078bab1c60" xlink:href="exdx-20201231.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_c537026a-8774-4e9b-8dea-9a078bab1c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_06c56434-f3b9-42b9-a4da-ddfe2d346b0c" xlink:href="exdx-20201231.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_06c56434-f3b9-42b9-a4da-ddfe2d346b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_d1f830b1-8b25-433d-bb76-39d0fa25c037" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_d1f830b1-8b25-433d-bb76-39d0fa25c037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_d1a4a183-4ef7-4138-acd3-d6bd1b8baac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_d1a4a183-4ef7-4138-acd3-d6bd1b8baac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted_c4ff3cdf-6a33-4e86-85b0-00362be4c732" xlink:href="exdx-20201231.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a730ac98-2584-4e49-8275-56c2b19b5332" xlink:to="loc_exdx_ConversionOfTemporaryEquityAmountConverted_c4ff3cdf-6a33-4e86-85b0-00362be4c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20201231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84332bac-1262-4a88-92ff-520537326913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73cd74ae-3a15-4f8d-b621-16d501b236ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84332bac-1262-4a88-92ff-520537326913" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73cd74ae-3a15-4f8d-b621-16d501b236ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15346243-63f3-4c6f-9a97-776644afc437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646de0b-ed4f-49d0-a4bb-380b05c59be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15346243-63f3-4c6f-9a97-776644afc437" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646de0b-ed4f-49d0-a4bb-380b05c59be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4be6333-bdaf-4909-9be4-6c2d816fd51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15346243-63f3-4c6f-9a97-776644afc437" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4be6333-bdaf-4909-9be4-6c2d816fd51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b956786f-0383-45d5-aca7-c19a57a4fdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_27f490b4-458f-4afb-9ced-86a156db1431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b956786f-0383-45d5-aca7-c19a57a4fdfe" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_27f490b4-458f-4afb-9ced-86a156db1431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c2288555-2062-4b75-924e-bab171257c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c2288555-2062-4b75-924e-bab171257c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_09fc9b7d-95aa-4d06-b06f-95edfbc259b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_09fc9b7d-95aa-4d06-b06f-95edfbc259b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f11f4f7a-8320-4252-8252-73c9e9aceba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f11f4f7a-8320-4252-8252-73c9e9aceba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_246a0563-ee0d-4816-9745-4f52133193b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_246a0563-ee0d-4816-9745-4f52133193b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_70d54aa3-75bf-4184-b1eb-7da5399d19df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_70d54aa3-75bf-4184-b1eb-7da5399d19df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_d3cfc7f6-8ac1-4075-9b74-609bcb281b3c" xlink:href="exdx-20201231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_d3cfc7f6-8ac1-4075-9b74-609bcb281b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c9648171-9ab9-42f9-a2c1-a8c3a232ca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c9648171-9ab9-42f9-a2c1-a8c3a232ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8d06c523-f70a-41fb-9631-380ac8c28ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8d06c523-f70a-41fb-9631-380ac8c28ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ee51272f-0825-44e1-914e-b8d783348bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ee51272f-0825-44e1-914e-b8d783348bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_aba74fd9-5ab1-456e-97a3-d575f8596b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_aba74fd9-5ab1-456e-97a3-d575f8596b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_38ea7999-5de8-4cf0-8f03-f37bc8936e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_38ea7999-5de8-4cf0-8f03-f37bc8936e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_60f54f5b-74c4-4aab-8481-fb0a0327317b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_60f54f5b-74c4-4aab-8481-fb0a0327317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_da415556-5d7e-4281-b83a-68aeec1bc92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_da415556-5d7e-4281-b83a-68aeec1bc92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dfb6bca4-7943-4e41-a3ab-3c8d02a0a9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dfb6bca4-7943-4e41-a3ab-3c8d02a0a9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b9dea9b1-51c0-4190-af07-cacd1643bffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a46cabf7-4174-4e2c-8679-777bf1a66cec" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b9dea9b1-51c0-4190-af07-cacd1643bffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_26803dd6-b368-4366-9709-ebea3b3ffe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_26803dd6-b368-4366-9709-ebea3b3ffe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_71b52187-f01e-471d-a6c0-4d0fe2e69400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_71b52187-f01e-471d-a6c0-4d0fe2e69400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9638c5ea-c93e-42a3-9634-6cf95cdf8193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9638c5ea-c93e-42a3-9634-6cf95cdf8193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ae4f548f-e077-4ff5-8866-3eb3d06df5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ae4f548f-e077-4ff5-8866-3eb3d06df5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8da3d6bb-cce7-4f74-80ea-5b4dc1354244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e65911d6-70e5-4595-b926-b2505a817ef8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8da3d6bb-cce7-4f74-80ea-5b4dc1354244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a62680b-7d08-432a-9764-16194cdbedd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a62680b-7d08-432a-9764-16194cdbedd6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_82e199ad-ebff-4135-9701-025c3b2170ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_16f0f5d2-2f16-496f-a499-0c35458f64dd" xlink:href="exdx-20201231.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_MedicareMember_16f0f5d2-2f16-496f-a499-0c35458f64dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_9f1e8c7a-13ed-48f5-a99d-da1efa35f9a8" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_JanssenSIMPONIMember_9f1e8c7a-13ed-48f5-a99d-da1efa35f9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_e244241d-9dc7-4d34-b674-bd4c4028a590" xlink:href="exdx-20201231.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_BlueShieldMember_e244241d-9dc7-4d34-b674-bd4c4028a590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_aba5c58a-cb92-4963-8858-14680644e91d" xlink:href="exdx-20201231.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_MedicareAdvantageMember_aba5c58a-cb92-4963-8858-14680644e91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_6b177f57-3ce9-4d15-9dca-a018b0ceafd4" xlink:href="exdx-20201231.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e933a179-461a-4e14-9778-7b8920c161a4" xlink:to="loc_exdx_UnitedHealthcareMember_6b177f57-3ce9-4d15-9dca-a018b0ceafd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d310116b-b9cb-411d-9ec9-89fc4ccfb4e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c0d60f9d-fea7-4422-815b-d4c2ce91167c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:to="loc_us-gaap_SalesRevenueNetMember_c0d60f9d-fea7-4422-815b-d4c2ce91167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_94696447-9b70-4af6-993b-ccc6b0ffaeb6" xlink:href="exdx-20201231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dbb1413d-f1f0-4f05-b24e-d0b7fc906b77" xlink:to="loc_exdx_ReceivableBenchmarkMember_94696447-9b70-4af6-993b-ccc6b0ffaeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b8a925-0cf0-4021-ac21-b3ee8ec9a845" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5d780d13-5d57-45d6-8305-a4bf15ac6412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab0ec29c-6c13-4a2b-83c5-9bc3510a34c0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5d780d13-5d57-45d6-8305-a4bf15ac6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_78309981-bcf8-435c-9db3-03fb0b6e1237" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b994e5df-9231-458e-baab-d28a8babcda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_acf204be-c6f7-43be-aa9c-2ad8c412ebf8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b994e5df-9231-458e-baab-d28a8babcda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d0b8ca56-b3df-4414-ab72-9a13c0307cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0b8ca56-b3df-4414-ab72-9a13c0307cba" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8437de92-64ad-48f2-9a6b-4d13bca17a21" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_a47d9d90-063a-4ae3-ba47-cb96672cca0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d276849b-634b-4a34-838c-c7b71880ec20" xlink:to="loc_us-gaap_OtherAssetsMember_a47d9d90-063a-4ae3-ba47-cb96672cca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aa79fe13-1f86-47cd-a8a1-1e9b3028a93f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_21dd0e28-5009-4775-b658-333b84be4697" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e74614-97c0-4865-9c75-f76594ee48ee" xlink:to="loc_exdx_JanssenSIMPONIMember_21dd0e28-5009-4775-b658-333b84be4697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e191ce4b-bbf9-4821-a42d-7c28277bf8f7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7451066e-2a64-47d7-ab1b-7f1fcfd0c86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_941bea20-fb04-44dc-a4be-bb76ea9da793" xlink:to="loc_us-gaap_SalesRevenueNetMember_7451066e-2a64-47d7-ab1b-7f1fcfd0c86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d141ed8-6e73-4637-9dd0-1c37ff621e48" xlink:to="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_7f2b121c-7d08-4d51-b218-22db79942520" xlink:href="exdx-20201231.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:to="loc_exdx_AVISECTDTestMember_7f2b121c-7d08-4d51-b218-22db79942520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_b099fbe0-2947-439d-bc1f-7a1f965f04ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81f4b458-3e00-4c75-8c70-3b944313d35b" xlink:to="loc_us-gaap_ShippingAndHandlingMember_b099fbe0-2947-439d-bc1f-7a1f965f04ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f4853743-8630-4217-805b-ce6c5b62b859" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4c9a8d6f-a67b-440e-9e55-47802da6662b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4c9a8d6f-a67b-440e-9e55-47802da6662b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_aeeda7ba-2525-4b8a-9703-dd812f465e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_402aced4-3021-49ea-9912-ce7959ecf251" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_aeeda7ba-2525-4b8a-9703-dd812f465e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c28112bd-8b11-4e97-b76d-d0a19c9734b1" xlink:to="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d4d6f1a-fc93-4fde-8875-95862c7e3819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:to="loc_srt_MinimumMember_4d4d6f1a-fc93-4fde-8875-95862c7e3819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e87ffcaa-3f0c-4ffe-9a2e-2c89ce9ce40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5044c1a-7510-494c-b2a3-469ae68177f4" xlink:to="loc_srt_MaximumMember_e87ffcaa-3f0c-4ffe-9a2e-2c89ce9ce40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9c8c8675-93d9-40a8-8212-8838c5f96645" xlink:to="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f5f22667-1991-48f2-9c98-1cd86b1da10a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_263fc4ed-7c7c-4dab-bab5-1d06084e9d3e" xlink:to="loc_srt_ScenarioForecastMember_f5f22667-1991-48f2-9c98-1cd86b1da10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58b2ad7f-7ca9-40ad-8fa2-3374c875f59c" xlink:to="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86e95ca5-b6de-4188-9cb6-213ad55e6d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aab455fd-37de-4fc6-9267-5ae22b417f4d" xlink:to="loc_us-gaap_CommonStockMember_86e95ca5-b6de-4188-9cb6-213ad55e6d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9c5c09b7-e3ae-4843-9ed7-5daf0e70a351" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9dfb5085-2d45-4f23-bbdd-dde8dc7dcae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f015dec-dd4c-4eab-a530-7fb81bafcf2a" xlink:to="loc_us-gaap_IPOMember_9dfb5085-2d45-4f23-bbdd-dde8dc7dcae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_01a7385c-cf55-4204-8545-d6b061e1ef8e" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e1ae5fe9-5da1-4c36-bd5b-4ce8b77898bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e1ae5fe9-5da1-4c36-bd5b-4ce8b77898bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b1a9247e-0ef2-4e4d-86fa-392b5001f5b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_RestrictedCash_b1a9247e-0ef2-4e4d-86fa-392b5001f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3805cdef-1c64-45b2-b071-713e7f345035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3805cdef-1c64-45b2-b071-713e7f345035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_27c453b8-4000-416c-9489-1d3a99f7076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_27c453b8-4000-416c-9489-1d3a99f7076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_0c64b3ac-0deb-46e7-9870-479f03a595f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment_0c64b3ac-0deb-46e7-9870-479f03a595f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_c0e126fb-04f2-4115-a0e5-5085350dd283" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_c0e126fb-04f2-4115-a0e5-5085350dd283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_7912c640-80ad-4449-b742-1822fb401c13" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_7912c640-80ad-4449-b742-1822fb401c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cdc3a8a0-25e3-440a-8b14-adbc810dd52e" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cdc3a8a0-25e3-440a-8b14-adbc810dd52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits_7b3de061-d155-4722-aef4-774e2d059158" xlink:href="exdx-20201231.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_exdx_JointVentureQuarterlyPrescribedUnits_7b3de061-d155-4722-aef4-774e2d059158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41c075c0-1c53-4a50-b7b3-df93d503a3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41c075c0-1c53-4a50-b7b3-df93d503a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_d8347ca5-34fd-48ba-9f7b-777855e0c411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_AdvertisingExpense_d8347ca5-34fd-48ba-9f7b-777855e0c411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_dac26ebe-b487-48b1-a966-e0e8b1e1693a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_CostOfRevenue_dac26ebe-b487-48b1-a966-e0e8b1e1693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a74a06e3-c9a9-4552-b4c9-754f8dd4999d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a74a06e3-c9a9-4552-b4c9-754f8dd4999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d69307a0-759a-4f08-97d7-77dda6619a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_6e4c9993-5673-43a1-a641-4db69e9f3961" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d69307a0-759a-4f08-97d7-77dda6619a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f3b8e527-8736-45d2-8e3b-c1e187b14134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3b8e527-8736-45d2-8e3b-c1e187b14134" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_808a6fc4-a6c8-4318-99fa-3eaaab1296a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_34bb7125-635a-40db-8110-e2b042b19d9c" xlink:to="loc_us-gaap_SegmentDomain_808a6fc4-a6c8-4318-99fa-3eaaab1296a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:to="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_993da155-cded-4621-a4c3-1354e940c8a0" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_ef6fd7bd-ebeb-4704-a3a1-0d42a01617b8" xlink:href="exdx-20201231.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_HealthcareInsurersMember_ef6fd7bd-ebeb-4704-a3a1-0d42a01617b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_fbc25a89-a298-4f96-b8b5-bf987dbaf050" xlink:href="exdx-20201231.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_Government1Member_fbc25a89-a298-4f96-b8b5-bf987dbaf050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_8b368aa5-5325-4b98-8cc0-5e19ba9f9fe0" xlink:href="exdx-20201231.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_ClientMember_8b368aa5-5325-4b98-8cc0-5e19ba9f9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_198cc09a-1029-495e-a6e1-784dfff4d480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_us-gaap_OtherCustomerMember_198cc09a-1029-495e-a6e1-784dfff4d480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_b29bed6c-cf44-4f80-ac0d-c7cc78eda4f3" xlink:href="exdx-20201231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3b8d56d-90a9-433c-ad67-f0015d3eeb92" xlink:to="loc_exdx_JanssenSIMPONIMember_b29bed6c-cf44-4f80-ac0d-c7cc78eda4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_723e1a76-dc8f-456f-b0c4-c68d9e620662" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27c3533e-f046-47b7-84b0-63346cd5816a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_488ddea7-55f7-442c-b1b4-7fc99e0966f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27c3533e-f046-47b7-84b0-63346cd5816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96eb20ff-4db9-4a6e-857e-ca56307110a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_185f0816-86b6-4857-8abb-86adacdc94e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96eb20ff-4db9-4a6e-857e-ca56307110a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_185f0816-86b6-4857-8abb-86adacdc94e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e91c0d49-fde7-4821-bbe0-f9a4304bf52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96eb20ff-4db9-4a6e-857e-ca56307110a6" xlink:to="loc_us-gaap_RestrictedCash_e91c0d49-fde7-4821-bbe0-f9a4304bf52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fce572c-af26-4bd2-82c4-0f6c5a068613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96eb20ff-4db9-4a6e-857e-ca56307110a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fce572c-af26-4bd2-82c4-0f6c5a068613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba0e9339-deba-484b-a992-b18eaae5578b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba0e9339-deba-484b-a992-b18eaae5578b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c19b10d2-18c6-4ad2-a776-7d56f456b16c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8546daa7-a587-41b5-9511-94f6f14600e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_WarrantMember_8546daa7-a587-41b5-9511-94f6f14600e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_4b702c4a-4dc1-4072-85e3-4c120c1775f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_StockOptionMember_4b702c4a-4dc1-4072-85e3-4c120c1775f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_78c5e382-653b-41b4-96d8-505bbc405910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f4d9be7-811d-4df5-ba71-0f7b6c5d8e9c" xlink:to="loc_us-gaap_EmployeeStockMember_78c5e382-653b-41b4-96d8-505bbc405910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8fb8d5ab-7da6-4bed-88a7-52dbc13cadd2" xlink:to="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c31010b-d6f8-4151-87a6-f9391d9f03f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65bb833e-b228-478d-87e1-66f06f249918" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c31010b-d6f8-4151-87a6-f9391d9f03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_851384c0-36c6-4f4e-8093-4a1ed49febbd" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_dc155038-dab6-4399-985b-37184ceb348e" xlink:href="exdx-20201231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_851384c0-36c6-4f4e-8093-4a1ed49febbd" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_dc155038-dab6-4399-985b-37184ceb348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_e8fbe714-8841-415a-9ba7-5903c09445cf" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_5a38b3a8-d173-409a-a0aa-449f965394a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e8fbe714-8841-415a-9ba7-5903c09445cf" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_5a38b3a8-d173-409a-a0aa-449f965394a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_98f637ba-16b2-42ec-a07a-30db653c7185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e8fbe714-8841-415a-9ba7-5903c09445cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_98f637ba-16b2-42ec-a07a-30db653c7185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f05ee79-e5e9-4c40-b3fd-cb6661d4955b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e8fbe714-8841-415a-9ba7-5903c09445cf" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f05ee79-e5e9-4c40-b3fd-cb6661d4955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6f96d5f8-3ff5-47bf-83ac-ef41a6263795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:to="loc_us-gaap_OtherAssetsCurrent_6f96d5f8-3ff5-47bf-83ac-ef41a6263795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_57eda4ab-548f-4df0-af40-a45435d5e18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:to="loc_us-gaap_PrepaidRoyalties_57eda4ab-548f-4df0-af40-a45435d5e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_7d49963c-1bba-4bf1-a0e8-2edf6b97911b" xlink:href="exdx-20201231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_7d49963c-1bba-4bf1-a0e8-2edf6b97911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_500e5180-2e4b-430d-bd8c-30ff8fec5308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_500e5180-2e4b-430d-bd8c-30ff8fec5308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5742ad21-2662-4e4d-b58e-15fb4a9b5d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_71805c41-6ee0-47eb-9159-616fb9d7f8f7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5742ad21-2662-4e4d-b58e-15fb4a9b5d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_8f7fdc77-a089-469a-9390-465ba83cba98" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_8f7fdc77-a089-469a-9390-465ba83cba98" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77b1bab8-45d8-448f-a347-8153f75b5d50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3202b152-fda3-4dd4-a285-f25ed81facdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3202b152-fda3-4dd4-a285-f25ed81facdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_3d4bb0b3-33d5-4e79-b8f4-046536d2046e" xlink:href="exdx-20201231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_exdx_LaboratoryEquipmentMember_3d4bb0b3-33d5-4e79-b8f4-046536d2046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_32a33286-871b-4fc5-b6b8-f547e4cb1451" xlink:href="exdx-20201231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_32a33286-871b-4fc5-b6b8-f547e4cb1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a9fd2519-88e8-4db4-8548-44934de00f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a9fd2519-88e8-4db4-8548-44934de00f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_77539844-8191-47e2-9b41-ca5aea81a813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0b3ed0f-b333-4ee5-8e47-f7fb65a9d68f" xlink:to="loc_us-gaap_ConstructionInProgressMember_77539844-8191-47e2-9b41-ca5aea81a813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820051eb-fb41-483b-afc8-c74f5f0a925e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bf24137-c0de-4309-873e-d6a92563261a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bf24137-c0de-4309-873e-d6a92563261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a93f5e0-a30a-4817-8728-aff9cd038463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a93f5e0-a30a-4817-8728-aff9cd038463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffa061b2-c830-45df-98f1-efd03a5512ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bcff504e-0d62-4f02-bf31-82da7edb57c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ffa061b2-c830-45df-98f1-efd03a5512ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_af5719d5-4498-4a33-83cf-0bc907a50c20" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_af5719d5-4498-4a33-83cf-0bc907a50c20" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56b4ebf5-198d-4402-a186-95c748d32fa8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_88c401fa-0bac-4fc3-84b8-4f086b11d32d" xlink:href="exdx-20201231.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d8c2598-d49c-4dd0-9597-bce8123fcd78" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_88c401fa-0bac-4fc3-84b8-4f086b11d32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00437e25-fb3d-4675-bcf6-d2db46ea54d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1540d262-9d39-4d52-81dc-8b6aa7195300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1540d262-9d39-4d52-81dc-8b6aa7195300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_770c1a7b-0b26-464a-bf77-1fb949fea57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_264593d8-2ba8-485e-9008-f829b67e1ce1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_770c1a7b-0b26-464a-bf77-1fb949fea57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:href="exdx-20201231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_58043a7e-45bb-4cc0-87f9-4c643574bddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_AccruedSalariesCurrent_58043a7e-45bb-4cc0-87f9-4c643574bddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_3d94791f-82b0-4826-ab1d-ceb84241428f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_InterestPayableCurrent_3d94791f-82b0-4826-ab1d-ceb84241428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_ea740811-6414-40ec-b7c3-7e3ed0b025a2" xlink:href="exdx-20201231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_ea740811-6414-40ec-b7c3-7e3ed0b025a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_9c00f378-0d87-4ff9-9698-35efe370b9a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_9c00f378-0d87-4ff9-9698-35efe370b9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_b9e7b92b-d118-4402-a664-791f3ea8f439" xlink:href="exdx-20201231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_b9e7b92b-d118-4402-a664-791f3ea8f439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_7a6fa9c0-777c-440c-af6a-62d2d0deb654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_7a6fa9c0-777c-440c-af6a-62d2d0deb654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4aa6edc4-9696-4a9d-bdb8-b64c164fdb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4aa6edc4-9696-4a9d-bdb8-b64c164fdb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b0f7aac5-9adc-4b17-a7e5-e515ea6e49b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a806c614-bca2-4997-98f1-a7767507f241" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b0f7aac5-9adc-4b17-a7e5-e515ea6e49b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20201231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bcf4379c-db29-4e9d-a01e-0ef5daef7992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_12ab8a0d-cd33-451e-8db1-931fbd302eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bcf4379c-db29-4e9d-a01e-0ef5daef7992" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_12ab8a0d-cd33-451e-8db1-931fbd302eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1cfa9f61-be95-4bdf-8f45-950df0a8452d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_de2e15dc-d5c4-4119-a18d-fdbeb8c9121d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1cfa9f61-be95-4bdf-8f45-950df0a8452d" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_de2e15dc-d5c4-4119-a18d-fdbeb8c9121d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c13303a5-b67d-49c5-8af6-a7af43f2b4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c13303a5-b67d-49c5-8af6-a7af43f2b4a0" xlink:to="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea90ece5-ae17-4174-98db-306f51357d1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_c6d1feb0-1668-45c5-a7c9-caacde32fbf3" xlink:href="exdx-20201231.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa8023a2-b19c-477d-9c29-94fffbf16eda" xlink:to="loc_exdx_Term2017Member_c6d1feb0-1668-45c5-a7c9-caacde32fbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b69dd1f-b9ee-4dda-8d08-50d5f2cdca2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0b784f5b-9ed1-4240-9a93-919cd1c1e911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:to="loc_us-gaap_LoansPayableMember_0b784f5b-9ed1-4240-9a93-919cd1c1e911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_aa150c68-c73c-43d5-954c-6a0629ae689d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0db513f4-4ce9-4546-8781-25690f9a9d88" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_aa150c68-c73c-43d5-954c-6a0629ae689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6e5834f-1f44-45c0-a3dc-46fd49382650" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_318edea6-25de-4a3b-80a8-f47677a93d45" xlink:href="exdx-20201231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_318edea6-25de-4a3b-80a8-f47677a93d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_c2b3c699-3740-4cf5-9727-493a7d7e99f2" xlink:href="exdx-20201231.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0357bf4-3098-4f26-9e18-1521f100bf02" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_c2b3c699-3740-4cf5-9727-493a7d7e99f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7a357ae-661e-450f-a709-5dd1a5dfd6d3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2cb90fc0-b014-4e39-a027-2b7a7ccf775a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2cb90fc0-b014-4e39-a027-2b7a7ccf775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5a947055-0efa-41fc-aa09-5ae972b66f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5a947055-0efa-41fc-aa09-5ae972b66f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3e2b978b-573e-4309-97be-ad1a324f99f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3e2b978b-573e-4309-97be-ad1a324f99f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_2efecab8-64e0-4e92-84da-de5d3b831541" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_2efecab8-64e0-4e92-84da-de5d3b831541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_09b68968-2683-4626-84af-a96e5beb49f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_09b68968-2683-4626-84af-a96e5beb49f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_711756bb-748d-4012-a547-efcddb33639d" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments_711756bb-748d-4012-a547-efcddb33639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c89459a2-4562-4f52-8b06-bc9bd7f28aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c89459a2-4562-4f52-8b06-bc9bd7f28aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_d0e7b38c-3e71-4df9-a6dc-3b826253d5ce" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_d0e7b38c-3e71-4df9-a6dc-3b826253d5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c4f801d1-d93e-4319-a549-5c814274ab8e" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c4f801d1-d93e-4319-a549-5c814274ab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c7e12dda-e195-4e45-9d01-93e71d27f6b0" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c7e12dda-e195-4e45-9d01-93e71d27f6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_9ebe4359-c2a3-4f64-bda4-4d7714f3a494" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_9ebe4359-c2a3-4f64-bda4-4d7714f3a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_2c33f069-e24f-4b9d-8b3f-55fcf80ff69f" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_2c33f069-e24f-4b9d-8b3f-55fcf80ff69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_84e11815-0676-4c8b-a04b-0f06e39e9429" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_84e11815-0676-4c8b-a04b-0f06e39e9429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_7f31a04b-ee30-4426-8c98-26b19ba902b8" xlink:href="exdx-20201231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3e96b3dc-b5e7-4dd2-90b1-652f2d5241ba" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_7f31a04b-ee30-4426-8c98-26b19ba902b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_114743a2-3bc4-49a9-b5c5-116e757dcefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_114743a2-3bc4-49a9-b5c5-116e757dcefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_67f056c5-fb3a-4f0a-b40d-c188e6226d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_67f056c5-fb3a-4f0a-b40d-c188e6226d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5627f22f-5da0-403e-9a9d-7f014bb8ad73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5627f22f-5da0-403e-9a9d-7f014bb8ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_791f97fc-70c6-449e-8b6d-16d38a295575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_791f97fc-70c6-449e-8b6d-16d38a295575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_e1c1bb3f-619f-4d93-83dd-c3ba1de38c50" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_e1c1bb3f-619f-4d93-83dd-c3ba1de38c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5915033c-cd01-4083-98bc-54d2fc50dc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5915033c-cd01-4083-98bc-54d2fc50dc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_35834890-2308-48de-bff5-1d57084b4d2e" xlink:href="exdx-20201231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_35834890-2308-48de-bff5-1d57084b4d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_70291d20-4cc1-455e-8f72-cefd246a23a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_903afa64-4262-4225-a1c0-1239a585a2f5" xlink:to="loc_us-gaap_LongTermDebt_70291d20-4cc1-455e-8f72-cefd246a23a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_67e463f7-a794-4cf0-93d5-44cba0f662e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24e3f373-b493-4b3c-b578-69392106fb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_67e463f7-a794-4cf0-93d5-44cba0f662e4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24e3f373-b493-4b3c-b578-69392106fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6dc49bd1-e71f-4b4a-8e0a-ff5a5f89b212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_8274bb80-b8e2-4d16-b817-6b9975793630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6dc49bd1-e71f-4b4a-8e0a-ff5a5f89b212" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_8274bb80-b8e2-4d16-b817-6b9975793630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_415982aa-0026-4fbe-926d-e07d94320e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6dc49bd1-e71f-4b4a-8e0a-ff5a5f89b212" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_415982aa-0026-4fbe-926d-e07d94320e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec304d59-b5ae-4077-83e1-d036e76c44ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec304d59-b5ae-4077-83e1-d036e76c44ce" xlink:to="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:href="exdx-20201231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_2c45f60a-3229-464b-8b26-fffce15b8936" xlink:to="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_38fabc7c-6cd2-403c-800c-1d91e98e0f2f" xlink:href="exdx-20201231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:to="loc_exdx_OfficeAndLaboratoryMember_38fabc7c-6cd2-403c-800c-1d91e98e0f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_669601e5-aad1-44c6-a62d-bd5dc7c90cb0" xlink:href="exdx-20201231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_91b92368-9ddb-46ce-be8a-634b552c5456" xlink:to="loc_exdx_OfficeMember_669601e5-aad1-44c6-a62d-bd5dc7c90cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_39b26928-a15e-450c-8bff-123b6e1c83fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_a60afdab-c014-4971-a93a-22deb3f80af3" xlink:href="exdx-20201231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ae7ba608-b847-4ab6-9e11-0faa7c56f682" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_a60afdab-c014-4971-a93a-22deb3f80af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dc3875e7-71ac-41f1-8d82-d221fbc8b9b4" xlink:to="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8cb1e52-6d1e-408d-b038-68b51f734f77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:to="loc_srt_MinimumMember_c8cb1e52-6d1e-408d-b038-68b51f734f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f63f130-6fb3-470a-96fa-dca10224e792" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab578eda-98af-4455-bd4f-abfac27af29a" xlink:to="loc_srt_MaximumMember_1f63f130-6fb3-470a-96fa-dca10224e792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3e3dd523-8841-4091-972c-a416f8fdd4fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_95f687d0-c8be-40ac-947a-2a62141ed6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_adf39d0e-e888-4f19-8959-a14c8f9142ed" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_95f687d0-c8be-40ac-947a-2a62141ed6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9273e30b-67d9-4066-b88b-1268fafd0ffb" xlink:to="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_2d4bd42a-7abf-4b81-ba73-159c17abca48" xlink:href="exdx-20201231.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_2d4bd42a-7abf-4b81-ba73-159c17abca48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_fb2a54da-a579-4863-b269-9c2f3d1fb739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_LeaseAndRentalExpense_fb2a54da-a579-4863-b269-9c2f3d1fb739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_46e9e740-9780-4ecf-9d2b-a948caaee08c" xlink:href="exdx-20201231.xsd#exdx_MilestoneObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_MilestoneObligation_46e9e740-9780-4ecf-9d2b-a948caaee08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_15a2faec-318d-46a3-a0dd-ede56b01ea8d" xlink:href="exdx-20201231.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_15a2faec-318d-46a3-a0dd-ede56b01ea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_5f4947d0-415c-4f9c-a804-36c55db3eed2" xlink:href="exdx-20201231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_5f4947d0-415c-4f9c-a804-36c55db3eed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_99164b63-c286-486c-8d17-8bc38cc10e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_99164b63-c286-486c-8d17-8bc38cc10e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_b48c9617-f5c6-4691-b785-2c9f997a705b" xlink:href="exdx-20201231.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_AdvancePayment_b48c9617-f5c6-4691-b785-2c9f997a705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0e3adfe0-1b28-4221-bcd5-a597066793e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0e3adfe0-1b28-4221-bcd5-a597066793e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_6fcadec5-b9ca-4eb3-ac04-b09f89315f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_6fcadec5-b9ca-4eb3-ac04-b09f89315f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_a1395952-e7d1-4bbe-b9f2-8a7369160d5c" xlink:href="exdx-20201231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aa0841d5-d7e9-44e6-96d0-8a7b9d06f064" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_a1395952-e7d1-4bbe-b9f2-8a7369160d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9dcd14e-fd4f-4528-b20f-ded0af283118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9dcd14e-fd4f-4528-b20f-ded0af283118" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_57ad5847-9bf8-4ca8-9036-24af4c08d311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_57ad5847-9bf8-4ca8-9036-24af4c08d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2f900b18-8878-4f3b-9cbe-b3187c079b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2f900b18-8878-4f3b-9cbe-b3187c079b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_368d6a6d-3ae7-4b4c-999c-e9007b8c032a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_368d6a6d-3ae7-4b4c-999c-e9007b8c032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_6afa38f7-fb10-4cfd-89ca-44169d85c9b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_6afa38f7-fb10-4cfd-89ca-44169d85c9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_3f168e7d-1e94-448e-8889-cdac0fc6ee6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_3f168e7d-1e94-448e-8889-cdac0fc6ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_fdad819f-e5aa-44b0-8c3f-6ef5c0ca6457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_fdad819f-e5aa-44b0-8c3f-6ef5c0ca6457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_effcc4bc-392c-4e60-bc6f-f08be7860b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_effcc4bc-392c-4e60-bc6f-f08be7860b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_eefb3fec-8ee6-40d9-ac82-20baa00eb0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_eefb3fec-8ee6-40d9-ac82-20baa00eb0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_10a0f8af-a605-47b8-bb04-49e8f584f62a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_10a0f8af-a605-47b8-bb04-49e8f584f62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_2b6d2346-6353-48a8-8f51-ec87e17a2277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_2b6d2346-6353-48a8-8f51-ec87e17a2277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_c74ef86c-720e-48b5-bbc4-8c0e85fb2aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_549af103-8c2c-4cea-86b3-a11a9066afe4" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_c74ef86c-720e-48b5-bbc4-8c0e85fb2aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9dcd14e-fd4f-4528-b20f-ded0af283118" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_dbac19f5-f6ba-4402-8f82-769fffb20163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_dbac19f5-f6ba-4402-8f82-769fffb20163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_383d1c7e-5a20-4b4d-9b02-9247728d4972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_383d1c7e-5a20-4b4d-9b02-9247728d4972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_012cd7d4-7474-412a-90bf-b084c932b7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_012cd7d4-7474-412a-90bf-b084c932b7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_82db3e84-244f-4800-82d3-fc8d932ff061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_82db3e84-244f-4800-82d3-fc8d932ff061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_b597b48d-20c9-484e-b8af-6c631631d7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_b597b48d-20c9-484e-b8af-6c631631d7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_27cb2929-5f26-42c1-8d38-5bc322f1b872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_27cb2929-5f26-42c1-8d38-5bc322f1b872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_511a3cd8-77c1-4d13-a9cb-6bca41eeace5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_7a98fbe3-21dd-41eb-a39b-30b450641420" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_511a3cd8-77c1-4d13-a9cb-6bca41eeace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1" xlink:type="simple" xlink:href="exdx-20201231.xsd#CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c3876779-3cd1-4c07-b0c3-9586858b4b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_73c1ac8a-7011-44ff-9aeb-6353003a8e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c3876779-3cd1-4c07-b0c3-9586858b4b83" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_73c1ac8a-7011-44ff-9aeb-6353003a8e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_080818a6-13bd-43a6-af5b-3e14b925f0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e236f92c-434f-4d1c-ae22-af1144550996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_080818a6-13bd-43a6-af5b-3e14b925f0e3" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e236f92c-434f-4d1c-ae22-af1144550996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a947575e-9648-4788-825c-c7ffabb327fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a947575e-9648-4788-825c-c7ffabb327fd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6e883ad4-1a71-473b-a984-47806ccfd3ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_088857f0-1607-498c-b88f-9e8cc9d22574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_73a95e8a-0aae-49b3-8b27-dd8e9f7ab714" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_088857f0-1607-498c-b88f-9e8cc9d22574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fdb7f6a-28e7-4bf3-a731-ade36af6a920" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_74241265-c912-4575-9a11-e0b940318893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_74241265-c912-4575-9a11-e0b940318893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8e97d3d6-e858-4e9a-86d2-88162e9fec66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8e97d3d6-e858-4e9a-86d2-88162e9fec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16c27716-e735-4588-bcc3-fb171e4ad19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cecd3395-372a-4b73-a619-cb91c86810c1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16c27716-e735-4588-bcc3-fb171e4ad19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc90d804-4706-4094-8158-ba39e928fafc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_36673e76-ace2-4d95-8a29-272a65e1dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2a6abad1-fc66-4336-963d-f18870ce6294" xlink:to="loc_us-gaap_MoneyMarketFundsMember_36673e76-ace2-4d95-8a29-272a65e1dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f198014c-d7cf-4dc9-b674-500e022bc7c2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_27127c83-ce23-4d0b-96d8-8b1c876e7c74" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4db933f9-14df-42af-b8a7-850e21df65f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7a5120db-80bf-48e5-97d0-c60ac5404e25" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4db933f9-14df-42af-b8a7-850e21df65f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_b5743b78-9b47-47cb-92b9-fd33faaaab19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityTextBlock_d548442b-93e1-4861-97e6-4a83b55ad96d" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_b5743b78-9b47-47cb-92b9-fd33faaaab19" xlink:to="loc_exdx_TemporaryEquityTextBlock_d548442b-93e1-4861-97e6-4a83b55ad96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_f7739b2d-e6d7-46a9-8bd1-00511a2e6c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_f7739b2d-e6d7-46a9-8bd1-00511a2e6c7f" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d53d70dc-55f2-4fa8-9833-d35df7a9a1e1" xlink:to="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_bd22e94f-6357-4047-8450-d6be5eaf83ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_bd22e94f-6357-4047-8450-d6be5eaf83ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_83d7b86d-560b-4041-99aa-8b0824cee65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_83d7b86d-560b-4041-99aa-8b0824cee65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e5b6081f-aba3-4fcd-9ffb-f1645c231e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9559bd06-6854-4899-af01-9bef2755d123" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_e5b6081f-aba3-4fcd-9ffb-f1645c231e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96b04c4a-db0b-4199-884a-30a618a729b1" xlink:to="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b538a261-af63-4fef-9737-6bd2e995e22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_59af684e-db57-4612-8f0d-da198c3bf544" xlink:to="loc_us-gaap_CommonStockMember_b538a261-af63-4fef-9737-6bd2e995e22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_31a8d1a1-8d78-456e-9b0a-d8553321f465" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5f271ba0-0e28-4682-abad-91686f6a5dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43edf006-7856-4154-94c5-e82790b58c70" xlink:to="loc_us-gaap_IPOMember_5f271ba0-0e28-4682-abad-91686f6a5dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0bb5fb90-7193-4f18-941f-718100cc6642" xlink:to="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_ad1c05de-e01a-4f60-972c-bae0e4df511a" xlink:href="exdx-20201231.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_ad1c05de-e01a-4f60-972c-bae0e4df511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_2738693a-8238-468b-a901-8d02f0fd24e7" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_2738693a-8238-468b-a901-8d02f0fd24e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_37da8057-672b-4379-a684-e8f4f54ca5e4" xlink:href="exdx-20201231.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_37da8057-672b-4379-a684-e8f4f54ca5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce976855-421e-425c-a70c-18e6e2ff96a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce976855-421e-425c-a70c-18e6e2ff96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_40f4b2f7-64ea-452c-81a7-247c5cffb5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c50334de-0bda-4063-8e65-369eca6d72e8" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_40f4b2f7-64ea-452c-81a7-247c5cffb5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_12877a4b-f40a-45db-b960-2737ce3b08bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fb5bb331-5eeb-4232-b8cb-04cdfac9dfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12877a4b-f40a-45db-b960-2737ce3b08bc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fb5bb331-5eeb-4232-b8cb-04cdfac9dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c9af0f8d-b542-4c2b-9ceb-96e6de8fab18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_989fd316-1740-4053-bdcd-1f3032430e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c9af0f8d-b542-4c2b-9ceb-96e6de8fab18" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_989fd316-1740-4053-bdcd-1f3032430e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4ee69a22-796e-4888-abae-5726bd1d0c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4ee69a22-796e-4888-abae-5726bd1d0c68" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5d2ae28-9aea-43ec-85c0-ef0559758a53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5d74ed0f-c29a-4919-8d32-adbd58a4c22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:to="loc_us-gaap_IPOMember_5d74ed0f-c29a-4919-8d32-adbd58a4c22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_03679b6e-51ba-4514-8e09-c7f1365c3922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2b1307b-fa5d-4e40-a404-809f22569b4c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_03679b6e-51ba-4514-8e09-c7f1365c3922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c934d30d-0ed1-479e-bc96-5dbb1042967f" xlink:to="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_56493418-d0c4-4bde-b778-43d6d46068fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e4ee421-08a0-4ff7-ac88-3026e6334cb1" xlink:to="loc_us-gaap_CommonStockMember_56493418-d0c4-4bde-b778-43d6d46068fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32085552-c7fa-4855-8527-83c60a124961" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_01ab2039-087d-4d33-98d8-08fbe8c6bd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_01ab2039-087d-4d33-98d8-08fbe8c6bd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_baefa5ad-7122-4b6d-811f-61dbd47fd48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_baefa5ad-7122-4b6d-811f-61dbd47fd48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_94b3d699-f934-4416-a944-b4f2137a38f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_94b3d699-f934-4416-a944-b4f2137a38f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac3d2c01-d882-4a46-8cd8-b3a4fbe136e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac3d2c01-d882-4a46-8cd8-b3a4fbe136e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_e871208f-2d05-4414-a363-acafa4fe357c" xlink:href="exdx-20201231.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_exdx_StockIssuanceCosts_e871208f-2d05-4414-a363-acafa4fe357c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e0588f73-43aa-4a0f-a0e8-0bc2a167b83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_85b32da4-8f65-4368-a4ee-15bcf79b03e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e0588f73-43aa-4a0f-a0e8-0bc2a167b83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7ba604f1-b9eb-4eac-8e6f-876a606bd239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7ba604f1-b9eb-4eac-8e6f-876a606bd239" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d561155c-5157-472c-ab72-36e9e249482e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_aae6da14-bb02-4893-902a-1f30a08322f4" xlink:href="exdx-20201231.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationJan192026Member_aae6da14-bb02-4893-902a-1f30a08322f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_ebeaf357-bf95-45ab-96d6-7914733fc6e5" xlink:href="exdx-20201231.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationMar312026Member_ebeaf357-bf95-45ab-96d6-7914733fc6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_9d028396-d868-439b-a698-e7f15e35bb0b" xlink:href="exdx-20201231.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationApr12026Member_9d028396-d868-439b-a698-e7f15e35bb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_d49efff7-170c-4c11-8b0f-6545f76fd872" xlink:href="exdx-20201231.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationSep72024Member_d49efff7-170c-4c11-8b0f-6545f76fd872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_ea5f26d3-8cb4-4a40-9b79-2b66670021d7" xlink:href="exdx-20201231.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b540dbc-ade2-47cc-9971-25aa86ed81ff" xlink:to="loc_exdx_ExpirationDec72025Member_ea5f26d3-8cb4-4a40-9b79-2b66670021d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fd53b4d-4e5c-47e3-a6b8-8234c78d1ca8" xlink:to="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6cbf318c-abf8-4495-9085-b05426589464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6cbf318c-abf8-4495-9085-b05426589464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_898a9b8a-5ed3-4ae9-b1a9-26213d57579c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_898a9b8a-5ed3-4ae9-b1a9-26213d57579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_49e5db80-283e-4c98-a7a0-8e466f39a5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_52846041-6de9-4f0d-b7ed-687587717063" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_49e5db80-283e-4c98-a7a0-8e466f39a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_428f5c1c-1ecc-4418-b82d-9cac9bf7722e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c677e4bf-d822-4a89-9b18-b158e4129d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_428f5c1c-1ecc-4418-b82d-9cac9bf7722e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c677e4bf-d822-4a89-9b18-b158e4129d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c321222e-151c-4a96-97a4-5a9a5be647dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b6ad295d-0f72-45d7-8ad5-bdfea715a7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c321222e-151c-4a96-97a4-5a9a5be647dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b6ad295d-0f72-45d7-8ad5-bdfea715a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4373820f-1a40-4092-ad97-ee70acf7a436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c321222e-151c-4a96-97a4-5a9a5be647dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4373820f-1a40-4092-ad97-ee70acf7a436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_571b06bf-e5f1-4808-a334-22abe018c023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c321222e-151c-4a96-97a4-5a9a5be647dd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_571b06bf-e5f1-4808-a334-22abe018c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_fbcbb16c-f4bc-4b2f-891f-d9ea25412cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c321222e-151c-4a96-97a4-5a9a5be647dd" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_fbcbb16c-f4bc-4b2f-891f-d9ea25412cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_445df1a1-8106-432c-a02f-591d0872c0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_445df1a1-8106-432c-a02f-591d0872c0a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_90497a34-c955-4c30-80e8-639f79adef56" xlink:to="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_da5079a7-4038-4d6d-9fab-c79238b453b4" xlink:href="exdx-20201231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3877fc58-7536-494f-b4bf-541c4c5842d3" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_da5079a7-4038-4d6d-9fab-c79238b453b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_24bd2fe6-c0d9-4025-b17d-11d3455a3f52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb5e3c5b-9f7f-45a6-982a-94a5c8157b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb5e3c5b-9f7f-45a6-982a-94a5c8157b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_43334c0b-39bb-4f46-87a8-90f2ee31a110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f275c6a-a846-4bda-b70a-b8218ba3e4c2" xlink:to="loc_us-gaap_EmployeeStockMember_43334c0b-39bb-4f46-87a8-90f2ee31a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a6358813-c88d-470c-a223-8d842a451ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0ee7f117-3d22-4026-a5a2-91741b21d592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_76578182-1983-42f7-a259-86b2ebbd71b0" xlink:to="loc_us-gaap_SubsequentEventMember_0ee7f117-3d22-4026-a5a2-91741b21d592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9019b0b-b9ed-4f57-9151-0495f769b61a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf2e9d86-06ef-49aa-8bab-70cd02bf9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf2e9d86-06ef-49aa-8bab-70cd02bf9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_97b4942a-49e7-4a37-a6e1-39ac6a3baddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_97b4942a-49e7-4a37-a6e1-39ac6a3baddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30712351-75f2-424b-bb64-76c2bd9281da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30712351-75f2-424b-bb64-76c2bd9281da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_61e514a1-c49b-43d4-bcd6-a8bfcacd4852" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_61e514a1-c49b-43d4-bcd6-a8bfcacd4852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4d741b69-9bab-4f6b-a23f-716fccc08501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4d741b69-9bab-4f6b-a23f-716fccc08501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_32088904-044f-42e3-a811-64b7fb5430e1" xlink:href="exdx-20201231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_32088904-044f-42e3-a811-64b7fb5430e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d20bf71-3719-4a8b-a911-db0629644510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d20bf71-3719-4a8b-a911-db0629644510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aed4c8c7-420f-4d59-805b-9c5a4d377c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aed4c8c7-420f-4d59-805b-9c5a4d377c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6c27ea4-de70-4a32-941b-338196ea7bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6c27ea4-de70-4a32-941b-338196ea7bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_9c51160c-364f-4e32-999d-17aef22869b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_9c51160c-364f-4e32-999d-17aef22869b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dcacaecf-344a-4cdb-bb04-020ef33c344e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dcacaecf-344a-4cdb-bb04-020ef33c344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_406d5524-c385-41df-8ad1-7a1289766154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_efc774f3-d049-41ce-a8e5-8d75dfd2a7f3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_406d5524-c385-41df-8ad1-7a1289766154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3047e41-e729-4564-83aa-c1b1c7fab197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3047e41-e729-4564-83aa-c1b1c7fab197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_56c629dd-6325-471a-9555-bd7311a4cbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_56c629dd-6325-471a-9555-bd7311a4cbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ea16dad-7226-4f67-87b7-fada94c2b214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ea16dad-7226-4f67-87b7-fada94c2b214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3ba8fa0-5dfa-4fb1-a35b-381b376b193b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3ba8fa0-5dfa-4fb1-a35b-381b376b193b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_31b5237c-d31c-4c46-9676-4875746a7d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_31b5237c-d31c-4c46-9676-4875746a7d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_540aac25-16b4-485a-9e38-9910c3724ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_81386f53-1216-4fce-a30a-6e2898d258cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_540aac25-16b4-485a-9e38-9910c3724ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4829d5d-8201-4dc9-8e9a-bad3b2082d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4829d5d-8201-4dc9-8e9a-bad3b2082d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3f2db6c6-b579-4099-8452-e6a2fea9c44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3f2db6c6-b579-4099-8452-e6a2fea9c44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_041069d7-d72b-4d12-ba41-145e0e513133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_041069d7-d72b-4d12-ba41-145e0e513133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_625347c8-e680-4eeb-8777-3bd85069a0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_625347c8-e680-4eeb-8777-3bd85069a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a7b90da2-ab69-40a0-9454-8fc91a181183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a7b90da2-ab69-40a0-9454-8fc91a181183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c819e826-18d3-43df-be78-e53f20185814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3f9ba3c-a043-415c-88f3-90ebf14260e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c819e826-18d3-43df-be78-e53f20185814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f22a1f1e-e824-46b6-99f0-e31646eb1cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f22a1f1e-e824-46b6-99f0-e31646eb1cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21c2432a-273a-4f33-aa16-a0fd2ca0517c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21c2432a-273a-4f33-aa16-a0fd2ca0517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_b3c1f699-1ea3-46e5-9707-e3ab2b51d84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_b3c1f699-1ea3-46e5-9707-e3ab2b51d84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_711eec23-978f-407d-abcf-b640fd4237e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_711eec23-978f-407d-abcf-b640fd4237e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f1627f6-c7d3-4be2-993c-905bdc0d1e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3f1627f6-c7d3-4be2-993c-905bdc0d1e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8c7a6c51-dfb1-450a-ba56-f815d7170504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c223a062-60db-484a-91b8-c70088a43452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8c7a6c51-dfb1-450a-ba56-f815d7170504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_77df48cc-d2cc-4755-b686-4e771f0d18a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_77df48cc-d2cc-4755-b686-4e771f0d18a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2cd5a10e-0820-48de-98fe-5dc72db86c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2cd5a10e-0820-48de-98fe-5dc72db86c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fb9a5262-d233-491e-8e11-25ce2d9c7132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fb9a5262-d233-491e-8e11-25ce2d9c7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1ed5895a-af84-4fa6-8a72-844f032231bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2477ba57-f51d-4cf7-85ef-66ea76a1884d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1ed5895a-af84-4fa6-8a72-844f032231bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71004085-b399-4888-aaf0-7044d5a859e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71004085-b399-4888-aaf0-7044d5a859e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:to="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_499fb442-4d8f-4ecb-a76a-b16396e28db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2cfc8080-87e7-402b-9b6c-f3d5d8cce8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2cfc8080-87e7-402b-9b6c-f3d5d8cce8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_37e47f9d-b5de-4c0c-9d93-22083c4b498d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b5ef927-2122-448e-a356-a92d5c9e637e" xlink:to="loc_us-gaap_EmployeeStockMember_37e47f9d-b5de-4c0c-9d93-22083c4b498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:to="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_08e87a71-f8b4-4468-b6d5-3e29232fb681" xlink:to="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2ad8728-a872-4823-95f8-897ecacaeda4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:to="loc_srt_MinimumMember_b2ad8728-a872-4823-95f8-897ecacaeda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e48a4cef-0217-4228-9a08-3fed5f3aed4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a10442fa-9c6a-4712-b2fb-0cba46ad555c" xlink:to="loc_srt_MaximumMember_e48a4cef-0217-4228-9a08-3fed5f3aed4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cdb3126-1f5f-4487-9220-e47a5799b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c75c5f68-59ce-48a3-9f71-90a5c83fda1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c75c5f68-59ce-48a3-9f71-90a5c83fda1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9daa8222-e0d8-4286-a4ff-a86f4c95cfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9daa8222-e0d8-4286-a4ff-a86f4c95cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0402291c-a9e7-4ddc-b38b-585d727a716e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0402291c-a9e7-4ddc-b38b-585d727a716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e544dee7-cab4-4588-a2cd-a37bca83842d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e544dee7-cab4-4588-a2cd-a37bca83842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eb003031-14aa-4522-b5de-417746a473e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eb003031-14aa-4522-b5de-417746a473e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5a4053d-28cb-4fc6-bdef-c5e18b09c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c12fed1c-038e-4643-972a-9265b22a9bff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5a4053d-28cb-4fc6-bdef-c5e18b09c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_548fce5a-aa47-4610-952e-8edf211df566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_548fce5a-aa47-4610-952e-8edf211df566" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b8f0e68-5c0f-4442-8ad0-3b744d07b60e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c3a38a3c-cb6e-4475-96a7-104e8bffb80e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_CostOfSalesMember_c3a38a3c-cb6e-4475-96a7-104e8bffb80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17940aa7-c423-4470-96c1-9e79ebf30192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17940aa7-c423-4470-96c1-9e79ebf30192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_34a7efe5-edc2-4952-803f-9f5ff1c6b6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d71d5ec1-6113-4fc7-9705-ca5bb82ad30d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_34a7efe5-edc2-4952-803f-9f5ff1c6b6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36dee166-678d-4807-8a3e-561e0e3856c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b33bfe9f-44d0-45c8-a227-8900234e9d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91dd2f4-ed3d-4f63-8e75-c83742c3826c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b33bfe9f-44d0-45c8-a227-8900234e9d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2305b820-aadb-44e0-b7b8-35a7e64c22dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2305b820-aadb-44e0-b7b8-35a7e64c22dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:to="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_03f020c3-3766-4d9e-b90e-3af5e281caa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f08cc3b4-5da7-4f3e-a5ea-8d008fb55ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_us-gaap_WarrantMember_f08cc3b4-5da7-4f3e-a5ea-8d008fb55ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_7951dc3b-7f82-4698-ab4b-88ae9549241a" xlink:href="exdx-20201231.xsd#exdx_CommonStockOptionGrantsIssuedAndOutstandingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_exdx_CommonStockOptionGrantsIssuedAndOutstandingMember_7951dc3b-7f82-4698-ab4b-88ae9549241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_c83202e0-5196-4db0-b581-3f3d10c0db81" xlink:href="exdx-20201231.xsd#exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember_c83202e0-5196-4db0-b581-3f3d10c0db81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_edefea1c-d087-417f-b13c-485a720378c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fc423a9-cd77-4d89-bc61-0dc008298f7a" xlink:to="loc_us-gaap_EmployeeStockMember_edefea1c-d087-417f-b13c-485a720378c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4deb79-f6ac-4ba4-ab8f-aaa0869ce1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_420e2efe-f6b4-4279-9745-9934f40028e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ca2767c-3087-4ee6-b93d-9cf3825c6af8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_420e2efe-f6b4-4279-9745-9934f40028e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ac3b47c-4402-4cda-8401-d0baffe2c144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_28c2ff8e-1aba-4593-91bc-07f06f5c8f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ac3b47c-4402-4cda-8401-d0baffe2c144" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_28c2ff8e-1aba-4593-91bc-07f06f5c8f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_208c32f5-9069-4f57-9087-15dd755d9441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_24ff8b83-f221-4e6d-a01b-419067464a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_208c32f5-9069-4f57-9087-15dd755d9441" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_24ff8b83-f221-4e6d-a01b-419067464a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ebd10173-1597-4a11-8b63-489ab59af912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_208c32f5-9069-4f57-9087-15dd755d9441" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ebd10173-1597-4a11-8b63-489ab59af912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_75cc03d7-f0b3-43f5-b9de-ac64d9c52ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_208c32f5-9069-4f57-9087-15dd755d9441" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_75cc03d7-f0b3-43f5-b9de-ac64d9c52ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_d6b80af9-f2bf-4ca7-b8d8-24088ce2c675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_208c32f5-9069-4f57-9087-15dd755d9441" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_d6b80af9-f2bf-4ca7-b8d8-24088ce2c675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_42894a22-30ac-4878-b04e-ea6ba14834ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8f660c2e-ee15-49a9-a883-60e9460c4dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42894a22-30ac-4878-b04e-ea6ba14834ec" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8f660c2e-ee15-49a9-a883-60e9460c4dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9836645a-d5a5-4bf0-9f24-2c2aa77a3ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8f660c2e-ee15-49a9-a883-60e9460c4dd3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9836645a-d5a5-4bf0-9f24-2c2aa77a3ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_00b3b22e-9153-45e8-8417-d8f037cba9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8f660c2e-ee15-49a9-a883-60e9460c4dd3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_00b3b22e-9153-45e8-8417-d8f037cba9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be708858-fabf-4e18-a365-841d063e151e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_8f660c2e-ee15-49a9-a883-60e9460c4dd3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be708858-fabf-4e18-a365-841d063e151e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d6ecda0-1e83-4cb8-87a8-95eef4b1e37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42894a22-30ac-4878-b04e-ea6ba14834ec" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d6ecda0-1e83-4cb8-87a8-95eef4b1e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_366bea2c-81ad-4ee4-8c58-9e2f2b020a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d6ecda0-1e83-4cb8-87a8-95eef4b1e37e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_366bea2c-81ad-4ee4-8c58-9e2f2b020a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9f10a5c6-df45-46ad-bc1f-0f0c83ab0a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d6ecda0-1e83-4cb8-87a8-95eef4b1e37e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9f10a5c6-df45-46ad-bc1f-0f0c83ab0a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_57e09797-e4e5-4efc-a4bb-dd480f44aa94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d6ecda0-1e83-4cb8-87a8-95eef4b1e37e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_57e09797-e4e5-4efc-a4bb-dd480f44aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fb8c95a9-02ee-421b-9a06-4095ab21ee26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42894a22-30ac-4878-b04e-ea6ba14834ec" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fb8c95a9-02ee-421b-9a06-4095ab21ee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0cddce23-2b38-41b7-8a7d-01d0935e28aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0cddce23-2b38-41b7-8a7d-01d0935e28aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b4295c7b-9772-4f8f-86f9-f87bc9ab648b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b4295c7b-9772-4f8f-86f9-f87bc9ab648b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_85add1ad-fd72-4a4a-bfaa-6702f2c7fde4" xlink:href="exdx-20201231.xsd#exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent_85add1ad-fd72-4a4a-bfaa-6702f2c7fde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_81183a74-cb78-421a-8272-3d0f7d49bfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_81183a74-cb78-421a-8272-3d0f7d49bfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f7699718-8150-4070-8baf-0a2e5a6424f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f7699718-8150-4070-8baf-0a2e5a6424f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_4d7af627-7ae3-4169-b93d-e5fc9a1b4b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_4d7af627-7ae3-4169-b93d-e5fc9a1b4b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a969c19a-e998-4862-bf77-4af51b15e135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32094771-ea11-491c-a80a-c5f16ddf42af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a969c19a-e998-4862-bf77-4af51b15e135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_057784b3-9b82-4e72-bb75-4e756ae5353e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_057784b3-9b82-4e72-bb75-4e756ae5353e" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7da141c3-762a-430f-97af-774301db1f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7da141c3-762a-430f-97af-774301db1f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e42e645f-16ef-43ba-ae8c-0fa2c69d9bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e42e645f-16ef-43ba-ae8c-0fa2c69d9bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_0b7f191c-7023-4d1b-8948-c7ed14302136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_0b7f191c-7023-4d1b-8948-c7ed14302136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_dfcc7e77-6bc5-49cc-8d19-d46d9e48fa27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_dfcc7e77-6bc5-49cc-8d19-d46d9e48fa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_05985bc3-90ba-48e1-9ecd-95a078dcc3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_05985bc3-90ba-48e1-9ecd-95a078dcc3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2febfc73-bb26-4891-9bfc-61fd15742449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2febfc73-bb26-4891-9bfc-61fd15742449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3d211799-afe2-4f0b-9152-07317d7a57a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3d211799-afe2-4f0b-9152-07317d7a57a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0f775e9f-6353-47fb-9efb-51d482982205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3e6d682d-bfd5-4823-8ca7-e6aef4d4e3c2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0f775e9f-6353-47fb-9efb-51d482982205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b8829641-6f7e-4025-8348-c867c323ebc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_057784b3-9b82-4e72-bb75-4e756ae5353e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b8829641-6f7e-4025-8348-c867c323ebc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_fb7060df-9fc2-40c6-8ea4-b9830cc36ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b8829641-6f7e-4025-8348-c867c323ebc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_fb7060df-9fc2-40c6-8ea4-b9830cc36ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b4fe6d9c-5a6b-490b-9edb-4018f1d5c158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b8829641-6f7e-4025-8348-c867c323ebc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b4fe6d9c-5a6b-490b-9edb-4018f1d5c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_49e16c3d-0c02-4a05-af75-0678b2dea134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b8829641-6f7e-4025-8348-c867c323ebc8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_49e16c3d-0c02-4a05-af75-0678b2dea134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9c97b9fa-5d4e-4bd1-85fc-00733508232f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_057784b3-9b82-4e72-bb75-4e756ae5353e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_9c97b9fa-5d4e-4bd1-85fc-00733508232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed9e6403-0c97-4128-9421-a9ec9c048f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:href="exdx-20201231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed9e6403-0c97-4128-9421-a9ec9c048f29" xlink:to="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2035fc75-c561-4090-af6d-00332e7fe938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2035fc75-c561-4090-af6d-00332e7fe938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount_8bcdae3d-0744-4f38-aad5-32b495eebb1c" xlink:href="exdx-20201231.xsd#exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:to="loc_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount_8bcdae3d-0744-4f38-aad5-32b495eebb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7f5c44e9-d879-4e3b-be43-345dd2b6ff99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7f5c44e9-d879-4e3b-be43-345dd2b6ff99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bf981029-a1c6-4b7f-9ab2-44f919efecd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_75e2d59a-ff31-4564-ac31-31c3afc43768" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bf981029-a1c6-4b7f-9ab2-44f919efecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_64df47e8-d294-458b-817d-365382a32694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_64df47e8-d294-458b-817d-365382a32694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_4f7f4a75-bc7e-4473-9f3c-bb0ceef048a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_4f7f4a75-bc7e-4473-9f3c-bb0ceef048a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_027731a5-8e28-4737-8f8c-cca1471260ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_027731a5-8e28-4737-8f8c-cca1471260ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_670e1c05-99e8-4b86-ba2d-3242370f5dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_670e1c05-99e8-4b86-ba2d-3242370f5dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLossCarryforwardsNotUtilized_508221bc-50fb-4489-8a23-da385675feaf" xlink:href="exdx-20201231.xsd#exdx_OperatingLossCarryforwardsNotUtilized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_exdx_OperatingLossCarryforwardsNotUtilized_508221bc-50fb-4489-8a23-da385675feaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_efd0f653-75e4-4078-9d0c-d38d8df632a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72a6fbae-7a76-45f4-a505-55363bbfb6b6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_efd0f653-75e4-4078-9d0c-d38d8df632a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20201231.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9ab73db2-df9b-4225-b20d-b5de663f1ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2f6023c6-4306-4b8d-af12-0932e03bc4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9ab73db2-df9b-4225-b20d-b5de663f1ac9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2f6023c6-4306-4b8d-af12-0932e03bc4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d5de95-1c8c-4643-ac57-dfebf6095298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2ad8593d-8d34-45f6-8901-363a5e527414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89d5de95-1c8c-4643-ac57-dfebf6095298" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2ad8593d-8d34-45f6-8901-363a5e527414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20201231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e1ffe25f-b6eb-42e9-8413-982544231190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_333e0d60-9ae5-4086-9efc-a3673caaea2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e1ffe25f-b6eb-42e9-8413-982544231190" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_333e0d60-9ae5-4086-9efc-a3673caaea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_fa8409a6-505c-4d63-98ed-29b3b3d6a38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e1ffe25f-b6eb-42e9-8413-982544231190" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_fa8409a6-505c-4d63-98ed-29b3b3d6a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_2aefeb45-1310-489b-8efe-1bb5d02834f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_f1174d57-8273-4e79-aa25-474533017075" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_2aefeb45-1310-489b-8efe-1bb5d02834f6" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_f1174d57-8273-4e79-aa25-474533017075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20201231.xsd#Covid19Details"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_50676192-44e4-49b9-9e10-30627525c8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_50676192-44e4-49b9-9e10-30627525c8b9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f0037a04-4d79-4f0c-b0d3-a8fe41fd9dfe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_62fa288f-dd5f-4740-bea3-4d441523e613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_72507634-c126-4624-b85a-32db95a55891" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_62fa288f-dd5f-4740-bea3-4d441523e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f724efe-863e-4718-bfb9-b9b3a2e0ec94" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5da51042-f91a-4e54-bb91-cd792afd0c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_us-gaap_RestructuringCharges_5da51042-f91a-4e54-bb91-cd792afd0c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c8d72f9f-2e9b-4cbd-b85f-c71658aace46" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c8d72f9f-2e9b-4cbd-b85f-c71658aace46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_3b745e6c-688b-4d57-8adb-e3064d7685c4" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan_3b745e6c-688b-4d57-8adb-e3064d7685c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_548a5def-2dde-4b17-8bcf-cabfda9db43a" xlink:href="exdx-20201231.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a0257efe-495c-483d-a3f1-f281a6a08ea8" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense_548a5def-2dde-4b17-8bcf-cabfda9db43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exdx-20201231_g1.jpg
<TEXT>
begin 644 exdx-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W3_@Z[SO^
M OT\4?\ N(K\?Z_8#_@ZZ^_\!>/X?%'_ +B:\?\ ^#7_ )_;^\6 C/\ Q:'4
M/_3KI=?K61X[^SN$(XGEYN7F=KVO[[ZV?Y'Y=G&%^O<3NA>W,TKVO;W5TT/S
M?HK^P+RX_P#GFOY4>7'_ ,\U_*O+_P"(@R_Z!_\ R;_[4]/_ %(_Z?\ _DO_
M  3^/VBO[ O+C_YYK^5'EQ_\\U_*C_B(,O\ H'_\F_\ M0_U(_Z?_P#DO_!/
MC[_@@?\ \HG/A3Q_%KO_ *?;^OL,]::N ,"G5\#BZ_UK%5*UK<\G*V]KMNU^
MI]MA:/U;#0I7ORI*^U[*UP_"CC%%>'_MH_MC^'OV4]#T72(;-;WQ9XNN)+7P
MO93QL+=3'L\RXG<8Q''YJ?NPP>1G55V@O)'SOS,\?CL)E>%EB<3-1A'=OS:2
M7FVVDEW=CV\'VI217SSXB_:[\1?!?0=#^(/QROO#\GAS4HA_:,V@V\OGV!8C
M$Q5I9#)&O.Y%&_!RNXKL?W"P\-6-OXCN_%QO+J>ZO((X56:Y8PVT*Y.R*/[J
M%F8L[XWR'8&8K%$L:C)2V,\+F6&QLG"B]59M/1I-73MV?3T/)_VVM7_:*\-_
M 7Q=X_\ @Y\3-)\'MX8T6]U/[5)H(U.ZOH[>W2<*AE=(;1BT<\3;HKD%&1U*
M-E1\[_\ !'?]MO\ :*_:;\9>-O"/QX\5WWB)+#3;.[TO4!H]K;P6)\R5)(G:
M"*/+RY1D#9X@DQC!S['_ ,%7_C=8_!C]B3Q8JW,"ZEXJ@'A[2[>ZMY9%F-T"
MLX'EXV.MJ+EU9B%#HH.XD(WB7_! OX3:SX:^$'C3XR:C]HB@\4:S;V&GV\UB
MT:R16229N(Y"<2HSW,D7RKA6MF&XDD+G+F]JDGZGYSFF*QLO%#!83"UI<BIR
ME5BI-QM9J-XWM>]ME?5,_0"BBBM3]6"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@D#K7@_[
M6?\ P4&^#O[)GBWP]\+M3\)^+_'/CGQ2LDVD?#_X;Z(-4UAK- Y>]> R1B.W
M!1EWLP+%7V!A%*8[ITZE67+!7?\ EN9U:T*,>:;LCWBBOFGQ=_P4Y^%_P8^(
M&E^"/VK_ ()?$;X/VNM^1%I/C#QOI-C-H$UU-*T<5F^H:7>7D%O.0DTI6=HU
M2*%Y'9%*EOI/[1!_ST%5.C4IV<H[[=GZ,F&(H5-I>O=?>?C]_P '7?\ K/@+
M_N^*/_<37C__  :_$_\ #?WBS_LD.H?^G72Z]@_X.N_]9\!?]WQ1_P"XFO'_
M /@U^S_PW]XL_P"R0ZA_Z==+K]&P_P#R0;])?^EGP.*_Y+)>J_\ 24?O)111
M7YH?H@4444 ?/_[??_!0_P"%G_!.GP;H/Q$^,OPW\9ZQHNO:I)IT>H>$[*SF
M6TNA&94BF%Q=0$&1%E9-@<?N)-Q7Y=WS[\(/^#D3_@GY\5_B7H_PWU#2?'?A
M"/6+P6R^(O%VE6$&FV3L#L-Q+#>RM$C-M3S"FQ"P:1D0.Z_9W[0GP,\ ?M-_
M!3Q-\!?B?IWVC0_%6CS6%[MAB:2#>OR7$/FHZ+/$X26)RK;)(T<#*BOY@OVS
M_P!DKXF?L2_M$^(?V?OB=I=XDFEWDCZ+JMU9B%-:TTR.MMJ$05Y%V2JN2H=S
M&XDB8AXW4?7<-Y7E.<0G1JMJJMK/==[>75'RN?9EFF55(U*=G3?=;/LWY]#^
MK'/%?#?_  6R_9S^+7Q<\#^!OB?\(=$U#5[[PCJ5U#<:/I-J9KN2.Z$)$\:J
M=[^6UNH9$5FVRESA(W8<_P#\$$O^"E]Y^V'\$9/V>_C#XCOK_P")7P_L%:YU
M?5KR.6;Q!I;2LL5SD!9&E@S%;S,X8L3#*TLCSN$^^-'NKS4=*M[[4='FL9IH
M5>2QN)$:2 D9V.49D+CH=K,N<X9AAC\WF&!K8'$SPU96<7OWZIKR>YIFF P/
M&/#\\).34:J6JWBTTU\TTC\,/AGHW[8W[;>NVOP3\&66I:K'%<QV^H74D+I9
MZ8K;R)+N4*1"H$4A .7<QE45WPI_<OP[H=CX8\/6/AS3O.6WT^SCMX/M%P\L
MFQ%"C<[DL[8 RS$DGDDFKR111ME(U'T6O%/V^/VLK']CS]G74OBA#:P76M74
MR:?X9L;I9#'<7TH8J7*#A$C265@2F\1% ZLZFN&,?9Q;N?/\-\,X/P^RW$XW
M%XJ55M)RG+2T8WLDKM]=KN[Z'P'_ ,%?_P!H'7OVF_VIM#_9.^$\W]H6OAW4
M(M.CM[>\18]0UZY=8RA;SO*/E!DA!D$;12/<JQVG-?IC^SA\&='_ &=_@;X7
M^#&A2PRPZ!I,5M)=0VODBZGQNFN/+W-L,LIDD(W-@N>3UK\[?^"(/[.FK_$_
MXPZ_^V-\1+FZOO[$GGM-)O;ZX:26\U:Y3-U<._F[V9(9-I\Q&5S>;@V^,XI_
M\%MO^"VY^$O]K_L;?L;^+/\ BKOWEIXX\<:;<?\ ( _ADL+.13_Q^]5EF4_Z
M+RB'[1N:U[,IRW%9KBE3HK5]>B7=^7Y]-3P^")-PQ7%>8Z3Q,K4X]53B[12_
MQ6]+).Y]4?MR?\%E/V+_ -@[Q2WPV^(OB'5O$7C&,0->>$_"-BEQ<V,4T;O'
M+<22R101 A4/EF0S[9XI!$8W#U^=GQ0_X.E/VH-7\017/P6_9N\">']+6T5;
MBS\375[K%P]QO?=(LT$EFJH5* 1F-B"K'>0P5?SW_9S_ &9?CO\ M;?$R'X0
M?LZ_#B\\3^()+.:Z:SM98H4@MX@-\TLTSI%"@)5 TCJ"\D: EW13^K7[-G_!
MK=X*A\+M?_M@?M"ZM<:S,O[O2_AN(H;6R822#)N;VWD:Y#Q^4V/(@\MMZYD&
M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
M@H5\7]1^"WP5\0^'--U33?#LVM7%QXGO+B&W:WCN+>!E5H()F+[KE" 5 P&Y
M! !^LR6&%J<'QCB7:F^;F>VG.SP<XGB:?$[EAU>::LO/E1^NW_$41^P7_P!$
M?^+W_@ATK_Y8T?\ $41^P7_T1_XO?^"'2O\ Y8U\?_\ $+]^W[_T5GX1?^%!
MJO\ \KJ/^(7[]OW_ **S\(O_  H-5_\ E=7C?V?P3_S_ '][_P CU/K_ !?_
M ,^OP7^9]@?\11'[!?\ T1_XO?\ @ATK_P"6-'_$41^P7_T1_P"+W_@ATK_Y
M8U\?_P#$+]^W[_T5GX1?^%!JO_RNH_XA?OV_?^BL_"+_ ,*#5?\ Y74?V?P3
M_P _W][_ ,@^O\7_ //K\%_F?LQ^R)^U#X!_;._9Y\/_ +2GPPTC6-/T/Q)]
MK^PVFO6\45VGV>[FM7\Q8I94&7@<C#G*E2<'('SC_P %J/\ @F%:?M[? K_A
M-?A7X;T\?%CP?"9?#]]*WE2:O9#<TNE/)G;\Q8R0F0%4F&T-$D\SUZ]_P3)_
M9>\?_L8_L1>"OV;/BEJVCWVN^&_[2^W76@W$LMI)]HU*ZND\MI8HG.$G0'*#
M#!@,C!/N5]#/>+]DM-0N+619(I6FAC7YE$@8QY=&7#A2C8&X*Q(*L58?'1Q/
M]GYFZN$EI&3Y7WC?2_JMSZR6'^O9:J>*CK**NNSMK;T>Q_)S^SO\>OB%^R_\
M;O#/Q^^%6H1V^O>%=42]L?.W^3. "LEO*$9&:&6-GBD564LDC $9S7]/'[%?
M[6_PT_;;_9U\._M ?#/5+-EU2SC37-)M;PS/HFI"-&N=/E+)&V^)FP&*()$,
M<J@I(C'\EO\ @XH_X)K7GPG^)LG[=?P<\-7DWACQA>?\7 MK'385M=!U,B*.
M.[)BPPCO&+%W="!<AB\I:ZBC'C7_  1%_P""F-W^PM^T"OP[^*'B'4&^%_CB
MX2UUBT^V1K:Z+J#O$D6KE9!\JJB^7/L="T3!V$K6T49^_P YPM'B;*8YAAE^
M\BM5U\T_-;KO\SXG*L56X?S26"Q#]R3WZ>37D]F?T222+%&TCG"KR:_&?]L'
MXS>-_P#@J/\ MK:3\*_@=.MUH<-PVF>"5OHS;(4V"6[OI0Q9@K>4[\*'\F&,
M>4) RGZ:_P""TG[<MIX(\%R?LF?#'7;:;6O$%M_Q6,UM>2+-I5D?+=+?]WA0
M]PI.Y68D0Y#1E9T<;?\ P1A_8I;X.?#'_AI?Q]INWQ+XRT]?[$5;[>MKHL@C
MEC+*HVB29@)&RSE46(?NW\U#^537M*GLUMU/GN+,56XWXBI\,X*7[BFU/$37
M9--03VO]^O\ A9U_[=/QC\,_\$IO^"96I3_".>WL]3T?1X/#W@7[0T$<LVJ7
M&4%V5\EHIYXQY]\Z&,+,8) =H<D?SS_"SX:_&']K;X^:7\-_"*:AXC\9^.->
MV?:KR26XFN+F9R\UW<28=RJCS)IIFSM19)&. 37ZH?\ !U-\6YH[/X0_ C2_
M&4/ERS:IKVN>'XY$,@9!!;V-TZXWJN'U%$.0K$2]2G'F_P#P:\_ ;3?&O[3G
MCW]H'58]/N/^$%\+V^GZ;#=68DF@O-2EDQ=0N?\ 5,L%G<PL1\Q6[(S@L#^H
M9#R9+PS4S!)<TKV^_EBO2^I]!F5&.,SJCEM+W:=-122V22N[?*R/U*_X)[?\
M$]_@K_P3M^"L?PS^&,']H:QJ'ES^+_%]U:K'=ZW=*" S $^5!'N=8;<,5B5F
M)+R/++)[X*.V*0D@Y-?G-:O6Q%:52I)RE)W;9^@T:-+#TE3IJT5HDA:***S-
MCS/]K+]D[X*_MI_!34O@1\>/#7]H:3J&);6ZMV5+O3+M0PBO+64@^5.FYL-@
MJRL\;J\;NC?S'_M+?!/XT_L?_%KQ=^R7\5M2^SWFBZQ;2ZQI^EZH9=/OI$@=
M[.\ ! ?-O>.T9=5DC2Z=66-FD2OZNL$FOQS_ .#IK]GN6'7/AC^U5I6DW31W
M-K<^%->OFN4\B%D9KNPC$?WM[^9J+%AE<1*#M.-WV7!F92P^/^J3?N3VOTDM
M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
M<>!_B=XB3P^EAKEK'M\'6(MUAU:3]\Q:V)=V:[.(B6X(&!7M?[/'B?QAHG[,
M'A_Q[^T3\:O"7B/4O^$=_M;Q!XX\/>7:Z)+ ZM<>?!(6V&UCA90+@E1(D?FE
M8]Y1=*V'K4).,U9JRMKU1G1Q5*M%2B[IIOIT=M3TNBO/_A;^U7^S%\<?$$WA
M3X+?M'>!?%^J6]JUW<:;X7\766H7$5NKHC3-'!*S! TB*6(P"ZC.2,['B3XT
M?!_P=KU[X3\6_%7PWI>J:7X<E\0ZEINH:Y;PW%II$;E)-1EC=PT=JK JT[ 1
MJ006!%8RA4C*S3].II[:FUS75N]SJ*.]<7\)OVBOV?\ X]?;Q\#OCGX0\9'2
M_*_M1?"GB6UU'['YF_R_-^SR/Y>_RWV[L;MC8S@U\[_M#_\ !23X;_#G]M[X
M2?!GPQ^TW\+[;PC-)XJC^,C:CXOTU)-&FL[:%+."1Y)U-M,;R1D,1'F-LD^7
M$;E=:.%KUJCA%.Z3;NGT5_R6AG5Q="E34Y25FTE\VE^I]>?44@.3Q2\8W"OB
MWX1?$[]N7]M;XE_&'7/@Q^TWX=^&OACX??%K4O ^FZ#J'PUCUV>=].AMEFNF
MN#=V^!++([K'M8H#MW-C)*-!UDVY**5KMWMO9+1-_@.M75*459MRV2MTU>[2
M/M+\*,XZFO.?A-I_Q1^"_P ,-7U;]J[]HK0?%$FGS7&H7'BE?#47AZST[34@
M0LLR&YF4+&4FD:9G4!7P0 F3-\+OVJOV8?CCX@F\)?!;]H[P+XNU2WM&NY]-
M\+^+[+4+B*W5T1I6C@E9@@:1%+$8!=1G)%1*G+5QU2ZI.WXI?C8OVT-%+1OH
MVK_G^1Z!F@9K/\3>)?#O@[P_?>+/%_B&STG2=+M9+K4M2U*Z2"WM((U+/++(
MY"HBJ"Q9B  "2<5S?PE_:*^ 'QZ;4%^!WQP\(>,SI/E?VI_PBOB6UU#['YN_
MR_-^SR/Y>_RY-N[&[8V,[3B>6HXN23MU=M$4ZD(R2;5WLNIVE%9.E>.?!>M>
M*-5\$:-XNTN\UK0X[>36M'M=0CDNM/2<,T#3Q*Q>(2!'*%@ X1BN<&K&J>)?
M#^B:CINEZQKUG9W6L7C6FDV]U=)')>W"PR3M%"K$&1Q##-(57)"1.V,*Q"]Z
M]K?UO^17-'<O4 FN#^(_[3W[-GP<\5VO@7XM_M">"?#&N7UO'/8Z/XB\66=C
M=7$3NT:2)%-(KNK.CJ& (+(P'((KM+Z_LM,LYM1U"[CM[>"-I)IYI J1H!DL
MS'@  9)/ %.49QLVGKMIOZ$QJ1=TFM-_(L$X&: <UY_\+?VJ_P!F'XY:_-X2
M^"_[1_@7Q=JEO:-=SZ;X7\7V5_<1VZNB-,T<$K,$#2(I8C +J,Y(KK?%OB[P
MKX"\.7OC+QSXGT_1='TVW:?4-5U:]CM[:UB7K)))(0J*.[,0!1R2C+E::?9K
M44:E.4>9--=[Z&GFCVKP?XR_MK?"'4/V4OBW\7OV7OCSX(\6ZQX!\ :GJJ2>
M'_$%IJD=E=)97$MKYZP2-M#R0G"MC?L8#.#CT3]G/6_B=XC_ &?? OB+XTZ9
M]A\97_@[3+GQ99M;B(V^I/:QM=1[!PFV8N-O;&*J5&I&GS25M;6>FMB(XBG4
MJ<D7?2]UMVW.TP*/<"N3^.GQ(;X/?!?Q9\6(M*6^D\->&[[4TL6F\L3M;P/*
M(RV#M#;<9P<9S@UXC\&E_;V^)GP/T#XUZ-^T5X%N+SQ#X4M]6L?#NJ_#F=+<
M37%LLJ0/<PWX<*&<*9%C)P-WEG[ASZ['%BLSCA\4L/"$IR:<FE;1+2[NU>[V
M2N]#Z:)&<&BO ?V/OVHOB7\4O%GC;X"?M#>#]+T3XA_#R\@&L?V'=;]/U*UN
M5:6WN;8.[2*#'MWJ^2N^,DJSM%'V'P?^,]G-\!E^,GQA^*?@EK.:\O9I]=T'
MQ%'/HUM;_;9(X(H[QTB638GEQN[!290XP. #XA83-L'C*4:D&TFI-W5FN5I2
M33LTT]&CTX\\8HKG?AY\5?AI\7-(D\0_"WQ_HOB.P@NC;S7F@ZI%=113!58Q
MEHF90P5E8J3D!E/<5E_$#]HSX _"G6X_#OQ/^-7A/P]J$UNMQ%8ZYXBMK69X
M2S*) DKJQ0LCJ& P2K#L:>M[V.R6*PL::JN:47L[JS.VHSFJ]I?VFH6L=Y8W
M,<\,D:M%-$P974C(8$<$$<@BN)\3_M/_ +-_@7Q7-X$\:_'KP?I.M0/&L^DZ
MEXFM(+B-G570-&\@8%E96&1R&!'!%&H5,5AZ,5.I-)/9MI)_,[[-&:R-5\=>
M#-%\1Z3X0UCQ;IMKJVO>=_8FFW%]''<:AY*!YO(0D-+L0AFV@[0<G I?&?C?
MP?\ #OPY<>,/'WBO3M#TFT9/M6J:M>QV]O#N<(NZ20A5R[*HR1DL .2*5C25
M:CRN7,K+?5::7U[:._H:Q-%<S\1/C#\)_A#9VVI?%/XE:#X;M[N0QVL^N:O#
M:+,X&2JF5U#$#G R<5>\&>.O!OQ#\,V_C/P%XLT[6M)NMYM=3TF\CN()=KE&
MVO&2IPRLIP3@J0>0:>I,<1AY5'34US)7:NKV[V-BC@BN)_X:*^ G]D:;X@/Q
MK\*?8=9M[V?2;S_A(K;RKR&S#-=R1/OVNL"JQE921&%);;@UU6AZYHWB?1;3
MQ+X<U>WO].OK>.XL;ZSG62&XA=0R21NI*NC*0P8$@@@BBS"GB:%:5H34MGHT
M]+)]/)ES&.E-)'0UE^%O''@SQN-0;P7XLTW5AI.I2:?JG]FWT<_V2\CQYEM+
ML)\N5-R[HVPRY&0,UXG^UC\8_C9X>^/WPC_9Y^#?BK2= E^(4NN-J&NZIH9U
M!K9;"U2=42$31*0Y9@26R,*0>"&ENR.7&YA0P.%]O*\DW&*M9MN4E%)7:6K:
MU;LNK/H'@CY32GTS7S%\=/&'_!0/]F7P!+\5[7Q'\/?B5H?A^WFU#Q78R>'[
MG0]0^QQ;7;[-(+N>%B(_-<EE!41_*LS,%KV_X>?&/P7\1/ 'A'XAVNHC3[?Q
MIIMO=Z%9ZI+''<3&:U-T(0H<AI1"KNR(6P(W()52:9GA\VH5L1+#SBX3BD[2
M25TW9---Q>NCLVUUW1UPZY I 1T%>0>._CB/'DW@.W_9F^.GP]NGUKQ>GVY;
MO6HY_P"UM)ME9]0AL1"6\RY12C<<(,ERH(SZ3X+\:^#_ (B^&;;QCX#\5:?K
M>DWF_P"RZII-Y'<6\VURC;9(R5;#JRG!."I!Y!HUL=-'&8?$573@[VL[W5GH
MGI9]$U?U1KT$X&:R-*\=>"]<\1:MX0T;Q9IMWJV@^3_;6F6U]')<6'G(7A\Z
M-26BWH"R[@-P&1D5S7AG]I[]G+QSXIA\"^#?CWX/U36YI)$ATG3?$UK/<R-&
MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exdx-20201231_g2.jpg
<TEXT>
begin 644 exdx-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-U;FYI;F<L
M($MY;&4   60 P "    %   $*:0!  "    %   $+J2D0 "     S U  "2
MD@ "     S U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW'B)584_:QE:VIV2]*6F1G]V,^E/H.U:H**0D"C</6@8M%("#TYI: "BBB@
MHHHH **** "BBB@ HHHS0 $XZTA<+U.*YCQGXT@\)00DP&YN)R?+A#;>!U)/
MISZ5F^&/%!\<W$\;C[#%; %[:-R7E)SSO&/E]AR>YQU+HY)8NBJOL;^]V.@U
M+QAH6DN5OK]4*G#%(V<(?0E00/QK3M+VVO[5+FSF2:&0921#D,/K339V_P!F
M-N($$)!7RPH Q]*X_P"&_P#HL.MZ8FXP6.I2)%GLN>@_SWIC=2I&JHRM9G<@
MYHI%.12TCJ"BD/6C(H 6B@44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F:6
MHY95BC9Y#M51N)] .]'6PO,\[\>?%>/P=X@CTR*P-YMA66=P^/+!. /Y'\:[
MMKTR:.U[8J)]T/FQ#/W_ )<BO&/#NA-\0H?&VMS+DWY:WLL]MOS#'TP@KLO@
MUKG]K?#^&VF.;C3W:V<'J .1G\#C\*ZZM.,8Z;K<Y:=24I:[/8U/A_XX3QOH
M]Q=?9_LLUO,8GB+9(XR#_/\ *N@U?48=(TB[U&X.(K:%I6]P!FO*O"8'A#XY
MZUH;_):ZHAN(!T&?O#'YL/PK5^-VK20>%K;1+3)N=7N%B"CJ4!&?U*BE*DG5
M2CLPC5:I-RW6ABZCXQ6[^'UQXTN=#AG:XNEMXH+MBZA!W'ISFNZ\)>(+63X;
MVNO7<$&GV_DM+)'",*@#$<>O2N/^*6CQZ!\#K+2XAQ;20H3ZG!R?SS4VEZ-=
M:_\ LX0Z=8'_ $B6U)C']XK-NQ^.W'XU<J<'3375F,;PJ/O:YFZ]\2]<\2:-
M-%X?\/.VGWDGV:*XE;!D)/8?2O0? FJ7VH^'_+U+2I-,DLW%N(W.=VT#D>U>
M9> ?&&G/>Z/HVOXTLZ-$RB.4;1)-G /X"O;X95EC5XG5T;HRG(/T-95K1NN7
M0K#WG-U6_(\R_P"%K:U=:SJ%EHWA>2^%C,8G=']R!_(UJ:)XR\3:OK$-CJ'A
M6?3[>8,'N2^?+^4X/YUR/@'Q5HWAOQAXO_MF\2V,U[\FX'G#-FO3-)\<^'==
MOQ9:5J45Q<,I81J#G ZUI5BH.RB53;FKN1R<GAO41=G-H[RJOE!.B.WE;/,W
M]<;B6Q7I-M&T5K''(Q=T4*S$Y)..M2"EKEE)R.N,5'8****DH**** "BBB@
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MI:!14&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M6U_3=+NK^XTC36BM87FD":E)N*JI) _<<]*Z%1@<T +1110 4444 %%%%
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M(*^3=1C]Y%G/X@]Q70BF>S2JPK14X.Z%HI-P]:,CUH-1:*** "BBB@ HHHH
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M&+1110 4444 %%%% !6/XN_Y$K7/^P=/_P"BVK8K'\7?\B5KG_8.G_\ 1;4
M:KG&3[5X9X@U%]5UZZNG.5+E4'H@X KW1N017@-_:O9:C<6K@[H960YZ\'K2
MEL?.9\Y>SA%;-E>BCZ4=.M9'R?H:&A:B^E:Y:W:-@(X#@?Q*>"/R_6O=5/R@
M]L5X#96K7M_;VJ EII @Q[G']:]^7 09K2.Q]7D3DZ<ET.,G\::U)K^J:;HO
MA<ZD--=5FD74%C/S+D?*RYYP>GI5NR\:QZEI^DW5C:*5OKK[-,ES=) ]NW<
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MQ#I.I/;_ /",PZ<BPZ=)/+:S*[,Z-$BETW+L&<8/E_,0<999Z+=Z)HNDS/\
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M$^*M,U*^\?::^G+-%_Q(]2@6[5#L@E<P;,L.A^4D<Y^4URL,,M]=?#_3M/\
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MKL)!0X&Y12WOA_\ M.&XNK:'Q'JGVW7=)-U+JVGQP"9(YEW.(EBC<*J$!W=
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M,& 8'J" :R]9\#:7K6H:5++:V:VEE>3W=Q9M:*T=XTL+QMO![Y?<20<XY]:
M.*CU34;+Q1::38ZG>WEC:>*7M(6DNG=I4-A)*UN\A),@24XRY)4@ _=%4H]M
M]HGP]UZ[UF]N-4U76('NH9;UVB:3$AD18"=D?EL-ORJ",88D]?6H-$TRUMK.
MWM=,LX8+%]]K%' JK;M@@L@ PIPS#C'WCZU /"N@IJCZE'H>FK?R2"5KH6<?
MF,XY#%L9)'KUH UE&!2TBC Q2T %<-\0=<N/".H:5XB669[)8[FSN;17.R1G
MC,D)VYQN\R(1@XS^]QFNYJM?6%KJ, AOK6"ZB#JXCGC#KN4@J<$'D$ @^H%
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MJ!5.0-O %6=>AMM#^&U_JFF>*]2>_NO#UQ/%YVJO*;IA"&\^)6/R%20<Q;5
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M:/I[Z8GW;)K6,P#!R/W>,<'GI5G3]*L-)MS;Z38VUC#G)BMH5C7[H4<* .@
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MX\\2ZI:3:\WA_6-6:?2;%I6M],L+;[/:%8@^ZXEN 0Q.Y3LB8-M'W<\UG_\
M"1W\>OZS>V#1P7NL1Z#:K-Y>Y;<W!D4R!3G)4,2H/&<9R.*[W5/ OA[6;VZN
M-1LYIC> "ZB6\F2&XPNU3)$KA'8  !F!/RCG@4__ (0GP]]AN[1]/66WO;:&
MUN%EE=]T<((B&2V05SD,,-G!SD9H XSQ5X@\2>%8]=TRWUJ2_GCL;:^LKZZM
MHA) 7N!"\;A$5&7C(.T$9;)/!$VM>(]=\'WVL6+:K)JY73(+NVEO+>(&"22X
M,))\I4!C&0V#SA3\V.G51>!= BT^]LWM)KA-0>-[N6YO)IIIO+(,8,KL7PI
MPN[ R<=3F3Q!X>CU&"_N[.SLIM5N+!K)#?AW@D3)81N@(^4G.2!D>_2@#$TV
M76],^*-MH=[XAGU:QGT6>[VW-O DBRK-"F=T2)\N'.!CJ3DGC$'BKQ%KFE^(
M=2T>RO$%QJEE;_V(3$I-O,TWDS-C'S*N^*0AL_Q=1Q4OA3P/<Z5XNEU^_@AM
M7%@;&*%-4N-2=E,BN6::<*P V*!&!@98YRW'57^@Z;J>K:;J5];++>:69&M)
M2Q!B+KM; !P<CU!['J* /-I_'^M:EHMSJFF7)M8;.+2;>9/*C8B[N+B/[0AR
M#RL;JN/]L^@(R-4L+Y+CQ)]GU:=II/&^FQQ&>*(K&Y^S,KX5 3C<%P3C"COD
MGU4>#M!73;RP73U%K?7_ /:-Q&LC_O+CS%DWDYS]]$.!QQC&.*;/X,T*XU">
M]FM',]S<PWDJBYE$;30E3')Y8;;D;$Y YP <T 4?#%YJ,7B_Q!H&HZG-JB6$
M5K<P7%S%$DJB82 H?+55(!A)!VY^?DG K)^(FB6\FO>%]9FGN99XM;LXH(FN
M"(8@7;<RH."QW $MDX  (Y![6'2;*WUJ[U2&';>WD4<4\F]CO6/<4&"<#&]^
M@SS[4:CI5EJ@MO[0B\T6MPEU#\Y7;(G*MP><9[\4 <CXS_LZ)M3T31M/BO\
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M2(CIM<@H3M88((P>@ -"/QU;W6O6:75G);K'J&HVC2K>.$1;923(R* 'W 9
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MQACD #+$MQG;6?XMUK7=7T?QG;Z/_9\=AHUK);3K<Q.TETYMA*^UU91%M5U
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MZP$2W3:>&\JXF16=68Y9@2/ER3V[<5H#2K$+<HME;!;LDW"^4N)B>I;^]^-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B[_D2M<_[!T_\
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MVW_[^K_C1_:5C_S^V_\ W]7_ !H LT56_M*Q_P"?VW_[^K_C1_:5C_S^V_\
MW]7_ !H LT56_M*Q_P"?VW_[^K_C1_:5C_S^V_\ W]7_ !H LT56_M*Q_P"?
MVW_[^K_C1_:5C_S^V_\ W]7_ !H L'K2U5.I6/\ S^V__?U?\:/[3L?^?VW_
M ._J_P"-'0#S'1/^2L/_ -?=Q_)Z]7KR31IHD^*;RO*BQ_:[@[RPQT?O7J7]
MIV/_ #^V_P#W]7_&E$\?*OX<_P#$RU157^TK'_G]M_\ OZO^-+_:5C_S^V__
M ']7_&F>P6:*K?VE8_\ /[;_ /?U?\:/[2L?^?VW_P"_J_XT 6:*K?VE8_\
M/[;_ /?U?\:/[2L?^?VW_P"_J_XT 6:*K?VE8_\ /[;_ /?U?\:/[2L?^?VW
M_P"_J_XT 6:*K?VE8_\ /[;_ /?U?\:/[2L?^?VW_P"_J_XT 6:*K?VE8_\
M/[;_ /?U?\:/[2L?^?VW_P"_J_XT 6:*K?VE8_\ /[;_ /?U?\:/[2L?^?VW
M_P"_J_XT 6:*K?VE8_\ /[;_ /?U?\:/[2L?^?VW_P"_J_XT 6:*K?VE8_\
M/[;_ /?U?\:/[2L?^?VW_P"_J_XT >6?M'_\D[L/^PK'_P"BI:W_ ((_\D>T
M7_MO_P"CY*YK]HF[MKCX?6*P7$4K#5(R0CACCRI?2M[X+7UI#\(M&2:ZA1QY
M^5:0 C]_)74_]W7J<B_WA^AZ)15;^TK'_G]M_P#OZO\ C1_:5C_S^V__ ']7
M_&N4ZRS15;^TK'_G]M_^_J_XT?VE8_\ /[;_ /?U?\: +-%5O[2L?^?VW_[^
MK_C1_:5C_P _MO\ ]_5_QH LT56_M*Q_Y_;?_OZO^-']I6/_ #^V_P#W]7_&
M@"S15;^TK'_G]M_^_J_XT?VE8_\ /[;_ /?U?\: +-%5O[2L?^?VW_[^K_C1
M_:5C_P _MO\ ]_5_QH LT56_M*Q_Y_;?_OZO^-']I6/_ #^V_P#W]7_&@"S1
M5;^TK'_G]M_^_J_XT?VE8_\ /[;_ /?U?\: +-%5O[2L?^?VW_[^K_C1_:5C
M_P _MO\ ]_5_QH LT56_M*Q_Y_;?_OZO^-']I6/_ #^V_P#W]7_&@"S15;^T
MK'_G]M_^_J_XT?VE8_\ /[;_ /?U?\: +-%5O[2L?^?VW_[^K_C1_:5C_P _
MMO\ ]_5_QH LT56_M*Q_Y_;?_OZO^-']I6/_ #^V_P#W]7_&@"S15;^TK'_G
M]M_^_J_XT?VE8_\ /[;_ /?U?\: +-%5O[2L?^?VW_[^K_C1_:5C_P _MO\
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M<]**JZ?J%MJ-FEQ:ON1OS4^A]ZM YZ4 %%%% !1110 4444 %%%% !5+6O\
MD!7_ /U[2?\ H)J[5+6?^0%??]>\G_H)H \F^E% Z44 %%%% !1110 4444
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ME% Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9VJ2$,B#IU-9W3BM#5$P\<G;&T^U9]9N]SX/-.;ZW*_\ 2"BB
MBD>9=]S4TR0M R$YVG(J]WJCI<96)W/\1 'TJ\.@K1;'W^6J2PL>8****9Z
M4444 %%%% !1110 4444 %%%% !1110!!?7/V/3KFY/2&)I#] ":^?9IY+FX
MDGF;=+*Q=V]2>M?05_;?;=-N;4YQ/$T1QVW C^M?/DL+V\SPS*4DC8HRGL17
MJ8"UGW/.QM[H91117I;GG%S2+]]+UBUO8CAH95)'J,\C\J^@J^?M)L7U/6+6
MSC&3-*JGCH,\G\!7T!7EXZUT>G@[\K"BBBO-.\**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1VV(S?W5)KGV8LQ8\D
M\UORKOB91W4BN?QC@]N*B1\MGW-S0[?J%%%%0?-7+%C(8[M.>"<$5M=./2L.
MT0O>1@?WLUN5I$^NR+F="2?<****H^@"BBB@ J*[D\FUD<=0*EJ"]C,EE*HZ
M[:TI6]HDR*E^1V, ]2#R1WHH_P :2OL-+61\UKU%J[I4A6ZV$\..GTJE5O3$
M+7H;LBDG\17/B4G1=S:A=5%8W*2E/4TE?)GT;"BBB@04444 %%%% !1110 4
M444 %%%% !1110!'<R&*VD<=AQ6">O)R>YK<NT,EI(H_NUAU$CY'/6_:QOL%
M%%%0?/;:]2Q8R&.\3T)P:VNG'I6)9H7NXP!_%FMNM(GV&1N3H2OW"BBBJ/?"
MBBB@ HHHH */QQ]*** -#1]9N-'N_.A^:-O];$>CC^A]#7IFGZA;:C9I<6K[
MD;\U/H?>O(_QQ]*T-'UFXT>[\Z'YHV_UL1Z./Z'T- 'JP.>E%5=/U"VU&S2X
MM7W(WYJ?0^]6@<]* "BBB@ HHHH *I:S_P @*^_Z]Y/_ $$U=JEK/_("OO\
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MV2%LW+9W+TP-A''KUKEY8S#,\;8)5B"0>#S0 RBBB@ I1SQZ\4E+UX_# YH
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M_#<* (KSPP;#PW)?73.MV&&(P1M4$@8/!Y_&FVFAV$6G6ESJTTZ&\DVPK"0
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M(U\E=J>6",CWR36?10!MCQ5J MPF(#,J[!=&/]YMSG&:Q?S_ !I** "BBB@
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M!QI68E%%%<1TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>Q44#/'?(E_YYO\ ]\FCR)?^>;_]\FO8J* /'?(E_P">;_\ ?)H\B7_GF_\
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MKV*B@#QWR)?^>;_]\FCR)?\ GF__ 'R:]BHH \=\B7_GF_\ WR:/(E_YYO\
M]\FO8J* /'?(E_YYO_WR:/(E_P">;_\ ?)KV*B@#QWR)?^>;_P#?)H\B7_GF
M_P#WR:]BHH \=\B7_GF__?)H\B7_ )YO_P!\FO8J* /'?(E_YYO_ -\FCR)?
M^>;_ /?)KV*B@#QPQ2*,LC #DDBFUZCXD'_%.WO_ %S_ *UY=0 E%%% !111
M0 4M%:^@:!+K-QDYCMD/SR?T% !H&@2ZS<9.8[9#\\G]!7H]K:Q6END%O&$C
M08511:VL5I;I!;QA(T&%45./>@ 'O1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@#@?C=_R1[6_^V'_H^.L']G'_ ))W?_\
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M^ =53Q3\.;*24[F:$P3#T(&W^6#6\J/+!2N<\:W--Q.L25)%W1L&7U4YI2<
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MRY3Q]XL335N]2MK1=2_?QVB)D1HN""Q_*O3K%];L/!<LFNS0R:E#"[%X5PO
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M1O4$=L]J?10*R>XT#'6D>,.1N4,/<4^B@=D<MXBNI5\3:%:)*\:2S,SJ&P&
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M=-U.6$1ZQJ"2J.J6T9C#?7))I:G+#GA4E=7OL1WDLNNS-8V3%+)#BYN ?O\
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M7,NUA_BF/3[K19+/5+47JW&%6UR<RMZ<5S<NF>'O#.@P6/B.T6=;PA!$L;2
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ME(<AL*58<?,PR=LVJ^-O$MO%XNU*T72AIOAFYP8)H)#+=QB&.5EW^8!&V'8
M[6!R.!@[@#TK(_R*,BO)-;U;5;'7/'5U<O8:G8V\>G"&QN[1W0;W&WK(1@ L
M2 HW-@_+@@TKO[38>//%6K7]OHVIO'KNEV,1N--+20I+]F*[7,AVA0V< <R#
M?P/EH ]IS2!E/0YKR^Y^).L/<:E=:7I\UU:V-]+:QZ?#H5[/)=K%)Y;NMU&/
M*0DJY"[6Z %@6.V\_CG4H?' TO4KK3-)A>^,%O9ZE:3Q->0C:/,AN]WE.Y+J
M1&%)_A)!Y !Z%N'K2Y%<OX\T?4];\+_9M'$,\BSQ33V4\IB2^A5LR0,X!VAQ
MQR"#T(P37%6QTRP_M2U;PM>>#-4N/#UQ(^FQ>1]@NPH^9E:'*M)&2!D[&VR#
M(((P >NYI,BN:\.C'PPTO'!_L>+GT_<BN"^'>AZ)/X,\-23?"Q)Y7L[8MJC6
MNG$,=JYF),OF$?Q<KN]L\4 >Q;AZT9KF?'6NZAX;\*&_T>&VN+LW=M!''<EM
MC>9.D?)7D<,>1G!QP<8.5<>)M=T:YU73-:NM"6[BLH[RUU)P]I:JK2>6PE5G
M<C8V#PXWA@ORGF@#N\BES7BVN^/=:U/PMXPL+?48"]MH2ZA:ZC;Z5<V)=&,B
ML%663)X4%958K\W ."*V;WQA>>&[[6TFLK&ZU""TTJ)+JVLY%:YEN'E0%U0N
M[HA&0BY;!<#)- 'IY8#J<4;A_D5Y=>?$/Q!IN@ZW.;'[;+8VJ7-K=R:+>:=
M[&0(T+),22PSN!5R"#R!MYD\6Z_XGT_1_%.DW5]I\=W%X=FU.UO+*WEB:$*6
M61,>826QC;(&7!.=O&" >G9I-P]:\NO_ !AKOAZ&QM;^[TK3H%L+9HM0O]-N
M/LEW*^\&,S(Y2UV[5!+E\[\@<8KL/%>NW>B^#+G7-,6"Y^QHES*IS(KP!@92
MI!'/E[BIY&0.#0!T.106 &:\XU'XCW<%[XCM[6UMI!;^5#H;MN;[9.SK"^X
M\JLTD:_+[\CBLK6=4U>XOS#IDFGZ68/&<-G,\5FW^E?Z-$X>7;(N[D@')Y"I
MR"O(!ZYN'KWQ2YSTKR#1];U[P[8Z_JT)T\Z/#XHN();9XI#/*)+L1LZR!PJ8
MWC"[&SM/(S@>O*,#F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BD) ZT;AZT 4/$%M->^&]2M;5-\\UI+'&N0-S%" ,GCK7#:
M3X/UJUUOPZLL4<>EQV-K-J2;U)6[MXC&BXSSG>AR,@?9EYY&?1RP')/XUE:?
MKMOK$<,^EPS75LUQ-;O. JK"T196+!B&QO0K\H.3@_=YH \XT[P-K&G:3X5N
M;[2M1NWL=,DL+RRTO5C:7$+%PZN'2:-77Y2K*7[J1G!K1ET+7;/3]/BTS1M6
MLM,GGN)M2L=/U>.6^=F9#&7N)G& P5MXCDW E=KD9->E@A5R>!ZT[- 'D&F^
M#=8M/#<D.J^'-2EG_MF\N()=-US;>VD<R_+(DSR+YG7:P=P20"5:M6VTKQ=:
M3>'-:U.RN]8GT^2]B>V$]L+I8)0OE%SF.)G78H;:1][(+8Y]*R*3<,9S0!YA
MH/A7Q!'KVCW^IZ8MN(=>U2^F N$?RHIXW$9R#R26 XY'<5#>^"[R+4M>M;GP
M_JVM0ZK=R3Q2VOB"2TM"DH :.>,3*1MY!*1ON4C@GY:]5-4M,U>TU9KP64AD
M^Q73VDQ*D8D4 L!GKC<.: . U3P]KEOKLTWA;2=4TF^:YC=;RUU6.33KA-B(
M6N()3D,%4CY(BQVJ=_)QTGC[2K[5_"AATJV-W<17MI<K"KJK2+%<1R, 68+G
M:IQD@>_>M37M<MM"M[6:\25UNKV"RC$2@D/-((U)R1A<MSWQVK4!'XT >:ZA
MX7UJ\\*?$."/362ZUV1Y+&!YH]T@-I%'@D,0IW*PY/&/0YJ"]\)7UMKNO33:
M)J^LQ:L\<\#:=KSV<:MY"1-%.@GC&,Q@[U60D,01\H![[Q#KEMX=T2;5+V.6
M6"$H&6$ L=SA1@$CNPI+O78-.:)=2AFM3/?)8VQ<*PN&89#+L)VK][[VTY4\
M<C(!:TJS33]'L[.*%;=+>!(EA21I%C"J!M#, 6 QC)&3U-6Z:&&T9/6ER#0
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M;&7;';D9@E^(>GRZA#9Z)IFI:X\^FQ:K&;&.(*UO(SJK9E=!G*?=^]R, X;
M!NZ%HEKX>T>'3K%I7C1G=Y9FW232.Q=Y&/'S,S,QP .> !@5D:-X!L=&GTV6
M"^OIQI?VE;2.<QE8DGV[D^5 2 4!&3GDY)& *5EX[FU;QSHMAI5E-/H^IZ,^
MHK=80'.^+:Q!<,  ^"-N<NN,@$CMU^[_ /7H Y5_ &GK&6L[R^L[P:C/J,5[
M Z>;#),Q,B@,I0H<D;65N.>H!K9T72&TBT>*74+[499)3+)<7TP=V)]%4*B
M  !451QG&22=*B@ 'O1110!F:SH5OK;Z>UT\J?V?>)>Q>40-SH" &R#\OS=L
M'@<US^H_#6QU%;FW.K:M;Z=<WJWSZ=#+'Y(G$@D+#<A< N-Q7=MR20 >:[.B
M@#E9O L1O;N2RUK5]-M+Z?[1=6-E,D<<LA(W,'V>;'NQ\WENN>3P229;GP1I
M]WI7B.PEFNA%XB=GNRKJ"A,21'R_EX&U <'//Y5TM% '):G\/[#4[K4GEOKZ
M*/4X8([F")HPC-"P,;C*$A@!C .W!/RYP:FO? VF7]UJ%Q)/=![_ %&UU&7:
MZ_+);B,(%^4X4^4,]^6P1FKWB?58M'TZVGGFNH5DOK:W!M$C9F:294"D."-I
M+88CYL9P0<5B#XDV!GG(TG538VFI'3+C43%%Y,4_F>6./,WE2Q7YE4@;AG!R
M  6Y/!$7VNZ>QUK5]/L[RX-S<V%G.D<<DA(+L'V&6/<1D^6ZC))ZDY+SP5%J
M%\[WFMZM/ITETEV^F23QM 9%*LOS%#+M#*&VB3;D8QM^6G3>,HAJ5Q;VVD:K
M>VUI,+>ZOK:)&A@D.,K@L)'"[AN*(P'<\-BHOQ&L#'JMPVFZFMGI=U)92W9B
MC*RW"2",11J)-[LS,H7"[<G!((( !N:YH-MKUE%!<O-!+;RB>VN8'VRV\P!"
MR*3D9 )&&!!!((()!SD\&0RR3S:OJVHZM<R6LEG%/=F%6MHY,;Q&(HT4%L+D
MD$_*!TR"L/C.(/>0ZAH^JV%[:V_VG[#)"DTLT1.W='Y+.K'=\NW=D'J "":D
MGQ$L[&34(]?TG4]%DL+ Z@ZW2Q2>;"&*DH89'!(/&"0>10!9TGPA<Z1;6UH/
M%.LW5E;P_9UM;B.TV% FT LL"N<#ONR2.<\U!I?@:[T;2[73M/\ &6O16EG$
ML,,)CLFVHHP%R;;<>,<YS[U9'C&*TL;^ZUO1]4T9;)$D87<2/YP8[5$;0LZN
MY;"[-V[)7CD9C7QS96_VI=<L+_0Y[6S:],-XD;M) IVED\EW#8+ ;<[LLO'(
MR -^(N@W?B3P>VEZ>LKR2WMHSF*81.D:W,;2,K$C!"ACQSQQVIDWP]L[R&[.
MI:IJ-]?W+0$:C,\0F@\E]\0C"1K& KY;&P[BQW9'2G9>+M2U+XE:?I,VFZAH
M]I+I5Q=26M]'#F0B2%4</&SC@,X*[@1GYE&5)V;_ ,5QV7BN#P];Z9J&H7TM
ML+IOLPB"1Q;RA=FDD7&#V&2<\ X. #.?X;6%U-J\^IZKJFH7&L:<=.NYIY(@
M3'DX*JD85"NXX &#G+ G),TOP_TVZBU :C>7UW-?V]K#+.[QQR1M;EVBE0QJ
MH5PSYR!C*CCKFK8>/K>73[!--LM9UVZNH9[@1JENDRQ1S&-F;+1IC=A0%)8C
M''4U6U'Q\FD^*PU_+<Q:9)HD5S!8-:D7,MQ),42-8R YD/"[/7\: -6Z\$1Z
MEI=_9ZSK^L:C]NC2)I)Y8D\M4?<-L<<:Q@Y_B*%B,#. ,6]7\(:?K=]=W5ZT
M^Z\TN32I8T<*HAD.6(XR&]\X]JDUG6+NR\&7NKPZ;<+=0VKSK9R-$9$8 GDA
M]G'4X8\#C/2N8\->,[V/PWI4-Y9:YKFMW5BNH30!+-9(HFP Y*ND81FSL7)D
M(!R/E; !K2^!I);06J^*]>CC>V6UN%62#$Z+D D&(B-MK%2T80G )R0#6^-*
MM%T5=)6!38B#[-Y1Y'E[=NTYZ\>M<]'\0]/O+_3;31]/U'5)M1MFNHUMTC3R
MHT<1N7\UTVE7.".N>.O%=<M ''V/PST2RM_#L0>ZF/AZ626VDFD5FE:0[G,A
MV_-E\/QCYE4]JGN_ -C<K=&&^OK6:XU9=76XA:,O!<"-8_D#HR[=J]&!ZG\.
MJHH YF;P/I\V@ZAI+377D7^H-J,C;UWK(9A-M'RX"[E Z$XSSWKI1P.:6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :W7)X&*
M^?;S4=-N=>T74M/AT/3]17Q+ D\$8>YU:-3<^7*]U<;E:)3N*^6RLN"JAL8
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M'6@#R?PQX(NM+@T32-1\-ZI<2:7/%F_D\12_8"L3969(?.8[OE4B(Q!=Q(R
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M4@!8EVC!'8^DJ,"C(_R*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **"0.M9MUXBT2RU:'2KW6+"WU&X
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M>GM2 'UZ]Q0!YYX1T>&[^(_B'4->LX+C5[6*P"RR1JY@D-L/,,9_A)/4KC(
M[8J+QG9Z5'\5M*O+^WLUGFT._C@GG10TDP,6U58\EPK/@#G!;MFO2@._J*:S
MJ&0,R@LV%!/4]<#\C^5 'C?AK1[31--^&-[H-G#;:GJE@T=S<J,/<AM/:4+(
MW5@'1" V0NT 8Q57P3:VC7GAZ=O$.C6_B(3#^T;:VTF4:K+)AO/BNG$[-M+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTGP_I&@PR1Z%I-EID<K;G2SMTA#'& 2% R?K0!HK]T4M(.*6@ HHHH ****
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M1@HW[5W,  K':/F!X'2N@J.VMX;2UBMK6*.&"%!''%&H544# 4 <  <8%24
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %#6-8L=#L3>:I/Y,.Y8UPK.SNQPJ*B@L[$\
M!5!)]*Y;2_B%8W>I>));N9+;2M&6WQ)-;RQ3!I%;*O&X#[BP4*NW<Q88!R*T
MO&>EW]Z-&U#2K<WDVD:BMXUF)0AN$\N2-@I;"[@)-PW$ D8)&<CC-1\*>(_$
M%YX@U6;19K$R7EA>6ED;]8IKE;<,'3S(7/E.0<J0V,[<MC. #N[;QIH,VG7]
MZ]ZUK%IRA[M+VWDMI(%(R"T<BJX!YP<88@@9(-5)/&^D7*+]CU!K*87=M;R1
M7^FW$<A\Z0*BB-PC#?RJR$%003S@BN6N?!EYJ6GWUSIV@:CIUXCVDD7]LZX]
MU+=^1.)_)/[V543((#;\[F)*@<G6U^+Q!XIMK)%\-3Z?':ZOI]S_ *7=P&5T
MCN%>4[8W=0H501\^XD8V\#(!N0^--#N-833HKN7S9)WMXY3:2K!+*NXM&LY4
M1LPVL-JL3E&'8BH8/&FDP:/;7=[J(NVNKF>" 6.GS&29HY'5E6!0\AV;2&8<
M9&> 0*YRUT+7K/Q=#-H6F:IHL;:@[WP.IQ3Z9<0-(7=UB8F1)&]$2,!F.20,
MFOH'AKQ!X9GT?5SH\NH26XU.UN+&&>(3*EQ>&>.5"[A#PJY!<$!^^"* .OD\
M>^&X['3[L:@TL>I%UM%@MI99)609=!&JE@XP05(# @C&0:7_ (3OP^=-@OH[
MN:9+B>2WCAALIY+@R(2'0P*AD!7!SE1CC/45RVC>$=:B\2:+J][8I$7U+4-0
MNH!,K?8Q/#L2/.?F;@9*Y&2W)&"8KOPIJ(CU!KO0=0NS+KEW<VUQI6J):WEM
M')$%66,^8BD$@@JSCL=K4 >AZ5JMEK>F0ZAIDWGVTV=K[2IR"58%6 *L""""
M 0001D5<K!\&0:Y;^'$3Q-+))=^:YC\]HVF6'=^[65HP$+A< E>,]SU.]0 4
M444 %%%% !1110 4444 %%%% &'XBU^;2KC3[#3;-+[4]2E9+:"6?R8P$4N[
MNX5BJ@#LK$DJ,<DCAM%\3Z@-7ODURWN1++XL2PB@347\NV'V)7RI 'F1$J6"
M$ '?N*AABNX\1^'I]7N-.OM,ODL-2TV5GMYY8//C*L-KHZ;E)5ACHRD%0<\8
M.#9?#J[BNOM>H:XMW=/KRZU(ZV>Q21!Y7E*-YPHZ@DL0  =Q^8@#+SXBSZ7X
MFT[3-5T_3;7^T;U+:.W_ +81KY%<L$E:W"8VD@=)"0&]013;CXAZA':6NK0>
M'HI]$O=3BT^"Z^WXF.^80^:T7EX"9SC#EC\N5 )VU;?X6WEI#86D>NVD=C8:
MK'JB+'IFV:YD20-FXE,I\QMOR[P%)."<XQ6')I>JWCZ;X<TD:G#IUKKT5S]B
MNM%>(V\4=QYK;KO)ADC&"45!N.8P2<,* .G/Q$U +?7[:!$ND6&KG2Y[DZA^
M^8B<1"5(_+P5RRYRZG[PYP"9]1\>75K!JVIV>B)=:%HMP\-[<_;-DV8R/.>*
M'RR'"<YRZDE7P#@;I+CP)Y_A;5=(_M':-1U5M2\XV^?+S<+-Y94MS]W&<CKG
M':H]1\ WEU'J^F6FM+:Z%K4[37MK]CWSY?'G+'-O 57_ -I'(W-@CC  0^/Y
M+[Q?<:-IMC83_9;E8)8GU18[TH51C.ENRX:(!P=V\$@-@$X!HW7Q"AT9+H"V
MAA\S7+C3_M&JZLT5JK)%YA9I61O*R 0L:KC.?6K^O^!;OQ%=+!J&K6DNF1W*
M3VZ2:8KW=GM*G9#/O 7)3[QC9L,PR>HL#PAJ=I#J']DZU;QF_P!2GO)HKK3Q
M/!(DB!3$Z;U9L;<Y#+[@CB@#>T:\NK_2(;F]M%L9Y =T*SK,G7 97'WE888'
M .#RH.0.6@^(%Q+:V>L2:-&GAO4+Q+2&_6[S/\[^7'*\.S C9]H'[PL RDJ.
M0-OPEX6B\*:&VGPO$XEGDN'6"W6"%&<Y*QQC.Q!T R3ZDGFL6#X>W<5O9Z1)
MK*2>'+*]6[@L19XF^1_,CC:;?@HKX;&P$[0"QYR 1?#675]1N?$6H:X/WO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0-*>ULK^>Q5[O6)8W<Q/M+;5MF SC/WC76VAG-I$;Q$CN"@,J1R&14;'(5B
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M TI*MU'. #U<'(XHI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0C)%%% "8/>C!XHHH 3:?TIXHHH **** "BBB@
M HHHH **** $(-)@]OYT44 &#Q2$'&0!GW-%% !LZ8XQQZ<4NWI_.BB@!1G'
M-+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exdx-20201231_g3.jpg
<TEXT>
begin 644 exdx-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-U;FYI;F<L
M($MY;&4   60 P "    %   $*:0!  "    %   $+J2D0 "     SDP  "2
MD@ "     SDP  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M-N#:WML&W*KCG*GNI'(KJ:X+P!'YGC3QQ?1_ZJ74TB4]B4B4-^M=[0 4444
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MNC^8JB2\.@HH'044AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !17SGXAUB[E\6>,XHM8\3#5;:[5-*MM/:5H =@(#  J!GUQ76ZS\5]=
M\,SV]M?6%C/]FCMDO09F,S/( &("@JF"?XL9HCJD^]OQ!Z-H[JW\ Z%!X=U'
M1##)+9:C.]Q.LCY.]SDD'MR.*J)\,="&EW%G+-J,[3LCFYEO':9"GW=K=L5Y
MY?\ BSQ#')XM:_NB]M:ZU9PP)!.\;1ARG (_AP>1W.:V1\8[V3Q7):6FC^?I
ML.H?8'9%D:;.<&3A=NT'MG-*.MK?UM_F#TN=,/A5X=&B7&FL;U_M%REW+=/<
MDSM*GW6W^U;'A_09M'OM5FENY9TO;@21I)*7\L!0._3/7 K@M/\ BIXAN)+*
M[N=(L%TN[UA]*#I,WFAP2%;&,8XYYK:^$^JZWJVGZX^O7$=P8-6GAB*DY4*?
MN\]AVIK7[O\ +_@ ]-/ZZ_\ !._HHHH **** "BBB@#SOP'X+U73/'GBGQ3X
MC6/[7J<XCM0DF_9 O0>V>./:KOQ;\&77C?P++8:7L&HP3)<6C.VT!U/KVX)K
MMZ* //O'.DR:_P#")-$\0206NKWT44$0+94W8Y4 ^Y%1_![P-JGA#1K^Y\3L
MDNMZE<>9<2(^[Y5 "C/TJ7XJW2Z8?"NJ7.5L;+7(GNG[1J4=0Q]@6%=G-JUI
M%"LB2K.7&8XX2&:3Z ?SH \U^)&AZFGQ1\+^*[.&.>WT]&@\GS ))96)VJH[
M]>3V&:K.?B/X.U:[FM8-"U2/4G$\C7%UY,JN0 5YQE1T&.PKT:PTN>?4?[6U
M@ W(4K;P Y6V4]<>K'N?PKQ;P;I?AOQ?XV\9R_$>=)]1MKYXX8+RY,8A@&<%
M1D4 =;X8\*Z[?>/X_''Q#O=/M[F& PZ?8VLH*1J>K%CU/)Z>M8PTGQSX<^)7
MB;7?"L&AWMKJ\B,#=7H4JJCK@'CO4.@^$/!6N> ]?.GZA>:_::6UP;-[K>BV
MK;2=L;<;EX!SS7,6/A;2+?\ 9@N?$L5J5U>2V=6N?,;)'FXZ9QTH ]D\%ZUX
MUO\ 5Y8O%UIHMM:^43$UC=>8[/D<$9Z8S7<5\T^+-$\&:'\'M,UOP_>1VOB<
M0VLD+6MZ6E>4A2P*[C[]J^B-%EN)]!L);X$7+V\;2@C^(J,_K0!9N;JWL[=I
M[R>.")?O22N%4?B:2UO+:^@$UE<17$1. \3AE_,5A>+]-O=873+&R/EHUX)9
MIC&'5%0%AD'@Y8 5S\WAG4]*GU.;3YKR5A$L@\C]VLLKM\[*B\$J@&!ZT>H'
MH=,\^+$A\Q,1_?.X?+QGGTKSQ++Q$EU#_9G]HI9W<LD"BZE9GMXV5<R-DY!R
MK8!Z9K/OM+UZXM[ZUF@U9C<MBU,4C!5!D*L9#GGY .#V- 'JJLKJ&4AE(R".
M<TM>5Z9IGBR5)%GFOH6<""4*KH%S(.4)8@!4!Y4#.:]0MX%MK=(8R[*B[078
MLQ^I/)I@4M3U[2]&:-=4O8K=I 2@<\D#J<>GO5Z*6.>%)8762-U#*RG(8'N*
MXKQ@8[;Q#%=^==6,WV0QI<I;?:(9ANSY;+@X/?MG-<S-J6KI<::_V>[TZ: 6
MH-O%YHCV$C?MC4;<8/.[)%):@]#UZD=UCC9W(55&23V%>5'3M5FMS<-?ZP'D
ML[Z9E6XD \Q)?W0 [<'@=_>H+:_OKJ^NA%=ZI-J8O_+,!+F$0>4I<$?=[GWS
M2OI_7H/J>LV]Q%=VT=Q;.LD4JAT=>C ]#3+V]M].LI;N]E6&WA4M)(W11ZUY
M1I1U]-2TR![JZM3&EHMO L,I#1;%WY (3KNSNY%=_P".89;CP-JL5NK-*\!"
MA5W'.?3O52TV%'5V9>TKQ!I6MM(NEWL=PT0!=5R"H/0X/-:->?:GX8U&"&&^
MEU:YFO;F2VM6>UC$)CA\P%A\OU.2:H3PZI<:M+8VUYJL>IO=RQ,"[^4EKL.Q
M@?NY^Z<]2<T@/3);B*&2*.5PKS-MC!_B.,X_(&D6Z@:\>U653.B!VCSR%.0#
M^AKS"2]\37^EPZK +V&ZFF>)+?#?+Y=NX)V^[Y(]>*SIC>)=W<VAW.J&T>.T
M2ZN;I9F95R^\ \/UQG'3-'4#V6JD6J6,VH7-C%=1M=6JJTT0;YHPW0D>^#7$
M>%+?5;K6K ZA?W\MM#;2RQY#QK)^]PFX$DM@=,\D8S5#7H-0L/&FKZAI]M,[
M7_EZ<61"<!XQM?Z*P//;-'8#LW\;^&XXH9&U>W*3JS1LI)#!6VD\#H",5M03
MQ75ND]O(LL4BAD=#D,#W!KRKPR]KX5U.V74H)H[9+2ZACQ;N^3]I8@< ]1S7
M=>";6>T\*6R7,30%GDD2%Q@QHTC,JD=L*1Q3Z7#K8WZ***0!1110 4444 4-
M'_Y![?\ 7Q/_ .C6KG]?\<G1]5N[.WMK.8VD*RR":]$+N6SA47:=QX]NM=!H
M_P#R#V_Z^)__ $:U9M]X.L;]-1\]MTM_,DK2E%+1A=N%4^GR_K0 1^-]%9F6
M69XF5&8EXVVDKC<H;&&8$XP*'\<:+&!YKW",#\Z-;.&C&0-S#'RCGJ:S(?AI
MIT G,4^UV8M#(L"!XB7WY+8RW([]JEG^'UM>:E'?:A>-=S8 F:>"-S)ABP R
M/D'.,"@#1A\8:9))=K)+M^S2!. 3O!;8"./[P(P,]*8OCC0W9E2>5F&#&! ^
M9LG'[OCY^1VJ"'P)81WMM<//-)]GADC*' #LS,V\^XWMCZU2LOAM::=Y$EE>
M&"ZMW4PSQVT:E5 (P<#YLACR>] '0Z!KD7B"QEO+:)XX5G>)"X(+[3@G!''.
M1CVK4JAHFDQZ)H\-A%*\PCR6EDQN=B2Q)QW))J_0!QFI>)-4M]:NY;=X1IUA
M=P6LL+1Y>3S,98-GC&X<5;@\0ZB+[Q#'?V\,2Z>$^RK&Y;>&4X).!R3CBK%Y
MX2AO-::]-W,D$LL<T]J -LKQ_=.>HZ#COBK,GAZ&34KJ[:9_]*DA=TP,?N^@
M_&CH'4YK4/$?B'2=3C69K:Y>0OMTV*/,AC6,GS2P/'S#ICO46C>-;RYFFLVO
M[34+B2UAGB:"/:(GD?;Y;#)SC\ZVK3PA<V>NWNH1ZU,4O96>6(P)NP1@*'Z@
M#M2Z7X+BL-12^N+Z:[G0C#.BK\H!P#@<G+$Y[FA>8/R,#4_%NOZ/?/%/)9W$
MTD<A-K&F?L?S!8V=@><YZ5<?6]?B6\LKB_LH&L)@;G4I(P%6)H]R_)GKGBK%
MIX">"WO;:XUF:XMKQG>13 BN7)R&+CDD'&/I27?@![L1R-K4_P!J%S]HEE>!
M&$K!=JY0\?*.GO2Z#ZA9^)M;F_X1@W%G#'%J;,MS(20V0CL-J$< [0>3WKI-
M9_Y ]Q_NC^8JNVB-/_93WMX\\^G2F7S-@7S249>0.G#=O2K&L_\ ('N/]T?S
M%427AT%% Z"L:Z\5Z79WQMI9)25D$4DJ0LT<;'H&<# /(I#-FBDW#U'YTR:>
M*"%YII%2-%+,Q/  ZF@"2BF1S1S1+)$X9&4,"#U![T_.>E !169J7B32-(NE
MM]2OHX)67?M;/"YQDXZ#ZU!J'BS2M-E9)Y9'\M0\KPPM(L2GH6(&%'UH VJ*
MR1XIT0ZBMB-1A-RS! G/+$9 STR01Q6M0 4444 %%!.!7,:%XHU'5K=;^YTR
MUL],8.QN&O=S*JDC)78/3UH Z>BL;_A+M ^Q_:O[4M_)\SR]V[^+!.,=<X!-
M$/B_0+F&:6#5K9XX(Q)(P?@*>A]_2@#9HK!C\7:9-?0QV\\<EK);RSM<[\*F
MPJ""#_O5I:;JUCJ]NTVFW,=Q&K;6*'H?0CM0!<HJAK>JIHND37SQM+LP$C4X
M+L2 H_$D5A3>.!9:-=W5_IDZ75G<+;S6T)\P*6P0VX#[N&')% &KI'AJPT35
M-4O[(2>=JLXGN-[9&X#''IP*P=;^%'AW7M5O+^[:^CDOF1YXX;IDC=TQM8KT
M)&*U];\3?V5/';P6ANKB;RUC02;07<X52<<="<^U5/\ A-XDL+*6;3[A9[B^
M^PR1*-RP2;]IW/C&/3UH72P,@O/AEH-[=7\TIO!_:$L,TZ+/A6>(@JV,<'@9
MJ1?AQH2:\VJ1_;$+S_:7M4N6$#2_WRG0FKVJ>(KFUOS9:9IC7T^X+GS-B*=I
M8[FP<8 'YUDV_P 1$NXX[B#3)#9H(Q>3&4 P,[%0 ,?-@CD\<4+R!EF+X=:%
M#I]K9(+CRK74CJ<>9>?.))YXZ<]*TM \+:?X;GU"33#.%U"X:YECDD+*KGJ5
M';-8Y^(,<7F3W.G21V+I,UI.) 3.8CAAM_ASVYYK8T'79=5DNK:]LC8WEJ4+
MQ>8) 5894@X'O^5"_K^OD#\_Z_JYLT444 %%%% !1110 4444 07EE:ZC9R6
MM_;Q7-O*,/%*@96'N#5?2]"TK18O+TG3[>S3TAC"_P JOT4 %<]K7@+PMXBO
M!=ZUH5G=W'0RO'AC]2.OXUT-% %*TT;3;#2_[-LK&WM[(J4-O%&%0@]1@5 /
M#6BKH)T0:9:C2R,&T\L>61G/W>G6M2B@#F[/X=^#M/NH[FS\-:9#-&<I(MLN
M5/J..*Z2BB@ HHHH **** "BBB@ HHHH *@M;*WLC,;:,(9Y#+)@GYF.,G]!
M4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-'_Y![?]?$__
M *-:J.J>-O#>BZD-/U35[>VNR 1"Y.XU>T?_ )![?]?$_P#Z-:N;\0^'=2U7
MQK!J%K%$D-GIDZ6\SD?\?,F ,CKP!UI#.Q61'0,K J1G.:@;4;-=2CT]KB,7
M<D9E2'/S,@."WTR17BUI\._%T/AF]2>&X:YNS"DT,=Z@,A4DM(<\')X()&17
M3^ ?!6IZ-XDBO]<L(%>#2T@BFBEW!7+LSJ,DD<$>U5U_KL3T.]U;6M-T*T^U
M:O>PV<).T/*V,GT'K4FG:I8ZM8QWFF745S;2_<EC;(-<EXLTO6O^$RTS6M-T
MJ+6;>VMI(?LLDZQ^5(Q&)!NX/ QZURD?PSU]%OICL6[%G--:^5.5C6[ED+,
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MMK3_ /GX_P#'&_PH_MK3_P#GX_\ '&_PH O451_MK3_^?C_QQO\ "C^VM/\
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MG6.MZ:/+661'WS(NV0_*3R00WX58\'7-SXBU6%=05M_A>SDM)=P^]<G*[O\
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M?\)'I?\ S\-_WZ?_  K4HH R_P#A(]+_ .?AO^_3_P"%'_"1Z7_S\-_WZ?\
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M>5<#$8567(]_FKG%^#NEPWEI<079)AMH;>43VT<OFB+[I^8?*?I0O/\ K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZUF?\(UHG_0(LO\ OPO^%'_"-:)_T"++_OPO^% &GD>M&1ZUF?\ "-:)_P!
MBR_[\+_A1_PC6B?] BR_[\+_ (4 :>1ZT9'K69_PC6B?] BR_P"_"_X4?\(U
MHG_0(LO^_"_X4 :>1ZT9'K69_P (UHG_ $"++_OPO^%'_"-:)_T"++_OPO\
MA0!IY'K1D>M9G_"-:)_T"++_ +\+_A1_PC6B?] BR_[\+_A0!IY'K1D>M9G_
M  C6B?\ 0(LO^_"_X4?\(UHG_0(LO^_"_P"% &GD>M&1ZUF?\(UHG_0(LO\
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M=X&T/4]*DG?5C<B9HU23>R&.5P3EQAB23GJ<=J[&BB@ HHHH **** "BBB@
MHHHH Y/4O"MQJ_BVXN;B9HM/:" ;4"_O71V;!/4 <?6N?'A?6FMW5[2ZCE6
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M!H?\(YHO_0)L_P#OPO\ A1_PCFB_] FS_P"_"_X5DMXBO#]T1C\*A?6[]_\
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MN4VLXU-"1_X]5-3\6%4#_A"+#@8_Y"4?_P 50!UM%<GN^+'_ $)%A_X,X_\
MXJC=\6/^A(L/_!G'_P#%4 =90>E<GN^+'_0D6'_@SC_^*I-WQ8_Z$BP_\&<?
M_P 50!UM%<GN^+'_ $)%A_X,X_\ XJC=\6/^A(L/_!G'_P#%4 =917)[OBQ_
MT)%A_P"#./\ ^*HW?%C_ *$BP_\ !G'_ /%4 =917)[OBQ_T)%A_X,X__BJ3
M=\6/^A(L/_!G'_\ %4 =;17)[OBQ_P!"18?^#./_ .*HW?%C_H2+#_P9Q_\
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MY[67_?E__BJOT4 4-FK?\]K+_OR__P 51LU;_GM9?]^7_P#BJOT4 4-FK?\
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MO^_+_P#Q5&S5O^>UE_WY?_XJK]% %#9JW_/:R_[\O_\ %4;-6_Y[67_?E_\
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MM!O]3O[2>WT][PK8S0!DG"&&5BNU^2,@$$T=@.WJC'K>FS:FVGQ7D;W29#1
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M>NZ-IMS-(8)+=;F['F%O+,1(5,]\[E!]=IJNMA=+G9W.K:59ZA%:7%Q#'=,
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MA$UPLJG<H0APQ+9ZXX P:]#I@,$,07 C3'IM%+Y:<_(O(P>.U.HI (JA5 4
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M#E#AAPPQD?7D5*EU;2S!(YXGD*Y"JX)Q6*WA*!HW074B_>*,J@%&.WYL^H*
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M\7Z3$LGF3-NCX950MST('K@UHWFE66H1O'=VZR*\9B(.?NDYQ^E9U_X4L+N
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MRV[PKN?S(HP0<C;M4-M(;.3Z=*UM,O99+W4T9Y)_)D4QH5"X!7[H/ ZUKT4
M<UXBO]5M'6XL$E$:6DCRPA QSP >,\CKCZU2N?%NIVT<N;%5*N(T,BG)/K@'
MD'KVKLJBN+6WO(O+NH8YDSG:Z@C- '*R^)M3EN%AMH8PH2-WG\IB@R4W8YY&
M&//M4DGB+5+>.15T]IF7?(&VG&P.5]N<X./2NI1$CC5(U"JHP% P *=0!BF_
MN9]'LKB4>3+)<QJP3N"^/U%076H7L?B@V["06Q50FP],J26(V\@$>HK?>-)
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MYO\ T8U>1>,?"'B-O$>O:QHME/-]LNX;:6$=)H-J'>O^ZP/YFO7=&_Y![?\
M7>;_ -&-65>>)+2WU&>U;7((I8@7:$P$LJCO^G6CK<?2QY[?:9XRU*[U*T/]
MKK)(+Q9OGQ;M#L_<"/MNSCISUS3M-M/%Z:OHD4<NK6MA%;6P3S8G<[@3YJR
M$ >F6[8Q7J427\T*2QZC$4<!E/D=0?QJIJFI'18DDU368+9'.%9X."?PH6@M
MRUH#3-I(-R;LR>;)S>(%DQN..!QC'3VQ6G6/9W%Q?QE[35(I%&,G[/CJ,CJ:
ML_9]2_Y_X_\ OP/\: +]%8]I<S7\DZ66L6\[6[^7*(X@=C8S@\U9\C4?^@A'
M_P!^!_C0!?HJA]GU'_G_ (_^_ _QJK<7<UI=+;W.K012-&9 &A ^4$ G.?5A
M^= &S168_P!M2:.)M2B#R@E!Y'7'7O4GD:CC/V^/'_7 ?XT 7Z*H>1J/_/\
MQ_\ ?@?XT>1J/_00B_[\#_&@"_169-]MMU4S:E$H9@@_<=SP!UHE^V0*K3:I
M @9@@+0@9)Z#K0!IT50\C4?^?^/_ +\#_&J]M-=7<EPEOJ<;M;R>7*/(^ZV
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M+;9PHZDG/ J)=81Y)T77;8F!PDG[GA6)QC.?7B@#H**PI-2,6J+ITFLP"[8
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M)P._J:?,+RWC#SZG#&A( 9H0!DG [T :=%4/L^H_\_\ '_WX'^-'V?4?^?\
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MP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVM/_ .?C_P <;_"C^VM/_P"?C_QQO\*O44 4?[:T_P#Y^/\ QQO\*/[:T_\
MY^/_ !QO\*O44 4?[:T__GX_\<;_  H_MK3_ /GX_P#'&_PJ]10!1_MK3_\
MGX_\<;_"C^VM/_Y^/_'&_P *O44 4?[:T_\ Y^/_ !QO\*/[:T__ )^/_'&_
MPJ]10!1_MK3_ /GX_P#'&_PH_MK3_P#GX_\ '&_PJ]10!1_MK3_^?C_QQO\
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M110 4444 %%%% &5=30SZB!_93WDUDV4E 3]VS+_  EB"#@U1FTG3+GR_/\
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M H?VA<_] JZ_[ZC_ /BJ/[0N?^@5=?\ ?4?_ ,55^B@"A_:%S_T"KK_OJ/\
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M_P#Q5*=21_L#V_SQ7CX5CQ@;"V?TJKJ'B.VTYYXIHW\V)=RKU#C('49QR>]
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MWA-IKB4P:49+K_7O^[S)SGYCWYIS67A9X((7BTMHK<YA0[,1GKQZ5L?9X?\
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MG_7%OY58$$(Y$2?]\BJ^L?\ (%O/^N+?RH KZ?\ \A:X_P"O>'^1K4K+T_\
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MB37%TW3[Z_E:WL3YIGNH[,ON42 1L5_@#+DYHW8'6ZAI$6H:?!:22.J0R1R
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MVE_]?1_]%/4FK_\ ('NO^N3?RH LP_ZB/_='\J?3(?\ 41_[H_E3Z "BBB@
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MVELJ01D=<5M:E?VVEV\<UQ&2LDR0C:H/+L%'ZFJ-[XBM+6#4F2!I);"1(BF
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M '<A02..ORBNBV)_=7\J:YBCV[]B[CM7/<^E &#96N@:???:K:X17VA<'!Z
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M_P ?VE_]?1_]%/4FK_\ ('NO^N3?RJ/4O^/[2_\ KZ/_ **>I-7_ .0/=?\
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M'6-.OH]0:W6Q<NL0B5@Y*E3DGV-<A+XUU&2S3[9Y4:W%A(\:0_>=U5CDX.Y
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M&< 'C.!G%*NA:<FS;;XV=,.WJ#Z\\BL:;7]3M6EB:".1X00Q*-GC;\WH<Y.
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MN3?RJ/4O^/[2_P#KZ/\ Z*>I-7_Y ]U_UR;^5 %F'_41_P"Z/Y4^F0_ZB/\
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MOPYU$-:&SO8;<%9_M8!/+LLBQNO'4"3!^E9&M>%]0TNTM$>V+>89!.%E\Q7
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M .@G-_W[7_"K]% %#[#=_P#03F_[]K_A1]AN_P#H)S?]^U_PJ_10!0^PW?\
MT$YO^_:_X4?8;O\ Z"<W_?M?\*OT4 4/L-W_ -!.;_OVO^%'V&[_ .@G-_W[
M7_"K]% %#[#=_P#03F_[]K_A1]AN_P#H)S?]^U_PJ_10!0^PW?\ T$YO^_:_
MX4?8;O\ Z"<W_?M?\*OT4 4/L-W_ -!.;_OVO^%'V&[_ .@G-_W[7_"K]% %
M#[#=_P#03F_[]K_A1]AN_P#H)S?]^U_PJ_10!0^PW?\ T$YO^_:_X4?8;O\
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M?]1'_NC^5/H **** "BBB@"A9?\ (3U#_?3_ - %7ZH67_(3U#_?3_T 5?H
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M[?=?] FZ_P"^XO\ XN@"_15#[?=?] FZ_P"^XO\ XNC[?=?] FZ_[[B_^+H
MOT50^WW7_0)NO^^XO_BZ/M]U_P! FZ_[[B_^+H OT50^WW7_ $";K_ON+_XN
MC[?=?] FZ_[[B_\ BZ +]%4/M]U_T";K_ON+_P"+H^WW7_0)NO\ ON+_ .+H
M OT50^WW7_0)NO\ ON+_ .+H^WW7_0)NO^^XO_BZ +]%4/M]U_T";K_ON+_X
MNC[?=?\ 0)NO^^XO_BZ +]%4/M]U_P! FZ_[[B_^+H^WW7_0)NO^^XO_ (N@
M"_15#[?=?] FZ_[[B_\ BZ/M]U_T";K_ +[B_P#BZ +]%4/M]U_T";K_ +[B
M_P#BZ/M]U_T";K_ON+_XN@"_15#[?=?] FZ_[[B_^+H^WW7_ $";K_ON+_XN
M@"_15#[?=?\ 0)NO^^XO_BZ/M]U_T";K_ON+_P"+H OT50^WW7_0)NO^^XO_
M (NC[?=?] FZ_P"^XO\ XN@"_15#[?=?] FZ_P"^XO\ XNC[?=?] FZ_[[B_
M^+H OT50^WW7_0)NO^^XO_BZ/M]U_P! FZ_[[B_^+H OT50^WW7_ $";K_ON
M+_XNC[?=?] FZ_[[B_\ BZ +]%4/M]U_T";K_ON+_P"+H^WW7_0)NO\ ON+_
M .+H OT50^WW7_0)NO\ ON+_ .+H^WW7_0)NO^^XO_BZ +]%4/M]U_T";K_O
MN+_XNC[?=?\ 0)NO^^XO_BZ +]%4/M]U_P! FZ_[[B_^+H^WW7_0)NO^^XO_
M (N@"_15#[?=?] FZ_[[B_\ BZ/M]U_T";K_ +[B_P#BZ +]%4/M]U_T";K_
M +[B_P#BZ/M]U_T";K_ON+_XN@"_5/5_^0/=?]<F_E3/M]U_T";K_ON+_P"+
MJ"]N+RZL9H$TNX5I$*@M)%@9_P"!T :</^HC_P!T?RI]-C4K$JGJ  :=0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEX79C.[/?\.E69KC5F54CLE0EQF02 @+GT^E &I1110 4444 %%%% !1110
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MMT:H[DJA/5MHP.M>B4= "BBB@ HHHH **** "BBB@"N8[.*[>=EA2XD0([G
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M>T?_ 'V*X>;QO=6FI7=M/9PLD0*1OL907 C/+="/G)XZ 5<U3Q<=$O[*SO\
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M.<@=C5W[3!_SVC_[[%8UQXCM+25(9H&:5A#P@')DSC'Y5G_\)O:DYCL)I-V
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MX_ T44SR_P!ISM*TZS>8P!88SP/3(.#35\!P&> RZE/)##)YBV^ $ZYP!Z4
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MJ0?$*S6+S;G3[R"':&#L$.<IO48#=P*?6_8/(77_  Q_:>K3WBVFWR[<+&\
M3?.Y(SG) (  &#ZFJ.F>'?$%KJNB37/E26]H\FY1+M,2N'XV@8/51P>U:!\;
MQW$MK%964X:6>*.4S  1AV*^O/0XQD5<O?%UI97$L+6\\LD3NA6, D[0I)Z]
M/F%&W]?UW#<SKU/%:379M$FEC,L@B!DC4[6C8+@9Z!MIYY]JRS:>);"8H_F;
M)KO($A21&8R*05 Y& &SG\*VT\<6WVIHC;32H&&9(PNU%.T GYN>7'2G+XSB
MN]%O;ZRLY0+=UC1I\!'+' .03P,\T 4-/MO%W[@:G+<LC%A+Y)B5E;"X.<G*
M?>]^E6O#UKX@LY;2&^:X>%+39(T\D; 2#OE>3FK%QXDN+";[)<P+-<*(VDF@
M \L!WV@8+9SP:SX/'<K,LESILL,$ENC@[E;RV9G49PW(.T=* $,/BTP6X!NA
M+@^:3)#M\S*\_P#7/&[CK4,]EXNM;.6Z^W7$DB1[S'N0C/S[L #/ VXJS_PG
M8DN(1#;,(3$S/,ZC#,&C! &[/\?>MS1/$5IKJW'V970V[A&#D'.1D$$$@C%%
M@3.;@L?%-[8GSIKA(VAD98YGC+,Y1=H; QC=N_K4DUCXJDN9/++JJEO*E8Q@
MJ" ,*.< <_X5<?Q]8CS1#9W,SQ.RL$*'("%RP.[&,*?>I;#Q@EW>%)[=[6$/
M*H9P&WA-F#P3C[_3%&[#8QH+KQ#;>,K33[VXNVM%<_,J*PD4EL;C]-O(Z8IV
MJ>']2N/$ES>0Z:9;)V3SH"T:_: ">GS<]<_-CIBK[^-)+*XN8M0LV>59#Y4$
M"X8Q@,P?<QP00AZ=.E7H?%EO+ICW1L[A'69(1 =NYF< KSG'(8=32Z(#)T'0
M=>LO$-C<ZCY4EO#8M;EEG)*?<(&W')R#SFHM.TG5M-U:"6+396M([B1OOQB4
MAD(W,=V& /?K[5NZ?XJMM1%P\5M.D%M!YLLK@87KE< Y)X/M62_Q#M1+!+]E
MN%MI(VPK(-[MN0+@YQCY_6GUL!#966JZ)X'NT2UE@U#S%P8ECW29<9(()SP>
MK5'+9^,[A1!OFCA>*92YECW8(?9DCHP^3D<5K/XZL$^5K:Y678)#$X56"D @
M\GN3CZU77XA6AC:9K"Y\AO*\AEVDR%U+8QGC !H J_8?%D4L'V5Y(H6=3,3Y
M;2'"H,MR 1D-[]*=_9?BGSK22>[NI%25))%CDC!_C!'8$8*'%:EAXK74]>BL
M[6UE2!H97,LH )9-G &<C[_.15'3O%6IZC!8A(K:*:]>38TL3JB*@R>I^8GU
M&.] =#2T:?4QI\MIJUI/-<)&S;G9/WHR0%X. 3Z5RC>&-8ECL7BTY[8K.\SP
M>9'LB)=3M&&X7"]1SG/'-;,/CQ&U6]MC"DRPF..!8&&^1R6#9R0 ,J:N?\)C
M!:Z#I5]J$+![^-6*QD?)G'8G.,D=,T+>X>11MK+5-&T/6S:VK0':7MF"IYSN
M<DD[20>HP3S4"6_C&62!%:>.W9SN:26,N$/9L=QU&,U=?Q[ =/:6+3[KSF3?
M#$VSYP49PV=V ,*?>F:EXPN[&ZTQ5MD:*YMXYICL8[=S!>HX&,]Z0;&?%IOC
M"WBM%MWE0;(TG=C$\I(7&2<@$9SWSTJU)I?BAU!EN[EQYZ2E8Y(U( F;*CV\
MO;P:6\\;75CX=BU25;/-X0UM"6(V+GYMYSU ],<\5+=>-G-Z4LK8^1&A9I7Q
MB3;*B,%P<_Q'J.U5NPV1-Y?B<>';KRBYU!)]T'FL@,B9Z'' _/M64VD>+[FU
M)O9G\Z-"BM"Z*[;7CP0>VX!CBMW5_&NG:+J?V&\CF\XC(VJ,$$9!Z]S\OU-1
MQ^.;"2:2-;:XS',L3-\FT;LX8G=@#((I(&0Z3I>O:>+[;,^)DG>))G4A)3(Q
M3I[$9K+N=&\47P/GR7GEM!+$L;319!8)@MC@C(;&.>E=%J'BZST[5'L'@GFE
M6(R#RMK9P,D=<@XYYJ$>-K-VV1VEP\C%!&@*9DW*6R/FQ@ 'GIQ0!G&R\70W
M<$4-U(UHCL-Y\MG(R,;LD<8R..:T?[.UIM$TNW>\G-QOW7TFY=Q&QLKG&,;L
M=*:OC2UN(XY;6"40&2-6FD"@ L <8W9!P1SC%5Q\0;1I RV5Q]G2.5II,I\A
M39V!YSO'2C=6#J9T&E>,-/L[.UM+J4P(L8D),;.IV#(&2/E!S[U=>V\67%T8
M3)+! LI#3I)'EU,I.0.<83 YJ<^.(YY+6.RL;@-+/$DAF  C#OM]><X.,9J6
MX\<Z?;ZO)IC13_:D8IMVC!;( '7N#GZ9H>]PZ&4UIXU@M(8XII9I6,;/(TD?
MRG WC''&<TL>F>)[5\QFYD EDWOYL1D9#+N 0GI\N.#[T]/'UPT<,HTN5H@^
M)"I7+KY!E+ %N,>AK>N_$UG9W]A:R)(S7VW8RX^7=TR,Y_2GU#H9FO6&N7VI
M6BVPE-HAA<@2( &5LMOSR3C&,<5G_9/&<-B(+8NNT0@D&+*@+A@@SCK@Y.*V
M=0\:V.FW$T$]M<F6.81*BA<R?*6R!GI@'ZU&WCFU5I<V%YM3=M;"_,%8*QZ\
M8W#KBD@,^6+QF9[K:TOE^4HBVF++.",D9/ (SGT[9H:#QF9+QWDD'[P&&.+R
MMI7=TW$Y''!X^E69/&K+<31QV;O'&K,)AMQQ($QC=D]>M-N?'\(2.2PLYK@$
M89/E4[LH"N2< C?S0NC#R)=<3Q1)JL?]D QV_D$,=Z$%RC>O.0VWVK/O=*\4
MS,+5YIY[7S596\R,$X9"=_<C[V,5OV_BJSN(;Z3RID_L]"UP"!E""1MX/7C/
MT(JI:>*9=1\206,%K+;PI%(]R9 A*E=N!D,>,-GC-"W![%+Q+HVH:EKCRV>F
MLJQ6Y5;A)$'V@G&4;YL@8&!QU-1:=X?U"TUBTNH]/\L><WR2^6RV\)8G:#G(
M;GMD4P?$-IFF$,4007.R-PK2;8A&7W,J\YXZ5H6?C":37%L+V".%))/W<H!P
MR'[OXG*_G0MP>PV_M/%*WUQ-9W$K0O(X$0>,;8\Q[=F>C8\SK3(]/\4S(#/>
MSQ',:J%>/(7S#N)XQNV8Z<>E7;CQK9PZA<6,=K<3W$,B1A8RF'+-MX.[C!'?
M%,LO&4>J:KI]M8VLHAN21)+)@;3Y6_:!G.>G;%"V!F7)9^-;>P6.">6>9@A,
MC21Y1@&R,<<?=JW-H6K2Z3:Q1N\%S'?SW!>-UR PDV]>.K+6I;>*[2Z_M(0P
M3.VGC+JNUO,'(^7!]CUJA-\0-/MP9);:X$ 4$R@HP#%"P7 .<X4^U(91\GQL
M/M1D=V8JHB6,Q@#[N2"3U'S<$8-4Y/#WB:X+2W+3>9<6S),L4R!3(8T&XCZJ
MW2MX>-8)[69[:RN5:&(R2&15 C&2!D;N<X[9JI9>-)OMLL=[:R$R3O%;PHJ@
MMAPH^;=CU/-/K8G97%AB\1V>K6-DUS+);33.'=]I*1)M8$D#ODK^52WL?B0W
M%UY/VHH;D%?)DB ,.. F[HV<9W?A2KXW2/4+F*ZLI5MK?F2X!7$8W[.1NSQW
M(J]=^*[:TLK2Y:UN'%S"TX10N4C7&6.2/[PX'-'09@7&E>,+BPD$U[-YKH0R
MPR(H&%0@KQP2P;\ZMW-GXH6W9[>>Z9Y)I,('BW(N!Y?7C&<Y[T]?$VJ/X=EU
M**SR?MDL8#)N$<2%AN(4Y/W?UIK^)M9DV2V5M:R1M8K=O&RL'AW8P"<X/\1[
M=*/Z_4/Z_0;I46OZ/>;[R&:>U9I6>.-D(W-(2".<G@]\ 4NL-XDG\27,>BF9
M8XTC*,Q00\JVX'/).<=.*UO#GB%==BE9U6*2,@>5SD#'7GWS63'X\C_MB_M7
MMC*D4BQVHB^]+\^QN6P.&/KTH[(.C9 ]KXMDC9/W[QNLBB.=XB1E."Q'7YLX
M '3K35TKQ1:W%S-:F21XS))")9(RKY,9"#NH.'%7XO'MI)$&.GWBR,OF+$=F
M2FTDMG=CC:>,YI)/B#81(\C6=UY>2(FPO[TAE4XYXY8=<4=0,^32?$L%Y]L:
MZF!2"3<T3)AGV(067&2,JP]:MSZ?KFK:)H]TSLE\DSW+H2 L9:-]BD$<@$J*
MM:MXLGL[.VDM]-F)NK*2Z'F%08]H7Y6&>OS=J+;QQ:37T-C)9W273/LDC"J?
M+.<9.#TY[9HZV#I<CTFT\1OJ-LVHSW$=HA9G1WC+L=JX#%>,9W8Q^-0WOAR\
MAUB]O]&M+>.>66-HY2J]D;<?^^L4[4_'4=AX@NK "$QP0,06?#--E0%QV7YQ
MS4>C^-+K4VL',-MY4YACE",2V^12<K[#&*-]4&URSX?L_$?VR"36[J81(C%H
MSL&7XP#M)R.OI4EM9ZE!-XB-K:RV[W!WVLCR*V]MF,CDXY]:DF\964$L\<L$
MR- 90P;:"=BYSC/0CIFJ$/CV/RV^U6TD)$[*K[0RO&)-A(P<@].M&X$3V'BV
MU\TPW5Q=!@RJKR1@@?N\$<#G/F57N-(\875A#++<-]MA:%E0N@484[SQW)_"
MMBT\;VU^JBSL+MY&1I I"K\H ^;);!'(Z<U8T?Q2FI^0DMG-:RRVHN0'92"/
M08/- &4EIXNGN;E9[F6&)YD$>TQ_+'O&<').=N0>*FG@UG^P=0COA-+BY5HR
MQ4L\6\$C"^U+_P + L5MXY)+&\5Y2OEQ;5+,K*6#<'T'3K0_Q"T]([J0V=WY
M5N^TN=@W$%LX!;.1M/% %7[+XON;JX5I9;:V:8F,J\9(7:^ #Z$[.HS4NEZ9
MXCAU+S;EV=C(TF^X971<Q*, #!'S U,OC=!,YN+.6&W2212QVMN5=GS\'@?/
MFK6D^,;+6=3^QVMO<@XSYC(-O3([]P0?QH0,Q;S3_%;ZM/=HTV]$D2(QO'L(
M+H5"@G(^4$$GGTJM>>&-6OFO M@;>::65I;D3*/.C:, )P<]>>0,8KH+#Q?#
M=7D%LUM,3*X0S  (K'=@8SG^ U#+XEO=/O[S^TS;?9;:=8@88FW$%"^3EO04
MM+#ZF'+X6\3W,,UD98UCBF$D5Q(Y8R^6@$>0""#GK[K7=Z9=37=F'N;=X)5.
MQE?N1U(]LYK*TKQ;!K%Y#;VMC=*959R\@4!5&.>O.<CIFKFF:E/=:EJ5K<I$
M@M956,HQ.Y2N><]ZHG0U**R;'Q#:W^N7>EQ(XFMEW,Q(*L,XXP?7UK6I#"BB
MB@ HHHH **** ,V]BT:74(UU!+-KMDV()MN\J>PSSCK442>'HX0EN-/$8)15
M39USNVCWSSBJ6J^%SJWB$W<]R([4Q1KY:J-[,C,W7MU'2J\/@:&-HG74)-\9
M4!UC53M48"\>W4]Z70"]:7_AR66/[+]E\Q#Y?"J#&2I.#Z<$_G5O[/HDDBVW
MEV+.>%BPI)P"O3V&16*/!&GP1+!)>L(WX12%!+>5Y>0>YQS]14VG^"+73]3M
MKU;F:5X4 82<^8XS\_7 )+$U6EP+D,/AP7$ 6"QBGB8K"K*JNI#'[HZ]0:C$
MGAC4;RYD9=/EFW"&25PA\PD [<]^,57E\$64_G;[F0F5LD@#*_O&? /_  ,C
M\*JI\/;4W$<[WTCNC#("!58848*KC^X.:7J'H;JVVABWDD2.Q6)5 =U"@ <8
MR?P'Y50TO2O#NB6]W!#<P-%,H,R32H1M[9''7/4]:+7P=;VFCW^GQW+LE[*9
M79T'RN3DD8]^GI42^#5$;(NI2,?-24,\2L=X &3Z@XZ&@#0B'AVUC,41TZ)5
M"Y4%  ,Y7]>14K6>B6Q$3PV,1E^8(P4;\$G.._))K%?X>V)L4MTN9E*RB3?_
M 'L)LP<8R,5H:AX8BO9MXN6A1K46KJ$!RHS@@GH>?QH 7;X6B;S_ /B5H9AM
MWY0;P,<9[]!^0IUI!X=@O(6L6LHI<,\:0NJ[LCEL#KP.OUK-M_!6GS-).UY]
MI=R-S*B[00RG@#@?= J!/ "->7'FWK?8W.Y$10'SA_XNP&_H/2@#92/PW!"T
MD$>G[7WL?*"'>=I#8QU."1^-+8W7AYIFN;)[%)?,,3.I56WX&5^N /RK,/@2
M)B6:_D$C!E=TC5=RE0N..,8 I@\#V$\D4\5^SQI,SJ%QM;.W<#@C/*#]:.H&
MK>)X>TO[1/<Q6,4@1IY 54.P"G)QU/!/YU%<7^A)I%H]];1);:DZ*D;1A@Q(
M^7.,C@ <]JCU;PA;:M>S32W3HDP :,*#\P4J"#U P>E2ZIX3L=8A@CNY9@EM
M 8HA'(4"DX^;CJ>!P>* #3]:\/,LL=@8HPOF12*L6W'E<,#QT&:BA;PU-H4-
MY!86[6EPXC1/LX!+,P&-I''('Y54'@"Q,@D6]N 6AEBFVD#S0[[B3CH<9&1V
MJ[_PBD5I8BWTZ5PBWJ7:)*Y8*01N&3D\\GZF@"2U?PUJMFLT:6$D;PA2&5<A
M%Y"D=@.N.U0WC^&K>XFM+C3HF^SP*\A6TW(B#)7)QCUP*S6^'T:);)#>,S1R
MQ[F*A/W*YRN .<YP2:U-1\)1:AJ5U>?:/*-U;"W8>2I*@ C(8\CKTH 5[[P_
MIFK@1VR+?R[4!AM\NP9<CD#IA?TJ!I/"H-Y9"PMBMK/&)X_LXVJ[\!NG/7K2
MW7@\WL<@N=09WE"!W\E<_(" 5_NGGJ*@E\#V\",]G=3>?-\MP\TI82 R!R<=
M 1@XQCK1U T]631+)85OM/CE-TXA1$MO,+E06 P!T&":JW.H>&S:R-<VB-:Z
M8IQ(UJ3''MP"J'&,@X&!Z5/J/A^36+2P6_N8S<6<QFW"$,K'##&T^@;K[57F
M\')<6<]E)J-PMG)(\J1(%!1V)).<<C))P:!Z$TLGAF<VMK-#9R?:(P\<31J2
M%5"P)'8 9JF-<\+WEQ UU:HDMO#OB>>V_P!6H7> &QCIS@5%)X#4;6MM0D)5
M=O[Q0204$;?,.?NCIZU->^ K&^U:6\DG9!(FW8B*"/DV8W=<=\>HH>^@EMJ3
M)=>&XVB5[!('U.;RPDEIM:5NN2".GN?6I%A\-WT]XT*VBM R-<SQ[5!Y# %A
MUZ#-17/@];^:">_U2YDGMRN'0*@*KSC&/UI+/PC%:Z5=6D6HR9NUC42HJJ0J
M# QCKQU- &C/_8-[=(UR;">=D!4N49BH.X$>P(S^%58$\+W$-S<1P6'DQ7&)
M9BBA3(.<YZ'[W6J"_#^Q2Q%LUW,?N@2$#=PK#&?^!5--X3=-$DLK6\4RR7L=
MT\KQJ -I7.%''1: -&:+P]<W)GG&G2S2Q9+L4+,F.N>XQ5*;_A$X6,$MOIX\
MT *OEKB4*NX8]<"JB> +1$"?;7>/[Q5HU.7*E<Y]/F/R]*F_X0>$QINOYGD4
M8,CHI)!C,9'Y']* +=RWAJVC6]GALE#(!YFQ<A5]?0#&/PJ:ULO#LUO']DM]
M/>([F0(JD<J-V/PQFLP^ +$B=3<S%9F!"D#"#:00/8EBWUJSI/AG^S=>FO7G
M$B?9DA1<8PV,,V.@) 4?A0 FES>&+Z"WNK>WL8MA;[/O"!@%)^9?09!-7WCT
M)Y([]Q8EY7!2X.W+L!MX;N<9%8TG@&T:%81>2+$4"LH1<DC."#V^]T[U>U?P
MK%JNG6=D+J6VAM<#;$,;\8Z_E0 YY?"]O\Y.G*680979U*E0OY9&*M.FC2I:
M:A<Q6JD!?L\LRJ"O< $]*R(O!E@T*"UO"3$R#>JJWS([-S[_ #$5:_X1."*&
MP$%W*DEG@*TA\Q6 7;]T\#CTH 03>%;Z2X\U=/,I=3,)54,6.=N<]^N*-5N?
M#=I;(;RWM9HY2<*D:OG(+$_0[/TJ*T\%VEI<QR_:6=5D238R+\S+NQS_ ,"_
M2H&\ P2,?-U"=E'$:[%&Q?GX]_\ 6'GVH TXO^$>N)(QY=DLN6"(ZJ&Z\X'7
MJOZ4W?X8>3[)G36,JR2[!L(89&\_GC-5%\%6D3O(+J59'E$@? RIW,V!_P!]
MFJB?#RU6&5'U&=FE5UD<@;B&V]^HY0?F: -99-!TOS"DL#?VK.N5#!O-+808
M ZCC%3V_]A:?,\5J;&WD@5MZH54Q@XSD=NWZ5E0^"+:&>VE6\;]RR.PV [RK
ME@<G)')Y]:@N? ?]HWM[/?7K()9VE@6$8*9V<D]3]SI0!K7K>&?+<WW]FLK+
MY[!]AW  _-[\9YID^H^'(X1>2FU*QR*T;[5)9B!@KZG&.E9?_" I)=2)-=8L
M_+151$&YF"L,DGD?>SBG77@BSW"2?4FC+!8W+(@# ;<  ]#\@Z4 ;L5KH?VB
MXN(HK'SE8//(H7<K YRQ['/K4,?_  C=K<Q7,1TZ*;9^[D4H&*@$<'TQD55L
M?!\&G6VH107DP-Z"!(3EHP23@$GU)JO:^ K.WA"/=2RG<IWN 3Q(7_4MB@"Q
M%J7A>,#R19I%J!PT@10DN5+<GH>AZT^/2_#%K>7$^RP$@0+(&*?NDQC&/X00
M?UK/'@:TN+2)8-2+>4!&'6-&& C1XQTSAC^-/_X0"V#*4OI1Y3%X<HIVDLK'
M=_>&5'!Z4:7 MV3>%[RVBGAM[)(E&R)I(U48;L,^M: T[1KZ.1!;6=PH8AP%
M5L'.2#[YYKG_ /A7EB%@C^VS%HN0#P&&,'(&*V-)T.;2+I_(N]UI(SR/$4QA
MCC 7T'4F@#-FNO#&HVP@%HQ%XSVR-':D,X_CP<=..35_4[O0H[^STS4K=)9
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M>$5?_9:?470M0:=96UU+<V]K#%/-_K)$0!G^I[U9HHI#"BBB@ HHHH ****
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M'AZVURVNW34UD$0C/E;&C\H<GJ!SN_2L2/2/%9NGNY/.$[ !G+1,0P1QE!T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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3T;C0 ZBF[C1N- #J*;N-% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exdx-20201231_g4.jpg
<TEXT>
begin 644 exdx-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-U;FYI;F<L
M($MY;&4   60 P "    %   $*:0!  "    %   $+J2D0 "     S,X  "2
MD@ "     S,X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M<')K7B#_ (57-J<=W;C4HC+YLK1G;A9&7Y1V.!QG-=U$2T*$\DJ": '4444
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M"'*CIV/3TJQ:V%I8M,;.VB@,[F24QH%WL>K''4^]6** "BBB@ HHHH ****
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MV6NR&2ZDGCD\H1!XG *@.'XR#SE1^56-+T6#2GFE26>YN)\>9<7#[G8#H.@
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MZU*;48+JR:Y1KA5WQ,K*",J!D'=Z=J .HHHHH **** "BBB@"A+_ ,C#;?\
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M;PEHC64-K]A40P1"&(*[*44,&X(.0<@'/6MFB@##C\&:#"T;16.TQDL,2O\
M,2VX[N?FYYYS6M:6<%C;^3:QB./<S;0>Y.2?S-344 5=2TZWU;3I;*\5FAE&
M#M8J00<@@CH01FL)O >FR;I+B[OY[K<C+=RS[I$VYP <8QR>U=/10!S=OX%T
MJWMYX0]TZ3PRPMYDN3MD8,W./457U?P1%J&N6E[;7,]MLE,DSQ3%7SY7EKMX
M].N:ZRB@#FO^$#T=80D'VB%U$>R:.7#H4W88'U.]LYZYK;TW3X=+L([2W,C(
MF3ND;<S$G))/<YJU10!3L=+M]/FO)+?=NO)C-+N.?FP!Q^ %9MQX/T^:S@@C
MENK=K>21XYH)=L@\PDN,XZ'-;U% &%!X.TBVU"VO((622VM#:1@/P$]2.[<G
MGW-5/^%?:./)5)+Q(HC$QA6?"2-'C8S#')X'UKJ** .;3P+I2)-'YEVT,BE4
MA:8E(06#$(.W(]ZU]0TJVU-;8708BWE$J ''S $<^W-7:* .57X=Z(FF?88_
MM"1"*2(,)?F =U8\XZ@J,>PK3TCPY;:3=RW?VBZO+J1!&9[N7>P0<[1@  9]
MJUZ* "BBB@ HHHH **** *$O_(PVW_7K+_Z%'5^J$O\ R,-M_P!>LO\ Z%'6
M/\1+JZT_P+J-]8ZC-I\]K$9$DA526;H%^8$8)(I-V5QI7=CIZ*\@A\>:YX;U
M:WT*=I=;N@MN]Y+<KM8&4#*Q[%"@*,GFH=3^*NN7T6JV.GQ6=A<!DCM)-Q=\
M/,(U?/W6!!)XZ576R%YGLM%8/B;6KCPUX'O=59%GN;2VW$ ?*SX S],\UYW>
M>,M;\-W\<MMKL?B7S; S7$&Q!%!*S*L85DY )8C!).!2ZV#I<]BHKR'7_B-X
MB5VL(4L+.>*^ALYVBD+2[CAW,:D<J$XR:2P^,.LZEM%EHUNQNGA6SWLZ@%Y-
MNUSCKMRV1QQ0M=@V/7Z*BM3<&TB-Z(Q<;1Y@B)*AN^,]JEH **** "BBB@ H
MHHH HZ9_K+W_ *^6_D*Q?$-VUQX@M])>::"V^R273B"7RGG*D (&R,=<GD=J
MVM,_UE[_ -?+?R%/OM*T_5!&-1LH+KRSN3SHPVT^V:!GG=GX[N+.S2VTBWNK
MQ4W2DWH,C!3(46,.A(/*G#$GM6HWCG4HV@>2TM3'>&06ZAF!7$JQJSGI@ENW
MI76'0M),D+G3;7?;Y\H^2N8\G/'''-.DT;39H/)EL+=XMGE[&B!&W.<8],\T
M"///^%@:Y;ZIJ-OY$%V\+DJ88W:+:N%PN.06;(R3@8KL]%UF]U&"]O;JW1+2
M&1HX4B5GD?;P2?QR,#TJV/#NC+Y.W2[,>0Q:+$*_(3R2..*O0P16\?EP1K&F
M2=J# R3DG\Z.@=3"\2:E/_8EH+"6:SGO[F*%'9-LD8+98X8<':#U%<XFHWLO
MB$Z!)K$\NG2W107S,JR-MC#-&'4 ?>/4<\&NYU#2K#5H%AU2S@NXE;>J3QAP
M#Z\]ZCET/2IM/2QETZU>T0Y6!HE**?84 >=3ZKJ-MKCZ5HUWJ5SIXGDD$D$\
M;2A$C4, \IY7>P[D\&NZ\'W=S?\ A*PNKV9IYID+%V #$9.,XXSC'2IKCPSH
M=VL(NM(LI1;KLB#P*?+'H..!6E'&D,:QQ(J(@PJJ, #THZ!U'4444 %<-KEE
M>WGQ+C%A%I\A72LM]NB+@#S3TP1S7<TFU=V[ W8QG'.*.MPZ6/-)=?UZ/QE)
M9I=V]O'!<K EGOQOBV9+"/83ZX;=CBJD>I^(DT];Q]?N7(TR"^*&*/!=I-I7
M[OW<=J]4,,9E\PQJ7QC=M&<?6CR8\8\M<8QC;V]*%H!Y!KOBF]N9[^W.H/):
MW,=U"UO*R#844[<(!E>1U)Y]*V-/\0:Y-XV2U:\ACB6[\C[$TGS&$)G<$"9]
M]V[%>BFU@+%C!&23DG8.:=Y,8E\SRU\S&-VT9Q]:%I8'J0++>G4FC:UB%F$R
ML_G?,6]-FW]<UY[8K"WB>VB4 :N-:N&N,<2>04;!)Z[<;<5Z931%&)#($4.1
M@MCD_C0M[ATL<'HUHL%K?Z3;&0K/K4@_>.78JH#MDGD]*S_"\%M<:II5M"-M
MXMO>)JIC)5P2XQN(Y!ST_2O3 B@Y"@'.<XH6*-'9D159OO$#!-"_K[K >?Z#
M' GA6RTZ5Y%M89[N>9BQ+"..1^<GG.2.:YNV?2;]K34[1[*#2XY+>&2SBD#O
MY <GS9\=\X^G>O9/+0 @(N""",>O6HTL[:,,$MXE### (!D4+>X=+'D1^PJU
M\]^J?V7+:WPTO</E+F08">Y[8_"KFGH5O;>&\ _M_P#M6W<;A^\\H1+N/KMQ
MN]J]3,$3*JF)"J?=!487Z4[RH_-\S8N_&-V.<?6A:6_KK<'J.HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A+_ ,C#;?\ 7K+_ .A1
MU'K]QI\&E-_:UNMU#(ZHMN8PYE?/RJ%/4YJ27_D8;;_KUE_]"CJIXBTV]O6T
M^YTSR6GL;GSA%.Q5)!M*D9 .#SG.#0!6M)]$U+4?MFHZ5%8ZG XA4WL:"7ID
M!6!.1@]C3DTWP?#:W#QVNCI!YH,[!8PN\'(W'U!YYK/NO"^KZM)-<:G=6XN#
M9SQV_EC(MI), ;>.<!>O7DUBQ^ =;@M0(&M0[@*Z/,#MVJ0A!\O!Y+9X!Z<T
M =M)KFBS37%A/>6S".!99E=QL\M\@9)XP<51EM_"&AZ;M^RZ9;VTA698HHT_
M>D$;6"C[QSC!%<P_P_U<6UN(WM@\!AX6;&\)#LP24/1LMTYSVJ>#P!?0/#:L
M+.>T%Q;S-/*Q,J+'@E%&,8W<]1UZ4^HNAV3^']&FU(:E)I=H]YD,+AH%,F<8
M!W8STI+?PYHMH0;72K.$K+YP,<"C#_WNG7D\UI44AE+5=6M-&LQ<WSL$+A%5
M$+L['H HY)JJOBG1VM[&7[:@&H2>5;HW#.V<$;>O&.?2JWBN"X/]EWUO;R72
MV-ZLTL42[G9=K*2!W(SFL2'0[PZ+I<LEBPN/[9-V4*@M#&TC-SZ<$9H7]?@#
MV_KS.DU/Q/IFDS>3=/*TVX*(H86D8G&[@ =AR:K_ /":Z&;BWB2Z9Q<*C+(D
M3%$W_=W-C"D^AK"UV34[.&&2UTZZ-Q?7,K374%KYTEK'C:-H[$@ 5C:AX<NA
M''8Z!:ZI;6MVEL[K)$I5O+8$ER>4; Y'?BA>8,[G4O%^D:5,8KJ:4R*6W+%"
MS[0N-S' X49'-+'XOT634OL271+GI)L/ED[=VW?C&=O.*Y764U""&SL?[-O0
ME[ [W]Y9VOFR@.V3"#_#UY/M4,6E7EJJ:=!HURT%O?M?JS)\K0^7PF?[Q^[B
MD!UUCXRT2^CGD2Z,,<$0F9[B,Q QGHX+ 97W%:MA?0:GI\%[9OYEO<1B2-\8
MW*1D&N+\+P2ZH+VZUC3KR.^DM/)6&>T\J&&,<B) >O/?VKI?"=M-9>$-*MKF
M-HIHK6-'1A@J0O2J_K\Q%G3/]9>_]?+?R%9_B'Q*N@WUA T?F"Y+E@HRV
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MV\KFW)E &=Q4[L#)9CT[UV%G:Q6-E#:6Z[8H(UC0>@ P*70?4FHHHH ****
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M * : .:M?B<E[:175IX2\2S03('CD2Q!#J>01\U2_P#"Q9/^A-\3_P#@ /\
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M] #QI_X!1UZ%5)=8L#<20-=1I)')Y15V"Y; .!GKU'2@#BO^$RN/^@!XT_\
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MB+EF.P\ =S6I10!Y%I?B30+[P%HNDZ]HFONUK:Q*PCL+A,,$P>5QD=:DDO?
M4DPE/A?74;[.+8B.PN44QA2H4J.#P37J"ZC:-J3V"W$9NTC$K0Y^8(3@'Z9!
MHM-0M+]IQ9W"3&WD,4H0YV..H/OS0!YY8>)?"6F:/-I=IH7B%;.92KQO87+\
M$8P"V2!CTJ&XUKP5<+#GPWKD1@@^SQM!IUQ&RQ\?+E<>@KL9?&FEQPZS(!,_
M]CC,ZJG+CU3UY!'U%.7QEI;V,]VC2-##9I=DA>2K%@% _O94C'K1YAY'#C4?
M H,.?#&N,D$1ACC;3KAD52"#\IXR03SUIBW?@);$VH\,Z]L\U9=YL+GS RC
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M*_Z!6O?^"J;_  H_X6?I7_0*U[_P53?X5VE% '%_\+/TK_H%:]_X*IO\*/\
MA9^E?] K7O\ P53?X5VE% '%_P#"S]*_Z!6O?^"J;_"N=U#7]"U#4+V\:T\1
MI)<A-J_V3*5C*XR0-O.0H!SVKU21UBC:1SA5!)/H*R[_ ,26%EH$VKQ,UY;1
M*6/V4;S@=?I^- 'FG]IZ(L.(4\2QRDY,HT>3/\><#;@?ZP_I6AX?\2>'_#T\
MTEOI_B"8R#"F329BR+QQG'3@?E7<'Q)&=86PBL[B3]PD\DP*!(U;.,Y;/\)Z
M TW1O%%MK5T8(K>X@+0_:(6F4 319QO7!/&?7!Y%'470QO\ A9^E?] K7O\
MP53?X4?\+/TK_H%:]_X*IO\ "NFFU>W@U1K!P_FK:FZ) XV@X_.JUIXHTF\B
MMC'>1K-<Q++' [@289=P&/7% S"_X6?I7_0*U[_P53?X4?\ "S]*_P"@5KW_
M (*IO\*UH/&6C33O!)<B"6.".=U?H%?..1P3QVK;BE2>%)8F#(XW*P[B@#CO
M^%GZ5_T"M>_\%4W^%<W+KGA^;4)+N2R\0L[R>9SI$OR_/O./E[X4?A7K%82^
M*%FN+^*RTV[NA8N8W>,H S#&0 6![]\4NH=#SI-0T!>MKXA<_9O(&='E^7[W
MS 8P#\QIK:EHEQ<W+7%EKB0.P$4,6C2#:@0)@G;G[N>.G-=L?B#;)I]K>2Z5
M?I'<PO<("(R1$@!+G#=/FZ=?:K<_C6RA>1TM;J:S@9%N+M$'EPE@",Y.>XS@
M'%,#AFU;P]YUU(MCKX-Q*LBYT>4^7A@=HR.GRCBF1ZIH<=X+DP>(G=9 Z;M%
M?@;F;'W>>6Z^PKO;7QOI5W/<0Q^<)+>\%FZLN/F/1ASRO!Y]JM:7XB35KA?L
MMA=_9'W>7>,JB.3'<#.['H2.: /-3?\ A\Q^4UOXC:+:!M.CR9)VA3D[<X(S
MQ[UT.E>/-%TFT>"'2]>*M*\G_()E&-QSCI6[-XWTZUU&XMKN&X@B@D>(W+*#
M&SHF\@8.>GJ*CD\=6=K"SW]A>V9,(FA695!G7<%R,-@<LO!QC- %/_A9^E?]
M K7O_!5-_A1_PL_2O^@5KW_@JF_PK3NO%J6L?S:9>-.+5KIH%\O<L8;!.=V#
MZ\&HD\<682U:ZLKNU^TQI,HD"':C.$#'#' RPHW H_\ "S]*_P"@5KW_ (*I
MO\*9-\3-*E@>,:9KREU*[AI4O&1UZ5K7?C"V@U3^S[>RNKN?SFA'E; "50,W
M+,.@(K?#?N]S#;QD@]J-T'4\<^U^&X(8UL].U\)$PD$#:3*$D;8%.["]\9_$
MTZWU/1!Y<T]EKJS^0R.J:1*45V9FW+QU!;KCL*]7M]6L;J,/!<JZLI8'D9 Q
MD_3D4@UC3S',XND*0+OD;LH^M 'ES:CX:,LI33]?$<D*0B,Z1*0@4!3CCC(!
M!^II#JFA;;Y([?Q$D=XI#JNC2?)\Q(VG&0.<8[UZZCK(BO&P96 (([BH)=1M
M()TAFG1'?A03U_&A@CS*\UWPW?:+;Z9<:7KQAA+L0NCRC<[*1N/'49S]:JG4
M]!>Y,DUOXBE3.?+;1I,=4)R=O/W /H:]8M+^VOT9[29954X)7L:234;.*X>W
MDN(UE159D)Y 8X!_$\4=0Z'C%S>:=<WWD_9=>33V!9V&ER^9N(;&!LX&6SUK
MK](\>:+I&G):0Z7KI"Y+,-(F&X^IXKT#</4?G37FCC(#NJEC@ GJ:-@.._X6
M?I7_ $"M>_\ !5-_A1_PL_2O^@5KW_@JF_PKLDD1T5U8%6&0?6FR3QQ2Q1NV
M&E)"#U(&?Y"@#C_^%GZ5_P! K7O_  53?X4?\+/TK_H%:]_X*IO\*ZB75K&"
M62*:X5'B&YE.>!T_'J*5]5LDM([EKA?)E.U&&3N/I0!RW_"S]*_Z!6O?^"J;
M_"C_ (6?I7_0*U[_ ,%4W^%=7#J-I/=-;0SJTR#+(.H_SD47NHVFG(C7LZPJ
MYPI;N<9_E0!RG_"S]*_Z!6O?^"J;_"C_ (6?I7_0*U[_ ,%4W^%=F&4C(((^
MM1?:X-Q7S5W*<$=QSC^8H Y'_A9^E?\ 0*U[_P %4W^%'_"S]*_Z!6O?^"J;
M_"NTR/6HA<1&:2+<-\:AF'H#G!_0T <A_P +/TK_ *!6O?\ @JF_PH_X6?I7
M_0*U[_P53?X5U<FH6D0B+SIB8XCP<[OIBBVU"TO))([6=9&C^^%[?YP: .4_
MX6?I7_0*U[_P53?X4?\ "S]*_P"@5KW_ (*IO\*ZR:_MH+E+>695E<;E7V]:
MF61'4,CJP89!!ZB@#C?^%GZ5_P! K7O_  53?X4?\+/TK_H%:]_X*IO\*[/<
M/4?G5>\U&TT]$>\G6)7.%)[G&?Y"@#E/^%GZ5_T"M>_\%4W^%'_"S]*_Z!6O
M?^"J;_"NS#J1D,"/K47VN#<5\U=RGD=QSC^8H Y'_A9^E?\ 0*U[_P %4W^%
M5-6^(^G7>BWMM#I.NF2:WDC0'2Y1DE2!VKO\CUHH Y_P'!-:_#[0H+F)XIH[
M&)7C<892%&0170444 %%%% !1110!Q:?#'1AXYNO$+(Q,\&SRO.D&').YL[N
MX.,=JE\(_#W3_!]QJESIV?/O97:-F=R(T.,*06.<$=>M=>3CK01D$'O0M-@>
MNYPB_#J:*W*QZO*[W%J\%UYJ@JQ9M^5 QCYL]2>M/E^'CG5KR2WU-X+&[EA=
MH$0!H]C,Y"DY&"[9Z>M=')>Z1%%>227P5+'_ (^2;AOW/&?FYXXIQN=+\N1S
M>?)'"+AV^T-A8SG#9STX- &5#X1EA\+7>B?;FDBDN?-ADD7+(N\/@XQGG/IU
MKF;#PIJ=YJU_!>020K))+)%<NO%N?-#IMYPP)4$_2N\FN-.@TY=0>X<VKA-L
MJS.0P8@*1@]\BK0M(2!AI/\ O\W^-'6X=#(\.Z#=:7J&H7M[-;-+>E"4M8BB
M J#EL$GDYYK?JC)]BBN!;R3LLIC,H0SMG:,9/7IR*IPZMHEQ>QVL%^9)Y45U
M1)G.589!ZXY'- &U15<6D)Z-(<?]-F_QJE9WNDW]Y/:6=X99X.9(UF?*\X]>
MF: -6BH/L<7/,O\ W^;_ !H^QQ>LO_?YO\: )Z*@^QQ>LO\ W^?_ !H^QQ<\
MR\_]-G_QH GHJ#['%ZR_]_F_QH^QQ<<R_P#?Y_\ &@">BH/L<7K+_P!_F_QH
M^QQ>LO\ W^;_ !H GHJ#['%QS+Q_TV;_ !K,O]6T32[R.TO[YH9Y.41I9,M]
M,4 ;5%9\$FGW3[8+AG<J6V^<X. <$XSZU8^R0\?-)[?OF_QH L45!]CB]9?^
M_P _^-'V.+GF7G_ILW^- $]%0?8XO67_ +_-_C1]CB]9?^_S_P"- $]%0?8X
MO67_ +_/_C1]CB]9?^_S?XT 3T5!]CBXYEX_Z;-_C1]CB]9?^_S_ .- $L@9
MHF"-M8@@-C.#ZUS-SX09=#U2WL+I?MVJ1F.XNKA,@@@CA%( QFM>ZFTZRF@B
MN[KR9+E_+A1YV!=O0#-,U&[TO2$C?4KMK=7.%+S/@_K0,QK_ ,)7>J/8?;)K
M%#;"/?<0V["8[?X58MPI].>]6/#OABYTB[AFO;R.X%I9BRMA'&5Q'NSELDY;
M@#CTJZVIZ*E\]D]^%N$0R,C3L,*!DG.>PYJ73KG3-6A>73KIKA%;:Q29^#^=
M/S%TL5-:T.^N]42_TJ[A@E-J]K()XBX*,0<C!'((K.B\!I!$$BNE^62V96:/
MY@(D"8SGOUKJ/L<7K+_W^;_&C['%ZR_]_G_QI <B/ UQ%:?9X[FVE1K*"V;S
M8V!#Q$D.I5@1U_2NKTNUFLM*MK:ZN#<S11A7F(P7([T_['%ZR_\ ?Y_\:/L<
M7K+_ -_F_P : )ZYQ?#=RWBM]6DFMHE\IX]L$15Y0PX\PYPV.W%;GV.+CF7C
M_ILW^-9RZGHK:C)8#4!]ICSOC-PP(P,GOV'- &)=_#V#4-+TNSO)TD&GV4EN
MC^7R';;AQSQ@K3Y/"&I/;W=E_:4'V'4'62['D'?NPH<(<X ;;W!QFM.+7?#\
M\4\L6IJR0+ND/GN,+G&>O(SW%++K>@P6RW$NH;8S'Y@)E?[N<9QUQF@#(E^'
MX?4+.[BO?+>"]>>4!.)HV)8(>>H/0_6I-)\&W6G:OITTEW;R6VFJ\<!6$K,Z
M$$!';."!GTK3@UK0;F.-X=1#+)@H3.XW L%!Y/3) I][JNB:=,8KR_\ *DW!
M2GG.3DC(& ?3FC8-R@_@6PN'UB6[)DFU%Y"LF3^Y#H%X!.,\=<4P^&=6N9$G
MU*\L;F6WM6MH$-L?+8,1N+C=R2% XQ71);02(LB-*589!\U^1^=.^QQ>LO\
MW^?_ !H Y?3/!$MC%()+Y6\RRFM0BH=L?F/N&W))VCH!5B;P<MS$D4UR"BZ5
M_9YPG.<@AQ]".E=!]CBYYE_[_/\ XT?8XO67_O\ -_C1_7Y_YL/Z_+_(Y%_
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MV;_&CK<#C;[P??Q)"L+"]'FEY,X&['3.2.?<<UH1^$9CJ+WD]S#(QE$BIY.
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MAS]Z3)_Z;-_C0!S\_A.:625DN85W$E"8R2<L&&[G#8Q@5)_PB>;N29YXV,H
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M&>F47_"@#0HK.CM;B6-9(M5=T895E1""/RIL$4MS&SP:N\BJQ5BJ+P0<$=*
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M +]K_A0!>HJC]AN_^@E+_P!^U_PH^PW?_02E_P"_:_X4 7J*H_8;O_H)2_\
M?M?\*/L-W_T$I?\ OVO^% %ZBJ/V&[_Z"4O_ '[7_"C[#=_]!*7_ +]K_A0!
M>HJC]AN_^@E+_P!^U_PH^PW?_02E_P"_:_X4 7J*H_8;O_H)2_\ ?M?\*/L-
MW_T$I?\ OVO^% %ZBJ/V&[_Z"4O_ '[7_"C[#=_]!*7_ +]K_A0!>HJC]AN_
M^@E+_P!^U_PH^PW?_02E_P"_:_X4 7J*H_8;O_H)2_\ ?M?\*/L-W_T$I?\
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M'8ML:+Y2V.J[^,FNU_XFW_3G_P"/4G_$V_Z<_P#QZ@#F)XO$2>$-/67>(PD
MNHK9&%R%XW\@_P AFLG2K/6+$V*QP:DT3W%QNMY59<*[DB1F'&<=F]?6N]_X
MFW_3G_X]1_Q-O^G/_P >HZATL>:G0;V_\.6]O::/<VTL&F26]X9(?+,[-C"
M?Q<@G-3/HOB&WN-1T=+*2XMY(K>SM[AW*H\ =V8%@"1A3MZ>E>B?\3;_ *<_
M_'J/^)M_TY_^/4!T.4AL-6;X<3Z1<V;+=VDZPQHC%P\:RJ5*G R O?':N<:7
M4=;U'4H1<7,KEY1':^8^VZ1)EW #[HPH*\=<UZ=_Q-O^G/\ \>JO#I]S;W,E
MQ!::;'-)]^1(R&;ZFCK<.EC/\*27,FH:D6L6M;+]W]G,EIY#'@Y4CN!QS73U
M0_XFW_3G_P"/4?\ $V_Z<_\ QZ@"_15#_B;?].?_ (]1_P 3;_IS_P#'J +]
M%4/^)M_TY_\ CU'_ !-O^G/_ ,>H OT50_XFW_3G_P"/4?\ $V_Z<_\ QZ@"
M_15#_B;?].?_ (]1_P 3;_IS_P#'J +]%4/^)M_TY_\ CU'_ !-O^G/_ ,>H
M OT50_XFW_3G_P"/4?\ $V_Z<_\ QZ@"_15#_B;?].?_ (]1_P 3;_IS_P#'
MJ +]%4/^)M_TY_\ CU'_ !-O^G/_ ,>H OT50_XFW_3G_P"/4?\ $V_Z<_\
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M^440%.?3]:[_ /XFW_3G_P"/4?\ $V_Z<_\ QZFW=_UWN'3^NUBY 0UO&0"
M5& 5VD<>G:GU0_XFW_3G_P"/4?\ $V_Z<_\ QZD!?HJA_P 3;_IS_P#'J/\
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M'S&M^1/#LMX+N6RA>X";!(;8E@N,8SCTXJ=;O1T*%8E!CB\E"(#\J<?*..G
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M4W_?HT?:U_YY3?\ ?HT 3T5!]K7_ )Y3?]^C1]K7_GE-_P!^C0!/14'VM?\
MGE-_WZ-'VM?^>4W_ 'Z- $]%0?:U_P">4W_?HT?:U_YY3?\ ?HT 3T5!]K7_
M )Y3?]^C1]K7_GE-_P!^C0!/6)X?U"_N[_6+;4FA8VET(XS$I4!2BL <GD\U
MJ?:U_P">4W_?IJS=.TS3M*O+JZLK>\66Z;=,7>5PQ]<,2!^%'4.@V[U>X@\2
MO8KL\E=.>Y&1SO#@?EBL/_A+KO[#87SJSI;Z:M[>QQ #>TF%1!GISN/X"M[5
M-*TS69(WO[2Y9XU*J\?F1G:>JDJ1D''0\5%!HVG1PWL4EM-)%>,NZ,Q$!54
M*HQT Q0OZ_'_ #_ .O\ 7E_7S,>Z\>SQVUVK:3+:RQ":-9))%=1*D9D P#R,
M#K776$S7.FVT\F-\L2NV/4@&LRXT?2+I9!/I\KB21I'^1^69-A/_ 'SQ5C3+
M:TTBT%M917@B'($K22D>P+$G'M0!IURC>/+.WU.YM+Z!K86\[1F1FX9%4DN.
M/4$8^E=)]K7_ )Y3?]^C63=:'HM[()+K3'D8-(P)C;.7&&_,4 ,B\;Z)//##
M%-*\DWW0(6XZ]>./NFH7\=:8S 6JS2CRY'+F-@J[&4$$XX^\*@D\(Z<VK17<
M9OHTCB$30X=@Z_-P23G!W&KL?AW0XHUCCT^<*N[_ )Z<[L9SSS]T=?2@!)/'
M&APQHTETPW8&!&<@\DC\,<UT"L&4,.01D5@G0-$.2-.F0F=I]R+(IWG@G(/?
MTZ5L?:E QY4W'_3)J )Z*@^UK_SRF_[]&C[6O_/*;_OT: )Z*@^UK_SRF_[]
M&C[6O_/*;_OT: )Z:[;(V;KM!-1?:U_YY3?]^C2-<HRD-%,0>#^Z:@#*T_Q&
M;VV@F>V5!- \ZA)"V H4X.5'/S5&WBH1VMQ-/;I%Y:*T2/+AI-V,=1C&3UR:
MG72=,2.)%MKO; I6/YY>%.,CKTX'%.73-,%Q',;.=WC ";P[! /0'@=!1U M
M6^KVL^F+?E]EN81,7/W0#[^U55UX27]O$L&RWG4%9IF*[B20 !CGIW(ZU9MT
MM;5&6"VF5&ZIL8KU)Z=!U-0_8M/$J.+2=?+;<J*KA <YSMZ9_"CJ'0EU355T
M_39[F%!=/"RJ8D<9R2!CV/-4X?%NFR,JO(4,DFQ!@G(XY/IR<5?F-O<1F.6V
ME96(8CRF&2#D?J*I#2=*2;SHK&:.3>TFY%<?,QR?U'3I0 B>+M)>,N)9-@D$
M6XQ$ D],?F*(?%-C(JO*)(%9"X\Q"#P6'3'^P<52L?#.FVL(CG2[N51@R!E<
M!>GH>>@_*KYTK2F38UC,RY#8*N<88L/U)XH LV6N6.HW$L%I*7DB!+ J1T.#
M^M0S:S)'H=O?I;AS*5RI8@(#W) )_2I+:WL[2662VMIXVF)+X1\9/4XZ"FK;
MVXTR.R=+IHXP!E0Z$_BN* '3ZPB06TMN([A994C<QRC";N_O3-/UO[9<NDL(
MAC\MI(Y#)G<JL5)/''(]Z6:RL)[>*W:UG6*%E9%C5TP5Z=,9I;6UL;.622WM
M9E:7.[*.W&<X /09.<"CJ EYK(MM2L[6)(Y%N4:3S#(0 %*CC .?O>U,C\3:
M=*&(:5<(7^:(C*[2V1ZC -2SP6=S<0SR6]QYD(*H4#K@'&1@=1P.M4!H&E!I
M0UM=-&X "'S/E 4K@'.<8.,=* +2^)=/VOYDA4HQ& I.1SST_P!DU)'X@LI9
M#&GG&102Z>2P,8'=N.*C.F:67W&PD)V,F?+;[K=:8-)TO!_T2YRRE6.9,N#U
M#'//XT 3:=KMOJEW+'9_-''$'+$8.=Q!&/PIZZO&FCPZA<HR1NH9RHR$'J?:
MH[&RL--WFSM)HRPPQV.Q/)/?ZT^*WM4L8+66WEF2$#;YD)/([T 02Z^5GDBB
MMA)S$(&\S D\S.#TX'%7;#48[RSAE?;#)*67RRPSN4D$#UY%5)=.TZ>>6:2U
MN2\P4,?W@QM.1@9XQ[5:@-M;0)%#;2JD?"CRF.* ,VU\4I+<3I/;.B1R&-&C
MRY=@Q7&,=>,\9XJ67Q38+:R30EY5C + (03D$\<<GBIY;6QEMOL[6LXC#F0;
M5=2&)))!'/<U"-*TH'/V&8_*% *N0 .V.U+6P^HJ>)K#YO/9H<*K ,IS@A>V
M.OS"K>F:M::O"TMC(75#@DJ1VS50:9I>8R;&9C&VY2R.3G;M[]>*L6,5KIT!
MAM+>X2/.=I5VQ],U1)H45!]K7_GE-_WZ-'VM?^>4W_?HTAD]%0?:U_YY3?\
M?HTY+A7<*(Y1GNT9 H EHHHH **** "BBB@ JMJ5_#I>EW-_<Y\FVC:1\#G
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M0@8Y?&UD-7U"UFB>.WLHT87'WO-8L4VJHY)##%7O#VNKKUC/=+&8TCN9(5#
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M$8R2,!R<]:W=#L[;1=/:V^W_ &EFF>9Y'P"68Y/ ^M"!FO147VNW_P">R?\
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MM[M>"WU%([=)@<&UC8MC'?EC^ %0:CX%O+#1'%A!;NYB:-XD!_>%KE'7(QR
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MKAH@!A<=A^%/K8F^ESJ?^$@\>?\ 0D6O_@X3_P"(H_X2#QY_T)%K_P"#A/\
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M(/'G_0D6O_@X3_XBC_A(/'G_ $)%K_X.$_\ B*XSPQ\4=:%C<V]\JZAJ4UW
M;9)U, 6.?@+TY"$8SBKZ_$77[^^V&WM+6W&F7DDR+*=XEA<H2A(YZ<9H>G]>
M5P6ITG_"0>//^A(M?_!PG_Q%'_"0>//^A(M?_!PG_P 17(Z)\2=4L=4D^W(M
M[8S2VL8#S_OHR]N&^5 .1G.3[U=C^+E^(8S-IEFTE[##-9^7<':@DDV 2G'R
MD=>*?6PKG0_\)!X\_P"A(M?_  <)_P#$4?\ "0>//^A(M?\ P<)_\17$Z?\
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MA/\ XBNTHH XO_A(/'G_ $)%K_X.$_\ B*/^$@\>?]"1:_\ @X3_ .(KM**
M.+_X2#QY_P!"1:_^#A/_ (BC_A(/'G_0D6O_ (.$_P#B*[2B@#B_^$@\>?\
M0D6O_@X3_P"(H_X2#QY_T)%K_P"#A/\ XBNTHH XO_A(/'G_ $)%K_X.$_\
MB*/^$@\>?]"1:_\ @X3_ .(KM** .+_X2#QY_P!"1:_^#A/_ (BC_A(/'G_0
MD6O_ (.$_P#B*[2B@#B_^$@\>?\ 0D6O_@X3_P"(H_X2#QY_T)%K_P"#A/\
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M% ')HVK1J0GPUO5#0^01_:\?*<\'YN>II@_MIKNXN9_AU>S23OO.[5(<+@
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MG7;V/B.WOK>*98I$66%YERRM\J@$_=)Y^8<4Q/$UL]O<S"";;;J#@[=SDXP
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M_&NJM]3L[J5X[:=9'C&64=JB;5 -'74$MY)$*;RBLH('<\D"@#FO^$M\7?\
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MI[=?YU)P>F* *7]M:?\ \_ _[Y;_  H_MK3_ /GX'_?+?X5>P/2C ]* */\
M;6G_ //P/^^6_P *5-7L7=46<%F. -I_PJ[@>E&* "BBB@ HHHH **** "F3
M#,+C?L^4_/\ W?>GT$9'- '!KX+\/Q0QK!K.QS T,[-=;_.!8.3AF(7YAGCU
MK0GT;2WO?M4.MQ12?:VN3\Z$?-'L*]?3O6S::GI-[=7MO;20M+8N$N!M V$C
M(I9]3T>VDMXYI[56N6981E3YA R0/6@#$/A[PVVDVMF;JSWVXA5KC<F^58R"
M WL<5#_PB^@-#) ^JQFW:&:&.,2H/*61P_RGMM*\5O7FJ:;8Z0FI7$9$$A0*
M%@)8ECA1M SG)I;/5='OK..YAE@6.5S&HE 1MP."N#SD'M1N!BZ-X>\/:3<V
M]P]_;7<]O:16T<DSQEEV%CN![$[JDN-(TF>WO!_;$2W-S=K=BX\Q"4=<; !W
M  QBM&+6M,GO+NWBMY6-IN$KBU;8"O4!L8)]A1::YI%YIEW?1KLBLBPN%D@*
M/&5&3E2,].:/,+=#/&E:4=!DT^76(I'FN1=2S^8@+R!P_3H!P!7,:%X;*M<P
MZC?6MNC-YJ7"W"-(DHD+*4Y/R\G@XZ]*[Y]3T:*(O+<VD8$7G%690P3&<XZ]
M*;I>IV&K[OLMM*H4!@9K9HPP/0C(Y%'4.A1T&WL-&:\DEUBVN9[R42R/E(QD
M*%X /H*V/[5T_P#Y_K;_ +_+_C4WV>'_ )Y1_P#?(H^SP_\ /*/_ +Y% $/]
MJZ?_ ,_UM_W^7_&C^U=/_P"?ZV_[_+_C4WV>'_GE'_WR*/L\/_/*/_OD4 0_
MVKI__/\ 6W_?Y?\ &C^U=/\ ^?ZV_P"_R_XU-]GA_P">4?\ WR*/L\/_ #RC
M_P"^10!#_:NG_P#/];?]_E_QH_M73_\ G^MO^_R_XU-]GA_YY1_]\BC[/#_S
MRC_[Y% $/]JZ?_S_ %M_W^7_ !H_M73_ /G^MO\ O\O^-3?9X?\ GE'_ -\B
MC[/#_P \H_\ OD4 0_VKI_\ S_6W_?Y?\:/[5T__ )_K;_O\O^-3?9X?^>4?
M_?(H^SP_\\H_^^10!#_:NG_\_P!;?]_E_P :/[5T_P#Y_K;_ +_+_C4WV>'_
M )Y1_P#?(H^SP_\ /*/_ +Y% $/]JZ?_ ,_UM_W^7_&C^U=/_P"?ZV_[_+_C
M4WV>'_GE'_WR*/L\/_/*/_OD4 0_VKI__/\ 6W_?Y?\ &C^U=/\ ^?ZV_P"_
MR_XU-]GA_P">4?\ WR*/L\/_ #RC_P"^10!#_:NG_P#/];?]_E_QH_M73_\
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MY%'V>'_GE'_WR* .:GM87O'ECUBQ"CRC$'<,V8R?O'=SG-:-G)8VNEI:?VK
M&!+-)'*HY+%CC.>.:U/L\/\ SRC_ .^11]GA_P">4?\ WR* ,#4+/2M0O9[F
M74X [VZPQXG'R,-WS8S@GYOTK/?1[9H@$U?3XFR_"$;5#*%^4%N.F<UU_P!G
MA_YY1_\ ?(H^SP_\\H_^^10!R1T>S17^S:Q90/N=XW1@"&8J<GGG[I_.K.F6
M%AIVL&[_ +8MY$V;54RKD< 8SGD<9KI/L\/_ #RC_P"^11]GA_YY1_\ ?(H
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M;_P(D_\ BJ +U%4?[&L_2;_P(D_^*H_L:S])O_ B3_XJ@"]15'^QK/TF_P#
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M'N+[4&]BZOGK\N!DUNZPE]/I%W%;ILE)41-'(<D9&3Q@COT-2_8;K_H)3?\
M?"_X4?8;K_H)3?\ ?"_X4 M[F)G7=.;[+$[SA1E7,+.I!!)RQ)/!P .IIAGU
MV:2"4QSQ*01(HC^^=C8X[#./3K6]]ANO^@E-_P!\+_A1]ANO^@E-_P!\+_A0
M!@RW_B:.+9':\1E5+E"2P(SD#D\< UU$!D-O&9L>85&_ XSCFJOV&Z_Z"4W_
M 'PO^%'V&Z_Z"4W_ 'PO^% B]15'[#=?]!*;_OA?\*/L-U_T$IO^^%_PH&7J
M*H_8;K_H)3?]\+_A1]ANO^@E-_WPO^% %ZBJ/V&Z_P"@E-_WPO\ A1]ANO\
MH)3?]\+_ (4 7J*H_8;K_H)3?]\+_A1]ANO^@E-_WPO^% %ZBJ/V&Z_Z"4W_
M 'PO^%'V&Z_Z"4W_ 'PO^% %ZBJ/V&Z_Z"4W_?"_X4^&TN(Y0TE]+*HZJRJ
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M;O<0+'*VX-$8"5/3GY^]=KX?NOM.B6V;>X@:*-8V2XA:-LA1G@]O>I/LE_\
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ME3]U<Y!_'&/K2Q>([TR,)8HUC1&99%A<^=CLH['ZUL?9-0_Z"7_D!:3[)?\
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M^O0!>HJCY&I_\_D/_?G_ .O1Y&I_\_D/_?G_ .O0!>HJCY&I_P#/Y#_WY_\
MKT>1J?\ S^0_]^?_ *] %ZBJ/D:G_P _D/\ WY_^O1Y&I_\ /Y#_ -^?_KT
M7J*H^1J?_/Y#_P!^?_KT>1J?_/Y#_P!^?_KT 7J*H^1J?_/Y#_WY_P#KT>1J
M?_/Y#_WY_P#KT 7J*H^1J?\ S^0_]^?_ *]'D:G_ ,_D/_?G_P"O0!>HJCY&
MI_\ /Y#_ -^?_KT>1J?_ #^0_P#?G_Z] &9JLVLKX@MT D3225S):J&D+YZ/
MGHON ?PJGX/FMAK?B&WMGF9?M8=?-WG(V*"06Z_-FM_R-3_Y_(?^_/\ ]>D\
MC4_^?R'_ +\?_7H6@,P=?O?[+\4BYNO.6VFTR2%&1&8&7>"!QW(Z5BQMJ?\
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M,@R#D],$BJRR:A=W%@3-/!*TA::-4VHJ+U!R#GD@9SS6CY&I_P#/Y#_WY_\
MKT>1J?\ S^0_]^?_ *]'6X$&M37O]DW L1);SAT6.3 ;.6 ) YXQGK6+;^(]
M66Y6*6Q;+3LC&1<!=I4$ \>I(/-=#Y&I_P#/Y#_WY_\ KTAM]2/6\A_[\?\
MUZ .9M_&=_/ LBVL;EYE58TC)(4XR3SQUX]<=*LQ:]JT,0DFM_M#;0K!(V #
M%W4<?4+GV-:]MI=S9JPM)+2$,<L([;&?UJ;R-3_Y_(?^_/\ ]>@"GI.K7U]?
M7<-W:B!(<@'H<@X]>0>O:@S7$GA**999OM#1C:T>-S,>!U!XS5SR-2_Y_(?^
M_'_UZ1+74(HPD=U;JJC 408 _6@"C?W5W8V-DLLLR2)/'&\FT-YX_B/&<#\J
M9HU[>S7T_G--,!&Q>-E"A'#D!5.!U7WK2\C4_P#G\A_[\_\ UZ7R-3_Y_(?^
M_/\ ]>@.AGZI>W<>M::JF6&&2)VDCW 98%< D*V>IXR/K6?'XLO-DC2P(VU,
MD)&^58QE@A'KD8K?\C4_^?R'_OS_ /7IHM-061G%S;AVQN80<G'XT 9(U_4X
MRZ?86=L/(A*G[JYR#^.,?6EB\1WID82Q1K&B,RR+"Y\['91V/UK8\C4_^?R'
M_OS_ /7I/(U/_G\A_P"_'_UZ ,W0-5O=4NYY+J)H46$!5VD*2&;D=>V.]3QW
MMXGAVTGMU-Q<,!\A4GS/;/;ZU;\C4O\ G\A_[\?_ %Z1+74(HPD=U;JJC 40
M8 _6@#&N]3O%OKJ(SS1K^X+A$SY )._:<<]O6MC3+BY;1(IIXY)YN<# 5F7<
M0#S@=,&G>1J?_/Y#_P!^/_KTOD:G_P _D/\ WY_^O0!EZK+K":U))8%C;6]L
MLK1$\.<OE<8Y)P.XQ5:7Q'J MR1 CAMZAXHVRQ"@C /3G()YZ5N^1J?_ #^0
M_P#?G_Z])Y&I_P#/Y#_WX_\ KT 8:Z[JEONDN(?.6)I"Z)&P(0%,?4X8U=TS
M6=1N]8-I=V2PHJ98^^ <CGD9..E7_(U/_G\A_P"_'_UZ7R-3_P"?R'_OS_\
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M&C[1J?\ T#X?_ G_ .QH OT50^T:G_T#X?\ P)_^QH^T:G_T#X?_  )_^QH
MOT50^T:G_P! ^'_P)_\ L:/M&I_] ^'_ ,"?_L: +]%4/M&I_P#0/A_\"?\
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M;I\IY%0'Q]%-S:6,VP12L\CE3L*,@Q@-SG>.E22>%89-3AO5T>"-HE"K&EP
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ME]D9(4CAN)#*<#:HXQMSW[%@#6_54Z78D*#9P?(Y=?W8X8G)/US5J@ HHHH
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M^M[_ . K_P"% %ZD=@B,QZ*,FJ7]K1_\^M[_ . K_P"%-;5(G0J;6]PPP?\
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MS6J"/S)[FX$ RX#!5##DX(.#CK74@Y%<4O@:6[TP1W-ZMF;J*-;VW@B5HRR
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M_:USN"GOCS.E<''X&\66.EF".U>]%S:VPN4GO=Y\Y2WF,,N 3C;WQ3;#X?\
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M ,&ES_\ '*/^$ T#_GG?_P#@TN?_ (Y6MH<5U!H%C%J$<<5TD"+*D9RJL!R
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M_P#%<3I:P0S%8T$?F7%OG^X Q;/).6)^E'D!-_PJW1/^?_7/_!K-_P#%4?\
M"K=$_P"?_7/_  :S?_%5GW/BCQ/#>1V44*RWF&(A\C_6J QW'GY>B\5V6@R:
MA+I,<FK,#<.2<",IM'8$'O0!SO\ PJW1/^?_ %S_ ,&LW_Q5'_"K=$_Y_P#7
M/_!K-_\ %5VE% '%_P#"K=$_Y_\ 7/\ P:S?_%4?\*MT3_G_ -<_\&LW_P 5
M7:44 <7_ ,*MT3_G_P!<_P#!K-_\51_PJW1/^?\ US_P:S?_ !5=I10!Q?\
MPJW1/^?_ %S_ ,&LW_Q5'_"K=$_Y_P#7/_!K-_\ %5VE% '%_P#"K=$_Y_\
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MR!-HQM'N<\UQ-I<7Z:K9:;>3W5LEM;V\'EJ[[2Y@_P!45'&2QSD^E)@CH_\
MA =.^SK/_P )CXC\ER LG]L':Q)P,'%3?\*UM_\ H:/%/_@U;_"N5@\,:Z-
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MAB!R!UP>>:GN?&6HS6L^9(9A)'*S6\65>T*2A0&(.>0?:@#N?LE__P!!/_R
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MZ<BJAUZ7[3I[2R0Q1W#2!X!DO\JDCK@YXZ8H T?LE_\ ]!+_ ,EUI?LFH?\
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M/^)?8?)]W]X?E^GR4AAO3C.G6'RG</WAX/K]RM2B@#/#:F,XM+,9Y/[YN?\
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M"ECKGB(*!DG^V)O\:J:9X&\.ZU9"[TKQ+KUW;EBHDBUJ4C(.".M 'H%%</\
M\*YT7[3]G_X2#Q!YVS?Y?]M2[MN<9QGI4@^&.EGIK?B,_P#<8F_QH [2BO/K
M3P1X;OKZ[LK/Q-KTUS9D+<1)K4I:(GID9XJQ)\.=%ADC27Q!X@1Y21&K:U*"
MY S@<\T =S17G-CX0\,ZE>&ULO$OB&681>:4&KS [=Q7/)]016E_PK'2\X_M
MOQ%_X.)O\: .THKSE?"'AEM2:P7Q+XA-RLODM&-7FR'V[L=?3FM'_A66E_\
M0;\1?^#B;_&@#M:*XO\ X5AIG_0:\1_^#B;_ !H_X5AIG_0:\1_^#B;_ !H
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MG_0:\1_^#B;_ !H ZFVTVULYII+:/RVF)+X8D9/7C.!^%$6G0)IL=E(/-BC
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M@KQ?X74VVGPPWUI!?07D26L@@#C84D3#,?\ 9;GKS76_\*Y/_0W>)O\ P/\
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M3_T-WB;_ ,#_ /[&@#M**XO_ (5R?^AN\3?^!_\ ]C1_PKD_]#=XF_\  _\
M^QH [2BN+_X5R?\ H;O$W_@?_P#8T?\ "N3_ -#=XF_\#_\ [&@#M**XO_A7
M)_Z&[Q-_X'__ &-'_"N3_P!#=XF_\#__ +&@#M**XO\ X5R?^AN\3?\ @?\
M_8T?\*Y/_0W>)O\ P/\ _L: .TK/\0?\BUJ?_7I+_P"@&N;_ .%<G_H;O$W_
M ('_ /V--E^&BSPO%-XK\2/'(I5E-_P0>"/NT :?P\_Y)MX>_P"P?#_Z *Z.
MJ>CZ7!HFBV>F69<P6<*PQESEMJC R:N4 %%%% !1110 4V1_+B=P"VU2< <F
MG4C E2%.#C@XZ4 >76]AXILOM]RED\$NM0&0O;REWCE$F5R"HVG8V._W:OW.
MDZFNIV;7/]I7,-GJ$HA<.Q;8T7REL=5W\9-=K]DU#_H)?^0%H^R:A_T$O_("
MT <G>6&NS^#=-6ZA6XBA%O)<V:QGSG"D%U/.#],=J@UVXU*:2R/AO2K^RCWJ
M^5A:,,?,4,&08 ^7)RWY5V?V34/^@E_Y 6C[)J'_ $$O_("T=;AT.*N[+6UM
M5EO9-6ECGO)_.CMV.]4&X1;0.B]/TS5/3++7;'2;6"[M]1CLU,"SK; B7:(,
M<;>?OXSBO0?LFH?]!+_R M)]DO\ _H)_^0%H#K<X&WL_$=NLEW=17 E9H6>5
M@-VQ8Y.2?4?+GWINB#7[K3[2YMUU)X)%M'<W9W,9,,9&7/1<%>G%>@&SOV!!
MU+(/4?9UI%LKY%"IJ(55& !;KP*.X&#X3M=9MG*ZI+=S+-I\,CFY.=L^6#@>
MG&.*XZQFO[;5['3;Z>ZM(K;RE*J[@!F+G857@[LKR:]1^R:A_P!!+_R M5GT
M-Y;Q;N2XA:X3[LIM$+#\:-V'0\UC\+ZZ/#*Z$;&;[%'$E\OO*< Q8]0V6KV!
M!B-0?2J7V34/^@E_Y 6C[)J'_02_\@+3N!>HJC]DU#_H)?\ D!:/LFH?]!+_
M ,@+2 O451^R:A_T$O\ R M'V34/^@E_Y 6@"]15'[)J'_02_P#("T?9-0_Z
M"7_D!: +U%4?LFH?]!+_ ,@+1]DU#_H)?^0%H O451^R:A_T$O\ R M'V34/
M^@E_Y 6@"]15'[)J'_02_P#("T?9-0_Z"7_D!: +U%4?LFH?]!+_ ,@+1]DU
M#_H)?^0%H O451^R:A_T$O\ R M'V34/^@E_Y 6@"]15'[)J'_02_P#("T?9
M-0_Z"7_D!: ,S5;/5Y/$%O,KO/I:E<V]O)Y3HV?O,?XU]LC\:K>$HUM]:U](
MM/N+2&6Z$L1D@:-7&Q02">O(-;GV34/^@E_Y 6C[)J'_ $$O_("T+0'J8.M0
MF#QC'?7^F3ZC8M9>3$(H?-\J3?DY7MN&.?:LVTL[W[1;Z9_9]S&T6L->&4QX
MB$62P^;IGG&*[#[)J'_02_\ ("T?9-0_Z"7_ ) 6A:?UYW!Z_P!>5B]15'[)
MJ'_02_\ ("T?9-0_Z"7_ ) 6@"]7G]YK_B/3-7N/]'FO+9KF9H%6+HJ(?D)Q
MT)P0?K79?9-0_P"@E_Y 6D^R7_\ T$O_ "76@#D(O'>IMJ%O;36D$>Z/S'.T
MDD?-@ 9Z_*..<YI!XKUZ[1)!;""-HY@%$+!G963:0<G'#'UZ&NHDT-YKQ+N6
MXA>XC&$E:T0LOT/XU8^R7_\ T$O_ "76@#EIO&&N1HNW2,$3FW=G4A=R@DGJ
M.#Q@_6NW4DH"1@D<BJ/V2_\ ^@E_Y+K2_9-0_P"@E_Y 6@"]15'[)J'_ $$O
M_("T?9-0_P"@E_Y 6@"]15'[)J'_ $$O_("T?9-0_P"@E_Y 6@"]3)V=;>1H
MAND"DJ/4XXJI]DU#_H)?^0%H^R:A_P!!+_R M# P/[4O8K.&2UGNKNXDC;S(
MVC V2E1@=!@ G]*U=%O+V2Q6*^1OM4*NKK( &<@\'(^7D$59^R7_ /T$O_)=
M:7[)J'_02_\ ("T 8USJEZR6ZSM+9WDDX A6/Y%48SN;!R,=QCDU8\/W=Y<W
M4WVF661?*4N)$VB.3<V5' XP!ZUH?9+_ /Z"7_DNM'V2_P#^@E_Y 6@"OK4V
MH-IJ_P!GJ]M<&X106 ;(SWQG@UAP>*M44R>=8,$422$S+M.!NX'TV^G-=+]D
MU#_H)?\ D!::]C>R1LDFH!E88*FW4@BD,YR'Q;J<\4(CMHVEF8K\D;80=B?F
MZ^U6K;7M4"P;[;SS,(TW*C !RH)X[#[WXUJV^E7%I'Y=K>1PIG.U+90,U+]D
MO_\ H)?^2ZTQ&;8ZQ?:AI&H37-O]E:*-MF.&4X/!Y/3UJ75-4N+#3[&2 [I9
M0 59"5;CG<>U7&LKYT*OJ(96&"#;KR*465\J@+J(  P +=>* .>GU2Y>^F\F
M]NDLQ)L=A'ED8*Q^7Y?ND[1^%='83W+V=K]J@<2O K2OP K8Y&,Y_2F_9+__
M *"7_DNM+]DU#_H)?^0%H P+?4-;L+,7%VX=;AR$\U2_EXW'D* 1G  '/UIM
MSXAU:2-Q#;B&5#G'ELRJ-N>?4]>.*Z#[)?\ _02_\EUH^R7_ /T$O_)=: ,=
MM>U.&25$LC<$[WB(4@,%&2/;/&/K6MH=_<:CI_GW<2Q/N( 7N/IDT[[)?_\
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M<'G& >?6NVD2^EA:-]-LRK+M(^TGIC'_ #SIEI;7=C9Q6UMI=FD42A47[2>
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M_P "F_\ B* +]%4//U7_ )\;7_P*;_XBCS]5_P"?&U_\"F_^(H YSQ->V_\
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M\11Y^J_\^-K_ .!3?_$4 7Z*H>?JO_/C:_\ @4W_ ,11Y^J_\^-K_P"!3?\
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MD@?^BZ -.BJ'GZK_ ,^-K_X%-_\ $4>?JO\ SXVO_@4W_P 10!?HJAY^J_\
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M#R,[:U]4M=-UAHFOM.OS)""$EC62-U!ZC<I!P?2L_4/#^D7FF?88M,NH86>
MN!;L=RQ'*KS[<?C2Z!U)1XU9K2YO!I<HMK8(CL90&\U@I";?JP&:;)XVN$G^
MQC1V:_65XY(?M"A5VQB3.['.0?3K5BXTO1KJYN)I]*O6:Y7;*H20*_&,[0<9
MP!SC-4;GPUHUS):;K#4/+MY'D92LA:5F7;EGSN/'O0 ^W\?+>0F6STN9XV:&
M*-FD50\DBA@OM@'D^U1_\)U<#44$FGK%:0VUS)>$RY>-H6 (7 ^8<^W6M%].
MT=[.6U_LBZ2&5D<A(G4AD "D$<@@ =*8-*T55@4:3>X@615^23Y@_P!\-S\V
M>^<T 9O_  L-'MUN39S1+'O9D W"51"9!ACCGC'UKH-$UU]96[1K-K.XMRH,
M<C!@0RAE.1[&J TG1OLJVSZ9J$L2[@JR^:^T,I4@9/ VDC%7X'L[:2=X-.O$
M:X"B0K"^6VKM'TXHT%J4])UG4)O#&IW=\T+W5G+<(#&F%.S..,UDP>/Y[A5M
MX;-'G%H9)9?,QL<0B3.S'W><9S6QI]EI>F6ES:VFG:CY-T6:99/-DW%NI^8G
M&?:L2V\,0VNNR7<0ODM)"0UNL$@W)LV>6><$8'7&?>EKMY%:%.+Q_JDVAZ4J
MI!_:C7$:WPV_*D991N [;@ZXKTFN:72M#2221=%N \B1(["!\D1'*#\,"M?^
MU5_Y\[S_ ,!VJG8E%ZBJ/]JK_P ^=Y_X#M1_:J_\^=Y_X#M2&7J*H_VJO_/G
M>?\ @.U']JK_ ,^=Y_X#M0!>HJC_ &JO_/G>?^ [4?VJO_/G>?\ @.U %ZBJ
M/]JK_P ^=Y_X#M1_:J_\^=Y_X#M0!>HJC_:J_P#/G>?^ [4?VJO_ #YWG_@.
MU %ZBJ/]JK_SYWG_ (#M1_:J_P#/G>?^ [4 7J*H_P!JK_SYWG_@.U']JK_S
MYWG_ (#M0!3O/$20Z_%H]M;M+=, [&1A&BJ>X)^\?89]\4GA_4+^[O\ 6+;4
MFA8VET(XS$I4!2BM@Y/)YJ6YGL[S9]JTRXE,;!D+VI)4CH1Z55TZVT[2KRZN
MK*QU)9;MMTQ?S7#'UPQ('X4(&)J-_J5SXH71],N(K01V@NI)9(MY?+%0H&1Q
MP<GZ54@\1WS6=L[^49)-8:R?"\; Q'Y\5<U.TTS5KB*>]TZ_,T0*K)$LD;;3
MU4E2,CV/%11:;H\&I_;XM*O1,'\P#9)L#XQN"9V[L=\9H7]??_2!_P!?<=+1
M5'^U5_Y\[S_P':C^U5_Y\[S_ ,!VH O5RC>/+.WU.YM+Z!K86\[1F1FX9%4D
MN./4$8^E;O\ :J_\^=Y_X#M63=:;HM[('NM%N9&#2,"8'ZN,-^8H DB\;Z)/
M/##%-*\DWW0(6XZ]>./NFH7\=:8S 6JS2CRY'+F-@J[&4$$XX^\*HR>&].;5
M8KN.+5(TCC$30^6[!U^;@DG.#N-7(]'T.*-8TTB]"KN_@DYW8SGGG[HZ^E $
M\GCC0X8T:2Z8;L# C.0>21^&.:Z!6#*&'((R*YHZ5HAR1H]VA,[7&Y(Y%.\\
M$Y![^G2M<:HH&/L=Y_WX:@"_15'^U5_Y\[S_ ,!VH_M5?^?.\_\  =J +U%4
M?[57_GSO/_ =J/[57_GSO/\ P':@"]3)95AA>5_NHI8_054_M5?^?.\_\!VI
M#J:,I#6=X01@@V[<T,"DWB%[>UCN;ZU2&&6)ID(FW':%SSP,$U<TO6(=2TZ.
MZ V!D8N =RH5."-PXK/6TTM51?[,OF5#E5=)&"^P!/ XZ5:@GM;:1W@L+Q-Y
M)91"VTDXR<=.U "2:\K6L5U90>?;R2K&'+;2V2!E1CYNOMTJU::CY[W@GC%N
M+6782S@@C .?;K6=)!ILEQ'-_9EZCQN74QQN@W'O@8!J:WDM+66XDAL;[=<-
MNEW1NP8_0]/PH ;J_B2+2;A4>$R1-;O,)588R.B_CZTV7Q?I$*R[YV)B.&"H
M3SWQZXQ3KT6&H1NEYI=U*KQ^4P,#?=SG'YUG7^DZ?>1%8;2_MB9?-)2)R">>
MV>.O:CH!HS>*=/BF2%1-)*^S"+&<X8@9_44I\4Z;'"7GEV$.4*[2>1^%5(]/
MTM&\Q].OY)BH#2LDF21@YZ\'*@\4][/29"Q;2;HEDV$^2^<;MW\^<T :)U:*
M2SM;FU_>1W$RQ@D8QDD?TI9]52&_^Q>6?/9"T6X_*_'<C./Q%57D@:"WA2TO
ME2WD5U_<L2<>YJ*X@T^ZN)II;#4-\R;)"JR*&&,= : )[76Y+A[$-:;%NFD0
MN),A2N>G'(.WKQ5G4M4CL--N+I-DS08W('Q@D@<XSCK5!8K!&M2MCJ.;0GR>
M)?ER,>O/'K5F:[M[B%HI;"[9'(+#[.PS@Y_I0"*]OXIM&MP]W') XSN 1F4=
M<<X[@9%.?Q/:K/$B1R.)5W*P0\?*6^;CC[M-N$L+FY^T3:=?&0@ D1NH..AP
M.,CUZU&MII:*H72[T;3D'RY,]".N>>&/YT 3/XKTJ*)&EF*EA]T(20?3]#^5
M:\4J3PI+&<HZAE/J#6"]GI+[B=)NP696++$X.5&!R.G%:*ZFB*%6SO, 8'[A
MJ!&A15'^U5_Y\[S_ ,!VH_M5?^?.\_\  =J!EZBJ/]JK_P ^=Y_X#M1_:J_\
M^=Y_X#M0!>HJC_:J_P#/G>?^ [4?VJO_ #YWG_@.U %ZBJ/]JK_SYWG_ (#M
M1_:J_P#/G>?^ [4 7J*H_P!JK_SYWG_@.U']JK_SYWG_ (#M0!>HJC_:J_\
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M?Q+_ .@3X;_\#IO_ (BNTHH XO[7\2_^@3X;_P# Z;_XBC[7\2_^@3X;_P#
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M[7\2_P#H$^&__ Z;_P"(KM** .+^U_$O_H$^&_\ P.F_^(H^U_$O_H$^&_\
MP.F_^(KM** .+^U_$O\ Z!/AO_P.F_\ B*/M?Q+_ .@3X;_\#IO_ (BNTHH
MXO[7\2_^@3X;_P# Z;_XBC[7\2_^@3X;_P# Z;_XBNTHH XO[7\2_P#H$^&_
M_ Z;_P"(H^U_$O\ Z!/AO_P.F_\ B*[2B@#B_M?Q+_Z!/AO_ ,#IO_B*/M?Q
M+_Z!/AO_ ,#IO_B*[2B@#B_M?Q+_ .@3X;_\#IO_ (BC[7\2_P#H$^&__ Z;
M_P"(KM** .+^U_$O_H$^&_\ P.F_^(H^U_$O_H$^&_\ P.F_^(KM** .+^U_
M$O\ Z!/AO_P.F_\ B*/M?Q+_ .@3X;_\#IO_ (BNTHH XO[7\2_^@3X;_P#
MZ;_XBH;S5?B196,]U+I'API!&TC!;V;) &3CY/:NZK/\0?\ (M:G_P!>DO\
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M<O$&-V;D-C'*N>2.:Z&@#D?[>\:_]"7;?^#E?_C=']O>-?\ H2[;_P '*_\
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MBC\6VAC$CQR!9.8\*.>%..O7#9_ T 9?]N^/_P#H3K'_ ,&P_P#B*/[=\?\
M_0G6/_@V'_Q%;5OXFAN+A(([2X\UQO"DH,)@'=G=C'(XZ^U)IWB./5-56VMD
M9457W[L'D;",$$C&&H QO[=\?_\ 0G6/_@V'_P 11_;OC_\ Z$ZQ_P#!L/\
MXBNA35&32I;R5 WERNI 8+P&([\9K)N?&&V9S!$5B^14,T3@L[CC)Z #- %3
M^W?'_P#T)UC_ .#8?_$4?V[X_P#^A.L?_!L/_B*Z/3]3,UNQO=BR).T&8P=K
M$=Q6?-XAN;?6+B%[4R6L+B/<B$'<0,?,3CDG&* ,S^W?'_\ T)UC_P"#8?\
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MMX[N+*W=]7M5,AOWA:,3+NB7S @P /F SUXHZ@=7$=1A0)#IUG&HZ*MR0/\
MT73O/U7_ )\;7_P*;_XBN?N?'\%LLPDLV69;K[-'"TF&)^;YF&/E&%)!YS5J
MY\3O_9^BWT$+11WT^V6.5?F5=C$CZY6CS#R-;S]5_P"?&U_\"F_^(H\_5?\
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M-K_X%-_\11Y^J_\ /C:_^!3?_$5?HH H>?JO_/C:_P#@4W_Q%'GZK_SXVO\
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M 9QT9#=W-P+JX#W  ;YE(4#L,C@?XTP^'[,6!M8M\:L,.ZXW..2<DCWK4HH
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MGDM%*F9BS @<9))P<9ZGO6A110 4444 %%%% !1110 4A(522< #)-+4<_\
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M_A@YS0OBC16DB1=0B+2G"CGUQ^'/K0 [_A)-*_Y^O_(;_P"%'_"2:5_S]?\
MD-_\*5?$>D.8@M]$?.;;'U^8YQ_,CFEN/$&EVDT\5Q=HCV^/-R#\F1D9/TH
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M-Z]JI0^-=>N8+V9(K6)(RW$DL:M%MDVXQOR25R?FQS2 [/\ M:[_ .@'??\
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M .@'??\ ?47_ ,76I10!E_VM=_\ 0#OO^^HO_BZ/[6N_^@'??]]1?_%UJ44
M9?\ :UW_ - .^_[ZB_\ BZ/[6N_^@'??]]1?_%UJ44 9?]K7?_0#OO\ OJ+_
M .+H_M:[_P"@'??]]1?_ !=:E% &7_:UW_T [[_OJ+_XNC^UKO\ Z =]_P!]
M1?\ Q=:E% &7_:UW_P! .^_[ZB_^+H_M:[_Z =]_WU%_\76I10!E_P!K7?\
MT [[_OJ+_P"+H_M:[_Z =]_WU%_\76I10!E_VM=_] .^_P"^HO\ XNC^UKO_
M * =]_WU%_\ %UJ44 9?]K7?_0#OO^^HO_BZ/[6N_P#H!WW_ 'U%_P#%UJ44
M 9?]K7?_ $ [[_OJ+_XNC^UKO_H!WW_?47_Q=:E% &7_ &M=_P#0#OO^^HO_
M (NC^UKO_H!WW_?47_Q=:E% &7_:UW_T [[_ +ZB_P#BZ/[6N_\ H!WW_?47
M_P 76I10!E_VM=_] .^_[ZB_^+H_M:[_ .@'??\ ?47_ ,76I10!E_VM=_\
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MWVG14T\7A18[H7"':3C Z8SR,\FI]4T*^UJTM$N;I+9[>8LRP@[77&!]#WH
MV(PYC!BN4*#@;5&!CM4372+:?:GOXE@SCS& "]<=?K6'=>$9WT :;:7<-M_I
M+S>8L/.&)([]03UJW-X::Y\,G1KF=&BW*=P0Y(#;B#S0!J)*9)I(H[R-I(\;
MU !*YY&:DV3?\_"_]\"N/3P%="XCG?5V>7<K3-LQYA7.#UZXQ3T\$WZQMG54
MWLTC;A$<#<H' SQR,YH ZW9-_P _"_\ ? HV3?\ /PO_ 'P*Y:;P5=7,,QGU
M+,\KJ=RH0H 9B5P3T.X?D*<W@AS-YRZBZR\XDY+#D8/7J "/QH Z8B55):Y4
M #))44?O=F_[2NW&<[1C%<G#X#D6W$<^H>80FW)4X[[N,]P:N77A.6ZAL(1=
M11QVT"PLJQG'!'*C/&1P<YXH U?[3M_+@?\ M*+;<?ZH[?O_ $J1;V%[5[E-
M2@>"/[\BX*K]3FLV'PY+9?8/L4T"BWLQ:2*\1(*\'*X/!R*H:=X'FL=&FL_[
M1.YF1U"J3'N3;@L"23G;TR!0!T"7T+Q^8NHP[?+,F3@?*.K=>E30N;F(26]Y
M'+&W1D (/XBN9U'P?J&I74]W/J,23S0M;E8H<*(RI&!DD]3FKD/A0VMQ-]BN
MS#'+:O"3C+[V_CSVY/0"@#;D,D432272JB@LS%!P!WI5$KH&2Y4JPR"$'(KE
M1X%E-FL3Z@2ZQE V#@9+9P,]P:9<>!;E_+CM]4$,$>[:BQG(R,$9SG% '7;)
MO^?A?^^!1LF_Y^!_WP*YB?P9<.DL<&H*D;)MCRA)B&\MA>>A!P?I4]IX5N;:
MSO8!?\7,"Q*=I)4COG.<=L4 ;<,WVAF$%XCE#AMJC@_Y%2[)O^?A?^^!7'_\
M(+>QHHM]2BB E678D1 !#%L*<\=<57T?P7J36I?4+C[+<J?E=3DY)7+<'&>"
M/QH [=O,1"[W2*H&22H %(ADD!,=RK ''""N4E\"W$UGY$E]#AED5E\HE<,H
M7@$\'(R3[FM+2_#=QIVH&Y:XBF4H5";"/+.3]SG@<_H* -O9-_S\+_WP*B$^
MZ[:V6\0S*H=D"<@'H:Y&S\#ZDR6TMYJ7E,C!WA3<1GCYLY^]QU]ZLOX$VP@6
MUS&DK11I(S1D[RJ$%CSDG)W#W% '5;)O^?A?^^!1LF_Y^%_[X%<R? X?RO-O
M#(49F=F!RY+@Y//H,5 O@6[>X#76JB2,1",H(R-V!@$\\XH ZW9-_P _"_\
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M/QIUWXJU=5BBM--$DDEIYOF9/#[<XQQR#VYZUEOX@\0*T_V:2>81X^S;K?\
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M^CQM?[4<&_N4N9AO_C4@@#T&1G'N:YN^B\2O.EM</J$L'F1-&T<2G>=R%PY
MX4#..G>K%WI\J>,]2O&M[GS"%-M)'8>9TBQ\LI'R\]J W-(?#W1BY\QKN6(1
MO%%"\Y*0JY!(0=N0"/3%7K#PI96%U!=":ZN+B%V<2W$NYB67;S[8KD;K4O&%
MO##+(EVDL<;&X_=@Q9^;)'';Y<<TEGJGB?49HY=.NKM[+S'$3M;JQ?!Y#$8
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M+NV*6 9L=\ D_A7)ZMKT]MI4]EH.M7.I7=Q,D<,\<(E:'*EFP5&&X'3'&:]
M(!!!&0>H-,2"*( 1Q(F#D;5 Q2&>=0:YK^OWBRZ4;U&2TMW:-3&L44FYA()
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M5M%:.7E58W.X84LP.1G)(VCTZUWA1#G*J=W)XZTS[- "2(HP3U(4 T >??\
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M/Y56S%NBGJ6GZX/$][=6$MZH0L\6 "C96/"C(Z$AJ@^W^+(?.;RM0EW1,N#
MORSD-]W ^X/EP:+GQSJCP2K"EI#*I,9!W%@1R9,9^YP1_6KFM^+;_1=;NTC$
M%W%'#&RVN<2,2C$E?;CFEL/J9$%WK>N:E(D-W>;K,[G**N(Y,2C"\=.$ZUOZ
MTWB,Q"2PDGC*V<1=4C#?.6^<@=20.U94'CO4A-"BZ;: R99W65<2<D?+ASDC
M'.-WX5L1>*+[^PIKJXCMHYTDB0.=PC02*K;FYS@;J.@=3(AO/%EO>1-.+^XC
M"(9 +8* N1GCG+$9XSGVJF8O$_VV:_QJ4,DJOPD0;O'C*^N 15V+QSJ4=\D)
MBM[A))B3(' 0KE1A,D$]2>A--B^(6HS0S/#:VLODAG)4D97"$=3Q]_DG'3M1
MTN'6QHZS=^(5T?26L8KQ;DH'N-B!CD;?E88[C/I4.FGQ2/$%D+R>Y-LPW.K0
M J02V0S#&W'RXJ*T\9:GJ&I:?;R?9+8/<HDB*^YIE.[YDP2-O'J?K5MO%]^^
MN"P@AM3YEP8@"6+0@/MRXSU(Y'2GU%T(K]_$L5V[+)?&UDED\SR8E9HT#@+L
M&.X/OQ2VL.O#P[>FX6X>_>YBD = <#"YVC&/7\:37O'-QI.NRV42VAC4JF^4
MD;&.W);GIANP[=:J'XAWW^D^7%8R-"WEK&K-NE^4GS!S]SBIZ#>Y'=Q^+(IH
MY8YKYW6#;O\ *#8W"(M\H')'SX^E3;O%Z6?FF:\D?>J%1"JGR]F2P7GYL^_7
MM5BX\;WMC<S"Z@MI([<GSEBW;XE4J"Q&>AW<?2JX\>:L;F2">SM+4@A"\LG$
M)XRS#=G;SQP/K3W HVW_  F$$DBV;7JQ$R/")K<%I 2W+G@*WW<#]*TX[76/
M^$>DDMSJ!N/[2\V,S(%D=,<;ACIGVIDOBO4[33]&NOM%L[7%K-)*DO F8.N
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MJOGK$H+Y9 Q8$L 3C;C)SC@]*=:>,-4CN"LJ17"33I!"H!W(S#@GVX- !O\
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C@%+10 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exdx-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exdx="http://www.exagen.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20201231.xsd" xlink:type="simple"/>
    <context id="iac638a334d2d4a41982db55571d79004_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i140e1c0c979f493ab5bbee92875a255d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ied1333e512914d588c7ba153b4b54d39_I20210312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-03-12</instant>
        </period>
    </context>
    <context id="i161aa9f12f5040b598e25e1d7896f041_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i616b08c4738d433b924c1dc44c268b4f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3617efc1423e40249453b903e951175d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdd8f716641546a99b2b0acc6ea44d50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6884440164f1463aa6e4fed299d3fe16_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5a5cbdb8b75149f1a2107742fed852bf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0e3a91a5115e431d98f3d1ae4a1da9ec_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i000894d3cadd4d209d2620841a05dcf0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69da35ef92234938bcda9473aefd88f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i724b6d08dcb54c94ae1352b8b23c595f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic85d4c855b6840b89f8a4974a7609bdd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31e794abff7a43f59c1e323fa7e55d45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6dbfbafdf8a408ca1bbfc730926cc14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79849924192d4855a9bbf663964883f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9563b9ab6fbe4adcbdfbac8e2cf19b22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8c6b3ac4c664091b47227b153e9eb44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac265b2ebdbc43e59ef20ea50e78de9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb52827a0d5e4d20bbb2e688d4965f2b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id90ff0582bfa4beb88fa29365bcf05c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i075b7f5ce30f4250b3fa7b1319fa76d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7cbc755e54584988a46ac09b03ba0a03_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia683090804ac4bbea90d92b75159efe3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i031b116f01f44ea5890d77e14040a529_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5031346fd2374b0e97451ce84bad8260_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if76b41f869c640688904f2ecf988e33e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie09521d642ec49dd9f6fb93b6226a986_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc34f2aa5b494ba4b697db93d5108663_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6e601deab964329936be94a4d256bc9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15b8ceb139cf4e0d97db9be7ea8aacf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd041b98c6ab476eb80888f8676c3df5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5690cf2946e8412bb86195a6c74a9316_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcaa2249e3c640468e6ad463c58824a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8a5f71713fcf420b86e6051da049e7ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18229da67eb54a6b8110b348c32b2f80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06930bdf59ec4a7490fb90caaee4d192_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94d5f0f3606b4c66949b12896e3d82ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d2d0f3c92004d4d8ea0b1587e20bd73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie26b529fa0544e3fa5ffa639ffaaa3da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie43dd45431384ad48a4a7cd39396b772_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8f51ada9f8b45298c0c793b85f782e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e3c2fa4dc5f49e8b1099bc7e449e3a2_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i69d2e2c6f0774bcdb394050b9d53ee76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4573db3dc09e4fa8a58677b574d5c416_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc003e40daf641ccbe499297076b288b_D20190923-20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-23</startDate>
            <endDate>2019-09-23</endDate>
        </period>
    </context>
    <context id="i854adb164db541fa9bd24fb1ccb21010_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia5c2c61809374714a756188ab1adadbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ce5a530334e4915b0436079dca953ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20146f37e33a40dab402238b6ea56800_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9156fd411b7741a8a39d1c43983a5800_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic0b7b9ea1d814dbbbeed9b14692e78ca_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3d6c90706d94887a50acb583e7d32ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9dcc6ed5d40246baabade8cb1d9fba6b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i695ae53d59f94e27b87eefce82393e8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a03a4097faf4d70895448f0b1cdccc9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f45eef28e7d4c2e8752293801f70ab3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62cb5f8c97194f02924e255c54bed267_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddf6e035476945cfb9d2423367a0fd96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i358dc56770ab42ceace2ba4c29570329_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf8dba0b2d464952ad492cfb4b91e9c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33102e8052874bcf8f4819af73b17cd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1320fd0f2999411e8bd7d1a4b841aa24_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01e558ece6214f16b6c3df7e771db6be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc02f1f51b5c4b199fc8848ae372e425_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib235ec96e6b1472d9f54d1de7b43b02f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c1e7be53ff34ffab13c26e9df1ddc43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8fa1a8305f5404892b12cd15d2ac129_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i280bdc8f8aa947aaa8f3ba67d5a4d42e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1aa0e2237a4349c6975a3792c1a40fc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i856d0b8d5d514828b59f52af21200f9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i674956e7e0a8446f921f15096e981198_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied9f4988242043ae86e49c5b25240e58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e6f34cf3e1b429c8056d14a2e90b57a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i611274158822483e99565868e2143ccd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c15b3b387924344b6a488918b7724a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3795b5fddf0a474ca1f456c3011836fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12d22bc21e2b4d42828df3456f0b74ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ddb14c3a29441f2a69234c84b0a601e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife50f4946ea24f0c9f4e38cbd7f1110e_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i54e6b9922db74a3a9cb86c52f2a90cc9_D20181207-20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-07</startDate>
            <endDate>2018-12-07</endDate>
        </period>
    </context>
    <context id="id42bbd7899154e72a4ec0bed957b96f6_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e96141de3c64fe29a0de8fc804cff2f_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i5149cc8ef1ff4fac911ed00c49b7db71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5ddd398de1458e8e1e64f2e9afd8d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0b28ea3fe8a47bb9b1c724647721207_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cd6af4be1f145b0979bab0cafe7ad2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf87f2f3f4094314ace80d3de6cfbb51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i626d033bbe12451bb544fb9ccd602d11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if5eb4831058d4b62a7506f80397c58e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90378dc8f33d4c0db9c9f5e510cefc73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13eef4c0f9f34ead9206411d3e70f27f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b416cd8bb1f4d6f86d98f542ac3cc5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe0eeb17dc7c4414a87f1ab0a5c0341f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44d0579e1e494431ae288f59027174a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0a61521b77e46aa90eed63b0c7ba9b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a24aaf692c5444cbf9b46ed5a052bee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafb32079e8ef4b6ab57b666c86ab1379_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9202b030fd1b4086bdec9b70b92d1d84_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ic80f1b4b2b84440db98c9a7375a7570f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaf86d568866c4251832b028da29ff071_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5b650b6b9d754c97a85b32a60d451667_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ccae1c8177a4c3b9f45dfceb5efa42f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e709efd0a0841ec93329ef2a03791d0_I20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-23</instant>
        </period>
    </context>
    <context id="ia73d28ff344b45b7be16393a226e65c1_D20190923-20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-23</startDate>
            <endDate>2019-09-23</endDate>
        </period>
    </context>
    <context id="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i466315a145504f92bab9954a4653b6ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8a60c0a83494af48451bdffb74f8657_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01c677925f1f405988f482d6e0c41691_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8548f93c1bc48f8ae505f3a7aa3a457_D20190906-20190906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-09-06</startDate>
            <endDate>2019-09-06</endDate>
        </period>
    </context>
    <context id="i7a2f80c2b6c5444ba34456f703d38c67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dcffc3099e440189a3fa6ca69d78390_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9df7a83f79940ddb50644d9534b8e4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3119fce349b4f6587c19f908367b2dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c062635dbd2451889987f0af257f830_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i039ef34e84814a89a51794da58440c49_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieeaded307e5245739ed101c326ac2e81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41b5f6bca8d2400bb78d64d3ee723516_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i1a0359964fa449d7b394ee812510e987_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i702cbb6d8580485a8ed9b7d9da8a2093_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a70ce52ba824bfda7ecfd9065c1b7c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i703d6361d7e7459d8f59cb73b645d79e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5d73be98d664ccfa3f52b1b3925d8b1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id612b120136c4606a30275dd302975ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieeed2007d8ce423190963dac6498acc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3d9a5ee720049a2943b6461407a26c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb4954aca44d475bbcf2bdfd5f3e8918_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonStockOptionGrantsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib009a5d12eec454f807f70204c3f2c94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderTheStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95195c5be0cf48859f028de27b41c233_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a7dd8fe1c69457ebd695bca19af30c8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i801df2af82e6463ebc78fe5a1417689d_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ic992af68648c493b97deed5f40c92944_D20200416-20200416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-16</startDate>
            <endDate>2020-04-16</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>exdx:unit</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <unit id="payment">
        <measure>exdx:payment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV81LTEtMS0xLTA_1514ecab-4413-4396-a445-82805306ee12">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV82LTEtMS0xLTA_d79d13fe-3a32-4555-9ccf-ad352e713a47">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGFibGU6NTA5ZDAwOTI4Zjc0NDIyM2FlMmQ1ZTRkY2U1ZmMxZDUvdGFibGVyYW5nZTo1MDlkMDA5MjhmNzQ0MjIzYWUyZDVlNGRjZTVmYzFkNV83LTEtMS0xLTA_6bbeae4d-7c6f-4bd5-9b75-c8745bd3010a">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl80L2ZyYWc6NjIzNjdiYTBhNjg3NDg2MDhmNGU4NDgyZDNjZWNlYmUvdGV4dHJlZ2lvbjo2MjM2N2JhMGE2ODc0ODYwOGY0ZTg0ODJkM2NlY2ViZV84MA_4b9dd082-c1b1-4fa4-9a88-9a72bd8da972">0001274737</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i69d2e2c6f0774bcdb394050b9d53ee76_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia8548f93c1bc48f8ae505f3a7aa3a457_D20190906-20190906"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83ODQvZnJhZzpkNDJkNTc2ZDc1OTI0ZjUyYWEyMmE5Njk2NjAzMWI2Ni90ZXh0cmVnaW9uOmQ0MmQ1NzZkNzU5MjRmNTJhYTIyYTk2OTY2MDMxYjY2XzI3NDg3NzkwNjk1NjA_fe834be9-baa0-4754-80a9-5e38fdb6143e"
      unitRef="number">0.0054456</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV84NA_bc5de619-f932-4f3d-9868-bcaf5615d07b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8xLTAtMS0xLTA_32d5726a-db96-4f7f-b11d-8b082220a7ce">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzI3MmYxZmFlODQ0MzBmOTY4MjUyZWFhNTY2Yzg1N18zMA_b78ed932-761c-48e4-9abb-25185bec0f76">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjphNzI3MmYxZmFlODQ0MzBmOTY4MjUyZWFhNTY2Yzg1N18zMA_63660815-1a2e-4f0b-8d33-4eea793f2470">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MTVkYmI1ZWNhYTU3NDViZGI1NGRkYWEzMTEzNjY3N2QvdGFibGVyYW5nZToxNWRiYjVlY2FhNTc0NWJkYjU0ZGRhYTMxMTM2Njc3ZF8zLTAtMS0xLTA_44d1329a-2ad0-4fdb-9f62-223ef3b308a8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xNzQ_6e1e8aa6-529e-404f-9989-66638415a9f3">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xNzg_49fd3bd6-66e1-40e0-bf2e-d5d561a683c9">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8wLTAtMS0xLTA_f51ea8de-ea3f-4664-b7ad-2a0676cf401b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8wLTYtMS0xLTA_cf5d64b8-f71d-4987-ab27-52d9f28bb0bd">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV8zLTEtMS0xLTA_52d608fd-30d1-4d79-95f6-9be4e3c73330">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTEtMS0xLTA_1e3dc09b-b0d8-4c93-8d2f-343243b544cd">Vista</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTItMS0xLTA_982cc3d8-5934-458a-a2f4-c42294c873f6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NTZlNGY1ZjgwNzJjNDJjMTkxOGJkY2IwOTMyN2NhZGEvdGFibGVyYW5nZTo1NmU0ZjVmODA3MmM0MmMxOTE4YmRjYjA5MzI3Y2FkYV80LTYtMS0xLTA_ba6d3d2c-044c-4aa4-b8fa-a3019c40cadb">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6YTFkMDRkZWI0NmRmNGM5MzgwMmQ4YzdkOGU2NGRhOTYvdGFibGVyYW5nZTphMWQwNGRlYjQ2ZGY0YzkzODAyZDhjN2Q4ZTY0ZGE5Nl8wLTAtMS0xLTA_1ac1dd49-fa3c-4323-845d-ea6928db0893">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6YTFkMDRkZWI0NmRmNGM5MzgwMmQ4YzdkOGU2NGRhOTYvdGFibGVyYW5nZTphMWQwNGRlYjQ2ZGY0YzkzODAyZDhjN2Q4ZTY0ZGE5Nl8wLTEtMS0xLTA_cb6a946c-5502-42c2-b17b-81ead4028d16">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTAtMS0xLTA_30fa1133-b121-49c7-b12d-fb597dfada62">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTItMS0xLTA_f1749afe-babe-4df3-b058-e60efc705188">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6MzM5NGJhYzE4MTYyNGNhZGJmY2NhNGMxODNmZTBmYmQvdGFibGVyYW5nZTozMzk0YmFjMTgxNjI0Y2FkYmZjY2E0YzE4M2ZlMGZiZF8xLTQtMS0xLTA_1e608a9b-de5f-42f5-94f0-7c3efd240d17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTcz_085025c4-613e-4384-85ec-82b7dbd62ba8">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTc0_a779178d-cee9-4b3d-b086-ad0de7151288">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV85Nzg_07a5142d-1331-4d9e-9e81-5a57a11da851">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xMjgw_3f8c3bb3-072a-46f5-b8a1-f7ce6eab168c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M18yLTAtMS0xLTA_7e8c37fa-4fd0-4948-b160-369f6eee6a5b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M18yLTQtMS0xLTA_e6d75e67-a3a3-4e9a-8dd5-57b3bd5493a0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGFibGU6NDNmNzQ0YTFhMzNiNDgzYWJhMjgyZmI2ZDgyZjk0NzMvdGFibGVyYW5nZTo0M2Y3NDRhMWEzM2I0ODNhYmEyODJmYjZkODJmOTQ3M180LTQtMS0xLTA_1bd81a4e-4543-46ea-a7a9-50e455fad29f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8xOTE1_47afb3b4-130b-4b65-9e9c-0804ad5e229e">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8zMjk4NTM0ODg3Mzg5_81af924c-e234-4665-bf7c-6c51fff4eb0a">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yMDM1_bffc0dbb-11f7-4687-8b4c-24d0df8fcdbd">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i140e1c0c979f493ab5bbee92875a255d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yMTg4_b9f8e9a7-8a8c-44a1-9023-73bfee4f021c"
      unitRef="usd">83400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ied1333e512914d588c7ba153b4b54d39_I20210312"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yNjIw_54f53d00-cbde-42ad-8f53-86449bf436f9"
      unitRef="shares">12669816</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xL2ZyYWc6NGU5MDU0ODFkM2ZkNGEyMzhhY2RlYThmZmIwMjJlZjEvdGV4dHJlZ2lvbjo0ZTkwNTQ4MWQzZmQ0YTIzOGFjZGVhOGZmYjAyMmVmMV8yOTc1_010eab0e-6370-404a-b2a1-6936291a92b5">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2021 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMtNC0xLTEtMA_31ae29bf-59d4-4c45-b747-58e7dee32781"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMtNi0xLTEtMA_d51bb770-f1e6-41e7-9ddd-f211e061eaa6"
      unitRef="usd">72084000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzQtNC0xLTEtMA_9818f7da-b40d-47a0-a695-6f8ac1919543"
      unitRef="usd">8910000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzQtNi0xLTEtMA_7dddff8d-04d5-465e-acf4-e82ebda9828a"
      unitRef="usd">5715000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzUtNC0xLTEtMA_0a3f2208-1277-4efb-95a8-6931f8ddd676"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzUtNi0xLTEtMA_da9b0535-dc40-413b-8a20-abe2ed31b1c8"
      unitRef="usd">3451000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzYtNC0xLTEtMA_3dfa1f97-ee8b-4e5e-bcff-ae4c924213e5"
      unitRef="usd">70517000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzYtNi0xLTEtMA_051bb0e3-def0-4e56-8924-63b0a5dd7c54"
      unitRef="usd">81250000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzctNC0xLTEtMA_c54b5f37-32c5-4023-9175-feb7a1e5b2b7"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzctNi0xLTEtMA_02ee460f-7ae7-423f-b98e-278983c9f6e5"
      unitRef="usd">1380000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzgtNC0xLTEtMA_ad98b527-1e49-4523-bd46-da513e4f3078"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzgtNi0xLTEtMA_1252ce76-9508-4c06-917a-576550c51119"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzktNC0xLTEtMA_00030cc6-0887-43d0-809e-38d8f960d30a"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzktNi0xLTEtMA_6bd890a9-f5dc-4067-b22e-bc3d12be7958"
      unitRef="usd">174000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEwLTQtMS0xLTA_c2b745fa-5960-4dd2-a365-f0d9d0789ba6"
      unitRef="usd">78375000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEwLTYtMS0xLTA_4a0136da-fe74-4333-87b6-3e57a9683257"
      unitRef="usd">88310000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEzLTQtMS0xLTA_58ce0402-cbba-4163-8947-b38b63c21645"
      unitRef="usd">3014000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzEzLTYtMS0xLTA_5c1a3bf3-3f7e-4f8f-8824-e7e531b8c1e8"
      unitRef="usd">1476000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE0LTQtMS0xLTA_9e5d88d1-9ac5-4c04-a877-65765b1f5cdf"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE0LTYtMS0xLTA_c28d522a-08bc-4b72-b582-3fe369d6dc89"
      unitRef="usd">4419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE2LTQtMS0xLTA_45282170-a20f-4c37-85aa-5234561b169a"
      unitRef="usd">8771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE2LTYtMS0xLTA_eb8959a9-822b-470d-88cf-2f296a5b6ffc"
      unitRef="usd">5895000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE3LTQtMS0xLTA_5221d41a-126f-4031-995b-1b97e0b016f7"
      unitRef="usd">26659000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE3LTYtMS0xLTA_9ce14864-4600-4db3-a773-a62216099e95"
      unitRef="usd">25854000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE5LTQtMS0xLTA_ba3930f0-83f0-4c13-b8e4-a48595ade7a8"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzE5LTYtMS0xLTA_79e227e0-be2e-4336-8230-4fa9f94c05d2"
      unitRef="usd">264000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIwLTQtMS0xLTA_fc080b07-7d5f-43bd-9c97-20ce667212c0"
      unitRef="usd">948000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIwLTYtMS0xLTA_619310af-9d54-46d4-8512-b032c678a2ae"
      unitRef="usd">638000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIxLTQtMS0xLTA_d10735e7-c6f2-465f-8bfd-8e963b5552fa"
      unitRef="usd">36536000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIxLTYtMS0xLTA_20b37527-4f50-4f25-8ef3-d93fff63caa7"
      unitRef="usd">32651000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIyLTQtMS0xLTA_3333b57a-3d85-4185-907b-4530cc19fafd"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzIyLTYtMS0xLTA_860c2a37-f9be-40c9-8944-d0d7db736229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8yMQ_643c2f96-1e5d-4842-aea7-5cb379bc4a7d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8yMQ_8d15e96e-441b-436e-8cce-8a91f6d658cb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8zNQ_7cd2a1f1-c9ff-4e48-9eec-718e7dec2b96"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl8zNQ_a6ca3629-6c72-45d9-a0e8-85bc92f5a290"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_27dd6383-9461-4db5-963d-376d18075343"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_5e846a68-1142-4fd3-bdad-073d59e7fb00"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_989460a6-c762-453a-88a2-1ea4b6a845a7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTY3ZjI3YzZmZTQ0ZmMzOWIzM2IwZGE5MGFlZWZiNl81Nw_fba9d52f-f838-44d0-86b7-51638eda7268"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTQtMS0xLTA_236e174b-4d72-467d-b7f3-3d11190b93e9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI1LTYtMS0xLTA_9a706612-c859-4875-b768-1a798936d5ad"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xOA_578a4852-7f86-415f-977e-434dda58a912"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xOA_795f99a9-5e4a-48f1-a2b2-cc9bd8174754"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18zMg_397770a0-e3fe-4611-b89f-dc0f3bebcbd1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18zMg_c9b2a9a1-1f53-41cf-85a0-ca5e3dcbb2f0"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMTg_466c6449-e9f1-4c2b-a8b3-dc86d9d4ad60"
      unitRef="shares">12652308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMTg_9660ed2d-c441-487f-98c9-c3d2a28a5334"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMjU_084ebfef-3b44-45ab-b280-4a0d300cad0d"
      unitRef="shares">12560990</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1NjgxNzg4OTA1ZDc0M2JhOGM5NjhmYjRiZjJlM2E0M18xMjU_778fe8fd-6b35-4f73-9745-15da24e9432c"
      unitRef="shares">12560990</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTQtMS0xLTA_9ed1327f-8984-418c-84cf-e988d1a3fdab"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI2LTYtMS0xLTA_062b9263-c1e2-48a1-9ffe-38b6f53ef77a"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI3LTQtMS0xLTA_dc52b1dd-81b2-436c-92c3-8f964e34de2a"
      unitRef="usd">223115000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI3LTYtMS0xLTA_86a2a8b3-de20-4572-8c65-a86eb83e2f22"
      unitRef="usd">220248000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI4LTQtMS0xLTA_73145ba2-8e17-44b9-b32c-ca116ed141c1"
      unitRef="usd">-181289000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI4LTYtMS0xLTA_9eb3174f-a1c5-4fcc-9a75-a02ae83ce3e8"
      unitRef="usd">-164602000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI5LTQtMS0xLTA_3eccc39b-17b2-47e3-b893-d6667207b9a4"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzI5LTYtMS0xLTA_daa5c10e-965d-4305-8670-19a86ea17540"
      unitRef="usd">55659000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMwLTQtMS0xLTA_a58f0e3f-e0af-47f6-8fd0-65d9ca8aeb15"
      unitRef="usd">78375000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDMvZnJhZzoyNTBiMzk2OWUxNDM0M2I5YmU5ODdmNmNiY2RmYjhkMC90YWJsZTo4ZmU0ODVkMzM3MjI0MmZjYTU1NWJjOWY3ZGZhYmM4YS90YWJsZXJhbmdlOjhmZTQ4NWQzMzcyMjQyZmNhNTU1YmM5ZjdkZmFiYzhhXzMwLTYtMS0xLTA_01b2291a-2b91-41ac-9b25-122d203fb888"
      unitRef="usd">88310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzMtNi0xLTEtMA_b6b1f265-b538-43b9-a293-69624e6092e6"
      unitRef="usd">41975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzMtOC0xLTEtMA_a07d6680-4963-42d5-8615-1fb03525cf12"
      unitRef="usd">40387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzUtNi0xLTEtMA_92cec360-2f8b-404b-93e9-1fb0de2308f6"
      unitRef="usd">16559000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzUtOC0xLTEtMA_d8bdf4f1-4d26-4dcf-97fd-14ce1f8b8747"
      unitRef="usd">18808000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzYtNi0xLTEtMA_703a186d-dfaf-449f-bc3f-dead8e6e4e81"
      unitRef="usd">37033000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzYtOC0xLTEtMA_6e2e969b-2855-4e96-8c0f-a5d5103e3d4c"
      unitRef="usd">28702000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzctNi0xLTEtMA_ec352c04-9aa6-463b-bac1-3a370c8195c1"
      unitRef="usd">3568000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzctOC0xLTEtMA_c353d09d-8b5c-4914-8cb3-883afbce8d5f"
      unitRef="usd">2176000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEwLTYtMS0xLTA_001ed7d2-295c-436c-9dde-736406708d49"
      unitRef="usd">57160000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEwLTgtMS0xLTA_cb90f252-d9f3-4705-a7c8-1c8fdeb69f5a"
      unitRef="usd">49686000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzExLTYtMS0xLTA_c484398c-bd3c-41a3-9846-c30b73d8341e"
      unitRef="usd">-15185000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzExLTgtMS0xLTA_7fa6d723-05c3-4dfd-a0b5-01f4db519db5"
      unitRef="usd">-9299000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEyLTYtMS0xLTA_ac19ee01-2c00-43ef-a81f-29e6873d6f71"
      unitRef="usd">2565000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEyLTgtMS0xLTA_79a1ff69-2450-4fbf-b0d9-d0ec0bbab5b4"
      unitRef="usd">3491000</us-gaap:InterestExpense>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEzLTYtMS0xLTA_1c2eb117-7ad1-4bc0-9ea4-4ab3e4e0d8f0"
      unitRef="usd">0</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzEzLTgtMS0xLTA_3edc9866-24fb-40f1-ae26-29f011deaf72"
      unitRef="usd">267000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE0LTYtMS0xLTA_3555c0ec-b81a-4620-a897-3ace6538de33"
      unitRef="usd">984000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE0LTgtMS0xLTA_58388825-79a0-43bb-840a-b7fadc4c5663"
      unitRef="usd">510000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE1LTYtMS0xLTA_09e7a421-fd85-4629-9beb-20a10fd091db"
      unitRef="usd">-16766000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE1LTgtMS0xLTA_7ecc3d7f-dfa8-43c8-b37a-603b5491df71"
      unitRef="usd">-12013000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE2LTYtMS0xLTA_626bef7a-32e4-49ae-9a87-d5609750fcd8"
      unitRef="usd">-79000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE2LTgtMS0xLTA_a408641a-7920-48a3-8ffa-8929d0f50cc7"
      unitRef="usd">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE3LTYtMS0xLTA_58ff90b5-d72e-4115-bf48-89331be0595e"
      unitRef="usd">-16687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE3LTgtMS0xLTA_2263a104-b12a-4c7c-bddf-010dd70f9973"
      unitRef="usd">-12038000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE4LTYtMS0xLTA_0ad703c7-6537-426e-a8ed-ef3154dec86c"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE4LTgtMS0xLTA_b90f6b98-a5a9-4342-a588-c1af483726f2"
      unitRef="usd">4640000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE5LTYtMS0xLTA_800ce1e2-4101-46ab-9c15-b3a55021d2b2"
      unitRef="usd">0</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzE5LTgtMS0xLTA_454940ba-7a79-4016-bc85-7b09b3c00c17"
      unitRef="usd">13601000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIwLTYtMS0xLTA_bbb3fd8c-48dc-4e4b-a015-02d74f88c509"
      unitRef="usd">-16687000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIwLTgtMS0xLTA_5aa7e53a-8773-4878-8037-1c5ab00ee131"
      unitRef="usd">-30279000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIxLTYtMS0xLTA_636e3f0d-d82b-4bfd-b580-2a98cfd845f8"
      unitRef="usdPerShare">-1.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIxLTgtMS0xLTA_02e5aa83-bb50-4e20-b7fe-a443a1df4f7d"
      unitRef="usdPerShare">-8.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIyLTYtMS0xLTA_63331411-3b44-4548-9426-8cc931464be6"
      unitRef="shares">12632780</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDYvZnJhZzo5MTFiM2QwZTg5N2Q0MDkwODkyODljZGJkNjdjMzZhZS90YWJsZToxNTA4MjcwZWVkNjI0ODQwOWYwYzdmYWQ5N2I2ZmJhYS90YWJsZXJhbmdlOjE1MDgyNzBlZWQ2MjQ4NDA5ZjBjN2ZhZDk3YjZmYmFhXzIyLTgtMS0xLTA_df3085f6-37b2-4105-9df1-ac766d416d96"
      unitRef="shares">3578771</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMi0xLTEtMA_11372114-e4ff-41b8-80e6-7b0f8ac098c8"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtNC0xLTEtMA_dedbf4a9-ca59-481e-b1ed-e22ac0629497"
      unitRef="usd">105232000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6884440164f1463aa6e4fed299d3fe16_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtNi0xLTEtMA_84379aad-9ca0-43ab-aef0-51df3a847c75"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6884440164f1463aa6e4fed299d3fe16_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtOC0xLTEtMA_2ea54a7e-5830-4fd0-9df8-ae85e915ef3a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a5cbdb8b75149f1a2107742fed852bf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTAtMS0xLTA_aac02bd1-2f90-4d9e-928b-729b3410f694"
      unitRef="usd">40598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e3a91a5115e431d98f3d1ae4a1da9ec_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTItMS0xLTA_bbbce9c5-e542-42d3-b09c-7b4e9eace0e0"
      unitRef="usd">-152564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzgtMTQtMS0xLTA_df2db667-dfcd-4cc9-9b84-509df52798d1"
      unitRef="usd">-111966000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktNC0xLTEtMA_cccc8424-405e-4187-81e7-bbbbed87e642"
      unitRef="usd">4640000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktMTAtMS0xLTA_7b2022d7-75f5-4e21-b234-79a9cf9c739a"
      unitRef="usd">4640000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzktMTQtMS0xLTA_5722380f-d786-4290-80bf-e9e9e6493203"
      unitRef="usd">4640000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTYtMS0xLTA_0641b0a6-a66e-4d95-b081-48c638ffe2ed"
      unitRef="shares">1548</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTEwLTEtMS0w_69009976-ec7e-4b48-9ffe-a68199d1b272"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEwLTE0LTEtMS0w_dd7d13e2-f456-45e1-8dd0-a25c6b534c0d"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzExLTEwLTEtMS0w_adaec370-8482-4b30-90e8-8c4832512672"
      unitRef="usd">572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzExLTE0LTEtMS0w_e466d560-4df6-4655-851e-d18a13ac8f72"
      unitRef="usd">572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTA0ZGNkYTkyNWQ0MTI2YjliMzNhOGVhMDlhNjE0M185MA_63a43e61-7508-45c5-b4a4-c629fff5d530"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNTA0ZGNkYTkyNWQ0MTI2YjliMzNhOGVhMDlhNjE0M18xMjk_d640c9c1-9508-436e-8e44-9dca3a311435"
      unitRef="usd">124000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTItMS0xLTA_3f564dd3-b161-4f44-8278-4a75f6b865f9"
      unitRef="shares">148928337</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEyLTQtMS0xLTA_7c35bcde-5c40-4c33-9edd-96f3b57bcf17"
      unitRef="usd">11492000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZTAyOTliODZkMGI0ZjI0ODZjNzFiMjgwZTUxYTc2N185MA_f18c8003-d7f1-4e82-835c-7a82759cfc54"
      unitRef="usdPerShare">0.047</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZTAyOTliODZkMGI0ZjI0ODZjNzFiMjgwZTUxYTc2N18xMjk_2c072dee-3e7f-4a35-ab69-424258cce0b8"
      unitRef="usd">318000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTItMS0xLTA_6bd5fc8c-8feb-4fa0-8d3d-d01a0b4c03d7"
      unitRef="shares">233446519</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTQtMS0xLTA_45cb176b-684c-401a-8172-23762601eddb"
      unitRef="usd">3941000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTEwLTEtMS0w_82f5fc95-2305-48e3-b7bc-eefbcc10115d"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzEzLTE0LTEtMS0w_a6302082-e0dd-40c9-966e-8d0765d22962"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTQtMS0xLTA_d25d3094-df8d-4796-b06e-8644899e2bdf"
      unitRef="usd">6741000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTEwLTEtMS0w_593dc169-3771-446b-8ce9-290f66b39c2e"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE0LTE0LTEtMS0w_b4982da8-fcbe-4eb3-b764-26237bc6f0b9"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividendSharesIssued
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTItMS0xLTA_d06c6d4f-6dbd-4be0-be2b-22f682082de1"
      unitRef="shares">97592739</exdx:TemporaryEquityDeemedDividendSharesIssued>
    <exdx:TemporaryEquityDeemedDividend
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTQtMS0xLTA_65b4c8d4-e618-44aa-811b-41535eec6412"
      unitRef="usd">6860000</exdx:TemporaryEquityDeemedDividend>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTEwLTEtMS0w_aadd7a60-b421-4b28-81a9-7e7f2ed0c101"
      unitRef="usd">6860000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE1LTE0LTEtMS0w_d52e4b4f-2bda-465b-8305-7741312b1ba2"
      unitRef="usd">6860000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends>
    <exdx:TemporaryEquitySharesRedeemedUponConversion
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTItMS0xLTA_775e49fe-cc64-44c8-8e3f-dc8f2e959e51"
      unitRef="shares">1012573679</exdx:TemporaryEquitySharesRedeemedUponConversion>
    <exdx:TemporaryEquitySharesRedeemedUponConversionAmount
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTQtMS0xLTA_93a2e433-5a07-4b74-bbb9-710a40ba53b8"
      unitRef="usd">138906000</exdx:TemporaryEquitySharesRedeemedUponConversionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTYtMS0xLTA_96420639-73b1-4ecc-9e0e-5d6443466338"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTgtMS0xLTA_97ce7924-441b-4e38-a6cb-e03c8ba64a50"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTEwLTEtMS0w_f05dda18-6ea1-40a6-8d67-bffe751e1658"
      unitRef="usd">138898000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE2LTE0LTEtMS0w_887ff9da-021a-4e11-b578-88d7ba55396a"
      unitRef="usd">138906000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTYtMS0xLTA_0bcea484-4660-4863-8189-a9ddacaa66b5"
      unitRef="shares">4140000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTgtMS0xLTA_4fd5418f-d55d-4a13-a21f-aefdb162d47e"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTEwLTEtMS0w_773cb117-d9ef-42e9-8239-eff30cea5dad"
      unitRef="usd">50440000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE3LTE0LTEtMS0w_1bedad57-1c68-4ea9-b609-8f2d8c0cd6ff"
      unitRef="usd">50444000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTYtMS0xLTA_dc3c8003-28f7-46f2-8f24-75274f5acda4"
      unitRef="shares">539794</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTgtMS0xLTA_9b5a15ac-b50c-4bfc-83d2-3a844e3eed7b"
      unitRef="usd">1000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTEwLTEtMS0w_572211d0-10c4-4f17-b3de-670b05355713"
      unitRef="usd">510000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE4LTE0LTEtMS0w_cf6648f0-2301-4832-986c-fecc3cd4cf9d"
      unitRef="usd">511000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability
      contextRef="iec9c6a63268f49088d28e756daf8e252_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE5LTEwLTEtMS0w_ce7d3c92-f868-44fb-b832-81f8d559845f"
      unitRef="usd">726000</exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability>
    <exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzE5LTE0LTEtMS0w_d504f147-7acd-41b5-baa8-01c5349ef09e"
      unitRef="usd">726000</exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability>
    <us-gaap:NetIncomeLoss
      contextRef="i000894d3cadd4d209d2620841a05dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIwLTEyLTEtMS0w_b97eefb9-b941-43ad-b7c8-80dc2a581d82"
      unitRef="usd">-12038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIwLTE0LTEtMS0w_b452239a-5410-41b7-96b4-492eb585a534"
      unitRef="usd">-12038000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTItMS0xLTA_a4f284f1-7e31-4793-97b8-d04a5e11b5df"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTQtMS0xLTA_4c53b5e3-f7ea-45e9-8a51-fba69df1b640"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTYtMS0xLTA_ba779cf6-0ce9-4725-8961-7f170e3f7875"
      unitRef="shares">12560990</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i300aabe27b694c5aaf0c9a700cbe11ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTgtMS0xLTA_c703d93a-23e1-41e0-a984-cecf3f67adcc"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69da35ef92234938bcda9473aefd88f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTEwLTEtMS0w_112169c8-0b08-4310-9524-6ae660c368cf"
      unitRef="usd">220248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i724b6d08dcb54c94ae1352b8b23c595f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTEyLTEtMS0w_adbd3310-eda9-4352-900b-7057f7deda56"
      unitRef="usd">-164602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIxLTE0LTEtMS0w_d310e147-bd0a-47b2-97f8-fe965c4d8fd0"
      unitRef="usd">55659000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTYtMS0xLTEwMQ_2ac8db5b-8a82-4dab-a992-49a569857210"
      unitRef="shares">47549</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTEwLTEtMS0xMjg_62a9a885-58b5-44ba-b106-5360f05a458e"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIyLTE0LTEtMS0xMzY_75d88d91-b0e3-480a-a85f-c33d2fd8882f"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTYtMS0xLTEwMQ_420a8f71-3ec0-4cfe-9be9-40c73f18f258"
      unitRef="shares">11649</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTEwLTEtMS0xMjg_c7601199-efd6-4da0-accd-7a032511b003"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzIzLTE0LTEtMS0xMzY_d5d7d842-0769-4a6c-a14c-e82fba8c79a3"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI0LTEwLTEtMS0xMjg_017b1b2b-9640-43a6-9a43-99693162f3ec"
      unitRef="usd">2694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI0LTE0LTEtMS0xMzY_17f4afd5-a44d-4565-a4b0-02f5849d282c"
      unitRef="usd">2694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="icd0eeddf8cc6442eb98678ca3b18bcdd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTYtMS0xLTEwMQ_3815202f-ca3a-4620-b50a-19394bc139ee"
      unitRef="shares">32120</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i412f9e5c8a1c4205ae72e84686f1ca98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTEwLTEtMS0xMjg_09c21b16-9589-4e80-aad0-47c6fe445f2d"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI1LTE0LTEtMS0xMzY_88215e08-84b1-4348-b92f-e6c4251f323b"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="ic85d4c855b6840b89f8a4974a7609bdd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI2LTEyLTEtMS0xMzI_0d87408b-8f22-4713-a295-3ebad6397366"
      unitRef="usd">-16687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI2LTE0LTEtMS0xMzY_212dbc3d-666f-4146-a10f-2fa4cb4d7fa9"
      unitRef="usd">-16687000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTItMS0xLTExNg_135806b6-4b88-4290-b9a6-3606a2771312"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTQtMS0xLTEyMA_435f6593-6603-4972-9be2-47222ae51ef7"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTYtMS0xLTEwMQ_1be86c69-a8ef-4584-b547-15d29ad2236d"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iecb93b3b0cdf41e3bf8d1a677147f799_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTgtMS0xLTEyNA_5e1a1975-21f7-452d-92e1-93fdfa1c07bf"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31e794abff7a43f59c1e323fa7e55d45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTEwLTEtMS0xMjg_b726ffbc-2a4b-48c2-b549-7b9cee742182"
      unitRef="usd">223115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6dbfbafdf8a408ca1bbfc730926cc14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTEyLTEtMS0xMzI_ed5fd58f-f5b2-4444-9995-c2f73de39058"
      unitRef="usd">-181289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMDkvZnJhZzowMjUyM2VlMGZjOWU0Y2RlOTgwNjlhMDc4Mzk2N2NiMS90YWJsZTo2ZmMwOTY2YmRkMWU0YjQyYjA5YTBmNzA5ZjYxNDJmNi90YWJsZXJhbmdlOjZmYzA5NjZiZGQxZTRiNDJiMDlhMGY3MDlmNjE0MmY2XzI3LTE0LTEtMS0xMzY_37694814-8a9c-4dbb-8d88-823d1701fd4e"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQtNi0xLTEtMA_6e6568cb-a1d5-46bb-b0d9-37dd8306d335"
      unitRef="usd">-16687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQtOC0xLTEtMA_2950fafb-9df1-4c05-84de-76b8f9d92bd6"
      unitRef="usd">-12038000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzYtNi0xLTEtMA_544089f1-91ac-4ddd-90ad-0a66f4b8d2d5"
      unitRef="usd">546000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzYtOC0xLTEtMA_de231a07-54bb-4d04-b450-dfe7d37e1357"
      unitRef="usd">591000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzctNi0xLTEtMA_c7731aad-a730-4a53-8c09-8434ffae897d"
      unitRef="usd">274000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzctOC0xLTEtMA_a5500d03-f03d-4f05-9a61-1e710b35f4e1"
      unitRef="usd">691000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzgtNi0xLTEtMA_f0a5b4f6-62d2-4601-a5f9-ec5f9ab17b2f"
      unitRef="usd">531000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzgtOC0xLTEtMA_f8a6eacc-c849-459f-a2b4-127d9d5a5205"
      unitRef="usd">546000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzktNi0xLTEtMA_7d43e419-a1a0-4126-acb4-776643240df3"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzktOC0xLTEtMA_92de762e-6017-4c3e-8522-f264a384302b"
      unitRef="usd">-267000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEwLTYtMS0xLTA_88951393-4b7b-4751-a917-07b0ff2a1851"
      unitRef="usd">-106000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEwLTgtMS0xLTA_40835c0c-cbe8-4112-a0f4-444567431776"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzExLTYtMS0xLTA_f49b5148-d87f-46d9-951a-914e8d7853b8"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzExLTgtMS0xLTA_1e049ecf-b56e-48ce-b8d8-50f113a4b111"
      unitRef="usd">-20000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEyLTYtMS0xLTA_2b5bb34c-0fdc-40fd-a2e9-6866bd28f9fe"
      unitRef="usd">2694000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzEyLTgtMS0xLTA_a86aa1fa-c3d7-4c46-bd86-20eb881cdcd2"
      unitRef="usd">572000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE0LTYtMS0xLTA_823e7f9b-6be2-45da-b7f8-5816c3f8f98d"
      unitRef="usd">3195000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE0LTgtMS0xLTA_c082547c-876e-47d1-aaa8-9728cfd3d57f"
      unitRef="usd">-237000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE1LTYtMS0xLTA_d058f9f1-9642-465f-bd8e-834b5859f6b7"
      unitRef="usd">708000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE1LTgtMS0xLTA_756330f0-ffef-47fc-bb72-2d3aae38d7dc"
      unitRef="usd">1255000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE2LTYtMS0xLTA_9eaa92f1-2f25-4ebc-947d-24bb97d7c2c1"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE2LTgtMS0xLTA_f53b7687-d037-45ea-ac64-6878f8b97e61"
      unitRef="usd">24000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE3LTYtMS0xLTA_ba5c5ce8-8f3c-42d8-8b70-c4a5af9443b7"
      unitRef="usd">986000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE3LTgtMS0xLTA_4ab790fd-495a-4fde-bdf1-bd030079cec4"
      unitRef="usd">528000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE4LTYtMS0xLTA_c2e371f7-e7fd-4ed4-b0a4-691404f26d00"
      unitRef="usd">1596000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzE4LTgtMS0xLTA_ec0e59cb-2446-410e-abe8-c6fceef5ccf1"
      unitRef="usd">688000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIwLTYtMS0xLTA_8241f105-2e87-49ce-a562-6870a87775fb"
      unitRef="usd">-14084000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIwLTgtMS0xLTA_9efd2d4d-d576-430a-b36e-4f072e841568"
      unitRef="usd">-9711000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIyLTYtMS0xLTA_2d7cf7ea-596c-4f14-8c9c-3408c670d2a5"
      unitRef="usd">455000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIyLTgtMS0xLTA_4fd19c63-677f-4117-81ec-814ff8fbd6bd"
      unitRef="usd">403000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIzLTYtMS0xLTA_156ced16-2eda-4895-a403-25cfac089c3f"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzIzLTgtMS0xLTA_d837d82c-261e-4fd8-8b42-957c230bd986"
      unitRef="usd">300000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI2LTYtMS0xLTA_f80b3dc9-a1e8-4311-b837-c5bda66420b9"
      unitRef="usd">-455000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI2LTgtMS0xLTA_ef98572f-8068-4872-8c93-655466cadab8"
      unitRef="usd">-103000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI4LTYtMS0xLTA_68d91bfd-a7d3-4121-aa44-d4c0248702f2"
      unitRef="usd">13000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI4LTgtMS0xLTA_748d45cf-de48-40ed-9f85-2112da12b83b"
      unitRef="usd">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTYtMS0xLTE2Mw_7a8dae1e-c7a4-4b7f-b246-d271c3eb00ae"
      unitRef="usd">142000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTgtMS0xLTE1OQ_3c525bd4-0f94-444d-9135-87e7c3051526"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMwLTYtMS0xLTE2Mw_79366000-65f4-4298-abb4-2af38f77281a"
      unitRef="usd">18000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMwLTgtMS0xLTE1OQ_7138ad5e-b575-4c98-8cf0-a4554e1ca3ef"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTYtMS0xLTA_d3aa1031-5205-4c59-8257-61b1f5d4ddb9"
      unitRef="usd">249000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzI5LTgtMS0xLTA_733b0fba-d5a6-47d7-923e-fdaeecb61a4e"
      unitRef="usd">138000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTYtMS0xLTE3MQ_b87bcd42-503b-4203-a6ad-a6184cb57f15"
      unitRef="usd">2865000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTgtMS0xLTE2Nw_72f6b3a2-6d52-45ab-afdc-1953633eda7b"
      unitRef="usd">0</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTYtMS0xLTE3MQ_3e25f041-8ffc-43e9-9963-7c826ad6c8d5"
      unitRef="usd">2865000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTgtMS0xLTE2Nw_3655a537-9776-4be9-bd6c-396668ec9c2c"
      unitRef="usd">0</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMxLTYtMS0xLTA_d6a8f464-c015-4bd9-8224-9b7d5bc35682"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMxLTgtMS0xLTA_fdf03ebb-8d32-4a94-a3cf-e063deaf0660"
      unitRef="usd">50444000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTYtMS0xLTA_47237215-49ca-4059-874d-61f91b3e5add"
      unitRef="usd">0</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzMzLTgtMS0xLTA_1b8b5334-3c50-4fd4-bb7f-68977eb1f33b"
      unitRef="usd">7742000</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTYtMS0xLTA_807defa2-56da-4c67-b6c6-621aaf783a06"
      unitRef="usd">0</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM0LTgtMS0xLTA_af94cf32-f49a-4e41-98ef-4d784b29431f"
      unitRef="usd">10682000</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM1LTYtMS0xLTA_047adf37-f4f4-40a0-b6cd-e1eece6f4868"
      unitRef="usd">21000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM1LTgtMS0xLTA_801fc878-064a-49b2-8668-feceaff429b6"
      unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM2LTYtMS0xLTA_5dbd50e2-87d0-49da-8bda-8f055d01008b"
      unitRef="usd">-97000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM2LTgtMS0xLTA_c0985424-f20c-4b1b-a8d6-5c47ad0d6e05"
      unitRef="usd">68734000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM3LTYtMS0xLTA_b5a6f063-5c48-4504-92b0-0ba6e64d8844"
      unitRef="usd">-14636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM3LTgtMS0xLTA_72fa05a7-afbc-4432-984f-6d8c06a1cc15"
      unitRef="usd">58920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM4LTYtMS0xLTA_0554a641-94c0-48da-b3e9-f5878bac6d1b"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM4LTgtMS0xLTA_9ec18dde-fa8b-4124-890c-c2d4a42b2bed"
      unitRef="usd">13264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM5LTYtMS0xLTA_d587f621-a239-43bb-80ae-ae58755e5581"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzM5LTgtMS0xLTA_cea1ab2d-d93d-4765-9893-ff7ef0bf4bad"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQxLTYtMS0xLTA_7858ab3c-8ad8-417c-8d14-274d1718268d"
      unitRef="usd">1758000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQxLTgtMS0xLTA_ec7871c2-c7ee-4d0e-b8d5-46f272fa71c6"
      unitRef="usd">2288000</us-gaap:InterestPaidNet>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQzLTYtMS0xLTA_ae05c099-bd68-4d7b-a3de-f1b6c6fba137"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQzLTgtMS0xLTA_fb8ebeab-6518-412e-9812-da6e23467c67"
      unitRef="usd">4640000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ0LTYtMS0xLTA_2a75bd17-72ed-4d23-93dd-98acf1c444ee"
      unitRef="usd">260000</exdx:EquipmentPurchasedUnderCapitalLease>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ0LTgtMS0xLTA_b8342b7e-5df2-48a5-b629-30e9f6ea0e07"
      unitRef="usd">654000</exdx:EquipmentPurchasedUnderCapitalLease>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ2LTYtMS0xLTA_00606cc5-4a13-4a53-95aa-c0cb3384b767"
      unitRef="usd">553000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ2LTgtMS0xLTA_eb0a4927-fa96-45ec-b181-b2246212cdbd"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ3LTYtMS0xLTA_320eda23-4d80-4354-a263-8df93880a140"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ3LTgtMS0xLTA_3d866601-3a30-4314-a9a7-2ae6a60ce323"
      unitRef="usd">138906000</us-gaap:ConversionOfStockAmountConverted1>
    <exdx:NoncashExerciseOfStockPurchaseWarrants
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ4LTYtMS0xLTA_32087ccc-c63a-41c2-91b1-1b84b0e908e9"
      unitRef="usd">0</exdx:NoncashExerciseOfStockPurchaseWarrants>
    <exdx:NoncashExerciseOfStockPurchaseWarrants
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ4LTgtMS0xLTA_26343829-cde3-40d4-af53-6b62dcd54ebb"
      unitRef="usd">511000</exdx:NoncashExerciseOfStockPurchaseWarrants>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ5LTYtMS0xLTA_e203bf8d-4fa3-4844-b6e8-e983c9779fe2"
      unitRef="usd">40000</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzQ5LTgtMS0xLTA_cea6ebde-9ea2-44fe-aa3c-2a594c47d8c1"
      unitRef="usd">0</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUwLTYtMS0xLTA_49480aac-3f35-4e51-81ad-5f1fde831dec"
      unitRef="usd">0</exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity>
    <exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUwLTgtMS0xLTA_5da337a1-ea36-4775-a18b-99aca4cab77c"
      unitRef="usd">726000</exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i58bbeeeb7ca04910aa09ec0626a71e3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUxLTYtMS0xLTA_c9f58ab3-9269-4f99-9085-9739d7618c7b"
      unitRef="usd">0</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i0d13881d6e83434597f3a5e81badbe4e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUxLTgtMS0xLTA_5f620cbc-4ba9-4e34-81ee-4f12f85bf8d9"
      unitRef="usd">6741000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUyLTYtMS0xLTA_0d924560-2b7e-407f-b206-81e54d94d7d4"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUyLTgtMS0xLTA_88957708-a2e5-4665-8be4-c659472fb27f"
      unitRef="usd">6860000</us-gaap:TemporaryEquityAccretionOfDividends>
    <exdx:ConversionOfTemporaryEquityAmountConverted
      contextRef="i79849924192d4855a9bbf663964883f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUzLTYtMS0xLTA_b195f0c1-1e4b-444c-8962-a027493b6274"
      unitRef="usd">0</exdx:ConversionOfTemporaryEquityAmountConverted>
    <exdx:ConversionOfTemporaryEquityAmountConverted
      contextRef="i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTIvZnJhZzozNWYzZmVmNjU1MzE0YWZhYmU1ODdkOTkxZjA1YTMyOS90YWJsZTo2NmJjNWE4YTUxMmE0YTdhYTE1YTA2MDVmZGFhYTEwOC90YWJsZXJhbmdlOjY2YmM1YThhNTEyYTRhN2FhMTVhMDYwNWZkYWFhMTA4XzUzLTgtMS0xLTA_ab81e2bb-0184-4c76-a908-caa64a5e1cc7"
      unitRef="usd">11875000</exdx:ConversionOfTemporaryEquityAmountConverted>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzQwMTU_f93de78d-3cc0-47a8-93db-d4f9e1f20771">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2020, the Company had cash and cash equivalents of $57.4 million and had an accumulated deficit of $181.3 million. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its initial public offering (IPO) and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzI0ODM_58b599c0-d0f5-4970-8418-72b616c966f9"
      unitRef="usd">57400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMTgvZnJhZzo1YmUwM2ZjNDRhODY0ZjBjODYzZTA4NTM0ZjM4NTg2Yy90ZXh0cmVnaW9uOjViZTAzZmM0NGE4NjRmMGM4NjNlMDg1MzRmMzg1ODZjXzI1MjA_6879f0c1-cf85-4ac7-a2a7-61e934f5b7b3"
      unitRef="usd">-181300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAw_447dfdd8-bae9-4ec9-94ac-f86e7eaf8dab">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customers, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019, approximately 70% and 82% of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2020 and 2019, approximately 97% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the IPO, the Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of 7,816,643 shares of common stock, excluding warrant conversions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 8 for further discussion on the remaining warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. The Company is responsible for the costs associated with its salesforce over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for that quarter over a predetermined baseline. For the years ended December 31, 2020 and 2019, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement). In accordance with the June Amended Janssen Agreement, the predetermined average baseline for prescribed units for each remaining quarter in 2020 was adjusted and is subject to further adjustment, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarters of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $0.3&#160;million and the fee will be capped at 10% above the adjusted predetermined baseline. The Company continued to receive a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline for the quarter ended December 31, 2020. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional 12 months upon 180 days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon 30 days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $5.1 million and $1.5 million during the years ended December&#160;31, 2020 and 2019, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are included in selling, general and administrative expenses and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.3 million and $1.6 million for the years ended December&#160;31, 2020 and 2019, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $1.4 million for each of the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock, options outstanding under the Company's stock option plans and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the years ended December&#160;31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,414,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,836,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Assistance Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and are included in other income, net in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company does not anticipate the adoption will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement: Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company adopted this guidance on January 1, 2020, and the adoption did not have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAx_01b44d5e-32ac-499f-909b-1cf9214e4481">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEw_d952876c-b8b7-4bb4-ad10-087a353ee92a">For each significant payor and customers, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzMtNi0xLTEtMA_6b85d91b-db94-4899-be63-9d4ed443d945"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9563b9ab6fbe4adcbdfbac8e2cf19b22_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzMtOC0xLTEtMA_2f2ae038-ac49-4228-9be1-ffa12bac0154"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id8c6b3ac4c664091b47227b153e9eb44_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtNi0xLTEtNDU5Nw_3ced5803-dcac-42b6-9e58-52d8aa9143e9"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iac265b2ebdbc43e59ef20ea50e78de9f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtNi0xLTEtMA_5e60cef5-bb34-4bd6-b66a-e05359e468be"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb52827a0d5e4d20bbb2e688d4965f2b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzQtOC0xLTEtMA_5f51a9a7-943c-4c7c-bfe8-7d0e6aa0e652"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id90ff0582bfa4beb88fa29365bcf05c9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzYtNi0xLTEtNDYwMg_7626cd86-40d8-4ba2-8148-fa4e42d37166"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i075b7f5ce30f4250b3fa7b1319fa76d0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzYtOC0xLTEtNDYwMg_70b39b76-51ec-4772-9976-42bb3b525345"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7cbc755e54584988a46ac09b03ba0a03_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxN2E1M2I3NjdhM2I0ZDQxYmJkZDdhNjZlNGQ4YjM2My90YWJsZXJhbmdlOjE3YTUzYjc2N2EzYjRkNDFiYmRkN2E2NmU0ZDhiMzYzXzUtOC0xLTEtMA_f2054647-bc87-41b5-b8be-ab37a54de351"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia683090804ac4bbea90d92b75159efe3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzMtNC0xLTEtMA_c8c04030-ae16-45f4-a127-011adc74a969"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i031b116f01f44ea5890d77e14040a529_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzMtNi0xLTEtMA_ec1fc714-b57c-43ab-aff7-a14973888d98"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5031346fd2374b0e97451ce84bad8260_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzQtNC0xLTEtMA_01582b63-6a84-48c7-b0e8-716b3a3ee0df"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if76b41f869c640688904f2ecf988e33e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzQtNi0xLTEtMA_853b8bd5-b190-4f63-a75a-c54acbd53bcb"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie09521d642ec49dd9f6fb93b6226a986_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpmMmY1M2U3NDcxNTA0MTBkYTQ3ZDc3NGU0ODAwZjA2Ni90YWJsZXJhbmdlOmYyZjUzZTc0NzE1MDQxMGRhNDdkNzc0ZTQ4MDBmMDY2XzUtNi0xLTEtMA_c2e7ad11-beae-4dac-99c0-195df49026b2"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc34f2aa5b494ba4b697db93d5108663_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIxNTU_2887f0e9-d7a5-49b9-baf6-d8671f0ea997"
      unitRef="number">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie6e601deab964329936be94a4d256bc9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzYxODI_e4bba5cc-5373-4ddb-8ff5-93cde687156a"
      unitRef="number">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i15b8ceb139cf4e0d97db9be7ea8aacf7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIzNDI_010665e5-564c-4d57-9c26-767827e742d1"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifd041b98c6ab476eb80888f8676c3df5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzIzNDI_61879554-e021-4d6e-b52c-5a8298ae2e16"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEx_ba84613a-6c22-42f4-a28e-ab411b8316cb">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5690cf2946e8412bb86195a6c74a9316_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzMtNi0xLTEtMA_ce1f3fd0-049e-4b0a-a499-48b1cad70d00"
      unitRef="usd">22456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcaa2249e3c640468e6ad463c58824a6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzMtOC0xLTEtMA_b8fcf027-401f-4524-b266-c9e89bead76e"
      unitRef="usd">23984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a5f71713fcf420b86e6051da049e7ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzQtNi0xLTEtMA_0bdda7ec-5b20-4d81-a08a-7ca9715b7ddf"
      unitRef="usd">8446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18229da67eb54a6b8110b348c32b2f80_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzQtOC0xLTEtMA_e2179643-da60-4dbd-977d-4117f0e8b59f"
      unitRef="usd">9896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06930bdf59ec4a7490fb90caaee4d192_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzUtNi0xLTEtMA_274bcbae-ae65-47c0-a89a-9cd460f610ea"
      unitRef="usd">5109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d5f0f3606b4c66949b12896e3d82ad_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzUtOC0xLTEtMA_1d54e436-6182-4e2f-bad7-0b04fd44822a"
      unitRef="usd">4392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d2d0f3c92004d4d8ea0b1587e20bd73_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzYtNi0xLTEtMA_b4b4a2b9-1bb0-4052-ac07-7942bf421f35"
      unitRef="usd">836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie26b529fa0544e3fa5ffa639ffaaa3da_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzYtOC0xLTEtMA_eff468e1-dcf4-418a-b6cf-3dab1d08a002"
      unitRef="usd">639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie43dd45431384ad48a4a7cd39396b772_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzctNi0xLTEtMA_98271406-a712-46af-8cae-b446f3fcecc1"
      unitRef="usd">5128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8f51ada9f8b45298c0c793b85f782e6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzctOC0xLTEtMA_71ce1de2-7649-44ae-b5aa-7a913871dae2"
      unitRef="usd">1476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzgtNi0xLTEtMA_8dc8aab5-d051-4bfc-b916-81ba1d29e02f"
      unitRef="usd">41975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToxYjlmMWE3Y2ExNTc0NjZhYjNlN2FkYzRjM2Y0MGIwMy90YWJsZXJhbmdlOjFiOWYxYTdjYTE1NzQ2NmFiM2U3YWRjNGMzZjQwYjAzXzgtOC0xLTEtMA_ee0573e1-1d58-4399-aab0-33efadf7f6eb"
      unitRef="usd">40387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk1_b8872d3e-6981-4fae-9c5c-6e4d835a1fe7">Fair Value Measurements&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the IPO, the Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA2_13b4d5fc-04ea-4bc5-8675-2915b1898c3f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i4e3c2fa4dc5f49e8b1099bc7e449e3a2_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzUyMDk_85601167-8b3e-42cf-a7be-5a1a49563cae"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA0_0a9459aa-0aaf-4c4f-a0be-8b9342e1f971">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA0_4f5a02b8-d59e-4593-9edd-22d232d5e263">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzItNC0xLTEtMA_ae56ecac-9fbc-4f62-ac6a-a050b71e3de9"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzItNi0xLTEtMA_0e39f14f-751e-4a58-a28d-3d93e89df7a0"
      unitRef="usd">72084000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzMtNC0xLTEtMA_c44a2ee0-62ee-4c11-a7af-972b1c941e3a"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzMtNi0xLTEtMA_fe3b52a2-c1c6-40e7-a4ed-2ab6a5022df6"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzQtNC0xLTEtMA_b400e13f-8388-4cd8-a0e6-118560c53280"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZTpjYjJkNzQzZWY3NDU0MGNiODZlNWZkMTExZDFkOGQxOC90YWJsZXJhbmdlOmNiMmQ3NDNlZjc0NTQwY2I4NmU1ZmQxMTFkMWQ4ZDE4XzQtNi0xLTEtMA_a040391f-745f-40ec-ae46-a2b019125655"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTky_f2dde299-75aa-4a58-a7a3-678754aeebd9">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and &lt;/span&gt;&lt;/div&gt;accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4573db3dc09e4fa8a58677b574d5c416_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNTk_8d8d09f8-f9b9-4980-906e-811e236f99a7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA1_453e97bb-42c8-4cb4-9da6-7828e2ce1c53">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <exdx:ClinicalStudyPolicyPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAy_d7a52ea7-4134-4655-a2f7-1fa8bead2377">Clinical StudiesFrom time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</exdx:ClinicalStudyPolicyPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzEwOTk1MTE2NjQ4NzA_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MjA4NDY_383cdc71-882b-4912-84e3-4dfe925a28f6"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk3_c96ea6ed-c49e-44ab-984d-d45342ff420c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNzY_8738f572-fb83-4103-903d-08d112ac0515">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing</us-gaap:ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i854adb164db541fa9bd24fb1ccb21010_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5NTQ_6305ff44-5e3f-497c-be7f-5c5700dc75a3"
      unitRef="usd">750000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ia5c2c61809374714a756188ab1adadbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5NjA_9548cad7-4ac2-4e94-bd0f-d9abf4ea8c5e"
      unitRef="usd">1250000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i9ce5a530334e4915b0436079dca953ff_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5Njg_3974ee25-4ace-4bf6-8595-0aca80b9c37b"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i20146f37e33a40dab402238b6ea56800_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5Njg_83d5e84b-8edb-456d-b6a6-dff4e9f3b745"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTA_753bb84d-08b7-4ba0-8729-94b7372a131c"
      unitRef="number">0.05</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i9156fd411b7741a8a39d1c43983a5800_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTA_f8b46d92-f3f1-498c-bf0c-1bdfeaf966cf"
      unitRef="number">0.05</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPrescribedUnits
      contextRef="ic0b7b9ea1d814dbbbeed9b14692e78ca_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyODc_1e2245f9-8bfe-43af-af96-83ff0d70bde1"
      unitRef="unit">28750</exdx:JointVentureQuarterlyPrescribedUnits>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ic3d6c90706d94887a50acb583e7d32ad_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODI_9578bf39-d791-407c-aaf7-a7bfdddd82ec"
      unitRef="usd">500000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODI_a5b4b7e0-b168-41d4-a0d3-c0d81313cc58"
      unitRef="usd">500000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i9dcc6ed5d40246baabade8cb1d9fba6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODg_1d2400e4-6892-48cc-a975-27779e53a7d5"
      unitRef="usd">1000000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i695ae53d59f94e27b87eefce82393e8a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5ODg_1e6a9e87-df3d-4162-9888-e4bb25e3fc10"
      unitRef="usd">1000000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i397b406c9c0747b0a7f3b67d4d6870e3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5OTY_3a79296f-801d-42c9-add4-37d356f7f341"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="ic3d6c90706d94887a50acb583e7d32ad_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTc5OTY_e9ac6035-b8bd-40d4-af75-8948ad958fe2"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i3a03a4097faf4d70895448f0b1cdccc9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTQ_27811fca-383e-4923-a418-ceee0451399b"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i0f45eef28e7d4c2e8752293801f70ab3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTQ_62604043-de50-4a57-aeef-372b98d335d8"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwNDA_c275ff58-685e-4762-bfe8-62b76742c9df"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwNTQ_0472941c-c024-44bf-af04-d141ac19670f"
      unitRef="number">0.05</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62cb5f8c97194f02924e255c54bed267_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzIyMTc_03eb8742-5936-4df9-8608-e165f5454168"
      unitRef="usd">5100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddf6e035476945cfb9d2423367a0fd96_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NDkyNjc0NzIyMzM_80b9deed-174d-4096-ba2f-44c9d164f15b"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk0_78a4044e-745e-421e-a27f-0f9f0d33504e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTkx_5d23dd8a-d69a-447c-9cd5-aab3f5d2ca01">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.3 million and $1.6 million for the years ended December&#160;31, 2020 and 2019, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NjEw_124738af-bdc9-4e57-93fa-d8cf622b5a21"
      unitRef="usd">1300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2NjI1_34f3431a-1620-4806-b4a9-58ca56f9df13"
      unitRef="usd">1600000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfRevenue
      contextRef="i358dc56770ab42ceace2ba4c29570329_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2OTY3_c3560e08-afa2-433f-aa88-2dbb73bbae25"
      unitRef="usd">1400000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="iaf8dba0b2d464952ad492cfb4b91e9c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzE2OTY3_f662338a-efcc-41ad-a95d-fbd6de922587"
      unitRef="usd">1400000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk4_f6d524c6-06d4-4d10-84ca-4d59ab296cbc">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNzc_a586d33b-6e1b-4730-9dc6-7eab56fb6e5e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTk5_6f466a75-c962-4a87-bf95-669d14e47959">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MTkw_2ad1aea9-b55e-44c7-aaa9-d962cce0bf0b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjAz_29be53ff-9528-4f57-803c-18d7fd148b19">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock, options outstanding under the Company's stock option plans and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the years ended December&#160;31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjEy_d81b7d16-1a39-4b52-98ae-9959ea4875fe">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,414,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,836,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33102e8052874bcf8f4819af73b17cd3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzQtNi0xLTEtMA_18e96241-b0b8-42e7-8481-2168b3a5f01b"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1320fd0f2999411e8bd7d1a4b841aa24_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzQtOC0xLTEtMA_6fe9d694-efa6-4e1c-8be0-5997522ffc39"
      unitRef="shares">461273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i01e558ece6214f16b6c3df7e771db6be_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzUtNi0xLTEtMA_16c82196-11c3-4141-a764-ae4fdeb60a19"
      unitRef="shares">1975761</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc02f1f51b5c4b199fc8848ae372e425_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzUtOC0xLTEtMA_85e1ce03-12c5-4914-8512-71c8abadcf70"
      unitRef="shares">1375542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib235ec96e6b1472d9f54d1de7b43b02f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtNi0xLTEtNzM4NQ_249dce89-9ae7-4662-a888-2e81dd906d45"
      unitRef="shares">11640</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c1e7be53ff34ffab13c26e9df1ddc43_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtOC0xLTEtNzM5MQ_a8079a40-652d-4718-b4c1-03fa52c562a2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtNi0xLTEtMA_3a9d9b9d-b51a-463c-8b7d-c806cb4c4e5d"
      unitRef="shares">2414228</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90YWJsZToyNTdlNWMzMzI5NmQ0Njg4OTNmNDlhODE4YTdkMjg2YS90YWJsZXJhbmdlOjI1N2U1YzMzMjk2ZDQ2ODg5M2Y0OWE4MThhN2QyODZhXzYtOC0xLTEtMA_054831ec-967a-4fe3-b1e6-644d02f19c0b"
      unitRef="shares">1836815</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA4_3e488d74-03fb-4bef-9ee4-a850619c73e7">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzMyOTg1MzQ5MTgwMTg_cef3e900-9a7b-45bb-9a4f-8789460144c5"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI2MjA5_42aa40fc-e189-40e2-ab31-916443130951">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company does not anticipate the adoption will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement: Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company adopted this guidance on January 1, 2020, and the adoption did not have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyOA_d0d79432-2fe2-4a15-90e3-34503b98149a">Other Financial InformationPrepaid Expenses and Other Current Assets&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019, was approximately $0.5 million and $0.6 million, respectively. At December&#160;31, 2020 and December 31, 2019, the gross book value of assets under capital lease was $1.2 million and $0.8 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNQ_005cccfd-07fc-492f-be0c-0af5adb9e9d2">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzItMi0xLTEtMA_86d19727-0f9f-4cb9-8054-26e8074c8ea4"
      unitRef="usd">1203000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzItNC0xLTEtMA_fd3b6389-662d-404e-926b-5b5879329c0b"
      unitRef="usd">1427000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzMtMi0xLTEtMA_536005cc-3cc7-4c39-9995-3a9f1ac4b5c9"
      unitRef="usd">68000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzMtNC0xLTEtMA_3d58af98-9844-4f9d-a16f-520792bb1c7d"
      unitRef="usd">123000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzQtMi0xLTEtMA_c422ec39-8906-41ac-9242-934f2416262d"
      unitRef="usd">2229000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzQtNC0xLTEtMA_424f5335-1469-4146-b0dc-7112f98ce14b"
      unitRef="usd">1768000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzUtMi0xLTEtMA_84ef1dc1-5537-44bf-9f30-c193fa79d143"
      unitRef="usd">659000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzUtNC0xLTEtMA_fa5fc4bb-c3ba-427f-86f1-694a24f3e7e2"
      unitRef="usd">133000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzYtMi0xLTEtMA_45e0eeba-a16e-43e6-8048-e2f1a6b2a7da"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTowMGY0OTliYWE0ODI0MjNhOGFhYTVmNGI1MmFjODhjOC90YWJsZXJhbmdlOjAwZjQ5OWJhYTQ4MjQyM2E4YWFhNWY0YjUyYWM4OGM4XzYtNC0xLTEtMA_048e85f6-f542-46fe-8044-956bc606ff1b"
      unitRef="usd">3451000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNg_685d05cd-fd39-4af2-b393-de401ff1130d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8fa1a8305f5404892b12cd15d2ac129_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzItMi0xLTEtMA_b3041513-a89b-4383-8cd4-1d273713e8d8"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i280bdc8f8aa947aaa8f3ba67d5a4d42e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzItNC0xLTEtMA_feaeaddd-938c-4d2e-a988-903e8dba6c38"
      unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1aa0e2237a4349c6975a3792c1a40fc6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzMtMi0xLTEtMA_790644e7-ca4e-40a8-92bc-84caaac6a1c9"
      unitRef="usd">2679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i856d0b8d5d514828b59f52af21200f9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzMtNC0xLTEtMA_2ff6e9b7-fa85-4de8-842d-16933f7f5ea5"
      unitRef="usd">2228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i674956e7e0a8446f921f15096e981198_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzQtMi0xLTEtMA_47c27849-71c3-46e6-89fa-f07aa7677ece"
      unitRef="usd">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied9f4988242043ae86e49c5b25240e58_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzQtNC0xLTEtMA_a3180a84-ae49-4f47-9031-5fbe9e379fa5"
      unitRef="usd">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e6f34cf3e1b429c8056d14a2e90b57a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzUtMi0xLTEtMA_bade0bfc-85e0-4963-b5c9-73ff487e6676"
      unitRef="usd">1072000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i611274158822483e99565868e2143ccd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzUtNC0xLTEtMA_a5142d3f-7080-406e-a68f-52b1c5d324ba"
      unitRef="usd">424000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3c15b3b387924344b6a488918b7724a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzYtMi0xLTEtMA_720a7478-87a6-419d-908a-f3b859780dd6"
      unitRef="usd">301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3795b5fddf0a474ca1f456c3011836fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzYtNC0xLTEtMA_c9a3ef7a-7b03-4494-b225-4b08796ffd13"
      unitRef="usd">247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzctMi0xLTEtMA_34a023d9-c87e-4286-a963-865360ef548f"
      unitRef="usd">5043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzctNC0xLTEtMA_60379ed0-fc24-4d11-99d5-3b867ad48fbe"
      unitRef="usd">3775000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzgtMi0xLTEtMA_6f3f2354-33c8-4751-b24b-a4df204015f2"
      unitRef="usd">2941000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzgtNC0xLTEtMA_2875bb1f-5a2c-42b2-8dc4-0168a1abec65"
      unitRef="usd">2395000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzktMi0xLTEtMA_ed66b1a5-021b-48af-ac40-276051475988"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTo0YzM0OTQzOGIxYzE0ZGI5YjM2YTRhMDVjZTgwY2FhOC90YWJsZXJhbmdlOjRjMzQ5NDM4YjFjMTRkYjliMzZhNGEwNWNlODBjYWE4XzktNC0xLTEtMA_60f01cad-6c64-41c2-a952-b5e3df1f4fc1"
      unitRef="usd">1380000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzM1Mg_e78952e1-0f0f-45ce-99db-2a30a78af63e"
      unitRef="usd">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzE2NDkyNjc0NDIzMDE_28085f8b-1d6d-4571-8b73-47519dc5d242"
      unitRef="usd">600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i12d22bc21e2b4d42828df3456f0b74ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzQzMw_7bcbbd88-b76f-4f8b-93e5-7be2e64f923d"
      unitRef="usd">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ddb14c3a29441f2a69234c84b0a601e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzQ0OA_06517220-556d-45cb-b758-bb6c6a6a0f3d"
      unitRef="usd">800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90ZXh0cmVnaW9uOmZhMmJmOTg1ZGNjMzRkNzBhY2YxODg2ODAyNjBmMzQxXzYyNw_9fd1334f-45a5-4760-9331-b29cb3e9eaa5">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzItMi0xLTEtMA_c5a1e0b5-52d2-4b26-9f98-4ae064a0a1dd"
      unitRef="usd">3589000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzItNC0xLTEtMA_aa6715aa-8b92-47ee-98ba-e6ea203328b4"
      unitRef="usd">2362000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzQtMi0xLTEtMA_5e9d3873-e59a-4137-b912-1a9cbbdc281e"
      unitRef="usd">147000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzQtNC0xLTEtMA_2f1be1a7-7948-4782-be90-c7e02422a931"
      unitRef="usd">145000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzUtMi0xLTEtMA_205edd23-7bea-4b3f-a729-cd932086467b"
      unitRef="usd">311000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzUtNC0xLTEtMA_d1401c83-5141-4e49-98d0-812d8b5ce458"
      unitRef="usd">319000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzYtMi0xLTEtMA_9780a7c9-97ff-4c6f-9d7d-d75a1bfaa973"
      unitRef="usd">221000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzYtNC0xLTEtMA_fc703410-8710-458a-804b-f37331530b6f"
      unitRef="usd">727000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzctMi0xLTEtMA_5bf15af6-61f0-4d05-9e5d-0c915d82ac26"
      unitRef="usd">228000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzctNC0xLTEtMA_3986ae98-cce0-4ae1-a882-ffa9e6ce417a"
      unitRef="usd">40000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzgtMi0xLTEtMA_01a494dc-26bd-4b06-98dd-0e4ea5ca9eed"
      unitRef="usd">308000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzgtNC0xLTEtMA_ab1fe99c-e8ef-4563-a6ef-d8e2b32f6ea6"
      unitRef="usd">238000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzktMi0xLTEtMA_974b1658-c772-48b8-84b2-a1d26bbd474d"
      unitRef="usd">953000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzktNC0xLTEtMA_db581f9a-3cfa-45c6-83b4-80e0aae96728"
      unitRef="usd">588000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzEwLTItMS0xLTA_4bc84171-5484-450a-94c2-47a06e46704e"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjcvZnJhZzpmYTJiZjk4NWRjYzM0ZDcwYWNmMTg4NjgwMjYwZjM0MS90YWJsZTpkYTM4OTFjYWMyY2Y0NDk0OWU3ODg5ZjFjODQwZTc4YS90YWJsZXJhbmdlOmRhMzg5MWNhYzJjZjQ0OTQ5ZTc4ODlmMWM4NDBlNzhhXzEwLTQtMS0xLTA_949041de-aeb3-4216-bab5-5941dbe51143"
      unitRef="usd">4419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzYyNjA_78faf463-c778-4781-9e6f-e575d89fd71d">Borrowings2017 Term Loan&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At December&#160;31, 2020, no additional amounts remain available to borrow under the 2017 Term Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in twenty-four equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the years ended December&#160;31, 2020 and 2019, the Company issued PIK Loans totaling $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after November&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, and commencing with the quarter ending December 31, 2019. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Company's revenues for the twelve-month ended September 30, 2020 were lower than the specified targets, as a result, the Company and Innovatus agreed on a new management plan and target to bring the Company back into compliance with the Loan Amendment. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity. The Company is required to maintain an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company was in compliance with all covenants of the Loan Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ife50f4946ea24f0c9f4e38cbd7f1110e_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE5Ng_1039ca99-c422-4f97-b84d-e4e63aac4c8d"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzIwMA_b74293dd-ea04-48f9-b756-0826ef3492c2"
      unitRef="usd">17800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i54e6b9922db74a3a9cb86c52f2a90cc9_D20181207-20181207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzM4NA_a0accddf-db26-4ac0-9168-68e9d63aee77"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzY3Mg_a54cbcd6-b559-4111-bef3-a64dfc8c9b06"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzY4NQ_5fff7f58-bd56-4cd0-b378-0379012838ac"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id42bbd7899154e72a4ec0bed957b96f6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzgzMA_a54cbcd6-b559-4111-bef3-a64dfc8c9b06"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzkyMQ_0ad3e638-a09c-4cab-b793-77f468f3ee39"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <exdx:DebtInstrumentPeriodicPrincipalNumberOfPayments
      contextRef="i0e96141de3c64fe29a0de8fc804cff2f_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3NjE_511c55ab-a0d3-4615-815f-b49d1b0f6626"
      unitRef="payment">24</exdx:DebtInstrumentPeriodicPrincipalNumberOfPayments>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzEyOTA_c1f41086-2500-47d7-a192-46f71ee1fb94"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i5149cc8ef1ff4fac911ed00c49b7db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE0OTA_4ad86c41-4d8f-4700-be6b-1694fdb79229"
      unitRef="usd">500000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i6e5ddd398de1458e8e1e64f2e9afd8d4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE0OTA_5e71b29b-ea62-4533-a449-ddb26e9b8781"
      unitRef="usd">500000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzE2NDI_632075b6-eb35-44e7-8953-ec847587144d"
      unitRef="number">0.03</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3MDA_51af8d64-d137-4818-b824-7de4c1da91f8"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod
      contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc4MjE_c5159251-87a9-4712-8919-9e12e01f2193">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet
      contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc3Nzc_aebbe43e-b250-4489-990a-2fd92ce372c4">P60D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod
      contextRef="ia4e8d767ab4e4e08b29e497a8ba26739_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzI3NDg3NzkwNzc4MjI_35001460-bb4a-46a5-8426-9eca16d3ba9d">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzMwNjI_365c5ed7-65d1-4446-92ac-78ba419a4a78"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="i93863c5d02f74d6fbddc2c9e1ada92b6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzQ0MzE_14233ada-041c-400c-95d2-33d64cf996fd"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90ZXh0cmVnaW9uOjE1NTZlMzU0ZWQwMzQwYzJhMTEyN2NkYjQ3YjU5MGJkXzYyNjE_ff725a3a-b648-4b4c-9b69-0cae915a9e2a">As of December&#160;31, 2020, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzMtMi0xLTEtMA_4affd64f-34b2-442e-a606-d34cbed3b895"
      unitRef="usd">1755000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzQtMi0xLTEtMA_7086c7f1-9e4c-4c66-969a-021aced9566a"
      unitRef="usd">2996000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzUtMi0xLTEtMA_0f7146f8-c624-4353-89e6-96efbafdd795"
      unitRef="usd">15619000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzYtMi0xLTEtMA_d33af9a9-b236-4558-9d8d-fa14660ea1c1"
      unitRef="usd">14280000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzctMi0xLTEtMA_9bda6c13-479f-4c72-8fd4-2231e2c649c9"
      unitRef="usd">34650000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzktMi0xLTEtMA_edde505b-6e24-4137-88a7-aec2d0342abd"
      unitRef="usd">296000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzEwLTItMS0xLTA_476dcbb3-69ed-4c47-a847-f1efd16e8959"
      unitRef="usd">7695000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzAvZnJhZzoxNTU2ZTM1NGVkMDM0MGMyYTExMjdjZGI0N2I1OTBiZC90YWJsZTowY2U3YTQ4Nzk4YTI0ZThjYTY1NDdlYjA2NGE5MjFmNi90YWJsZXJhbmdlOjBjZTdhNDg3OThhMjRlOGNhNjU0N2ViMDY0YTkyMWY2XzExLTItMS0xLTA_0558d1fe-eb07-454f-8ba2-9063e82f9fad"
      unitRef="usd">26659000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODc_f46f0ced-b805-4cbb-891a-2d1340f3c202">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Capital Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term capital lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019, rent expense was $0.6 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of 2.5%. Future royalties payable under these arrangements are limited to the lesser &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of an aggregate of $1.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 2.0% to 3.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="ic0b28ea3fe8a47bb9b1c724647721207_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4MTc_5a476150-bbed-4186-9a5e-4f30bab2bb92">P5Y</exdx:OperatingLeasesRenewalTerm>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="i1cd6af4be1f145b0979bab0cafe7ad2b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4NDA_2b4c0d0c-335a-4c1e-affa-5204851a17c1">P5Y</exdx:OperatingLeasesRenewalTerm>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODg_90ae3ed9-82f6-4df7-833f-9610cbfe09d8">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Capital Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term capital lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzM1ODk_1f340024-0914-40cd-943e-18d404d79680">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Capital Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term capital lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEtMi0xLTEtMA_30d7d8e3-9e72-4e0a-aa86-b9b99ad436c8"
      unitRef="usd">344000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEtNC0xLTEtMA_77580fa0-fd91-440b-8e93-c98e0122870d"
      unitRef="usd">590000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzItMi0xLTEtMA_a968358c-e9c2-4575-8ad7-d325d2d21c14"
      unitRef="usd">318000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzItNC0xLTEtMA_82339cf4-76e3-4477-a940-92165950752b"
      unitRef="usd">613000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzMtMi0xLTEtMA_4412dc76-dd1d-43fc-957e-006b66d212cb"
      unitRef="usd">231000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzMtNC0xLTEtMA_e5cbbfd5-11cd-4d62-8a57-e20bedae57bc"
      unitRef="usd">626000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzQtMi0xLTEtMA_722bf575-0a36-480e-9920-5db761103bac"
      unitRef="usd">58000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzQtNC0xLTEtMA_67802f9a-f9cb-4142-bafd-da2f33340c80"
      unitRef="usd">640000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzUtMi0xLTEtMA_7da67c09-197e-4367-a785-d22618e7b934"
      unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzUtNC0xLTEtMA_268aefd7-1973-4046-8cad-ab3c9919e0c7"
      unitRef="usd">654000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtMi0xLTEtMTUzNA_ac943596-3036-4946-94d4-f95649fc961c"
      unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtNC0xLTEtMTUyNw_7e425711-aef0-46f6-8328-13b1dda273ff"
      unitRef="usd">55000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtMi0xLTEtMA_8425e70d-69de-4ebd-b783-4462461cea1f"
      unitRef="usd">951000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzYtNC0xLTEtMA_54a13c61-a3ea-4f39-a180-f6ee232b3eac"
      unitRef="usd">3178000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzctMi0xLTEtMA_0be59907-de05-47d1-94b0-edb62dd81891"
      unitRef="usd">67000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzgtMi0xLTEtMA_3802f8a1-9a05-40cc-9ffa-909f817e11f5"
      unitRef="usd">884000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzktMi0xLTEtMA_ef24b2af-7027-40a4-a3ce-d8cbdcf3161d"
      unitRef="usd">308000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90YWJsZToxMmFiNGFiYTdlMGE0YzQwYjlhODlkY2FiMGM0ODUzMy90YWJsZXJhbmdlOjEyYWI0YWJhN2UwYTRjNDBiOWE4OWRjYWIwYzQ4NTMzXzEwLTItMS0xLTA_1709ed05-c73f-45c2-85e0-37ea26ceccf9"
      unitRef="usd">576000</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:LeaseAndRentalExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzY5OQ_906b456e-4b9d-4b48-9c65-c85e390f588d"
      unitRef="usd">600000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzcxNA_537bdb0b-9a16-4bae-a432-76d404f101ad"
      unitRef="usd">500000</us-gaap:LeaseAndRentalExpense>
    <exdx:MilestoneObligation
      contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEyOTM_c228474f-18bb-4371-840f-b31798162cdb"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE0MDA_2f98fd2e-d285-4273-880a-6d76a60dc397"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="i626d033bbe12451bb544fb9ccd602d11_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE0MDA_3b767749-0cbc-4310-a3c5-28f2cf224421"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE1Njg_a1b680cb-d4fd-4cb7-937d-e6c14ac662d4"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIzMTA_377badf6-c79d-4077-9299-e8c2f02e569c"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="icf87f2f3f4094314ace80d3de6cfbb51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzE3MTc_d53bd181-9f03-4f00-9393-409cc0bcab03"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="if5eb4831058d4b62a7506f80397c58e7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzIxMTk_3ca7cfce-2d9f-4e90-9f33-7fe5152c1279"
      unitRef="number">0.020</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i90378dc8f33d4c0db9c9f5e510cefc73_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzIxMjU_4defd53f-c965-47c2-a411-2a46cde8b9f9"
      unitRef="number">0.030</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIwMzM_d82edece-5451-4e12-a4d4-4f6f343690f2"
      unitRef="usd">4100000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzEwOTk1MTE2MzIwNDA_32dd2429-cce4-43e0-be65-47b33620b6ac"
      unitRef="usd">6000000.0</us-gaap:PurchaseObligationDueInSecondYear>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzYvZnJhZzo3ZGMyY2IyN2MzNDU0ZmYzYTkxNGZlYzg1NzA1NGU2MC90ZXh0cmVnaW9uOjdkYzJjYjI3YzM0NTRmZjNhOTE0ZmVjODU3MDU0ZTYwXzMyOTg1MzQ4ODc4MDY_314cb15c-affe-445c-b27d-5afc331bcff9"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90ZXh0cmVnaW9uOmFlYTQyNjAzYTJlZjQxYjVhYjFkYjJiNTVjMWUwODY5XzY3NQ_8e33f583-87e3-40a0-8cbd-4165aa13151c">Fair Value Measurements&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's money market funds is based on quoted market prices.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90ZXh0cmVnaW9uOmFlYTQyNjAzYTJlZjQxYjVhYjFkYjJiNTVjMWUwODY5XzY3Ng_fccc6a66-33d7-4f8b-9be4-83954fe1d760">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtMi0xLTEtMA_863309f0-7c2b-4283-a818-8070837c4a9a"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i13eef4c0f9f34ead9206411d3e70f27f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtNC0xLTEtMA_f6db0336-8fdb-41d7-b802-a5e4e12cefb9"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1b416cd8bb1f4d6f86d98f542ac3cc5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtNi0xLTEtMA_f8c2c774-ead6-4986-b05b-662a16c3e9b3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe0eeb17dc7c4414a87f1ab0a5c0341f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZToyNjQ1ODAzYTE5NmM0ZTlkYWU3YjIxZmVhMTgwZTVlZi90YWJsZXJhbmdlOjI2NDU4MDNhMTk2YzRlOWRhZTdiMjFmZWExODBlNWVmXzMtOC0xLTEtMA_376cf697-839c-448a-b3f4-7c044498a4e1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44d0579e1e494431ae288f59027174a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtMi0xLTEtMA_b2838666-de05-47dd-94e0-bbc7226fe032"
      unitRef="usd">70760000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if0a61521b77e46aa90eed63b0c7ba9b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtNC0xLTEtMA_c6e69e56-a6f0-453c-aff9-22cbe7643587"
      unitRef="usd">70760000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a24aaf692c5444cbf9b46ed5a052bee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtNi0xLTEtMA_7e06d124-1c0e-4cc0-9818-432b72851b3c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iafb32079e8ef4b6ab57b666c86ab1379_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMzkvZnJhZzphZWE0MjYwM2EyZWY0MWI1YWIxZGIyYjU1YzFlMDg2OS90YWJsZTo2OGI0ODgwN2I1Zjk0YjA3YWFkNTFmYzE0NTUxYzAxMC90YWJsZXJhbmdlOjY4YjQ4ODA3YjVmOTRiMDdhYWQ1MWZjMTQ1NTFjMDEwXzMtOC0xLTEtMA_48ba90c3-4b93-42ab-a8c1-001fb5374ab6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exdx:TemporaryEquityTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzI3NDg3NzkwODQ4OTQ_89ece0e2-f99b-4a84-ba7b-b0eae7818e79">Redeemable Convertible Preferred Stock&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series G Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at a per share price of $0.078 in each closing. In conjunction with the issuance of the Series H redeemable convertible preferred stock, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each share of issued and outstanding Series G redeemable convertible preferred stock was converted into shares of Series H redeemable convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series H Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $0.04712. The Company accounted for the difference between the effective conversion price of $0.04712 and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $6.7 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders&#x2019; equity. Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $6.9 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders' equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Company's IPO in September 2019, an aggregate of 7,816,643 shares of common stock, excluding warrant conversion, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of redeemable convertible preferred stock remained outstanding at December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</exdx:TemporaryEquityTextBlock>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i9202b030fd1b4086bdec9b70b92d1d84_D20190101-20190131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzM0MTc_daee7d80-8cba-4284-b37c-b7485ccafbbc"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzU4NTY_760b5aa6-80cb-4a09-bbb4-de58e19b66d1"
      unitRef="usdPerShare">0.04712</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i6b9462e096714f6a8a52d7ae7c4dea8a_D20190701-20190731"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzY3NDY_4cccd382-ae85-47e9-a002-c2b9e4a6195d"
      unitRef="usdPerShare">0.04712</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="ic80f1b4b2b84440db98c9a7375a7570f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzY5OTY_64c6a421-3c42-45b3-b2b4-53f545316b41"
      unitRef="usd">6700000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividend
      contextRef="iaf86d568866c4251832b028da29ff071_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzc2MTA_3f125328-80b9-4959-ae40-48c96fb20e50"
      unitRef="usd">6900000</exdx:TemporaryEquityDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzE2NDkyNjc0NTU4ODI_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5b650b6b9d754c97a85b32a60d451667_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzMyOTg1MzQ4OTc5OTc_493523ce-a319-4e8d-bd8d-e3ead4fadde9"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0ccae1c8177a4c3b9f45dfceb5efa42f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDIvZnJhZzpiZWM0Mzg3MTY3N2M0OTcyODhiZDRkYzJiZjBhYTVjMi90ZXh0cmVnaW9uOmJlYzQzODcxNjc3YzQ5NzI4OGJkNGRjMmJmMGFhNWMyXzMyOTg1MzQ4OTc5OTc_6bb60c65-e849-47ce-ab77-1ce2cbea3cc6"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEwOTk1MTE2MjgzMDIw_a6c87178-a088-444f-9d7e-c78ddadd48b9">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying financial statements and notes to the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 23, 2019, the Company closed its IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, warrants to purchase common stock were exercised resulting in the issuance of 32,120 shares of the Company's common stock and cash proceeds of an immaterial amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzk5MA_6be84362-5132-4224-8add-cd33027d6e6b"
      unitRef="shares">4140000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7e709efd0a0841ec93329ef2a03791d0_I20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEwNDg_0462092a-e1f9-48a7-8509-16cfc31da57b"
      unitRef="usdPerShare">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia73d28ff344b45b7be16393a226e65c1_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzExNDE_cb3ecbd6-e93f-4fb8-b16b-02dbdefe656e"
      unitRef="shares">540000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzEzMzk_33597de9-5ed5-42e2-b9df-58a2cdacd4d8"
      unitRef="usd">50400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="i7e709efd0a0841ec93329ef2a03791d0_I20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE0NjM_3b6fbad8-dde2-4844-9273-7d0c61ee7d78"
      unitRef="usd">7500000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="icc003e40daf641ccbe499297076b288b_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE1MDQ_4a868c68-a6ed-42e9-a94f-b1cd9f7b6448"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzMyOTg1MzQ4ODY4OTg_15295c4b-cf04-4246-bd36-f6ba5eecb03c">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzEtMS0xLTEtMTg0Mw_fab855ab-936d-423a-87ff-713b0c0114f7"
      unitRef="shares">252798</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1a07d69f07f04c6387c8ad004db5b9e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzEtMy0xLTEtNTI4OQ_b74bd5d9-a96f-48bf-bdf0-0d05caaf8490"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i466315a145504f92bab9954a4653b6ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzItMS0xLTEtMTg0Mw_c713a43e-75fb-4f1e-8ac7-fea95c592ba7"
      unitRef="shares">69176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i466315a145504f92bab9954a4653b6ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzItMy0xLTEtNTI4OQ_c12b56c9-16f9-48b6-bed2-be71b7d9b922"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzMtMS0xLTEtMTg0Mw_71955b5f-bdc4-4a83-b544-de3d3491041d"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib41d9dd15cfd43ffb4381905d0b9593e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzMtMy0xLTEtNTI4OQ_1ae3c647-9d07-4a3c-a129-1d5482034d46"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia8a60c0a83494af48451bdffb74f8657_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzQtMS0xLTEtMTg0Mw_11702e10-02a6-41eb-8898-2e89d03e6184"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia8a60c0a83494af48451bdffb74f8657_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzQtMy0xLTEtNTI4OQ_cb5e5a07-6e57-44c5-8849-4d65ba90e741"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i01c677925f1f405988f482d6e0c41691_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzUtMS0xLTEtMTg0Mw_e47239ee-06b8-428a-924a-b4220cd41c08"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i01c677925f1f405988f482d6e0c41691_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzUtMy0xLTEtNTI4OQ_2dffc826-9d4b-4b91-aa88-e54d7529c232"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90YWJsZTowNDdiNmNhMmVlYTQ0MzVjYmY4MWQ5MjI2OGI0YzE3My90YWJsZXJhbmdlOjA0N2I2Y2EyZWVhNDQzNWNiZjgxZDkyMjY4YjRjMTczXzYtMS0xLTEtMTg0Mw_da7cd686-f65c-4377-bf66-c28c547ec201"
      unitRef="shares">426827</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDUvZnJhZzo3ZGQ2OTRjMjQxNzE0OTQ4YTA4YzQ2Y2Q4MmIxZDcyMy90ZXh0cmVnaW9uOjdkZDY5NGMyNDE3MTQ5NDhhMDhjNDZjZDgyYjFkNzIzXzE2NDkyNjc0NDUwNjY_6c1d2869-4f4a-4f9f-9faf-4aec562c5481"
      unitRef="shares">32120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODI_93ae94bc-e517-4d8a-8374-eb9a45ae839b">Stock Option Plan&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). A total of (i) 2,011,832 shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and was initially be reserved for issuance under the 2019 Plan. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2020, 1,139,323 shares remained available for future awards. Under the evergreen provision, on January 1, 2021, an additional 506,092 shares became available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under the Company's stock option plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;951,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(293,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2020 and 2019 was $7.55 and $7.79, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock is $13.20 and $25.40 per share at December&#160;31, 2020 and 2019, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2020 and 2019 was $1.0 million and an immaterial amount, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46%-59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 120,000 shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 calendar year through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on December 31st, or (ii) such lesser amount determined by the Board of Directors. Under the evergreen provision, on January 1, 2021, an additional 126,523 shares became available for issuances under the ESPP. Stock-based compensation expense for the ESPP was an immaterial amount for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%-83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, total unrecognized compensation cost was $8.5 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,139,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDYxNjE_2579dd28-debd-429f-9961-f1e9fa2d905a"
      unitRef="shares">2011832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzNzQzODk1MzU2MDc2_35b68021-200c-4453-865d-13ec0512ced1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzNzQzODk1MzU2MDc1_1bf27ebd-3ee9-4c55-b763-c9709db0b73b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEzMzg_a05d5fae-4f3d-49b2-b8f0-30e66cf739a2"
      unitRef="number">0.04</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7a2f80c2b6c5444ba34456f703d38c67_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE0NzI_a3ffbf36-2cf2-49f4-a468-c2064e34264a"
      unitRef="shares">1139323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="i2dcffc3099e440189a3fa6ca69d78390_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE1ODU_ff71be1b-1d33-4904-8614-472d38509970"
      unitRef="shares">506092</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODM_e4cc3e15-b738-4081-beff-bd196ec0a3bb">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under the Company's stock option plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;951,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(293,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtMi0xLTEtMA_79721e9d-28b1-465b-9d09-25dda1dc8e89"
      unitRef="shares">1375542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtNC0xLTEtMA_740b8529-58d2-40a6-9340-95d23336371e"
      unitRef="usdPerShare">8.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtNi0xLTEtMA_0e4e5dc9-6777-466a-a47e-137e6aebe100">P9Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzEtOC0xLTEtMA_09c4b2b3-b5e6-4c51-a9a0-f536b8976a3b"
      unitRef="usd">23654000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzItMi0xLTEtMA_9bc21f86-133b-46ca-bc82-7f3b3d817797"
      unitRef="shares">951031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzItNC0xLTEtMA_de5e9994-2949-4e67-a19b-ced430286b22"
      unitRef="usdPerShare">16.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzMtMi0xLTEtMA_f6edc8e5-cd69-47dc-aefe-e954fbdc8085"
      unitRef="shares">47549</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzMtNC0xLTEtMA_23990498-8b15-4d82-86f7-dd1988b3ee43"
      unitRef="usdPerShare">0.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzQtMi0xLTEtMA_3f0aad63-896c-4d04-a90a-d247274a2bdd"
      unitRef="shares">293412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzQtNC0xLTEtMA_005ee4ac-e3f4-4184-95f0-b1ec40807570"
      unitRef="usdPerShare">10.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzUtMi0xLTEtMA_70e8f1cb-48dc-4ee5-b871-ff20b3986393"
      unitRef="shares">9851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzUtNC0xLTEtMA_52978c14-8681-43c1-8656-9b23f7ce11b3"
      unitRef="usdPerShare">29.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtMi0xLTEtMA_6b871a89-beb5-48eb-a357-4d6d31989918"
      unitRef="shares">1975761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtNC0xLTEtMA_c849805e-0b30-412d-88e2-6803cc5747b5"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtNi0xLTEtMA_e9c09f5f-31f2-4790-877c-f9b7eac4ee34">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzYtOC0xLTEtMA_a88b97b8-c605-4c7d-b70a-082246b38b0e"
      unitRef="usd">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctMi0xLTEtMA_258193e4-7661-433d-95c9-77c58b648b25"
      unitRef="shares">1975761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctNC0xLTEtMA_32ecd42d-e14f-4fc1-8163-b7cba3da0ec2"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctNi0xLTEtMA_10adb853-cc71-426a-b314-1b65114f50c0">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzctOC0xLTEtMA_5cb29cd9-501d-4e61-8e28-d399595151dd"
      unitRef="usd">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtMi0xLTEtMA_a899c502-41b6-4bb3-94db-71cfa1635c7c"
      unitRef="shares">464606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtNC0xLTEtMA_fdc79410-5740-4852-8926-db94d07aa043"
      unitRef="usdPerShare">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtNi0xLTEtMA_8855d3a4-cd75-4793-a615-6e55b379f386">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToxODA3NTU0Y2RkYWE0NWY5OTJlNjRkMDA1YzZhYjE2NS90YWJsZXJhbmdlOjE4MDc1NTRjZGRhYTQ1Zjk5MmU2NGQwMDVjNmFiMTY1XzgtOC0xLTEtMA_1d67d251-dfc7-49cd-83ae-42731f3c2088"
      unitRef="usd">3362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIwNTQ_17b3950b-f4a2-474b-8cca-3d5ae006a0c4"
      unitRef="usdPerShare">7.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIwNjE_b5dca806-a06f-44ea-b043-a3d727873d88"
      unitRef="usdPerShare">7.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIyNzc_1c2ad7f8-2e3a-4fc9-b57c-c168ef1d7952"
      unitRef="usdPerShare">13.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzIyODQ_968a80f2-6562-420f-baa0-70f8781c44eb"
      unitRef="usdPerShare">25.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDY5OTY_47d4155b-3f19-4a9e-bdc7-c4adaefca20b"
      unitRef="usd">1000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzE2NDkyNjc0NDY5OTY_de88747c-a7d1-4912-b5b6-84ca185ca7ad"
      unitRef="usd">1000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwNzc_aacb9fed-9080-4971-8f32-79372d52f410">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46%-59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%-83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItNi0xLTEtMC90ZXh0cmVnaW9uOjNhYjVjYThkOWQ1ZDQyNDNiMjliODY2MmExMDVlNWVmXzQ_9aaa0051-29ef-4558-a578-287d3a470f42"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItNi0xLTEtMC90ZXh0cmVnaW9uOjNhYjVjYThkOWQ1ZDQyNDNiMjliODY2MmExMDVlNWVmXzc_67beea30-c0af-4d46-b186-8038354b7bfd"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItOC0xLTEtMC90ZXh0cmVnaW9uOjYyY2MyNjVlMWE4OTRkYzZhZGVmMWM2ZmJmZDdiNTA1XzE2NDkyNjc0NDE2NzU_4544e0af-5e2b-4e2a-bb11-ffa2a10ad8ea"
      unitRef="number">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzItOC0xLTEtMC90ZXh0cmVnaW9uOjYyY2MyNjVlMWE4OTRkYzZhZGVmMWM2ZmJmZDdiNTA1XzE2NDkyNjc0NDE2Nzk_325663c5-d1ce-46a1-b6fb-75f91d7d9200"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtNi0xLTEtMC90ZXh0cmVnaW9uOmI0YmEwMDdjMTA3NjRjYWM4MTViMmMxOWVjYTE4N2U1XzQ_08b594f7-7329-4fa3-a047-d6a9dd26186b"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtNi0xLTEtMC90ZXh0cmVnaW9uOmI0YmEwMDdjMTA3NjRjYWM4MTViMmMxOWVjYTE4N2U1Xzc_54b34635-c31a-43a3-a1f1-357f6704c183"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtOC0xLTEtMC90ZXh0cmVnaW9uOjk1NzJlMWQ5N2JlNDRkYTZiNWRjZjI4NzFlZjVlMjYyXzQ_f485cb0c-0f7d-45ee-a49e-cd1ae84c612d"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzMtOC0xLTEtMC90ZXh0cmVnaW9uOjk1NzJlMWQ5N2JlNDRkYTZiNWRjZjI4NzFlZjVlMjYyXzk_e8a87b5e-ace6-4496-a8c5-67859884b6aa"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzQtNi0xLTEtMA_d4c7d88b-0fc8-44b7-b237-9dd79d883e68"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5baedf86b8244d9b8762ecb0ae605c30_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzQtOC0xLTEtMA_3363579c-8ccd-40d1-b50f-d872c83ecec4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id9df7a83f79940ddb50644d9534b8e4a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtNi0xLTEtMC90ZXh0cmVnaW9uOjY2YzlkNjZmZmM1YTQ4NzhhN2Y3MGIwOTlmMDFjMjQwXzE2NDkyNjc0NDE2NzQ_c5b1eb90-35d2-4f1a-bf04-98b2f08f98e8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib3119fce349b4f6587c19f908367b2dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtNi0xLTEtMC90ZXh0cmVnaW9uOjY2YzlkNjZmZmM1YTQ4NzhhN2Y3MGIwOTlmMDFjMjQwXzE2NDkyNjc0NDE2Nzk_fa6d3f71-d368-4bd4-840f-744f403df976">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4c062635dbd2451889987f0af257f830_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtOC0xLTEtMC90ZXh0cmVnaW9uOjExY2I4M2VmNjEzYjRmMzhiM2YyOGMxMTQzZTVjMzgwXzE2NDkyNjc0NDE2Njk_aa28a0d7-0590-4028-909b-3e4dfa6d4e9e">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i039ef34e84814a89a51794da58440c49_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTpiZjEwYTI5ZWEyNWY0OWZmYjk2OTcyNjQ2MzZlMjg0Yi90YWJsZXJhbmdlOmJmMTBhMjllYTI1ZjQ5ZmZiOTY5NzI2NDYzNmUyODRiXzUtOC0xLTEtMC90ZXh0cmVnaW9uOjExY2I4M2VmNjEzYjRmMzhiM2YyOGMxMTQzZTVjMzgwXzE2NDkyNjc0NDE2NzI_69b1acf3-d48e-406a-9504-7ada22ea01a2">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzMyOTg1MzQ4OTE1NDI_6b5d3405-cc25-4d0d-884e-36a964e2f1c2"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEwOTk1MTE2MzQxMDM_975ef891-3ae1-476c-b85d-f0ef3a74fe8a"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzMyOTg1MzQ4OTE1NDc_615d6a5c-54da-4550-ba88-37e9f34d1d05"
      unitRef="number">0.01</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="i41b5f6bca8d2400bb78d64d3ee723516_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzEwOTk1MTE2MzQ2NDk_0cf4c60b-c802-4b1c-bf07-69e0b53f1e7a"
      unitRef="shares">126523</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzItNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmYxYTQyMTNiN2M3MTQ5YTdiOThlYjVjZjY3ODYyOTkzXzEwOTk1MTE2Mjc3OTA_bbb72f63-86a6-45cf-9e06-07edc8e971b3"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzItNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmYxYTQyMTNiN2M3MTQ5YTdiOThlYjVjZjY3ODYyOTkzXzEwOTk1MTE2Mjc3OTc_b4c99e66-3707-402a-8770-7a3e6ef83fab"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzMtNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmY5ZjUzOGI3MWE0ZDQ3MjliM2Q2MmI0NWY2NDFlYmFlXzEwOTk1MTE2Mjc3OTM_1e38dcc1-a779-4ccb-a555-306e5bec7273"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzMtNi0xLTEtNTg4OS90ZXh0cmVnaW9uOmY5ZjUzOGI3MWE0ZDQ3MjliM2Q2MmI0NWY2NDFlYmFlXzEwOTk1MTE2Mjc4MDA_cc502fa1-2e4a-4733-8ff3-243daeb180c1"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzQtNi0xLTEtNTg4OQ_7c66489e-456b-49c8-bcbd-24c29bf38999"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1a0359964fa449d7b394ee812510e987_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0OWUxY2JjYjU3OWE0MjUyYjNkNzdmNDExOTg0NTIwYi90YWJsZXJhbmdlOjQ5ZTFjYmNiNTc5YTQyNTJiM2Q3N2Y0MTE5ODQ1MjBiXzUtNi0xLTEtNTg4OQ_bd897ee5-6d1f-4174-a94f-4be1ef7d592b">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwNzg_a4ab0cd9-1e1e-4771-b856-654dcd512b6d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i702cbb6d8580485a8ed9b7d9da8a2093_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzItNi0xLTEtMA_e20a1eb2-580a-414f-bbb7-24a202cf8645"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a70ce52ba824bfda7ecfd9065c1b7c3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzItOC0xLTEtMA_5c75006a-f45d-4193-bbcb-6326c971b3d6"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i703d6361d7e7459d8f59cb73b645d79e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzMtNi0xLTEtMA_a30affb2-3f37-49bc-afb3-1e64b8c72133"
      unitRef="usd">2419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5d73be98d664ccfa3f52b1b3925d8b1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzMtOC0xLTEtMA_5fc0876f-1200-42f7-80aa-6494c2f8c4f9"
      unitRef="usd">445000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id612b120136c4606a30275dd302975ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzQtNi0xLTEtMA_54d37793-783c-4a85-9df0-f2d369f9fd41"
      unitRef="usd">242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieeed2007d8ce423190963dac6498acc6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzQtOC0xLTEtMA_5ed61bc1-19fb-481d-89dc-b87e9cdd2de1"
      unitRef="usd">118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzUtNi0xLTEtMA_ca2309ac-f90a-4c85-a18d-b355778a52d4"
      unitRef="usd">2694000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZTo0NTIyMWZkM2ZmNTY0NjJhYWI4NjgyM2Q2MWMzOTA4Ny90YWJsZXJhbmdlOjQ1MjIxZmQzZmY1NjQ2MmFhYjg2ODIzZDYxYzM5MDg3XzUtOC0xLTEtMA_409ed6ab-9dcc-4011-9b74-db582033ba27"
      unitRef="usd">572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzI4Mjk_9d143de1-47fa-462e-855a-2d5d9251b04a"
      unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzI5Mjg_980aee86-9ef7-4350-ad8b-ff1b280b9890">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90ZXh0cmVnaW9uOjRjZGE5YjYzYTNjMjQ2NTNhNjFlYjU2MWU4YjQ2OWFmXzQwODE_e5a20180-02cb-4049-bd4e-19ebd120e17a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,139,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib3d9a5ee720049a2943b6461407a26c4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzAtMi0xLTEtMA_8ad0721b-518e-4370-b07b-828f002a3cb5"
      unitRef="shares">426827</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icb4954aca44d475bbcf2bdfd5f3e8918_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzEtMi0xLTEtMA_483bccf2-54fc-4ce7-9c87-6432e2c84d85"
      unitRef="shares">1975761</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib009a5d12eec454f807f70204c3f2c94_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzItMi0xLTEtMA_640dcb91-2535-4270-84b3-e1536468cabd"
      unitRef="shares">1139323</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ieeaded307e5245739ed101c326ac2e81_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzMtMi0xLTEtMA_4e289750-76c6-4bfc-bb96-51fe58119e00"
      unitRef="shares">233961</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNDgvZnJhZzo0Y2RhOWI2M2EzYzI0NjUzYTYxZWI1NjFlOGI0NjlhZi90YWJsZToyMDdlMTdhYTkxZTU0OTNjODBmNTFjZTczNTRlMWRiZS90YWJsZXJhbmdlOjIwN2UxN2FhOTFlNTQ5M2M4MGY1MWNlNzM1NGUxZGJlXzQtMi0xLTEtMA_8ec6d6c2-c808-44e0-9f1a-a6ee5861dc06"
      unitRef="shares">3775872</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjQ_414e4f30-6ac9-4184-a428-e23b0eb4a1dd">Income Taxes&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefit) provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in fair value of preferred stock liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Limitation of net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2020 and 2019 are shown below. A valuation allowance has been established as realization of the Company&#x2019;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing and acquisition-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2020 and 2019, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases recorded as benefits to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company had federal net operating loss carryforwards of approximately $70.6 million and $60.7 million, respectively. At December&#160;31, 2020 and 2019, the Company had state net operating loss carryforwards of $48.9 million and $43.5 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2022, unless previously utilized. The federal net operating loss carryforwards generated in after December 31, 2017 of $27.1 million will carryforward indefinitely. The Company&#x2019;s state tax loss carryforwards will expire in 2032, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2019, the Company's deferred tax assets are primarily comprised of federal and state tax net operating loss carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $61.8 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize net operating loss carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#x2019;s tax years for 2002 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any accruals for, and did not recognize any, interest or penalties in these financial statements in any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Uncertain Tax Positions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjU_8f6bda9d-441f-44d2-a485-dfd7ff53edce">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefit) provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzMtMi0xLTEtMA_57ce76a9-b3ea-4af4-9fdf-f5cb71f6f17c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzMtNC0xLTEtMA_e3d88338-cd41-4ecf-9345-54bae71623c2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzQtMi0xLTEtMA_c52d5a2f-d394-44c0-9527-a1e5e04c6407"
      unitRef="usd">27000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzQtNC0xLTEtMA_1f4ec0e5-55bb-4f1d-a832-c96c4a4d3d97"
      unitRef="usd">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzUtMi0xLTEtMA_18ec53c3-5c9f-45af-8749-80533c25d639"
      unitRef="usd">27000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzUtNC0xLTEtMA_863afb2a-09cf-4169-93d2-ef8f435fe5a0"
      unitRef="usd">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzctMi0xLTEtMA_4d369936-153a-40fe-9690-7d3d489d2bb5"
      unitRef="usd">-117000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzctNC0xLTEtMA_0dcb9e77-704f-496e-9f93-9becf6c44722"
      unitRef="usd">10000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzgtMi0xLTEtMA_40b57fc0-4cca-4b70-a9a9-3b61b6a63830"
      unitRef="usd">11000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzgtNC0xLTEtMA_276eaedf-2d8c-4803-839c-7bc87064eb1d"
      unitRef="usd">10000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzktMi0xLTEtMA_d13021bd-343a-476e-baee-13aa269d9eb9"
      unitRef="usd">-106000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzktNC0xLTEtMA_0261c533-277f-425c-81d2-6dbad9e5cbc5"
      unitRef="usd">20000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzEwLTItMS0xLTA_5d782a67-edee-4d30-9df3-d6a4ca41d7a7"
      unitRef="usd">-79000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo0ZTI3ZWJhMGE5ZDI0MGUxOTcxNWNlYzI5N2NkYzU5My90YWJsZXJhbmdlOjRlMjdlYmEwYTlkMjQwZTE5NzE1Y2VjMjk3Y2RjNTkzXzEwLTQtMS0xLTA_9b9ecac0-5b0b-4098-9a37-9499e09df1c7"
      unitRef="usd">25000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0MjY_386048bf-748d-465c-9a3d-3f25f63a9cfb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in fair value of preferred stock liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Limitation of net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzItMi0xLTEtMA_ed697b75-158b-468c-8cf4-f530b8c28fbc"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzItNC0xLTEtMA_433f9060-a663-4cc3-a2d6-1f8fc92921ea"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzMtMi0xLTEtMA_08d0321e-007a-433a-9ed4-6bc5c2ad24ed"
      unitRef="number">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzMtNC0xLTEtMA_dba27235-8c43-488c-9d52-429338ff9460"
      unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzQtMi0xLTEtMA_61a57bda-2cb1-4e51-931f-7f664e551b27"
      unitRef="number">0</exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent>
    <exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzQtNC0xLTEtMA_ddfa92fd-65f7-458a-b6d4-c3e23db16e2f"
      unitRef="number">0.005</exdx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzUtMi0xLTEtMA_dd103b97-b179-4420-b9a5-e889f4128dce"
      unitRef="number">-0.226</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzUtNC0xLTEtMA_5742b95d-3b4a-4167-83f2-aa46aa2905c5"
      unitRef="number">0.361</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzYtMi0xLTEtMA_d5bc1ac4-d657-4d06-a9b2-7549a5b7eb13"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzYtNC0xLTEtMA_4d662c67-0e23-47bf-9bc4-b3dde79530aa"
      unitRef="number">-0.598</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzctMi0xLTEtMA_208a67bb-7132-4dac-9b40-a3ce5d9cb4ff"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzctNC0xLTEtMA_18a0b36b-fb48-400f-8bca-d5754f610345"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzgtMi0xLTEtMA_035831dc-d4d1-4753-a2cb-f99d16afa461"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZToyOTdjM2ZlNjBlYzM0ZGRiOGMwMWJiNzY3ZDAwYzdmZi90YWJsZXJhbmdlOjI5N2MzZmU2MGVjMzRkZGI4YzAxYmI3NjdkMDBjN2ZmXzgtNC0xLTEtMA_1f330244-cde0-4b0c-8a2b-a832128c8c5a"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0Mjc_6f34b525-65ab-4ee7-9947-14a29ac51d59">If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing and acquisition-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzMtMi0xLTEtMA_22645481-b322-4c94-84cc-7f4be2011cbc"
      unitRef="usd">17733000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzMtNC0xLTEtMA_9ab4e2ea-64aa-48be-981f-98ceaaab38cf"
      unitRef="usd">15287000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzQtMi0xLTEtMA_f0d46a9a-4338-4e85-8058-a7c775a066ac"
      unitRef="usd">629000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzQtNC0xLTEtMA_afb96717-c642-40a2-ac01-35defd072b17"
      unitRef="usd">419000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzUtMi0xLTEtMA_8c5aa826-4b03-4171-8487-1aa2ae278f36"
      unitRef="usd">1448000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzUtNC0xLTEtMA_1d4478e4-e9e9-4f04-b78d-ecd9f2ddc1b0"
      unitRef="usd">590000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzYtMi0xLTEtMA_0bbb5bb2-074c-44f4-975c-ddefea9d514f"
      unitRef="usd">1306000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzYtNC0xLTEtMA_e046d9ff-39d4-41d1-a3c1-9cdb94130dcc"
      unitRef="usd">744000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzctMi0xLTEtMA_7c7b6040-0082-4121-a94d-1afb382eb3cf"
      unitRef="usd">117000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzctNC0xLTEtMA_0924ee96-90b2-4d67-8546-674f30b44bfc"
      unitRef="usd">225000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzgtMi0xLTEtMA_1fc6da29-65c7-4ece-b124-7c658e817c13"
      unitRef="usd">21233000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzgtNC0xLTEtMA_1997290f-5641-44db-bd56-53c4ae8557ba"
      unitRef="usd">17265000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzktMi0xLTEtMA_c9e92e99-99ed-4c82-9089-9b3091c97da4"
      unitRef="usd">20596000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzktNC0xLTEtMA_3ebce777-65ee-486e-9425-21dd025ec57a"
      unitRef="usd">16797000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEwLTItMS0xLTA_d8390f52-8d6e-40ca-801c-7f2712bb271d"
      unitRef="usd">637000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEwLTQtMS0xLTA_9fa017d9-0458-4acd-abeb-f428b72b51cf"
      unitRef="usd">468000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEyLTItMS0xLTA_b730d8a3-6d68-4e5f-9747-ab561349adef"
      unitRef="usd">336000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEyLTQtMS0xLTA_777d976b-1b79-40b0-8ee4-cbc78d6e4e6e"
      unitRef="usd">336000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEzLTItMS0xLTA_4da26d93-4efe-4aba-b750-bce385a49767"
      unitRef="usd">459000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzEzLTQtMS0xLTA_04290bee-5775-4e21-b7a4-068c08a1ad05"
      unitRef="usd">396000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE0LTItMS0xLTA_3c0e1cad-c678-48cf-93d3-cf37fedf2df9"
      unitRef="usd">795000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE0LTQtMS0xLTA_381edc78-858f-4bf7-99c4-c5f8ba54e5d5"
      unitRef="usd">732000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE1LTItMS0xLTA_66ad2656-f177-4c43-8b45-27e11db67d44"
      unitRef="usd">158000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTpmNDExMDE1MWVjMWM0MjY1ODA3M2ZiMzhjODBlZGZhYS90YWJsZXJhbmdlOmY0MTEwMTUxZWMxYzQyNjU4MDczZmIzOGM4MGVkZmFhXzE1LTQtMS0xLTA_cdc175bb-08e7-4a4a-84c4-79ad285a02f5"
      unitRef="usd">264000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzM0Mjg_7dd13d93-1467-416a-98a3-330833f1f6c3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2020 and 2019, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases recorded as benefits to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzItMi0xLTEtMA_d97f47bc-2e67-4d7f-b888-44dc6230ab07"
      unitRef="usd">16797000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibdd8f716641546a99b2b0acc6ea44d50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzItNC0xLTEtMA_09dd5e25-849b-457f-94a5-d76d633082a5"
      unitRef="usd">21138000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzMtMi0xLTEtMA_93b20a29-2e6d-4604-9f07-01e6de131a1a"
      unitRef="usd">0</exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount>
    <exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzMtNC0xLTEtMA_9f59de48-6ac1-4776-9b11-34562be897c0"
      unitRef="usd">4341000</exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzQtMi0xLTEtMA_6d8e3da8-5720-4ce8-b76a-0366c0da342f"
      unitRef="usd">3799000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzQtNC0xLTEtMA_4d0a6fff-821c-4749-94b6-4e072987c9e1"
      unitRef="usd">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzUtMi0xLTEtMA_4ddab1b9-80c4-4040-939b-e394c9c0074d"
      unitRef="usd">20596000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90YWJsZTo3ZTY0OWQ2YmEzOTk0NzIxOTk0OTJjZGE4ZThkYmMwNy90YWJsZXJhbmdlOjdlNjQ5ZDZiYTM5OTQ3MjE5OTQ5MmNkYThlOGRiYzA3XzUtNC0xLTEtMA_55c78c67-d1bf-438a-9e90-4e634b67d728"
      unitRef="usd">16797000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEwOTI_4339675c-8aba-463c-910b-3ad6cd6069ba"
      unitRef="usd">70600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzExMDc_20ce9b6f-6570-49ab-8d15-6bc699c6f3b2"
      unitRef="usd">60700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyMDc_3e482589-7e63-46bf-b831-8822eec1671a"
      unitRef="usd">48900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyMjI_e382eb9d-03cc-4955-8009-66f34e9788ff"
      unitRef="usd">43500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzEyNjI_74f59515-e601-4bc8-af0e-79e80ddfdc66"
      unitRef="usd">43500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzE0NTQ_78fe2e81-2937-407e-857b-4cf6b3a4f32b"
      unitRef="usd">27100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <exdx:OperatingLossCarryforwardsNotUtilized
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzIwNDY_c1fd82db-5581-42d3-98ad-72e4da4cf219"
      unitRef="usd">61800000</exdx:OperatingLossCarryforwardsNotUtilized>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i161aa9f12f5040b598e25e1d7896f041_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzMyNjU_0e5f1fcc-a055-4ad3-9e31-83618f320a14"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i616b08c4738d433b924c1dc44c268b4f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTEvZnJhZzpjNDhhNDAwMzhlZGM0OGRkOGE5MTRlZjlhNGE1M2QzYi90ZXh0cmVnaW9uOmM0OGE0MDAzOGVkYzQ4ZGQ4YTkxNGVmOWE0YTUzZDNiXzMyNjU_b6b28be1-ac93-41a5-ab69-1539106ca7d8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTQvZnJhZzo1NmJmNmRmNWNiYzE0N2QyYmU5YzczZTQzMjg4MGM5OS90ZXh0cmVnaW9uOjU2YmY2ZGY1Y2JjMTQ3ZDJiZTljNzNlNDMyODgwYzk5XzI1NDk_fdaa94e2-d0e0-41e6-831c-69fdb74d79f7">Related PartiesThe closings of the Series&#160;G financing and the Series H financing described in Note 7 were issued to existing holders of the Company's redeemable convertible preferred stock, including certain members of our Board of Directors.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzUxMQ_e3b44d3d-d92d-4a29-bdff-4d055fdef5b0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 12. 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2020 and 2019, the Company made contributions to the Plan at 3% of qualified employee compensation, which totaled approximately $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzQzMw_2b823f2f-91aa-4396-a167-2fe13309f919"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzQzMw_dbe0ec20-7749-480c-b087-d11fa9ebf921"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzUwMA_f9b56f5d-82c9-4fe9-8908-4785116480f4"
      unitRef="usd">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3617efc1423e40249453b903e951175d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xNTcvZnJhZzoxNzZmMjA1NDZkYmE0N2Y1OWJmMDUzNjc3ZDBlY2JmNi90ZXh0cmVnaW9uOjE3NmYyMDU0NmRiYTQ3ZjU5YmYwNTM2NzdkMGVjYmY2XzE2NDkyNjc0NDIxODY_378440df-cf78-4b31-b452-66252be099a7"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzMyOTg1MzQ4OTI4MzU_c2515fc1-4101-4ad4-b650-f77dfc923ffa">COVID-19&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The reduction in headcount resulted in a restructuring charge for termination benefits of $0.3 million which has been paid as of December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp;amp; Human Services' (HHS) standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have &lt;/span&gt;&lt;/div&gt;been met. For the year ended December&#160;31, 2020, the Company recognized $0.7 million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its statements of operations.On April 16, 2020, the Company entered into a promissory note with BOKF, NA dba Bank of Oklahoma, the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the promissory note.</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i95195c5be0cf48859f028de27b41c233_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzEwOTk1MTE2NTAxMjk_08c07e19-1095-413b-a9ed-f914ff1cc9b2"
      unitRef="usd">300000</us-gaap:RestructuringCharges>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance
      contextRef="i9a7dd8fe1c69457ebd695bca19af30c8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk4ODE_c3298fe4-1f3a-4b48-8067-8d1d481f08f7"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
      contextRef="i801df2af82e6463ebc78fe5a1417689d_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk5NTg_918e784f-759d-48b0-ab05-989d1fca6102"
      unitRef="usd">700000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense
      contextRef="iac638a334d2d4a41982db55571d79004_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzI3NDg3NzkwOTAwNzY_6ee78c31-d15b-4247-9caf-2e60597f9326"
      unitRef="usd">700000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
      contextRef="ic992af68648c493b97deed5f40c92944_D20200416-20200416"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl83NjAvZnJhZzpiZTU0NzYzMWU1MTE0ZGIyOTgzODQwNTg4YThjOWVmZS90ZXh0cmVnaW9uOmJlNTQ3NjMxZTUxMTRkYjI5ODM4NDA1ODhhOGM5ZWZlXzE2NDkyNjc0NDk5OTM_a236acba-6ec0-4947-a0f6-e97970de1701"
      unitRef="usd">2900000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631457336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,669,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2021 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631925992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="nump">$ 72,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">8,910<span></span>
</td>
<td class="nump">5,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,159<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">70,517<span></span>
</td>
<td class="nump">81,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">78,375<span></span>
</td>
<td class="nump">88,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,771<span></span>
</td>
<td class="nump">5,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">26,659<span></span>
</td>
<td class="nump">25,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,536<span></span>
</td>
<td class="nump">32,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and December 31, 2019; 12,652,308 and 12,560,990 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">223,115<span></span>
</td>
<td class="nump">220,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(181,289)<span></span>
</td>
<td class="num">(164,602)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">41,839<span></span>
</td>
<td class="nump">55,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 78,375<span></span>
</td>
<td class="nump">$ 88,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651714635448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651707707608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,975<span></span>
</td>
<td class="nump">$ 40,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">16,559<span></span>
</td>
<td class="nump">18,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">37,033<span></span>
</td>
<td class="nump">28,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,568<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">57,160<span></span>
</td>
<td class="nump">49,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,185)<span></span>
</td>
<td class="num">(9,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,565)<span></span>
</td>
<td class="num">(3,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(16,766)<span></span>
</td>
<td class="num">(12,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,687)<span></span>
</td>
<td class="num">(12,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Deemed dividend recorded in connection with financing transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,601)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (16,687)<span></span>
</td>
<td class="num">$ (30,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (USD per share)</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (8.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">12,632,780<span></span>
</td>
<td class="nump">3,578,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187283-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651624048024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series G redeemable convertible preferred stock</div></th>
<th class="th"><div>Series H redeemable convertible preferred stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock', window );">Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,928,337<span></span>
</td>
<td class="nump">233,446,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock', window );">Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,492<span></span>
</td>
<td class="nump">$ 3,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendSharesIssued', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7) (in shares)</a></td>
<td class="nump">97,592,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividend', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversion', window );">Conversion of preferred stock to common stock in connection with initial public offering (in shares)</a></td>
<td class="num">(1,012,573,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversionAmount', window );">Conversion of preferred stock to common stock in connection with initial public offering (Note 7)</a></td>
<td class="num">$ (138,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(111,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,598<span></span>
</td>
<td class="num">$ (152,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="num">(4,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity', window );">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 7)</a></td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature', window );">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="num">(6,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="num">(6,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock in connection with initial public offering (Noted 7) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock in connection with initial public offering (Note 7)</a></td>
<td class="nump">138,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">138,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8)</a></td>
<td class="nump">50,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">50,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common and preferred stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common and preferred stock warrants</a></td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability', window );">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</a></td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 55,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,248<span></span>
</td>
<td class="num">(164,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">47,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common and preferred stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common and preferred stock warrants</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,687)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 223,115<span></span>
</td>
<td class="num">$ (181,289)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesRedeemedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Redeemed upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesRedeemedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesRedeemedUponConversionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Redeemed upon Conversion, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesRedeemedUponConversionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631390040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="nump">$ 318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651624462584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,687)<span></span>
</td>
<td class="num">$ (12,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Revaluation of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,694<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(3,195)<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,084)<span></span>
</td>
<td class="num">(9,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from sale of common stock upon exercise of stock options</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payment on capital lease obligations</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan', window );">Repayment of Paycheck Protection Program loan</a></td>
<td class="num">(2,865)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs and offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">68,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(14,636)<span></span>
</td>
<td class="nump">58,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">72,184<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">57,548<span></span>
</td>
<td class="nump">72,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to redemption value of redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderCapitalLease', window );">Equipment purchased under capital lease obligations</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">138,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_NoncashExerciseOfStockPurchaseWarrants', window );">Net exercise of common and preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities', window );">Deferred offering costs included in accounts payable and accrued and other current liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity', window );">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ConversionOfTemporaryEquityAmountConverted', window );">Conversion of Series G to Series H redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ConversionOfTemporaryEquityAmountConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary Equity, Amount Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ConversionOfTemporaryEquityAmountConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Repayments Of Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included within Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Capital Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NoncashExerciseOfStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Exercise of Stock Purchase Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NoncashExerciseOfStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Temporary Equity and Liabilities to Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627341512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2020, the Company had cash and cash equivalents of $57.4 million and had an accumulated deficit of $181.3 million. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its initial public offering (IPO) and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627684696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customers, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, approximately 70% and 82% of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2020 and 2019, approximately 97% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, the Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of 7,816,643 shares of common stock, excluding warrant conversions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 8 for further discussion on the remaining warrants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The Company is responsible for the costs associated with its salesforce over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the years ended December 31, 2020 and 2019, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement). In accordance with the June Amended Janssen Agreement, the predetermined average baseline for prescribed units for each remaining quarter in 2020 was adjusted and is subject to further adjustment, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarters of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $0.3&#160;million and the fee will be capped at 10% above the adjusted predetermined baseline. The Company continued to receive a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline for the quarter ended December 31, 2020. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning with the quarter ended September 30, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional 12 months upon 180 days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon 30 days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $5.1 million and $1.5 million during the years ended December&#160;31, 2020 and 2019, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.3 million and $1.6 million for the years ended December&#160;31, 2020 and 2019, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $1.4 million for each of the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock, options outstanding under the Company's stock option plans and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the years ended December&#160;31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,414,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and are included in other income, net in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company does not anticipate the adoption will have a material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company adopted this guidance on January 1, 2020, and the adoption did not have a material impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631834024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial InformationPrepaid Expenses and Other Current Assets<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019, was approximately $0.5 million and $0.6 million, respectively. At December&#160;31, 2020 and December 31, 2019, the gross book value of assets under capital lease was $1.2 million and $0.8 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627134328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings2017 Term Loan<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At December&#160;31, 2020, no additional amounts remain available to borrow under the 2017 Term Loan. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in twenty-four equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the years ended December&#160;31, 2020 and 2019, the Company issued PIK Loans totaling $0.5 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after November&#160;19, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, and commencing with the quarter ending December 31, 2019. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Company's revenues for the twelve-month ended September 30, 2020 were lower than the specified targets, as a result, the Company and Innovatus agreed on a new management plan and target to bring the Company back into compliance with the Loan Amendment. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity. The Company is required to maintain an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company was in compliance with all covenants of the Loan Amendment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627191416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, rent expense was $0.6 million and $0.5 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of 2.5%. Future royalties payable under these arrangements are limited to the lesser </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of an aggregate of $1.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 2.0% to 3.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627134328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's money market funds is based on quoted market prices.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625737048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series G Financing</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at a per share price of $0.078 in each closing. In conjunction with the issuance of the Series H redeemable convertible preferred stock, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each share of issued and outstanding Series G redeemable convertible preferred stock was converted into shares of Series H redeemable convertible preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series H Financing</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $0.04712. The Company accounted for the difference between the effective conversion price of $0.04712 and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $6.7 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders&#8217; equity. Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $6.9 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying statement of redeemable convertible preferred stock and stockholders' equity.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Company's IPO in September 2019, an aggregate of 7,816,643 shares of common stock, excluding warrant conversion, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of redeemable convertible preferred stock remained outstanding at December 31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627263416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying financial statements and notes to the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2019, the Company closed its IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, warrants to purchase common stock were exercised resulting in the issuance of 32,120 shares of the Company's common stock and cash proceeds of an immaterial amount.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627375752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). A total of (i) 2,011,832 shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and was initially be reserved for issuance under the 2019 Plan. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2020, 1,139,323 shares remained available for future awards. Under the evergreen provision, on January 1, 2021, an additional 506,092 shares became available for issuance under the 2019 Plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">951,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464,606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2020 and 2019 was $7.55 and $7.79, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock is $13.20 and $25.40 per share at December&#160;31, 2020 and 2019, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2020 and 2019 was $1.0 million and an immaterial amount, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-53%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46%-59%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6%-2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75-6.08</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 120,000 shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 calendar year through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on December 31st, or (ii) such lesser amount determined by the Board of Directors. Under the evergreen provision, on January 1, 2021, an additional 126,523 shares became available for issuances under the ESPP. Stock-based compensation expense for the ESPP was an immaterial amount for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%-83%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total unrecognized compensation cost was $8.5 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8&#160;years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance consists of the following at December&#160;31, 2020:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the stock option plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,139,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627142952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefit) provision for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of preferred stock liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Limitation of net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019 are shown below. A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2020 and 2019, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases recorded as benefits to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had federal net operating loss carryforwards of approximately $70.6 million and $60.7 million, respectively. At December&#160;31, 2020 and 2019, the Company had state net operating loss carryforwards of $48.9 million and $43.5 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2022, unless previously utilized. The federal net operating loss carryforwards generated in after December 31, 2017 of $27.1 million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will expire in 2032, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2019, the Company's deferred tax assets are primarily comprised of federal and state tax net operating loss carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $61.8 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize net operating loss carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#8217;s tax years for 2002 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any accruals for, and did not recognize any, interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625634760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related PartiesThe closings of the Series&#160;G financing and the Series H financing described in Note 7 were issued to existing holders of the Company's redeemable convertible preferred stock, including certain members of our Board of Directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625628728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. 401(k) Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2020 and 2019, the Company made contributions to the Plan at 3% of qualified employee compensation, which totaled approximately $0.5 million and $0.4 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625613976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReorganizationsAbstract', window );"><strong>Reorganizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock', window );">Covid-19</a></td>
<td class="text">COVID-19<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The reduction in headcount resulted in a restructuring charge for termination benefits of $0.3 million which has been paid as of December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.   </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' (HHS) standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have </span></div>been met. For the year ended December&#160;31, 2020, the Company recognized $0.7 million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its statements of operations.On April 16, 2020, the Company entered into a promissory note with BOKF, NA dba Bank of Oklahoma, the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the promissory note.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReorganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReorganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631292216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, the Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ2Mjk3YWVjYzUwMzQyMTg5Y2U2YWQwNTExYjFlZmQ2L3NlYzo0NjI5N2FlY2M1MDM0MjE4OWNlNmFkMDUxMWIxZWZkNl8xMjQvZnJhZzpmM2U1ZTg0MDdlZWY0MTljOGE0ZjdiOGQzZWQ4ZmVmOC90ZXh0cmVnaW9uOmYzZTVlODQwN2VlZjQxOWM4YTRmN2I4ZDNlZDhmZWY4XzI3NDg3NzkxMDgyNDg_5d33f4a2-8289-402f-bda6-723da8e7978f">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and </span></div>accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in other income or expense in the statements of operations in the period realized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment, finite lived intangible assets, and goodwill. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded. There was no indication of impairment of goodwill for any periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ClinicalStudyPolicyPolicyTextBlock', window );">Clinical Studies</a></td>
<td class="text">Clinical StudiesFrom time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses associated with these efforts as subjects are enrolled in each study. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.3 million and $1.6 million for the years ended December&#160;31, 2020 and 2019, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div>Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock, options outstanding under the Company's stock option plans and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the years ended December&#160;31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company does not anticipate the adoption will have a material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement: Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company adopted this guidance on January 1, 2020, and the adoption did not have a material impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClinicalStudyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Study, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClinicalStudyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627396584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customers, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,414,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625903656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid expenses table</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625613976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text">As of December&#160;31, 2020, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651723015640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future minimum payments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum annual lease payments under non-cancelable lease arrangements at December&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628766008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures and Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627315144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629270216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">951,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464,606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-53%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46%-59%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6%-2.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75-6.08</span></div></td></tr></table><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%-83%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance consists of the following at December&#160;31, 2020:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the stock option plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,139,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627336360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefit) provision for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of preferred stock liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Limitation of net operating losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2020 and 2019, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases recorded as benefits to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651711653304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="nump">$ 72,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 181,289<span></span>
</td>
<td class="nump">$ 164,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651707796152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651620169448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 23, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment', window );">Contract with customer, timing of performance obligation and payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPrescribedUnits', window );">Joint venture, number of units prescribed quarterly | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,975<span></span>
</td>
<td class="nump">40,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares) | shares</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Supplier Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | AVISE CTD Test | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPrescribedUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Prescribed Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPrescribedUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee Per Prescription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeePerPrescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629480840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,975<span></span>
</td>
<td class="nump">$ 40,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">22,456<span></span>
</td>
<td class="nump">23,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,446<span></span>
</td>
<td class="nump">9,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">5,109<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,128<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628351832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="nump">$ 72,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 57,548<span></span>
</td>
<td class="nump">$ 72,184<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629398184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,414,228<span></span>
</td>
<td class="nump">1,836,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">461,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="nump">1,375,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">11,640<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625647016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and other current assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 4,159<span></span>
</td>
<td class="nump">$ 3,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651708669224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,043<span></span>
</td>
<td class="nump">$ 3,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,941)<span></span>
</td>
<td class="num">(2,395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629577096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember', window );">Assets under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629395848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 3,589<span></span>
</td>
<td class="nump">$ 2,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 5,757<span></span>
</td>
<td class="nump">$ 4,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628427656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>payment</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan payable | Capital Royalty Partners II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments', window );">Number of payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod', window );">Term loan, covenant, revenue performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet', window );">Term loan, covenant, number of days to cure covenant if performance measure is not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Revenue Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantRevenuePerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Principal, Number Of Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651725161784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">15,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">14,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">34,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(7,695)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 26,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627978984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in next twelve months</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation, due in second year</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneObligation', window );">Remaining milestone obligation</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneContingencyFairValueDisclosure', window );">Remaining milestone obligation, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating leases, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating leases, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneContingencyFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contingency, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneContingencyFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627980968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract', window );"><strong>Capital Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: amount representing interest</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">$ (238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Long-term capital lease obligations</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 3,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651724938312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - Money market funds - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 34,507<span></span>
</td>
<td class="nump">$ 70,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">34,507<span></span>
</td>
<td class="nump">70,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628485864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Beneficial conversion feature, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividend', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">532,606,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Beneficial conversion feature, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628561304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 23, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 06, 2019</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0054456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering (in shares)</a></td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net | $</a></td>
<td class="nump">$ 50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses | $</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering (in shares)</a></td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627658296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">426,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants exercised common stock (in shares)</a></td>
<td class="nump">32,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">252,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">69,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651627966296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Employee options, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 7.55<span></span>
</td>
<td class="nump">$ 7.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 25.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance under Stock Option Plan</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum Employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance under Stock Option Plan</a></td>
<td class="nump">2,011,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards</a></td>
<td class="nump">1,139,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628547368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2019 (in shares)</a></td>
<td class="nump">1,375,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in Shares)</a></td>
<td class="nump">951,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in Shares)</a></td>
<td class="num">(47,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in Shares)</a></td>
<td class="num">(293,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in Shares)</a></td>
<td class="num">(9,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2020 (in shares)</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="nump">1,375,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2019, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 8.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">16.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">10.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">29.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="nump">$ 8.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6,750<span></span>
</td>
<td class="nump">$ 23,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">6,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, December 31, 2020 (in shares)</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, December 31, 2020 (in Shares)</a></td>
<td class="nump">464,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercisable, December&#160;31, 2020, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628156536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629358216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,694<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631589112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,775,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">426,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exdx_CommonStockOptionGrantsIssuedAndOutstandingMember', window );">Common stock option grants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,975,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember', window );">Common shares available for grant under the stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,139,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Common shares available for future issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">233,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exdx_CommonStockOptionGrantsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exdx_CommonStockOptionGrantsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625555224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income tax</a></td>
<td class="num">$ (79)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628301512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefits</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent', window );">Change in fair value of preferred stock liabilities</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">22.60%<span></span>
</td>
<td class="num">(36.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Limitation of net operating losses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">59.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Liabilities, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651628540744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,733<span></span>
</td>
<td class="nump">$ 15,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Accruals, reserves and other</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest expense</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Basis differences in fixed and intangible assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">21,233<span></span>
</td>
<td class="nump">17,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(20,596)<span></span>
</td>
<td class="num">(16,797)<span></span>
</td>
<td class="num">$ (21,138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Financing and acquisition-related liabilities</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Indefinite lived assets</a></td>
<td class="num">(459)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="num">(795)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (158)<span></span>
</td>
<td class="num">$ (264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629320120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Change In Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward', window );"><strong>Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 16,797<span></span>
</td>
<td class="nump">$ 21,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount', window );">Decreases recorded as benefits to income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 20,596<span></span>
</td>
<td class="nump">$ 16,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In The Valuation Allowance For Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Decrease Recorded As A Benefit To Income Tax Provision, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651629368456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 70,600,000<span></span>
</td>
<td class="nump">$ 60,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">48,900,000<span></span>
</td>
<td class="nump">43,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">43,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards, carryforward indefinitely</a></td>
<td class="nump">27,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLossCarryforwardsNotUtilized', window );">Tax attribute carryforwards cannot be utilized under IRC Section 382</a></td>
<td class="nump">61,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLossCarryforwardsNotUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLossCarryforwardsNotUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651625705896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Qualified employee compensation contribution, amount</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140651631590744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 2,865<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense', window );">Other income, net attributable to COVID-10</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Other Non-Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!N)XXG6\4;RTAT9;KA3/[>6>$@W:".CW.ZZ)J;XQYU#-N>/F'U!+ P04
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M.TLCFY;&'_:D!]DUQX6!)U<B]M4:Z7'=V 0TV6O,JOE,.\RP[O"_,@U8ITT
M]Q0,992RT&=1W*]'AZ4?1'$4]5.?7QP#*U!;>SK6B+T7ICE<=4^[$_B=/7?V
MGM_CR;PY1Y_#-,?Z3UQM489)"1L,Z=U$V%E5<U)N;HS<V</F6AH\NMK+'#A6
M=&V [S=2FM--/4#W_XK5_U!+ P04    " # BG!2#:SJ?/P'  #U*@  &
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M<FMS:&5E=',O<VAE970X+GAM;)U7VV[<-A#]%6)1H"U@[*[73A,$M@$[:=
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M^(VHW ?2<_% !GL%+:*"C=Q:\AYE99E/[=/@.?KF)I90WR'(I*OY-T?@NN3
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MEP+!.^--82;2O!Y$;D>IS@5O:Z[2DN"5E<@V*GM<BQ(+_043B)O7V.JY?XH
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MJ&HD]N4"+"!(,N"Y.'135P_H%2&/'+?4,X4+ K!(MJXS"P6$OF14Y5+NG8X
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MO:I2907]E@B_4.*#J9:RW@CUK++&JUQ(X4FF)!DYMTHA>[PXIK/;&D_ ,K^
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M@6GV5G-QN@J[8JT=;9X@EK3JT7@#TA>:@FXOGJ#[\UC\!E!+ P04    " #
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MC(=KPS#!1QQ9/H#]I3&^GK""YK/PX!]02P,$%     @ P(IP4D=GJ?<K!0
M]PP  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULI5=;;]LV%/XKA%&@
M&Z#*DBQ?4B0!<BN: D6#>EL?ACW0TI'%E1)5DHJ3_?J=0TJ*G-A%AKW8O)WO
MW#]2ISNEOYL2P+*'2M;F;%):V[R?3DU60L5-J!JH<:=0NN(6IWH[-8T&GCNA
M2DZ3*%I,*R[JR?FI6[O3YZ>JM5+4<*>9::N*Z\=+D&IW-HDG_<)7L2TM+4S/
M3QN^A378WYL[C;/I@)*+"FHC5,TT%&>3B_C]94KGW8$_!.S,:,S(DXU2WVER
MFY]-(C(()&26$#C^W<,52$E :,:/#G,RJ"3!\;A'_^!\1U\VW,"5DM]$;LNS
MR6K"<BAX*^U7M?L(G3]SPLN4-.Z7[?S9!#5FK;&JZH1Q7HG:__.'+@XC@55T
M1"#I!!)GMU?DK+SFEI^?:K5CFDXC&@V<JTX:C1,U)65M->X*E+/G:ZNR[Z62
M.6CSEMW\:(5]/)U:1*;]:=:A7'J4Y A*G+#/JK:E83=U#OD^P!1-&NQ*>KLN
MDY\B7D,6LED<L"1*HI_@S08_9PYO=@3/>\;^O-@8J[$4_OH)9CI@I@XS_9^Q
M^^\H["O<XQ28VV3K1@K+OM1L#8V%:@.:+2@R\4G ; GL2E4-KQ\9% 46.^2,
M,U7#.VS9=_%J%BYF<^P?#V@<H'& JF#"&I:IJL+^\#N_$-X![;^&[#?<:;AF
M]URVP'B=.]V\M:72XA_4:DJNP1 L;>S![D #JY5E//\;BYI,-&@E'L?NZ24.
MJ W9A91,&-.2"*I$7C$6!Z+>[FOH[<E432B.,S@V?@^N(0?DLXWLCUA!8V2R
M K0FZQU,R>^!;0"(<:Q6GC3DXY/=5A$7$:D@K# ',X6!9QSM;D +E1M28J F
M:5'[H&693QFY48B:UYG@$DW@F%X\:9P[&"\,)RHDD4.G0LH\A< KWRN09':H
M0C*I#)F!&F[OOE!LTB!.HR"*HE'Z7E0%Q\2A%R*#WIRFW4B1T>$W<1JB-/KJ
M$0)T,I.MRQ"=A ?0F< (H>]%BU'9/+KU%IE"[[2P&+XN24(SU3BR1BU-J[,2
M^9;-._MXG@O:I!#L55KGW-M]HT-V>]B.3NJ IA<:?/#X=JMABT%G-=Z2C589
M0#XDI@]MH57E@;$+-6G=48TW>/Y!X/5!5?1F'H4ITKB4J"5P<&C-$ D2RH7)
M5(O)#9PW6/IXU->#0G3]! \/>#,;,M+5VV!DOT[0S]0OPWFOG<(S.!P@_@@!
M!9?!*EX$BW0VBO4XN@&JZ:.[XUKSVHY:#VUR'=\U;A>ICN1>IFV-#J&*BW=8
ML]WX<C2^&D;7P^AF&'UPL>DF'U_9Y[TI;:/JGL841@E+>D0@%$ YKK97D@CZ
MNU^)7T:L]<U'RS@^+93$9Y'+IB?^3'+,>"$0:]<?')?H2U8=,R)W5N+=Z3F@
MOS_?L[5WX:;O@3O7R[>8'B058#EE_>:A$8XR:S^_VE/5&Y/,DV!YLF)O6!RN
M4O:)URT^YA@1#=+-XME"LC@"LS@)XN7"8WSFZ%QG+"*,IT?EXUGLA2^0EB3K
M94>SHZ*K6;!<KAC2UBP9$>;202R?KR3IL4!$P4F:=C!#R#W*ZME",F=IL@A6
MR9)=M[IGI$? VQ3HP?0R9<%KT]_36MY=I@3>W3*B3R_6Q"P)XB1Z%7&Z?LJX
M*9^HCAJA9J(B'M%T!_&*."H\](B:CAZC%>BM>W*3!A3P[])A=7C57_C'[--Q
M_TF E; 52'X2"A2-PN5\PK1_9ON)58U[VFZ4Q?9UPQ*_3$#3 =PO%%ZAW804
M#-\ZY_\"4$L#!!0    ( ,"*<%+@<U\@#PD  'H8   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;*U9:W/;N!7]*Q@U;N,9FN)#3]?VC)VX[79F&T^R
MC^ET^@$F(0D-27 !4HKZZWLN %*2+2G9[GZQ^ #N^YY[0-]LE/YL5D(T[$M9
M5.9VL&J:^GHX--E*E-R$JA85WBR4+GF#6[T<FEH+GMM-93%,HF@R++FL!G<W
M]MF3OKM1;5/(2CQI9MJRY'K[( JUN1W$@^[!1[E<-?1@>'=3\Z7X))H?ZR>-
MNV$O)9>EJ(Q4%=-B<3NXCZ\?1K3>+OA)BHW9NV;DR;-2G^GFN_QV$)%!HA!9
M0Q(X?M;BG2@*$@0S?O$R![U*VKA_W4G_B_4=OCQS(]ZIXF>9-ZO;P6S <K'@
M;=%\5)N_">_/F.1EJC#V+]NXM:-TP++6-*KTFV%!*2OWR[_X..QMF$4G-B1^
M0V+M=HJLE>]YP^]NM-HP3:LAC2ZLJW8WC),5)>53H_%68E]S]ZE1V6?VH;8A
M>BIX=3-L()9>#C,OXL&)2$Z(B!/VO:J:E6&/52[R0P%#V-,;E71&/21G);X7
M6<C2.&!)E$1GY*6]DZF5EYYR<L6UN*+DY>R);U%3#;O7FE=+8:__=?]L&HT"
M^?<99:->V<@J&_V6B)X508UX;6J>B=L!.LT(O1:#UW+9=Q7[).I&E,]"(U3Q
M/&#-2K!WJJQYM?V380^*ZYRI!7LO-;I :<-XKK C#QBO\A>K#2E8J2(7M*ZN
MM5K30EI$PJ$N0[#00^Q^0W*M#6_[UW1[&;)[UJB&%Z3UK;QD21#%<3!+$V8H
M"8:>9ZHLX8/5Q^JB-5B)I7Z!:9__ V,AAG'28]@2F8+-K$5YZ<Z>U.F''(6^
M%( G85^)Q4+83F<Y;P2I.[ 02S->"L;77!;\N1 ,.YDTIN5P[U"%WT&1VG##
M9"4;R8MB"QG,IR7_ZO:0_?CZX4&BT,Y;YZ,/B;(Y-H&_I52(3'*;>$TH@U?0
MWVB945CLJM=/8(QLC+5>09ONHHFXRBJ7:YFWO#!LLT*<7>PJ)LJZ4%LAH$ M
M%C)#)02L4M55]X+E?27![PQ6 OU@N>D"W?E$46EL,HW,)==2F)#]@ 7>.;84
ME= VFN)++<D Z-\*3K6W:'S NA2ZZ) K9*KX(G0FC<T>O+%9_])0(Z\1 Y&'
M["?\RFJ)Q#!<8:$$0N;L>6L7'VL+B);[1BU4J[TY"ZW*U]8X;W95@E@TF($D
MB@W$6NBE%O"(NDC2!$.KKSA\*# &:5&%Z",1&2:I$51<5D75VF:&$M\-)^I4
MN>4+J4T#N[:T0_!LQ3)>B"KGSG:LT:I=KMC?.=3I+7.0.B=M5-BE:A$T\0N9
MX@-9"&.L =>V?4<776(QT!%)% ["FO%:4H_[<JV<:J"V@Z(T-DU %>#:NL4[
M+]9KS 42C&%V+B5 $EM4>U+=/ C@19S.@S1)NR!I0?0#T@ZCM6B;%N7BZGZ_
M#X^D)R W#L,4!S9(>2ZI8N'N.)H$T;Q'LE^-)'")D$DVV[VW+_#7]P=@D:.6
M4)(&Q R"FQ7TH72NV3_Z$OG94@Z17^U=W2_AV)(*]<,N8<'+*,*@.$BGXV \
M2M@;-@O3E,W#>(+K) TFXQ'[J\?<^3@.HC3&BW@21@E[=+V'-V]'4VR?7^)5
M%"93!I*T$)+VO$WF:3"*$WH51^%H@EW4XG@S#V;CF)XG<Y)VSL8D@HUSV#B=
M6/5Q.(MAZ91N)L%T'-DNIZ2C=X$APD(?RIA X/^0]L$#TQZZ'),RFHR"2421
MFH33,41$)"(-TDEB$6'3I8*CR$!K/799[%APJ=F:%ZU@-63:.K*=VZ%K#XX^
M^O"FAV26MYJ:CXK& 9,@NG7$1 J(S3%-K3?3<#RVCW UG=LY4;L)66P=B,D*
M@P,T._.VH>H (UE;<!M>X\!/8K!J0:7]+)H--8]%H)U+AQ, !7TPYSN^X<.+
M"&!8]9L.!I^SZILEP]PW<1IZQ]\DXW 4[<47H'LZ1-\2#FA7A[7AQ_ZOS40<
M1J#P16%/(S3+*B9Q% (6@E9X;'QID&5]5P^6NI+_. XY(H"6PK4X$JJ^F@Z"
M:DV@L5C:K+:FJZ6%HI%$=QS85?K5J+P>I8\D^E"T+]=K]D\;C<<3T;"1>.PZ
M=:U07[(@-!Q-+Z[&Z05Z"[_S"_91FL]7"P TY4(0L6&:^@=8<G$5A],+%H=8
MFN /!@:8#.+/ME(4.?OC'V9)G/RY_^W5D2\82)YC7+)Q.(ZN &DS7$W'[NJQ
MBYSCVD^MSE:(_%FV?9ICV]=G15KR_/CIZ>G251Y==F-EQV/]K*<IWZVWR>S4
M^!%ZCO;OB:\IIV!F-=>-S&1MR1NR77>6'?161R!JOM6H$]1$WF8NZ9#?UK0S
MB3J2@ H1A5Q*&H;97K$>G IBC/ HBDZ=!PZ9]M=H-KD44FJZ,1T<IU$OM7QU
M:+LHHUF)[#NV!G,ZOI:?)F +:0">CG[M(;8M/X]C)#N W*6L*GJ_D9CNCBF@
M2WXW!F<)7/QM!.[WYFZ_F6O%R208[QC>6:YE7A6$0TUWX-\O1,L3"#4[^-XU
MTQ$L/@#Y4QCOA]51$-T NX"T;I#W(W4W\(Y92#IM(?GC<=>6]N!WY"A,'GP-
M>(]A[GAV<35+SV%M3%@;GT38D\@:A6/V@^UV.CEFW*Q.>]OE X6C-!FOA6,=
M"-A+,D0C\UA0CGT@L'GU9RI4?>.^\]A)#E;FY((W(/$N<\8ZT*Q4:Z#&7'[3
M*'NGC)6I4>,5YB)H8(H_<\P)#'FBM/X\Z:9]CJZ1])W)HGH"ACQGH]&8?03&
M<3AD5^605:C:FIN G,?QS <3G#F8S$?X'4^3TX<CA[-M11%=5O*_+R.>D=&6
MCLR0)T]' K9925A Y^4])OWL$N/%J#6A@#]L6=QZ2777_MB-&$ME(2$)9ZXL
M0II/._P]P'5_3NM1F#XK(%#]-X6]YCK"Y:[9SYR^Y9T;8R.@R0QGE ,;_$EK
MZ?:2=E]D^TBY.S1T>X^=RQW'WY7?JZ/<WIGUG)R7D7 2;3$G:1K,888KAC28
MPJP9"N'8%\OAWO?@$O!KOWH3:P:HN4_#_=/^P_J]^YZ\6^Z^RG_/]9*^:A1B
M@:T1J-+ =5UWTZC:?EU^5DVC2GNY$AQFTP*\7RC5=#>DH/]WP]W_ %!+ P04
M    " # BG!254++(ZD(  !5%P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6R=6&USV[@1_BL8-6WE&8422;W99WO&=BY3=^[:3)Q<I]/I!X@$)204
MH0- R[I?WV<!DB)CRG'Z12()[.ZS[PM<[I7^:C9"6/:TS0MS-=A8N[L8CTVR
M$5MN K43!58RI;?<XE6OQV:G!4\=T38?1Y/)?+SELAA<7[IO'_3UI2IM+@OQ
M03-3;K=<'VY%KO97@W!0?_@HUQM+'\;7ESN^%@_"?MY]T'@;-UQ2N16%D:I@
M6F17@YOPXG9*^]V&WZ38F]8S(TU62GVEE_OT:C A0"(7B24.''^/XD[D.3$"
MC-\KGH-&)!&VGVON[YWNT&7%C;A3^;]D:C=7@^6 I2+C96X_JOW?1*7/C/@E
M*C?NE^W]WC@>L*0T5FTK8B#8RL+_\Z?*#BV"Y>0$05011 ZW%^10ON.67U]J
MM6>:=H,;/3A5'37 R8*<\F U5B7H[/5]D:BM8)_XDS"78PN.]'V<5-2WGCHZ
M01U&[%=5V(UA/Q>I2+L,QH#2X(EJ/+?1BQS?B21@<3ABT22:O, O;O2+';_X
MN_JQ=](DN3*E%NP_-RMC-2+BOR^(F#8BID[$]/\TX>NIV:>-8#NM'J6+>:0<
MDW[9NN5$(1F,-4QES&)KIG(DE2S6;"@+?%&EX45JSB[8OP77E5,83"JV*Z$;
ML^(G/&=WI=:BL!?LO4B%YCE[P_[RIV441C^UGAXLMX)%"S9CGY3%IL13^4_O
M1";PFAYY#,-P<<;"2448AO3L*=-J,_9,YF? P(:WHA"9M&<G=0:2X>+\#'_1
MS!E'9)EP>>Q6-<F +52I7S);*D$%<V1:;;W=*K0&($NK],%SXJ:RJ'F5 =\_
MX])@&D9A,#EC?SX^>'NT88U8@9H+]#4:HEYYBQ@VC(-SQR .YO1_M^'%FABP
MC$O-'GE>.M51B2NSHE0D7UDN^4KFTDKH73L17";!K,N%&'!?%TEC7B1P<Q3,
MG<AY$-+N7^166K\)DAS:'9!:"C@DDNF(F)T'2_S]$_;5+'3/H6/W\W.7U7 F
M042FD>M"9C+A""N89Z<*!%@3XW?XPHN#$[3XR1S#B+AQ@,!6;GM\A$SP?N)(
M>+-1^P+6A:H!N^G5?@/WKX0HF(!#5[E$34TI)-#J<OE'8X;78B)VA;)L"[,1
MS58!1BZ_BOSPUL(-;VG1;K0 M#R%E-]+J07:G0W8?;^8+V6ZI@TL<6XT3D5I
MF20$5FBT!\*PX;9-CH:2Y]",02GX0%4*"=IC1!_VD2/OA*,6N?<[Z(FG%H_(
M* 1M99$^@^*ESS -G"1196&Q2 D+:W%P34O?K"&F507$$V808.U6N>!48KY[
M+O6"_>-9^+*$:WV \#W7J4&-"1>C11S3PVP4+1?L(^S#=;)Q=DZA<:YVSO[$
M-X$ LLP\.F=3"+U)$EWR',:#2X5^K-RC?#Z,IM,E4F3"[J$Q-MA&IW 43^9L
M,9VR6VYD7:P$#&A<MLLG"D-R=&'A=4E.K"R)6HN<K2OS6I-.?1:/PE$$O:!>
M-)^Q7X2!.7[K<=@PFHQFYR@WPW ^6IRCD/=8TI>M>;Q@T_FRNZ%5>] 19 &F
M9&L"SQ.$MY$D\*V+)9"T2]4PCDFN^[U'T<UD(2WERZ-+0J?&<#H[ISV$\)1<
MCPX] _5EN(BC,^?W],1N:B_A;$G]91C-IV=5?72&/Q75%*Q]1DY+[?(#9 ?7
M.\2)WE'7I1';;R2"JS;'3DN,Q3(_5,&/-#4>RO/*VPW=$>62+D7JTK) 8_ F
M]P'I7IJ8W".V6HWNV>!P(J7ZPJ4J,RNQED5!R*I:0.I3$KD8HM8=CL*80J56
M28M$Z=17UZ;"=#/^V,WK#C.<CN)I2-'QC,TITA@ SAL&+Z@@*%$[X'TF'+6X
M>:G#C#KE=L/3IJ5_SW,DE>^ ^ F^MV@-[,UB@JZY18UT2"'AS7P2+.HOKKKL
M?#_-#\&/XC)N"GD-JC?397#>Q3&-@]E)'%TEVEN;8;4UYO3(K-K"6KKBC^J(
M;DC!#XVB$2N+'&6+IIU'B6"%C-)*ZF)IX.;"5QM\C7C3+M_ FV<HQM\:$$65
M](\60=BHX,"U&8&Z+E*D_J>>;NUM_9*V;27C[RCYW-'?^/>O)T8C+5J5A<8K
M+8U(VW,G.?<(]GL6["CK&.:"S,F9NR&@<;A,#S39J'*].>94;SFDZ<SUUF9Z
MP9B&P6(C=\V0LY=V4]7CK>!UH7%]M("XCU7)NU,I.MC]Q[NS$7NHCOSQ,G)A
MKQ)W;$F]J2<QB9XL'8"H<GF=,P&U8<+A)7*(.* MCY"&--1^$]-'VSN36ZOE
MJH0AN\ZN;?$\T##STAB(::CV-(( 7F'0HZU%Q^B0YCN8ZQ05X8]$_JFP=T%)
M>*K ]%!(3SH^WY76]Y*_JY7!N./.+D37C0B>?BF-K8.P:Q'6@/%>[PG7A&HZ
M-'!%Q3CAO?N,48ETVE!\- /K28&N[V5ECB10608>; 6L?1T>W11AK:F^J8*@
MM,;2*@Z/CNB;$/8TR^9&-0W*%<LR=XZA=MYI5Q*L$MNU(<9 4ZZ^P/_D8>SB
M;>F?@X>@F@@A7U.IJ/+W"V80DTJ'U?17)1+IYQ,:9) &D6-5ES5W5CJ*%D\<
M:>FEKPY=Z<>2P4M,$-I/5&GISABTLU,O$2MET01Y[UFRGE-Z1^YJW.[:B0R,
ML^,?;DRJYFH0CJ$9AFN>.T3U?-6=$M"I+-T)P(8T?9R^/>A*3)7PQ[H-?Q3N
M)-2,62 <>=@R=5L:=+1O=$380>=]BG- YN?EZC[!'03=*LF I:2B"1$;Z<04
ML,\(-&TYUBDU/R@_6IL?G0<0BF71X$P[9[X3BN,,+04=YNMCYHKG_KB7G>;E
M2PM-!QH:4B/R%Q&MVEZ()_#;B_R1SLITIQCTW<V-6U>=6Z'7[D*7;L9PE/2W
MGLW7YL[XQE^5'K?["^=?N<:T85@N,I!BR)H-F/:7N/[%JIV[.%TI:]76/6X$
M1TVD#5C/E++U"PEH;M*O_P=02P,$%     @ P(IP4G.89>ID @  / 4  !D
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M!Q2B&2T(L=68S>24"3_EQA-[%>?YU35JX5'"1I!7Z!:I9]#@2LL!8-T#Y,\
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M;S\^Y^W4> IO9^\=,UM.10K<$#2-/UY$8-IYUAI.5V&&K+6CB126)7T"T/@
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M1HX/8+^TN!KV+VQ@^%8^^1M02P,$%     @ P(IP4F+]UKHP&P  5E,  !D
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MS1L2,>K"N2AY4 #(Z\9*U205J -L]$"YC&WMFJ"!C^I(WC6K.FH/S(PDX7<
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M4'Z6Y%#JUJL5Q6K^'-/R@P>C0\Y9_KCK,@I\G"&%@AKW+H+Q(^$3T0:=<Q;
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M(V^\1I]VSBVXJ8:GSWT?KBAXM#$BNBX\..0@&Z=R 7>O8Y;#=YY+,!^WEXJ
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M\EA7ZNR'7U[>XLKY>&82\-)';&]R70'F1;AUS6.OI"X8T9-'QIJ*<AS_7D2
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M4TU?W59+Q@N4ABL)&A<7G<OP["IQ^_V&/SD^F6=C<)[,E7IP'[?91:?G *'
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M$(^&\.G%(7L%<1B,1P,WZ 7]9 3.S.TZ<KDR):?]=&Z5,P>"S155%*6I= 6
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M-*)RA_O0X[(SN F##TK:M8&?9875/P$B<G+PE.T]?6 7$9^PO(4T"8'%++Z
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M!74FW3]G^H55K7]"+)2E!XF?KND%B-H)T/E2*;M?. /#FW+^-U!+ P04
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M5B87)7Q63%=%P=7;#>1R>]4+>LV'1[%:&_HPFE]N^ J>P/R^^:QP-6JM9**
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M:GH&E.L]8E;:8M6CW.SOG5X]RNW^*)U*E#8LB=6Z<%;KPBE@W1K8>V#V]47
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M."1<#8#G4\;D\D9]DK#ZMN?\/U!+ P04    " # BG!2*]])43D#  #0"P
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M)+2Y]-VP,'T9D=; [.="Z.W$!N@ZO>D_4$L#!!0    ( ,"*<%*75EGCI0(
M %('   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)V5WT_;,!#'_Q4K
M0Q.3-O*S"; T$K1"XV%:!6-[F/;@)M?&PK$SVZ'PW\]VTB@T+>KVTOCL^YX_
M=[[:Z8:+1UD"*/1<42:G3JE4?>FZ,B^APO*,U\#TRHJ+"BMMBK4K:P&XL***
MNH'GQ6Z%"7.RU,XM1);R1E'"8"&0;*H*BY=KH'PS=7QG.W%'UJ4R$VZ6UG@-
M]Z >ZH70EMM'*4@%3!+.D(#5U+GR+V>)\;<./PALY&",3"9+SA^-<5M,'<\
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MW!Z5PVA\P'>;%:6C=LI)([*$]H*=JS3++;R FG>+ VS4VFZ9YGV$--I*@C_
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MZI89/7A<6P4Z7RB%ZXUUT#ZA\6]02P,$%     @ P(IP4O***X$& P  /0D
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MWE4"C2G:N[H=*%Z;ZV[)%5R>YK& [QLBM &LKSA7NX&^0?LOIMD?4$L#!!0
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M\:E<;AI2<*)SO#VEK%M]R8;Z?SBJA$WW"?V?<5@)F_81NMO'D09<OM*4W+K
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M=@#V;Z0T^X:]#G:W^=7_4$L#!!0    ( ,"*<%*N;\)T$ 4  (X4   9
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M,ID%\'XIA-X]F VJ*\CIOU!+ P04    " # BG!2>HK:Z.\$  !<%0  &0
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MA=:"V\<-T 1D,<"\7PFA7QO%!/6]T>P?4$L#!!0    ( ,"*<%)F'P<8! ,
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M= PN8XRCZEFJ-HPLW?PRDP:G(;?,</X$92_@^5Q*LS;L2-1.M.-_4$L#!!0
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MH=4FK5I%=_DP[8-)3HA5QV;VH;3_?K9#0R_!5/L"L>/W/>?Q<6R/MU+=Z1(
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MS293K CNI$F.N7W"<[>EJM!=N:P])\ZS/7V/TR2( _L;^X_[63LVC(/DT/
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M;"]W;W)K<VAE971S+W-H965T-3DN>&ULO59+;^)($/XK)6L.B43B!\^, (E
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MRV&JZ[(22._*\;[6Q)=%N4SY#P.-4^#O&\UM7@ONQFC^6:;_ 5!+ P04
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MJ^[:?( "D;+G,E389=7BT:%\X8KK4K V:@XPI0A3>D@F=L+>K;@-/]F(]HD
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M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ P(IP4BJF+D^3!@  B!H  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,"*<%(&V^^M4 4  (,4   8
M              " @=8.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " # BG!2*F"IAZ@"  !N"0  &               @(%<%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ P(IP4LDCG23M!
MNQ   !@              ("!.A<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( ,"*<%(-K.I\_ <  /4J   8              " @5T<
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " # BG!2LG-4
MMJ0"   )!P  &               @(&/)   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ P(IP4@UAH6;O"   1"H  !@
M ("!:2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,"*
M<%)__86#F04  )8,   8              " @8XP  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " # BG!2E>'BZ<HF  !;>P  &
M        @(%=-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ P(IP4FK_@A:0!   \0H  !D              ("!75T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " # BG!2@U, ^E(*  #7&0
M&0              @($D8@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( ,"*<%+!GF%O9P@  "44   9              " @:UL  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ P(IP4A)SV<^O
M @  2 8  !D              ("!2W4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " # BG!2@SMKYM<$   B#@  &0
M@($Q>   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,"*
M<%)'9ZGW*P4  /<,   9              " @3]]  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ P(IP4N!S7R /"0  >A@  !D
M         ("!H8(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " # BG!254++(ZD(  !5%P  &0              @('GBP  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,"*<%)SF&7J9 (  #P%
M   9              " @<>4  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ P(IP4MV,0*+W @  8 8  !D              ("!8I<
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " # BG!2672H
M\-4&   W#P  &0              @(&0F@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( ,"*<%)B_=:Z,!L  %93   9
M  " @9RA  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MP(IP4N!:YT-;!0  ?0X  !D              ("! [T  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " # BG!2UM3LTR@$  !?"@  &0
M            @(&5P@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( ,"*<%+(O6'VZP(  !8&   9              " @?3&  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ P(IP4N_*;<(T P
M!PD  !D              ("!%LH  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " # BG!2ZR$7A<8"   Y!@  &0              @(&!
MS0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,"*<%(4
M9:@4Q0(  $4&   9              " @7[0  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ P(IP4JGM)P]K!0  E@T  !D
M     ("!>M,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,"*<%(KWTE1.0,  - +   9              "
M@=KL  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ P(IP
M4C<^V.UR @  GP8  !D              ("!2O   'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " # BG!26B>+R08#  #U"0  &0
M        @('S\@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( ,"*<%*75EGCI0(  %('   9              " @3#V  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ P(IP4@%BN5U_ P  5 T
M !D              ("!#/D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " # BG!2QB-]SK$"  !.!P  &0              @('"_
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,"*<%+RBBN!
M!@,  #T)   9              " @:K_  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ P(IP4L^*9X-0!   6A   !D
M ("!YP(! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #
MBG!2W\\3E:$"   J!P  &0              @(%N!P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,"*<%(=[,@:" 0  !$0   9
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M970T-BYX;6Q02P$"% ,4    " # BG!2@1W8I(L#  #9#P  &0
M    @($<'0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M ,"*<%*N;\)T$ 4  (X4   9              " @=X@ 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ P(IP4GJ*VNCO!   7!4  !D
M             ("!)28! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " # BG!2*/M'0L\#  !#$@  &0              @(%+*P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,"*<%)F'P<8! ,
M #@*   9              " @5$O 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ P(IP4E4?G0GQ @  W0H  !D              ("!
MC#(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " # BG!2
MV :=C-H"  #C"   &0              @(&T-0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,"*<%)ZU\-!( ,  #H*   9
M      " @<4X 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ P(IP4LU 2-;? P  _@P  !D              ("!'#P! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " # BG!24NT =MH"  ":!P
M&0              @($R0 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( ,"*<%+O[(*,P@(  -0'   9              " @4-# 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ P(IP4C(S9SQ^
M @  , 8  !D              ("!/$8! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " # BG!2USGA#0H#  "_"   &0
M@('Q2 $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,"*
M<%+7:\4H80(  &X-   -              "  3), 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ P(IP4I>*NQS     $P(   L              ( !ODX!
M %]R96QS+RYR96QS4$L! A0#%     @ P(IP4I7\L\25!   \28   \
M         ( !IT\! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,"*<%)9
M=@'X]0$  #@C   :              "  6E4 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,"*<%(7R,P;VP$  -$B   3
M      "  996 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(
' *)8 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>419</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets - (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets - (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - Covid-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19</Role>
      <ShortName>Covid-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Other Financial Information - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Borrowings - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/CommitmentandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Fair Value Measures and Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables</Role>
      <ShortName>Fair Value Measures and Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails</Role>
      <ShortName>Other Financial Information - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Other Financial Information - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails</Role>
      <ShortName>Borrowings - Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails</Role>
      <ShortName>Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/RedeemableConvertiblePreferredStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Change In Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/A401kPlan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exdx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Covid-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19Details</Role>
      <ShortName>Covid-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Covid19</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="exdx-20201231.htm">exdx-20201231.htm</File>
    <File>ex1025-amend3tocoxpromotio.htm</File>
    <File>ex1034-amend1to1221liberty.htm</File>
    <File>ex1046-executivecicseveran.htm</File>
    <File>ex105-formofrsuagreement20.htm</File>
    <File>ex231-2020bdoconsent.htm</File>
    <File>exdx-20201231.xsd</File>
    <File>exdx-20201231_cal.xml</File>
    <File>exdx-20201231_def.xml</File>
    <File>exdx-20201231_lab.xml</File>
    <File>exdx-20201231_pre.xml</File>
    <File>xgn311-123120.htm</File>
    <File>xgn312-123120.htm</File>
    <File>xgn321-123120.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exdx-20201231_g1.jpg</File>
    <File>exdx-20201231_g2.jpg</File>
    <File>exdx-20201231_g3.jpg</File>
    <File>exdx-20201231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 152,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 549,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 6
   },
   "keyCustom": 62,
   "keyStandard": 357,
   "memberCustom": 27,
   "memberStandard": 38,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Other Financial Information",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Borrowings",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Fair Value Measurements",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.exagen.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Stockholders' Equity",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Stock Option Plan",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Income Taxes",
     "role": "http://www.exagen.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - Related Parties",
     "role": "http://www.exagen.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - 401(k) Plan",
     "role": "http://www.exagen.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://www.exagen.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - Covid-19",
     "role": "http://www.exagen.com/role/Covid19",
     "shortName": "Covid-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Other Financial Information - (Tables)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Borrowings - (Tables)",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Commitment and Contingencies (Tables)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Fair Value Measures and Disclosures (Tables)",
     "role": "http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables",
     "shortName": "Fair Value Measures and Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Stock Option Plan (Tables)",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.exagen.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets - (Parenthetical)",
     "role": "http://www.exagen.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets - (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - (Details)",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i9199af1acdba490286a4ab9fdd0909e0_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i5690cf2946e8412bb86195a6c74a9316_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails",
     "shortName": "Other Financial Information - Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Other Financial Information - Property and equipment (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails",
     "shortName": "Other Financial Information - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Other Financial Information - Narrative (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Other Financial Information - Accrued liabilities (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails",
     "shortName": "Other Financial Information - Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Statements of Operations",
     "role": "http://www.exagen.com/role/StatementsofOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac6c4076618141cbb3d72f35bc91b3a9_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Borrowings - Future minimum payments (Details)",
     "role": "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails",
     "shortName": "Borrowings - Future minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails",
     "shortName": "Commitment and Contingencies - Minimum annual lease payments under non-cancelable lease arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iba13f5e80e074fd6b19a2bdd3acd9e2c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i3617efc1423e40249453b903e951175d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iaf86d568866c4251832b028da29ff071_D20190701-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "exdx:TemporaryEquityDeemedDividend",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i9108d9e9df164e8eba47e0ed7eb067a1_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "icc003e40daf641ccbe499297076b288b_D20190923-20190923",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Stock Option Plan - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i616b08c4738d433b924c1dc44c268b4f_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "ibdd8f716641546a99b2b0acc6ea44d50_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "role": "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "ibdd8f716641546a99b2b0acc6ea44d50_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EmployeeStockOwnershipPlanESOPPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "ib1c2da91d4274340b7a12109641dbffb_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i616b08c4738d433b924c1dc44c268b4f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)",
     "role": "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
     "shortName": "Income Taxes - Change In Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exdx:ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.exagen.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i161aa9f12f5040b598e25e1d7896f041_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - 401(k) Plan (Details)",
     "role": "http://www.exagen.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i9a7dd8fe1c69457ebd695bca19af30c8_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Covid-19 (Details)",
     "role": "http://www.exagen.com/role/Covid19Details",
     "shortName": "Covid-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i9a7dd8fe1c69457ebd695bca19af30c8_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exdx:SaleOfTemporaryEquityPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "role": "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "i7b1f74c554494d0aa167b4a49c8d556e_D20190101-20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exdx:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Statements of Cash Flows",
     "role": "http://www.exagen.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20201231.htm",
      "contextRef": "iac638a334d2d4a41982db55571d79004_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Issuance of Temporary Equity",
        "label": "Adjustments to Additional Paid In Capital, Issuance of Temporary Equity",
        "terseLabel": "Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 7)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability",
        "label": "Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability",
        "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liabilities as equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value",
        "label": "Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value",
        "negatedTerseLabel": "Accretion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends",
        "label": "Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends",
        "negatedTerseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature",
        "label": "Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature",
        "negatedLabel": "Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AssetsUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Under Capital Lease",
        "label": "Assets Under Capital Lease [Member]",
        "terseLabel": "Assets under capital lease"
       }
      }
     },
     "localname": "AssetsUnderCapitalLeaseMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CapitalRoyaltyPartnersIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Royalty Partners II LP",
        "label": "Capital Royalty Partners II LP [Member]",
        "terseLabel": "Capital Royalty Partners II LP"
       }
      }
     },
     "localname": "CapitalRoyaltyPartnersIILPMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In The Valuation Allowance For Deferred Tax Assets",
        "label": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "terseLabel": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]"
       }
      }
     },
     "localname": "ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClinicalStudyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Study, Policy",
        "label": "Clinical Study, Policy [Policy Text Block]",
        "terseLabel": "Clinical Studies"
       }
      }
     },
     "localname": "ClinicalStudyPolicyPolicyTextBlock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_CommonSharesAvailableForGrantUnderTheStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Available For Grant Under The Stock Option Plan",
        "label": "Common Shares Available For Grant Under The Stock Option Plan [Member]",
        "terseLabel": "Common shares available for grant under the stock option plan"
       }
      }
     },
     "localname": "CommonSharesAvailableForGrantUnderTheStockOptionPlanMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CommonStockOptionGrantsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Option Grants Issued And Outstanding",
        "label": "Common Stock Option Grants Issued And Outstanding [Member]",
        "terseLabel": "Common stock option grants issued and outstanding"
       }
      }
     },
     "localname": "CommonStockOptionGrantsIssuedAndOutstandingMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ConversionOfTemporaryEquityAmountConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Temporary Equity, Amount Converted",
        "label": "Conversion of Temporary Equity, Amount Converted",
        "terseLabel": "Conversion of Series G to Series H redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfTemporaryEquityAmountConverted",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]",
        "terseLabel": "Covid-19"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/Covid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Other Non-Operating Income (Expense)",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Other Non-Operating Income (Expense)",
        "terseLabel": "Other income, net attributable to COVID-10"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Proceeds From Loan",
        "terseLabel": "Proceeds from Paycheck Protection Program loan"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Repayments Of Loan",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Repayments Of Loan",
        "negatedTerseLabel": "Repayment of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Revenue Performance Period",
        "label": "Debt Instrument, Covenant, Revenue Performance Period",
        "terseLabel": "Term loan, covenant, revenue performance period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRevenuePerformancePeriod",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPeriodicPrincipalNumberOfPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Principal, Number Of Payments",
        "label": "Debt Instrument, Periodic Principal, Number Of Payments",
        "terseLabel": "Number of payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPrincipalNumberOfPayments",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included within Current Liabilities",
        "label": "Deferred Offering Costs Included within Current Liabilities",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued and other current liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedWithinCurrentLiabilities",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Liabilities, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Liabilities, Percent",
        "negatedLabel": "Change in fair value of preferred stock liabilities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_EquipmentPurchasedUnderCapitalLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Capital Lease",
        "label": "Equipment Purchased Under Capital Lease",
        "terseLabel": "Equipment purchased under capital lease obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderCapitalLease",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInFairValueOfFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Fair Value of Financial Instruments",
        "label": "Increase (Decrease) in Fair Value of Financial Instruments",
        "verboseLabel": "Change in fair value of financial instruments"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfFinancialInstruments",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Janssen (SIMPONI)"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JointVentureQuarterlyPrescribedUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Prescribed Units",
        "label": "Joint Venture, Quarterly Prescribed Units",
        "terseLabel": "Joint venture, number of units prescribed quarterly"
       }
      }
     },
     "localname": "JointVentureQuarterlyPrescribedUnits",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee",
        "label": "Joint Venture, Quarterly Promotion Fee",
        "terseLabel": "Joint venture, quarterly promotion fee"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFee",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "label": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "terseLabel": "Joint venture quarterly promotion fee cap"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeePerPrescription": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "label": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "terseLabel": "Joint venture, quarterly promotion fee per prescription"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeePerPrescription",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MilestoneContingencyFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Contingency, Fair Value Disclosure",
        "label": "Milestone Contingency, Fair Value Disclosure",
        "terseLabel": "Remaining milestone obligation, fair value"
       }
      }
     },
     "localname": "MilestoneContingencyFairValueDisclosure",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MilestoneObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Obligation",
        "label": "Milestone Obligation",
        "terseLabel": "Remaining milestone obligation"
       }
      }
     },
     "localname": "MilestoneObligation",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_NoncashExerciseOfStockPurchaseWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Exercise of Stock Purchase Warrants",
        "label": "Noncash Exercise of Stock Purchase Warrants",
        "terseLabel": "Net exercise of common and preferred stock warrants"
       }
      }
     },
     "localname": "NoncashExerciseOfStockPurchaseWarrants",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OperatingLeasesRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Renewal Term",
        "label": "Operating Leases, Renewal Term",
        "terseLabel": "Operating leases, renewal term"
       }
      }
     },
     "localname": "OperatingLeasesRenewalTerm",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_OperatingLossCarryforwardsNotUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Utilized",
        "label": "Operating Loss Carryforwards, Not Utilized",
        "terseLabel": "Tax attribute carryforwards cannot be utilized under IRC Section 382"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotUtilized",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20201231",
     "xbrltype": "stringItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Temporary Equity",
        "label": "Proceeds from Issuance or Sale of Temporary Equity",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfTemporaryEquity",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of Temporary Equity and Liabilities to Permanent Equity",
        "label": "Reclassification of Temporary Equity and Liabilities to Permanent Equity",
        "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liabilities as equity"
       }
      }
     },
     "localname": "ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_SaleOfTemporaryEquityPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Temporary Equity, Price Per Share",
        "label": "Sale of Temporary Equity, Price Per Share",
        "terseLabel": "Sale of temporary equity, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfTemporaryEquityPricePerShare",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "terseLabel": "Annual percentage increase in shares available for issuance under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "terseLabel": "Increase (decrease) in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Estimated offering expenses for aggregate expenses"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "verboseLabel": "Net exercise of common and preferred stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common and preferred stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityDeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividend",
        "label": "Temporary Equity, Deemed Dividend",
        "terseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7)"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividend",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityDeemedDividendSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividend, Shares Issued",
        "label": "Temporary Equity, Deemed Dividend, Shares Issued",
        "terseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 7) (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividendSharesIssued",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividends with Beneficial Conversion Feature",
        "label": "Temporary Equity, Deemed Dividends with Beneficial Conversion Feature",
        "netLabel": "Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock",
        "terseLabel": "Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 7)",
        "verboseLabel": "Beneficial conversion feature, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividendsWithBeneficialConversionFeature",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Issuance Costs",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock",
        "terseLabel": "Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock",
        "terseLabel": "Issuance of Series redeemable convertible preferred stock for aggregate proceeds, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquitySharesRedeemedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares Redeemed upon Conversion",
        "label": "Temporary Equity, Shares Redeemed upon Conversion",
        "negatedLabel": "Conversion of preferred stock to common stock in connection with initial public offering (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesRedeemedUponConversion",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquitySharesRedeemedUponConversionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares Redeemed upon Conversion, Amount",
        "label": "Temporary Equity, Shares Redeemed upon Conversion, Amount",
        "negatedLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Note 7)"
       }
      }
     },
     "localname": "TemporaryEquitySharesRedeemedUponConversionAmount",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease Recorded As A Benefit To Income Tax Provision, Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Decrease Recorded As A Benefit To Income Tax Provision, Amount",
        "negatedTerseLabel": "Decreases recorded as benefits to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount",
     "nsuri": "http://www.exagen.com/20201231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r249",
      "r253",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r278",
      "r280",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r465",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r278",
      "r280",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r465",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r249",
      "r253",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r165",
      "r249",
      "r251",
      "r437",
      "r463",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r165",
      "r249",
      "r251",
      "r437",
      "r463",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r259",
      "r278",
      "r280",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r465",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r259",
      "r278",
      "r280",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r465",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r208",
      "r279",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r41"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r41"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r191"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r26",
      "r314"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r282",
      "r284",
      "r317",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r284",
      "r307",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r78",
      "r392"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r146",
      "r157",
      "r163",
      "r173",
      "r362",
      "r364",
      "r380",
      "r441",
      "r453"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r53",
      "r91",
      "r173",
      "r362",
      "r364",
      "r380"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r285",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r16",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Capital Lease Obligations, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Capital lease obligations, current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsNoncurrent": {
     "auth_ref": [
      "r45",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.",
        "label": "Capital Lease Obligations, Noncurrent",
        "terseLabel": "Long-term capital lease obligations"
       }
      }
     },
     "localname": "CapitalLeaseObligationsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.",
        "label": "Capital Leases, Future Minimum Payments, Interest Included in Payments",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Capital Leases"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.",
        "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r33",
      "r80"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r81",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r86"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r381"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r89",
      "r91",
      "r113",
      "r114",
      "r115",
      "r118",
      "r120",
      "r124",
      "r125",
      "r126",
      "r173",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r238",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants exercised common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r207",
      "r446",
      "r459"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2020 and December 31, 2019; 12,652,308 and 12,560,990 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r167",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r167",
      "r377",
      "r378",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r167",
      "r377",
      "r378",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r127",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r131",
      "r132",
      "r167",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r167",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment",
        "terseLabel": "Contract with customer, timing of performance obligation and payment"
       }
      }
     },
     "localname": "ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62",
      "r437"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r63",
      "r91",
      "r173",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r346",
      "r353"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r346",
      "r353",
      "r355"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r346",
      "r353"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r129",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r442",
      "r444",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r43",
      "r221",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r94",
      "r229",
      "r232",
      "r233",
      "r234",
      "r390",
      "r391",
      "r393",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r219",
      "r392"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid expenses table"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r347",
      "r353"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r92",
      "r347",
      "r353",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r19",
      "r20",
      "r337",
      "r443",
      "r451"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r347",
      "r353"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Basis differences in fixed and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards, carryforward indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Federal tax loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r343",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "terseLabel": "Accruals, reserves and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "periodStartLabel": "Valuation allowance at the beginning of the year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r330",
      "r340"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedLabel": "Financing and acquisition-related liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Indefinite lived assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Qualified employee compensation contribution, amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Qualified employee compensation, employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r285",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r332",
      "r356"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r332",
      "r356"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r332",
      "r356"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Limitation of net operating losses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r332",
      "r356"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes, net of federal tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "Common shares available for future issuance under ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r87",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r123",
      "r174",
      "r228",
      "r235",
      "r311",
      "r312",
      "r313",
      "r349",
      "r350",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r78",
      "r223"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Revaluation of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r371",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r370",
      "r371",
      "r373",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r260",
      "r262",
      "r267",
      "r274",
      "r371",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r260",
      "r262",
      "r267",
      "r274",
      "r371",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r371",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r186",
      "r187",
      "r440"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r335",
      "r342",
      "r351",
      "r357",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r108",
      "r109",
      "r144",
      "r331",
      "r352",
      "r358",
      "r461"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit (expense)",
        "totalLabel": "(Benefit) provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r87",
      "r327",
      "r328",
      "r335",
      "r336",
      "r341",
      "r348",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r140",
      "r389",
      "r392",
      "r448"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r41"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r91",
      "r158",
      "r173",
      "r363",
      "r364",
      "r365",
      "r380"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r91",
      "r173",
      "r380",
      "r445",
      "r457"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r91",
      "r173",
      "r363",
      "r364",
      "r365",
      "r380"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r39",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r220",
      "r444",
      "r454"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r95",
      "r217"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r95",
      "r217"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r95",
      "r217"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r95",
      "r217"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r56",
      "r59",
      "r79",
      "r91",
      "r100",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r116",
      "r146",
      "r156",
      "r159",
      "r162",
      "r164",
      "r173",
      "r380",
      "r447",
      "r460"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r112",
      "r117",
      "r120"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncement, Early Adoption [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionTable": {
     "auth_ref": [
      "r102",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.",
        "label": "New Accounting Pronouncement, Early Adoption [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "One-time Termination Benefits"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r146",
      "r156",
      "r159",
      "r162",
      "r164"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumannualleasepaymentsundernoncancelableleasearrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r110",
      "r134",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r41"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r462",
      "r464",
      "r466",
      "r467",
      "r471",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPreferredStockDividendsAndAdjustments": {
     "auth_ref": [
      "r111",
      "r237"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of preferred stock dividends and adjustments classified as other.",
        "label": "Other Preferred Stock Dividends and Adjustments",
        "negatedLabel": "Deemed dividend recorded in connection with financing transactions"
       }
      }
     },
     "localname": "OtherPreferredStockDividendsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r185"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r261",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r285",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r5",
      "r7",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r310"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from sale of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r190"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r192",
      "r458"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r87",
      "r192",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in next twelve months"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase obligation, due in second year"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred\u00a0Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReorganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reorganizations [Abstract]"
       }
      }
     },
     "localname": "ReorganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Principal payment on capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Loan repayment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r323",
      "r482"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r86",
      "r439",
      "r455"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r78",
      "r196",
      "r200",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r235",
      "r314",
      "r456",
      "r475",
      "r476"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r174",
      "r311",
      "r312",
      "r313",
      "r349",
      "r350",
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r155",
      "r160",
      "r161",
      "r165",
      "r166",
      "r167",
      "r248",
      "r249",
      "r437"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Initial public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r131",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r284",
      "r306",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.",
        "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]",
        "terseLabel": "Future minimum payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r86",
      "r439",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r198",
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r285",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r290",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r89",
      "r124",
      "r125",
      "r224",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r238",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r128",
      "r131",
      "r132",
      "r133",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Common stock, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum Employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares reserved for issuance under Stock Option Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Employee options, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r292",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, December 31, 2020 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2019 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2019, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, December 31, 2020 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, December\u00a031, 2020, December 31, 2020, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, December 31, 2020, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r283",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r303",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r188",
      "r194",
      "r197",
      "r203",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r89",
      "r91",
      "r113",
      "r114",
      "r115",
      "r118",
      "r120",
      "r124",
      "r125",
      "r126",
      "r173",
      "r228",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r51",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r123",
      "r174",
      "r228",
      "r235",
      "r311",
      "r312",
      "r313",
      "r349",
      "r350",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r123",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r228",
      "r229",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock issued upon conversion of redeemable convertible preferred shares (in shares)",
        "verboseLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Noted 7) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r228",
      "r235",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in Shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Note 7)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 8)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r91",
      "r170",
      "r173",
      "r380"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio, common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r388",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r388",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r388",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "verboseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock",
        "verboseLabel": "Accretion to redemption value of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedTerseLabel": "Accretion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r12",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Redeemable convertible preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r326",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increases recorded to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.Q)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187283-122770"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45023-112735"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121638524&loc=SL117422543-158416"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=d3e14931-158439"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782768-158439"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=SL117422267-158473"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r486": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r487": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r488": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r489": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r491": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r492": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001274737-21-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-21-000015-xbrl.zip
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M$NR")P^!]>Y8]I0R*1A.>+<)'D0*LOLT^H4%ZCO>T 49_'G^9M?<VZ_Y0&*
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ML@21K4X0*<1_H$/^J9##?P!02P,$%     @ P(IP4C%9#)E5"0  16,  !X
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MD 'CV$VC:GDH^1^( 9!.B,Q$<)-1G$H@=V,UC]BB>B_$HKH ,+"@H=+Z#-$
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M'I][GG<YTRL'-\M5@0\M9G(M+&<.*UHHF!V0B]1;9.EU%"JX4*\Z_*50 3\
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MW,PB$'!1'\NVLV@0'#%([")-\HB4 ?Y1QVSO>J"9G"6S4Q%+SZ>(+OY$0C4
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M:Y64:#*&2@S!9ZS[YEP R,D"G:Z%?P<Z_Y:70:#RG%-:R[%!J\O4!LOFAJ(
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M'+XV0&0_%@FX%BDC-6'*L-Z%/PJB+"CG6) 0J)R^7$1%2<A59QJ]'2&U"CF
M4/T6T<KY"ZI.@4'(_6%1=E'AFV^NP/2SA8CL@QXBK[^5<L/77)-RV_%WNW2;
M[P4&9->YYT3.;.6#WF.<K=6%&@1[IL#93.6\=Y850M2+63AV7,+^1UN* =VK
M'4G/VZ'.F[YJDR6K9HIC:,;+NV)'37H#L$C__K>CYS_ G%_Z&8(_V@NE-;!^
MJU<B6+(2H*_3X,[@'9Q;"?XI]A:QST>BC>=A_)E.12H/+6[@3[?>SL'^K@>#
M619!^6(SO::)/4L+U"E4#ZIAEV"AJJL4?ALT8"!8@$$4?!/DW@,7C(+U9.>"
M,H'A8$H*!-H]S,4RV!DVJD+T85TU&TC':?L"GA4%2&Y9<(F5-IY-$2F^1^%'
M,;^YCX8&<6Q6#0U$']HL@_L*16K-$%5Y;XG%O=SW0CC\/";I=.'1[386F5&V
M%-I]UL<DY4K/'"RL.'0K86D*\?.D^XT&()&[50L+!DX<GU3Q0_J>9@"+8:22
M,-?C.)1Q6(,/XX1@.JEH03XS?9WGF]WEG</=)3'SMCWFQM'K8B#PWB3U8K_0
MA=C/&I.K/BVBK+*9ZR43NKKI 0M\L)F8N+OX0/KE17TUPJ.E9);>759!#0%%
MOSZ@[QYH5+Z(7ME,/-DI_+A0-'_>*"2.C+42&7]>,/#@(1A(,KB96#)'T?=!
M]/@8(_(&DSV1O#.3PENC>"2(&Q@3,Y\N]% *&YN(?:DE= )M=+CLM)%_!6F)
MH2[T"_)=]_0D43]CT[[EI#+%-X=F-PP\E[X'3%]W.'#XL;%-0#@XJ+%; C+;
MXQ>JT [K\A&1?I!>4ZT[S(&/?B&=N_Y5ICB[U BW$$N+R:W?\F%OO!@T>8GC
MV7+QI]4WD+8!0I4$MB[,553$MTSK P8#TXSHN$"FR%<50T10]K0 YD9F&31Y
M"HR*T%*>][-0>_C7:11JCHPP+2<%AGX*-"KPE9"#VMQ\X$2CD/<&2TFK5]#C
M>3'R"$37S^Q'K.G0/W0\&-FOU8G1 HI3MBBS16JX6R+I*1!]E0K]7JN\S80H
MMNWJ/NB^>Y7Y'3Z<NR*$FPD\;*\L[H,8:MS,O3&&=YX^#1=03O)5+]>9/N(?
MI-A_2WRL%L:!8V745<9MM3]3#:C:J,/2D(JU9B64#^.%QUFRO6W?BYL)O#P'
MR]+O!Z/E_2IY#A^. !*[S01,VA#<:S&.^R"!-I#H-.AJM>1!-7(VMQ)FE%()
M0KF9"ERPF/-2LA=&?,VIHIVT?BY3/P-^2QIS?(\[?#,QJ4L#XOW:[*W9,7[]
MK]$%ZBO([Q:"HPY["([JLQHYW$RH\&5:^+$AK>B#WGB "]][Z@YZV41SK*$2
M+F,V&F0,XL+@V#0*UGY>.4UF1?:TA6F@'B!I;_T,#I[ATP'U;)?O5-,$].5!
MQ1YM#_,/"%DRO>5<1 6 @Y'P.E21F@-,E$ILFJ([(['5^^"PE_O D9*UB_I%
M.?E#J-"=<.^122P5]9U [96S!:9(L'#(5**#$%+N VPWWTF<V?+W_C?2KNS>
M'IQ\NP,Q;YT3$!F=8YA[BT0>8!3S#X?.7GV"U<DE^97K9M)Z(0=XF5G#ZI_Q
M>T$631 P@Z5AFM0_B/#?,C8T_[9*C"U>YM:V]Z)ZLA2\\X^*NRI01DPC<.2K
MB4(*#F)6S4"0KC&P&2MCX?N57>(.H5798B0@5-C\ "?'UOI*>P)3P"9-O\N)
MH5Q@EO^4U2P3@U-?!?HI;Y*(8*0X*N2!F+XEQ\,F8/$!\/P*05A2GYSE[[^S
M\NUV]2!OW7;G'=GDZ@%4O1'&KF&E8&>PS RLD,AZV=2F'Q2N6%4'LN,RDE>;
M+=S,%'^_WC:TTNYFU^H:;&\28ZH<;YGCR4M!H<A2]\)U=/#!$F/JGO8(59*C
M2LJ+AY-05,I1+T_"?D4EO_84T1U?4>_V8(5)VZ*@VU%WR_5^F@ICF$6N#+I=
MLZLR;L"7_J0$)/7DR6OZ'K4G7@(F CQ0<<5@0QDCG26-CSM<$0K^6GG-S>KT
M)-HR#J*C[M;D_138^AKW@% 0A/>43V>G*J0JKTOEE)R3I&'^MN(&N"\;UY4-
MK*&,,*]*UC])D\>9NG8JIGQ/,K;+L'@V.\KFG?-*U T,S ONW@:;Z<]2Z!ER
M#PTCW*EAU4!T80IL"BU\,I*U>=<<::U:N;E5E]?Z?C$#:)4;]64/+RD[[>D>
MKM92]&,+7[8*:XN$8MYUCIA7),?!QGW2VJ@ZJ(<JC2^7M&V)[3QS,,,ML[_C
MYTY<':Y_F/#."7?<U(4?L;AZ<3E?@/:?Z]*FP_VO\HK/]X9/5YG#9F*R2!>O
M'A_NO<"OPZK#[O1C4<]8D\7S6\S6*LDA*!![EG7D=E?TYI=7?'_SH7T?!V=W
MY7\_]<7:VUQ4XNQ,M.68@::4-U0$=&@I!.>N?93MP5BF'Q>S@*A>X-%14K*U
M2O4:R"1GW;)Z>?!5EI8+N0&5=.25]!1-5-T^;JW6KOF(8>KE*1OD+>8K-W7&
M;M1DQU)%"KJ/-!ZRY#,5S2?P(JH58DMW)#[T!?.AV\ZR=>^VRP/0M2RF""['
M0*5CE#B&1Z4X-??G2L/0O!A.RIC\ZANJ4>=P(_H/:*^LA%N>^:%P!.!4B3ZK
M/[3U'C)9.9XTG(K4E[>HQUT0@D(*_Y4/^X"[6="O2:A_Y*YIRWI;V$)>IU?'
M0RN++]BK06%?W-0A3ZB+-6>?G?TVI>HM1P=4MCVCVD&_H+0)>6IFEM'9^AN0
MD>MK$X1=L*[O( ?9B78%M,:3[:I9R>IAOLD 7'$E3;E:A%00!26F HP]:&(Q
MF^&KT4!(XT-B_&H[$>"+F-53G[ 5KFW@+*$/?:<*E>[1_LN1B-0E<G%@=_ES
MD_FSV>(]O/#Q$+SIG:>[ ^YQ&U69.+#@$!,_-TA"6#(Q"1-YX*O*S]>JJ='Y
M\3@]+0>7KM  A4Z]<D7\330'6\?7LU%X?1S-HT(B2'H4!\^'STR*L9S ';Q?
M^5D7*KO&W-D#%-")?O80"GB/$-:W5AJCH-C5P4H\NR-*@@9^3E0RC:@(@8!
MY?D1X=ST)C(F$ID1;%@1+RO3PV@WM"7R L_$(P$45<$T:/PH.OSA-^Q1#W\6
M6U1O0_>\]W;D?+)OI8D_"HXF['X1=^P[BBUV4W+U\Z1U";5)WQ?K/FIU;@M4
MMCEC*V\Y4W$K:96?UZK<VY#A%6 ?<W$B0S>CF)9E". (S0*&JFQ5OJN3]:2?
M\MR#,KL6&Q'T.-*-79'Q'R5:S(A+@(I0D[0BRB;":&Q_$&FWU:#.S1(=0N%'
M3/]P9Z96T\[-%!.N*<F049KM"KZ34:J*\UYH5")%7%X[121GA94:=:\&]V _
MY:(?#?OZ[WGU8/]H7TMS]!T,F0X/C9&CI_PS>%@61DAN!#B\PI)8]01V'1J]
MM@-!4[38+5'KZNE3C6)"T6DPV7$L5V0*.?EB<</:/)&!%Z:*W#KZPD=A)-3)
M98G!T-^<YSP0^3WM)7#MC?$AOVO$VG)\VAI5?).;E0(M&O%<J?9M'+)1%UDA
MW*PH&3:56$Q5E+MQVJFT$LJ$N-,"=87!H1VGTG*L"U-LVW&^TB%ND<35:#O>
M5W"PMUXZ@4W-RDE#G)L!EBT$<#WKI5IQ8V^]T"O;( @;!CW]A<WS=<-^.AWD
MI15#I+)TP@QIT+!V2%)W+8FD9D :+SQ1"/FG,!@:<3HX[9:EV%H%\W#4JU>E
M<+U%>5Y6^QJU.FNKGB@="=-J883)F0G!'=U?DUT@OU"'KX:5(?JLD- A6KF1
MKUF0T"=T OOMDT;Q:-4Y>7IF!AVE*; XD?0O0PJB "<4K>8P74B!(E4,\6"<
M6B#*;/G:VJV6C]P]3Y@4J98)+3 9GD64)TN]'7]7#YT7I-I!P"$"]&_)$*]-
M;?=\:9)!+(E2F90>HRQ18^'"_^05.DAFZ,$['\]9D<ENQ3UI@P'\I:6KMJ3X
M2GJALX:A75/HC-8ZM=6@9W,R2V_0M%OOE,C> ]O60@.'+D4E2G?#A#0="[.B
MO?B+FA.C2I FVXY:,)J [NDH HQZ93:A8:Q98\."JN-2"S*^D=9?"@X)=;)5
MMLJ&51V\3XE(U8^]B^C3X[<IHDU.0)NMNVBF,RY;.]FKN/PDE5Q=7H-^MI1H
MU@X:">\0H AF@G$W$BVR4,?.GD02*LSQ ) &$GARY9R;UD09JS3(Q4,%4_4'
MNSNC7<0HX &S4GY_MKO[>78.G+UF<'K^*I3$&?V;4_O?@$XZEU'Y1KJ!Y&5<
M,,@6#A4*XB*<"Y\:3;BV@^>\:[BO<;A8<R*(";:\=&.2RML1RRY(*=JK&!&7
MAVNL1::NH[1$I#3: V(S&>4XC;(<C+4RCXCFH@EF%?P5A_KJPK"C^\)KT!9!
M@LI%FKBH$4D9!WYB9+!C\ ;UP&.@SB9+YG#@6;Q$R] [F2EWNX(<.J+A3C>A
MI!\C2KJM(" HYR5#)_3')$4.X,YB20A$IVV[ELQW):I:GVH],Z96F'/9WZ).
M> LQ(T][B!GI\TF_8?G6B]K1)+"I-9_SHVZ&^VH0MM:N2U,1-!C8NV,"[.E(
M&ZZV$T8?+JZG3YJMR0:?I(DNXD7$\E31NP25MG=\Y'=I?3HPT%@V)T^#8]F9
M"LD&DYHLJH7 ?IQC2'LU V1%^X-S;6U3RQ0<;?.+$'&8!RX%+9Q7<MYWH-^C
M^5%UP/HZ>(,X H\$+]0V';[X:L.]IVP?^_-)%OE?*S"[!:E ."TW2RF>NY"]
M]28*ZQ';U@AD!6+H=,]H\,;4O!L,TUD-ZNBS2D2LK6I98Z%7\$ .P7S?&8(1
M?[TKQB#&D8G^R#'=JXZ9.Z9*1T%L;K\H\-M@]](AX/3=.P&;=3Z!WPZ'N3%]
MB7"T:L@W.4BQ7CT!N_0&*8(2/D.D1E9LV8JBTU-?0?97<9Y10GVIZ5'VQ/*Y
M_,,Y97*. M/C=7PY4]4[FP.IY2$V*%/XG\B<QD?:%&.;Y9^A@%GFI"Y!JHS9
MO&+E^'7JY>/H3XQGZC9OZI.T7-%Y5WY).4&W*O;3V0"EG\KOU($5KUGU_5PW
M-5!QZ%U<I4EK&BL58C/"9HM9H! #AV+!=IIV5MN)RETP44U[&I5%&04=<] /
MT?N*V3(TDT0]Y;1 4R?/(YOC: R$/72S9UVH@8, M]MXI;=LW@Z-I(BGN3Z$
MG T_3O+!]*/ZY0E%S=#R$O)0U&48&R:IF"C.&X9,.6@?@IH*0QF@=^T-L.<]
M3DU1F'E?X:@YV)E0R"B**&+T80;:YII*J_1]ZY,C1!ZY<XD39;"V*Q^E24G'
M"S:< N^6%\;GAI>ZB:R^BV-26[80N;59$O>B6H*NVB9VJ\W'YWOK5:#M4!"+
M)/,L+<^Z%>9VB\F& 4)>8^P2!,<[]A?]RZN(P=;AU$=- BCKDSBA$GV^A,+5
M.5'V+]2>T#UKG9J_N^[&C?P24?\,&[Y_,ZJ!8;9TJSPIP4&1!3=.5#%C%PSC
MRS(T<?5+F@Z+N]X.*OBJ=5W%%=B1X@.:D$'P;Y2M-V $=*8#2HS3[ST4O7>,
M]-K_=!R7'7(#4R[0P/3XKF.A!9BJ0,A(-$<3M#U7\_+ERPTH"QCS8"[]3WU8
M!UU4*<A^_R.GMU"N VJO*DC=L.1)%FU3%2@;YIA85&_-$3AXL?\+EU$:$-/R
MK=O*KM0%\&([3O*&BM^7R+6)@1G!7TFM<:K1!I;6N*T@U-RIZBQ81%6>LM)-
M4K>3>\L<17F=9L]* H50T@2]H2DALO#C1!5.R(/FK7I+:KB7I_H=J4>N+"0\
MJ<@0&R)JK7JOJ0H1_S@@M#:;_7$:P)U!%V(Q'VPT=#]DL?3M:^.Q#VN3&G(+
M9U3[5!9,)*WF()\8C!=9XELP1S3<F$%H_/>"LZDZ)[GD-79Q7J_(GY+0$T8\
M=#(4 6,K3:7)9-I'T5+NX,)\^2EMF<JB$N!R1,-XP_7(7T.#PN[23-%ZE&72
MD]7K>I%O4?6\A:GB9P^IXGOY*QL&"CM6&56J@II 4O=UEU UPX,:P,2D2$)9
M+UI.IT]<O=;0QAR5Z3PP!YZA'KWKX)6@';HK"PG<Z];D<'V[:D4N_1N?W!O=
M/(;;%C#&GOX TY;@L4 >  ;AJWD;DUT50V/U!"\/"^TE.+X&9BX0^)E4U#2C
ME0V5W)T62/>=>!J,+WF38;0/;K. %10.7_R"8?X:>.S;41$S3&UZE=#I(+>C
M%'Z4S3? &C^U@_)&V$ CS?KA'YF^1-6FRTX-;+NP@8DR*VW ^#/%;N=@UXT!
M=)KUU2\=(2)R5^J $P_,GZ#4O4UJV[<JK.T6V8K2ZDAIVVH.G(G*;0*SEEG%
MW)A@$W()))-H)Q0D']Q[_HX0+<E<-9\"IU>7K!-2U8FY9Z"G/@(!IYH0KOO6
MASC%,5J75?.X=6"L(U!O&3X5?(UK/RZ5SBHB8S=Y1SJV(P$6 YMI"?](!^ZP
MPR$T<767$Y %N6V-V@J7.+$$SXD6L6HDEG)R*'="G X>WM$24_*[B["^Z&4@
M_BSUWH*A?-6#IES>60<-B-0+4>@N5^JCQ"(<*!=*/QQ_6!$E6?T;IN-F#P8_
MG_,H.ZN,.VJEFGZ>2>JWW*22WM?>$T9J3>RSHL$T6J,".:E!ZE? R=<BMZ(3
MMVAKO>SEUKHH SQ&UFR=W#DUVR >&Y;;TK5@/9&@1F?0*"DS4WE@+) I-P'1
M6EOW*R-0KEOA1AY90<!;&1V'MG*DEL&VU2/6L/RAMZ.=4>931GV)=Z:?N;,/
M?PQJ%MS98$8$@T0O,P"[+[M2&9N3:2P JT$=;64J*ZC4ASKW9376)_IC!51@
MM*^I>7'J9V$LRAP'\$LICBA%RJEE'??Z9F/85!KFM6=L+U'%RTT+[[A']B9N
M6Z)D 9$,%%E!DV977B/P)H",0')U19QI5#">%!2<S0?"JT:>G.]6R>4#9]</
M/'A?_,>48BG\;JC P:"?N"VDRLT>E9<.(A_!5ES55DV"A]P2,8J54WT@!)ZY
M6S/5["ZL<TH#SZ2?V^&U'8Y/,^EM\D]F,LS4U6:,>X&Z$V5<[-8</&4LMD@=
M#/=[25S##4;7O<NQ@2FV=2T3(;6N]J>=HV>$9VP6Y70>=R <,9>?107C1T(W
M'% I$J+BP["$,_$*>YKC\8N-3!&&J.+HFD,O4_\3_H/;+F;TBOQ$4:F%))J0
M=3<A*&7@9QEQ]6?>;PF59UZ@A.=>@,U:"/V'-\!RF*+,$A,:1L^0^$M1SX38
M_U<QGUT=NV^2P7(9I1SQEO8/B3=%M6'VLSZ#G3:Y4K_?=0N!E;A:!4E$:-JF
M\-I1/E.&JECSM)A)KZH55$<,S$G,B"HQ1?U.SL/Q81,7,=ELXBL!G4KI\H#B
M78M")\6I:2[27S($'0\(>88EYG1ZPH,DD(DG4$Y9FFU23L->NI_'S%[Z/DL#
M%<+!SV'%43:)^M""?:O$8]/<3Y*<-9]J0OB%:'E'H0HY4EI4@H)B2X'*1Z<*
ME! Q]U(542;-SS52OP.-1+8D&*1,4C-@!"4W1>]_0HS6R^]'BQ"8X#A2U[H:
MJ]+H@T&9L!^I;]!<-W@RM#QBD7 ;$+D:+Z'"B]K5TR@LQ0^HV-QLHV2*>9D?
M\"4.8F(C\"5K4M(%NJ)@UA:18MXR(Y)Z<QGG2UQ>_+(KUM=1RGQE4OK"H*Y*
M&95[.V\.XV6+LZJU!HY-.+#6:,5B(]<^RETB-:$7S'4$2[C+#;C</)=P$IVO
M://'<@/_"CWGZGY#8Q]?&?2G\V=K1M9*;KN9<@9=!'OTVE%A$^>TK2F]"!J:
M%/I51ET/B&P%!CYUZUQY1?*T1-]")^-E H@?H7),T$I,%"U&J+/&+_>9:MO2
M9YLN568J&;OZ,0$1)"HOR]7R,4EO#*1CZF/[NM2MF)7S*>?^9P--1="<*PQ<
M<GFI87^QXB$1GNHWI!NM]$SVS=L.\ W$7QIHS'^0+F[U:\J"+[2]R&&&2<Q>
M"Q^7IF)L:#JJ;GG=#,[$)EIWUB_H08RR*L&HH8A.CT]]+8U3V0Y8 ^DHJ!VI
M.P5%;'OX1GWOX7O<IVY\B%BC28PX8$'DA12T24/8:LTP J'8X6(,TWI8D$[+
MF"MWN5@/53H38"[$Z0X@H6/+!=IV&WP?TP">#3^,GU+(6A),OG5IG7I=$"MD
M_IJCUD;X3Z[;Q*F<8US:$&5=O$/=!Z(V=L>4>[&%BN/1N01T.* %,\(9>@&_
M*#C#HDE5<MN.6WKJKLA_HYZXJV8BRJ5]W!6A'A)'OWME;FN[S5OH4QQS3\XT
M.2]'3X7S5XJBZ0O;KM,/>AEM/DY!1-$'WNIZ9EB<#0NGG"M,;W&XU*SANG,&
MRZE-+$V"26E+HZ7V@LL&>@H4E:.PF+T!K<B%<$374.+MO8NY3V9HB+]UMHW+
MV^RD!GI208OO7>U1NG_*'!4^$N@.""Z) (# M, D "5BL8K(_@$\$$3C7DD=
M*KZ!;[K]&@B7AEJ;LC=0U\6-4HTFQO5.%7QLUML8:^Z#KGEH]-5 !TX1KD!@
M\FTS86VAM*^VT"A)U*=^]27>=LVZ8:[,.6<#8?.\I^A@L6Z&Y:^M5E6W5NU2
M'Y(QK:8/*:D'*D3_&J9!R2AP+D@ERWU!X23I=.KTEM!?6LB<4QDXH46XN:MA
M!9C=YF#KQP-NXIZE2134X%91]WLOTCQ7>2X0+:*F3N/MWI^'O31+WT9Y ,>1
MGZBTW'+3]'#33-,QF$@9*Q5.#Y^KV- 6OJ-=/-)6SKI-UDL3I"[2*]8PQAHT
M"H3>G6$YNMM-"]F)C7>+B<>6E.+9H/DQ9"Z:_AR?H*K(&OR[-F0992,Q43%Q
M,8&H0@J8WTHK>X<JP251P.NKC]4F9:T<8*"M1J1'G#&Q6*T=F@M#)2#M)(_"
MB!KVZ._2Y/&WVV(3K6."%;APF1@ZSB4,UMN&,:D7EA3P*=P&&'F3&\)!YE4!
M?=52NCWO]2TO!2\VPV8JQ1I^@$F(;FX8%^C7L-<##-S'*KR2+ <ME]NX:,,7
M$5<(?R(8%K;C#*4^U@)Z6G-#[31#]4OI3<V$NU-3\Z0<_)!3Q&/]J;12W!,K
M&H'C;MT*9'4EKXM,FO;)W-T=6!J/:MI*.)F7+#=\4EUM"5/F4IBHY\%I@H&N
M'%BJA>@B;C,OI=A![&?DJ[:\Q[W?P.%,L8]K64SL,HZ155%R#^ERIUSO(5W>
M/3FM@CRH":L^#LQ!*/6D.C:DB7X^\_#>=E-SPWSUME7N@TG9ECTW: ._+&8I
MJ^5VI +C<,F_-:US*:=BC135,%$(L<8I+1U+%-2M/D1Q'YE.O&1]S-P&W362
M7>F):UBOG4A#5SM=IV'ECM]O=%N;X/0"Z>:;JGO*C;*Q@##YB+#AQ"K>U8MA
MVS-LAYO6Z>4L]<YU&._89";ZT>\%]@2U<:M8V;4"#V2HP[0("*4D86YK1O.M
MC5/JU(OT!%=:$]6J$UN<$V[W:4E.,*.,H3N?"<YJ)?O&4G"?Z5RCV>]9F99@
M(0L)-+<6#7:YBQ6R3+MU_[;1* VH]M9H!NO&YDS<C4LHCCV\^BQ:M 06$@V:
M2C-#/'?LE_E656$=;EHK$B=O1D?DR+;EG-+N6//.?:_/#(*$@/"5\[DY+7SO
MF"MPB%J&XM_.L2W%/H35$8)@+=5A:YF/)S$,PXK5 NMI-W+VO)_Q4H=_\+/>
M5F@QY(T'C"Z*%/D-^:)M& (H-?M9?5I0'9*VF@0=29JE5JV*O+26;M$/K]$%
MP4)NBCQ85HYJMU;]4H&D6OG%=!+".<VW:]=O6 ^.BQ)4^O7:F\5KL.QS;Z>=
M[GYWX !JO9T["[8X"6>^<@!?T?G^71W@X],^IQE0IB[9V*#4+2?*JBS?VB_1
MD#TYB U28=L][6<;)OYUG\][9QDFUF^JMK<@MK8KD[8/VM/A-;ZD6OY!SL3&
M9=4D0M-NU19N1N :BU'==L%_OEF"_P$D:Y;&N# ]""QI:>L**9D\A7&[F*B9
M26UD*.A^"8E%7DZ1^D+<)600RQ&;72&Q'@B#M53HP%LE0F-MRB5A+\3^C723
MH,>HN%FT="^2M&7!C.]Q6[S8K&UA5@^4KS<BEB5<Q#5OD3';]KY;VF04-I\!
M1%Y)XDKDH^+-9[9UM;#Q+>G1:.H!?#-NLN1!KO,I2#?\S@5WNHM%E%"T8>"I
MR"&=BF_E7;@<58PGW$<NGLDMG],Q@MA:?LBI0U0PS$&EKF\'WI5/M!"2VR,P
M(O^\H"RTO!$.DKF+V2:$R1"Z0Z5YLW1,18], [=:.!LLO^A?G=0X\J7+XD H
MLP34RP74EMB*>\[ZDPCAN&W4-GO4;LSI(X;-Z,L&P* !#T O+\*8MD8/!%@(
MA'$C)PH+/I]/1$/ZYF(GS/U0V06N1FZY.N6J]#.P$.C].[A[MLL3?+E9JF]D
MRXW>^#<], HT3,:%R*!V2D"$IR7]1;=Q3A=@-!BJ81V&P 8L'<S&O^U=['DG
MV!BPT"&N-_X$)+>EY=_!TX/]O>'^T>.#PRK;#ZF!!?*MAY:[BTE]*,?$'&'4
M!U'Z%S;(L,;GIQ>C]M:[W&D#]6;DVMD<*,(/B? 9'X2$1O">I&+9325&(/SE
M1,%?89M3P;'3\8J>  ME"G7+7/B2&2OS1YE%>1@%NI,X5W/[-[D0ME-_S*]@
MRVPA>.+E1H G>J17A_N;I5A_AXD,H[7C[5&E1LFUO P#H@R-H3$V!*S>[,37
MWEO:O5W[S98V]^-26KXS$P^BDIR6V.P*[\5ZE -KV^4W#3<,'7WL+_H0,T,A
M#^15.G*\VNB%3Z^QJAG/8@(UVK.= A )6AL^X1'3BOT@'1<RZ:&E_0$T!!JQ
M8ENB87I(;Y<1/-PPZ-58NL_W0(Z5O JS"FKK4N-CJ]XEF*Z):HG=5KBC5X[8
M?I>"N&$@FM^TC].#U/ME0][PJ'90ZKI;%'MH3O=U<="TPZ8]M&FMGY9Q@QJQ
MX%I+B[G_T>EMR6H[MZ41$T7="#$:0NW[. 3+[3*$HL[1\ ;',Q KA1HL5L P
MY&SF*BCQ^5=,L^<%\$M$* $A?*K4+;<5!31J-YS""@3)D!ED,C*-2YJM+@:2
MMB3NID5*WIM+^7QKO\[4S]72ZD"7@[3"-"V7$<(G,7Z372M++(U+B9&T%!YD
M2+RL39<LG6H<BQM!DXB=\+ &IG>(\,*;^)?S%O3\2LLFS3W=.H^:_%5>JAHE
MP]?-3"+87M5\:5N/:OM%UR)NRH1I!;GJN/0"QXAO;>#6,4I$](4*7\])V[@=
M>NW,P+6T8,KWT]IRUP@$I#ZT=MG7/ V^DG^]6BWF?WN>_?]#X,$Y%/>[(P_X
MNE'X/X\B]7Q_>C1\/@W]X>1H.'SVXNC@Q6'P[.CY,Q4.AT]?_NOYH[5'*^9^
M=@4WDZ48UEJIKE'X[L'HL#F#>O33^?CB\OST^/+T][%W_.[W\=GH[/+B/@-9
M!1%0,1T?#U^LS78TG3B;_[VLE8C)@8>Y:+**-./C+?JD?H!1D6F:N19!'7!+
MYY#"DU@J^0TW"]R1F!CYB#:UEWA9Z!=^H]BVV4%&$!R:E=*?3J,83_"\&H>Q
MS/7I1$P\\2NJA13MQ49M'1@L2+GFH'!+&OMH03V2)4.&W*($.R1P1KOC&&J(
M2D2VR):W([*(6M>(!FL,CH&92(W3'N4>[TNX 9[+2#HV8AAGM3IAA;'6R?&;
M);1FT .3 J7R:0*ZMN VZ[@<9GRS*6'75A;H@FD[0BQF.76+U-T/6':BZS*^
M4M;@6"YFVA;%:MR:S>PN*@PFQVX(E$<6!&DD#5VU_>,P2#.%:7.!Q.;2'2M-
MY8^A0'87,^?6";>K3 .#Z/_B1+2N)CQ@OL 4:9[2ZTYO5S.R-EY+3CJUY =J
M,2.PL6;#U\Y=P7UVKL"6J)%*V2Y2F*-'K4H281#,AJOJVFE18;Y4U[AM^C'-
M'/6(#E2"?1V$_>IFV7BX!P458TC]!3YP>.#-80IG+D?NB:3H*GQ5W9/A@BMT
M3R\2,V+J0C@%=E <<" ^2$NDYJ(YLQ4IS E:QH7?U"=.W?<=IT6U**0@,NAJ
MK0JO4K-(Y)['DG03"; ]&7M@Y&Z9-K;-@V[5$6@T6?M,1PDL-(X-?>*2:75,
MD8OK).J2&_X;AS-(=!BV]F_Z!34'[.(8BWN$H-WI@^1_E(2TQ==+_]=*)TQ<
M<%":)3>20H.@N!5WDYOP6D:A)J,T@MNN4GI.$)09M3\AMQXD 1]MO$<$_A=P
MD$AP12^D2P8G5<KBK5.[MP(T%Z; C:.M3&TG)Z>UR.%&.K$%_L[D_]?2@U,O
M%_@3N'F6;1*,@U!Z.T.XBC:D&B?G\OU. [ES6X%D@*:FAGEQ1#"D:Y!/0?=(
MTLM'QJ>0IMZH'R-)<S6?8!N?%=31L@V(%U>V6F':X;@0)XJ.Z7>8<HG*7WF'
M[V(+?<?'<=!Y'%_8:)!&N.R$NU7[=^ R<;39N;H2\,Z]RDI*PTYBTSZYPD@B
MA$$M)#/,*8,BA87@)44EV5K+04_1#AAT'(V,JR,4#2DT2[:F36OB*_9CL3\Q
M+TA'I%@1,S^;3\M8 I:9FE+A>H*\QF!8X-/$)FDM]$3^F*5:QG9.H <;(U[S
M:CI"O2!EA%^Q7,3X,\IYP&T  \HM/I[39J $)<*CZ0M39H8#.<WG/, J0RC5
M%_A9V(P;4B^2RG%LQQNA>LL++AU0XJ' D:"X22$N 77Q,X<!(J2D&SI%SEV6
MK.]O^X6=VZ^SJH/"P:X#ZB(Y3=R6*H>3]B+FUB\;MX3)U 6JRT?3#FI"YP]F
M>_LP[UFB;G?RW5T^+7:B76SZP&S@P0S/?!(?;#.W2#/:X4A#2*0*QJLFF1+8
MO7;$,HNP0_!K@Z$*92Q*KI%Z7*N*VP$+KB"*-9T2CI& ?!>8H(D*?4R-/TD[
M-I#D>432/]@BSI[51%3BCX^'/82??>;V7]-,_@S'4!)@B.X4M&Y>9+<:19K"
MCR-+BX(B./X3+9"QM7;?+7#[E E:]'5Y/2/YA^LU-E7OJM<I*&R^YAW8] M]
MW84_55(M\ZOR8]@C3EFSN2WM&7Q62M"MG\N"V.TOP6C&O55_BQ:L[/_BA ?*
M' GL)]A=F-GQHZ8/, FEXNEC]^^FM@=36Y7*' K74&U.Z_4[L+ QP_/QE.\U
M(<LOU+>3IFV$$Q&M%UFB^5@&'"MCRUEJ-_(@3G-N<Z"M$B%$JQ0/WL Q4\1J
M$E-S(0MK(F/%Z5A15_8#.$*B7;?Y*O8WTY8;'R5U#3^PE8E\.)B(G$NMYSI[
M^:Y$IBEN;EF"6M;!A.*-VS%USC(R)<TA1*<>%;C3;%2BQE1R@S*,QZ1]V7H,
MT>:ANTY:7< "0_%C3>6.. OK46KN8>F_1%<C*KN,G(NNS%AUP%.%9!4Z$1)8
M"U@,CJ^R%>(A3IPJX2IO;;+5'1.)(/#W99:7/M?:#5]XOUT<V\+K%X>'.Y/=
MIF5/*'()\E%579!%:,_';,8'\%KXHU3-L/CA\[4Q@5E[TA455Q^E3B^KE6BF
M7*A<R!'GG,I:_OZWIR]^\'8^M8E.HV;0J"8[RVSX1D3>W"R$<AT2#FCA7,NJ
M<Z$  C#BVR\HCQQHQV6^W64A^5Q9<L4G$BB&F($R>[(V*+/(SEAF^#UKHG8;
MIK7*CM2VXU*XLU755*WMKB*#XX"\,YR2>4HV(Z%N,%W"2T?89/3 %JE*?-0N
M)4(F,H+4.">+-/JR@_X#] JOI]-G/&(01C6-X%:T85BMEG>PT)M:IJ+:D%,Z
M]NB1T&9)=)\SUS/,>+E)KTHS9PIR-'<EO2IL!L%D<YU<9[RFEJ6@@I44W=O<
M[10G#B=M2 YCN_K#X%5D,GG<\!AA=@OM +O#+EMLAQ]\"3#&</\!C?%9: S=
M:VPC\1C'?AR4]@"PW$(:Z66KTT>,E%MQE S8Y0;T9J>A_GR,)KB_R-4K_<,/
M&+>*_=M744(O2%_ZH7J[IS :2C' ^2GS1E/('XO(O7RQ=W#X'*6N %$K0OU@
M$<@]$L@G1=C\[/G>B^<'G9_N[PT[/UMVU\/AWM.#9U_^MD_WCHZZO_JYMSW8
MWWO^;+7;/J'YY3F&5<Q!\__/H\-'M84F?QO$D#(BH:>%63XMTD7+A^*KOSI8
M?/*&;?ND+@7S* QCM:;=<QFIS.P'F;1MGH]C/Y]Y%WZ,L"6C.!XFR$[0:8(O
MQ1W*YEBBH<N%O_!<9?S,[WDJC]^]/A\))79EVD0YU>S"IP=\(&V+_'7@=M>V
M&?%VG5/1Q?ATL/?LJ1/ 9:F6/_;%"!\>//U/[S7B3"I;>A&7N7=)^ :O?=?7
M;.&6!<G2&_[YH+XXVI3L6IYOL'APDS7-^/LL?9PA;G7$T+X.I;JSX.O0T<7V
MW[H4,RDU<($ZC]^D&?;G<)+6M\K/F*Q&]Q%OP5L)( 83EA7RLR+%T%GM&7 S
M\G#QSKO__:#D5]]<3P7\MH*&/WA^MX;_QONFAS-ZL+KT_;7)^M+2^?T>(/O[
M7^L Z?-Z]G!O&*AM4]L\H:"$$_7XO*+FI=5OZQGT?R-/+A.VN8UR]?'G)PF>
ML9,T*;'@%E-[ OK$L"XR@.Y@:Z<D]6*_T)C^MWX&7P7E+:%<.E&Y?SL>LO<Y
M8'<?(K[.8HT_S?:6 R_N$? ]7'_ MQ]AT*71W7_\>OKZ]-)[?>]BU<TH<?WY
MW?E;[]W/WOGXS7AT,?["HUP>^>X;T\/>9M$\G*L8ZQO62_" /?6N_;BD$T2S
M-PAJP\%9S%SJA<R2&G &6*?\C_2!,?Z$V!^T>_;@9R+S1..GWOG R4YPCR7\
M[K<!]= =7T7@[$7!"MNL^J+]P/$06P6F81=,ANR'ZL_2#PBF*X=_IG0?2Z=G
MIZ#'N"<B[&/TGE/E=+PDL33DR-<"$6+@9V]72'93+T!6+H$'[:F\$$RWLS$&
MGF\X&N&J;"$JHL>[0$ "/9CAW48O6$NWY6=%0EAT%X$_L+0E^+.#Q3<<2? S
M@MOY4M@7^,,5EP\XJ'8+=7?P[;6*XP$",&[IHBA!&!+=5#K&<_E+KIE8)@3Z
MR-+R:C80=<I@,! <>(ZMB9H/JC!\_'UJ.]3H"@Q\A%#RX,>&J$PJ8T @?:&,
MH1]R>Q65DPEX#PO+_BP)NHJH("HTF. _6/"4#TRW*IHCW?F::@[F44X3H&F,
ML4@*&W;@'9!U%'_PYS"Q>!$UK\>[Y70G@4;ELI;>5''M@:;#&NBR"' Q$-QU
M,_.+/.5"8E1O"5,;TH\#;QI]8L0,M^K I?1VF#*;,2Q8Q&:)BGJVU6C2^K'3
MK)_GGADPR=[,-Z77IO!'"'0<?B2CFIL27.7R(?[N@HJ'2#BE4(8PH6:II2$3
M$2F <:II?4V')NT"2S]NM@"97HH[Q\@!9^C3V<Q1@RH9N39[Q%L66LM*4267
M&<E=G<9JH'!R>BOLF3P=2/@:^\D-&, 5^U(T2>6:E0+:SE:(^NGN$DC,NG-^
M-84YD4LH+*9&UQ#64B9;-XK"#8^5080\;6M#U[P1[%2W4%3_F3%R2.^415**
M!P,Q+Z@WMJ%6JE03+Q^MY6-WWZ."?W10H@T\N= F<^572+A]92W<00L3_<"[
MC JPBG\_/37U48A-Y0Z'.:8OJ,#[Y;,CMJA&8!^=()E69);P-'$!_Z- H'BC
M.>S) #:GA\TX\$NL+1&;/ J6MKW<*)?L8,-<,MG+V %"9#9<KWO6Z 144T $
ML-55W-IR[Z\!V0.7U_2EM27+NK"8B :T\R/\;Z3CV()IT\!8&T=MC%?WC:NN
M9#MIH+D?JCO+(.C0QRE=Z,;0<9 "F5LIMEC^4J3\R;X3[+_M,>H6Y[HCK9G;
M ZDC0+AU$&0E6UK7 DS63ZO?A P%, \(4<Y\A&9:G4/;>4NGKF1!TT45L;>V
M!I:,SJO,GP^<L\MMFMHDX]F)KG=U4<.Q&*<VUB&+S=408+,FIM&A6T7AA]>X
MAOJL,H2M^NRW(VC<Y+Y3S4:M+L*9W#(7/_H&?%.*O,/[.RZD)7" HPC[P7+)
M M7=:.Q_O>1WISXI8O?!,27%&C<^.#?2$M)RB\A(&_4_.]<@'FW"73G3Q6ES
M>NI::IZ.$B%5+Q!2M6*;P5)#P*G>,)4 ]V(#Z.]Q>[AAQ^UO[*IYZW=VOA,!
MN/QU[/UV=C(^OSC]Y6Q\XHV._^_9NP]OQB>_C"^\RU]'EU[]BE]'%][K\?C,
M&YW\?GH!?WC]3^_-^)?1&^_XW6]G%^,WWNCLQ#N]\'X>O3U]<SHZ]SZ<7OY*
MMWE__@Z^<OKN[ (3$,>C-Z<_OSL_.QUYQZ>_G^+W3\;>Q?CX$J[PAD^/#@;>
MAU]/CW_E[YW "\&C?W[WYLV[#Q=4A_77* &J&(%56 +6N$YBG(V\7\9GXW.8
M;$G?>"?O8%[.WEUZXW]<CF'B+]]YQV]&IV^=U3L^'Y^<7KX[]^#__+73LU^\
M]Z/SRW_:K^.RXP47OUV\AR7 ^XS_<7IQZ9V>>;_":L)'OX[/85%_AY_DQI>G
M;\>XDN-_C(]_N\2;XE_UFZ$8X#L,O-.?Z?9G*"J_GKZ5>\'JOOOM#0K4[V/O
M[>AR?'XZ>O/FG][HYY_A!5#2[&,OQI>7;\9OQV>75II.QJ\K@X)OT)CVQ&![
M2"/7TLBO-Z5^OS?5^C7=-P#%AU(^^C Z)\&_&)V>5-36 *5U#&(^_L?[\_'%
M!8CSA]'I[ZBZSO[IG9_^\NOE14.COAW]DS?!)7Z9/AF@JOLP?O,&_Z6_T W>
M7=)FN!Q=_G8YILUQ_.[M6]"6;T8?0$N>GAV?OG\S)NUZ<0K:%Y3OF';3=W):
M'6V8N<*]&'O0ZN1.(AGQ!>]#'Z._4B.-J?LFO66$P2LKY>^^J885TKQOSGM0
MJ[I?!P/"_5TAY^8#CZ%A$A2EJ*_#"[(J]<X].$>D2+R;=F1W#=0-73ZK3E=]
M9?*&>[ LN!OU@67A.V19^#[._:<;=NZ?.]G]]1_^E[6-;K 'K(9O_"Q#QE5/
M4V4C!H@:Y:B$.B)7^B +D;>F"I4<6KU%"\5G.M+ .J1K,KY+LKTZL%D)=C+/
M(VQ;'2AE' -1Z3OWHG: DKODNR%+8USA-'5 !\>=H ,!&]B(+6846Y$'<!"6
MF5!Z+!M5+E LS:IKV4C;>T[+#6Q^0>*M5@DO^;9.:)^2>L4'$Y6*RTXOG)I:
M HAMA::6*&F%5%-X2$Q#&V(&1O+(2,A_5*!"E>@&.*B,;QL)YTJ:WUU5;3RY
MS_Y.M->S#=->9RFFE)UZDY[H+;WQG08 [L<63X)6,]H+N6R-J%@)82$-,5R>
MUA;\AXNXLOWCJ9T2 AQ64FIW/T!X?;IU'^Q"_&>IOHLL$[T9&!L:K-H8,Q-6
M[L,' /I,Z-7=0\WATT(U5>Q@5LB.F&HIE/G-?6):8IN&)N [V>?/-W"?A^))
M]6RK3YD:3/Z&40LY=AT5D(AI[Z2_[5DZQQ_G*3I;B1CQBF'E3ON6:@2#&K5&
M&O(CK0D+2E13ES8B^,IU7^**]>""S>Z"6"$Z+F4#2)"^\.)$C?]1,UQ+>-D8
M9+>FR6SK$YL>YW>RH5YLV(9Z]^'U^U'/=I+L&-H\%M'OFGIZ%UCY1\-.>/3I
MB]=I7((OD]UR0C^C/VK@"^X%V#URDC4.90?O64=YMC3C<(Y&QV1$"OD"G?%B
M)A!,!W[1'G-R7JD*L,!;OXOQIP_( Y"9X,QK:;+UGN-YN/\0KZ<]D!:H7E2'
MZNU1[Y< 1".TE.GW?& S+A.90@LB16=UQ+65^?(TZ/8FNI80Y/4IT55)2C]?
M01FOE:<^ZN2I;]OU,*^\<Q"QF]?/7#97W>.=T%]T*1FRTZFB8H%J2=D4P5JF
MI5=#SX551%Y7.9+;?\*QF-TSVT0(ZA9Z+?M!<;W/QB'T?\E77W-W+7&%"*I/
MJH"3$62EN +06E*&>IP.&7?R:<'G@I-73ENL4+!L70'W3I//E:LFCKL=S-DJ
M=N9@0\>&6C^[-*KZW:Q<FWA)8T=\]Y)T/_4A/U8L%&V'1#'O7=OKIXEOK=6F
M8G]!.+LGS1W<5:U2L9;@<BZ6+%BO(!]'CLH(.8&;]K=GFU7>==M.']U"8M..
M6T4NX2^E+&,I>OB.Q>AZJ109S4Z64M,<);PH]1C3.6";E.-6FG"%: TZ<FK[
M\UY5%ILUL\LGMKX]*3EP!7H:)]##"2J\O__MY?"'@R'\<_AU'+2G>ZLTJVXQ
M=)&KYO'!WHLFIRS& =EY&Z[3<3.L8;+3T8JYCN#>NBM>9*+C(H[HZM6Z][4<
M3\$L37/I4@=_J:I3(_!\ET64F8RE;KL6I2VUWVU^9%-"0FS[FJ>NTL8,#(;^
M*#E+[RPE>,X(E6,@U#9KD)8)K):X9"V/-18$-I.%DU@K5C_F)U&6B%TILC%T
M&F;N1QS4Y=/:E>/'L# R$::<[#O6 :N?T6CX@(RF'U55J'"ED/U.H6H@J3;5
MEZ&NVG/O0W73U5OP^E;N"=Z\='EFQP -1 S>MX@N20:^F51/2&/5MH2!KQ-;
M.(S:,X4>D#8"#<:1!$O57TVKXFWRU6\S:!VEEY1Q+&&7B"T)&%62>F15$CJ)
MI@#+))T(J%/ZT54=T@7VT*9#+?G16@UD:2*D%)0:+8I-*QF56K05'Y^DR6-G
M36JF+S;.3F[=19O#SL!70XV8184.1.627J0=NJY"M?:]D_CS-5>I@;8:>->1
M[REL>)2E213 +HTPB=/'"5/\;F&(4M2#F>,BJ(G"D '/UU.*KNWO>XN]^9[W
MWJ<VMG22T%<T?1IM:SB><&-KU]39UI%V0VWY]?<7J7^Y89'Z7TQUVQO_9KT1
M^\N:L(18ZQ<RD(L"5 2M"3F"$K'(7102^#@&:0"!32*? VKH3<:QKI_+);,U
M8<A'!@J[0#(?B5#PR<"HN0I\E2Y.&'-KJBU;GUEM((WGR0)K%1<B[ YV]TL*
M^O.#M0GZZ1D6H)R-+RZ\#XC6?_=STSY&N\)L^2JZ&G_Y%_R/E 7,Y;_L_P;T
M2_<TW9-;\LZO?7LUVZX@-DMQW'<4WK+_W?=FGSN%WX]0T+G,^X7.X*\_(Y]'
MZKC\6UWTO),87.N6/CCR%V+<W;<YJ*?[I :[%"I>_JSN@MHR1^UO?@VKX=G>
MT[\0J#G<:VG^\]4#-?NK!6K.+D\8G>[]!@K]Z*F)W/C>59:6"Y>/1Y_)W*+.
M+1+(U)6?<59+\]F$!O>1/S#@-C.ZAU^$ ??9-V? W8)V:$*8>]Q[ZML35?A4
M62%YQ?=82A%B;='7X_I=[_EJBG[V-HWKEBL(S JM&55U;"E>:L0X:/P3%:UQ
MM70?4/':&H @O29/]P^)X//\]&)D8G35&C;=REO7!PHZEYXL6"^G9[?IBLH)
M:0QM:Y*44"'/&OAO^.)A26!_!W&O.QIJ.LA,3>$QA* 6#Z_M,3A6>ZF.'E*H
M4S^/:AUN5!PO>=NY_U'14T/EG)T$^Y*'ZU0\HRZ=KJ0#68T@HEI5/R:_M:#8
MI5).S10Q:!+P$I]&A0LD7\L6= >A(<BYVNNFX229,!5]8,C:\T:>?A_&:W ?
M]G^SH+B,ITP#14%L%$!8!LYY@T1,&QQ N.J\7M4EJCP/%]> \*WDXW=EA>L+
M/%/<2%@YF0#L48LA$DK%I;$2H#]NR@%'I;$V#QZ 8>E")?)>!NE7$7",:X-<
M5RYU8C)Y.9GC)Z$):1N_YAN$ ?H2.MSQ.W-._=QQK(ZSAA'1 ^"O2-A"OY+!
MNB"QL1P[,-\B@EB)3N@50K_;$XXVA]:*W9*X2FKS2\CF&J-].\,-D\U+1"<3
MN^V)2B(_7K-,2I:T>NK#HD;.$=RB:4%&DWZ?NGYX#2:%,B=+Q73IPU'LU(]5
M9Y\2OYH%#]NY!P9!"4,EF@IM=MFCE7/ZOFWPKG1:77B4B2>$L5-8G.Z]W.>X
MB(5J5M]"#EH&8) <#'0/^S:!X<DUK!L))QQT*0YA.Z:IE,;GN93"2[TJ9>LE
M)WU= <HL?PI7U+J/<NXY,(=Z=0KMQ3J;/RTS>,;,LC>;6954(WV-D_R<>XD*
MV+@R@QH&9' 'E\V'X,S+M/O.LN@E,/"+[H=H.()V0NP#9'3T'*1-"#2$ VTS
MO$,094$Y1]@O.@L\/0;PT%PE_02"@B ,QP ;JXN!M=8!8Q_!N3!,EF:WL:#N
M81!]J\^G@PT[G_A40CJB*.B#P=3FCVKEJ*B O>)?4'HVB6BGM3B0#"DUJ@'E
MV$(QK*(@']R*,+Z'N\],K1,7\.H"8]@*$YUG+-+4@ GT"RXO!:ILAN'^B\_?
M#=4['1VM &E;IW>Q'-%&:@Q1';JG0"8_Y09&OO2H7XZV_FM3]7TM0_<Z5")(
ME44A1\1ESW(["%;6 7<FE?0_+,@7J,?PI5IBX;9)<,"T<VS\&#'EDYO52A2:
M7U@GJC>/T9[(6* RPBT:DT]:,^!A#PLME3=2[W#;)-:")38/N!N+^[#4J]1,
MU&9?S$/<=Y:T;+%0FEZ,8@K:AB.#CHJF<I?4#J'FA!XWR16WV,IGUJX*G[@Y
MP.K4WI.,@9^Z*5&5'__I_@'&,FP(G7P-]BSX45-D+UNNP!FPRF-<,=2QW<)T
MN&$6YXC%MR\1D4M7*5*(G-_/3XQ3MEQ>)[<Z;LPRKHU-N4]KND;\]V?B$1*+
MG=XE]1  V>?R&VGIVDNO5'%.WM;VH!..^T"L?"^@P8-"6\%!P.W)>\VF<(A9
MBKK;"5<C]?+#!"_7]W*^L0KUL=12UO1Q_<8[*@L?UFH5+T+'VW3+FP&?[!B1
M0EY"*LB50F]F ABXT4R?.CIROA +[A:1]#G$M/0]5EI=B[';:MAT+?V#'?N7
M719:?HDJ4Z":PJ8<ZJ6,/\'G$8I1(G4AT3W=>RO;A&TM]M+8Y'P:VQYQC/=C
MUT;1?1ONS8V?.P_@)I14%*E+UFW8MM4RV.Y$W=&&F:4G.M>"K#\D+#TP3%LR
M15C;5R(-DC?598E3/\KT!G,-1>,8KF3(MCX2*5QS81;/8CA]@QFXD(C8FRN%
M^RNWU>9_EGX&]XMO[X06=5C22*?F<WK*3QIT(DM>@M5*!.HCQ([ Q!--;$Q-
MYUEWVZ88BK;1Y4RJ9+RJ'V&L@SF@Q70_%-.=258U&XY^7](E\G*<[:*_!,RS
MTS%\M&[@O*0ZH\GM';.1*Q2$I9/"<Z!?K6L6FF/E-/&R?)(BZ6-"P+L2?]WC
M-; ;3BA1/]KZD&&NL^6C3-LRVG]QZ(U$HSLTV6B5W&,7($]G+AK)V[NRE0--
MCZ+'T+X<E>P=]^&S\=CV6==F&8K9H,HXH%E:W5B0>:/632UM*['DF%O,T>6A
M[%<G4<J\](9#TNPR,RD5)AG#J>I[<9I<N5*V1+?@5$YK9H",HGTJ\'Q/^5_3
MZL)0UUDYG*(%XR3/X3Z&< -G<;O/^:<;=LZ?F0UW4A&&_A[[JZJ29G;3-*R4
M'&?[-B!'"?>JQ64$FD<R66XSL.83'<;OV9$L)8;SD$$7#UG3AZSIIB[#%\^:
M+@\N5[*H#Q&IOYQ&M;DN SHSRA1Y(1SB%8E=?&;8:E"-6PW^6N"J(T[U( ]_
M+=?JB(-C;J.I:@F6Z]E67,VIRFS(B7:WZ??<F3I-)]BM3=QQN]+^!"6IEI]=
M;Q!R6U-&/: H_H8IHQ[1&7X]",(V5>U,.N?7ZZ<G!MO.QSD4\]/[WS*D%G%<
MP$-!M74WZCI+M9CYA6X.B<RV?Y;8\<$$L"996HIX2I^ESAI&.%6BN(ZXDA@4
M%U76>'%U:1Q6D%+(07U26<"L\W+H5,J#M*7"W^=0%M_?WD(@LRV%'AP PQ/P
M#[T:MKT=6D@T'.F,D1J,0P6HH)&X:*UD^D!E&Z>R9QDD).W+,-#B>ZA8F?U[
M&H4E%9'J8@0N%Y"V@U*X**R'6+E79!%U$[0M!ZK?P/!=?.M\L0V7(;1W-&EM
MX]<D>!P)EO-?^2#/Q%4I31)1_R3*NX4/NLHMC%IC0)2I\W!8**R$"%XF\V"+
MM]W9*;^U!;;&JM5!O=!MR=*4&FKUF)=*"UW+\"4X\4>913E\:*@$KU52<FBT
M0V[J'1]J[9W,R^C0I/H4Q&4.Q@;S2'-HLL0R4OC-);NJ4=$+MY5<BRTHF>\)
M^^?E8+''H;FF,@CU*:+0+Q%_P2[PKS)_,?-V@ET;6:RVGT'PI-M>M\8P3NC,
M##X4$DP*:)+AOV*LT)+"?%='5+!AL<+V/6LRA2 MKR/JHK7F8^KU70P("^SP
ME2:XG]H+  -0D[2]\"[8:Y4:-&3*=CWR.QUEN-^<0X<Z=D'MJ9L$#6UYDIFT
M7I3"].*6VT@*-YX9RH#/5G@S1!/,)]%526V+Z>^45$3N]]*O<Q9("97]+IV-
M%(5Q59""[1))'R=69'"ZS@F9 -O95-YZWD4Y^4/7P%?:1G,3.:/(*8G70C5!
M0YVDU\W*X)Q3C(2/A:=/(FG;QOR!NA\D<:[J566V;[SEW/\4S<NY36.$)ACE
M8R:,3RLD_8,3SL.F6=;@UB<&_!7/=3I\D0C / 9&D'$/W1NL8(P*8?[-B>[?
M^KZ=^5XV0D+41OS(Q. ^2#FCQL1V(P9@D;.%Q1$5N/LB0\.!YOI.)J:M<UN7
M\# ]F:3A+?PS*^;Q3_\?4$L#!!0    ( ,"*<%)&*$7[ 1D  +*D   >
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ME^*3;/"'\%)'[2"MPH3Q"%6TR">[)6%J2/=*?)8921RA?)-/@O6 X?KL-N#
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MM^JA(/LD41:,E6H5; P-[*\7#7R,$N%E&A#@5JM0)F)%T)YP@Z<4M$KI$WD
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MW M-&0N@ M#TM>") F&/_#.+[ P+0,DP%+Z$S\&$<(X\ PKBJ74&P2(\#@I
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MY[Q:WI8_9GV%\*!"1VC>VKOV>J&38CJ"EVF-*Q! JX&;(;XYY%X"&FW@G+=
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M2<"BH:8:<P[,B/ES"ZZA*E.3RF*T+S-[+;BVW^_>EXDP1@[L^S$88:LWL G
M&+G<3J?;S7N/@0@S\^Y_QKJ-?,-B;"?-%0]4I"P-?>%+QD(;!KH13X (K6>
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M^(V_DC5ZXV_?>JH(U@@+[_38%V[%17-!?:[ LU;<?7 @>+9_K?@KS25]:="
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MI.3U.^V+;7^G>WA^U'V3[6Y^(#L7K[N[!X=\Y^3CZ.@S/ON0'5X<TS:-+W9
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M -A\/<\9>:"[XKC(SP:=J7>XYTI7S8]G"T\> D*/ZA6[7VMHXI#ZWK"KX";
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M3<^H*I=MM<K5-*'V"JRU"H;*VRHH:*O>_LG__H/Q\(]CX$ 8SJ#1'_"H4<_
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MV]Y>\MI;>.UOQX!67> "ZG<G- L7VD4^<%IEMKATGBL);%?,N$G^VI@G )(
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M^WDV.@:%0[H679A<N'/P[_=OI^I;:Y$TYC(3Y>C*P4P'8-Q9ET/G-BBN+R+
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M*F[DEVD3BN,#GE[HP <<(NEJ>/&2Z,:U @KLEG7?J;GTU[FZ\42#B:S\-#M
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M'5SA.F>2(T7$6310D&Y@1I^G]2(-E@:9;JAC/P&@9R+(4M\O=\L]73?QN$1
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M=8<\A$(;G;$[Y9N1,=[/_7//6L.8JJ:513MM)?I2MKJ(_-6#WHL27>8=< _
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M*;0'H5AKG8MH^E[-G5K)2.+ ,R=RO1'>:2S@6T+;(P+0!3W"<_\[@PM]$19
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M\="V.L-JA8]68 GJ:*POV^XT;?-IZEX'." ][9_$6EM(%<)C=!B?HOY9>9+
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M*LX0%,,/L3K3MDYPX(+X)G_<5-EG3;)6Z1*U!)*[W=##=$TK[HJP5YE/ZY#
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M$42ED2.K4I!5V0&;I^0"7$F[JG7J/E%N8SN24832*= P$^@WF^L]^;==N9$
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MZW+TPI-4;3<^)BI_&6(#6U?S,K0$B3'9DSH?G=,?9Z,/GBCP+:@XD;O&0D$
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M3O]5CX <(0N]#J]$BR5-TQ4M*9"D_DZ4!-8=]D2<:*'+4*BB.%#YB6Z?8&H
M"]M-RE^PNY ;\I3S3K0HG@B@I@5;SP.W9>)R3=<PVFNG$>$'P(^@W5!/EO4<
M5Z4:@H;]KF65D?V?38/\M,UQ.W7>\TQRS0'BV\^4DW*(L/S?LOHDV8[;12>4
M0+$B7)J./&__)!$Q^[?LBS#[.)/?@22&I>W[31;S&.$K2$)QN3?/9LWWQZ?T
M"<><<FX2]?W>X9-_\8+_\3^?GIX<_<NS /$Z')[LGYQBXAN<US6GM'="C1H[
M/*>!:+@C^VRW<[_%SKG^<=V+PMNCNY7^35;:.63/(.R[-?TMUC0H61RZP;?Q
MI@QO*VLMP)9$/61*L $0V6R=3D#N<6+ <X\1Y,FJ*5=2(19YE7% L1;+*W@4
MPU?@5$ADSQY%A@^.?WP?H[^'-.Z)/)GH]:VT6ZI"O]'=MA*==-]_ 0.GL8S=
M#YP;93S F__[XNT/"7N,X@Q-U1-*V 7ZE$F/Q**=KW."_ I;VR*S;#D96\ZG
MG@75$EUXIKK&0^[./M,:#LV/W+M@382DG/%<4BK;'YW<C]QG4O:7]G%TV>9S
MH=Y%PK&>DAI.4636-W#V98%4<A"1T6ISGLZ/+S[2<V>ESI4C1]B\V4RQ*<$F
M6]S")?0L:"T/I"M![#9^'0)4>(BU;W105?>\;3QK'0_)K2-TA;?G$XVXU\I<
MZ:V3UVFU O0E&9%/7]2K^75:*##F_55)[OI%+7_6RS/F%Z8CLU?.]NQ@]ORN
M-<G<;\-7?J7>YENFC4:2@&8<N,XO))5'8O61@Z+;*!X?67_T?09E\30O4G)Y
M#ESD(I<>!H/^\W#UV/>CZQEFE&.(^)QH7 Z*'GQLKK,SI,X81$:TB 7[?YPC
M=?J%E,#/)(P3Z6_<9-42G*DR3-%A]? D]D?G?=-;(]3SG-3H#O.T">;I_..+
M9+=4&RT5R(7?"2X/QP/RN%NX31;N]<=_: J*3Z^S[20PE_K<CF$/SE]_B"*[
M]%$0AG>68)_0.!N9WGY5EG1OO:A:<;W/RWJ18=?.)E+EM(/UA+">PQVLIV\!
MO#@_2Z2O)WP)WVDXNU;TAR4U[-JK6JUK6)+M3^8T;"W<D/+I B@^%!RR]Y9?
M2[X27TB93;L87>?DU0&J<\D_0"Q:##=R#^9I)9:Y'* 49QR-$KTQ)WR 9<&U
MFO1W:;:NQ6T<E&JD B0@W8I0QP&VV+\;^>7<HYGU-T".T(SH#Y<&S0!AU\+&
M#0I" 4$'#TW41O /)VMS08:^E BY!>C#<*O,@3(]..G5BS,-G@:)0F\@0&_$
M6T;O.1NJ0^V4]V'?77VXVS\!P 1A5QN"*;5:0**.$\[%RCW@EO]9I[.L68&8
M: R]C$_(<J$M[^6N:1'W%&=%6TT2I9@:\U^2P'+3O/:B]#U-!;B)_YHB;9Z/
M6]N/SK(X:M*H/RBMAO,JT\;]QFV*>RC]9%HN,%N)[7/JEB8I/8<YK\D$*1+I
MSRLOB.T0)_W0JF:?EV75# T]0#-/U\Z#[4K!$(&3F!=M2W.K9_/FBDM@;"&N
M +%SOGG:TI\KA( DU]W;'EN7^VU"$KV.M(_"X[+/ ! B&(.SD!7T\XE =&CW
M)U7F E,@M]$_3\.K.G0ZNK1W[KR'K=L=_'&:P6$ N6&XQ2+9;:V%6AR#4$*:
MP DP!<=\ARP4]- (E<,I$S%)R.G7-$Q:AP^9.@>/?0I6:S^^^"AH9!S=S#JU
M<4WPSA#<S-G8F<WW-ILA=6(F@W<-1-UT&>P!&#E:YDL>Y8C<ZFG.^5J6UJCT
MD@$U)K&+@--["*44%]%W&H*0AG!QOENT@7&&WO+KTL(J^Z,?C+Q4#1^.4)DQ
MA6*!<M;<\-0K;^$$<"HV!] _&$9/KE<>JX@ D(0UY.CE.G-A.Z^#'[/+O!99
ME94-0'#< ;LDF28+2O]+:W:YQ';]DG,D"^OAD_,Y\@ETK\LEBHAIH47X!C"G
M*YC7# H/R*WYIB.+4;IBL 6OXQ@L XTA)?3_9!!P3)=^7@NNCK6WO8ZY2X"@
M O2N2">-E20BW>!#UQ(_JA!XGK+=Y'Z4TZT9&Y&>H\V'MAF<5@6=JH.0591)
ME+M&D9ANCCZ6S LM-+4A^M^M +])HE9TPOF"V49!?(7>+9]36,-)5T22R%!1
M8X'M"U?274[SV>HV(V)9DLFPZMD(<N%&+Z<O_[DEU73,Q<&')]YV 1B=$>SG
M9.17FAWR8_$#221Y4>7UISVIN":M6$ %X=LZ%'!1#(]U>)!O/>W-<7=D*G-
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ML:I8KS1KQ0&X='JEM3%,*0;>;CH<0?I/,JV=*P/C^9/XVW"E<)#$&XW-)6=
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MW *0$TE/HYQ1Z/M/UG2T(;)_:85()R.+BN,#:<PIQIYBSB44"*_0!%[G$E6
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MO5>#X.R6L.23==WS!B.V>EQ8*!GCA5U7=@R3)EY?20)&3P98=QPD!H[HX"I
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MUJGS<5K1PPSFM7P(%$E<W_HJU*)S6<3^'X*]/AOBMG6->IE9Z8Y3OLUPMO
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M:0DXZ7,D#-@+01Y"OYLM-81;D'81^OO1>N0;A"&)E=,=V4C\N2*-"O;"6EU
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M-F-"'L/::@E7\G1N?VKZ3:2ZI.Z2UNWH,$2B(3QJBVYQ1U')P[>_R!>3@I)
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MLP7ULV@,&9Z5LM#)!#HJH*@CT:Y/[2$%^:HT8<$"X:<8?VVZF#JZN99%_TO
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M+DUCA!L!#-0%1ZLK+Y7V@KK&,!=K*3>I2^,?IJ1:5+G<41?&O.U)8"",JS1
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M,#5Y.-?6*.&5V#;;B!4F*TD6=OKM$]\V?G4 N]=1ABG:NP9/9S^NRJKP &5
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M%1]-N=T0UB?1^52,;Q2,N!3(7:\:K5UNJKRN"R>AN66\7P@@FNHZ1FY3.IJ
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MTX -3PP1JOP&9SY]U60G;T<G)4G.!'4$&#*H3FH8;X<BBLIS8!]2Z\.YT)+
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M^*Z  )Q?G&<#U)H+%CE;%:'.4$%09EZ,&3"1O+!Y^&@YQOD84BV.VN=Y:Z6
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M=G_Q1BK,QG^"(>$'>!GV^,7I%+[;!O^^#6YU4YV]V%/J[$T(L)?+L--I"L/
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M93-&!M)WXR?<!R99I(_OW3L"O-0/:4UY"@CBSC#BXZEP=$8619*L,EVWPSA
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M,J(?@<LM%OMFB$Q*]D7)[W-=+ERUIV%5+BN,BF7$U)AMY-%@&(5[2\H_HSF
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MA6^<$=-93)7 _(F'B?:F50G5NJI<MFZ' )'6.;0=W,YXF<CD1YTE89Z0O!#
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MY= C:DW4VNQPV17(E>Q](A!WA)=_V(-20##&WZ#2\0OWCM,\<@Y+CCH^.?6
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M7,! \\FC_B,SB\D(X$YLZ,PH'N52?#:F":.AXU%UKH+F"8-):1L"%24.P0T
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M;ENG&;LUS,9:</YR0!M'T[(0YIR2.;!EIWI>47:%\A[LT\$7J3-NWW)T=7,
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M:^E4'+/H8CO_VDW5ILT'!F[DRR%1$26/.[A\5TDAVR$D%"?=3<O4LE?UW2S
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M=@-[[%@M<Q9T0?+9PFC[+";*QQ=/?7%R.KEB3>/O::IFQM2!CD8CFE'O;(&
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MKL)?X.D H0B9"/FMXT%*T[K7P6FF,)=B6>Z.&#75205!7- )ZH>+2Y S S6
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MQ;H<MJR3 540ZO7CF])MDBW"@43M]LGH*91,.9:^Y2YT;5PYG"JF]>(*)!M
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M19B2L*.4_.M:X)^'T9MAIH%BN.VV:I<@0$0R# 9TNA +JP="E"FL@RGF]ZQ
M",O<^&S(XET/;[,>W_MXV[%">77NE@A4Z$'BBLBVYRMN)7TRP?"O@S7_;<D
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MA8Z&0";$6V<9>:IRGEUE2F7C"4UHS]!%H9^.&_U@&^W9@^%#18ZG$@[2=OG
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M K,D6*6A,/S:,/LLS_WTLG"(#',(P["RFA6SO*51H-SXQAD7\,P7F-+G4FR
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MN$_@5[Q LHA^R!%ZKY_I%0Y_1NAR0LTO(+F_E>#1@R=9?CBH6F:5851255O
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M)4#$VIYW!C7?J_0</!%6YA/I1!SM[\J((XR.'5.;AJP+3"UQ/QA'"(\])^/
M:#]KCRN0[0/J?EK6YCO]Q_=(6Y(GJ^^R@A03_>A[FI<+[R<*$PR.,UL0,9+I
M:BKX_ZE>7SX^I(_^VJ3]S\Z.#R>3\[4?'QU.[OG9V<GZFV[ZY::'?7YX>7XZ
M/NL?_5DOCK>ZZE_I+/!Y@(.%9_3?GIT\<ZXBS>C[[GCY,9KHI$(^63BVKWO:
M^! _C%-U>9<#0F>9PU"K7.1U-[S)$;['LX&O'D^V>6MVP![SO7N^)+WW_Y#)
M_EO/9 <K\70V=_@EOR5C6[9PB90(9Z8067,N3DGNY;_0Y/_E(:3 ?57,#D7F
M>%=D&8GP1;]_ N*!_N<6RW'W.W[]"S5Y/B[4=@MU.2[4=@MU\55IX7=!#.D"
M"TI:?/=(2G='"7JBM]R/^]TAL%?)],-U5;9%>B!R-YT:,YMM.IQ#D@R/\YB>
MXEOF!MQ&A]WU@MTEWV5ACJ(]..C#*_1-=VUV>B__?2J\ZI=_H=-)_/SB;#A$
MV%&8HQW?<12O/X!X'<4GEQ>C>(WB]5E>Z.0X/CT]&L5K%*_/\D+'Y_'ET1?4
M7CM[F3/Z?WON9;ZVA-N*/=HF0KKS9;=Q\L=K? 77>*#8B_7H\[T['B\55*A,
M[=^:C\K[FBR0W^5WVX"C.,S4F]2U38YW9POE2@"[K?.@M=H3[3XYC\_.GC]Y
MY^&KW)I+,+R7X];LX]:<Q2<7XZG9RZTYC2<G3]]=W5?#_(XQUG%T;0H$[#,5
MJ,>\?F.L1_M9'=I-(CNPI/LLLB<7\=')R8XBNT%L/I<V^0-NS?%E?'%T/&[-
M'F[-Y'E\OG/2?MR:Q_)<CW?-2#[@UGSEP?%;4QLD86&V"0B0\W))#9Z?9'C_
M@+[B27QV/@98^[@SQ_'DXGS<F?W<F>.G7RK_&G=F$I^=3<; ]S.M[HM.UAFG
M@!?7&;%-TRBO,=K=%HE_>3PY_GYTW,>]&?=FI\3FKLI]W)?'"79W=53'2'?K
M,K EY9@A_PO//J1A]_]J,R9=L)PT.D0U&^/?SZON1V]^W)MQ;\:]V<^]^?9L
MT@/_/+7P]^1B[RSQ^Q+)?<L>:O%+1[W;M0#NL\">7<2@1N[G0F[= /E4G/ZG
MOYVGS^/S^T8$XW;NW7:>7,0G]RUECMNY?]MY&I^?WA-J\WFW\^MLIOT9J6^9
MT\OV@W_IZ/SI2_&WD[-X<GFVLY^['PIIW$I_*Y_'Q\^?CSOY%>SD:7QY>33N
MY%>PDQ?QY<GYGNWDU]D&^0JY>$QMH6M?.IWP9$3T.#X[W\$!&$N!C[(K)_'I
M\QW2C^.N/-)9N3R_''=E[W;E^>F7V96O.-0N"["DF*!OLWK.0W]F0GUIQ]70
M"M5*N7T2O3?5@D;5?>G _*F([EC^&_=FW)MQ;[ZFO?GV/#XZVSU[,4:VNT+7
MW%0);QKM&/:.^.2GOC?'Y[NR+HS[\CA)B<D8_.[;GCR/3[Y0HNCK#'Y?TP@G
MG):],#'.-QUCV>T6[OGEZ>B/[^&^G$V>/J/KU[@OD\FN;##COCP*[/(+]J1_
MG0$LY9-E&CD;UJA)/HZ([X> ;YW'%^<[  P>!8"X3UOYM';S.#Z:G#S<;GZ-
M&_IT=O,B?GYV.A[-KV GC\_CR2Z O$?9RJ\S_'YE_0/P& HSRQHD["9$U\C$
MO>4:CGS">[DMWQ[OCK,?M^3S;LG9#@GM<4L>)5UU^@6UU]<9?__=-%$.,?@8
M;S]$O'U^>;%GGN"XE?<-MD]VKV>.6[E_6WD9'TV.QYW\"G;R^"P^/]F]G#U&
MVO>@(9U.*Z,<I)5)C5DDR$$Z+0MZ,/SWLC(S4\&'\$3E],,8@(_PU*>^-]\B
M;\.7@:>.N[(1QK0+N&S<E<=)C\0G9SO4H\9(_(X%_1&,+!C3-+O)4E.D8':G
MZ+FD".X&NUN8*1GDVZR9*[R[N(Z:"NZ83.]/>?('Q$6.^.[]W9MO)R?Q^='8
MW;QWVQ)/SG8/H\==^=R[<O%\]]KS&/?>E0V/DJ:ILJNVH:BW*>$5%XNRX$AW
M7N:IJ3X+P=A=O_N$+,[0ZCZ^Q'[S>>AN=I#>_:T'/"6JIE%0OR)!/3F*CR^^
M4G:X45"_(D&=7,:GESMXH:.@CH+Z933J<7QQL0.^=^3V^W27?6DJYB"*HZND
MSJ8\MS;+V\:DGR,SMD/=\01V+"U;C"6^SA.[XROOXY&=')Y\$DQ@TPM_X=3'
M**E?E:1>'IY^4E?7**FCI#X28N?YR>'))[4YC;(ZRNHCE;./CP[O06'SF67U
MZTRS_TK_8=*#!)XCN391T2ZNP'U7%M$Z:FN32MY]"0X\<JU\)B__X3GI>0>[
MXH#+^"DJ84_.R>0X/L?H]O*>Q"$/M49/"-&S\96_!IDXB<\N+N.+BUTG1S_D
M^GPM\O"5B,3Y27QT=$^RE%%%C"*Q9R)!;MA?"0T _YMF-__^?^#_Z&,ODNHZ
M*SAM>QRN_=3@Z!%9YG__/U?57__=OGOW,K):I\>'%V=PE67)H\>_H]'CV8WY
M_C9+F[FLIO]#698C]Y/DJB[1)5K[DW6/N(4DO,\6X*#]W=Q&;\M%4JR1B<G1
M74)Q3.WH9^%R^/]W7NG3+,%'/+BJ3/+A()G!PWZ7Y+?)JG[VUW ;8 \Z:]A]
M_?7[L&Y396W/X6+;;#,#1NR^D%#"6N;)LC;?Z3^^3[-ZF2>K[[*"5H1^-."2
MN\<_/.)7D$A KB\?'])'G:/$GYT='TXFYVL_AHCGGI^=G:R_Z:9?;GK8YX>7
MYZ?CL_[1G_7B>*NKWA$9WVF5=_CJ\:3WW0$SRSK@,>WLQ1H<^=10-'TRB0,[
MN^6*[4$Z:OC%OLV*J)F7+5PBK;<A?-E!!K:NO.[CCA\?'1]MD_NX\QV__H6:
M/!\7:KN%NAP7:KN%NOBJE.P/29X44Q.]FQO31#\F3?+=(VG:'<7FB=YR/^[W
M2&6%QT\RO$SJ.94$IO@/\Z\VNTGR>\\^^43(WE=7YAMZKSW,-)U=Q*>GET^^
MPWX4K_T4KXOC^.@KF&<PBM=^BM?D))Z<C^(UBM=G$J])?'QZSTKM$T*A/_["
M_EI6'Y"189HLLR;)HV_[3>P/ 3O;JJSXQ/J8SR?QQ>GYR,>PAUMS@30ONU9M
MQZUY)"C6R?FN,*QQ:QYC:R[CXXLON#-?;7KG?8F6-:EK\WDR.KM@=IZ*+%Y<
MQB<77W!NU;@UZ]4$;,TX@6\OM^;X,KZ\W'74\+@UC[(U1_')\R]X:K[:"/:'
MLJK*6WC$.HZ*LCB8ME5EBB9:EA6B"FGB+?9HI%D]A?=K:FZ^,%=-E-5U2W7#
M:5F/@^:W'V8>GY_M.M)B]. ?96O.XLNS7;.PX]8\RM:<QN>374WSN#6/DI(
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M ,J^_[J^/7OD^@UX+F*^*L/.,P)-=YOK>KUUA]&;9,4W'+Z%,-O5\AH,\45
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M%W";ZWT(7H:WJ$,U$-!(Z9YM9I+4Q+=R0+*?^O_9^]+FMI$D[;_"T/;LVA&
M&O?AGG&$VD>/9MN6VW:W7_M+1P$H2+!)@@N0.OSKW\JL P42E$B)DB 9&SMN
M200+=61FY?GD4KV8]+!@R+#IJ;64L+P,*]G5&0W/!RLJ,(D/94V[R>Q*6[,U
ML)>;UFQL5HH]H&1L*QP:A^P:;]K:6O%%+5S#L@ILIU7BNRWAYF >(F"\"F4Y
M:*.;:J,R/5<@ 7>W]&XU34)@NEI>).\.WAR@T-#ZOVN"(FWRA'GMVZ0XU\K&
M\-M( W,%H(?=61"0<ZIUP0")PT..PZ'?^-!7CAC"+GV\1P]JF? ,Q@A(MJ&5
M]JZ:Q@NYW8VJ?4E'>7&U#/VW[Z"K_$#K.Z7U;O#WIK7\0-:W2=9#=IF>768/
MV64KF\(5D?ZTKW\@48DCA8.Q7(_?FXEWG_<+K)=A1]#CN(J:8U._*,K^:@F5
MPJO/5\I^$MD5$V]RZ9>1SF39Y9Z[R4$=+Z<<N%UT\%Q^KVC>J'(S:OZ((7HM
M<O^UH;7OY(Z?O"+UO )8\.J2R:HNZG):!C3YG"$4$K/A*F'#S2NVDUBBKCV8
MC,LR4W_0G$DUF/'0U!$A8]"MGL'FI46#H\+TRS+E;2T9'Y\P#M=CN<J[Q;$/
MBLO*IN^11EZ!AQ3MVU;#  US7@]<&+(IYFF1+7AK1V'*UIBZ-!=-,'#MW(,J
M7:3R PB$R[ATXR'='QTT?2R-;BKB,/^M<+?\:$V1.V\KP/,*P(SG/VD> :3=
M6N$+BBB+\AQC"MG_J#A&/T_PH*X7&+=?<J/*2T2V(EA!Z!<^[9/N)M=-$@AO
M4]1U(KQ?HY8&+'684<8XB? V)FU#0+8!DPT=U==U2)ZE=\NB4<Q-1A^\<$!+
MSS!FRD)2ECA:T>8 H4K0BU].-=F#CCXE(7C=H\J-$%^EX,B%M!CPY(HLN6-$
M!=IF0>M\ #?7#/C%SU-!L/4K;V&NGT5[Q\3.P#$64\W_+<(E7>ONGP[1S0 ?
M*'*G,?J-AWOQ- \R\,S6V(/JE&ZE7=PU ZOY'VOS)^WYJ]M/"S*KSN[R-FTN
MGWI>IM\$?!:VEI_6_-X2XZB;M^DW+=]@8,1S(3OR9:,QDQMC[6.8@?"\B_=V
M7X9+=Z'1;DNL,-<Z+M9^WYB?5@5CO<T)7BTT%;SNJJ]3A+*NCVG,I1_^)"%[
M9!=V2!V0CFR92BT;CF=($JV '+\GKT&$]W6J6\?0-T0.ZQ-QOE^'$Z3(3^KB
M_.(KIAB(S71D4IYOT_!G9^Z-Q/Y* 1P4LK=0,J#ZK,%324U;A&K7HU<I5%0L
M1VV@I#9\MU0R^:)V)2.5RF#HX((PO7'1+0F[411J.L>'%C-]'UKP6W(K-A*E
M2T)21J.GD(B !1]K:$ >N<P;!8\"_*JJ6B]&/&.)T\1#D;YKUWM[(G<#S%\-
MJ Z=@0+B_5((\76,U1^QW .7T:&$_Q=RN(]4JN8H^5*()+2>4E*?B$*IJ8F_
M%,N/=^&PB%Q[T,HJA'W ="/]9(&MF9CB8*NR; (S7$55V>\ET4NM<.C#Z;0\
M)?-%WY6ME3U"XV7".^GAYHJJH4OX&,%OE[^"V1SHHAZ!UCN&A]V'P@P<S R6
M_9H4U>@OI@FB8Z1)4S^<@@\-::6/!_Q.K\ 3V:A:Y\_#=T?H#DC'C"5X'1;V
M#5G,(<:+5'^&[,#S4P6P,.7-)91#$K*)V+E#XB\[>(Q$P<_,[,@I:C\H$X%H
MQ@6WC0M>@<@[((\Q^[,^H71>BR*XHLE+9)HV;/TI;GU=3$5=!G+?^(+?V1N]
M'@M4FW6"IX$"6COXM< U.K_8'QVT2O!0U^?!JT+USC94YHHLH>N::+:H%*8[
M=XMAFT^>G,G?3AK7+FXD^D?8^J FZ(G@PJ=#M\96:,P90F,=ER&0_51D::HD
MZDYF!YIM"IE%FWHH_[@5AJ>\&%65H&;@WC[C37OQ6Q+P;H-7@O,<^G)P20)J
M/":.LPECIV#00*?E:%PRSJR6"H$G3&];5)NG!/?@WCG"C3M$86 P[ND;D*$V
MR4),<DKG1J.'-9474#<L=0LAW9A&/VT2T)6^AC^ )#Z%LF>AKR/J!FKA"MVH
MJ5=]<?#^U8?10?I@SI6?Z.@C.1_]*FK_G@@]^VD?CUC,=T[.-==&SKA?>N%J
M;%Y0M!_KJ$':9''>$IZQXZ%8WELOAG<YSF85D[ZC5TS>967D>U$F!,#[/*K/
M>.V!D/T+M!6*NFDS]AF1^5YM4LK^[*I%"H4&$9__R4L/E:H#%6XF.,[(K*;/
MY ^_9$4]&Y.+9\44)XM?6DZA8GO7: 3[%M<*YA7[7R;'%Q_OXT<_S[/5S_QX
MWW."M1];^_8U/_/=]2^][)N73=9V]EW_>L,.D[UTLO&^$WD;C?HS4IC2924;
M>9RXL2 'N.%?>^Y>H^\B]ODS9W8^LJ7LXS0,<.@KJ8'(+KN1"-%5MXC5]%M3
M;"RVX)*56+".O8Y'XTT6S4V4NUSVBM3#97?).,#:V<5&L$>K\HS_[#RD3>$>
ME=86K"%Y9R#Y]J/B-L,[?0;@(>,B&\GY/X"CAUM]@QW9:)F;;Y?0#E:'>OC;
M:<?7)3#!<@-[[=G^H^&O)VAYE0LV1%8_[1*Q:UF%I-^.*V9E9Z:889I2FN>7
MK;J+$-C6W95Y:G6!KEPB#*Y:X3*!;+,SUN@>&&7#+?II>7.V6IB^H I&[<&*
M/-N(0[]; FQ)SZ,M%SD0V ]!8);A1N% 8 .!W=**;,./HONCKZV5@1S_K^_*
M0%/K)!.3GEU+,5A:[2:6QC#&#<9XI+KI<G78;2BI:@QGN^WJ%/>]D8Z!X?OQ
M@[]^'^?91$9DW>/5-9S-^K-YXAB.%S\=-(J=[>@VE4.WJFI<1J8=6]EK,G5#
MPW+=+45(-[W<J@CY$<\&>O!8SG V?3R;R'!=^_Z.YI%JZ5<6= UJ^Z9RW?"#
M03/LY=$XAAT&P]'T\6ALPXVWO7#O3G&7:7+3$I#$+CO-'^/)1VKG?,3N@N6*
M__2^;9J- _*]9G$_-!A[7T]SVR8EX:%HW(_C5+W8"*)M+]7A5'M^JJ'AA5Y/
M#_616F"_EW7-D<3*U;*&>U(?'P<Q/[%]PX[\K3W"O1%/PXDNGVAL./'V+O[A
M0'M[H+X114'_#O21&CK+N"'W;> \'#IU##_8XB898@)W<RRNX<7V<"P].Y;8
MN:9A.)@)Z].I%!*/AK("S8\5$D_1@<0SN)^OJJ.)'-OY98@-]/%PG.#A)Z$_
MRH-YPDYFR+/:8>;V,I#,H)=OJFE$U_16#BK@+0=][&M&?(:#N>6XS77]^X-N
M?KD+/Z%Y6;6AH.Y;#7\D/D([,,*@AT["X42O?:*.8=GN<**/YT0](_1[>*"/
MU&!H8 G9M2-@%.DRC.*@"5V1Z[!MC=V@H=Z1=V$(M/3M3&QKL!IVO:=OZ7PT
M9I;#?:#WM+'!7'8P6;D X-"MP<$>%7+&#K>ECUP,EE00;>^ZW=VVW+-B/K#%
MP!9KS%$W&MAB8(N!+5HV?7 -/(7[YPK4%W]&3//G?4>&[W%[]_=-=W7L_):-
M?K+W16+/!#I6EU/LU^WNQ_\PL"L< -M?4%*-Z&6X]GKCK V^ 2U:FFX:HL_P
M4B]BV3 :/IG-JO(<&Q*QQW_R]^V1F"Q/LN>M84SVT*24S6$^'+YY=_3V4!["
M#K8XV/<WV...ID5PT*:+WUZF<;96& #!7T/OEQW.=D."N.89+YV(O>\W)[+9
M@':,#3@[CQRZ6D$?>;8Z;+:2U\RL2BY&I.G?+1IR-#VULX(<3\N:[:YHKYVQ
MG67;37GS=O8\C(B-&+&3>2V[-J@FVFS/,SHI4NCXLIB-91^]]DL)&Q(:R:LF
M]EA8#RVS#_XZ_/!J(+<KR.W%QY=X/OSPF^,;=F^;W:L-T8!5]-V&/FV,[4+K
M'QHXV^:L;2@21^9FJH+A^=8*'PF>VTY2V)9ON.':P6HRH2@-1$NY@2YN1!?:
MQ0XM+",CL&Q%!_.3BM+1A UW4F]^@$YHV*Z[W?F1K)S)BQB>&DYQFU.$JZXZ
MH0MVN[(7'F/OL<VOZ38%&+YEC5 YAR+X$TK&\Y,4.C:S^_NT8'^N5_J>&FX4
M7_&5#9GW\D':,L<(8NN&E&H;H16NG=N#:2LE(#9[;$4LPX!J1_F3L^^LFA.V
MLV_=KCT!I%<T-,55R&4+HYEF5E38=1X74B_@)JV;WNT(G#0T*=5./'*')J4K
MFU(O9K,Q=/U=;KT-%-NR5$"HG[*39B*)8W)).JS*"R89+P0A=HU#SV<%KR '
MAB/J&Z+1Y(M?S1<'[Z#M;WHRA=OBX@9<]E!EIL*T_$W#M#QH8UJ^6L9_Z1$A
M;8/)J;MNHGUW5=8Z\1W)6F6Y=\I:W9O#"/<G?S]0+@)H0SV9C<L+"H;T& E>
MKD]O3H^-<<T$%PNS9 ]P3N!=V=-J4<Q;P':&>F>M!@:+?UHO*FS(K781IF3O
M6R.U<V-ZS#8^I^(S:S]4T\738#.:XT],@<EI7;,/V//LP$^+=/4[7!/:2%F#
M]J/0-Y::<R:Q1U#*6RW2.>^UG9XPJN3#+[E<K'U'O6P3F@ZD?WZ;!J+W[4?5
M< Q?:CB&?>;E*\$7V[Y7;Z3S;N#=!>_2+5G7;DCM-EE7=$96K]88.&7[#+8:
M&W:17;2Y>%M&Z,%]I4KV7RV5[/>(CI=A!70=W]J/.^X=9I3W0,>'D<;E&=9>
MB154T,YY@0VV066"?NHF]&\?)655E6= KMBK_1B=N=O8VLM+8+-AW\7O/2P-
MJJE$?@V5R'_)2N37JA+YL*,2^?+KYD[)%:1:NDTY=9N>VWK471(Q_-Q0;EI.
M3VE5"TE[AF3)YLH^G2W8I0)?F%4TIQ6\$F4LD'G9_20VHB\GDW*J'H473)GE
M"R]0)@:L84REB0'?.GQW! ]_H+,Y[_#*9WY0@P&"/;L-;C6K]TY+Y"OV: 7=
M[BO&A 5)BG'!3!7AI 8^XUYK/D3C1&3W07D\+>0,1+D-.P,A>QX*%_&:ST-1
M\_E6J_GLD6!?*4PU=(W$VCZ2MPL3HE@CR5MZ.",3RDRA3,AR#-X=O'_U8720
MSN67QB4(?.Z68M0ZGU=%LN#]T]FG*M:7<?4:C5Y&?$SS^+\%J>;<;0E+>B@D
M)ZH&/I+ST:^R:N#5<M5 CZBOH\JA17WV75"?4G2U*P-F-"9G7;2UO]X7>,O$
M<.G1_UXP09NA@&7T^X+,@&A&S/Y@$CSMIW'TB8Y.R"G:'PN\PJ8B7YKQ:EV
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M,@JJ(1N!?S.#Y CP[LE=/RG'F; _T)(0ZB::$F#5*R.DL<(FY!O5-%J<!6?
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M! .&(.($N$,==R)G7#MO1S*5B5QAK 8"7^PA'CO*JN)4WRZ][(\O0"^2!HD
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M"@&X6TQ/>'BWH\T4!D71:E&=$)<X XD-\''Q8]D[D8DNDEYH5YF*&\OD-!$
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M;>^#[>VCZXMP 20%$H0T$?P;'"RC)R53@X%6X$)%V6(PX\+_QU,%]KC 2#"
MK;7.5E$J^^O4E D9JSHE4]/&C'P1GFW- %QGY9/46KAR_59O"M%4DDH=7[&1
MZ/O&K_@9*7B$>#1>3&9\"9P+76N'9W*K_8'G)_?0&QA*-MKU&1W'U6S[+QN)
MXH%!K\F@W?O/- VS:MIFKG+,DP:6@'<JUAYYNA4__3(<[PZ.]P4W/<UZD3"5
M#1.=7AS]^AXZ>=%)P623NOODV307*/9V*]!.P[M:^'-4\SC^G<4,Y;G3+<W]
MI^(F_P6&&XYT!T>*P!9Z#9;LZ"2!&!H485FC)MMKJ?JU&:^!8D8J?'E4EV/$
M*-*[!,Q(78LR4D1F[J/B^[%32''\R"5MKS&!.K4]R+00K=DY$$8;B*I;&F84
M6C56%QR0I05G;&#U&2\H;:#-I8>;7<989 ;VV9@4$Q5!S<FI@,SI?F.#7[N<
MXH7^I:8Z%R!&JT)F9S'UGVR*"'#79]ART;3L%94Q(R^GQ5H[9UX><T ^M1?<
MR.7 0S57RI;/D1LWAH#T4*?=>D1F+&#[#D"*:>.0>7$<2V5U!=.1P_QA%JZB
M.6F4\)KQSJY>^ 7\G-NBLGVB !M)N&\4 ',PLFG"K 0(T8H,[^6)8RU.6='C
M$E,!D/%F.ECLDGNC$%V"908TL"MX;2O*1%L"3DB$7.'@/&C9@82$&Z-[0 ,3
M&&?HD13X5K4(=S >?G5^4B3%G%DH^UZ@^BA?DBB#M>/8@4EZ,3*X+VDQ;4UN
MZ*?6"OT[NPC]A]80^K]^Z)^7J1T>KJ?,;9>UX:FYCZNTB$F*T<NF4=5JV'+)
MQ_D;*-+@!GV0)6<?3^BHLW:F52JY@4"4CN?E>#1>X:*SIGP&(XA"!K^A5*J[
M'W1$[3L/6]]O]NH5Q6 9;64DO"BGH% @);YBZTI7:[SZ0&&VSRN].&*2"**0
MT0;+$=JBR%H69".#BH8>FH%<"1ER-1H%H(G)"H# ,YI@SQ>H[CH[VZ<8QMEG
M>C>/P6PR)X4C)!7_XT61H8^-V\XI_XKT=ZE\CB5##5O!U'/%')@GP38,33>%
MS0,XHG( RM^O5),&Q4]$13ABKO2HBZ7P;TG'OE:--J%D*EE.:KY6H+0K4B6$
MO=8\.A_3"\S?99\XEL4;6(KH9G!E?/9,-M+#4'S%%L^A\'G(= 0EU(@L2G@O
M>5XOA"D4LDTX)CY=DU8N*3XP+B_4:#[4<IYE70(_90A3C/EO,T:/$',6CC'$
M5RH8[P ZS6*:-MV!GSA=ZSTC!<=Y42$ZT)#!%DR9TBH_Q2PETL!7-12EG[0H
MA&Q::L)63+6N!TWA8<-)?$H3JO!.^((8(Y6MH; -!LQ&F;,ZJH[X:(G56FV/
M;Z>N.0P>F?)AMZ+*F_2:'Y2+QZ=<;$K]\2.C?F=?8F==C(X4VCLD (O*T%_1
MP<<S#O!SD5>@BI[@U_>B49-VY.P1\+/T%1Q@X*)[Y*+(>61<Y.XK?GG?RNC3
MF>.CEC%G"-@5KE0S-4X&A0:;=F"8#H;Q'QG#>/OLB*76WT -C5Y345DK^CD-
MU\</Q0T_LD/?W85#/XH&A_Y-'?I_W;$[/^Z$EV-K2$WVOHII#,\XX-'%+WT0
MW?Z^#/'52U!PC8"2]5 [%M\]< RO!=W<;AMZLQYP"D)#Q"YLQS[,>DLTRC+7
MRP66\QHX\(CL/5-1[M?[]>71Z,\/!\;H]]_?&;(F2J1H78W+8&"9BFHS(IN+
MB%S:JB/>W?0L P0'2!&*@QZ'0L"-^GIUKT=UGXA[31M,P)R2T]20%TJL/\D4
M,M1\G<+&%:8&LG0NE#31W4?+%V)&'&0\G91G4^6%[230JMV@IL\'[SY5DKX/
MLUQSQJJ)$I6W$AP$/S*5.BZ34L#0/F_JS<8 0TY3JK > 2V(APMF,G?OUK)7
M-M0.6CBBO2$.K@L$^]I.?.!*RD.TV*X# _LCVRK>+FR5^+YQ1VZJ<?;:EM'4
MH*MR& 4E!IC&R)NN*QJM,EJ9;*9C,JOI,_G#+UE1S\;DXEDQQ3?CEY;+8>;E
MK#F5?8N?S+QB_\OD^.+C??SHYWFV^ED8[UMVL/9C:]]>^]EEP]K1?AAY&PW[
M,TZ93YNM'[;R7WO!7D.PF&+^S)F=CVR9:*^?^DJ5$.[V7=&"Q5.$X=9CRDR7
M]:*H8^UBW97%6K!4;?,N>;3/^_*.L<AUEM^Q)J@P6+NBRVZS/-_E;69=7ES^
M3W+/,QB=,(WH7WO_=?7MP :"1H42(^]0L\DV@ LDRS)_/:$*&8=-WF98RE%D
M(]B87VYPW->X P9"N(00XF#-F0X<VZ.#<O>>MUI3UDL(LJHK.UI-CF7'6W'J
MP(^].>8X'/BQ_P<5[#W_T/*-"N /R)"4I4Z?*:GJT:L6;NC IX_E^.-HX-/^
M'U2\S*?O:4;I!"WQ%UH#QG?H3JQDHAU/E- "_/\S>L7KE0?F_A%H)EYW<@-S
M]^>@;&>9N5\ \L?K<7DV7,(_QO&ST09&[?])^=B)EA<T=3M*!_9[B(=J6_9E
M[/<S!B^&L-\&83]_%V$_].<-.8K7C>M=VR7^H*+R6,?<RET&)>A7"12KT )6
M,>SN<H(Z,NV]3N0O=OC$T(#QUTWG?C-'<*Y'LV**%;4\,Z<SH;)GJ#OMJOI%
M5L@"7<@%Q!)S8+-$N+YK[OINIR*.GHA:<0F'S+XD"L6?7NDE-T3F(J\C:J<[
MELJE9P#HD70;I)K;8*;<!K5R&]0:;PET+ %VQDN3$)XP;QDI%VBD &(H;S.D
M6D"JF?',MB>0)<#A^,<B TJVQ\2ORZKYKOPXN258V8X(!)Q:C/49=6QU-8C
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M<S-A4M=TF,B-W#3. S"*;,.-;JPP_1@>J)[I1+^59796C,>/T=GT""7I'2A
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MW8JTT^I'"0FI[Q(S"D.7B;PP,B/+#4T[]4EB693:+O3*LPRG(Z^V9]+N<3I
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MM)WSG*7: =K8;X"" )MLM. !#WNVW3BQO4&FI(.CV(]3329 A0;Q<H^)^P[
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MYGHOR@)@!<"6 ,#F*8N,([.&6$' >'-&@M&)!6(CMR18$_WM"#9_->0"90N
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MN4!/_:&'2:)B\H13%CFFW'#!G,$L&D&($E6M$F)&T$-,@9[GAYZ]UQ?00XW
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M15Q8AVP*'A$CF&0L!JM<B0T^E79>>'QYO?11"%@)#=86FI\X-/A(#.QRT*(
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M%Q3RJQFO7(J$M=<S,\EFP\7#5J>3 X+=U#BIM*G$ U]L%HLDTF$-7B+3@3.
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M/6D7JIC5+O:.^]FZ +14Y&7$9T:/6PTA?(UMMX=T:7@^#$Q^E\F=LG#8D%>
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MXBSZN1=QYE6C(.YXU$?U(R9.:[*M7N-[#A#ER9G<N]4!$GTZO/DQ.%RG68U
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M*9@11XA,F"3.HQ4:($6I2#C(KQ74E(6?9X6420Y[]"1Y13AR0GG$F77(IJ0
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M#49Z^\H8;B]4-?ZW&DS=H5/8=HX]1R]!<YGK^.\/C>-V\HZ>:B%*9C-'"BG
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MJ) B7SFB>G"8(IODE]PIY%J(MY:*)^8_Z%VYU<]WTL^O^AZ.!NYP-/-$9$*
MAV,A%$M=02C%(CJ39TRD(=&4WW>B:8O5M%6L/[AB_4:YK*UB_6:*=>;X*C"5
MF:2>E#SWZ/@:HAPOB&(ZT#0O\CSDN.A]Y[@V"ZYI"=!CX?>O6XOY<CRZA 5?
MOQRHX018'9G[<@;X\D,78)Z\NS[US%K'I"0EP@;'3&RI,E*4HLRY<DY;N8C/
MH1CL>)':'*C#A?$REZDQ7GAM#>.ENFW_4O[=^Y=:[@BG_1UK;&*OTMQ*7;O2
ME1U"0S=IBMK'8!)B67TH;+_ ]L'8H+J;[/?_'( R+BZG>)]IC26F 49D,E:X
M!(++22[<Y'QD$YS2'H$HNE[%:>W\=) ,JO>N;HM58S_!3G+FAM@),;CN4!_F
M-@VVPY#J SFO@ V'/_U(\@<VY2P[^OCNP^'^V37\?)K;+/-<,2*8D& P<#J=
M504I66:5<*4LA7_T-/20-1P:R/HI!<KS,K,ZLR:5CGLE0+R+LM1YR6UN."U6
M*M">:X'D^<E.QU=@-VHWO+5R_2-PQ&^5=S^>7IVGZ\F[4V&%3:47Q$L-=)4B
M)3(M'!&4.I857DI5/GKJ$5+BVJGQ$@36;O(;]@>?CP8VJ2XNQR"!#10'"'\C
MU+&C2"V(;&QL[B06VPWAQT9"5\BO#PW)L0F_[6I<A7,PP/7L)H<*^V2&H3FH
M;<ZIQG%=YAQT96R,<Q\NW;!&E8!]S]BR;'?"]?,O,T0$FPD^KGLY,")!E</K
M[29_GKMAVZ:$?QR[284=@RWPPU4%S\ ,V"A &_D&6B@@UZ"8?+(S<@LLM@0L
MEFT^L-B-0&$+CDN:J4Q*;C-:",Z8$BPW><H=U4HJH<N-Z2U9_;HW^EU/E3'3
MBVD4TGG['P3F8A2PH<:CBWY78FSLBRY"@#*HIX/0/'N&_:S8ICRJ:W01&@2#
MV,;2@JV WQ"T1BOE38?+?%,+FHG8?]O!2T7( N"<*-[+$IA\RUZ[7T8C>U4-
M!F#$#H83-3Q#G(F]H&RV@<+AVSUZRO/,R5)K[*;%/*'F1 ;O!+P5QXRC)K]M
MI]8& !?\AHAR@P"5%JF\B3Y_K]'V____!*/EOQHHO+CPGBU$YWU<U1$M*<*V
M@<>-8#$(6; R=-C!!N9JXI)XLZKC^LYUQ\O/&KG8339Q@P[F@ (;$"Y?!<2S
MIJ^_43>F&H-FQ$YA[ ]N_1AP3G"#EO9T)ZFG"+*P;N^B][*X8\GC'@16NW%/
M=AJHGJ$-[<;U&L!#7'_S4$32PWYE1+>*F'[HP45XK/[KXNU1CZ*_CJ 'X$Z!
M^]6L3PVNP??;3?:6WF[U,B/2(&ALVP!2Q+LAS@7Z70$5;X@(<:/IL.MKC&V*
MJ/G-I/MBC/@:Q*<9-N#C4=-DGF#JZO))X-L(@($+Z2[L.+W;(W!QX9GP*L$X
M 0T"3L3L98-YZB 09Y _<:OCMW$M$23B$P^*Q' ?C'-V&5(RX /U@!8CW@_B
M36!G^33F>EMV6PEH.8=L%>UMXR<'_(AH(^%+C2G=3)EK+65T"-Y7[JJ!FYQC
M/S#BJ($>0^S89A/\:#J>G"?_F:HQ.(I/(JPD8C:.(UX27%[Y5DY&X^ W].X9
M(#V ">HY&8B;UL#R)9BY0'RQ;B=K=];)ZPP^"1/R\Z+D(6R9!+K@?W&- S E
M >7/*Q-6 Q2R+B(5.)2)Z/X$#*[P&H/JG0OX<$ (E-P@]0MP7!T?]%>"=YC)
M 7+= N=''HNQ7,1=C<O *^87,G2@W6HUOL;5=IH!7P?T8O,^\24#(EAR $%2
M<-N;3_&.*]Y]?J^Z7:C;I\+;WF4+U%TW(#Q_V+Y0^'S=.^&]IL-N'_ 56[76
M?;CSB:^'MNQQHZ5OI%P  UFYX!D$Q\R"-M;JQKOV%=#2C<]ZXH=[W,.W;37V
MOV;Q\,Z"79AY\E%]!3 /H-R5PKNUPM?@</2^![]U#X[0LM>-!U_/FMNW:/-S
MH87[8#_\] P>AX<EKR=3>[W%F._BB>M36ZJ<.5423C-.>)'G1#%?$NHA$G?*
MLJQ<PIBWC#F66U>4J<2)LD(7W)<0#VME2^^7,.;;W4]P^\$M_#2X_&;8U]6A
M_XUO_O1%B.JKBPC5#?^_B*]UILZBG70>1#AB$M:FBBZS">:ZA5%&<VE')@)6
M!H?I\G+0:H;@"7O\BNE"C/<*=,$4;NDB[!:XS>@11; @3/W-T+S@HNO+YGF-
M-S>W4+1<X/RJQ+OP*HA=7(TM093HZ]Z"&U2VZ@R=A>3QM(X>ATHNS\'S-57
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MIPU.L(X<EVQWEFWRXKVN&K>B!C$.Q0!A<%\S4A/'4N%5W[4")VJ1$_5AJT)
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M:!6PQZ,D0,:Z)"*NPA7OW>Y:J-8EJ+]/(S5O%-SL]X6'WC-F/'5Q:$N<L=8
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M6UWVY;JLCUZABI+F2A$!]"*\=(Y(H15QA5,LS3(&E L5F<5=JX V%8BZS7W
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M3F>$,UH0K1!#0L*GVN64\NS14[[#O[P2>&-4YBU@R_%W9/!J. W)W![:WAJ
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MAR8R/WIUFGOO2X^#="PX$=S8E.BL%"3-2G#CF,B$,N!#KE#+_T IOH2=!#5
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M"M]S[>36\0[+]9H;S<\G^\>-H]WF-CSCZ_'NUA=6S\]KMB[^<U4GNUO^('%
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MWT0AC>/# TN<U#!)4. IY(J\"AFF H*>SMTN)0T\K[&+?LL_-FKE?O_0AO)
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M.*\HE2EB1M<^*+RNY*)V1A7IKT#B)I!(V$HB*'%*12ZM-3C&()G#7CEK'*U
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M "\:6Z'=.&D<U4^^=EK-/5R_@G:>M'C]VYZH'^\44H&M*_#_+N>E #=Q@^[
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MM;*8=OQO;LIP)G7B8% TX+>;25[9T,<C>=.*Z?>> ./B!/-$#J9#9KCV<%+
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M$VL?.)7KFJK7LUFT^-VI^-_J ]O,TE]J,91""X-BT1\*,DP5T[H7T,WUQKV
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M]'WDVQ1TS= #.8U#!X61Y+''*?4) 3FUS3&:.49;>WQ:N6]KA$]3SGF#4JM
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M=SEA@E IWKQW.H\Y85W-;:*&JVX&,YY803.8\:*8,:&7B8@1GS@NV'\4]+(
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M]LVQPL, <RJG/+$#YOE1A'SL$-"V& ? I#9B#I>N"'E$X_C->_QXO%QKV]6
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M&)S.?-JFI9"R3KK$\3#Z#ET_R78O!TFN#8E7O2>@?]]\&KNA"[PB/1LC&O$
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M'&RL9?#Z>W)&>Q,9M*@XHLM^*%WGZCK]#CRX4<E((O17QKU3W]NX[N%4[RH
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M?#T_[2L,.\6'?__>AV=^'GSG@$L?H$W N5D5Y_NN<] _O8+OV8"!R:G"L.^
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M1X<>62KC. BH>A]H0L-<*TMC'*U;J:YU7[^W4O+@.]>KH[K.>+<:]?6C^E*
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M\EOGFU$FKN"_;MGOO?__4$L#!!0    ( ,"*<%+[2R?X$A,  '7.   1
M97AD>"TR,#(P,3(S,2YX<V3M/6MWXCBRW^=7^/)E=\Y9.AB<YYGT'D(ZL\Q-
M.MDD/;/?Y@A;@+:-Q<AV$N;7WY)L8QMC63:P]ETSIZ<[ 5655%6JEUX__?UC
M86MOF+F$.M<=_5.OHV''I!9Q9M>=;Z]WW8O.WS__\,-/_]/M_NOF^5Z[I::_
MP(ZGC1A&'K:T=^+-M=\L['[7IHPNM-\H^T[>4+?[60"-Z'+%R&SN:?U>7]_\
MEEU9T_/)Y84^Z)[B\W[7.!M8W0MSHG?/]'/=O+@P+A&:_&UVU>N9V.H->EUT
MCLZZAMDSNQ<]T^CJ>& 8T^GE!3X/D'ZX5ZXYQPNDP< <]^K#O>[,/6]Y=7+R
M_O[^Z7WPB;+92;_7TT_^]7#_(IIVPK8V<;ZG6G],F!VU'YSPKR?(Q5%S_&%]
MI)KC#S3#SB>3+@"@W]/[ SUJRS$1"6[BN!YRS#5NQU]L;VUY[,1;+?$)M,",
MF&L ZBC 4*>[ <<;6=X:+MFKTY/@RXZ&/(^1B>_A.\H6MWB*?!M ?.</']ED
M2K %2F-CKA:I!HFO/<1FV/N*%MA=(A,7LNWS#YK&94D62\H\S<D 3I$[$1UU
MF2? NCV]R_D=2/^>FL@3*IT<6 ;H!-N>RW_KQB@^?;A6YT2] [[;G2&T+-^)
M)&#0D?"3\IU)J+9^>7EY\L%U-;<;6?43[;O\QZ[>+T<V3X_5:<-OW0AN'WV(
MYVFY/D1P._9A^VQ3Z4H2\FL R/MRR?NBG^W6EVK]J-J)[69$41P1 "=[6H:@
MB\U/,_IV8F%2.!O=/"#^0^X$1(Y#/8&%?Q)^MEP29TJ##^ CKD97D2X]XVED
M:#/>9<N$%?]<(68R:A?,[I,EHTO,/(+=I&<2".8,3Z\[W#]U(XOZNXTFGZ G
M49,,@?2$X%^?  BV[^.11+!<-ZX[+@C#Q@%OFCQP$]EE!PX@IF\+.?^_'[Z%
MIV6'#R#$(?\5HU\R7';T .)")%-%^AS^%;[7B'7=&5$(JSL:_^S;\S@OXA$D
M@Z81K@A;+(;//8A7X8_6C>/OKB:@?CK9;+N!Q7>Q]>A\%C]O#BT$#IM( #<F
MA#)<6I.V@H4?1JR3,/0&V3Q$>)EC[+EJC$V#2!BL"P;W@:LOP!X<<C@$UP+X
MMK+Z"3$8R1Q[!/I6@>]I>+D0^#24"@$^^&L*X8\M$LN:+2Z=/H(9%-U1G HY
ML')Q#'H]8T,<,1Z-3K484TO%\(PM#,'EQ,8CZKQQSP0_/H$GPHQAZ\6CYG?D
M!/_.J6UAYG[YPR?>JKS0*E.2B]B (%LJXIBNEB"LK2EK@J0&M+4D\;]H ?FC
M7I225@5CNW^R<HTY[?7.#JDQ1P,O1#E"[OS.IN\5['L,*I?D6:]W+I4D1Z0)
M3"T2PB.;(8?\*7JAQOL4A(3E?;VGZT$83US3IJ[/,/R2!&\IGV^QAXBMJ.K;
M &5<-WKP1\IU'E6&F%IE;OS% K$5G;Z0F4.F8&T=;VB:U'<\XLR>J$U,2+05
M[8\:+OGL&.@B!TO)*43,S5$"M1;CUB+D1\EM</L0$E229+]G]+,S3EV2(LL+
M?SY.R$T1O/+0:J]"#3'*1#KHG0YV%6E YBC03?8_XS?L^'BR>D#_INP)K2 :
M+N41=R<C]Y]GQBYV&1J'I+7)2A/$M8#ZT>OF"NLK8KRR\H8/H @9W'+IGQNB
M*%==^FMZ1WGGR@2XBV8SAF>BMSR3%S/F -(OH"37A0M#5 2KZT*:>E N"&S#
M43?R),;3<!/^QW_XY W9/#M'C@4#]Q@Q/6SQ[PZ@*&7(RK7FTA!%QNI:P[OR
M-XT3U!*]$26DN#_!]T<URI/G"S9]1OC:Z0&4)8M<JA)ZSQ!5Q.HJ$1-LI<@?
MO3EF=\1!CDF0/7:FE"W*E*QRP:49.OR7C04$+FV-3$M@.PJ$.F72M2(DT@Q-
MAR0M$Z9+A-/.E"R7Q4\,+Q&Q\,<2.VY)&UD6J=PV#@Q1ER\AQY",%M$YFL2T
M$,2FH16$"SQZ6/+UC7V)-Q^S7,8&Q-)E91S0$E'/FMI1TDEY5,N:U=')97H*
MD6XYF;8[,\[E.T1\S,>63="$V.4CU@IXY8(]@WBUG&!#2EJ"5"M%?$,9H^\0
MNJONV(O;RP/1<SU;B(B!6\GA,H%F!DH>65X,LF%_C**=@60\_FI>1P(OMT:7
MAIY9B$D)H]U>)6;%G>\!=Q: >N$OEF@E]K54E)$4EU1>_9ZA9]*RE+P"W%J(
M7(NPMU)Z([I8$(^/'\+<$15E'^RHKV)+X*4.!5Q*MD89(Q-!=PK=428EEZ(+
ML4A=4+\_R#I\F7S:Z)+R65S-197 )S>! T//Q ]2X;7=B>5S_B'P$LAQ?&3;
M&+DX\A>^8V'F4,?DYR5LKOSB:\Y' "[O_ [<![G&&(9>;KIWM;!76M M31".
MG:GHF<8/Y<9]"]LD>W?4MKU+^G>]"?KVNW[4N.9HW!TB[%=D^_@!^,$#:\X)
M-379#BH/[D[U[&HCQZ,)1%H24XN%P)?W8Q:5"N[44,DCO+-!-@+/"BE8]4_@
M;F.@MW4.E'+N4@QR0WENZ IR:J]M4SB$I28C%41RNW>A9U<2U8YG'>659'.I
MJ54"GWRB71IZQFLI'JYKX[RK?LJVS)G9OC[HZ=FUV]:??=WD8:E3"GG0TH!A
M )+([B';>J*T?1%"EJ45=Y07XY$:L4'?T#,N:*N0VE[RR7)Z1T&IR6=@Z$K&
MK+TR>5R*K3XV4MQ;N0DD=R:&GMTT$OCP (7&<;27Y:7=2 94[D-.!]D(.</^
MUCJ0F)D[> \)$KEI.C/TXJEQ]!MI'B=^'9K E$I^1 F=7'CG1C^S9VJ;\%*?
M122.@D3.ND(S=%U_(3XN>7!#'9]<E!=&/WOR=XLH$T6@!(VC+,-9=(, V8@N
M^!9MT;TOP6[MG:=G$6*Y="^-?O9P;]Y$[0I:6I*8%E([RADY?+V(!D)YAF&Q
M-VS=41;L[QG#E.#K0+N(NPQ^J=2-GM'/'NK=(O6 8OA51%,#HM&NI8AL*\4_
M=D!2^!5]J(:H20!I7F#PHU:; @J@-0'>3BZ720>R8-)4 "9$MJR7Y'@;LX $
M#[G-ITYPP]CZX]#VWV 'J)8[5%,-M=RJ@1 S:_@I$0J#%M+BYTSC+V,W%E+\
ML>T6[1F;U#&)3<*+ KY,IYC'YWC=YAEYY=Q99>QRL1M&/[,BN2'V-#DN^C7!
MI!)PFD>YIR5S&RXMP9<0UF-Q"\!]Q:,YNY.1:\*IT<\L"11J0D19:$! 6VPR
MN&_YX9VDA9[S_4ICAV=WP5$JVZ;OI</94ACEDCXS^IG"W::I%R3@4VU-1%M3
M:;M$JQ7T9 CD\CHW^O+HJNUUO&=L\Q>UGI!XWD!UJT$*1IY17.C9<T,A BW$
MT")V#XV>_EU]42=N+F?RI9X][ .@?_W^8]L6<M8<*V5@,E!2JW+:,_J9)8($
MNUMI2$;TC5CZI?+;(Z*Q5*M/P7)L.;\!D%W]LGV<+7F*(@4C5^>^,<@4?2(^
M_[?K\D\GZ=>T@M]3+V[Q][;"EP:%//AC/[_?XHDW=ER/B8=QQ$THJ_"G!?$7
M3YB9?/PS/!2[])^QY9L<84=#$X!"IG?=F2*;/R3$'Q:[[E1'Z!!;[/*_[@ P
M?YB(/_MXM<2,4.M5/!P4/'3''T/S@3CQ? [X,Z/^\KH3M"8>7G2TX)DAQU]P
M:$YN#!]S%/%C9!E&C("I_,;\%\^W5N*FK/#O5_SAW=ABVVG.D%5 BP=G^<%C
M(*JC$V]67GD1"84A0L#(^ &*6QS\.XY7M1ZGB1L?(N&YN2.N@*D, X+O)L';
M-=<=H&$15:D'GRRH ].=K12X\B6Z#.;)9^:<+]!\XT=/1FA)/&3?8_%(5@X?
ME& ;._)MR6.ZBA#)EV?]S,+6T!V&];U7NDYFGAC86/X$[G#!;YK+9=:AR.W
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M:"QI0@X7\Y6@4O<"P9;A%!]RDP,UU01OGZG/&/[U<>(JB$"&)2=\/IKZ+QX
MFP._DS<LRB@\3NKW],NBHKP,IO:Y'E>B0120B#)7/IS\]K4/)3QN'YV,_9E2
MBY_9?\'LC9C85;SFHQ"\J8EZA:2HZCFC0Y!JJK%+'C0+5FC!06T[<:9T5*T
M0U-UZQF;F+SQGH$,S?D"L>]R,R$!J-U.E%Z;$&=I(!!=9Y/!JG-X+\C^UD"*
MZ#1UBOP,KILY_#-=KA5;&M:N#>$E+P^(;S3GQZ7X\IWP;4$DYHAQY(=PRO -
MS4 KKR)E;Q^,;@;;7%7:_PI6&=K[3@M+Y@7A6?KXGHYXC0UZBVS)+B$5T'J3
MWHVU'4&5F$^0PYEDB>Q(**'H9/NA2N+YSQTV$7=YN^8<$M#//_P?4$L#!!0
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ML#<[6@FZ/@.NKC?>AG"D@S:EDPQARGDB.=?$&:U(!B^3MHX*V"_IL_<CAY0
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MX9>Y=$&$T3I*BHN1;6V>=OAT%2:X9>_ >(8QI72$4EIN>;.1..<H25YQ!9"
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MKN$DANM@'9QF#WA3?W8_?J[4,.+1\>OVB3AL.A5;<-1HZ?70<%7%U+:5USM
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MC+AE$'1D/*"!;# EUR3^T@G=-\FC/12TAD;[E>T\2O6_PV0"9(K>!"M_Q=G
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M&PG=^=F T L5"C ;"_D+)9*_(" S94V1SL1P,"M\.^#?%N5::;1!5*K[Y?Y
M<8G1.<E4J7W2HQ$LRH(,G"M2DJ<J8Y,#L3O$;S(WHI$&&QR9&Y"^'GW&Z1;"
MDL8&R%XRE#528B3Y'@#5B,S*<PG>89,"J'[@GVKR84LM-DAQ((/@>J!$^N?5
M<(*T'@(Y^U(;I<]HQZXEHI?U5P:H%$(@5X6[.GB+UQ9I5M>&*T$ 6%UR;'+G
MTQWBL]GWFI+@P85T$PVVX-IDG,BXG/Y,8EQ4F&^&6B0AU5G441#T9D;R;[PK
MB97@.5I0$'R3S6T+C-\FVQKIL$& H[NT!AAYL<D9EFWM QKK,+AB#"MD=VCM
MDS>NU0B&CA"_2;(UTN#A3+J;-+..PC+*%Z$39P&B9-KF2,)RD7%=;+:E.&N:
M'+']P#]5DZZE%EMD$-[=HFN=WMGE'-_-5+J!14@^),NR\R0CJ0L+JLXS=,%
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M&**J?4Z"ZI+/VJGAUCH )VLQ]"+Q'M/-*IYW>+F<XOOBXP070TY6(%[7-'0
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MP.SJE)["T7%0;2[:-R(Z?;NA%UTT:#EZ!TXME3PK'R8PFB[F"MPXNT\C;&E
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MH+3!6AXQN,%C^':351^QWT<^K4?Y;17=53P'X$![M-6ZD)=@E"I&&')<'>K
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MAF*!#CXR4P0&T:0IR4,HAS_^^U#2 [WO)>$67386MW&+6_NWK__KU_'L&AF
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M'>X>M;5%!3!MQM_LC?QD.==,?2T2MM(GS%=W@@OS%2WB"*YDHZ*N\2B3R$'
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M;JG5^T\X.:WN(<"^*VEN0?V(J8(RUQL(F")M5LRGJ/__]JZMMZT<2;_O?R'
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ML97HI\B8'5F!1F@0+.E0[U[-FL64+<DYE@0I:V_VB\(T)?/%:.^9(=YBC/-
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M?0AOJDAGD@5R%;6MPT6!1<?IBY?"1U"H4YO+ 9^-\CYA))VY[G;!M\7,Z-O
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M"JUH<D_S4X0=WX >",-I0P"VAIZVU'>M/ZY?ZMUI__U?_P]02P,$%     @
MP(IP4N/G=QYQ<0  DW0  !0   !E>&1X+3(P,C Q,C,Q7V<Q+FIP9YR[=UA3
M3]<V&E1$FDCO1 5$*2)2%20VNA@!Z24J2!41I ID*PA(%Q!0^ $J36JDAA[I
M @+2!81 :%*3 (9 VMD\[_-][WO.>?XXYQNNO:^09/:L-;/6NN^U9L+XQ9B#
MG#+4-="%,#$Q07Z#?Q#&-.06Y C383N\'SELQXX>WIF/'3MZ[#CS\>/_NEA8
M3X 7R_'C)]A/L+(=-O 5!SL;Q^$_AP_YKZY'F(\>969C.<["]O^[,;Y!N$]
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MA6#44D6XEV(,IC:WFJ9=*MI__=#55##W,-QNM*RIW:T4?7N2,V2>\@1H-6=
M'!&_+IX;IBM1;Z;<(VKJHKC"FA399MT3\C_O9['G6;0[M>FH\^@LGX6E+U].
M1>4 <S48@A4%\^OS%)843/M00Y-8QX7NGK/W67-E_DEH+NGBD!_*F<DL"F"5
M3#">=[RWK6MA%8N4('-]0XA@W!/C+5I.$'132@,'N[65QZ5<%]RF@IMUMTR'
M^[6&>['X/OGA2^;WMO5;S=^_^"#(1GN1.$[T6<QO^#-E_Y3D$ KP#@YHI*RE
M(E$1=F-JH::AR;88R=V<!4NJN#*QW7Q4 4?+PCC#V5W]W_8_NUA 3,M_7FP0
M)&'9XV3D7"WP ^*S9O/ Z M'(RL@ET,_:08N=X+1@A 5+HYN__/$,=$CT!_&
MWD>Z<A+^P[J<LRMH\Y+8R:LK4QBG'++J7@?]]+!\DS7%+>1)R@V/-WN#<]BC
MW6(3]TJ^Q<4J4%L_&21;^"9KS&=?EF26\=Q'E&A#@=8&@' 'Q1*HN]"N+4U@
MB:9:AWK+QT/?^.$%[;J#G@@?>:U3H49:/,.<'B)OX%CWM2WQ;H%ZV#-X,I_=
M@6LFU6EBMD4O"\[263>(-+^B6%Z.#;,)&4Q$G@!:1Z"BOOW.5@R(&]=D;KO(
M>,ZUSH9V[[G,]:S+'N?1ZMF;XB,S"B.>LB9'OS'=%$X@F.T6DD1 =;.1/0C"
M/>.K.-@KI%(#FL@<7V*WEGV2R%\\M9;VC#7NYJ.80;&AE*_ID0;\6G_2;B;,
MRRU@8A $#]C&4#$9*0>$Y51C$JK%S;WX"YJ(QF5I*"_IENX?'AS<DY57G@OS
M" M!2M5X6M-W9$C5M-? $SSYG&*GO3:E>UQ]RG:JWPL629<DJZW]<=O^?5FY
M>'KV=32N_I;8QXZV*WII=A?BDW43-V:%!GDCCR,'4+?QJ)[5/<V_BNO46RDU
M\G:A^=HH/:^,";P%+!@V]P5#N)=(]L=^LX<N!)(-&!#63V--B.-1M'1:,RUG
M*:@6;2D1\&'1N!'J/%WE.D#=$GV&?$H+@\W-==/0#(B'(BN]KXPBQ<4!M)F0
M\.1LH"V(A*T*S6C#X6GP7V>QC=\G]R9$=P8N(25I:'"X> H AH/S(<IS^#B1
M\21HI]<)JL/(B'5UC?:=C(%LE;(;CF,6G,71];\Z+]^VYKE>]L8")Q25!?9A
MU@7F2A%L-Z"=Y<!J)#T.QCGONA@84U<,-$>IH4/Y1PQ75<?<BE3KPKEM-7(Y
MKL%G^KN-+I;WJWL48LT.;D,--9_KU:,&L63Y0:J [6U:5#6HK0M^<L^T<I1^
MT3TMJ.Y#JDMXF\7VZ0O>5T]9&!5:<'$V.D$LW.YW.28LX"YIR-]]&!//QMV4
M\SO=_T J-$U9..K;_(Q->4_H)LE^*WAB$\Q<F6_0DC%SV23_VAPQJGW <QRG
MX>#F"WAXB*8+J>SN%G; *J[1.OF\F?1WM\4W^J??ZSH%3LKM  L35'%%8I3)
M1-HTR9&6J:6>Y^:_EVXXD7VUL6[THN+F'FIR<=O3"6VK-R74 _WP[/*<W#P[
M[!L#4B6S$4^Q &?GMO9E!U> -42UB)QIV3*:MM+I(#^V)>5ARU*?-(E29>_^
M?<.GRF!@/U^IIT+*NYI>@>R%$I[D;$S.&6O>(4(W/8E<5L3ENOKT>P1ZK._4
MT]B=:=E,G^_,BW2[+CWK<5O@DGSPIWOBB,VEM&<#M_@J*OW<28C%[&Q+I$M7
M]R4<QYKQO.3&ZA[H&V/8GB"H^""8C,@"K7K.Q'=(F03L/%5-J;NF21,:*4T1
MBY)9EI\XOJ!%>G^21?SY'P0[9FX5,07H3RS7D\<H:F3!#A'KJL?H*D+GS%;B
MLW31GZ7Q*ML.<J?OS75)FAI=F#V2ZH6)HI[2I+->84!TBP%"PP2P?[4IAP1R
MDW WS$.018_[.(0<(4+?T(768ETXU"IL9[4K"O9CE5PR7!7%?NMO"BN]3#?Y
MG!I?RR-FD-&OH7YJ5";2VW[3BW;.F"ZHDF;?^<YQD&T-7H/?STOTI44#<U]S
M*BPWYW',!*XVO.#:56AL >\U5#C5WBDM?<*DHW%R7JE'BI?:F-.78/%6ZNE&
M3+%-2X'$!]12.FF>]A+DJ8-D&6Q'(R*2 8%6LWLV9*&F?!6Y78>;IIQ+1#9W
M;O,T2'I%OY=/:I"*K1<J[Y$,H.F 4RD%+JQG8N=('K(+6PN/!7#E^_)4SH4L
M0V"?:]=J0U'*:Q_YI^)'-TWN]7-2?)E?]S_/.J\&(LJ7ME<*/6H:C9K'5_TL
M&BB;$ZG>_(;O$XL7<GO,G$C&)+3NP;4/!R4.+!0P@VLU9D >*?[JZR8![!@W
M6'P.(7Y]8DKK17Y9(E7R1>K*!]?M/IZ>EO&I^\*!TO;YX9SUDL=X\?_"3I;K
M1 H0"*?WG,QA0 KM39N>0OM<ER??/?MK:U"P6[/[%[Y]S0Y_J21M3MS=3=VW
MIKEFUY7VGI:.\<!,KI,&")PKG5R3*!P752I#(*?4(-\! 3C-3.X'N/&95@=?
M_!P]P!.8^<RTT)_I^^GG0"V4RF=$TJ=%[,J,PERY8L;]7U2G12X8$[(SZ:DE
M:Z?SNF"R8R>7#$1F]=."0AJ]3[-M?U(E8RD\0*M)'NTE;.Y=]CD"HHW3T2 3
M5QBG?=&=]?/TS*4,8X%VBMQ=:U6+< ^Y^8G>"&G9Q#/.'7U>\L9S.96)5-YU
MTMPAG0E$WR>BVV$G9SSN&90)44V(+)T-5=+%#OI:W6[ET@H*/^H>!UBEN=TW
MC.L]6J1-T^;[=+?9IJXX@>^,W+G-H! 25358LK.H8VS-I!#.!<\N39VRK-SW
M(O]!QH? 0:LM:N%==3B=@)T;W'B%4P@V4',?<0C,[10X,&X;K$>?CCSAQ?_V
M_$UH_[&TAU\]F>M;#U-]#08DDP-!O0JE;91BCH$+6>R@,:JEZ!) %"4-#^^6
MN>OWC*K01+]5N@M\K5UX)=Z!3L.?GPY/87N0?,D[!=K!15:%XP0RYS4;!R.P
MM<Z)I>M)^\##$3\\LU'!5/\'/MB'Y_QC(]VO9]M/M2R;FU4K^6W$:S/%?YSV
M\L"X'5@CHZ0*NY+WABMG9U>62FAP%. ,\C -23KK&.4FN0#.XCZK--XB/JNL
M6ZL<HE,1-C!.2$W*%+P'USIUC#LN,^JU4M(1+ZE7I#\/XU!P&SH8Q)YX_;(E
MI=/"J0#72Y@KANGP@:ZT3[OBS@-+3U5H#D*/E:IK=Q2I3#],CWW@<8U+*GS_
MD6;"@!P#+3BL.1!-@A&W4BA*(1[CMO?(<)R"M<+&EB**!T:^?7%+NK7!0/JQ
M3J5+Z!ZW,O.=:N(\=;2N^_*\F-97P+9/9E#48>+N>ED.(,. 0+ 7<2&WO6$6
M/\[TXCTF2[33$<4P('"%?Y^9R-6A?9$@LZ%,"4&.9K,3L6^J,6_B*7>,YO\2
MTW)PHG5^)U0:.5WNQ P,7["X_C#A?/G6F2/7ZJ/'E=_=-J>%L,C],]$%U A2
M>:-PXNA.KE,AKK2HW9R(('*JMQ<#PIXR']6)XJK!1FK=)VW*UQY$6SU*UO>2
MS+BY<>K$LC^OMI2>,C7;TB%+!)4U;=7L[^]6U](S76590T%]_O%EM,Q80VY2
MM6!MK0=E=)"M2, :#+?(T2>@U7H;KRAW/')XFHX2RG?F0LNHLTSDD05N'&MN
MHL_^K'3%J->Y%G1%0O^ 1D,6\J>%Q9FRIDRO?D04 T*PQI,O(-JP3*X 1Q,K
MY4YMSB=R@'[M\*X'E'QKUQK9[^'%T\D7O%CM$OHEIO%#K)A3LH_'W^F%Q(T4
M2@!]EGX&#8^9Y2%[$&3:IL83:5$+_49M-E4>V5=&=P.WEI+MI545*UJ96W)\
MM>HY;@69_0C32;9UIRC/X]L3CX7($4Y&$=J_9<C^^H,4'=JL;A;I'@A"#KK]
MUY#. 5-O<I\K.<8EWS4.?F^WP/(REE3M:-X[NQ6OD^^\-5J^M#@[G7U23J;+
M<>.3R8A)2YG*8F9S:1FZT&S;@WZRD<* ,,'1,; ];H00T"H&\^)ZG4. PZ:"
M[<@3Q)SV;*DQE6:C;V@;A69,I/SF<IUMM.*30HO'V8'WSTV['(N4D0X\G:P]
M +IN>0)B[B*L$9=(ZYA8@6](4D!" ]IC1 AB%,D>PD_DBE*9,3,F;$R-=79'
MXR^>07L$;BG,/;8(8WW?LO[N-/]1IOIC$&25=*1 (4N71KJ[5^:'S4)-+3%<
M8$;(W:4HRPSWOL%4:#F6R*>W(<B W 9P>_03OBBZU1 #PGT;V0KLZM$5@;DH
M0P9D*3X$9%>G,$@L9M<"R0W,WRAF0+8;$LD1%!*- ?E<18AE0-@X+1F0U+$%
MP(4 IS(@0# #(CEZP(" SQY$M0(?2"Q4'6X*,P,R!"4W@XJ(RS$@:2I APGT
M*X(&YG*Q6/*98<R^(P+*@'0H8M%X&G_.:P3YGCN&6IY+/X.D88 _I=2S#$A;
M.)@7+?E!)ZE@A@7#SC(@W[4QG0S(SCH!L8S\@?R>4\/U$N2VDROM#$AU83NG
MI-7(+HPG%+6AEO&WR<2^<')KN090>I0& H]8W)7>5!F6TR$+(,?Z DKUT 8Y
MBSV"F5<E6\XW:X58$4+.(;BPAK/W,YK?_AY>A9_SIW;&O?W =/^])R</7'D"
M!;1>!A[CH?0N6(5@&,9Y,,:F-C&TG.Q%,=J<L.'LJ)PR(,4;KJUJU::=_V=>
MYKI/.(<01QSOEN7/P4",4_7H104GZ[.I!9&J^^_TA;K3=>TT3.-?U<GQL%58
M0,7%X"2D\]J\=)[3/B(0:W10-EB:!EV?="^,2:B,:=C8+&N6Z-Y^3M&DO@!7
M0I'ZE##8C8^P>>U_L!?A=[NY8@>]K_R2K<?KO*ZNZ^/X[ O\UD92<4S"_0 <
M6H'8]"*,D*9I62&:E.LARF/RDWY&&B-VPYY>'(.?W6^J>&1IF_:(>D5G,L6<
M3N+P^7+AK!(U#;3*&-A<QD0.*_U<#\6/*D886YP5(D:L4.W8/<35^&M^^ET^
MFZ!9^:C]!%ZH(L#WM%VDX@6/+[D2JF P/20>[V?H;=AJ-JHF^1-._$:+(!DW
MK^ 7"Z_5K6VX^!'/HU.2^C:D^$N+'46<_7;K+\/Q(5TD W*E;0CWI.!*I#!R
M6\Y\HA^FVH#?T9:1[;28IPY;R=_:D]I;79Q(F<P9DDJ6-ZE.>%;2@^H"IED6
MU.,9D#EP36MK4PBH.=]UOT_MSZ9<PBP.E)]$J+$^Q>=S6(>AW^';HK8?Q@7=
MO-Z+S  E'$;^KLT^0;#+J71I%_>?\O3H$, 2K?H]@\[VYUM#%8:Q>X'W]MCN
M+CE+W7H[E)HEY@GBHQ#P*(U\A=!-%T%T3SW%\I#[X(@-'=O-=8_/WR73+O?F
MNB8[']'MNW+?*FH+VW]K__Y$=='&^ P\&_?#_*DZ3C9$.2Q]ZT*-UNT)IY%[
M< \:Z#016<#F"#&Q'48P]"*?L\B'M5W9W/A[#:H7WC[+3+EU0ZS*/5WXAK]E
MCVMAMM(*]JI0VX\';\4_]4 '86V#D1@AP,,K,0/1#IPH^(2#"9,7'"9))3W2
M=1FX91=%U9F.]P&RN3\RW#(U39R2$IA4#SZ!N&\68INA"7L-.Z*"$;ZUU*=6
MA/+(AB;<OGS\!G-S_$BY>O'\7[Y;;TMO-QMZ+X,1W&/PFZ=Z%Z9Z)1%P%;>X
MIKU /X5@GUX]>*)N\<C@8]-H?HK@O7H&Y'X?<]8/>;T?%AMQ<U]A7YRT/BAR
MC/[@L1MN;J%;H8S60H\_UM7XL99@:S13:*PC56L@UQA2FCB*(LN@J;S8.125
M%SU7"G#0A5IIGTK=)>SHBL30L>+N@+*9\Z>5(?#48\%9#]$<%M+.4DV)\I7!
M<[FU%UA/+TZLJ):,=UBD&B;[O,N:=OFCXCK</GQ_M43'-5D@YGQI?Z(RK13C
MA _#U.:T&AO-Z74G<@*N;E<CI6L:T(^-FB]OWCJ!4GA\>M^L8+G]08F<UE.4
M:(/Z#I1B%,)+'J% J3;$@(UTHJTIY=IR;*FM4:G;@<.7QR/X/'WQ#3SD&$M_
M\T+UXS&G^(M9UH[.27('#:WG,&*'54+4Y):5WV DK,8B-6]&)4 -K<TW@<I8
MTGIC+5R^(<E-V\0ON\M;/?;F":]>")A\YOQ87ANVEH)<)&$,%,P<:M&9:,?%
MP"K%B"?0\4?-9*^G1:LNJ\&TE7>@$:(Z&)!V(+ *),V?#DGS18PS[(GBE%D;
MI@*_T;>@. 7O\L>Z5A'*WTZ<^K65I#WCO_%U:@JOOZ@4-,%SB^N]21I,.3BD
M6)_J GHYHIZ&H5HS($Y1()$?*4A'F .M/QD04<P\-RTUA)T@T6XV5N:EY;G
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M9=\XD_K*R2]P9@B3CIDRF].+Q3@K)F9?)#,MO'<628]078_7-EBJ"F3^[<J
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M4W]6S6_-A3XH[*&H^'=J&1A<V!B07BLZ']!<#JS&T%O P!G^D0'Q,);KD+A
M@&_8SAM[7Q2]Z4Q4C%.8WY:RNI@7U_Z0]W)]VH4TEH8DW./KCHVUWIAGT]LH
MZBFS'+(<M"UQKV:0=@D[L2:L+5( #??H17C>15RT56R9H,('GMO=]O VEH96
MG>]>\<7./-_X]ZD\!UA4)Y02C0H'YG)R#L\U)&((II*X);(H#GO"#4&(I(53
MS.@\S3?7N-0W ;=M*JIJVK@1^CC%?[.N=^&*!LT4E#L3":9;;:VT6"T8<="
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M8'!AB\^>2@W\/MDLS\UBSG\$7M&NTAV8\(WM03>Z5Q# SU\@E5MG0BW/F7R
M*7+.)2F-W?UXVROT4?. F<;N_(M+.D9M!MYG!SL!!YI\S"STE)[($-F#B":A
M2D>)M+!/J;TM77)D=KQ?@7(5Q^V3IOD3_9 <O?4LY1*1.Y$/+IFU#6Y=V6.,
M=6D"3L7(?SI2!_#<)5# O$MFXXEK>/B30A[^NU>V[V9P-1[F46Z+*-P6H;]"
MC QJO7PC6@X65=9SMK63>%V[J!&YBYGTVW8=W0S+;8D^K\4XMT[C09XD#V[%
M$_ 7@'SB4N(R9WA?D0"<1@JTF;0QRY2U;I&IX7ZO,M'WT?PGG^']%Y$95NIU
M148$!Q*8PD[<V6(G@F/; EKAH93B-4<L^4QB2;_ZM:'W>.=%L\!?8Q^-KNSZ
M(UC4OC!<*@S26H_(P=3T/ASXN:[VWM(/Y_4_ 87>SB:>7@DB$1[WLDQZBA4R
M.D"L_RC^9&9'_M8Z<31X.3\3XK] 8K5BC% LTYH4CT'Q9'C&%H*D4G@D:Q\K
M:O3SJ(6;Q,EF^N).ZB_C+/X'*F[IBJMVUW#?=<6AOBWG[MA/3F!4-9L"S/(F
MPI\,NY=/0!L#/Y,$J(\ ,!$?]X=SQ<VHV''K4U=V!'RXW$.YO_O\MM60VM#E
MT;[+1U6[3Q4'0L"092TZ7Z;KS'X^0M\,""?G+9C-%-CWK!<T_5YO33/,C',W
M,QC*DG#P_3YRGK_K[8-UJ I03I4X*B\Y>HL,I:P1!DEU@8169&20=ZBR'I[8
MV;F;1)+859[N'.WURE5KS;52NZIS"\>';+[IO\*>U$LD8\@Y8L:V!0%7@\P-
MKR*;UW)L,3F!M7,;3V1)JTPU@F<_!GGL)+G+44[_QB@L\74T-KJT7PT2G7/@
M%I1(+E;H[AV^),]1>L4$*?=0#T'&;Y'*X6!NB#=Z7J!?*Y^?1 A,^%.>Q) "
M+-PL_FED__=M$W=^ZE6+FF#E'PCQW02NZ^?D)9QN]A+KMLR7#RB,5Q1;:LU1
M25-=2MM ;- O(,JR;9(P%1)U+B=F8\OQ]K\_.](ZN@/$DMDO$?4-,W1JP%34
M5 T*1O*@OI[5T-YN$L&><P+"#5I29HTST#YB?7,7=P(U\L+R'-+6AO6%>RK5
M6H<L%AU^M_:F?*6TSBIHIQFHW/TAH.BW<37K]>L"1-385=>*3OX:O*7(#%V,
M_.WOOWPP!.D"9)]GRG0=#S*66-:ZC%"9TT]0C#+*MF[+Z"_>M;G"=VMO5<98
M:5=^:Z$^!H3TRZ=: .:4]L]+LE,(SS8R5Q_)5/54!)<I]^$HK (3?L/@]55<
MR2<!-=>& =/KYF-GV=D5HD\0T+$%Y0D07[0H\LDLW;^MCBXC[)U;[MOF6F S
M@).I*1[Q3/99NE>E--7Q'G%/E*L0E*DS R$4=7'/8A&M$']ECT%<_$SU*"Q*
M*RY V2/JN@;<Q0..>-*7Q97+K2R\M2?U[RM^JW,9Z$,&>":Y)M<[1T')D*?
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MFOR+=0<7)YN_V38U83.S,;,ULW,&/XT&.QL5V_^_-I^&Z%^,_L/A?_+QJ8Z
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M++F*?8TYV$SY",QFMW#+C; H.1\(A#.@(E0@*T-4[<BRE3$LX2S_K5=Y7,J
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MRYRRCH(BC:2L+TFUL-C[V9E*&%S@9/%PZWUD(QB1W18"O&;ER_:4=VZ$EPO
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MH!HZ25:,EGH>/5G&0-C/46MS)[.QEMDFNMNK]%M/)N#N;1LIC-"$\0T^!W'
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MC\&/2^$ YH%B^SV4E^7"^#V>OHWE5C=FV9F"&:]7)04&_9_UCVQ24T0OYS4
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M0:F*EH0A!S4-8]^IH@.8I+E)L/7,77XD0==TD9*RV.0'_CI_J\O@JZ($>OK
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M UGV1)3QU3-YI9#PL\)X,P4YR_.1"I/I%@LZ.D.&AWT[RE:0.L%LL8TYE47
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M8DT8VI98(GH7WX;,2N4?*[G_VWWS6C4:?;ST^[K?HE8]JG&2JS$: A[5973
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MGTB^;XT44B3+;6'*\/W6=$))NF!;]]C'MD[<WG7A,E0!.\F&K%NM=%A]=(%
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MQ!^W)3JT1DQUHT%7W#FEJ@GK1?L&\PSF^G+UNNP=SEWF49I0^_$4#\?B"R4
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M'I#9'K^+@6\,N(,GMKM1#BGN;VJB!_.L\-/5>V@*D1;N]BU(X3+=VZH?W[&
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M$EG6?1>"]*Q]*A@>P9G)6 MIF8NCWK1,PUWZ5BQV[+O#E9<B29N#3N" "YL
MQMZ*@QE=Z$R,<^]<*BHHR00^,'>@5 #9(@3!0V,:8L0.@K8+U7UZ!7;L!W)
MYC36X: #8P20;'M.*O0>LIJ  .9HZX."Y@45R0]H?OR. +SB?VX!]N<>&9RO
M((#3KHS.6+A[X_6!Y?CG5+S_E]X^(E?(_TQ9MK_FH]X$">&V?ZF0)-X5%6DR
M>'70X!H8-.6A_<"HXK5Q0<&9,TFS<M6^^@*3I ]ZIEXR66?YSL_W",O2=<&
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M^&U\/"PJ-,G26"19P%>7X?QOEP3?SQNK/+$)*#6W98<4XO#&JM:,&_(=!)%
MA<Y>2/ZD6U;=DV95 -ZA?G!+GBWYHCV;P#OWY5@IE2U+M3>7_,%"Y75E[D4N
M\&/G/+L"TQ[/64+-$$KS'Q:ES8%F&Z)(Z!I63Q#_^)X 8022]SEG0.1+Q8P_
MW]:H,E4O/R$F"$^4L]15#5<OMM%)TR1@9Y3_LKKO#+$O]3U!8WK'I'-M"6*C
MX!U]R^J6^@A+V5"^L#UW (HW)*B'!5XONXA/T#BW>'J=LWR4.Y0PDKO3Y:\+
MUY2\'+/Q:"]YTIZBRKVB H/\OTY/5&\*M#9J7"_)-W*!CIU]!C>!1)NWT/7:
M<OMU]OD"%A=WG7?W6))JW+*!H=<E) RJ,+&9QD<T=?_7<8>U_C]YLAN(2TC$
M;VXEJ2Z1P<^&F (:#P)6(##]B>SL5&?II@7E;<2SI.S5 WN?=.RN23R^Y9\!
M O47I3M5%-L/-\\5:_P#@C)+W]"MX%TOPAF9HTN?5E:CZ]3!=/-@C'$>2?AB
M[QK'LZ&T]RTZD3IM@VOL4*DP=I>O;H#5=JLI\0M/Q]P9T0C]NG0JS8( 8F)&
M_UP@]V&]G1-6G%6 CQ\W?OS&Z:ZK7- KE"%$E,MO:_([+./8KN[\3LC&UN4>
M>1U9S+;>3A%H6"!/1^5)IK<?2'PD+M!V:>GF[64,J:OC;M(KBG!!B7^HUKXL
MBHAB-<_R+M$,5?.D[C-+L)Y>;VO=*ND#T?3D8"9\F6>K?KE-67WTW O'WC-)
MWLJE.A)GZTA=_!(-IXT2:,S%ZH[=B;<SIY!C* Y3N[-C\Q#./U.2;V<"QIZ]
MGV>S4$M0G#ZO+J:F:_MR<$G@VR01PWF\^(I':A)EQ];76!>YRU7E2>]#7XXJ
M1#N4"7%TIL(6M4!.="HW-3WT[3\;*!%*+&Z$L%?F9%;(;6%!&M:Y%B!22/V5
M BJ.X*WF3[$%HK%4%B;@K3_T8D2]=P;^\F]6^LH2_-V>%E%VVM$U( ]A^=Z9
MG^I2=PM\=)70=L_$)J&>?O):K@ENB9I9^%9+13LX?P'O&@>,B4QB0:'J5#99
M=VNS+TQ/L 1B?Z?9FZUK_<-:GYDGIY/':V.4?F5D4%!W>DU486=#BB/;M-R8
MO!"U-O;W'*JY2I 'IDV?S@564:E2JCX1!C["'UL-D\F,)S!"_[.)3/W<T)_\
MH%V=69?UW;^ 0[[Y8^<E8W_.AH:YLX4]:V@<S?=;&VK0X'65WTY'=D"9MW4W
M[PE+3''\9GWD1QMF_EM!<DVZ>0]XR2&L*BUOM&Q97[KVD02V%Q)LA#AI(H&6
MYB5+WKHZ4IA40;<ZFMR]SOX *FRHV(HS/..OY<CT,!/>M2@;?$1N$7/K2_2N
MW[0NJ?A,V4M7BRN+Y5ECEI@Q.=_FLIV+>^1F)\P0RL>B?_ZS[WK]@_P4)>KP
M&XC5)6@A[%+\7A(JV]QNB\I")9+]"Q?)).<DYUXV,2Y9;5ZOYU(UV"-.J;LE
M8*TSCL^0<2^2>Z4G4.N.?+'8VT:Z=<J]'AA0L6I?Y\1V8!1P2KD&G'AAV=[
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M2L":+#S.\.AJC5L]U5/ LRG&9! :]73U,YA;*_ZIV=' RQI(Y2\R!YGOA,Z
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MQ<;/A[Z)U[BA)2]IJ39F#(]U6Q3B32-!+S6)0BQ0!-^;3XFOR4A-QO =R/0
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M$UF!U25TWEO I'.1][F@7&\4Q ;N_D;OQP3&/7I3ALNJ"3C$.@71;I9UTV0
MCACSU"61;8>J1+;?C740W/X%? ]9<GD]31E^Z#5<%)799%G363TZRO\+ ,J
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MJMC .PHYXNM#^,8I8/67K&?/+!&SEC,W#688%;^KBE$GIF-DL$RYWDB#;_M
M"9#@_)=-G('YJ73,?MPIF%Y]8(9KZH /\A?P_H6WQ75#[&84SR1.5'9!,RJL
MV[B'!E65DPOQ6V-6,+=\.7^'!"1!<Z$3FGO:0)A@0Y$#LB+"XX6?H^Y9^ DQ
M('PZ@ 6S+/D+-H<<&JV?Y#HT@3SXRDQ/O_%0-UYE<(4_ZHJ&#B,"SB6XK,OR
MJAKAR8H=(2RE9S<5UDF/ZVM)9%&2?P&RVIX >=V)] X-26K$"22G8TK!*=Z5
M TA[:SHE=9P(N'"2HC2HQ3I1K5#4[;FGB3P+R]ZV3;]@=%L?PN*SGZD67)HA
M"*)WCW!UTKA"8OP6\4E^>(@\A!$1)(NR,\!D1U3RH#'UEBBUYVH"Z'HE2Q]7
MP('WTV-H0#N".:#?->E!SFB.-7_&XR\ QW#C"$>)K"5.L&CUA"Q"BG;=3D.)
M^?PCWZ0@3$7.RFBA?7MWVM\XSS;.SH5I/D>&>]")I=)/ER9%0TAP0AXF)$@^
MA<S>?GFA-@_R^",^V(>C=]1RVK._36.VKT2>J6YH\1C\UHE-0:/P:LDL*YJP
M W\1"G(:N-O1".!1F.<CB-9*ZH/4]=_9:J^C*@%:PW=9M;N8N4*$3L#^=GG&
MQ^K+4C[TC]:V']//K/3H4UPQ7":T9,_Y&T<J54=6G5THJN-YT4\FZV!K1O+G
MM+:%SQC;+ D<=&WI: X_@U'[K*( /]XA!POY.:$#Z[T'^Z>.?*.F;UI[@4[/
M*XA,25SVD0:H J4Z5-R[$8!O@RC"KOY\C?U'-9U)LV/AW>Y7B>'\JC;)9):Y
M6>3!6M]^O)L4(NU AQMX=_8,5\0H@#\K?>3EEOJX8T$.6BT((MZ3Y4F<P]%_
M0ND#\VA<KAS#8KT()8_Q]&50E@Y\Z*T24Z3MZOUCM;W>EWMN?1N8#48Y#L19
M>)'ZO:X/7*=N_+$JUBK;D.$<3=S6G/I)$1)_.M[HZ'6&2&Q2N-IZ&=6\ /TC
M:7+ZNC1+4W/U4ODH(KJ1*]+A\-@N>+0 =0]P4UFL5%Y/<3F0K8.P@\EDX4,E
M&/&QB#18QUVD8\WPBP@0'TI]SKFSQAZ(<LO!!FCUZT<KQI9HGM?[0L+-2V<I
M?(1LI\UL7=F,]9U>W[5VR(YJ2,^IB1[)]J]/[^)EU)GQG4F^/?YZ+T=N#8%L
MH$]:;7\#&Q\GF8ZY-YV2CZ*Q".F3O(P5 R9>0&@H!-3PAA"/ZM-:+X[<NX2Z
MQT[+S--73YX]GV=1\)^&\XF+M&I\J1UCY ,=96&RYB]U7Q;@BB#Z]TK,(0:\
M6=6I8__VEC@W)<)"DIA0 M-J]LQ=GNTV"U/D2_,L@XN#]GZT>:S^.Y>])D9.
M%?B9NFTG9O7-Z 7F.']U24P0-F\XNK*$XC.OZ^./-L?)YX7'X:\KX2BF:?M#
MA[.#E%0!AL]B3I;7RMU0/#)]F5;5OP#1[\_^OQ]W;!W.D5QRF$!MP+QU^^&2
ME;61F5&6;OSB&:L0.SR11'J6O59,\%4%WE5C?AZ6A?'ERD/09ILX,?19IR#(
MR2'UR7]A(;YO[<,&1BSR%FF$#-VO,XIQ3TKB:8O+BS#(&27].BMXAN;#"0W"
MM= ] ^USLK:#J$W><4NE)Z&N1EL]R5M<L<+I7F?-BW=%5JCTG*I#@]1X4WB&
MH[,+P83_U79]1B_#Y7ZV#, 2]A"XOM*7UG*0SMOH]:,? 9?[9[C@Z/M2SG=O
MFQER5*=T/ :_;0;HJL]5\H%TO[3,T8?[8&8=EM?)A@F\M;0"C4A^W?H&*T$(
MYIN=EB2'B*,H 76>V=LK#3>&/1?32'^ZR>U/?I"BF@CG057[IL61"EAZ!]B=
M^[SU)U9GBIB/37%#(_S8L+:"-C$S/-4(%1WY,PG&F[A6_KB*X'=O/>).C!9R
M=P3Y6)869N7G#54S/!MCM'%D06MSB5DHW$BKA2B6:"I"NY8(@SWLK.;1'+C
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MEWT'1"<Z#&EY8Z?[7PZ-IJ[5*)Q2@!8^A-(YY,=:5'+CT)V:-F'G(5-1BH1
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MX$ ,BI#BS.@7K_K5H>KF(2$'6'EG(642OK/NE@>>WCC?B[!+=+ X_QC#Z7T
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M4OK=^:KC;+>M9&7(YU6OJT.FT&4-=N4MD7',8KH_ZE#P_?Y\E0_FV^;*P[\
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MI31\)<CYI]'*\_4D/&C3<VDCUU[<]T8_,X?,03+R@>QMYXOV\<?&/58?G2Q
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M*H, VC/P)A^T)0KS$<'.D%"/6",%,:[5B+3G&JH;C?=]^)=I&N,(A;.)% D
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M;?Z)3;"=<J_]W3@:,5)B[GG6]T=TM<L&T:Q)@:QRU([EWIBP IG7K #(5GS
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M-U@%JQZK'N^_]F((+!OBXZM16TA#)?V#QI$V^].OZ"ZI3&TS2!U^*M=,:*!
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M;._O?/^YYYY[_WO^^YS4//5,KUZUZNVJ[M5=M5;//'Y[7 :>RDO+20,P,#"
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MUC<VM[9W=H]/3L_.+RZOKF]^V@4#P,'\C?ZE75A0NV#AX>'@$7_:!0/K\5,
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M]<1L''NWGULP:A:75_EB'[$79.NW6-XE9C>2TX8")>9O,K#O@R,9\CAR(AF
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M^*U**4\^^>05#L%:4B E\HC+ERV"S>3)OC2_C2S(#//;!E!2?:RT:IBE?2Y
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M7FR<F?42^!]"2N]]<Z:+<QM/EK)!Q@TEU%6QW#YD1L&8/();C27="C?]!CE
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M588H":8R\S['B:XZ%)EQW@HG.Q<(C6")#KVXSBZE+!_E%[5?DX6Y-];6!\J
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M#Y<237P>I;D*4N>AR1\ZRJGR-6_/^H=L[8D=UTS69K8 D2VI\@Q5U24!";X
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MK7D/8>_UG:#42^#EN%>()OD:PO31-._VL'7&%@#D5J)&[H"ZE:1M@7HU*3&
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M7Z+8%$8\>*OH\H8#29-/P DI68L"#L+/LH-F\9)4'F$I_IG4'!V90D?$G(N
M[53]MS:9'5"138!!C7O![&> T.D+?L*?F@"Z!7_V$XHA'A(47*.1R]>DCVZR
MP">!E_R^OT?ZB$<+_?B7^V2M?]\GZYSXTH5P&.R[46T>Y1?(PDKWVF96%YG8
MX$?$KE\2377]N7VG8-J3;JPHMPZ\Y:1@RL;ORTD;Z.?;:L /IF-)\EC^YIAH
M(5=IML]2@=UZ)DR-;@C-6AIV@+ T9R,YQ)#>./J.^H2J.9XT7J /L?(J0/L9
MP.!K)])E(V V[C+7A[+OPA^?!0S*#&8C8#%BS/8QZB:F=S[-\<?[V;0U&5B(
M-X]V#KIUN6VVXCY6E@4[=Z003UL[NF9Y?[K"X*;&2Y9Y?U;C"_.>B*NE"73C
M_*&V?-+JZ'C.3*L31YY_[(COXQ=.86[8R$%U0::RX#F+D*A>5,4#QN\#RB"T
M6+Q;STOS3@\0NUVC8B$C#39)?Y=79';9]?L'(9 KPG>..IJQC4I(W0^2-^_P
M,?R1750I[8<Y!K5O1-4(.!.Q0^(L!ZP5>506&CRZ"6?0$5IP1W>7>,>M+G*:
MZC4LN^?X_8,F*GDH[# 1KN,B/S;SC#^-Z=6HQ7C\8(XR5BS_8<S@.\/-K_"E
M+I ZL!2XN"20W-31_]/PG.8';%0%ZZ9RP(XP/Y&]2C4&\KYF4W%'W!3AW,=:
M!MAH!JQZT\4W/-UB@K\:M.T[5-V(4^/M!L;J^22(3+5J)GM7G(@'C9\!OZPM
M'KVORSO&M3HMB,X^I/DKMF(VE'M[ZDGLP/"+9.DL W?WC> ZWDN Z&506>GK
ML=-H\;GYP[64[=4MT%88W-ERQ:]%?O5"EZT)+-H K6S]0M?B\UP>=K'J]]R4
M@^QQ1ADCQ6AM-WM3EV!\(CB30F$Z-5I.)[-CDP76YJ5XNYV8)O6_R)2,;':7
M*<JMBK\ ]'*!LWQ8_<9>-X#!L Y2[\0I!WN\36VP6G-KXHS6 TLBL$O8WDP6
M.T69*@=Z$@9/9B8K'8 I:0;T&O*U/!8N.MV$4]BLMX])5!?O*[M8DJ;>GL:"
MF:*\6/4K7FWZ6-TG046U&E#9#KDI3'")P[J]+LOY8FG(M6R-77U:2V@2,KCP
M!K_GUVFHTUK%^DE.M3U<_QZOZN:];/&ON:!7<)'A\9 M@88HI)+)1H.,$'\?
MYH=>?)48<A8$NR.%) -*!]RX+)<KE&1FAD-UJ@Q9[+Y@F".HA8*P+/LD1QPR
M%LJ3EN\DZTK17#J686]E*\B[^2U7"DR<5CZ$H@.(SC7GY *M]4^6&JQQ,W<K
MM(?&-3\:H_:>,2]$?!8TVDV8B.OF167C5]2NC42"^QHW) P+3A;F(2_B"F$W
MK%/7//4T0FM!^-)W!( (2V[C.*#GXH-66]Y\BJ-^G&<.6.-X SA,$-?NG<XH
M2/(P][KY0!6G&FDX_LG&RU3.;IRR[6NGBZ1.(#_+KC9UW%H/A_OC!P;NF78S
MJVB&GE#_:RL!Q-UN73?CH'40FVI%M:OA>ZW/D=&$F;3]X/>2&X98"4P>0J7[
MPC-#4Q?%5MMMO$:^<X\%A_I(=I^\*]Z'AK4S0MV6#WGLH;Q#LZ!S!;G;&7$I
MR)C%<N%#O7Y/M<Z]L;VOC78=I!\\UGO1T[S(\=!%:(A1KAX:2U7>"B7'S8';
M';Q2J>I[^9I8G+LC"GC,F(?42M7:A6'N//6D!V(TWDLAF7 DQ>23IN1U7Z(,
M+>31ZB(SXH=)LJ8('JPX>:K#;1Q=GI6U=[J"9K HMQ,:G1%7SK^MC+(=%O H
MU-$EG96@AP'91(9<542F4.]A)=(#MK.UK?'-3/$?5BD_4;R_?9N\L90=V ?O
M!FWNAI$_)+/*I$BLT][+I6L$1K09E2[2C^'4*G<:'EP(G?QX<OS=,%S)/00_
MXWR*6O)+%&LQ><.K"-T?%%9V(ASCNSH<D*:QJ*L]5I\TL'Y9@!/A^0.9C:!F
M4]Y-[%+?L%R]O^ XVKD^IQ*8O\;&B^K1K(6%(MP:]2;60WK-5<>4QL7+EA(]
M1<NK;GXS"FA#6#E"TLV1O;J,L:0YO_]M-^S+.R9%[@Q7OUA;?%07&GSJHN[U
MTILL,(0IQLZ*EKRFJ@[[?[#WED%U==G:Z$:"2W!W=W>'8(%@P3<:W-TA6'#8
M6(#@[NX:W-W=W=WUDNY[NM\^M[KK?G5OU5?UU?FQ?ZV]I@R98XRYYGR>YE.<
MCG6]K?I:)\P$Q=6%+B>P%?1^ N0",M+ >N'4)),4K7O)[AC-Q=*V_MDKNJU1
M"&H&/U:(--8%',+&0KS.QYV>V8*KW,&6"UD2L"V6*EY],H-F(9K;7@F'$?<O
MZ ) O1K)5"U7/N7?B4F'7(*:VK\^+UO1#D<'/Q*I",G^04 ["\YIH2>+H3MC
M;IB672^/UU_:.1G]?E?'-Y<U(4QHG(8[*^3X!ECXRA!30WK8OD)C$:]B.XIT
M[$3K1IRBFJ,)E6^USD GSVE%!M2R::J2#C0,\R!(#@'<0,>.TC5D^7"7([IJ
M'HYIU4W7PCM])2BIS-M#& _\647IL2%')W@G.GM5()YG-H<RSQ[&71MO.OKP
MJ6,@>,]'0@X;],6= =T9 E13.X,,(I^AG'*"83C-"G$N&3\1;?:]@MJ45[QS
M4/&4R3Z:>Z65OG[2CNKSJ8<EC1A4](5FB![ !P/=K$P(W_+OWZNIU=1*Q:Q:
M%']CT-E=.M%@JPI$1:AV/Q&PM=/DQ$7*MUCWX(-9-V4D:[M*HOB%6OFP4]G,
M_YS7_)D:I5O#U4,AH8-W--K%+%) VZK[N-6P4:=,A(SG;+58?(-OP[,IH#0E
MWH&D&H4J#:I'CAP2PK]#2/,:COK(EKL<:E^S+-'!B;-D3M#AD^)"(H(#YZ9+
M. OYUC3<7HT\XA'7(SXK1<FM!4<+C: UZ,B/ D&W3 *-+(703J=44NXGV-X<
M(<XL5"GKO @Y*OWQN#FAZR+Q95T)T"']]PGHH2C))<BIE/>% UZ;T!32>&G$
M1YO&;! :Z?LM;P5_FL44=:8I7II7OJN'*JLPQPBO3!OKTI#JDS#IS%VCY=6H
M&)/L=0\P2+2U_MXEWZS"; 0_?@QKT0I3!<I1B<NG?2NM)5J[%AVLV]6DLU[U
M.VFD<FNM^HQ>'(EJ%)]P*:4*6^R$-]*,\CVK=*TTZA<NHV8+9.?+G,Q/T37T
MT&)IV-=WY2)9D4<7#=ZZF7N\:H&>(IC5^4.% XY#<")U4ML2E[>&K)4,*83W
MT!S>.N>_IQ=/7O/-C"G1X/7V8SZX;4E0?AH@P\$^FFUVIX88Z?MQDV^:?OQ$
M!LW2>1G(G+^(T6DB\),P_;/\O82GL*8TB9\ZD[YTDHR_+8L'U2]<>H?V]CYB
M ^YRZ2R0C]OOR, 698;3^%<U9[ARL*L^)K+B0=YKK8\"1:WE6>:/@F$.[OSK
MESV\RVBVZBQFTWV]KG@.![XZF5*#.%)Z, (BZ&#M^[-7\N>7FXB4PR-LVO6)
M:"=P]NMU8\F0 ->'RA[ENO/XED=SKQQ9JOI:.DO!J8@8M^.A=NX-EN?B2145
M=%IJ!5X BXPD,$B&T((JB%_<K="<5<:8!.2XJ/RYV5"?M:I^E?PYX]+N0+$^
MJ)9!<TZUKC&@/&O*.CMPE-+[IJ *%OM2>!3/1FBE7"X#P(N@4 ,1<K[K7Z3I
M6N8Q(JR59?,S$R&0*R)X/A\!2,O=R\QLCI>*W WO5!00=J):>?J$8,7UV$$7
MZ!D>V>P'H&P>?)<GO2?;)A^0ZV?[JZ6=+_YW^T!:1ID?Z^N>:?<GXGU!GM+>
MWQD9)P^IR9/4I#+C.3WLM3"LU9%2[%+4<B>$\<N#'$<D!H_4-=:C]7_%!VJL
MR(*Z4RYSSKD[N#D";-9'-%=AMB/'L&AL+-N3ZXAEB>Z"/E3>N99+9OGP]Q+!
MW4<[-N^P:GM5WH8(NMYJ^3+N$I^.?KZX,O /C?,D*_ATQ*_Z=8COX.ZC)'DY
M[N_F:B-)1!\>8KT4M9SWQ<C&.^,(URMU-3^Q^W J0=]6_C2B%1TL_<QWZD@R
MT'%GQA.Y7+W/)KGX)TG4NH1Z+P!.#&4IS3WIVH^5V0U]^E.$'6Y1I#"+I(1_
M9;O8N^NZ)MS6V6M\P:Y6CQV#^)8IJ$>,3PC[.'/V85\S+[% ZTMQ[4!<5'8U
M.LNP2VR+?@@5889=C[/CU]9ZC!KNHPAHU2>!\VIP'.-9S!UL;J*FSO#T_@OU
M1Y,?3O[Y.5AKE@AWF&\ \Z^L1?U%W<W@)=+]1REH.K'B%/D;]XB'#CJTU4W1
MCKE3CHU,@B-NZ"7]^_PU8OU#S$)QCAG;X!("OZG?;1=#[%_VC-J4.?Y?'4)+
M<-I@JADJH)ZF $V^BM!7P$QO]*Z*.?4-<I=^^>O6D=H^!/A=9^6*N?$K72-)
M^EBH?@ D>*@:]AWDK%=^UQ*>N"/H$^QN2?"0M9]("&2RS(U^M+87NB4T1<D]
M'*+!"4EY;@2C48STQZRJY\/B\3L\5X$J"^,M"8\(S#,YBP%P+:IX?&HH]G9(
MA._\3[.YZ(X53HU#0%>XSCZ5T-/!S4WN+=-MYI8(8F-Q(VAZ:7Q.EF.:_/:*
M8%7LLUWUUK%;-ZAV%U^2*/S;#LJF)FJ(U.D6(@LG5OE\*?:%V_X8:83/GCU1
M@ 7H-HBD7"X?DD0X;U-I;,QO$Y\_942!;_QZ V!R7J0EEK6& G:G.B:D[>LU
M XX37'0<[?G#0S/CP, X08"'"(7:>Y/<]EZ>4^O\6F2V/N2D@8I^0*^RG[!B
M#<3\G(DXX)L9+\-,6BICLH?+;1B%K]4&I.>3:)0,D8[WYRQ^ ML*3=JCK["6
M6Z8DL0-RI$: 0H*Q09[;LKQ0+D20.3+D O!3I1A_41@]*O7ZUJ!VQG?N'%U(
M3:KY2@=.!M) "DCD7Y^>>K_GS'T1)]2?[!-<1:VSR.9IB*5TV^N%UC"8EUSG
M*;E_Q3^86,9DK"+KK)3>%2[9+O'@HKO1$:"KR/)A9O=&(&"52:2:IFCV"'.L
M&R(MZQ86[N6[4I_3 8OV%'*R0GQ.4/,V BU.2L(%8D@,IH!RT%+F[,3Q GLQ
MY@(-$F2FK$X8=4:]F(N!LJ%X9G#*VX0PQ$D@>3B&8;4VR[9XL_)O(!ZC^>([
M["AA(LU]TPRD[T*P?819C(C;X6'N<R$H(I?5$@KA=_B[!3WK,%;\(?1..!L-
M]0L[@XI ,,6H<R\QW*."#"2.5H*EEU ^UQN<=JFMB/JLBBAB_2LFL;NK&_":
MI4[GDZP#39M%<I0#'T@]*%V4GWOGEK,OZ-;07%1^C@\EU\T\A")6^>6P:-CA
MY?6FQK0B_3C/1U]%)]7$)C:FLN)V0A$[69_C9&.P!,Z1A.#&LU+_!@W_[Y"/
M_O_X_2^XI8%94VIN;7$/?RZ!20*M8MM>MH=*VU]H9W^+ _XM?VWY>[W_;_EK
MBZ<5/OP[_EK:&W2P?T>8^S\=_D^'_]/A__X.-YF>[3;Q&$RT V6\&.AKRNEQ
MJLG8V-/M;/FNQV9+\WO*D4];5)\^^8VR3LJ@>T3WZ_U@XAG=\DTQJ<7SG?7^
M"^F\XDMM_AM@K.^5>VU#O97B0N T>3U^COW(]%L4U2_]Z3 )X3YXW]B&%(#
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M6EF1JZQ1E"+X)MKAV3F/;^@;#L<%X?&D]F=_[,GFZ;EM2_*V+/T-('2[]N?
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MXC9XH?6^O^)LV,)YSPE_O=XB"<9YB%U@[):7Z'Z:E4%,41"CEQOU'$MUT4_
M5Z-.1^$PV,#!B5E[LAA>]C?IU^L]N;]5D)P%9;2 &NY%AP\>X^IN$0ND?^\L
M<C'!,2/G#P$/FQ6HCUFTT%RK58B6JD/DZ(D,%;VB'KP^;@\L/_>%GJ&$?2IQ
MCX,"^1W:<Q$AL2_%5[-JR2)6?<$[:;^*%WY?^P]:-JLX(H/N%#H,DY3$N$-2
M^@U"2!A^PC7[M.O/"0TFFFQYV0/=*'1I'>.>XZ)+!RE: KT91(3Z^H0"3,UQ
M]X)KGHI_\TO5&T]WT=?; HTFL1#35_9BX$"I$8P!3O1$8/!+VVW3Y=C#$ZPM
M=AF=F&%#>B5N\ /$RG/?(0(?.Z6L:W&&Q]!90B9$JQ[<.H@4I#B2O3:ME#8[
M'_>DI_50-,,,\---EBE0P6+]7(^2:IE"G!C8-$UM=D.!=&8;@9LV3&;@4@.(
M)U=ZW]F[=?T[.#E;B7%3P!D+9&VL2T3$%^$J=US!FS0WV-=0CW@C@QD8MIW]
MX(,_3):HIIGT3S(KC#P+4>,_S;G(9SC!46=%_0G(V"Z"1 XVGO$)\*UG,7.P
M+>4\1U%V^WS*MX]:%^:[%_DJ$K+\=M9@2P!#/ZDM@@"&LV!+RRK^,8ZNX-M,
M@+5 /2I@WV,FS$N:D6EUYENTQC<-EQ0KO85]D;U<&+C%^$ .;*OLF(VQ:#(I
M@@H@A3HX"^C'WGG9][V.^@EU(LJK$[;2IMYLZ^4H9KLQL3FH)B\9U?K)Q;D3
MDMOED1TZZOZO?O9>#059%YB)Y+!DRR7 J>'%%^$CX5%W(FBMY45@;G<T,,>N
MB5U0G?QTF8?X^L&WKU8GMM.^7VYIC4(+A;3[%S8<^%8:<Y=0A-G I@ MGZ*M
M]72O2J(4]"Y\RM:E4)P QXI =T 9"J0KE5T?-+90*3@-T-1!_=YY<X# .%[.
M'FI<GJ#9L;C^E@OKJWH+ZB>_55V6KDR*5B5F9M<C.2O-A9H#&X84>7QMY\<W
M0*RT4XF(A9>-:9=C==DZ%^T)3J\;&?\M_L0T[T>SQ4^W2E*]^T68@V(X?%BO
MC^2O$!CPIJP!M9=E&!0184/<" 0#EO5BX41B2>,UTZJ7?/[XK'0B).'9ZYC$
M$'T"EW3\]UD+8C9U#;KTZ4*GK_O62[%C9(*)&?"+@4DV)=:EPY=@MIFV\K#7
MO<A'&@DZF&JIB"4A^,((9PBC,.0Q>#Q[_+.@Y.*>PGA8](JH,-*'7P_13<P=
M@G$8MVU6^D4]!JP\9AA 5[H R"AN*H%F.'HHR^]H47C.\:Z&G,=P-&$[V QG
M<XASB]FQ'=7\A.K32#/*\[FLK"QM_)=X$)>EY2<O[(4TCB!;*<7I=9/G)$-!
MDJG=E.YJO6+T;\MZSRT>+QN3/EA/O%()GT%"J59$>]\\W"S;AD.)I T*Y#TP
M.D!F9-2^:G#<AUWWP7>%ZS,EUM:0'[7ZR/.Y503L/B>%2^"%:+'FH&+/;PFP
MC!%I<H&'X^(!=34';%A[T&DQ.D]7&,&>EM<O':8XS-\ <A[%L'JHL#AKMFS;
M 7O\5AW8)PHKKGZ+4T/.DC&P*J'R.$HY/M($#DN3F?+HP-HNT=EZF O6DO:
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MO:-.ULJ$O(09N\>5>0HN>Q9PXF@.(3/511 ,]*$M[:]*5V@R6B:I!HEFMV*
MZ+B^W/OK>UG8"'3+FY+[[B1J[60:&>$Q\\:V&,S63"[8,#*=:(>6S-KU2AV"
MJ6+$VIT?=@+7:B5=^%F]HAE>%5@:X>)B"=N('\?KYQZ7>7'AMP1XM3_WCD(V
M1)^1QPB2Z.^P J1L)0G$'3%&@:XRQW>S=WL*T6>H.WOQ7W$WM0?1R_@0J,M
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MP9N?TX]"@@BVL>P?0,)]3,UVV%LX/=)Y]U.2T[-L,(Y,3A2%J,1*X:'#TF\
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M6D^-B6!!^;%RA*#<Y&EHMO+]/4/M:'1N9M3U-661C19AR?V4RO<E\KK788>
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M[#=^ 9CPL=R)W$=*:")MWJ-<A*/0J[%CDV%T9_.>!&OB]:<;&Q253\K7<2]
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M86)6-K:-#^L@9Q>B;9)4$%\?C/E&.TC(HRB7PI?EX^ODNJY;UIH&#RO,FP*
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MKK!V2[<M5!ESA@VB2IA%)ZMI8V&P0Y$9[H7,$5L[#W*,<D;2-6I_GW D?E;
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M3FGXH:,G^]DM9TL1'N>G*3L-4BM.K7#- E@RMMT[F3>5GL^RWM8.<5369(,
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M)*V;HCV'IS6[5^>YUXP5Y1G7M$@:6^0,#@FL8 XU-"SI*QFUK8*D93@&NA7
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MM/G_T<Y7?D4!=?T.TM(2#M+,$)+2W=(-TBE=0_< T@K.$(. ='?#,'0*0X>
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M@$87@ZRMU1(:^WI8TG4D=C,8?%3UA/;FPC1Q#]>>?;<U(!03UOKHO!Q+8^D
MJR$S;Y,MJ'=;94_VGQX+2Y.9*&+F<2P)3U2@C]1(;*T);H9*2;GR_EA)Z&Q&
M? V)4TAVL4F/#WW8J$1=#)<NS2Z/.?MG:MV#85P%/(>TXC(2)]F2RY*6R>K(
M"[KOHE.5,SX,Q33.JL$33:OMQ"8PYT"!GPMBO?3=;TU[^C[7\>[FF]F[['/U
MI+8QW1]1G>B.Z"\'1W_O)]#REA^B"1/23L?R68GPF5+]1TJ.#-WQ7ZR%&'ZT
M_P!ZLK9GX-O["5@2K@?QG7E[_*!Z,PI>/"VG8!5PF1[(W 6<<( :RM0ASE4*
M8N_@=;6H,^^@U=%+;B_(Q]&]W0)SA!>MF0+/Q03.Z"RM$MXJX7+'M-!L4E8U
M^<\;.=[>+Q P6&>\ 2G8;:<="Z./F:^CBZ)<#D8M3;W8L+3"(ZYN -M&W7=3
M]!_*.IJTSTF_#GA-W+PNMO;:Q4RO$Q=HV'VQ_H]I\$I[02*J>8[Y-E544IX_
M[N/$/ACSH!C]-F7Z^<$@NR %L3+ESH,JWL-W9$Y6B)D".+)5O*_HZ# [=8SG
MR,*!:KWA@:*]?74"]QBY7+<7WS0&$)S%SF'VS06'-:4M!D!$)YI_ 42/AB&[
M"$VZX1"-.Q^(P61M68QW.+X.4FZ(5P;4F;*R<6=\ANQ8%B.W$,=M245>R%-'
M3&#N<VKB7!U1*-<$6 U:S:HADJQ(2A*VT&F=A1$/X!?=7UD>G?-J=_2W'"H!
M$%-<81ORPV>U#C#3II Y=:JFU;7TP+ '1OR9[-;2G^@)LX4_(^Y>OJ1"!X(D
M/8)2MSA,Z%CBX>[Y!^-?R%N7>:^7J:P"W5 "OCC%:%]9/06. HVZD!VX^5W#
MHV6ZD/(,XXP]K9)I> F  U\F9(_8KI.([.FG@!#<%@LMK7KR20!!;9"MO<0?
M;+T)C,6&[)^K>ZVU\(S5@'= .\@0%7]:Q@\J9..OC[X_+89N7TPY.,+M$U^#
M39Y(V/-G1*JF$# ?-G0N!95;:0<Y,1YL;*?KH$U.50UD6K+'Y[HM\)I"2'KJ
MX'-91KG=4?)&P,,&B=%OV1WE;H8;;N;I=>,OHQ>-3,<%I#[4A\R$%ON+<-;F
M,)&O;AUEAEJJ8=P=UR?5N#Z)[^(O+;96_=< ]53/>Y5,/7@ 3HL[2OL=^UIW
MU;'0M.2"/L?;DEBV]ODAVP]&VGE^72ZW,^+5Y@UQTW48RB"9T:2%X6=W;B50
M02$QZPU5C0:RJ")X<< ">(M6C\'>2.J5+3_CAFZH%:#']<W.F&/R<9_C%?E=
M&%<,+9<.607.GP"OXU]@!&];IMUTL&EC:>ZC'IEX9;MD'-?SEXWJH8-B.U1Q
M.&WI^WN,A_2_E;4K?K(NZ2Z<-!@?N%I38<7FWB4)75WW@YM$S"V)4C[M#/@
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M0$9^X)O!]WS*ID66:*D.)T((5B(+?=RCM.2<I(JH 4PDB9SY^15/TS*PA.A
MF;76PF??N_]BUJDXKEM$-(YDCX;FQ-4;(ZS;$JDIA 4O]1EE2G_%"&@2)*2Y
MV::)-RU?E;]2ZL7H2-([. 36])TG*KO:\?[X9LFZ6;8*KC=]CN-)*R%]&5$>
M"6Y]0^*&<A=V?0WV(C"@-6%YFE(:B%TO]4HL>:<&FE#')_PUY_B<>]1XWI>5
M.'T,+>/-+=++I)+@D;(I).P[TI$8^WO\D#M28MI;O4Y;=5#?[5GZE\-5Z9(
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M1U^W3DA= _AQ%4(JE: DDPD\!(]""KJETM\_8FA6Y6AS W20++ZM;-W,7;P
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M9^RZ!5A=2Q(NNG#7X!X\N+L3/+A[R,8)$-P]2' )$"1(T$" X.[N&B ;WYM
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MC)-[FJJ&+1N..@\Q[G_@EAIE[(D02MC1<A"CME: O'\D'V;>:&_"D+(,X4,
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M:/T.8\9U'&W)6'^A[*M=Q!*TLP-*4R'V%F:QJ$\U?'^H%.)#W;.*T9]TJ>N
M*4&36X$XN2\B U'%M;MR#UW+1BXZI^OJ?MQ02]6,[8TM*EDA?6$#+<TFUMO6
MN:J-U-MN4IZL;8ZD7PP-=WOH$RS$DE ES\\,BRS:Z_)FU9C%T"]=OX*A7@\L
M8);B-PR;$!</FH[.7-65W\4AS@C,HV\!3_=Y7\:R/I/D7<J/7<CQ4:632EG
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M7;?=$LW%"B/W,AK]FYA_2S2L7XSFY+R2MDO^/1 :Q7"+TL9P#W3 W .]ZO<
M&H'JU2-?U7L@$.X>B"R9NM&LKDOSG[:J@C,['Q>T0C!?3:P\.DF(]0;Q]%SD
MTAB59X'1ATN56!0PBL"/[#Y%&/'=A7S3[*5B^_>Q_KLL'>V5GO/),O9]]C+?
M$T<O6N5'SQ)J;$OR0\D.^O9KL@]K-^KNIGQNR4IDBEG?I^F''RA(W /\1D[C
MBL#L_^6X/RF;0O)/OAK&/'K6&*G#5^;"TBE1CSM<;X.4%(]%Y:W='K&"0W\8
M6UD !BO8PE!:M^K'C3Q?)$097U[/OD#)NR-"F[J13)%/0WKMJTU,<T 7N>['
M]47U[A%SW!7@.7T/ 'FEJD=<\$=P\P$6(_8IZ^#;^E&),%7F$3CX37B/+;UJ
M7ZV&MH8Z9:'QX432LTC/1.VW*C%H#:CSV^X3B.$W]+J4I\!1T1V,G-POO-KH
MD?&!H:HCE@VK%T+O(L'QP'$HJGETH_K=U"E/0-=:?4!=;5N4&X_[=9U\^..Z
MP<HHI^/8VXL<E/8UKH8'_T2*$3]$%1+_-;-WVGSVA2?#[ONY?4.T/)^ V^9D
MN$&];&?C9OMAFE' !%Q?]@4".>4OO#<^'LS_;RJMALNW#H>.AL7Z%%K"X''"
M%IJ/^P6W),@<_V(&C-/MO'WKH^SQ1QQ&*=\1Z^'3"/3Y>8HGZX5=S4)4V=#>
MY?OEUN4%O_*!3@4*J%X\*Q?_#@-5O8&-C?N%;T6-!$[R(%^?#7,>_H@1Z=7(
M;>NE!%83KE #?A%E$BH#>!W\Q3A,0K52]3[SXTK,J><G#'[#=T=+Z1 @WIEQ
MS<%D_M4)\W[-E$^M&$RSY<G5M]>[.7=R,EY&9I+Y<:H:&ZJXO&ZO P7//V*7
MG#G+P:3YZQ[&_#P4ZT(+,M3KM-2(LGD]X5<IV@K?U"XQ+0;QY;W,;RH4F7S?
MG],+.&7_A<G=)[=GN6#NDG$K-3J-.X3E-.-4A+Y$L#UNBE"R9U(F%L B1:1\
MEX.)])=#J)#Z$"CRXS]4YV2BIP,G*W]A^Z9F2CP;?@@(?R#&C(I;!?WYI@!5
M'1<FAH(%A%SHRB:1.:(C%H1:+=_>8C;#+BB0@\DG3C",$\#>O<QCO-=8:4')
M,)M]#Z D]]\"(C8/L41]SJ&I/&M^P>^E,QJZ8DO0S%F!L49GG7UKO7 G\QO=
MC7XC%W"@0,!?C*:9><F]JZ^3G<*1C_!5Q',*RXU3HBO-G-F:A0A0BO \D,C)
MB$&E@RHK277,"!?U@/&'H'>!%#P/08WQ^[_D=AI("H(X@WP<TV1!M]LWT!F7
M466$'GYUKY1I.2XKTKSGW2=X, _;<Y>%TST@@442L(KG&O!+QNV[EAI2UN_Z
M7^L'?1U9L%NJK4VXY:$:8WUC(H @?2M!]8WD/4 ]6_1PKDM\.-<A!C)9[Z8O
M1UE]_+HM%!A\C)_.\0T.P2PAH;[,9L&@MIG3[N/FN(UBIK^$#D/W^"7],L4]
M\-E7_ HHC_T[OAH^$H.NL>I1\\2</_D<T6@IC 5X\'Y\6/H$J1!EV.L. [:D
M"NOTZ]JR3XI=PFBON^$[OSDES.8G_NC0>$8G1CBGWC;&&A';]0VO#Z]8(R^D
MDW<;K1C,EW^.YD3<+-]3ANG__/4J9:'DAVFUFG:;WO==S^S7.16Q-T&Q.=<G
M$A1>9A!3%)MT$;!Q82@$OSI-L<71S/D&)QKV*Q5H*K=AM@7_U>?-;N]U662Q
M<5+)(B/984I*-EV*X&9B7YN"?LQJJD?BYP(CVQ^'X[3.UG'.\+X=I:2<<R_E
MR4]T6Z::AZZ7$L!(W)UK17M/;E#(8?)2PH9@^G*6<TGBA DLJ#28:U.%'&=Q
M28J<%;*N!*;T@./0=Q9$OJ1Z?6X\@6/LZ+Y="^KCGFK%;Y$Q%^&GJ&L#&0P4
M=R!<AD$0D<_@3]1-/.MEJFRFE&:\<HQJ.&_&O.  #T$J/V7 Z^S+7* CX:,+
M4V-!2U 46D+S*YCJV)Q0,A^MZFU_I$:?L*1N[T.[< 6RPFSG?"%T9G2_Z5@N
MYBF>45EE2;+1HL6O7 FA#0LG<(OV]!5J2&^-;,40FQN#(9O=!J>)"R5,PGI&
MB5)\WY9N(5@NZ>T>D H44R/C<:^U44L;Q\?8S\8+GGG(<H=N]6M.M5)' L>]
M7VZPZR!8%[)NU41)HV"P?>>PE[])P$'6DW3_@E5[5J@/.X9=\=% 51Y?MO,Z
MUT=MD<T<VA>M!I' T2W]01>)?[!K\WM"XT9IWQ\+8<DBYHHC>C@U3M'0+9VP
MCZL%A%*B<#U.99.LU')6KJ6)SO)PH8,[D6>VC' AGR^"<FR\?0GX2-@:,6J0
M<07F%#-0D1R207<$_LD/?E[F<P\@: :$NK]50R)\0$CBB@^X0*?U'@C^V-X5
M=Z%_I7L+6WMP@Z]\AP]6ER SO6&Y9;X+,OAQAUIX#Z"*KUEMF9ZBSK4?:O-?
MZ-K( $X!A]6G%5<(=BL73!DWC \8++L@8(+9Y![HU%I9,R[ @^E]6&'C4^W?
M\2L"5DL<#_/^-QE'N8?:W"FKM%IKBYTJ3G[J8[Z*\V<%(.;H>+Z3^!RR\PJM
MA%E&L)R -GS2=V:V>Z GA<  'MSR;"YE\@GH7+UEU>W*GP=F(QOL3=T=H=E3
M.:3R+$\N2;P_$Z.!<@=KRX""\H@A_$949,IPZX[JW0!'H3+]BX$6ITS757_M
M14I<6;?0SY%C$-5%VN-GJ/ QA@)CAN)=WG#*DRWJ]F7&1-3U#8$UXM:AA6KP
MDU:D<_!'V484,N0R$WW_II?<OUIEJ_#+WNH7DL[NRU);AS=P,3G0DY+9+,8I
M1^HZSF79:J.>JGZX!ERSU%=$9[UP'.V_VE#]WZ>@-N<H)8;G #Z5&@44++AD
MFJ,[)DCVJ-]V(5(K"R^%'CV6GQD3$BAP\"\S-3I<[NEO+Z74R-(B-7;LE;F%
M>],N=A*7VH;GC[^#_[J-4;^<'5(U[; ?&O5N"<H(Q]$G@1!TL(+7%"X]EJ0V
M05A6$6%TFS% //GMTO_'""('UHA-V4?K5$)^5B>+<EK,#AET YX06WB48/?-
M_<W8S+F7_E0+]-EV7FS)_@F+73^0D:,3< &E3'[5C")3VWKQF)>Y7N2L#H75
M00D.;)-(J2C/D<=4?*)7R33APNP-NY?=9J) %2%.3 .-D]_$3(C(\VB*A@0*
MY4JLG9;1DI BWL]*;#7+^"-NO/1;]G)HZVI>,"7=TG59E*;,I*UO(7#XU' 9
M)TMVW$+A5S*;"J']4DZX6T<88.ZW; QEBECO?\7=3/$ZUAIN].&8&#[BKVEX
M$?,!C#B=-YCH'BHH[!+,W=_J*J0;QV-,/[D:KC0765/!<!-L0;3H$IO<S!]S
MNF,L"P'ODT90!\M%+%:%D K1'R-B>GM'QJJ2ZX.[Q@/,?"R?45OK6*A9&7<Z
M<\R351TZ14\@B/\Z'W@!OWI\F7 %0<&G +XTS^DHG29KPN'%RK!.P:60G<[B
MI'X",U:#[:']N3W._"%:9/<\ 8E^]%=<73$=>?_N&&G\/:-,>A2<A79#QHK[
M)%HMYFY;!G/^''4A6G?C]55-S=ECUG+)GV&UX?A9NG.HZ[O]#UPP6LQ#P#$3
M;B(N>_ZDP42SXRIS74^[).%LN%XGU"$(?VX]RNZ9+CL3Q?9R4;4H_W0G35-B
M@_M6U])RL<4-H0GZN4*W_LLGASPLA*&FJA2DA'C.I--U#0R0*N<(9 M5HGG=
M84BL!N;;:/&%]? 397%3G$%4*1JAI_E4:GC06"X8I&T;S(^Y]FWR>S=/$Y:?
M8);F*1S[]L04$<-E@EJ]MX4&(H\^6SQ'IFDHIINQIWK_.-U5SA_OT=Q1;K#(
MT(GQX=)YE&.AD8WW41CNKM3WXYBQ(5EHOWKFK>W'F5/"1BYE1\@33<'C!=DD
M<K7,]RVW'6)AK2^F[L"WQ'OT^MHJ*"9]B<JR8\SA]8D0WF1\_?@L"5!@P*->
M<NE<*"%_NMOHCZ1S8R^><X3W8:GL:0UA?8ACB(:B=A53(EX?MDB<#:0+=O+9
ME#BFZ$GC/D):X5Z=4;[GW8CE@FOZ" I$V;:>QQ3^MX!*^6L@9*Y2P)DTUL,W
MB_>SJ5(ET^@EK2/1D,+20 R(S\$4_X]W%J?J5 ;K4Z>OJ4-(TU0\R<4I/B2?
M&=+6Q'XK)QQ\NR=++!Q7 #BO_,>P:R04D_]#V1Y]>YIJF&I;?$R&L"FF,#-B
MKOH3TR:J86-?0#+@G/T?>WAG04,5+%9+"%Y=U!TU'GHEYS0F_G!6D/N/0Z\9
M."L.[9&UH5[D[\M]YPV723DQ@?3X/V\R7P:+#9Y2LPN] $4<NC1O1;+6HBD-
MTL;.NB7D7:_Y!&22 -_$_V/ ;!JLV,MI5/*RU$[N^V;J:)!F+J<VL-T9)HE4
MG(/)_Q_'6[TH*K>I?<!+JBR*<\"@ESR&E[5)?"<5**CZUZNY?$0H(;XCKDSF
MO($?_T37.>LO+*/UI8UF:\Z;=:]&2*7)/'U9?H*<33U1*PC<?!-GP B7?4CV
MR.!&;"*G\0TD79@H&>H4IH%GCF.,\.>GC4@$V>BN9M","NPJ3N[.ZJ&3?")G
ME8VQ_54H>8DI\HWH] VE4XG1UM>3 POWF+3%B DHJB0H$V>NS&T=6@9OCNTS
M43-/T9Q)?2.4SNQ<N7W<O&C00FAB&_Q)O_Z;1)_8RS.&,C'3\%@WNT'6,_[@
MOGT]XYRG,'GS(^M/!(G8OF[M&).E-CU5-U&@.]2JO ?B$AU(?XA8;6S&/NG;
M5#I>=_$ZED-N<+^6-@,)=EN)"O# )&.]M@COFO-F6$B7SV\\,4N4&:8^P J)
MMLJ\<BNW[.Y*?[]1%H"PCBM5I<"28-1TY. [L56?R4$G*:YX0-\PG3.=JN83
MSE?^Z&4I=WQG!*HLEF]D#>MC*K/\>Z!]](['K<&52T0X9\G&.RS7QX>W6LE;
M[6UMQ ?8G&^?%=8WTU=*N/PBF8,<:7>KWHWDHN^]SR,6]79FRA2J>^/D0_Z)
M<$/AFXS;T[0Q[3#)G5@Y'IA:&5V"^*R8Q_VW?(Y')3H>3<JWZ^<I'F'ZJQOR
MLU9#)W$F:3D8!DQ8E;WC7/? RL8]0"+63_BI_<=E>U\@PX><:[*?[YI6-O]>
M+C(\?LL7<)2#\KWXGZWB*GO[N?YH F1%ANPZ_?P4.R#CQOJ/>S?^6>$TTA(P
M;?F0'6G_4J/,=BRL=+T1YB7XU,9\V(]3@E1+QQ?7YH=J'5J8!Y.A8^;J*MFC
MZ*LO<572_:,,]0</'<+VXB/-0\Y2[^X!\8O)<X'&#9. K>J &$!51O)<X.?;
MKI\6](MEUP\X.+D'?BT?_V?Y/YHW;)B(_[R9$A0U:WI]<P] )7 'B#\\CZF-
MH.+C#MDQ&AU_3>PJJK'<M>6_5"(+:FAJ>!:,3/-: ^BS,]FV%QJRIFYN.C9O
M#&##\YHG=)3@?C;C<-KZF,9/<:_LRQA>RWC(U00WR0,JU/7.F_>KLL/CZQ+]
M@;WP^=W>'?Z+Q2>GFZUZAP=A;*Y1#9:M+;&K!OI1S&9D%DX4N]^J5 P#!4Y+
MRSY^_^A[KNI/L(8],##]N2LHT26K.SU5I7&:U]K$6&BK',?0#B_M0OR].*=K
MI:;!Q$'YV=/VJ?*U8$W;\RH4"!LJ)Q(-O#/RI^\MB/%/<9D++LWK+"SC-F!I
M4:(WVPVV?YW '?;;NX"C?"1J$0PG_**OT,:Z9)(A-,L3T'/I'@7, CV<N=/R
M"J7:]&'%NKJF!GYN&2+==]&$-*WB?TQV]K]-=F/OX=*P9]F9#7W=&]^BN)<X
M^%[2F"+=F7S"3H;9H*A8"^A=!O_%K/.V-[,MEQZ&A%^AR$'T(@<-'$.[V2CP
MPOA&-$1MZK19>'!*LNBK@D/<MV/RNK5^D>=E8JK(MJJ.'A:W!4CS;DCZ;/WQ
M'OM=X<@N@:2.KYS2IZ.,#V^.5%D,TJLDFO/%?*+9G+):HG_@5>UXHQ,,.['E
MUG%3OD-)OMMWRG3KLX:C-@U?.T,3;JCPK0\^VWP+#[&>3T'VVL:2/OO(DXVX
M9 -N>\^3ZGYL:%-RU*&#6RV$+2'W<C4H6W$ZQ&#" 12S-B/-\H[QV3X_;*?D
M^ND@;+9/R?=TUS[F!X,P*7<J>HVIR \0(4VG\V$,8:T:HH7/TC73*]02QG]*
M$V_$#/*$AXJX]7)<6.DT)C#,5+ X6-37VEEC+U"RAN T-"P-/I: XD_2U>!2
M#\0\T2%&&O67VU3Y93$"WT['X95 >,%*WQRYANS4(L-?^H/V29T5P$(P.O2'
MSHL]"<K.J&S)MUFO,C>IPBFEA'0E?RZ8OWNZW!^KB/]B\N>'TMU7-^T#ZZ8=
M]8C3"DM.%AYN5K158S]2>J>LDDJ?<W22EU8Q&BSF81.5H\#%)E/.0Z!I?U]?
M?RX=Z1ET9E-,$S 8+)6JEDV-%!3%7/?M>1X-:^>E_]OPKNF!9?U6/?LT-?GX
M7$3EAO7UA"QAU*5K6I&;*==[(.MAT;;_](I_1$"\3Z?N]=,&0_K#1<G?6 :/
M!VL>1==_IOXXO+80+L_J/XU2%6/XY)M96JS$RY#H0#^AV?YYR%;:W]8VI7EX
M9DWV3[>.Z2@HLGEDT,N?[7+]U1WCD&T100W)Z$K[ 9G+J;?QJR]><NU'(3GX
M:[],%C<19YHC<')#?%!F!:IP+A#0RDYY^K6]+[8>+J;MT.]& ;6KZ]2K8'T,
M<==U3'YST<4 YT(65-RZ_H-CH$^=NB@IL(5C;P5=\+P\;M?)9>379>5XE(/I
MH(HX<G@)4KO4HN]YDKSJ>WDV"%R_J%-^G3#X@)BY#!+)W^Q]KC@I#?C3"-GF
MX>Y+4^8G<8+M?>\[AELGV=EY41Q,-BC?5GP-BK[;A<7$$EF/#4"5/;Q9^=HF
MM83X=L!\V)R)DS:Q69ZFHLR.5*#Y[P9AF%\CNBPXOWU@J;A?NL+9E43U9SOI
M#<445(W,#V,K$$,_X_.>OZ'(/9=I3%$ U;M;HO<0#B5W,L<*EF:#7I_:_,.L
MXM[/LJ]>KD ER&[N'J7KTYDWAGK@JKT;9& A<MC$B'ZNE7WX9F-?(<MS?@AP
M/[Y[B<0:Z#*=J7/PIZO]&:)AQJ77GB2>@R%V)YP1-PNIQ)V7\J<" *4!V- F
M[*,'1]>GSQ]H*+Q(F_VIBZ[)C$[^%I[R_MQ9X#),D9>0%-H6/PJP-D(P<_:9
M%  ^F$O_Y()"Z\3YZLMZPTKD8+X8]_C<-X-CSEYE[+_L47_$O7N@+Y#[3)3$
M\#+WB5#.T_EC?+HEGX^=0,@^TVM_W.,]J=*%-#S9'*+8KI(&L*PW1;O!RB\A
M[J$3LG^,):7M,+3'V] OUHQU5E9ED= (ICYI.GKURXXJYIO3]WS+5^)/[/6'
MN_X+>V\9',>2K8NVF)EEL5H6,S-9S PM9F9FL"1;S+)8%C,S6\RRQ<S,S'"]
MSYP]LV?>@7@G;KQX]*,CLC(K5V9^BSNJ5D6+G_X(94'I=!PZ!?G_77'^H8D_
M8?@=-[E-X\UDOFDX&GWND^(VZ'47Y& .5/;OH4QO^>BY;4P%MCSZ6$W0"#8I
M[PCJ^AN-];^3$/R#!,KG0IE1ZZ]58P/DUW8ZYC"[Y#\W +[6Q<5_>F_[RR**
M>HO-Q.&X8W*T1PPA]%__**\"-O0B<7%7LR6(])HN/&-6GVHBSCR @1YUY$D_
MC4L9?F!#?V;#YK'9W!+_MD5U8>8*/T6<LZ&V1'5HP-?G(=$G9>N[+V'//$=/
MH#-(/*(L]SSO2 D32AMW0'VZ\>J',/K*,TMJR^-H#XDAN1S44WDV- ++A8=P
MPW[HH@B#N$8\^P[8U-4]4.E.F$3<-$#K[$\F)7$ H]SM'MJY*V^+(M:NC5ZT
MF;*FF&$T:<0.U1U < <DQ$H.+2CH;U7)Y0&VR8ND>59X""K;-MLZ%/JPKY=7
M=$#"R-ELO!MQ:JD1'S%WB)B0#"V6L&MRAYF;&SH6EGR8ST,MVG.&D:>;S1VY
M"<M^'>3/1?GK^H_YVCD(P/]J<*D%%:#DY\^Y;28MR)K%@FL-448&P?!=:B]A
M=7[G#*^Z)03))/\:\<U:O1\PO@HV?]#,'//<09$^HBJU!R78TF$JB9&&8*J+
M/N1)19\]+5:&91H8X\#5[[IG,,X#[W*0O&@^M@0JMLGA%T-]I0, 7-F5V-M@
MVI-7[3#N%?,G&3:K:=%AQJ<?Y  62HH?CH5IQ.V^HY"L1.PA5M]"=(@YEVDN
M'<[C3.F0@Y9++(E8V^QX'=>7 AC4L4N*5E<>XB?.J()[S:V9132=60VH7IJ<
MU6U\) K6E]M+G$CA*!./'?@*U0<<1 WV(?&E?)1R18$E#$4V%8AEB %# AHV
M!G[UFLCXVSW:4^7Q@Q:G7C85N9Q29#@DS*Q4H\CR?I^1&VJ*/-2MK8LKS4/W
M+&SI<9>7AYF0]GGC5R#J#0 P7'B57:=S 4-(8]PQ']X!'@(Z-Y,%0/<[IZ&:
M?E>$-L32\H!X?J$<F*4^DOIPTB[80#^WE57>K/VU@M)Y][L[/8DE8OLE"C2)
MP(R: T'I:'ZCGD])G;/X="JXN$/+XI<SSN(;NKG?O9<U%\I3F*DA@#@0X*'M
MC5IY7RO)T"59ONB8AE6?"V$HJ8D7&6BKX33N]+Y5>Y9=^7INY3_KUICHUXNE
M"FRL"=@750#DQ$3O1FU&!'YA&^X)M_MDZTNKMC8EDP*=!PY&-%F:20)G]@*8
M?$"VG@Y/($W+>+UZG*^LK7S6-:K7]]]<[VY*!6BF79$DQ-IJ:VLZ&1W)-RK&
M3!4@/C01?.;ON>YW+7%$K*UW'/\P](VNM#OI*3P^.G!N/_LXC:.A<G72WK&@
MWO&'V2]M!8*X1UORCWCI>RLP%X'1CQ7O "0MO8_?2ZQP&LT&3_64"]I8:CY@
M0&;F1RL<T'[/#?RC_D_/'P^%-<M,0JP>V5<,.SK]2BU,DZ$*Y0CU:+0#.A_W
MN[LH5T] GXMWSNG!V=?#V6[6U7+LP>Y'2M$FB\"C+H"YF9B$^T:'5<F:I:C*
MG3WIW-6DXKGO9E-](+ ;5.:J/ NWUS_N>N%*#L,2#&$X)P_%RT,K/0B:]S"\
MDL?3\B=K&3?O"KN=ADXI7M76(12N C9WR%#G(0<,* DQ.$B =V"'VZZ^ W3/
M".E?;0WCT U%1D:D(\O0XDX<^P7"J?_-XJB80GUWZ)".I9Y1:B;P[0IK $[O
MZX@WX<!A JLA2VT5]QVX3\1IC64;9[Y/:<]9\K5]R[W:_A8PY"")%+E?R)JV
MD!O O5?;I74SF+8F\_5[ZE@=W8@0E.0$,K\$[E9M SV*6LN<P"QA>PSQ<(ON
M-$,.8N1^R8[QV;RM&,#TD*-)/<U+HH&4R)HS<9VC#QB;!X,5X9EWS'RD@<-C
M)^CO<&6X'D+*%!53!>E+6YD;P*7%X"-F7Z(-FJ3_-7)&JB1@',\1#[<=.&G5
M0!CS98]9RFTJ^<.\V4TWU,^@WBZP5@U#,8!3[8^M8!JH;^76U"(JAA02J\[Q
M/-=Q(-FJ=P <I&V0QDDYW"#>2L/WWW<Z:UG5:>F4-Z:@O,5]^ &6!"M$# RE
M3^@^L'0=IU6>89?QK,B-I3,/.OD&XR#0 @%1O-_@ZJ((#1U<M+8HRGV%/;O$
M-6\=^R,#)?6!_QW (R?ZJ;5]7ON-&PO_@PEJ+ P+^(MY,4%,A0NF(H)HDJ;/
M)[?]21/>0"EM@2-NH-N$@R"/C;9?ATWD)8ZGL5O<I^C/3$O-P@?(L)6UX8#]
MFV_L![=&KMP1RY^WP=SBA;8KG9"]-83_AR6\E+2>]LI;&1(H-B/'-I/(OQ#8
MNY&JFA^)F66CR>6G1/3YB4P87>>!Q(SPW&E.]\OL#/@/('(KT:^[Y^_QZW$N
M=82B[ZOH-X!O5X0_8I%Y@LJ>9I_U"0?IRT8Y4MRJ]F5K/@5JY4>SAB94 52#
M!Y= $^A4E=KD];Y%HWV&:8),B/O<RX_*URCD\(S0#P&]"+J^H0JUY1:-;\ZV
M&7 (P\VGVX[+ RC2-24/C,KMS9QH"!ZSE>1N#:&Z$37&--#2:+WH7FJO@H.*
M'1WQ:TLK>.:PM<.(GM'<A.Z?^?9Y+:]]A*>-I@TZL)OB)?B<I(/8U#^R >JR
M/'#Y'T\5#%:_[7>G1;J/T.?5RGB87ANF[I@E"4584:YN0.]S[T\UGK53-G5?
M>/@K4 ->1R;)'#2AH9:YCAR\IC\,)D,SDTI5!,DTBC5_.:/=?4P%$&U$=W;0
MG!5LB==<9*Y5WSF!^&BOQ%Q#AH%0$W#;0*5:I,5):S_PEC1W.29A/DXFW+WD
M.Y&)R@D$22YN"G$86:,B>Y@U.&1Z&QU_JXA:F8QV;P?6JPL) O=!;=>J/JS0
MN<V&#^K-'@@U\3]DR#_EF DWWPP/^L2IR&R7S$DE$Z+OB8%VZJ*:2*[A #7'
MRVF"57V"5=T3TV_$*Z\Q(S-]3M+3W[-4N!W9C.1..$YQAR&"%.:J!C<6;1L4
M3F&-&RS%^J9M=]W!T\EEMP-@M#/]R"RNZ'N%4C#H@  CH35#QCH(F,KM=:(&
ML^4!MQ3\TH4/O$,[#$8,EU%E)'*[+"B41(DN8$_[8= 5A8>-2B&A"*!O.RY2
M>$RE*/"CX\[G&];'RN\ X^BY,PSZB06&/2=,F2:4YB 91.+)"I?6SA;ZBLS
MZ4TDY^*Q&J$F0+&(L$WU<3=,>(\__A&V5[V7[VY8-I\&NAC/8N7IQB>@NNY@
M- I)FK;UJQNQ_7$+5%5O8[2,6\<S^_2@$^%.+/I$$-(W/G_O#%5'#TJU("ZC
MA),Z0]NO+2R<J3 )D:6(3K_MD0HH>#"-.]0S,&$H:)72$Q9@&$##).\Y1,B<
M=3/T1F+I7(K@P5"4]+D@+YQI%])C10J&N(]WVH@K"J,W+:O$GD[?W*)2*3<I
MWWBWC*:-F+HV@W,\XV6U+"^BFY7L,9Q42XW^,\4N"YL8A;D/QZ\9 @<HZ]6'
M9['Z*)#W:'NQ7#-8T\<W.!*']C=V/06"7G?OHOZ\7KJ?.KIBF"D4@FZ<A:<=
MSAG&C517,"N#,=T\B?X6=)?C-".Z1#(Q\:ZL<!P\GX<VC($-,H+!M_U-J2<A
M\5*NA#/V]OM,T6 <*UBDG@/KPG,=T.$\FCPK>WR\.>N'/*LK4[#*$Q:#([7V
M9@F1C=)!>1"%<BXW2K+JU;]M0.A_5BSJ?^]/LCN)A "=2R 14*_NM"Q_<I16
M5T?:"_CBENVE7M\B:S<+Q#M,U+_(08*GY>$%?376(IO5_16JEH0:)$AC@R;C
M_($/OVVHM%^SE!&2 &TJ@.V@W*,PVF,GGA@5^!7G:4 4#^Z6OU3_HY[_EL,Z
MS;D@C4-GEX(78#JW3ALNF9B]P0TM%OFJ)-K+6<&:MT!YO%02$S%>R>.5"FRI
M,<F^_'#2W+V=',O@5^.<N$IL]U,0+9$"+/U 4Y'NVJJ<*W96Y9"937L\,T$C
M !<7$M&U[*[K<&3<M!(A1"64V<8 I0C+^(33_P8]Y>VUZD$16L:#6(&I'[>U
M72Q2NHLN!SM:?&5(GL?$U_>H(CN 'E/7MW7+$]W2Q"20&*T/SPT\CU#$41=F
MP>X=<$#!^/JL?Y'W5V+Z+Z0\3D?$UN'>S>$M\5Q32K6<U'4.N,<QVI+M* 42
MB#4)O*EY\=QX&:;!U69\B(A)A+0:_YBO=/>AZPE.YAW@-_]"!<%Q_\-+[7EL
M&BY8KCF^*A(;GH6_6RF\32 ,:BX)*V1G>F60X"NIIR:V4T6S>:0Q6<$STOHK
M9,'O+-'Z#=,W]/PMZ+<>KS>\ ^ !W\L>)!3F[)*MP[)(R-'X' 3ZXR#LP$)Y
MS((W:<F>D[V3^C?;%0D,=2)1N0Z<K-X!_\GIH!"(X30UEP9MXA6 J&-U8A^J
M>[" @=UX!/?CLC[LQGN>7Z8EJ.*U(,JNJDAZF>X'%:3K_GJ@O^X/L*HBWC1;
MOA7DGH2/HT66QM$[L)T'<:SEY$'6\^EW5+G;HJ6GWJH5EDK.<LK--;BZC;O5
MT-GK_@X0IO8_7WH'A! ;MKT#<A*[[D_]>P)8*"\^)CB@?62M5P*]9E$U18HW
M$T2S9H'MI'69;BZ#>+_9X6L5I>'N?-56;B]+HB0!"'Y6BZG^'6/]E-9_ONO:
ME/C+@7,0O[3#Y2\O]-I:F(<-9^Y'JSGHRB"B#9'C;N,>0,GR$1JT)KH'>9</
MTBCLP@'$XS0LG)CGB4,L7O^*N,!?MPK0RRW^/S%JO:0S^($OK?Q+.,O84 #8
MHR)T"%8RVO 7)),$IC$/N.M(<_*Y^)4/M5OSH.LQ<^LO/1S3!XY3 >P6Y<-D
MR1^7&:J'%B;P% G,B2?#I90VHBTIYK34H5:I:;))!IQ\N7*0I&D%>$&IQEKD
MLT 3 SS)*$^8BWR0=9B9ZJQN*C(NI&S57 ";1:G@7_ M*UEWN1NNA,Z$UB:M
MKGV5T ;,Y=;DI7'':T3TP1ZC/$T5LF <'TK>,PV"3[R111D9MIC0XRJS1NX%
M<!276YA%;XH*;\'NJF]@,L=Z#EX7M,31#>-X/0D) QY#V7=NCH4^8*I[+>FT
MALHIBZOC09+%2NS*_U56P+S"\_XS.?K_Q_YO.49]L;0B067)F)\DH4:5)Y@$
M /VEN@-$[$.,]99U-M)V#Z?1VJ:)W%$-=MS [7,^6J230G%E=+?>LL7E.\!*
M.D7#DLC4PYB*X)E!7I"G17)QR6W;C6N<D(Y0@:&I^E(N9?E,>7@C13M@2&]-
M^9P@5[926*G^Q,;]N<%O7VIF7J7..ON4]IO-+=PG!L((&XM.Y86CMH?AROFW
MC^LW^^^ &&7_ON6WC'? Y1%@CS*B3VH3B=]TC1P.T!J^B*L3LNU/\@X@31N>
M*K^-P#"J^5'"IN#HV+JF9MK3%@\T(S G3)^?:UM_2/>?SG[CEWB1ZSJ<? <0
MY16[U.P5"7=T7>QV=!3&.-O2X9LDWX=*^M3Q<C %^..09,Q,YCZ$KFTK_9H:
MD8GP)&NJ:VIVIXD!N)M!!0 -Y=>RD@ZR+SG> 46"+UXQ_TY=R(5;TH;=[,%1
M(,[9;-3=DJ<7GQP'!7^D0#H#,:#C<JEE($5I[I90&LW1F38E4<)Z3V Y7RK%
M >(LDHIV4&>^Z._GK$+.=K9WINC#3K-QEKK?D1PR>TK[XR7JR8O\%!8K_#AK
M[(;:U_7%L>0L42)DU>@-QW&76]$_X5)Z!V#8/SF_ P:+P5^Q_M_5;> QT*L\
M4Z]0>^@HRM+FGR]!5\A_ ,8K#.^5X8?U_1]WO@.^-KUROP.V9]):JZ=K^A>7
M=+3]>W#GT_A[UK1[R)L]#"TA97:QX$$0!'%QVGY8#<T*V%;S^F:I]&;A[!)I
MRT-+(Z =A!<AB,RUVY_O@#_Y(KAE^PZ0]W^X5;MMX9@:9-Y&8GB[UK:.X-7Z
M*'D2^Q)\SK)"GD3T+%PZ'1&EH-P6<S*/?7&LH=A7QH-IC&F9"J<R!(/[8EW]
MC]VAE6)#5B1+B(9NQ?\"/:UM>QTY-O%H?/G8D31UK1+-F7P &=6M)J;3&\VU
MX\=>L&E997N;OG KP]N0=2',F&8@H$6&A91\@+SA41G\'^"E#3'3I>?JN8FD
MHM@Z;Y=GVN3(=V[>R%\KK4V2QYC=-KS59O^O>E%@F$$_D81=_(N-1^PMT]+>
MP+#EZK2Q36"'"OSWZ%3^?MQDAXQYX5%:0)J<A%PWCUP?VMNV@=NU@(C*@V:T
MHV[5WQ7LS_VH>+T#=,_?C+0)7#IQ6YM#EV K9*'8*,0<FN$<*LOSCI-*60^?
M"GH.TV9ODV9P<#AKY9SQM1_/X1_%4#'WIV\KWP'_QY.5-+F_NC>[O+5IMH A
MV>,! E0-L)8DB#)+_B,M* 'S"_\/10/,+YV:#(=VAKI?^1^=_[ U^_6K1I<V
M-DM'6^J>%?F,<6WWS7)Y9Y&N?"KR):4AR6N4S2VMS5%\=?@!I)1X0R0 3TKN
M?A?_2_:;NC^7*?@#6462Z5N$X9MLYIQ5=P)RUS:?<A,\&,I".*PD[Y*C@"4^
MBOY>[&OZ'E08& A(@NMULJ;?0G9H_N<)9'Z;E[!B>F0G>N63;WDX\V+Y:8+T
M:WP0/:D0/ATP)-YIAZYX9Q@*G5=D<<!H:(M\7-YTRP$8O<Z9WQ;/2^N?#D14
MC!VY-Z\_=Q(AREXW"?33,1.7)7W4/#N=#SRQ+!KP"ET> $DN]+@-XG\W,T*
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MW8R/7^W J51+:@]>""=)P T2_50[A[?FEE,836 -Q7^):4Z O^N47I1()Q)
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M?0-)[8W,5U""RQ=\J@D.J2]J'%WRR:@6SI%[L;^[AM0OB#C=;32N\+.J5$,
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MJ&Z/=8)U*/FZ"Y@CWZN9LK5)T,1IF@_J?&G73\1N(ADI(,#$>^=/^LYJ0.R
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M@&+;W;SPUC-WXF+(O/=B] A\QN?,>]V[>X6K<0OL]_ N0NS= J=TC7M&UK=
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M!7O>04OS-R;^(Z?-KSCQWTJ/FOHM,/1Y*?$*M_+L7NX._[!YON?7^;]D+C^
M-ER]+3"H#$87Y*R+QI6E\J%9.9ABV1F\WO\&=X$+= <OSD9,UR5BGL5*!997
M;'ZS2Q3L5-,CA!@I2'A9L1_L^]0P:!*36Z=8\*L%6_85FU3TR0K+A>9JB8RS
M)$Z%'C2#>VW")"PSBL?15A8SIQ%A"XC>- ,!E!'&W6 S?1AZO?-A_3H'LW$B
MA!LVT5OIC91W>P(%2J7=2"Z+Y=9(^DOG!YG4(4_VP;Z5&@;=4$JZC5!<EAMJ
M'/]-?]M[2^H6<#_UUM[JO3C'I=N;&V<R"&_7HE24"^M4T@&NLHB0\F,$Z?R<
M9?EQH(W[!S=4HR]$?'0KZX.>'>-ES>X0JZR:-J>\0,_,Y.5UVG;FM3WYA#[-
M<HK*))=G$HU:9AJ2RD4X=P0Q^".Y4W\DD5WD^FGL+>!SU*^U?$T(ZGU;'9.D
MZ)^20A02;T,!391_+^!_(#O?F8$)8_"CLR2#\%O@T3WA<[&"CEE&:;8SRCRX
M/Y\'V86)GA<!@]H1E@/6HES*A9HIHC0?T,JL@11,Q&]Y<:+L;(O!A8)\F+]A
MN=3?..0F(3/^;V%\DS0?C4+9S,<FL+BN.-,OB,\2VZ$)DS;O>D/QLNL!M.^0
M@!A"4FQL21NQ]6\O+@7E^JJN580T\)O/+;($U]"/[DMQ9.1@JCLD+-U9TTP'
M?<; AW@#8C>(E?CUQ[9%2+_957,CQPC=1XGT2;/V^*2VM<YY>CBP%!D/,?B/
M\0X=,S'M11PMN9[ >VJ]0[4^[KI3SY,%?XG*V_&3M_N/0WWU$AZ^LGK IN(%
M*U?96 "&9X[+%WM3$BX3))IVZ!OV%-B53=LF,\!I!]Z 6XK*#KD&S\2<91JQ
M9Z^S)F\4=G^"U7]I5AI!ZD 5/1?59>29_.17RX09Q#>)='ZVRJ5"%96!ZV$X
M>%8OVV4#I]_= B4,W%\A&G^8%>5/&"@CUV>WM)''5#. <Y^G00IX\?()6^X\
M;^/(7]WUW-E9#U#OR;$S73BZB)>%T?X)+]X?R*DT4&EO;4Z;>**JP2B>_!GL
M*X:S#,O[,8,GV2+A":%8U X.%@*B'M)'_#"X8P)[61B97_?6\<G>RK:VZBU#
M7QH6?P+)QH$N5(*+%*M&76W 1@8=RZ3^1U^O!3@\:0AB5N??=:98ML\]-5_V
M2B!!+3$>;MH&5%?(4P^Q/!Z'Y5,N0Z-]R?TI4R-EFQ2:\@UWU0!W.Z#T&T:I
M-U_BG*1%(_=C#E@Y;Z%HM<C4(:Q+<+*4^6SK/_M*SF<0H14]+RG04]"E)3/[
MF/LK%.<O&<4*H38TB6D_*LR2VIU?X++X":#S3O$=U=;:1"0=QL2 Y$>, ^(G
M[Z[J5DX'G8#>W\QM:CQ]5+^T4I-;KS)6PLV;&K;W_0"?"7PR;7V.&I;[HI_J
M$SR-B-==4.M'Q&$6E)"9OP;.:[Q<N.:-CQ*FO)S:4T3IE:LJW7:VLVA%QE;L
M$3NOD(YO3>[5HK"-@N'O!\6!W)\V=/"/O(OQ1_J='\<S:42D>>JY%-TV1^DP
M*U[R2=&'^)B JB+%[=D&AWZ#?^J4493ZS: 1?"OA2:^IG'OXS%C/O]*>W_^%
MNC\7B,>WL!R.BGO29B*B@0MD_MLU^2]__XG(2>TM09&:PX(,/[$D+Q7H2A3*
MB.LTR*ME,Q@(N2_CJ^N!S%N@9)WB:>XV*\D,ZPJFB&3-W,.J#D$[LOUA-\[@
M_XPO4""PVVDOF_:9N/)23WC7AKU;#AU30*212$V%2Z:@.<MTE/#S]G)U$-;!
MHDX;E]9;IY.-73X"^_^(1#"1R+],\TJAQDTH2\3<G. (&-"5)61'"QKQ(K:"
MU2!TS-YQUL_J!_'H>;TFLRI5;X]\)Q#F">'#OD)D#.RX?G?>YKUR*VO4&^7]
M2GX?2Z)JED*C;JS.,O,ZY8 @==O09!G;T"XDU9YK!?%P2PR4I65T"TQ?Y/>*
M%G<ZDM%+G](0$[%!.(=[0B54)R$/_D?$#)#_YRO=;- C$7/FU?SW<#/>H1"L
MU&1Z+8O%(0#7H_$<M;-6Q8HA&JY^^7&Q\?8=-;&0MTM"SH[$4*>-6D* _2WP
MY\1R6;QVG>APEQY9U3T,3#$C"I0=+M>4D:\8IZ4-L!2$XI+M\!/,AD<6&ZRW
MYM .9$:SSYB2L,=M1TI#GXE1P R5Y)RL?/1ILA.0Q4MM^"<G\U6NAP7:LYOV
M45/9M4AV'A=?--I>&8=[^"<D.3>>CMDS0?QG.!#CX\?_[WJ[L2@M#<,Q\61A
MNHNN/%_+E/75NUS$'!'\2AZ0N;Q]%718CC1 P)::9<-!]R?'BE+O1F>DP4B#
MEV<=\S3-E7&U_62FZ7CZ04^CGP2_VU:*8-NX&4<9+VHLMR7ZEOMN03+\ZX6&
M](V=]):O0'#<U^I;H"%+K7!K\.I]?F-!XIH]T9\4_6M7:/ D+YFC\H/ &*/C
M[8H%-.^;\4AA5!#=FP?Q]S4K/+/XL[Y6E*K/BMA>IB'O=Q&M33&&<0Y!-71G
M@?\(\D#Q/9+-7:=A6\I;'K7[#:GIFQ-H6M.^INU]#?R!R%IL0V&-LA;67UVR
MH#+"!1T+T7?4?;26Z#]$YJ.67*,L*_T5QF#M]9GWVAR_F<V1( D.0>RRIUQM
MZ,'AJ4LP,]S^=?]P[O24$+XPNZ\N/;4J#C =B=/E!&S]U5K[KR6U):+6E6O6
MZ)8Z=L# 2$*0!)2L$TDZK=4*<4;@ZY*R)<%K_P,0REE)\+S_,^^S2XI%-;T5
MY850^)[]%3_CSZ=RSXRS($?J?++::G_;]K(P@FG8 <B05.B+!(X1O+;HXDYJ
M4Y)N6R9#TS#L5C=I=F+\%0,V)MLB I3_$#2CF!RULT:\Q@<X*RJ"7)1@Q\80
M9:.-KAQOK>AMCG<29/0B%L.P;GJ-/6E!5>S+&910(G_%SDC_<[^5BPB.KXQ2
M[ZQ7"4B^BE (8E!5!MQ$K >9E54F=FUFU5XJOC)^29EI_GSG;/U+$$\91#;+
M)WM+!"'NBVX\1(;RDA##]U(U%1^$S)V+A>LQ:"(@5$R74TL8"=SZ2DSX#DT'
M)U87+EW+Z:[(=UG23$WSEZ;QD\E"TXEUO#<BMR(V^/# ?V(8>\):(BPOQ<=0
MU/S*+ VWC8>)?CICZZD19&9,5)-F*U48K&7L)&A#2Y,F4A)D(V;#M7RJ7YR8
MSPG<Z41_!M$(_NNQ=)>YF_I82H"(@=TYUV&.,L*YIZ^/O9-M =?MS'.^I6B.
MN<MC=5F#4^A#Z* 0SNE5-D3AW\Z9?T'5A:!:8U9L:YD']S:*55Y/V1/KXXF[
MUV!ROT3>YHAZQ:<3.T/TM3=!>HKR@#PX(&C)C>;:X[#_D+<,RY5EYY)CG3#B
M;G;_Y@W59TLKEZ_]5-Z(GNHT?NH)7'5]'<3A6M95IZ%&N0(2?LT.29P_NJTT
M/3(4?B8WA!3\C\LJR:]3/?%=]O^VE^Q,L+:\T@'187E:?5FV3=26J3H611E"
M)EYBUDQ&CP='',))GX2$_8WNC6;Q)H0RV8)ZUE9WYE_!/0IB(SY_/=1DF;")
M&87IZD+FPX?J?VO,0U+EI])?YO^H3'VM/$;X*\0"_7JALQ,\,/V7C$[\,Y:/
M4+HQ@\S;?G96[$\I8F\DO:%2+8?>C=L.E&:K;4Z8KU)]F:X*V)E*0H=!WJF7
MX=)]#)'_9YB1SW\^C8M<D0=2=-%\)H(R(Y^MVYVR[)1Q"B+"["MJ)Q\K"2<S
M:I,)(7O31">]RG>2A#3XGT=WSA1+C>V[W(\-?:]1T6O]]<*P/>":[OJ8^/L>
M342J7Q+'!>TRPRH<\ TN*WW]2^7XKG:4EFT#\19(-- +>D,P9K."P4=XM&Q$
M]5S@Y;)@@J/$+6IJ;5C[_F=<%]<]JWFN)+DS("DVKR4\_<-\TDK+^F64U1#'
MK5K8K\8S"?2-81<#<_.2*C$%^I4UJF]Q@DW>-<O#H. /P9Q&N]0G?L/DC-ME
MC;4"[_?87TF"UWL&"\ 31#=/B\RX7M>VCL/T*')X[H8D]>),$\4$?SRY8I3O
MMBT F_$G=V8U/<7LMR7_7'G96T4I6]WI*D5@ E/D=2R;-9('&1X&[8US)]R?
MO;1?_.3IZ4-WZA-Q-:\=5CU+U^94/Q% 7D0;C2IDLR?I:Z;PTL_->WXD:IGP
M*/J&*UH<U!8U1JLO49WBR35(]]PO$Z>Y%W^/<PA6--LU# >]HUVSIBABY8;3
M2,68.B!07T^QX2 F".6&4V.&A[(^X4AC1H,F,G/:,W8ZOSB:)@3Y] 8_O-VN
MS :*L:?^G'=)^_6!R_P<4?3&@3RVN31CIHISIL7UXL(=CJ,I;HRMQKIL9:4X
M*S?G=P=3)P@7C'"=JG3I7,&RVIO[\69X&H&RB6WRB]V&IM1CB$]W%C/-YBV@
M6SJ3"N^\UD68:)>XMMEXN VZ!<#3MX!O[JCL R)6Q5L@$:1]>3-_)45H=J?
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MHWT+U$C)5\,9:M%0(FKM=2W-ZQR;--;G/EDN_1_LO7547<NR-SIQ@@8-"R=
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M0@HZ\D;UKR][N'(%W_H?:3N-FD+QK=C49'<O0(SS1(963UUCI-_XGV']C!A
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MZP1'=SHHP89-)#>:(S0"&:-RT<8[(7([$)+7HCGI1;$_-IIK=JEV F]K9.A
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M@[/6>H?QVX^9?^J7H'J3F)Y1?9!,1 )K7O(SQ @K#'G"S$L78(:=&\/W4^W
MVE ?+,*<'O;*Y[AU_W<ZRA *=XR?5GK:D*A1>QA,;M46"T?"+<2\GL(55EU_
MB(T<M6?V3D*X ,[%H&&$!_!/RTA'6ZFY^U5\J!#T !SS_OHY]4_]ZLF>1ND
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MFU4NBD?W(V,UT[4'(_A2,8J&+3JQPXQ+%%UUH"\K^!9#%NT7G!Q!@JU[NP_
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M\M>EHWJ9/K1_63J*YQ4"_%WIJ.H-+>S?E8[^7[(><OH&[NS/F:UBDK3PDWX
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MU5]J>E-M%[>IW#P=WI;D=-"_9[<2$#>QA^&YEF<!W[;*TTU]G$ZC;O=E5!S
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M<B@X7?-LUZY3%$,^D:B&N0YI\I]*R$\D0X:Q2S.P6&NGB$_MD=8&,4=\2!Z
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M3Q9.5*+*;)0NT5-V,^.)V9%'<>=OC 0_VBK38QK.!.O+XM4NX_UDV+QX\A_
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M*(5QPGB:<$0]$9EHR.!(IR9#.T!GX.;^/J^F:& #&E2HS?1H^&[NEK1)==[
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MZ?-6F9!J]O%605X]9*QI3DG%ZYM/;S_?L/)4_@Q](((Q/X8\PAY$B%.8*@V
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MA<S.>UDCO1;=<CV)SAY8R:_LYQ.'.F:G3G6\=$</6@;*;8?_$<I"G>GXG<-
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MW _5*=A*:V_X?ZZ+*MO67"8!BR@/(<="*,7#OE(\+F J L:B..+8XSW26?6
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M3*P_SF]D=-?++IT^D6RA-]G?K?*?]9;,' =!G 8XAB3 $B*=.RDE.(*A2+R
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M0C^-4H@P"F%*/0*# #$_#B+B2SR!;;D>IDU-"1L#@=B:\L?;CNOSBKWH=MS
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M<@<.IZ;5!OS4Z/-S-3_U/4=I,W= J^73#/""KU]KX#:1)C8*O.!W;AOX>>Q
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MZ[E\4(]%KL=^-NVA?M.#?OE3+K_+7]>KS;=R0>.4DB0AD'.E[5>:$4@#F<&
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M+_(J#G5!>11(A1$TE65->T,!F4EQQOK7A F]/PKMZY&[CCXW?J[D!]]K!>[
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MA+;JD/CP7"7-FJHZ=:QV66Z?ZM]5_;N_R!^;-QJN?RQX0)CD,H4XR[BI_!]
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M;8%JQ05'\@(CL&,^8 _.=@N&1_3&MN:N S="!*TE+EY3 7N&G#83T$[_LT1
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M)).)=3+=E4'FQBVMF& GIT,&U#4@NYG#%SPCL\4Y,N"/6DB7)+%K$#DD>'F
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M0(%5#%%,-5$P%L%8*!8I*FF$LD4=2O)Y0XN-'6<XR^'R>9Q*,Z(_3'[-5Z8
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MO=MLGJ1X7=43JT/+JOC3S1LMP.I9RNJB3_HM_V;:(^A7=C,7E"-$<PFR(L4
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MM5:R-'TY-^^6M7_S=UG>?S,Y+]_UYW4OVZBX3^N2RSE-<XKS) %I5B0 *98
MG, 4R+B(D22<9[%;D=R1%9@:AS7B2S&+6K&C1NY=%&I425[%"XO58D'7FT@S
M7QW'[1HZ//;[8L>D4WX+1CSJOQ2VO+&-6^[ L(]<OOEFC9BQ&6@>1TW4]*W#
MM/(S \V0<UIF*#D&9V.^+RDK%U4!Y.8 >'G?E7O."<*,I285"<6FP30!%.KW
M#!:B8%F29XQ M[P7A]&MF&W4A)>=F'5)-_[?3^6F-%,(UDW4^&*O4^^4S)NS
M8K<0^4;Z!5(Q.W+/HCWX7=&#Y&#:XA4H__+F\"^5>VF+RY6\2^M']".WTX#&
M.\[73YH9]N.VQQJ[/7?GW^8TCV/$BUQ/#\T!BF$!F$HI8 E31"J*,N%THCM4
MH*D9^8WT%0&NJ@-$_J2G5AMPO:EO\)S9\>&8,Q&8),^$IAL;N9V;CM"=@][]
M$=-[BYERID]?\/KDU,$RC4JTOA \9E]OS_5%R4?-4+OU\O),3V7"*<ARE9HS
M&6UP$I4!KA"23.:**3R,?B\//C6JO?"5G_3][5/:L-?D].59/Y"_#*?V1=L#
M?]Z&+2Q77AG_A7GQ-C*W.=#B&3W/L>E"?E2U6TV_;Q]5)SGU]>J!ELLYDS$A
M'"4@PS #2! .2*;-S03%B:"$D\2M^?+M(:?&;4;BRC-=A>K\40OIR%T60%L>
MV7J%+_0AJQMR[N>>UF!X/:F\/>JX9XO6*)R<!MK?.>S\KFHWJNVV]WI*34^)
MU8/4^^O&*?>K7$I5;N<2BB)5"01F]ZKM*1P#1A0'&.%$P"(IF'3RI[L,/CG.
MV?;H8NR M=NQG&\$QSJ7J^2NMI65Y%$M>G5<UP@?_=*(?]FAU_MPS@6U$*=S
M5N._R/&<"S*7SN><GM&/O=ZO-J8;H]EBRB77N\NOIL_J/,DXY4A) #.B]WT0
MFO(7& .993*-4Y(DU*H7VO5AIL9(1LKH0,SHCTI01TOH JAVA#0<JL#4TP,E
M9WZY#H)/)KDPTJB<<5W;8W:X<77/71+_)L63,97>/AG/YV_ELGQX>OAL,HL6
MC8_4.$;W!U)FVU8/;6+VJY#].<ESF*D"@B1#7--&;C924FC8$\(XP06BB=-&
MRH=44V.95BFS:ZC5BAJ]HEJQ-@9C$ZG5P3EQI9SCILS+O%KNV\:>K=!;NV$3
MU;!BF)06KUA[W3EZ$6S<S:5/+$_VGUX?WC.M1K_69O/;G,(@D3,2,PH2E0J
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MK3Q"=S_+S1R13 D6)X K O7.+2D %2@&O! "YVF>R=PI8?WB2%,CLEVD?%.
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M 4SR.%&*%!C2?L%$)V--;??2C5>I$_39<U2G[-]J+>\,LQVU> (O,*L,P&U
M.,]%1,)$[IP.]T)!.A?UOAR/<_F6?OSQM]5*_"@7B[NE>+?4E'1OUNAZYW <
MX<M39EH.:FL]+;3Q7J@,D#R10.2B*%B<\ Q*%SJQ'WIJ[%+%O"W*[]J&J>5U
M(Q,'S.VX)0R2@:FF%;IRK^_%WAUMC!%8[0Z<3T9R&'U4@G)'Y9BO>CS!C;[D
M3_&S?QGT?<W/VAR[>]I^6ZU-0[Q/4K_=6N)[.4<$82FTX21XG )$6 QH0C"
MC,44B13AU*K3=7A1IT:/=\OEDZG\NQ/0E#!9&W==M-O?1?0[+1?5YK"J<=*6
MV7Y:ZLF/MM]DE6UAQZLCO S7>7A:4QS:1!S>6J-3]KC9M.YUUL2_TWHRTR]6
M_,G<43L>_AROP8',_W^_#M;K_G@S5-L)9KQJ]8=)L_:/(,$HML)X2+:VQ8@C
M]FW6K@?1C]XT_WE?+B6<(Q;'L& ,P"2G)AF5 DPA EQ!A/."P"+E;HW:SXPR
M-0N@%C1J1)RU/T1&V.CCTI+8KP-[.Z3$"UR!5]/>2/5HS7X%B<%MV<\]>^26
M[%?4.VW'?NWBOI__FP>YOB^7]W];KWYLOQF"HLOG.1<"JSC.08+U%@(A$V'"
M& <*)@E,6 8AMZJ5?6.<B5) *VM4"QLUTKH2P'EH;2E@,&#CD( K5CTHX"H2
M@TG@_--'IH&K*IX2P?7+!W3W->V&I'C]9+H+?:K\VU7GM4[/T<V;G]KV*+6E
M,H]SP7&6Y  R(@&"RG3_U:9"CA""!<UP3)S.5ITEF!Q]-((91\30%L%.,V'I
MS0F);^@-? 5G+7Q42Q_5XL_J?I>SQO73Z!#ME/#<AK@/?M[;%#L),7X;XSX8
MG6USW.M!P^)R+Q4@3B3% B$"N&"FOG.< )P4"N0Q9R+G,1:%4T+AC?&<J&VT
M>F>B$;I?R.RPVLX> 0O,5;N@UW&*/5L"$R)D=1+%GRWUOQ1TZK<8='7@LX]-
MO7M<0XUA7G=JGV.I6003"GBB$$#*1-BE!0%2LE@*'"<\M\K]OCK*U*RBWZDY
MZ=IV(NXC+7"YB. L,E([')A?!-;"U>$#KM!;J@.$6GRB/VI!+:-_K@/EX!3P
M =A(Y_GG@?-T]'X+AZNGYA=O'N_ ^Y;\!V?5-R_N60[#'&=_U?=6#74RR1FG
MVGB2/-.V5$$%(&D& 4NQ((P5#+KE51\\?6KT5PD7&>EZM24Z1,[.5.J-1V!^
MLX?"O;+".96]5E,X&&#<"@KG=#NIFG#VHKY%2Z7I@-P81'=+\=$4$JE#8>:,
MI@E6,@8<(ZP_WCS3&R&J0(P4BE%*<F;G&[(9;&K?<B-KU+0.VIRILD)[Q-9=
MQ=OND_>%8F &: %LMT,&OTK26S&)/<J/W@;$;\G1*^.-7&;TMN:GI44M[G$C
MD\UZ._^-_C0E#AK;L\AHK)B$ )-8ZMU/@0$CF:ES3(2$'-)4614B.'GRU&BB
M$<Z.!$YQNO[%#](^\.?=R'5[QV+].5_4]LJWJ^_I?+?Z;\??[.E#1_E +^K2
M?HV7+^B]CM=G'-6!Z7$,R9P7(A44YH D* >(*FZ:UQ6 $H49BQ6$<>RXDE\9
M;FH?:1.U17<"]D_DNX&S]0KN";WP:WASOEE).CN-?_.ZBEN XGD=OS;BV"NY
MA?9GUG*;NWI2BGZ+OM&-_,@6Y7UU3E#5+?H@?VZ__I"+[_*WU7+[36_Q>4+T
M+CX!!<]3@(1D $M$0)SI'_,XE@ETZD1L.>[42*85.UKMY)Y%HB[JM33)(=M*
M^.BADMZ1=2RGPI)^_ ,<FH=:;#]VL-VN(F:*JY=B5E5,\Q..UA,DK[QD.?2X
M!.6&QPE3.=[>C[(.6[O,":8*44A!FL(,("03P(3D>A="8UKD!8?$R>HY?/S4
M".CSD#941\C9$4E_/ +SQ5'S)W^L<%YCGQ__T0BC?N/GM3O^E"]<U?>+W=)R
M*<4;NC:U9C:M[XH32AA"@, " <0X!#2A"&1YHH@@0M#$J5ON^6&F]@7?<?[T
M\+0PG=*CUU*5O'3LAG0!3=NO>2A&P;_J6L"HE=#CX8,="'X_]+,CC?S!7]/V
M],._>K6_@XMN81R!<\5)AD'&B )(L@(PC&.]I*N4F\,+3M'0DXN>%71&/+KP
M4H3H%M3]#R^F68+HTNE%D I$EK"$/K]XL?I#EOK;G& ,KSY4Y^*U8:4F<?O5
M:F.Z4"L5%P)+0)3* >(2Z@T!SX B<:YBGA-FU[[LPO.G1AYO-MORH;(F5DJC
M;,ACY\XT6>UTUZ*L_;5+1O,IO-<)Q -H@0EC'WE>Y?I7X@U#Q"4Q>Q R8V53
MNR#DF/9\4?_KN<JGMXV88'Q1YL.LX,N7]>"U#UHPT[BVB89O:BZU!RQ-"*;I
M32854RP#/(7:<"** &+B4;.,QC&*E4#4JKJ:PYA3X[\/TH2B[A-U^.KA8;6L
M(A&.JSS^:%1P^-PMY\&"%/VC&Y@H&X&C;A9430V[D]K?@P'JP*G^@1V)9WT
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M3YNMMNK67\L'PPSJBR:&C3)V@3G&TYL#M5H_5$&VNQ1JX\2H@TCF%,I,4$Z
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M.,6IN4D7_-ND=.(M'Z?CFY[/<0+O #(?<3G%U9^N)]G.32<:@[FX BD)DHQ
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M?^JMPKORI\4BKY[-\WGSSM7'Q2R_1*(J3;>0F.=G)XOE>OI?F_^<1!U]D3E
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MUFLZ6>J;_-/Z*Q.4$H.G4)#9.I.*D3\>C:H-KST/P:B28Y-+R=U)[+*"N2F
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M9$WW6'3<1QMCV\U6VND@?#J_K+W2U>'9^2#%&QWP62XD*P,%Z[@Z(^L<#I2
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M--RD[OQC;L%@=WKPVYKV,6'O.$-^=0%2Y&HQF^:+,9;OKQ!]690<9I?74S_
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MJJ?-@E,2<V'D45JG#1EH<BN]2AK0">M9U"[9)AF,+Y,V\K8V# ;N(VM8A70
ML;<?WF^,K:8(A,= RD9!<C%.U/B!0@=NG"DFZ)R;7%_?4# R8 96[7P(.7<
MD'NV^MU-FE?23$J5$5C, 12C'=JAT2"-QQ1,M@*;1/]/$31NWFCC+6T0+8R(
MIG7>P]42N\?*A\4TX0=<?/I*<IZ$S!/3Q XR3NP4P\CC$PEB0(8JEWI%N5-2
MR<OOZNHZ[4"%SMM)=VRPW+_(1@I2\^_3'].,L[S\C^GJZV\XPS*M]0=7!V)+
M4MT;#+5M^418Z8R7 9R0:R-;V^>PNN<S45C)0MV?P[U;<M)^9'1U3#0 Q$ZG
MDX/11^^,\^;XFTB;@V,4XAHK(BAI/02*>\D5*(IBW!0TJN/QU564UAH_>\FT
M \=HO;._72XOB87+FAE/9G8ZSVM+N[Q%__NR=5S_J6;1KQ/M)PF]-11R@!(<
MZ0^=(%B6@),H493B36CB;A]'=E=.UG&('$&/':#VG@BON'Q_N5K6F0[$_$2Q
MHJ(HM H5ACJY-H'CP8)0-NE42M2YR5'52X2-.\&J"?(&U<6 .^:@&<'KY?5U
M?D'Z65[Q>4CF[R-/&2##]R7:!LKDO7KT30(F%\[:H"(4Q:I6<X3HR14G_\@F
ME)&YV*2OPUTR!MG^[LCNK_EJJU#F-JN=8!JCE!PT(NWK0@J(+D5@*N42DL\E
M->%W9PI[N$@Y"!V/;F6#ZZ3/2H.'O!X^:N/)9S6Q,0T':MS#4O*! BN7(6HE
M0*5:69*PEF.BR>16A\B;'-$-;&EN1BD\CN__6 ^36BW?+SY.OWQ=;4V7\<Z7
M++D!;A6CS5E+B#EEX$4R*91DZ-M8GD,I[LH2[8.>I\=?M-39N5BFORJWJ^D/
M/*+V:8>G-K%6S]/>QFXI1..#$& ):Z"<<_6*!$%;86+FF25S#G;KY@KR_>+J
MR7_BZNL\OZ4P<KE"W+IQ^NWGPU^^_K6KRP,I& 696M21"N06U(#3:6'!R5K>
MS(7R;69B#\E$5]9M'XP]G6!P8LUV<(#P],5ZUEF$>J?I0XU6)5*TJA,#+$QK
M;[4+NDF9RW%)+B?(0#@U2'9.A]E'8SU [^4K>G)2N&26HJ>@,R@D%R(HIL Q
M7X30QD?5QN,[VW28O3"P?SK,/@KI &);:1K9*LRL0!*>Y.*YK^.V!80<,PF%
MW.$V,T+/)QUF+]4^G0ZSAYP[ ,C['[AX=7$Q7X]!?O^]BN-ZO(4TUD?R)32/
M]>"&DR20^6JQN30Z22^:5*0_2=&XM\^- 32,'CH U//Y]\E+E27+P+!.WK4>
M(29O0.<8.5/"FS8M'CJN?NG'KQI,<QW \/%T?H\4)BG!@;G 0)5B(22*E"03
M!HV4*K4IOCJ[.IF]M+U3G<P^HN\ /P^+-[11)!3N@$)I!2IF$HFM&=<RFZP,
M,Z[\^];)[*7=%^MD]A%U!UAY-!AY=W.E[G24(@?:MHO1Q(-QY!8@ M<Q%=K:
MF<0FCM3S9(V;B]7/IC><[GI XJ.7$^M//WV_F*YNTW\^5E7S">,A"B8]K5M+
M+FN6$KS+COY:(KID8FYS,KTOH1V>-AP(DIVNN ?26 ^(W J;+JMQI[^L\X*N
M,M3>SK;"J$D,2*%3R&"Y$&3W30;'>0'#*7A6MF3EVC2'V8/(7H*%X9'82E-]
MH?!N!8%7D7P*[Z&0PP%*<0/!*P51%<&E#9($V1AQ^Q=QG&!7;HFNPS70%Y+(
M-).T<+%6ST=,./U1&XUO+Y.09!:)U)^=HV42E &7R%A'&129:RY-(]=O'RK'
MS8$^#>8&UM78Q40W.=YAEO#U?+E:3M"1*28G $1FNJXC!4$:26%8*,0 2FWO
MW10]56GVX-GCIBHW ,@0,NS!%AV7Z8],.U>L)*$%"IL"*Q 8DB<9DPC<V.AD
MDVE_)ZC8,&<$QA&T>2YY9H.FES7-*CMA,IF-P3!5.$1?4YTQI%JA4<!90U_4
M5C*R2:%5TR3837WYU7D.A0]:1E6OT'0"9;'.T8RNUEFJ9%WF*;0YE'B:IA[.
M7 ]"P N)K ?+O8/M;].18)-ZN\F\W>2 &,XU\:!Y[=I42\)#M +(A?,HE%=.
M-#E'>)*BD8^OAM+YXYV*CU1 KTC:W&S(J!7+D1C(=4R?30F\MQR$#L$9S(Z7
M)C?6S]#41</B8[6^"Y8.4,'8D=D?__H^O8HR__\PXYZ4:S:76B&@R8%"BAB9
MJ+U2)7@FPKH0(# GA2B[E=@_^8H.<7&(!N>#B[,?4/P9%I)O<8$10ZG=N&/Q
M=;1W6,^6,V ]5U;*D@SJ/4%Q[Q5=M*5N!8ICQ-D/*%Y]7VPSX3,33GH#V9EZ
MY^TC;<G> =K"-4I-@(][8N+N&[IH(]T*$D<(LQ]$?,+OEIA0&R:R\EAJ3@6O
MG1A4XKPV6R]@M-+%FI*=%7LBXNX;QCT";HR((X39#R)^QU29T->&+N@B3);@
M4E3UL)J!C]:#B,88RYC@>;=^4$^]8=PSW\:(.$*8_40K]XX>M7#*U%D,)J,'
M59L41XL9C+/:64M@-\V'\KS;*[FHW25YVWCW",'W@YZ[2VN[28M)L4CN:NQ6
M:,=4Y$AYYC1$II4PVGEEFO22?XFP+J*;8W2_2\1[J")Z!=8?_\)%FBYQ?>=_
M\^5-F3R?..^"CRZ 1C+ *I 8(P]D>XW@,FNK;9N6!@=1VT4LU1J"@ZJL5US>
M9#C=7*"]#A<7F'_[^4=(7^_^[H0<1IVC8T"1!)+'2.%#L(&!0V5,D9[<A]-A
M=!_*NPCT6N.UF2H[OB6]*A#[<!%F!]^-;CUBJ!O1IZ@:Z![TMN]3O0/_]AUG
MRTTZST5885ZG<*QORV-88OX0?GY;E[/<-$@0KNC$$W"DD$'5\H+H1 :?0O*Q
M6"O:7 H=1_:QUF_GM_^V_?;;]C7)6(LJ%LBN)GH&YRDVJJ+CFM8,%SZS)NT3
MCZ1[7&?QA$B];R)/J>^S,)!'=E%[\*#AC67#_FE' C%)P06!#;@F-*K@#7@;
M%.A &V5$HVQNDB$VKLG<.CZX62C;5&RI;_DJK:8_KGO@W:ZB:$(67F=@Q8K:
M]-"""YE"MUPP6*Z#S:T;M1U(^ED;SGWP^DQBS"FTWD%@]!C'&Y&^^F=8Y&V.
M_Q$N+J]0L%Q>?KOZ[![W2EKI!"O P[K1G:\]+[P%1,M"*J0'V::48E VQ@WQ
M.\/_B=#0U5KX@UR#^4_$3[CX,4WXN#&HG3K2^J?WY2.F^9?9]/^0N-8)NVLE
MW0I"6QZ9(8<*=>&@'*.(4TH%0A 5C+O$1)LN8JTX&O=0H8L5,B9&.E@LVSIX
M@O=ZZ/)EW5YB^=O/QPW*=O/F%",W"8J*I)0H"CC/*03Q&(2FH(.^;NUF#L#'
MN)?H(RZ,,?%P%C'H8/URGWGD\''I23KE'GM40EYV60^_Y,R DC7EE!%>M.>9
M.2L2:S-UIN\(=:?EMKX.1\^XKZ.PH\<,JF@+GBP ,.5K,HR/YOY\NM,$JCMS
M<-;QZC[HW3=>;8.!#KR/*]/T#:_FN1.1-I"KE'P=690D U>KWHSTQ?J0L>@F
M0><V$=T4=YP2!_.!E-(1H*[SRYRU)6D'5DM:E%X5B/5 G!R/I.AS)7*3@.TN
M&>."ZG!U/H&+ V0[=N[EVUDB29'[LUXBE1'RQOQU$FG0C'BWH%B=_9A-!E]"
MA&2]D"ZJFF.V4_[E<V_I P.'J&[>0HX=F(HK:TF_O%X80L4L"AI(+'OB0&B(
MW&;@/$NE=9!%-^GN<8>*;E(M1]Q]#E=+!Y@Z7'"W;,_R_=5:A-7)! A.F=I!
M,4"T+-1[9.YBD*A2F\8S#9@9UPP>@:W['OO8BNX [#<GI[='#9N=H$2-,NE(
M]M^66KIEP#L1P*N@D^/:1L%:(/9)BD9VZT<'R_VNOH-HKC<(;EA0LK:HI<U'
M^AAI\ZF]GVQPX%D1B))"=-X>?#W4:_8-NP.TU0'@:L\@_*_+VFK[!_UQLY<$
M([5S7$)RCCR>6HT6A)#@,CG306E>&O4>?)R>D5L/=N%(#J&J/A&W68K6:.NX
M$\"]DZ#J+.8@M =GHL 8<[V(/!'F>G#N!M'WRQ@Z0/C]H>AZ' G6TFEN0>::
M(,J$@:"#H#5F%8^"9^V;=3-_0$UWZ#E$T\_CYP"Q]X"=EXSX4S;\W4VA")9D
MK2H2,EEN4#PA^0^H:0U:G4L6P98VB3-'DSYR0]4^=M+3 N"<(7^WV_:KR]77
M^:*F"DTBN;,^.P/,( 56/@0@=SD";4>9B5CH@R9Y,8-STGDH/3 4AUH)@^"B
MEX417Q9 O"^ VX8-5UES$V^C\N2 $<]H005)VZI!PJ\/%%[*&'*;>H3!..@\
MN#_!0C@Y#GI9 (?(??W'/W"YNND&S">262XD[<)6%W($A:+M.1H%UB01LQ>.
MYS89.P,R,?)10P?+8 PTC'VA?CCC.4_KKX:+^ULAB:%>+H<O.#$<-5>!0U(^
MUDEA"F+*%"6Y6%)(6;G[E[%/];]O2>;(H<$XR.],^^>\(]SS"7^$Z44-U=[,
M%W^K;0XF*M?C %.+=D,]&C<1@I %+#<EI<2<9DT&7+9B:.31$V>Z4PR)DK/=
M-=[.T@+IP]_QZO]O9T\&5'6 H/-, 5.* BI1FX(YSL&H:$O42C+D;?>.W8D=
M>?[%.>X@C9!PSOO(II!S;0Z6;S=QU7]@[9&#^=4/7-"FNO[R][#"-V&ZJ"6?
M.!%9L%@LF7_+?>T.08;#DWAR9$9XHY1N<T]^8CYW6F/V%UMCYX"I<UYRUY-K
MEZO%Y?KP_?WJ*RX^?PVSC>#^FE]-M=U!9@&S2BY9LE",S%2N5TNL9N D'526
MUB;3[B!L9.9W6ISNOQ=G'^CK9<4><NZXD<RF(6+UH-_.5HOI;#E-:T'P23!)
M6 P*,EI6#R(%>/*L04K'O<%@*0CMZD#Z199V6EW^5UY=XR.EES5SB"+^#/^:
M?KO\=I.V=QF7:3%=B^<C&9$)V0C.#4L@376PL<K!^PS<!BQ"..-C7[?Z+S"T
MV]4F^Y47S-@PZ6"Y[-00Y&:'74M@^7F^"A?;W]=JX;_FJ_^%J]MV(9.<0@J8
M"DBE JB4ZP%_C4\%PR)EHH^;=*ULQM%N"^9730;H RB_\HJY"CO?S!>;C^KO
M\8EB)FLM%"3I-.DLE]J:C8,-7#AOC>&Z25/[T[*YV]KZ5?,+.H;4672IV?KK
M=8/#X?K5///PX3O7[,I)'SULA+(V!FVA:)[)<A<+3F,!4\,"$[ASZE?LLGKD
M,>/6I(R/\XL+6IWURXGCTIFB)7#!#:A2#8AD 0S2HG19:)?ZRIE\EIVS[FZS
M#ZZ'/H0> !T=.$D#2N'JQFM"W"J+B@-:0?NK-@I<G1>?>.3)EA"YMYTOCRM.
MSC2E>$!XMELQ!V#EX,7R?>U;?5J%Q:J+)7/W]NIOB_ER.=$F&>%S!B,%>7J6
M!_!:U[[.5G(>5(KY#&X]U[R<:0)RO\OF6+STL,M4;_GM<GF)^??+Q4URZ55N
MQ';;Y^O)4'G",'"30P8K1)6XH:W=1MKI0PY>)1$%;Q).[T_JF:8:-P1\6VWO
MCV=_A><9?JE.91>; ,FYX'1%CN_-RIXD&8,K@8'.)9 0(B>9ZPC2\2BMH<U0
M=AE8/,++F28A][L)'(N77V+1W%;IW I!\JB%M FRK%VEDS+@C27U.*NM,L%F
MTV1Z5 ->SC03N=]%<RQ>?HE%\S#JTHJ%D,AOY*8.HW::G$>4#KSG+$DK%*9?
M*$+O+U&YWP5S'%:.C-#_F'6W8.XEJMV96UMU5C8ZR[+X&&3MK:TD**X3.%<D
M>(:Q<"4,PR[#]_U9/>OA19T<%[= 50]!_FDD-$G*"9]U!B=H1:B</#CT 6+(
M,@KF1+:];U_/\??+'#LW@?DXJW(OS)W/0?63S7EVJ;.X*R!91(XF&8C:UJZU
MG@2DM  T010,/BDUSMG%<#S^,@?;72S,D;!W#OOD2Z*YYGXWZ3#%F?'90K8B
MDNGB@JR6XL"51H::2R['28<>E,U?YA#^+!9G.P3^"NOSD;/:9^5CA);*)D<&
MRS%0B!&<M19DS$Z3Y *+;48YGYC17^92X"S6:$L4_@JK])'#X6?E$VST+ <!
MH;:U4"PP\$HK<"5Y'KCCW/6ZC^[%Z"]S"W$6J[0E"L]AE0X5GSONT0D#W&59
MFS,5B&C)EFD*#AAWVC7*%NGH3.@<+CJZ6),C8.X7N1JY;91V>Q*_->!9"!F8
M$6!8)C_?J0">1P?),N9<4%*U&5;6E*NSGD4_YH7'<%CI91^++PLC[FU3/F)M
MYT^?OY[/UJ*Y#!>?<?%-3(H0@1>.0$9&@3+1@/>% 4INE,'(4VK7AO6TO)[W
MG<> 2!^X6T1KV!V\,HF(..]D;?[CJEAS5IM 8Z(?/\_K1_O+CD\$3T))$4!8
M63/RI(00N"$OIF21 M/<MCO)Z4($YWU)TN]*'@FDO\#6^X3DMAKI["RY*!,O
MQGO@&,CC-ZC!6V;)-(8H(KE8!(DS6MX'B."\KUG.;GFW!FDORWN8:/UN0ZR)
MY1PQ"4GLNP**V0PA)@K2C2)+IX2TW2?EW>7HO.]/&B^^T2'T"ZREEYV,5U^^
M+-:Y[?<$)0LWPA9#^JIG81%K,RV9P#,=<V*9H^NK6^BQ')_W+4F_:_$T$/QU
MU^J6Q_"4H%RRP23-(=>*,:7KF.2@#13'=;;<,LVZO"LYF./SOCTYN[4Z, 1_
MW;7ZL-K&VER42PDH$$^@;*WH-\Z 0FMY(1OF@C^CI7E8P58S#_:,+U.:(.C?
M8F4]>X4K4M:!,P3F:%THEQ&\*P@Z)RMR=":)<I[KK=\,GU]Z%0Z&ME]W;6ZY
M!QN;5:(/6I /DX4DS]US!(><@] )1?;)<MEEWL"N#([K?_YZZ^TX!/U;K*QG
M[1#'K)W7 4)Q"E0)!ERP IQ2A4D**'CLLL_,<6R/.W'IEUZ%@Z'M+)H8WTRI
M>;5<7GZ[DM%P78R?>_KP;8QWYJ6//L:6,Z:8HYA&>D\>E',00F%@F5+D6SGM
ML<G1U<A]C--7S)<7N!DF>%"Z^>>Z3B<^Y2AY35DMNH!2SH(7Q#$J2\;%^^AL
MFPOLH3@XZV[%^Z#W@1$?!0,=^$I7E-,OO_K7=#E1WI>HE "5ZX4<I@AU_X/(
MC?2U0PZ%42T ?(>*D;,5QT'"?"BU=("IPP5WR_8LU_WSK_ -?Y_75(R)C^20
M>6%!<"&J-&O?)FT@>)%U\FBD;3)&IP4SXR+\"&P-5IXUD*([ /O-S));S^]/
M7$?-(I7DF&/@+%I03$3PT20H,NOL4D*7F[1.?)*BSM/ FX/EJ6DS1VFN-PAN
M6""^E2T^0]09*:)E"7SV$F@#<C*IJ'R;C)%':.D\9WE4V!V@K1$!MURL)A^K
MW-8[!W-('HSE4%SM7:B,@VBR!HG""RE*-([O #%ZZ!:\Z&_WH77GK2.#:53G
M\'#Q]X"9#=0#IW!,E  ^D9>A;.U60L0"2S$H$[+6>I<:CMU1,^;>=X3&[NO\
M /&-K/4_I[,Z(71#>!0A.RLH)J<_*3JO69^Z.'#>XGKP80Z[G"WMI/<[;QY9
M\X?H;3Z$$,?6_M5\V WAJ%Q0"0LPP>O4<6+!!^9 %LRZR#J/?)=,@-VTO_WF
M<?:+P;1_L! [<$L/OAAY=S-,,G%!O/$$3)*+I8RJJ>*"Q"B,CD($'TM?"20W
MI(]<R=/%(=:) 7#.D'_LHNCZ/O ?\PMZS,5T];,.UMYL")-D==*%7 CM$TG&
M!9),(=_"LZ"3DR4'/DY7L\%8[/RX8F#P#K5VVB+IWV2-76V[$Y]#<((B?&39
MT8;K*,)7I9#W98I*7J<2Q^E)-AB+G9_-G/\:.P!)O]H:^SA=_N>;!=8B!22
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M(7*34XM?Y1"]H,H8K8=B0@(5@X(072%Q!N:,3\ASFV2X_SY$WQ.][0[1]\%
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M#<H'#\&1BVP8>D7?J)R;[+R'$-MO1+,/FAX<WK966P=[[ET>'[ U\4X:HW2
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MU(7F *KHZ"[]AIN-\9Y]>4=<O0Z+Q<\R7]1V+<N)S8$KGB18(P(HR0IX<C'
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MZD!0*U,(&$2K 9D'DGP^EFT?Y#UR4'4*E79PT/ $IZ_)EG^\"8(G)3C%?#!
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M6LCO5 :Q"S?OL&C?=;N3XW)W/-=.M[?)W9T&!I/]7/<BS7R;3WBF5>("Z?Y
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M(6 2>1%.2U <+0E!DFG,@IBHS'PLY:<@(5=B-C!FBB.!,EQLRG2,&U0I!-9
MHS=%TT2(VYR@6$C\V:H;GA,(.T5]_1WU+X=Z(!%+$%<&HDL<%1'R.!V'Y<HX
M2R),FM1T#'@=\"Q$G8C5%= 4$>=,\AE)$6HF2DST<+X,@QR!ZM[2&&FA;46*
M9D;&<0)B7R! [7+*VA-0%9.(BZF:!X:$$5,:^QA-J'GH[$8KBROX5G-CUJQ]
MM1!OO$/\V1 ?WL'#_EZKYAV?J!S$.?\SB5!$$<-;BY0!H1(L)A%CS.=@L$,
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M\GNS<\.Q6P1[2&/.;^SAG[/KT%D54[6@-L@DJ T_""VMLOZ@2B38!LP(9S?
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M"_V0Y1,7F_6SNF,M;WM/_@902P$"% ,4    " # BG!2.S,-'&$*  "%9
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M,C N:'1M4$L! A0#%     @ P(IP4ECT:Z $ P  /0P  !@
M ( !KGH  &5X,C,Q+3(P,C!B9&]C;VYS96YT+FAT;5!+ 0(4 Q0    ( ,"*
M<%+_QR@*\-\# *-)'P 1              "  >A]  !E>&1X+3(P,C Q,C,Q
M+FAT;5!+ 0(4 Q0    ( ,"*<%+[2R?X$A,  '7.   1              "
M 0=>! !E>&1X+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( ,"*<%(_)T2KZ20
M .Q_ 0 5              "  4AQ! !E>&1X+3(P,C Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " # BG!2B$/&6[Y?  #V  0 %0              @ %DE@0
M97AD>"TR,#(P,3(S,5]D968N>&UL4$L! A0#%     @ P(IP4N/G=QYQ<0
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M,C R,#$R,S%?9S0N:G!G4$L! A0#%     @ P(IP4N9,?';"  $ J\4* !4
M             ( !\F4) &5X9'@M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( ,"*<%)W"TN+!Y0  ,>^!@ 5              "  >=F"@!E>&1X+3(P
M,C Q,C,Q7W!R92YX;6Q02P$"% ,4    " # BG!2,@/76C\(  "3+0  $0
M            @ $A^PH >&=N,S$Q+3$R,S$R,"YH=&U02P$"% ,4    " #
MBG!2GISE!BL(  !F+0  $0              @ &/ PL >&=N,S$R+3$R,S$R
M,"YH=&U02P$"% ,4    " # BG!2JR25O H%  !('@  $0
M@ 'I"PL >&=N,S(Q+3$R,S$R,"YH=&U02P4&     !( $@#%!   (A$+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
